PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CLONEY, LP; BEKKAOUI, DR; WOOD, MG; HEMMINGSEN, SM				CLONEY, LP; BEKKAOUI, DR; WOOD, MG; HEMMINGSEN, SM			ASSESSMENT OF PLANT CHAPERONIN-60 GENE-FUNCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-BINDING-PROTEIN; GROEL PROTEIN; CYANOBACTERIAL	Brassica napus chaperonin-60alpha and chaperonin-60beta genes expressed separately and in combination produce three novel Escherichia coli strains: alpha, beta, and alphabeta. In beta and alphabeta cells, the plant gene products assemble efficiently into tetradecameric cpn60(14) species, including novel hybrids containing both bacterial and plant gene products. The levels of authentic groEL(14) are reduced in these cells (Cloney, L. P., Wu, H. B., and Hemmingsen, S. M. (1992) J. Biol. Chem. 267,23327-23332). The assembly of cyanobacterial ribulose-P2 carboxylase (rubisco) in E. coli requires the activities of the endogenous chaperonin proteins. Furthermore, the extent to which assembly occurs is limited by the normal levels of expression of the groE operon (Goloubinoff, P., Gatenby, A. A., and Lorimer, G. H. (1989) Nature 337, 44-47). We have now monitored the accumulation of cyanobacterial rubisco in E. coli alpha, beta, and alphabeta cells to assess the activity of the plant cpn60 gene products and effects on endogenous chaperonin functions. Expression of cpn-60alpha alone did not enhance rubisco assembly, which is consistent with our previous observation that p60cpn-60alpha required the presence of p60cpn-60beta for assembly into cpn60(14) species. In contrast, expression of cpn-60beta alone resulted in markedly enhanced rubisco assembly in cells that accumulated normal levels of both endogenous chaperonin polypeptides (groEL and groES). This demonstrates that assembled p60cpn-60beta is functional as a chaperonin in E. coli. Co-expression of cpn-60alpha and cpn-60beta in cells with normal levels of expression of groES and groEL suppressed rubisco assembly. Increased expression of groES in cells in which cpn-60alpha and cpn-60beta were co-expressed relieved this suppression and resulted in enhanced rubisco assembly. Implications with respect to dependence of chloroplast cpn60 function on cpn10 are discussed.	NATL RES COUNCIL CANADA,INST PLANT BIOTECHNOL,110 GYMNASIUM PL,SASKATOON S7N 0W9,SASKATCHEWAN,CANADA	National Research Council Canada								BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BRADLEY D, 1986, PHILOS T ROY SOC B, V313, P447, DOI 10.1098/rstb.1986.0051; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLONEY LP, 1992, J BIOL CHEM, V267, P23327; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; TSUPRUN VL, 1991, FEBS LETT, V289, P205, DOI 10.1016/0014-5793(91)81070-O; VANDERVIES SM, 1986, EMBO J, V5, P2439, DOI 10.1002/j.1460-2075.1986.tb04519.x; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	26	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23333	23336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358883				2022-12-25	WOS:A1992JY16300095
J	KOCHHAR, S; CHUARD, N; HOTTINGER, H				KOCHHAR, S; CHUARD, N; HOTTINGER, H			GLUTAMATE 264 MODULATES THE PH-DEPENDENCE OF THE NAD+-DEPENDENT D-LACTATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; ESCHERICHIA-COLI; ACTIVE-SITE; CATALYSIS; FRAMEWORK; CLONING; GENE	Recently, we amplified the Lactobacillus bulgaricus NAD+-dependent D-lactate dehydrogenase gene by the polymerase chain reaction, cloned and overexpressed it in Escherichia coli (Kochhar, S., Chuard, N., and Hottinger, H. (1992) Biochem. Biophys. Res. Commun. 185, 705-712). Polymerase chain reaction-amplified DNA fragments may contain base changes resulting in mutant gene products. A comparison of specific activities of D-lactate dehydrogenase in the crude extracts of 50 recombinant clones indicated that one of the clones had drastically reduced enzyme activity. Nucleotide sequence analysis of the insert DNA showed an exchange of A to G at position 795 resulting in substitution of Glu264 to Gly in the D-lactate dehydrogenase. The purified mutant D-lactate dehydrogenase showed a shift of 2 units in its optimum pH toward the acidic range. The dependence of k(cat)/K(m) on the pH of the mutant enzyme showed that the pK(a) of the free enzyme was around 4, at least 2 pH units lower than that of the wild-type enzyme. Both the wild-type and the mutant enzyme at their respective optimum pH values showed similar k(cat) and K(m) values. The data suggest that the highly conserved Glu264 is not critical for enzyme catalysis, but it must be situated within hydrogen bonding distance to amino acid residue(s) involved in substrate binding as well as in catalysis.			KOCHHAR, S (corresponding author), NESTLE RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							BEAUMONT A, 1992, J BIOL CHEM, V267, P2138; BERNARD N, 1991, FEBS LETT, V290, P61, DOI 10.1016/0014-5793(91)81226-X; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P145, DOI 10.1016/0968-0004(89)90147-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CLARKE AR, 1988, BIOCHEMISTRY-US, V27, P1617, DOI 10.1021/bi00405a034; Fersht A., 1985, ENZYME STRUCTURE MEC; KOCHHAR S, 1992, BIOCHEM BIOPH RES CO, V185, P705, DOI 10.1016/0006-291X(92)91683-H; KOCHHAR S, 1992, J BIOL CHEM, V267, P8499; KOCHHAR S, 1992, BIOCHEM BIOPH RES CO, V184, P60, DOI 10.1016/0006-291X(92)91157-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	15	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20298	20301						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356978				2022-12-25	WOS:A1992JR85800087
J	MATTS, RL; XU, ZY; PAL, JK; CHEN, JJ				MATTS, RL; XU, ZY; PAL, JK; CHEN, JJ			INTERACTIONS OF THE HEME-REGULATED EIF-2-ALPHA KINASE WITH HEAT-SHOCK PROTEINS IN RABBIT RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; STEROID-RECEPTOR COMPLEXES; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; 59-KILODALTON PROTEIN; TISSUE DISTRIBUTION; HORMONE RECEPTORS; HELA-CELLS	Inhibition of protein synthesis in rabbit reticulocyte lysates occurs in response to a variety of conditions including heme deficiency, addition of oxidants, and heat stress. The inhibition of translation is due to the activation of a heme-regulated protein kinase (HRI) which specifically phosphorylates the alpha-subunit of the eukaryotic initiation factor eIF-2. In this report, immunoadsorption with monoclonal antibodies (mAbs) and Western blot analysis were used to investigate the interaction of HRI, the 90-kDa heat shock protein (hsp 90), hsp 70, and the EC1 antigen in rabbit reticulocyte lysates under protein synthesizing conditions. The data indicate that hsp 90, hsp 70, and the EC 1 antigen interact with HRI in rabbit reticulocyte lysate. The EC1 antigen is a protein that has been demonstrated to be associated with several steroid hormone receptor-hsp 90 complexes and reacts with the KN 382/EC1 mAb (EC1). The association of HRI with hsp 90 and the EC1 antigen in the reticulocyte lysate was found to be dependent on the presence of hemin at a concentration of 5-mu-M or higher; little HRI was coadsorbed by the 8D3 anti-hsp 90 mAb or the EC1 mAb in the absence of hemin. Hsp 70 remains associated with HRI in the absence of hemin, suggesting that hsp 90 and 70 may bind to HRI at different sites. The immunological properties of the hsp 70 associated with HRI indicate that it may be the constitutively express heat shock cognate protein (hsc 73). The results suggest that the association of HRI with hsp 90 and the EC1 antigen may be in a dynamic equilibrium, in which complex formation is either facilitated or stabilized by the presence of hemin, and supports the notion that these proteins in conjunction with hsp 70 may play a role in regulating HRI activity or activation in situ.	OKLAHOMA STATE UNIV,OKLAHOMA AGR EXPT STN,STILLWATER,OK 74078; MIT,HARVARD MIT DIV HLTH SCI,CAMBRIDGE,MA 02139	Oklahoma State University System; Oklahoma State University - Stillwater; Harvard University; Massachusetts Institute of Technology (MIT)	MATTS, RL (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM,454 PS 2,STILLWATER,OK 74078, USA.			Pal, Jayanta/0000-0003-1840-6458	NIDDK NIH HHS [R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES-04299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOND U, 1988, ADV GENET, V24, P1; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DENIS M, 1989, J BIOL CHEM, V264, P6005; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ERHART JC, 1988, ONCOGENE, V3, P595; ERNST V, 1978, J BIOL CHEM, V253, P7163; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; LANKS KW, 1986, EXP CELL RES, V165, P1, DOI 10.1016/0014-4827(86)90528-8; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Livingston D M, 1974, Methods Enzymol, V34, P723; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PAIN VM, 1983, BIOCHEMISTRY-US, V22, P726, DOI 10.1021/bi00273a003; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROSE DW, 1989, J BIOL CHEM, V264, P6239; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	65	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18160	18167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355482				2022-12-25	WOS:A1992JM22300104
J	SHIMADA, M; INABA, T; SHIMANO, H; GOTODA, T; WATANABE, Y; YAMAMOTO, K; MOTOYOSHI, K; YAZAKI, Y; YAMADA, N				SHIMADA, M; INABA, T; SHIMANO, H; GOTODA, T; WATANABE, Y; YAMAMOTO, K; MOTOYOSHI, K; YAZAKI, Y; YAMADA, N			PLATELET-DERIVED GROWTH-FACTOR BB-DIMER SUPPRESSES THE EXPRESSION OF MACROPHAGE COLONY-STIMULATING FACTOR IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LOW-DENSITY LIPOPROTEINS; FACTOR-I RECEPTOR; HUMAN-MONOCYTES; M-CSF; IMMUNOBLOT ANALYSIS; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; GENE-EXPRESSION; PROTO-ONCOGENE	Vascular smooth muscle cell is a major cell component involved in the process of atherosclerosis. In the present study, we investigated the effects of platelet-derived growth factor (PDGF)-BB dimer on the expression of macrophage-colony stimulating factor (M-CSF) in vascular smooth muscle cells isolated from human umbilical artery. On Northern blot analysis of total RNAs isolated from smooth muscle cells, with human cDNA for M-CSF, a marked dose-dependent reduction of mRNA level was found in PDGF-BB-treated smooth muscle cells. Cellular production of M-CSF was estimated by immunoblot analysis of cell lysate with specific polyclonal antibody against recombinant human M-CSF. A concentration of 10 ng/ml PDGF-BB significantly reduced M-CSF mass in smooth muscle cells compared with that in the absence of PDGF-BB. These results suggest that PDGF-BB plays an important role in the cellular metabolism of vascular wall by regulating the rate of M-CSF production in vascular smooth muscle cells.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo			Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; 				ABBOUD SL, 1991, BLOOD, V78, P103; BECKER S, 1987, J IMMUNOL, V139, P3703; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DICORLETO PE, 1984, EXP CELL RES, V153, P167, DOI 10.1016/0014-4827(84)90458-0; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FISHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162, DOI 10.1016/0014-4800(73)90014-2; GOTODA T, 1991, J BIOL CHEM, V266, P24757; HANAMURA T, 1988, BLOOD, V72, P886; HORIGUCHI J, 1987, BLOOD, V69, P1259; HUME DA, 1988, J IMMUNOL, V141, P3405; INABA T, 1992, J BIOL CHEM, V267, P5693; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHIBASHI S, 1989, ARTERIOSCLEROSIS, V9, P650, DOI 10.1161/01.ATV.9.5.650; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; ISHIZAKA Y, 1986, EXP HEMATOL, V14, P1; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; MAGEE DM, 1987, IMMUNOLOGY, V62, P373; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; METCALF D, 1986, BLOOD, V67, P257; MORI N, 1991, ARTERIOSCLER THROMB, V11, P1315, DOI 10.1161/01.ATV.11.5.1315; MOTOYOSHI K, 1978, BLOOD, V52, P1012; MUFSON RA, 1989, CELL IMMUNOL, V119, P182, DOI 10.1016/0008-8749(89)90234-7; MUNN DH, 1989, J EXP MED, V170, P511, DOI 10.1084/jem.170.2.511; NAKOINZ I, 1988, CELL IMMUNOL, V116, P331, DOI 10.1016/0008-8749(88)90235-3; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; OSTER W, 1987, BLOOD, V70, P1700; RAMBALDI A, 1987, BLOOD, V69, P1409; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAMPSONJOHANNES A, 1988, J IMMUNOL, V141, P3680; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SIEFF CA, 1988, BLOOD, V72, P1316; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; SUZU S, 1991, BLOOD, V77, P2160; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VELLENGA E, 1988, BLOOD, V71, P1529; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; YOON TH, 1991, J BIOCHEM, V109, P204	48	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15455	15458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379230				2022-12-25	WOS:A1992JG11300032
J	LEE, TG; TOMITA, J; HOVANESSIAN, AG; KATZE, MG				LEE, TG; TOMITA, J; HOVANESSIAN, AG; KATZE, MG			CHARACTERIZATION AND REGULATION OF THE 58,000-DALTON CELLULAR INHIBITOR OF THE INTERFERON-INDUCED, DSRNA-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ADENOVIRUS VAI RNA; MR 68,000; CELLS; INITIATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; 2-AMINOPURINE; PURIFICATION; EXPRESSION	The P68 protein kinase is a serine/threonine kinase induced by interferon treatment and activated by double-stranded RNAs (dsRNAs). Once activated, the kinase phosphorylates its natural substrate, the alpha-subunit of eukaryotic initiation factor 2 (eIF-2) leading to potential limitations in functional eIF-2 and decreases in protein synthesis initiation. We have recently purified from influenza virus-infected cells a P68 kinase inhibitor, found to be a 58-kDa cellular protein. We have now investigated the mechanisms by which the 58-kDa inhibitor regulates P68 kinase activity and how the inhibitor itself is controlled. The 58-kDa inhibitor did not function by degrading or sequestering the dsRNA activator of P68 but could repress phosphorylation of eIF-2 a by an already activated protein kinase. Utilizing antibody prepared against a 58-kDa-specific peptide, we showed that the 58-kDa proteins from infected and uninfected cells were present in equivalent amounts. Although kinase inhibitory activity could not be detected in crude uninfected cell extracts, ammonium sulfate treatment unmasked this activity and allowed purification of the cellular inhibitor with identical chromatographic properties as that from influenza virus-infected cells. Finally, we have identified and partially purified a specific inhibitor of the 58-kDa protein which we refer to as an "anti-inhibitor." Based on these data, we present a model depicting the complex regulation of the interferon-induced protein kinase in eukaryotic cells.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL SC42,SEATTLE,WA 98195; INST PASTEUR,UNITE VIROL & IMMUNOL CELLULAIRE,F-75724 PARIS 15,FRANCE	University of Washington; University of Washington Seattle; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVANESSIAN AG, 1979, EUR J BIOCHEM, V93, P515, DOI 10.1111/j.1432-1033.1979.tb12850.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1990, ENZYME, V44, P265, DOI 10.1159/000468764; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P335; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SAMUEL C, 1979, P NATL ACAD SCI USA, V76, P515; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	45	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14238	14243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378438				2022-12-25	WOS:A1992JD32500070
J	AESCHLIMANN, D; PAULSSON, M; MANN, K				AESCHLIMANN, D; PAULSSON, M; MANN, K			IDENTIFICATION OF GLN(726) IN NIDOGEN AS THE AMINE ACCEPTOR IN TRANSGLUTAMINASE-CATALYZED CROSS-LINKING OF LAMININ-NIDOGEN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FACTOR-XIIIA; YEAST PHOSPHOGLYCERATE KINASE; PIG LIVER TRANSGLUTAMINASE; BASEMENT-MEMBRANE PROTEIN; COAGULATION FACTOR-XIII; ACID-SEQUENCE; STRUCTURAL FEATURES; PROTEOLYTIC FRAGMENTS; GLUTAMINE RESIDUES; BINDING	The laminin-nidogen complex, the most abundant noncollagenous component of basement membranes, was recently shown to be a specific substrate for tissue transglutaminase (Aeschlimann, D., and Paulsson, M. (1991) J. Biol. Chem. 266, 15308-15317). Saturation experiments to determine the number of amine acceptor site(s) indicated a single reactive Gln residue in nidogen and none in laminin. Murine nidogen was labeled with [H-3]putrescine in the tissue transglutaminase-catalyzed reaction, and two major radioactively labeled fragments, T70 and T40, were isolated after limited trypsin digestion. NH2-terminal sequencing showed that T40 is contained in T70 and corresponds to the rodlike structure of nidogen, made up of epidermal growth factor-like repeats. Three radioactively labeled peptides, obtained by extensive trypsin digestion of reduced and alkylated T40, were sequenced. In all a single residue, Gln726, was found to contain label. Sequencing of additional peptides, obtained after further treatment of the largest radioactively labeled peptide with endoproteinase Asp-N, gave the same result. Gln726 is located in an exposed loop between the second and the third EGF-like repeat in nidogen. This site is also conserved in the human sequence.	MAX PLANCK INST BIOCHEM,DEPT CONNECT TISSUE RES,W-8033 MARTINSRIED,GERMANY	Max Planck Society	AESCHLIMANN, D (corresponding author), UNIV BERN,ME MULLER INST BIOMECH,POB 30,CH-3010 BERN,SWITZERLAND.		Mann, Karlheinz/C-4254-2008	Aeschlimann, Daniel/0000-0003-0930-7706				ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BIRCKBICHLER PJ, 1977, CANCER RES, V37, P1340; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; COUSSONS PJ, 1991, BIOCHEM J, V273, P73, DOI 10.1042/bj2730073; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FESUS L, 1986, EUR J BIOCHEM, V154, P371, DOI 10.1111/j.1432-1033.1986.tb09407.x; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1965, J BIOL CHEM, V240, P2951; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HOHL D, 1991, J BIOL CHEM, V266, P6626; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; NAGAYOSHI T, 1989, DNA-J MOLEC CELL BIO, V8, P581, DOI 10.1089/dna.1989.8.581; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1986, EUR J BIOCHEM, V156, P467, DOI 10.1111/j.1432-1033.1986.tb09605.x; PEREZPAYA E, 1991, FEBS LETT, V278, P51, DOI 10.1016/0014-5793(91)80081-D; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SIMON M, 1988, J BIOL CHEM, V263, P18093; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1983, EUR J BIOCHEM, V137, P455, DOI 10.1111/j.1432-1033.1983.tb07849.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; WILSON CAB, 1987, BIOCHEM J, V241, P609, DOI 10.1042/bj2410609; WU CY, 1991, J BIOL CHEM, V266, P18802	57	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11316	11321						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350783				2022-12-25	WOS:A1992HX16900060
J	REHABER, V; JAENICKE, R				REHABER, V; JAENICKE, R			STABILITY AND RECONSTITUTION OF D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM THE HYPERTHERMOPHILIC EUBACTERIUM THERMOTOGA-MARITIMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; AMINO-ACID-SEQUENCE; LACTIC-DEHYDROGENASE; PHYSICAL CONDITIONS; THERMAL-STABILITY; REACTIVATION; PROTEINS; DENATURATION; MECHANISM; DISSOCIATION	The molecular basis of thermal stability of globular proteins is a highly significant yet unsolved problem. The most promising approach to its solution is the investigation of the structure-function relationship of homologous enzymes from mesophilic and thermophilic sources. In this context, D-glyceraldehyde-3-phosphate dehydrogenase has been the most extensively studied model system. In the present study, the most thermostable homolog isolated so far is described with special emphasis on the stability of the enzyme under varying solvent conditions. D-Glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic eubacterium Thermotoga maritima is an intrinsically thermostable enzyme with a thermal transition temperature around 110-degrees-C. The amino acid sequence, electrophoresis, and sedimentation analysis prove the enzyme to be a homotetramer with a gross structure similar to its mesophilic counterparts. The enzyme in the absence and in the presence of its coenzyme, NAD+, exhibits no drastic structural differences except for a 3% change in sedimentation velocity reflecting slight alterations in the quaternary structure of the enzyme. At low temperature, in the absence of denaturants, neither "cold denaturation" nor subunit dissociation are detectable. Guanidinium chloride and pH-dependent deactivation precede the decrease in fluorescence emission and ellipticity, suggesting a complex denaturation mechanism. An up to 3-fold activation of the enzyme at low guanidinium concentration may be interpreted in terms of a compensation of the tight packing of the thermophilic enzyme at low temperature. Under destabilizing conditions, e.g. moderate concentrations of chaotropic agents, low temperature favors denaturation. The effect becomes important in reconstitution experiments after preceding guanidinium denaturation; the reactivation yield at low temperature drops to zero, whereas between 35 and 80-degrees-C reactivation exceeds 80%. Shifting the temperature from almost-equal-to 0-degrees-C to greater-than-or-equal-to 30-degrees-C releases a trapped tetrameric intermediate in a fast reaction. Concentration-dependent reactivation experiments prove renaturation of the enzyme to involve consecutive folding and association steps. Reconstitution at room temperature yields the native protein, in spite of the fact that the temperature of the processes in vitro and in vivo differ by more than 60-degrees-C.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,DEPT BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY	University of Regensburg								ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; BARTHOLMES P, 1978, EUR J BIOCHEM, V87, P563, DOI 10.1111/j.1432-1033.1978.tb12407.x; BARTHOLMES P, 1975, BIOCHEM BIOPH RES CO, V64, P485, DOI 10.1016/0006-291X(75)90347-2; CHAN WWC, 1973, J BIOL CHEM, V248, P2778; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; CONSTANTINIDES SM, 1970, J BIOL CHEM, V245, P246; DURCHSCHSLAG H, 1971, EUR J BIOCHEM, V19, P9, DOI 10.1111/j.1432-1033.1971.tb01282.x; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; HARRIS JI, 1976, ENZYMES, V13, P1; HARRIS JI, 1977, FEBS S, V49, P43; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HENSEL R, 1987, EUR J BIOCHEM, V170, P325, DOI 10.1111/j.1432-1033.1987.tb13703.x; HOCKING JD, 1980, EUR J BIOCHEM, V108, P567, DOI 10.1111/j.1432-1033.1980.tb04752.x; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JAENICKE R, 1969, EUR J BIOCHEM, V10, P158; JAENICKE R, 1981, ANNU REV BIOPHYS BIO, V10, P1, DOI 10.1146/annurev.bb.10.060181.000245; JAENICKE R, 1990, FEBS LETT, V268, P344, DOI 10.1016/0014-5793(90)81283-T; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1990, PHILOS T R SOC B, V326, P535, DOI 10.1098/rstb.1990.0030; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JAENICKE R, 1991, CIBA F SYMP, V161, P206; Jaenicke R, 1986, Methods Enzymol, V131, P218; JAENICKE R, 1980, P NATL ACAD SCI-BIOL, V77, P1966, DOI 10.1073/pnas.77.4.1966; JAENICKE R, 1990, PHIL T R SOC, V13, P326; JAENICKE R, 1992, IN PRESS ACS BIOCH; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KREBS H, 1979, EUR J BIOCHEM, V100, P359, DOI 10.1111/j.1432-1033.1979.tb04178.x; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; NOJIMA H, 1978, J MOL BIOL, V122, P33, DOI 10.1016/0022-2836(78)90106-7; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P193; RUDOLPH R, 1977, EUR J BIOCHEM, V81, P563, DOI 10.1111/j.1432-1033.1977.tb11983.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHULTES V, 1990, EUR J BIOCHEM, V192, P25, DOI 10.1111/j.1432-1033.1990.tb19190.x; STANCEL GM, 1969, BIOCHEMISTRY-US, V8, P4005, DOI 10.1021/bi00838a017; STANCEL GM, 1968, BIOCHEM BIOPH RES CO, V31, P398, DOI 10.1016/0006-291X(68)90489-0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; Von Hippel P. H., 1969, STRUCTURE STABILITY, P417; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; WRBA A, 1990, EUR J BIOCHEM, V188, P195, DOI 10.1111/j.1432-1033.1990.tb15388.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZAVODSZKY P, 1991, 15TH INT C BIOCH JER; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; ZETTLMEISSL G, 1982, EUR J BIOCHEM, V125, P605, DOI 10.1111/j.1432-1033.1982.tb06725.x	47	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10999	11006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1366231				2022-12-25	WOS:A1992HX16900014
J	TSE, CM; BRANT, SR; WALKER, MS; POUYSSEGUR, J; DONOWITZ, M				TSE, CM; BRANT, SR; WALKER, MS; POUYSSEGUR, J; DONOWITZ, M			CLONING AND SEQUENCING OF A RABBIT CDNA-ENCODING AN INTESTINAL AND KIDNEY-SPECIFIC NA+/H+ EXCHANGER ISOFORM (NHE-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; ILEAL BRUSH-BORDER; CHLORIDE TRANSPORT; MEMBRANE-VESICLES; DNA; ANTIPORTER; GLYCOPROTEIN; PROTEINS; SODIUM; RNA	We previously cloned, sequenced, and expressed two distinct mammalian Na+/H+ exchanger isoforms (NHE-1 and NHE-2). We report here the cloning of a composite cDNA which encodes a third mammalian isoform (NHE-3), which is expressed specifically in intestine and kidney. The protein deduced from the longest open reading frame of this composite sequence has 832 amino acids with a calculated M(r) of 92,747. The hydrophobicity plot of NHE-3 is very similar to that of NHE-1 and NHE-2. NHE-3 is also predicted to have 10-12 membrane-spanning domains and a long cytoplasmic domain which contains putative protein kinase phosphorylation motifs. NHE-3 exhibits overall 41% amino acid identity with NHE-1. NHE-3 is likely a glycoprotein as it has one potential N-linked glycosylation site, which is conserved in all NHEs identified. Northern blot analysis of poly(A+) RNA isolated from rabbit ileum using NHE-3 cDNA as a probe hybridized to a single 5.4-kilobase transcript. More detailed tissue distribution of message was performed by ribonuclease protection assay. It was found that NHE-3 message is only expressed in intestine and kidney, with the kidney cortex having the most abundant message, followed by intestine and kidney medulla. In intestine, ileum and ascending colon have the same amount of message, with much lesser amounts in jejunum. The message is absent from duodenum and descending colon, which lack the neutral NaCl absorptive process. Thus, NHE-3 might be involved in Na+ absorption in intestinal and renal epithelial cells.	CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205	Centre National de la Recherche Scientifique (CNRS); Johns Hopkins University	TSE, CM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIDDK NIH HHS [R01DK26523, T32DK07632, R29DK43778] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043778, T32DK007632, R01DK026523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGGERTY C, 1988, P NATL ACAD SCI USA, V88, P6797; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IGARASHI P, 1991, KIDNEY INT, V40, pS84; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; KNICKELBEIN R, 1985, AM J PHYSIOL, V249, pG236, DOI 10.1152/ajpgi.1985.249.2.G236; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8128; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T, 1989, DECONTAMINATION DILU; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER RT, 1991, J BIOL CHEM, V266, P10813; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	35	371	377	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9340	9346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374392				2022-12-25	WOS:A1992HR85400097
J	SHADEL, GS; BALDWIN, TO				SHADEL, GS; BALDWIN, TO			POSITIVE AUTOREGULATION OF THE VIBRIO-FISCHERI LUXR GENE - LUXR AND AUTOINDUCER ACTIVATE CAMP-CATABOLITE GENE ACTIVATOR PROTEIN COMPLEX-INDEPENDENT AND COMPLEX-DEPENDENT LUXR TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; BACTERIAL BIOLUMINESCENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CYCLIC-AMP; IDENTIFICATION; LUCIFERASE; REGULON; LUMINESCENCE; EXPRESSION	The LuxR protein is a transcriptional activator involved in regulation of the genes required for bioluminescence (lux) in the marine bacterium Vibrio fischeri. Transcription of the two divergently oriented lux operons (luxR and luxICDABEG) is activated by LuxR in the presence of a diffusible inducer (autoinducer). Transcription of the luxR gene is subject to both positive and negative autoregulation as well as activation by the cAMP-catabolite gene activator protein complex (cAMP-CAP). Transcription of luxR was studied using both luminescence in vivo as a reporter and primer extension analysis of mRNA synthesized in vivo. Mutation of the lux CAP-binding site resulted in a reduction in luminescence from the reporter and the complete loss of luxR positive autoregulation. Positive autoregulation was restored if luxR was provided in trans, demonstrating that LuxR and autoinducer activate luxR transcription in the absence of cAMP-CAP. By means of primer extension analysis, three sites of initiation of luxR transcription were demonstrated; initiation at two of these sites required cAMP-CAP. The quantity of all three transcripts was increased in the presence of LuxR and autoinducer when a plasmid with a wild-type CAP-binding site was used. Initiation at the cAMP-CAP-dependent sites was not observed from a plasmid with a mutated CAP-binding site in the presence or absence of autoinducer even with luxR supplied in trans. Instead, with luxR supplied in trans, initiation at the cAMP-CAP-independent initiation site was specifically stimulated by LuxR and autoinducer. Thus, in the course of positive autoregulation, the LuxR protein activates transcription from two luxR promoters by a cAMP-CAP-dependent mechanism and a third promoter by a cAMP-CAP-independent mechanism.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,CTR MACROMOLEC DESIGN,INST BIOSCI & TECHNOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [GM42428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P326, DOI 10.1002/bio.1170040145; DEVINE JH, 1988, BIOCHEMISTRY-US, V27, P837, DOI 10.1021/bi00402a052; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; DUNLAP PV, 1988, J BACTERIOL, V170, P4040, DOI 10.1128/jb.170.9.4040-4046.1988; DUNLAP PV, 1985, J BACTERIOL, V164, P45, DOI 10.1128/JB.164.1.45-50.1985; DUNLAP PV, 1989, J BACTERIOL, V171, P3549, DOI 10.1128/jb.171.6.3549-3552.1989; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455, DOI 10.1093/nar/15.24.10455; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Engebrecht J, 1986, GENET ENG, V8, P31; FRIEDRICH WF, 1983, ARCH MICROBIOL, V134, P87, DOI 10.1007/BF00407937; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P1367; Maniatis T., 1982, MOL CLONING; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; NEALSON KH, 1972, P NATL ACAD SCI USA, V69, P1073, DOI 10.1073/pnas.69.5.1073; SHADEL GS, 1991, J BACTERIOL, V173, P568, DOI 10.1128/jb.173.2.568-574.1991; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHADEL GS, 1991, THESIS TEXAS AM U CO; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; XIONG XF, 1991, J BACTERIOL, V173, P4570, DOI 10.1128/jb.173.15.4570-4577.1991	26	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7696	7702						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373136				2022-12-25	WOS:A1992HN48500071
J	WOLOSKER, H; PACHECO, AGF; DEMEIS, L				WOLOSKER, H; PACHECO, AGF; DEMEIS, L			LOCAL-ANESTHETICS INDUCE FAST CA2+ EFFLUX THROUGH A NONENERGIZED STATE OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; INDUCED CALCIUM RELEASE; SYNAPTOSOMAL PLASMA-MEMBRANE; RABBIT SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SOLVENT ACCESSIBILITY; INORGANIC-PHOSPHATE; CATALYTIC SITE; ATP SYNTHESIS; VESICLES	The effect of the local anesthetics SKF 525-A, dibucaine, tetracaine, procaine, and benzocaine on sarcoplasmic reticulum vesicles was studied. All the anesthetics tested inhibited the phosphorylation of the Ca2+-ATPase by P(i) in a competitive manner. Tertiary amine and positively charged anesthetics, in addition to competing with P(i), also decreased the apparent affinity of the ATPase for Mg2+. There was a good correlation between the octanol/water partition coefficients and the inhibitory activity of the different anesthetics. All the anesthetics tested induced a 5- to 10-fold increase in the rate of Ca2+ efflux. This was promoted by the same drug concentration that inhibited the phosphorylation of the ATPase by P(i). The effect on Ca2+ efflux was antagonized by the ligands of the ATPase (Mg2+, K+, Ca2+, MgATP, and ADP) and by the organic polyamines ruthenium red, spermine, spermidine, and putrescine. The natural anion heparin was found to potentiate the effect of the positively charged anesthetics on the rate of Ca2+ efflux. It is concluded that the local anesthetics increase the Ca2+ efflux through a nonenergized state of the Ca2+-ATPase, rather than promoting a nonspecific Ca2+ leakage through the membrane.			WOLOSKER, H (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, BR-21910 RIO DE JANEIRO, BRAZIL.		Pacheco, Antonio Guilherme/E-6378-2013	Pacheco, Antonio Guilherme/0000-0003-3095-1774; Wolosker, Herman/0000-0001-5508-9194				ALVES EW, 1986, J BIOL CHEM, V261, P6854; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; COURTNEY KR, 1980, J PHARMACOL EXP THER, V213, P114; DEBOLAND AR, 1975, J BIOL CHEM, V250, P7501; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1984, J BIOL CHEM, V259, P6090; DEMEIS L, 1982, J BIOL CHEM, V257, P4993; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1988, EUR J BIOCHEM, V171, P343; DEMEIS L, 1991, EUR J BIOCHEM, V200, P209; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P334; FROUD RJ, 1986, BIOCHEM J, V237, P207, DOI 10.1042/bj2370207; GARCIAMARTIN E, 1990, J NEUROCHEM, V55, P370, DOI 10.1111/j.1471-4159.1990.tb04147.x; GARCIAMARTIN E, 1990, J NEUROCHEM, V54, P1238, DOI 10.1111/j.1471-4159.1990.tb01954.x; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P180, DOI 10.1016/0005-2736(83)90116-5; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUTIERREZMERINO C, 1989, BIOCHEMISTRY-US, V28, P3398, DOI 10.1021/bi00434a039; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KAMINSKA AM, 1982, EXP NEUROL, V78, P331, DOI 10.1016/0014-4886(82)90051-6; KIRINO Y, 1982, J BIOCHEM-TOKYO, V92, P1287, DOI 10.1093/oxfordjournals.jbchem.a134047; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KUREBAYASHI N, 1982, J BIOCHEM-TOKYO, V92, P915, DOI 10.1093/oxfordjournals.jbchem.a134006; KURTENBACH E, 1985, J BIOL CHEM, V260, P9636; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACWHIRTER JM, 1987, BIOCHEM J, V245, P731; MARTIN DW, 1981, BIOCHEMISTRY-US, V20, P4597, DOI 10.1021/bi00519a013; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MELTZER S, 1984, J BIOL CHEM, V259, P4244; MORII H, 1983, J BIOCHEM-TOKYO, V93, P1271, DOI 10.1093/oxfordjournals.jbchem.a134261; NAGASAKI K, 1981, J BIOCHEM-TOKYO, V90, P749, DOI 10.1093/oxfordjournals.jbchem.a133529; NASHADLER P, 1980, MOL PHARMACOL, V17, P61; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; ORENTLICHER M, 1974, J GEN PHYSIOL, V63, P168, DOI 10.1085/jgp.63.2.168; PALADE P, 1987, J BIOL CHEM, V262, P6142; PALADE P, 1987, J BIOL CHEM, V262, P6149; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; PICK U, 1983, EUR J BIOCHEM, V131, P393, DOI 10.1111/j.1432-1033.1983.tb07276.x; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SUKO J, 1976, BIOCHIM BIOPHYS ACTA, V443, P571, DOI 10.1016/0005-2736(76)90474-0; VOLPE P, 1983, J BIOL CHEM, V258, P2434; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762	61	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5785	5789						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372893				2022-12-25	WOS:A1992HK31800013
J	MAUVIEL, A; KAHARI, VM; EVANS, CH; UITTO, J				MAUVIEL, A; KAHARI, VM; EVANS, CH; UITTO, J			TRANSCRIPTIONAL ACTIVATION OF FIBROBLAST COLLAGENASE GENE-EXPRESSION BY A NOVEL LYMPHOKINE, LEUKOREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; C-JUN; GLUCOCORTICOID RECEPTOR; SYNOVIAL FIBROBLASTS; TISSUE INHIBITOR; PROTEIN; DNA; PROCOLLAGENASE; INTERLEUKIN-1	Leukoregulin (LR) is a novel T-cell derived cytokine with unique anti-tumor properties. We have recently demonstrated that LR is also able to modulate the biosynthetic repertoire of normal human skin fibroblasts in culture (Mauviel, A., Redini, F., Hartmann, D. J., Pujol, J.-P., and Evans, C. H. (1991) J. Cell Biol. 113, 1455-1462). In this study, we have examined in detail the effects of LR on collagenase gene expression in human skin fibroblast cultures. The results indicated time- and dose-dependent induction of collagenase mRNA steady-state levels, the maximum elevation being approximately 35-fold. In contrast, the mRNA levels for tissue inhibitor of metalloproteases remained unchanged in the same RNA preparations. The enhancement of collagenase mRNA levels was shown to be dependent on protein synthesis, and it could be counteracted by dexamethasone or all-trans-retinoic acid. Transient transfections of cultured fibroblasts with a human collagenase promoter/reporter gene construct indicated up-regulation of the promoter activity, which could be blocked by dexamethasone and all-trans-retinoic acid. The observation suggested regulation at the transcriptional level of collagenase gene expression. LR was also shown to induce the mRNA levels for junB, suggesting possible involvement of the AP-1 complex in the regulation. The ability of LR to selectively induce collagenase gene expression in skin fibroblasts suggests that this cytokine may significantly contribute to the degradation of the extracellular matrix in physiological situations, such as tissue development and repair, and in diseases characterized by excessive degradation and turnover of collagen.	NCI,DIV CANC ETIOL,BIOL LAB,TUMOR BIOL SECT,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University			MAUVIEL, Alain/F-6251-2013; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368; Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R01-AR35297, T32-AR-0751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035297] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNETT SC, 1986, CANCER RES, V46, P2686; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHUA CC, 1990, CONNECT TISSUE RES, V25, P161, DOI 10.3109/03008209009006990; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; EVANS CH, 1987, LYMPHOKINE RES, V6, P277; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; EVANS CH, 1987, LEUKOLYSINS CANCER, P3; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRIS ED, 1989, COLLAGEN REL RES, V6, P493; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURPHY G, 1985, J BIOL CHEM, V260, P3079; NAGASE H, 1983, BIOCHEM J, V214, P281, DOI 10.1042/bj2140281; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; RANSOM JH, 1985, CANCER RES, V45, P851; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5644	5648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372007				2022-12-25	WOS:A1992HH74700096
J	XU, RX; ANTHOLINE, WE; PETERING, DH				XU, RX; ANTHOLINE, WE; PETERING, DH			REACTION OF DNA-BOUND CO(II)BLEOMYCIN WITH DIOXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND SCISSION; BLEOMYCIN; OXYGEN; ORIENTATION; SYSTEM; IRON; INTERMEDIATE; RESONANCE; COMPLEX; BINDING	The aerobic oxidation of Co(II)bleomycin bound to calf thymus DNA has been investigated in relation to the mechanism of reaction in solution in the absence of DNA. Kinetics of dioxygenation of the Co(II) complex were followed by spectrophotometric and electron spin resonance spectroscopy as well as dioxygen analysis. The reaction is slower than when carried out in solution; its rate is inversely related to the ratio of DNA base pairs to Co(II)bleomycin. The subsequent oxidation reaction, observed spectrophotometrically and by dioxygen analysis, is second order in cobalt complex. The calculated second order rate constant is also inversely related to the base pair to metal complex ratio. Once this ratio exceeds three, the reaction rate slows significantly with each additional increment of DNA added to the starting reaction mixture. Taking advantage of the high stability of O2-Co(II)bleomycin bound to greater than a 3-fold excess of DNA base pairs, it could be demonstrated that the rate constant for oxidation Of two O2-Co(II)bleomycin molecules is much slower than that for O2-Co(II)bleomycin plus Co(II)bleomycin. With the same technique it was observed that the metal centers of O2-Co(II)bleomycin and Fe(II)bleomycin also undergo oxidation. The binding to DNA of both solution products of the oxidation of Co(II)bleomycin by O2 was examined by H-1 NMR spectroscopy. Peroxy-Co(III)bleomycin, Form I, binds with higher affinity than Co(III)bleomycin, Form II. At lower ionic strength, the size of the DNA binding site for each form is about 2 base pairs/molecule of drug.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201; MED COLL WISCONSIN,NATL BIOMED ESR CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT RADIOL,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Milwaukee; Medical College of Wisconsin; Medical College of Wisconsin					NCI NIH HHS [CA-22184] Funding Source: Medline; NCRR NIH HHS [RR-01008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTINI JP, 1982, BIOCHEMISTRY-US, V21, P6777, DOI 10.1021/bi00269a025; ALBERTINI JP, 1982, BIOCHEM BIOPH RES CO, V104, P557, DOI 10.1016/0006-291X(82)90673-8; ANTHOLINE WE, 1981, P NATL ACAD SCI-BIOL, V78, P7517, DOI 10.1073/pnas.78.12.7517; ANTHOLINE WE, 1979, BIOCHEM BIOPH RES CO, V91, P528, DOI 10.1016/0006-291X(79)91554-7; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1979, J BIOL CHEM, V254, P906; BURGER RM, 1982, J BIOL CHEM, V257, P8612; BYRNES RW, 1990, CANCER RES, V50, P5275; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; CHIKIRA M, 1989, J BIOL CHEM, V264, P21478; CHIKIRA M, 1991, J BIOL CHEM, V266, P2859; CIROLO MR, 1987, J BIOL CHEM, V262, P6290; GARNIERSUILLEROT A, 1981, BIOCHEM BIOPH RES CO, V102, P499, DOI 10.1016/0006-291X(81)91547-3; KAKINUMA J, 1982, NUKLEARMED, V21, P232, DOI 10.1055/s-0037-1620585; KURAMOCHI H, 1981, J ANTIBIOT, V34, P576, DOI 10.7164/antibiotics.34.576; LEVY MJ, 1988, BIOCHEMISTRY-US, V27, P2647, DOI 10.1021/bi00408a002; NATRAJAN A, 1990, J AM CHEM SOC, V112, P3997, DOI 10.1021/ja00166a042; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; ROY SN, 1984, CANCER RES, V44, P1541; SHIELDS H, 1982, BIOCHIM BIOPHYS ACTA, V697, P113, DOI 10.1016/0167-4781(82)90051-3; SHIELDS H, 1984, BIOCHIM BIOPHYS ACTA, V800, P277, DOI 10.1016/0304-4165(84)90406-9; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIURA Y, 1980, J AM CHEM SOC, V102, P5216, DOI 10.1021/ja00536a016; SUGIURA Y, 1978, J ANTIBIOT, V31, P1310, DOI 10.7164/antibiotics.31.1310; XU RX, 1992, J BIOL CHEM, V267, P944	26	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					950	955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370471				2022-12-25	WOS:A1992GY96000044
J	WU, J; FILER, D; FRIEDHOFF, AJ; GOLDSTEIN, M				WU, J; FILER, D; FRIEDHOFF, AJ; GOLDSTEIN, M			SITE-DIRECTED MUTAGENESIS OF TYROSINE-HYDROXYLASE - ROLE OF SERINE-40 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; N-TERMINAL REGION; CELL-LINE; PHOSPHORYLATION; PURIFICATION	We have investigated the role of serine 40 (Ser-40) in tyrosine hydroxylase (TH) catalysis of basal and activated enzymes by protein kinase A (PKA)-mediated phosphorylation. Wild type and mutant TH were transiently and stably expressed in AtT-20 cells, and the enzymatic activities of the recombinant enzymes were analyzed. The specific enzymatic activity of transiently expressed TH mutants Ser-40-->leucine or --> tyrosine (Leu-40m or Tyr-40m) was higher than that of the wild type enzyme or of other mutants in which Ser-8, -19, and -31 were replaced by leucine. The kinetic studies carried out with the stably expressed TH show that the K(m) for the cofactor 6-methyltetrahydropterine is lower and the K(i) for dopamine is higher when the enzymatic hydroxylation is catalyzed by the Leu-40m or Tyr-40m than by the wild type enzyme. The kinetic parameters and the pH profile of the enzymatic hydroxylation catalyzed by the Leu-40m or Tyr-40m are similar to the enzyme activated by PKA-mediated phosphorylation. We suggest that Ser-40 in TH exerts an inhibitory influence on the enzymatic activity, and its replacement with another amino acid by site-directed mutagenesis or its modification by phosphorylation leads to a change in conformation with an increased enzymatic activity. The importance of Ser-40 in the activation of TH by PKA-mediated phosphorylation was investigated by comparing the activation of the wild type enzyme with that of Leu-40m or Tyr-40m. The findings that the enzymatic activity is increased by PKA-mediated phosphorylation of the wild type enzyme, but not of the Leu-40m or Tyr-40m, demonstrate that phosphorylation at Ser40 is essential for activation of TH by PKA. The findings that addition of ATP plus cAMP to homogenates from transfected AtT-20 cells stimulates the recombinant wild type TH activity indicate that these cells contain endogenous cAMP-dependent protein kinase.	NYU MED CTR,DEPT PSYCHIAT,MILLHAUSER LABS,NEW YORK,NY 10016; NYU MED CTR,NEUROCHEM RES LABS,NEW YORK,NY 10016	New York University; New York University	GOLDSTEIN, M (corresponding author), NYU MED CTR,DEPT PSYCHIAT,MILLHAUSER LABS,NEW YORK,NY 10016, USA.				NIMH NIH HHS [MH-43230, MH 35976] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH035976, P01MH043230] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABATE C, 1991, J MOL NEUROSCI, V2, P203; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; ANAGNOSTE B, 1974, J PHARMACOL EXP THER, V101, P370; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; DIXON M, 1964, ENZYMES, P65; GOLDSTEIN M, 1977, PSYCHOPHARMACOLOGY 3, P75; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUIDOTTI A, 1977, BIOCHEM PHARMACOL, V26, P817, DOI 10.1016/0006-2952(77)90393-8; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IWAKI M, 1986, J BIOL CHEM, V261, P2051; LEE KY, 1989, J NEUROCHEM, V53, P1238, DOI 10.1111/j.1471-4159.1989.tb07420.x; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; MITCHELL JP, 1990, J BIOL CHEM, V265, P22358; NAGATSU T, 1964, ANAL BIOCHEM, V9, P122, DOI 10.1016/0003-2697(64)90092-2; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; THOENEN H, 1974, HDB PSYCHOPHARMACOLO, V5, P443; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	23	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25754	25758						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361189				2022-12-25	WOS:A1992KD07300028
J	COHEN, D; HIGMAN, SM; HSU, SIH; HORWITZ, SB				COHEN, D; HIGMAN, SM; HSU, SIH; HORWITZ, SB			THE INVOLVEMENT OF A LINE-1 ELEMENT IN A DNA REARRANGEMENT UPSTREAM OF THE MDR1A GENE IN A TAXOL MULTIDRUG-RESISTANT MURINE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSPOSABLE ELEMENT; P-GLYCOPROTEIN PRECURSORS; J774.2 CELLS; MOUSE CELLS; AMPLIFICATION; SEQUENCES; FAMILY; LOCALIZATION; MEMBERS; OVEREXPRESSION	Two closely related but functionally distinct P-glycoprotein isoforms are encoded by the murine multidrug-resistance genes mdr1a and mdr1b. In a series of independently selected multidrug-resistant (MDR) J774.2 cell lines, mdr gene amplification and/or overexpression and overproduction of either the mdr1a or mdr1b products, or both gene products, correlates with the MDR phenotype. To investigate the possibility that mutations in the promoter regions of the mdr1a or mdr1b genes could influence their differential expression, mdr promoter-specific probes were used to detect and map potential structural alterations. An unusual structural rearrangement was found in the 5'-region of the amplified mdr1a allele in J7.T1, a cell line selected with taxol. To characterize this rearrangement, the regulatory regions of the mdr1a and mdr1b genes were analyzed. Whereas no gross structural alterations were detected by Southern blot hybridization using the mdr1b promoter probe, a novel amplified EcoRI fragment was detected by the mdr1a promoter probe. To determine the precise nature of this mutation, an mdr1a 5'-genomic clone was isolated from J7.T1 cells. Sequence analysis revealed an unusual DNA rearrangement consisting of the mdr1b gene, from its fourth intron toward its 3'-end, upstream of an intact mdr1a promoter on the amplified allele. We propose that this event occurred by an unequal sister chromatid exchange that was mediated by LINE-1 repetitive elements.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA 39821, P30 CA13330] Funding Source: Medline; NIGMS NIH HHS [2T32GM 7288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039821, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COHEN D, 1991, J BIOL CHEM, V266, P2239; DANIELS GR, 1985, NUCLEIC ACIDS RES, V13, P8939, DOI 10.1093/nar/13.24.8939; DEBATISSE M, 1988, MOL CELL BIOL, V8, P17, DOI 10.1128/MCB.8.1.17; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FURANO AV, 1986, NUCLEIC ACIDS RES, V14, P3717, DOI 10.1093/nar/14.9.3717; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HSU SIH, 1989, J BIOL CHEM, V264, P12053; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARTINSSON T, 1987, CYTOGENET CELL GENET, V45, P99, DOI 10.1159/000132437; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RONINSON IB, 1991, MOL CELLULAR BIOL MU, P189; ROY SN, 1985, CANCER RES, V45, P3856; SEHEE WR, 1989, J MOL BIOL, V205, P41; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; USDIN K, 1989, J BIOL CHEM, V264, P15681; USDIN K, 1989, J BIOL CHEM, V264, P20736; YANG CPH, 1990, J BIOL CHEM, V265, P10282; ZACK DJ, 1984, TOPICS CHEM MUTAGENE, P233; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20248	20254						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356977				2022-12-25	WOS:A1992JR85800079
J	SOLTOFF, SP; RABIN, SL; CANTLEY, LC; KAPLAN, DR				SOLTOFF, SP; RABIN, SL; CANTLEY, LC; KAPLAN, DR			NERVE GROWTH-FACTOR PROMOTES THE ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND ITS ASSOCIATION WITH THE TRK TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; PC12 PHEOCHROMOCYTOMA CELLS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; PROTOONCOGENE PRODUCT; PROTO-ONCOGENE; NGF RECEPTOR; LOW-AFFINITY; PHOSPHORYLATION; BINDING	We investigated the involvement of phosphatidylinositol 3-kinase (PtdIns 3-kinase) in the initiation of signal transduction by nerve growth factor (NGF) in the rat pheochromocytoma PC12 cell line. PtdIns 3-kinase catalyzes the formation of phosphoinositides with phosphate in the D-3 position of the inositol ring and previously has been found to associate with other activated protein tyrosine kinases, including growth factor receptor tyrosine kinases. Anti-phosphotyrosine immunoprecipitates had PtdIns 3-kinase activity that reached a maximum (9 times the basal activity) after a 5-min exposure of PC12 cells to NGF (100 ng/ml). Since NGF activates the tyrosine kinase activity of gp140trk, the protein product of the trk proto-oncogene, we also examined the association of PtdIns 3-kinase with gp140trk. Anti-gp140trk immunoprecipitates from NGF-stimulated PC12 cells had increased PtdIns 3-kinase activity compared to that of unstimulated cells, and larger increases were detected in cells overexpressing gp140trk, indicating that PtdIns 3-kinase associates with gp140trk. NGF produced large increases in [P-32]phosphatidylinositol 3,4-bisphosphate and [P-32]phosphatidylinositol 3,4,5-trisphosphate in PC12 cells labeled with [P-32]orthophosphate, indicating an increase in PtdIns 3-kinase activity in intact cells. Using an anti-85-kDa PtdIns 3-kinase subunit antibody, we found that NGF promoted the tyrosine phosphorylation of an 85-kDa protein and two proteins close to 110 kDa. These studies demonstrate that NGF activates PtdIns 3-kinase and promotes its association with gp140trk and also show that NGF promotes the tyrosine phosphorylation of the 85-kDa subunit of PtdIns 3-kinase. Thus, PtdIns 3-kinase activation appears to be involved in differentiation as well as mitogenic responses.	NCI, FREDERICK CANC RES & DEV CTR, BASIC RES PROGRAM, ADV BIOSCI LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SOLTOFF, SP (corresponding author), TUFTS UNIV, DEPT PHYSIOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM-41890, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERBST R, 1991, J BIOL CHEM, V266, P19908; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUTOH T, 1988, J BIOL CHEM, V263, P15853; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TSAO H, 1990, J BIOL CHEM, V265, P15471; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	48	224	228	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17472	17477						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380963				2022-12-25	WOS:A1992JL05300110
J	WANG, XY; UHLER, MD; BILLESTRUP, N; NORSTEDT, G; TALAMANTES, F; NIELSEN, JH; CARTERSU, C				WANG, XY; UHLER, MD; BILLESTRUP, N; NORSTEDT, G; TALAMANTES, F; NIELSEN, JH; CARTERSU, C			EVIDENCE FOR ASSOCIATION OF THE CLONED LIVER GROWTH-HORMONE RECEPTOR WITH A TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT INSULINOMA CELLS; ADIPOSE CONVERSION; PROTEIN-KINASE; IL-2 RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; METABOLISM; ADIPOCYTES; FAMILY; DNA	The ability of the cloned liver growth hormone (GH) receptor, when expressed in mammalian cell lines, to copurify with tyrosine kinase activity and be tyrosyl phosphorylated was examined. I-125-human growth hormone-GH receptor complexes isolated from COS-7 cells transiently expressing high levels of the cloned liver GH receptor bound to anti-phosphotyrosine antibody, suggesting that the cloned GH receptor is tyrosyl phosphorylated in vivo. GH-GH receptor complexes purified from transfected COS-7 cells using anti-GH antibody incorporated P-32 when incubated with [gamma-P-32]ATP, indicating association of tyrosine kinase activity with cloned liver GH receptor. The level of phosphorylation of the GH receptor was very low, as compared with the endogenous GH receptor in 3T3-F442A cells, suggesting that tyrosine kinase activity is not intrinsic to the cloned GH receptor but rather resides with a kinase present at low levels in the COS-7 cells. To test whether a higher level of GH receptor phosphorylation would be observed when the GH receptor was expressed in a different cell line, GH receptor cDNAs were stably transfected into mouse L and CHO cells, which have few or no endogenous GH receptors, and RIN5-AH cells, which do express endogenous GH receptors. In vivo tyrosyl phosphorylation of the cloned GH receptor in mouse L cells and in vitro phosphorylation of the cloned GH receptor in both L and CHO cells were higher than in transfected COS-7 cells but still substantially lower than in untransfected 3T3-F442A cells. Significantly increased P-32 incorporation into tyrosyl residues in GH receptors in the in vitro kinase assay was demonstrated for GH receptors isolated from the transfected RIN5-AH cells. These studies show that the cloned liver GH receptor can be tyrosyl phosphorylated when expressed in a variety of cell types. The finding that the level of phosphorylation of GH receptor appears to vary with cell type is consistent with the cloned liver GH receptor being a substrate for an associated tyrosine kinase and with the amount of such a GH receptor-associated tyrosine kinase being cell type-specific.	KAROLINSKA INST,CTR BIOTECHNOL,S-14152 HUDDINGE,SWEDEN; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK; UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064	Karolinska Institutet; University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute; University of California System; University of California Santa Cruz	WANG, XY (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109, USA.			Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067	NIDDK NIH HHS [DK-42361, R01 DK034171, DK-34171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042361, R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DEUTSCH PJ, 1982, J BIOL CHEM, V257, P5350; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SMITH WC, 1988, MOL ENDOCRINOL, V2, P108, DOI 10.1210/mend-2-2-108; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WINSTON LA, 1992, J BIOL CHEM, V267, P4747	27	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17390	17396						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380961				2022-12-25	WOS:A1992JL05300098
J	WELLER, A; ISENMANN, S; VESTWEBER, D				WELLER, A; ISENMANN, S; VESTWEBER, D			CLONING OF THE MOUSE ENDOTHELIAL SELECTINS - EXPRESSION OF BOTH E-SELECTIN AND P-SELECTIN IS INDUCIBLE BY TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; LEUKOCYTE ADHESION MOLECULE-1; LYMPHOCYTE HOMING RECEPTOR; WEIBEL-PALADE BODIES; CELL-ADHESION; ADULT TISSUES; NEUTROPHILS; GMP-140; PLATELETS; GENE	E-selectin (ELAM-1) and P-selectin (GMP-140, PADGEM, CD62) have both been described as human endothelial cell adhesion molecules for neutrophils and monocytes. Cell surface appearance of these two proteins on human umbilical vein endothelial cells can be regulated by different mechanisms: E-selectin is transcriptionally induced, within hours, by tumor necrosis factor-alpha (TNF-alpha) while P-selectin is transported from storage granules to the plasma membrane within minutes upon induction by various stimulating agents. We have obtained cDNA clones covering the full-length coding sequence of the homologous mouse proteins for both endothelial selectins. We show that synthesis of mouse P-selectin, like that of E-selectin, is transiently induced by TNF-alpha in several endothelioma cell lines derived from different mouse tissues. This induction was monitored on both the RNA as well as the protein level. The TNF induced, newly synthesized P-selectin protein was detected on the cell surface. Protein expression of P-selectin increased with a slightly lower rate than expression of E-selectin. In organ cultures of lung tissue from TNF-injected mice, the synthesis of P-selectin was clearly elevated compared to control mice. The bovine P-selectin homolog recognized by cross-reaction with anti-mouse P-selectin antibodies was also TNF-inducible in primary capillary endothelial cells from adrenal cortex and in aorta-derived endothelial cells. Thus, P-selectin can be regulated on two different levels. While the transport of stored P-selectin to the cell surface is controlled by regulated secretion of storage granules, the synthesis and surface expression can be induced by TNF-alpha similarly to that of E-selectin.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY	Max Planck Society			Isenmann, Stefan/AAJ-3788-2020					BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALANOS C, 1979, ZBL BAKT-INT J MED M, V243, P226; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HESSION C, 1991, J BIOL CHEM, V266, P6682; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KNAPP W, 1989, BLOOD, V74, P1448; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; ORD DC, 1990, J BIOL CHEM, V265, P7760; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH R, 1986, P NATL ACAD SCI USA, V83, P1364, DOI 10.1073/pnas.83.5.1364; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WILLIAMS RL, 1988, CELL, V52, P121	50	360	368	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15176	15183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378846				2022-12-25	WOS:A1992JF08800098
J	SOOS, MA; FIELD, CE; LAMMERS, R; ULLRICH, A; ZHANG, B; ROTH, RA; ANDERSEN, AS; KJELDSEN, T; SIDDLE, K				SOOS, MA; FIELD, CE; LAMMERS, R; ULLRICH, A; ZHANG, B; ROTH, RA; ANDERSEN, AS; KJELDSEN, T; SIDDLE, K			A PANEL OF MONOCLONAL-ANTIBODIES FOR THE TYPE-I INSULIN-LIKE GROWTH-FACTOR RECEPTOR - EPITOPE MAPPING, EFFECTS ON LIGAND-BINDING, AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; HIGH-AFFINITY BINDING; STRUCTURAL BASIS; HUMAN-PLACENTA; HYBRID RECEPTORS; KINASE-ACTIVITY; SOMATOMEDIN-C; IGF-I; CELLS; FIBROBLASTS	We obtained 20 mouse monoclonal antibodies specific for human type I insulin-like growth factor (IGF) receptors, using transfected cells expressing high levels of receptors (IGF-1R/3T3 cells) as immunogen. The antibodies immunoprecipitated receptor.I-125-IGF-I complexes and biosynthetically labeled receptors from IGF-1R/3T3 cells but did not react with human insulin receptors or rat type I IGF receptors. Several antibodies stimulated DNA synthesis in IGF-1R/3T3 cells, but the maximum stimulation was only 25% of that produced by IGF-I. The antibodies fell into seven groups recognizing distinct epitopes and with different effects on receptor function. All the antibodies reacted with the extracellular portion of the receptor, and epitopes were localized to specific domains by investigating their reaction with a series of chimeric IGF/insulin receptor constructs. Binding of IGF-I was inhibited up to 90% by antibody 24-60 reacting in the region 184-283, and by antibody 24-57 reacting in the region 440-586. IGF-I binding was stimulated up to 2.5-fold by antibodies 4-52 and 16-13 reacting in the region 62-184, and by antibody 26-3 reacting downstream of 283. The latter two groups of antibodies also dramatically stimulated insulin binding to intact IGF-1R/3T3 cells (by up to 50-fold), and potentiated insulin stimulation of DNA synthesis. Scatchard analysis indicated that in the presence of these antibodies, the affinity of the type I IGF receptor for insulin was comparable with that of the insulin receptor. These data indicate that regions both within and outside the cysteine-rich domain of the receptor alpha-subunit are important in determining the affinity and specificity of ligand binding. These antibodies promise to be valuable tools in resolving issues of IGF-I receptor heterogeneity and in studying the structure and function of classical type I receptors and insulin/IGF receptor hybrids.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; NOVO NORDISK AS,DIABET RES,DK-2880 BAGSVAERD,DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Max Planck Society; Stanford University; Novo Nordisk				Kjeldsen, Thomas/0000-0003-0094-9286	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; BURANT CF, 1987, BIOCHEM BIOPH RES CO, V147, P100, DOI 10.1016/S0006-291X(87)80092-X; CARA JF, 1988, ENDOCRINOLOGY, V123, P1341, DOI 10.1210/endo-123-3-1341; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; CONOVER CA, 1987, J CELL PHYSIOL, V133, P560, DOI 10.1002/jcp.1041330318; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DURONIO V, 1988, RECEPT BIOCH METHO B, V12, P19; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FELTZ SM, 1988, BIOCHEMISTRY-US, V27, P3234, DOI 10.1021/bi00409a017; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; FURLANETTO RW, 1987, J CLIN ENDOCR METAB, V64, P1142, DOI 10.1210/jcem-64-6-1142; Galfre G, 1981, Methods Enzymol, V73, P3; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MISRA P, 1986, J CLIN ENDOCR METAB, V63, P1400, DOI 10.1210/jcem-63-6-1400; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PANG DT, 1984, J BIOL CHEM, V259, P8589; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; SOOS MA, 1991, MODERN CONCEPTS INSU, P461; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; TOLLEFSEN SE, 1987, J BIOL CHEM, V262, P16461; TOLLEFSEN SE, 1988, J BIOL CHEM, V263, P16267; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALDBILLIG RJ, 1988, BIOCHEM BIOPH RES CO, V151, P1105, DOI 10.1016/S0006-291X(88)80480-7; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	60	107	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12955	12963						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377676				2022-12-25	WOS:A1992HZ48300084
J	LAVAN, BE; KUHNE, MR; GARNER, CW; ANDERSON, D; REEDIJK, M; PAWSON, T; LIENHARD, GE				LAVAN, BE; KUHNE, MR; GARNER, CW; ANDERSON, D; REEDIJK, M; PAWSON, T; LIENHARD, GE			THE ASSOCIATION OF INSULIN-ELICITED PHOSPHOTYROSINE PROTEINS WITH SRC HOMOLOGY-2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; RECEPTOR KINASE; PHOSPHORYLATION; PURIFICATION; 3-KINASE; BINDING	The interactions of the phosphotyrosine (Tyr(P))-containing proteins in basal and insulin-stimulated 3T3-L1 adipocytes with src homology 2 (SH2) domains from phosphatidylinositol 3-kinase (PI3K), ras GTPase-activating protein (GAP), and phospholipase C-gamma have been examined. The Tyr(P) forms of the insulin receptor and its 160-kDa substrate protein (pp160) associated with fusion proteins containing either or both the SH2 domains of PI3K, but not with fusion proteins containing the two SH2 domains of GAP or phospholipase C-gamma. These results demonstrate a specificity for the association of the Tyr(P) form of the insulin receptor and pp160 with SH2 domains that parallels the reported effects of insulin on PI3K, GAP, and phospholipase C-gamma in vivo. Immunoprecipitates of pp160 from the cytosol of insulin-treated, but not basal, 3T3-L1 adipocytes contained PI3K activity. Moreover, the Tyr(P) form of pp160 with associated PI3K activity migrated at 10 S on a sucrose velocity gradient, whereas the Tyr(P) form without associated activity migrated at 6 S. These findings indicate that the Tyr(P) form of pp160 associates directly with PI3K in vivo.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755; TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,LUBBOCK,TX 79430; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	Dartmouth College; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAY LB, 1988, J BIOL CHEM, V263, P12721; RICE KM, 1992, IN PRESS J BIOL CHEM; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SUN JX, 1991, NATURE, V352, P73	24	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11631	11636						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375946				2022-12-25	WOS:A1992HX16900106
J	MUNOZ, P; GUMA, A; CAMPS, M; FURRIOLS, M; TESTAR, X; PALACIN, M; ZORZANO, A				MUNOZ, P; GUMA, A; CAMPS, M; FURRIOLS, M; TESTAR, X; PALACIN, M; ZORZANO, A			VANADATE STIMULATES SYSTEM-A AMINO-ACID-TRANSPORT ACTIVITY IN SKELETAL-MUSCLE - EVIDENCE FOR THE INVOLVEMENT OF INTRACELLULAR-PH AS A MEDIATOR OF VANADATE ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PHOSPHOTYROSYL-PROTEIN PHOSPHATASE; NA+ ELECTROCHEMICAL GRADIENT; RECEPTOR TYROSINE KINASE; INSULIN-RECEPTOR; GLYCOGEN-SYNTHASE; GLUCOSE-METABOLISM; PLASMA-MEMBRANE; INHIBITION; ADIPOCYTES	Sodium orthovanadate caused a 2-fold stimulation of system A transport activity in soleus muscle, as assessed by the uptake of the nonmetabolizable analog 2-(methylamino)isobutyric acid (MeAIB). The effect of vanadate on system A was rapid, concentration-dependent and was characterized by an increased V(max) without modification of K(m) for MeAIB. Under these conditions, vanadate also activated 3-O-methylglucose uptake and lactate production. The effects of vanadate on muscle metabolism showed a complex interaction with the effects of insulin. Thus, the stimulatory effects of vanadate and insulin on MeAIB and 3-O-methylglucose uptake were not additive; however, the effects of insulin and vanadate on lactate production were additive. In spite of the lack of additivity, insulin- and vanadate-induced stimulation of system A differed in their sensitivity to gramicidin D, being the vanadate effect more susceptible to inhibition by gramicidin D than the insulin effect. System A transport activity shows a dependence on pH, and recent results suggest the presence of critical histidine residues on the A carrier that may be responsible for its pH dependence (Bertran, J., Roca, A., Pola, E., Testar, X., Zorzano, A. & Palacin, M. (1991) J. Biol. Chem. 266, 798-802). In this regard, a rise in extracellular pH led to a substantial activation of system A. Furthermore, lowering of muscle intracellular pH induced by ethylisopropylamiloride (EIPA), a specific inhibitor of sodium/proton exchange activity, led to inhibition of system A. This suggests that critical histidine residues are present in an intracellular localization on the A carrier. Furthermore, the rate of muscle glycolysis was also altered in response to a rise in extracellular pH or to EIPA treatment. Regarding the mechanisms involved in vanadate action, vanadate treatment in the incubated soleus muscle did not cause any significant stimulation of tyrosine kinase activity after partial purification of muscle insulin receptors. On the other hand, vanadate but not insulin caused a substantial increase in muscle intracellular pH as assessed by 5,5'-dimethyloxazolidine-2, 4-dione equilibrium. This effect of vanadate on intracellular pH was not due to activation of the sodium/proton exchanger, since it was not blocked by EIPA. Based on these findings, we suggest that alkalinization of muscle intracellular pH might mediate the effects of vanadate on system A and on glycolysis.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Palacín, Manuel/G-9786-2015; Gumà, Anna/C-5165-2017; Zorzano, Antonio/R-5479-2018; Camps, Marta/F-6557-2016	Gumà, Anna/0000-0001-9390-5252; Camps, Marta/0000-0001-5392-1792; Palacin, Manuel/0000-0002-8670-293X; Furriols, Marc/0000-0002-0656-1912				AICKIN CC, 1977, J PHYSIOL-LONDON, V267, P791; BERTRAN J, 1991, J BIOL CHEM, V266, P798; BRACY DS, 1986, J BIOL CHEM, V261, P1514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1990, ENDOCRINOLOGY, V127, P2561, DOI 10.1210/endo-127-5-2561; CANTLEY LC, 1979, J BIOL CHEM, V254, P1781; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; CASSEL D, 1984, BIOCHEM BIOPH RES CO, V118, P675, DOI 10.1016/0006-291X(84)91356-1; CHALLISS RAJ, 1987, BIOCHEM PHARMACOL, V36, P357, DOI 10.1016/0006-2952(87)90294-2; CLARK AS, 1985, BIOCHEM J, V232, P273, DOI 10.1042/bj2320273; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2360, DOI 10.1152/jappl.1987.63.6.2360; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FEHLMANN M, 1979, J BIOL CHEM, V254, P431; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; GUIDOTTI GG, 1975, BIOCHIM BIOPHYS ACTA, V406, P264, DOI 10.1016/0005-2736(75)90009-7; GUMA A, 1988, BIOCHEM J, V253, P625, DOI 10.1042/bj2530625; GUMA A, 1992, BIOCHEM J, V281, P407, DOI 10.1042/bj2810407; HAGGERTY JG, 1985, BIOCHEM BIOPH RES CO, V127, P759, DOI 10.1016/S0006-291X(85)80008-5; JAMES DE, 1986, J BIOL CHEM, V261, P4939; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KIPNIS DM, 1958, BIOCHIM BIOPHYS ACTA, V28, P226, DOI 10.1016/0006-3002(58)90466-9; KLIP A, 1986, AM J PHYSIOL, V250, pC720, DOI 10.1152/ajpcell.1986.250.5.C720; KRISTENSEN LO, 1986, BIOCHIM BIOPHYS ACTA, V855, P49, DOI 10.1016/0005-2736(86)90187-2; LECAM A, 1977, J BIOL CHEM, V252, P148; LEMARCHANDBRUSTEL Y, 1982, AM J PHYSIOL, V243, pE74, DOI 10.1152/ajpendo.1982.243.1.E74; MAIZELS EZ, 1977, BIOCHEM J, V162, P557, DOI 10.1042/bj1620557; MARONI BJ, 1990, AM J PHYSIOL, V258, pF1304, DOI 10.1152/ajprenal.1990.258.5.F1304; MARONI BJ, 1986, AM J PHYSIOL, V251, pF81, DOI 10.1152/ajprenal.1986.251.1.F81; MEYER RA, 1983, FED PROC, V42, P1248; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOORE RD, 1979, BIOCHEM BIOPH RES CO, V91, P900, DOI 10.1016/0006-291X(79)91964-8; NECHAY BR, 1984, ANNU REV PHARMACOL, V24, P501; ORZANO A, 1985, AM J PHYSIOL, V248, pE546; PAN JW, 1988, P NATL ACAD SCI USA, V85, P7836, DOI 10.1073/pnas.85.21.7836; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; SCHECHTER Y, 1990, DIABETES, V39, P1; SIPS HJ, 1980, EUR J BIOCHEM, V105, P217, DOI 10.1111/j.1432-1033.1980.tb04492.x; SPRIET LL, 1987, J APPL PHYSIOL, V62, P616, DOI 10.1152/jappl.1987.62.2.616; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VIGNE P, 1984, EMBO J, V3, P1865, DOI 10.1002/j.1460-2075.1984.tb02060.x; WADDELL WJ, 1959, J CLIN INVEST, V38, P720, DOI 10.1172/JCI103852; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21; ZORZANO A, 1986, BIOCHEM BIOPH RES CO, V134, P1342, DOI 10.1016/0006-291X(86)90397-9	53	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10381	10388						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375219				2022-12-25	WOS:A1992HV09000030
J	LU, HS; CLOGSTON, CL; NARHI, LO; MEREWETHER, LA; PEARL, WR; BOONE, TC				LU, HS; CLOGSTON, CL; NARHI, LO; MEREWETHER, LA; PEARL, WR; BOONE, TC			FOLDING AND OXIDATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR PRODUCED IN ESCHERICHIA-COLI - CHARACTERIZATION OF THE DISULFIDE-REDUCED INTERMEDIATES AND CYSTEINE -] SERINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; CHEMOTHERAPY; PROTEINS; NEUTROPENIA; CELLS	The folding and oxidation of recombinant human granulocyte colony-stimulating factor solubilized from Escherichia coli inclusion bodies was investigated. During the folding process, two intermediates, I1 and I2, were detected by kinetic studies using high performance liquid chromatography. I1 exists transiently and disappears quickly with the concomitant formation of I2. In contrast, I2 requires a longer time to fold into the final oxidized form, N. CuSO4 catalysis increases the folding rate of I2 from I2, while CuSO4 and elevated temperature (37-degrees-C) have a dramatic effect on the folding rate of N from I2. These observations suggest the following sequential oxidative folding pathway. [GRAPHICS] Peptide map analysis of the iodoacetate-labeled intermediates revealed that I1 represents the fully reduced granulocyte colony-stimulating factor containing 5 free cysteines; I2 is the partially oxidized species containing a single Cys36-Cys42 disulfide bond; and N, the final folded form, has two disulfide bonds. The physicochemical properties and biological activities of I1, I2, N, and several Cys --> Ser analogs made by site-directed mutagenesis were further investigated. In guanidine hydrochloride-induced denaturation studies, the disulfide-reduced intermediates and the analogs missing either of the disulfide bonds are conformationally less stable than those of the wild type molecule or the analog with the free Cys at position 17 changed to Ser. Recombinant human granulocyte colony stimulating factor lacking either disulfide bond or both has overall secondary and tertiary structures different from those of the wild type molecule and exhibits lower biological activity. These studies show that disulfide bond formation is crucial for maintaining the molecule in a properly folded and biologically active form.			LU, HS (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.							BERGER EG, 1982, EXPERIENTIA, V38, P1129, DOI 10.1007/BF01959725; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; CECIL R, 1959, ADV PROTEIN CHEM, V14, P255, DOI 10.1016/S0065-3233(08)60613-0; COHEN AM, 1987, P NATL ACAD SCI USA, V84, P2484, DOI 10.1073/pnas.84.8.2484; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERNANDEZDIEZ M J, 1964, Arch Biochem Biophys, V107, P449; FHELIS C, 1982, PROTEIN FOLDING; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LU HS, 1989, ARCH BIOCHEM BIOPHYS, V268, P81, DOI 10.1016/0003-9861(89)90567-5; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; METCALF D, 1984, HEMOPOIETIC COLONIES; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; NARHI LO, 1991, J PROTEIN CHEM, V10, P359, DOI 10.1007/BF01025250; OHEDA M, 1988, J BIOCHEM-TOKYO, V103, P544, DOI 10.1093/oxfordjournals.jbchem.a122305; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; SOUZA LM, 1989, Patent No. 4810643; TAKAGI T, 1963, BIOCHEM BIOPH RES CO, V13, P353, DOI 10.1016/0006-291X(63)90347-4; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TSUCHIYA M, 1986, P NATL ACAD SCI USA, V83, P7633, DOI 10.1073/pnas.83.20.7633; YUTANI K, 1968, J BIOCHEM-TOKYO, V64, P449, DOI 10.1093/oxfordjournals.jbchem.a128916; ZSEBO KM, 1986, IMMUNOBIOLOGY, V172, P175, DOI 10.1016/S0171-2985(86)80097-3	28	85	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8770	8777						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374379				2022-12-25	WOS:A1992HR85400013
J	GAVINI, N; PULAKAT, L				GAVINI, N; PULAKAT, L			THE TRANSFER-RNA SPECIES FOR REDUNDANT GENETIC CODONS NNU AND NNC - A THOUGHT ON THE ABSENCE OF PHENYLALANINE TRANSFER-RNA WITH AAA ANTICODON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; IDENTITY; USAGE; PHER	The redundant genetic codons NNU and NNC (where N is A, T, G, or C) specify the same amino acid and are decoded by their cognate tRNAs, which contain either a guanosine or a modified base in the wobble position of the anticodons. Since tRNAs with an adenosine in the wobble position of the anticodon, which are complementary to the NNU codons, are not found naturally, we have generated a tRNA(Phe), with AAA anticodon and examined how an adenosine in the wobble position would affect its biological function in Escherichia coli. We found that the tRNA(Phe) with GAA anticodon (wild-type) repressed the expression of the pheA gene via tRNA(Phe)-mediated attenuation of transcription, whereas the tRNA(Phe) with AAA anticodon did not influence the expression of the pheA gene. Furthermore, elevated levels of tRNA(Phe) (AAA) did not support the growth of an E. coli strain carrying a temperature-sensitive mutation in the pheS gene at 42-degrees-C. Since the presence of a multicopy plasmid carrying the gene that encodes tRNA(Phe)(GAA), a substrate for phenylalanyl tRNA synthetase, enables the E. coli strain carrying the pheS(Ts) mutation to grow at 42-degrees-C, the above observation suggests that unlike tRNA(Phe)(GAA), tRNA(Phe)(AAA) is not a good substrate for phenylalanyl-tRNA synthetase. Therefore, we postulate that the presence of adenosine at the wobble position of anticodons was specifically eliminated and the tRNAs with guanosine or a modified base in the wobble position were selected to decode both NNU and NNC codons in E. coli.			GAVINI, N (corresponding author), UNIV CALIF IRVINE,SCH BIOL SCI,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.							BARE L, 1985, BIOCHEMISTRY-US, V24, P2354, DOI 10.1021/bi00330a034; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAILLET J, 1985, NUCLEIC ACIDS RES, V13, P3699, DOI 10.1093/nar/13.10.3699; FITCH WM, 1976, SCIENCE, V194, P1173, DOI 10.1126/science.996548; GAVINI N, 1990, J BIOL CHEM, V265, P21527; GAVINI N, 1991, J GEN MICROBIOL, V137, P679, DOI 10.1099/00221287-137-3-679; GAVINI N, 1990, J BIOL CHEM, V265, P21532; GAVINI N, 1991, J BIOL CHEM, V266, P7750; GAVINI N, 1991, J BACTERIOL, V173, P4904, DOI 10.1128/jb.173.15.4904-4907.1991; GAVINI N, 1988, THESIS U MELBOURNE A; GOWRISHANKAR J, 1982, J BACTERIOL, V152, P1; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GRUMBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, V2, P1386; HOU YM, 1989, TRENDS BIOCHEM SCI, V14, P233, DOI 10.1016/0968-0004(89)90033-9; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; KNOWLTON RG, 1980, J MOL BIOL, V139, P705, DOI 10.1016/0022-2836(80)90056-X; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LANDICK R, 1987, ESCHERICHIA COLI SAL, V2, P1453; Maniatis T., 1982, MOL CLONING; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miller J.H., 1972, EXPT MOL GENETICS; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; PITTARD J, 1990, J BACTERIOL, V172, P6077, DOI 10.1128/jb.172.10.6077-6083.1990; RUSSELL RRB, 1971, J BACTERIOL, V107, P736, DOI 10.1128/JB.107.3.736-740.1971; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHWARTZ I, 1983, NUCLEIC ACIDS RES, V11, P4379, DOI 10.1093/nar/11.13.4379; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WILSON RK, 1986, NUCLEIC ACIDS RES, V14, P5937, DOI 10.1093/nar/14.14.5937; YARUS M, 1977, NUCLEIC ACID PROTEIN, pPP391; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P4271, DOI 10.1073/pnas.75.9.4271	34	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2240	2243						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370814				2022-12-25	WOS:A1992HB53200021
J	MCGEOCH, JEM; GUIDOTTI, G				MCGEOCH, JEM; GUIDOTTI, G			AN INSULIN-STIMULATED CATION CHANNEL IN SKELETAL-MUSCLE - INHIBITION BY CALCIUM CAUSES OSCILLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SOLEUS MUSCLE; NA-K TRANSPORT; GLUCOSE-TRANSPORT; CAMP PHOSPHODIESTERASE; KINASE-ACTIVITY; (NA+,K+)-ADENOSINE TRIPHOSPHATASE; FUNCTIONAL EXPRESSION; IONIC SELECTIVITY; ACTIVATED CHANNEL; SODIUM-CHANNELS	A cation channel has been identified in the plasma membrane of skeletal muscle that oscillates open and closed in a regular manner. In an experimental system of patch-clamped reconstituted plasma membrane in phospholipid bilayers, the oscillations are calcium-dependent and constitute regular closing events due to inhibition of the channel by calcium with a K(i) of 2.2 +/-1 x 10(-6) M, followed by reopening. There are 3.7 +/- 1 calcium binding sites/channel. With sodium as the current vehicle, conductance is increased by voltage, insulin (K(m) = 5 +/- 0.6 x 10(-9) M), and hydrolyzable guanine nucleotides. Cyclic GMP alone will increase the conductance with a K(m) of 3.7 +/- 0.6 x 10(-7) M. In the absence of calcium, the unitary conductance with insulin + GTP or cGMP at 150 mm NaCl is 153 picosiemens. Sodium current is insensitive to 10(-5) M tetrodotoxin but inhibited by mu-conotoxin (K(i) = 5 x 10(-8) M). These findings in the reconstituted system were verified in patch-clamped whole muscle cells where an insulin and cGMP-dependent sodium current inhibited by mu-conotoxin could be demonstrated. In the whole cell experiments, slow calcium-dependent oscillations of the sodium current were also detected.			MCGEOCH, JEM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; BAKER PF, 1983, J PHYSIOL-LONDON, V336, P397, DOI 10.1113/jphysiol.1983.sp014588; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Briggs AP, 1924, J BIOL CHEM, V58, P721; BRODSKY JL, 1990, J BIOL CHEM, V265, P10458; CERVETTO L, 1988, J PHYSIOL-LONDON, V406, P181, DOI 10.1113/jphysiol.1988.sp017375; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CIARALDI TP, 1989, BIOCHEM J, V264, P389, DOI 10.1042/bj2640389; CLAUSEN T, 1987, AM J PHYSIOL, V252, pE492, DOI 10.1152/ajpendo.1987.252.4.E492; CLAUSEN T, 1977, J PHYSIOL-LONDON, V265, P19, DOI 10.1113/jphysiol.1977.sp011703; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P415, DOI 10.1113/jphysiol.1977.sp011959; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMANI S, 1984, BIOCHIM BIOPHYS ACTA, V804, P77; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; FLATMAN JA, 1979, NATURE, V281, P580, DOI 10.1038/281580a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUIDOTTI G, 1990, CHEMTRACTS BIOCH MOL, V1, P447; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; HSU YM, 1991, J BIOL CHEM, V266, P427; ILLIANO G, 1973, P NATL ACAD SCI USA, V70, P2443, DOI 10.1073/pnas.70.8.2443; KAO I, 1975, SCIENCE, V188, P740, DOI 10.1126/science.1124397; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KONO T, 1983, RECENT PROG HORM RES, V39, P519; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEVITAN IB, 1986, ION CHANNEL RECONSTI, P528; LYTTON J, 1985, J BIOL CHEM, V260, P1177; LYTTON J, 1985, J BIOL CHEM, V260, P75; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MONTROLL EW, 1982, P NATL ACAD SCI USA, V79, P3380, DOI 10.1073/pnas.79.10.3380; MOORE RD, 1981, BIOPHYS J, V33, P203, DOI 10.1016/S0006-3495(81)84881-3; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NORGAARD A, 1981, NATURE, V293, P739, DOI 10.1038/293739a0; OFFERIJNS FGJ, 1958, J PHYSIOL-LONDON, V141, P377, DOI 10.1113/jphysiol.1958.sp005981; OTSUKA M, 1970, AM J PHYSIOL, V219, P1178, DOI 10.1152/ajplegacy.1970.219.5.1178; PATTON C, 1990, MAX CHELATOR SOFTWAR; RAFAELOFF R, 1990, DIABETES, V39, pA11; RESH MD, 1980, J BIOL CHEM, V255, P938; RESH MD, 1982, J BIOL CHEM, V257, P1946; ROBINSON FW, 1989, J BIOL CHEM, V264, P16458; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSIC NK, 1985, J BIOL CHEM, V260, P6206; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHANAHAN MF, 1989, ENDOCRINOLOGY, V125, P1074, DOI 10.1210/endo-125-2-1074; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TSIEN RY, 1989, METHOD ENZYMOL, V172, P256; UEDA M, 1984, J BIOL CHEM, V259, P9520; VYDELINGUM N, 1978, HORM METAB RES, V10, P38, DOI 10.1055/s-0028-1093478; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	65	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					832	841						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370468				2022-12-25	WOS:A1992GY96000026
J	WOHLFART, P; HAASE, W; MOLDAY, RS; COOK, NJ				WOHLFART, P; HAASE, W; MOLDAY, RS; COOK, NJ			ANTIBODIES AGAINST SYNTHETIC PEPTIDES USED TO DETERMINE THE TOPOLOGY AND SITE OF GLYCOSYLATION OF THE CGMP-GATED CHANNEL FROM BOVINE ROD PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; PLASMA-MEMBRANE; OUTER SEGMENT; FUNCTIONAL RECONSTITUTION; CATION CHANNEL; SODIUM-CHANNEL; CONDUCTANCE; PROTEIN; LOCALIZATION; BINDING	Peptides corresponding to amino acids 321-339 (peptide GS21) and 416-431 (peptide GS31) of the cGMP-gated channel from bovine rod photoreceptors were synthesized and used as antigens for the preparation of polyclonal antibodies. After affinity purification, both antipeptide antibodies were found to bind specifically to the channel protein after Western blotting, but only the antibody against GS21 gave satisfactory results on enzyme-linked immunosorbent assay and electron microscopy. Using immunocytochemistry, we were able to localize amino acids 321-339 to the extracellular side of the rod photoreceptor plasma membrane. By synthesizing heptapeptides corresponding to amino acids 324-330 (peptide GS2s) and 420-426 (peptide GS3s), we were able to affinity purify antibodies specific for two N-glycosylation consensus sites in the channel protein. As assessed by Western blotting, antibodies against GS3s were found to bind to both the glycosylated and deglycosylated channel proteins, whereas antibodies against GS2s only bound to the channel protein after enzymatic deglycosylation. Together, these results allow the refinement of folding models for the cGMP-gated channel and implicate Asn-327 as being the sole site of N-glycosylation.	MAX PLANCK INST BIOPHYS,MOLEK MEMBRANBIOL ABT,HEINRICH HOFFMANN STR 7,W-6000 FRANKFURT 71,GERMANY; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	Max Planck Society; University of British Columbia					NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COOK NJ, 1986, J BIOL CHEM, V261, P7033; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAASE W, 1990, J NEUROSCI, V10, P1486; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					644	648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370452				2022-12-25	WOS:A1992GY43900099
J	HIZI, A; SHAHARABANY, M				HIZI, A; SHAHARABANY, M			FUNCTIONAL-ANALYSIS OF NOVEL SELECTIVE MUTANTS OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-POLYMERASE; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; H ACTIVITIES; RIBONUCLEASE; MUTAGENESIS; EXPRESSION; DOMAIN; PREDICTIONS	We have generated by site-directed mutagenesis plasmids that induce the synthesis of specific mutants of the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). These recombinant mutants of HIV-1 RT, designed on the basis of our previous studies of HIV-1 and HIV-2 RTs, were analyzed for structure-function relationship by assessing their RNA-dependent and DNA-dependent DNA polymerase as well as the ribonuclease H activities. Three groups of mutants were studied. 1) We have investigated the importance of the only two sets of highly conserved double prolines found in the sequence of HIV-1 RT. The results indicate that the conversion of either one or both prolines (at positions 225 and 226) to threonines have no significant effect on all catalytic activities of the enzyme. The mutants in which prolines 419 and 420 were individually modified to threonines exhibit full activities, whereas the double proline 419/420 mutant lost most of its RNase H activity (although the DNA polymerase function was fully retained). 2) We have deleted phenylalanine 346 from HIV-1 RT, which is absent in wild type HIV-2 RT. This mutant of HIV-1 RT lost practically all catalytic activities. 3) A mutant of HIV-1 RT in which a cysteine residue substituted for alanine 446, was found to be slightly hyperactive for both DNA polymerase and RNase H activities.			HIZI, A (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1992, J BIOL CHEM, V267, P1293; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MULLER B, 1991, J BIOL CHEM, V266, P14709; MYERS G, 1991, HUMAN RETROVIRUSES A; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHAHARABANY M, 1991, AIDS RES HUM RETROV, V7, P883, DOI 10.1089/aid.1991.7.883; SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1989, MOBILE DNA, P53; Weiss R, 1985, RNA TUMOR VIRUSES	23	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18255	18258						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382052				2022-12-25	WOS:A1992JN50200002
J	FARSETTI, A; DESVERGNE, B; HALLENBECK, P; ROBBINS, J; NIKODEM, VM				FARSETTI, A; DESVERGNE, B; HALLENBECK, P; ROBBINS, J; NIKODEM, VM			CHARACTERIZATION OF MYELIN BASIC-PROTEIN THYROID-HORMONE RESPONSE ELEMENT AND ITS FUNCTION IN THE CONTEXT OF NATIVE AND HETEROLOGOUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIC ENZYME GENE; RETINOIC-ACID; NUCLEAR RECEPTORS; BINDING; TRANSCRIPTION; EXPRESSION; CELLS; BRAIN	In this report we have characterized further the myelin basic protein (MBP) gene thyroid hormone response element (TRE) by functional and binding analysis. Mutation and deletion experiments revealed that this TRE, confined to the sequences -184 to -167 of the MBP promoter, is able to function as a classical regulatory element in the context of the native and a heterologous promoter. it is comprised of two regions, containing a motif that is highly conserved among other TREs: AGGACA, arranged as an inverted palindrome. Any mutation within the footprinted region impaired receptor binding and function. Moreover, the deletion of sequences outside of the receptor footprinted region (MBP-TRE-18) resulted in a higher triiodothyronine responsiveness and a concomitant increase in receptor-dependent, hormone-independent repression. Results of transfection assays showed that both receptors alpha and beta-elicit indistinguishable triiodothyronine responses when the MBP-TRE functions as a regulator of a heterologous promoter activity. However, a preferential beta-receptor transactivation was observed when the MBP-TRE was placed in the context of its native promoter.	NIDDKD,GENET & BIOCHEM BRANCH,BLDG 10,RM 8N317,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Farsetti, Antonella/I-8710-2018; Desvergne, Beatrice/C-8892-2016	Farsetti, Antonella/0000-0002-8603-7925; Desvergne, Beatrice/0000-0001-5483-288X				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARBARESE E, 1978, J NEUROCHEM, V31, P779, DOI 10.1111/j.1471-4159.1978.tb00110.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P342; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	32	148	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15784	15788						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379237				2022-12-25	WOS:A1992JG11300080
J	VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE				VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE			CLONING AND STRUCTURAL-ANALYSIS OF THE HUMAN C-KIT GENE	ONCOGENE			English	Article								The recent identification of the mouse White spotting and Steel loci as genes encoding the c-kit receptor and its ligand, respectively, has shed light on the importance of this ligand and receptor in embryogenesis, melanogenesis and hematopoiesis. In order to determine if the c-kit proto-oncogene is involved in human disease, we isolated seven overlapping lambda recombinants, using a fetal brain cDNA, and characterized the normal human gene (KIT). The longest mapped transcript is 5230 bp, is alternatively spliced and includes 21 exons that span more than 70 kb of DNA. From the exon-intron structure, we have localized an alternative splice site to the 3' end of exon 9. The overall c-kit gene structure closely resembles that found in the CSF-1R gene (c-fms). This similarity includes a large first intron, the same number of exons containing translated sequence and very similar exon-intron boundaries. Using pulsed-field gel electrophoresis, we have linked KIT to the platelet-derived growth factor receptor A gene, with both residing on a 700-kb BssHI fragment. These data will allow investigation into the control of KIT expression and the potential to identify mutations or altered expression of this gene in human disease.	DUKE UNIV, MED CTR, DEPT NEUROSCI, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University	VANDENBARK, GR (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, BOX 3167, DURHAM, NC 27710 USA.			Kaufman, Russell/0000-0003-4612-4861	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38699] Funding Source: Medline; PHS HHS [H102643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDRE C, 1989, ONCOGENE, V4, P1047; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1986, SCIENCE, V232, P65; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMPE A, 1989, ONCOGENE RES, V4, P9; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGURA M, 1985, BLOOD, V66, P1384; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHERR CJ, 1990, BLOOD, V75, P1; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULICH TR, 1991, BLOOD, V78, P645; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; [No title captured]; [No title captured]	55	99	111	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377810				2022-12-25	WOS:A1992HZ97100002
J	RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS				RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS			COFACTOR RESIDUES LYSINE-165 AND LYSINE-166 ARE CRITICAL FOR PROTEIN SUBSTRATE RECOGNITION BY THE TISSUE FACTOR-FACTOR-VIIA PROTEASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THROMBOMODULIN; HOMOLOGY DOMAIN; FACTOR PATHWAY; COAGULATION; ACTIVATION; BINDING; THROMBIN; SITE	High affinity binding of factor VIIa (VIIa) to its cellular receptor tissue factor (TF), as well as association of factor X with phospholipid are required for optimal assembly of the extrinsic activation complex. In addition to the interactions of substrate with phospholipid and enzyme, we here provide evidence that cofactor residues Lys-165 and Lys-166 specifically contribute to the recognition of macromolecular substrate. Ala for Lys replacement in TF(A165A166) Was compatible with high affinity binding of VIIa when analyzed on cell surfaces as well as in the absence of phospholipid. Dissociation of TF(A165A166). VIIa did not occur with a faster rate compared to TF . VIIa, further supporting unaltered VIIa binding function of TF(A165A166). Cleavage of chromogenic peptidyl substrate by TF(A165A166)-VIIa complexes was not diminished, demonstrating that TF(A165A166) supported enhancement of catalytic function of the VIIa protease domain. In contrast, factor X activation was reduced in the presence and absence of phospholipid. Further, TF(A165A166) effectively competed with wild-type TF in the cleavage of factor X at limited VIIa concentrations. Selective reduction in macromolecular substrate hydrolysis combined with normal VIIa binding by TF(A165A166) indicates that the cofactor TF does contribute, either directly or indirectly via specific interactions with VIIa, to factor X recognition.			RUF, W (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; FAIR DS, 1987, J BIOL CHEM, V262, P11692; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; KUMAR A, 1991, J BIOL CHEM, V266, P915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MANN KG, 1990, BLOOD, V76, P1; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1989, OXFORD SURVEYS EUKAR, P67; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROY S, 1991, J BIOL CHEM, V266, P4665; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; SAKAI T, 1990, J BIOL CHEM, V265, P1890; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	32	105	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6375	6381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372908				2022-12-25	WOS:A1992HK31800097
J	HIROSE, S; MOHNEY, RP; MUTKA, SC; RAVI, L; SINGLETON, DR; PERRY, G; TARTAKOFF, AM; MEDOF, ME				HIROSE, S; MOHNEY, RP; MUTKA, SC; RAVI, L; SINGLETON, DR; PERRY, G; TARTAKOFF, AM; MEDOF, ME			DERIVATION AND CHARACTERIZATION OF GLYCOINOSITOL-PHOSPHOLIPID ANCHOR-DEFECTIVE HUMAN K562 CELL CLONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; HUMAN-ERYTHROCYTES; MEMBRANE-PROTEIN; REACTIVE LYSIS; COMPLEMENT; BIOSYNTHESIS; DEFICIENT; MOLECULES	To aid in studies of human glycoinositol-phospholipid (GPI) anchor pathway biochemistry in normal and affected paroxysmal nocturnal hemoglobinuria cells, GPI anchor-defective human K562 cell lines were derived by negative fluorescent sorting of anti-decay-accelerating factor (DAF) monoclonal antibody-stained cells either following or in the absence of ethylmethylsulfonate pretreatment. The resulting cloned cells showed deficiencies of both DAF and GPI-anchored CD59, some (designated group A) exhibiting total absence and some (designated group B) exhibiting approximately 10% levels of surface expression of the two proteins. In heterologous cell fusions, group A clones complemented defective Thy-1 expression by class A, B, C, E, and I Thy-1-negative lymphoma lines, but not H or D lines, the latter of which is defective in the Thy-1 structural gene. In contrast, group B clones complemented all previously described GPI anchor pathway-defective lymphoma classes. Immunoradiomatic assays of cells and supernatants and S-35 biosynthetic labeling showed that group A cells degraded DAF protein while group B cells secreted it but failed to attach a GPI anchor structure. [H-3]Man labeling of intact cells and UDP-[H-3]GlcNAc and GDP-[H-3]Man labeling of broken cell preparations demonstrated that group A cells failed to synthesize GlcNAc- and GlcN-PI (GPI-A and -B) as well as more polar mannolipids, whereas group B cells showed accumulation of GlcNAc-PI with approximately 10-fold diminished levels of GlcN-PI and more polar mannolipids. The failed assembly of GlcNAc-PI in group A cells and the reduced conversion of this intermediate to GlcN-PI in group B cells indicates that the former harbors a defect in UDP-GIcNAc transferase or in assembly of its PI acceptor, while the latter harbors a defect in GlcN-PI deacetylase activity.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University			Perry, George/A-8611-2009	Perry, George/0000-0002-6547-0172; Mutka, Sarah/0000-0002-9744-8439; Singleton, David/0000-0002-6154-6774	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAROTHERS DJ, 1990, J CLIN INVEST, V85, P47, DOI 10.1172/JCI114432; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GROUX H, 1989, J IMMUNOL, V142, P3013; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1991, FASEB J, V5, P2459; HIROSE S, 1990, J CELL BIOL, V3, P1094; HOLGUIN MH, 1989, J CLIN INVEST, V84, P1387, DOI 10.1172/JCI114311; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; MEDOF ME, 1987, J CLIN INVEST, V80, P165, DOI 10.1172/JCI113043; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1989, BIOCHEM SOC T, V16, P996; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; OKADA N, 1989, J IMMUNOL, V143, P2262; ROSSE WF, 1990, ANNU REV MED, V41, P431; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TARTAKOFF A, 1990, MOL CELL BIOL MEMBRA, P111	35	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5272	5278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371997				2022-12-25	WOS:A1992HH74700044
J	HARADA, N; OGAWA, H; SHOZU, M; YAMADA, K; SUHARA, K; NISHIDA, E; TAKAGI, Y				HARADA, N; OGAWA, H; SHOZU, M; YAMADA, K; SUHARA, K; NISHIDA, E; TAKAGI, Y			BIOCHEMICAL AND MOLECULAR GENETIC ANALYSES ON PLACENTAL AROMATASE (P-450AROM) DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING HUMAN AROMATASE; CYTOCHROME-P-450; ANDROSTENEDIONE; AROMATIZATION; PURIFICATION; MICROSOMES; EXPRESSION; PROTEINS; TISSUE; MOUSE	Biochemical and molecular genetic studies were made on a case of placental aromatase (P-450AROM) deficiency. Of the enzymes participating in the electron transport system of placental microsomes, only aromatase activity was decreased specifically in the patient, being less than 0.3% of the normal activity. Northern and Western blotting analyses showed that the transcription of the aromatase gene and the translation of its mRNA proceeded normally in the placenta of this patient. However, aromatase cDNA isolated from a placental cDNA library of the patient was found to have an insert of 87 base pairs, encoding 29 amino acids in frame with no termination codon. The insert was located at the splicing point between exon 6 and intron 6 of the normal aromatase gene, and the extra DNA fragment was the first part of intron 6, except that its initial GT was altered to GC. These findings indicated that in this patient with aromatase deficiency, splicing between exon 6 and intron 6 did not occur at the normal position because of a point mutation in its consensus sequence and was forwarded to GT in the next cryptic consensus sequence 87 base pairs downstream according to the canonical GT/AG rule, resulting in translation of an abnormal protein molecule with 29 extra amino acids. During the transient expression in COS-7 cells, the aromatase cDNA of the patient was found to produce a protein with a trace of activity. This is the first report of a genetic defect for aromatase deficiency.	KANAZAWA UNIV,SCH MED,DEPT OBSTET & GYNECOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,FAC SCI,DEPT CHEM,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University	HARADA, N (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,DIV MOLEC GENET,TOYOAKE,AICHI 47011,JAPAN.							CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; COVEY DF, 1988, BIOCHEM BIOPH RES CO, V157, P81, DOI 10.1016/S0006-291X(88)80014-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HARADA N, 1988, J BIOCHEM-TOKYO, V103, P106, DOI 10.1093/oxfordjournals.jbchem.a122213; HARADA N, 1984, J BIOL CHEM, V259, P1265; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; KEENAN BS, 1974, J CLIN ENDOCR METAB, V38, P1143, DOI 10.1210/jcem-38-6-1143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGCOPE C, 1978, J CLIN ENDOCR METAB, V46, P146, DOI 10.1210/jcem-46-1-146; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MANGO D, 1978, EUR J OBSTET GYN R B, V8, P65, DOI 10.1016/0028-2243(78)90129-6; Maniatis T., 1982, MOL CLONING; MEANS GD, 1989, J BIOL CHEM, V264, P19385; Miller JH., 1972, EXPT MOL GENETICS; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; RYAN KJ, 1972, AM J OBSTET GYNECOL, V114, P454, DOI 10.1016/0002-9378(72)90204-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER AE, 1972, J CLIN ENDOCR METAB, V35, P627, DOI 10.1210/jcem-35-4-627; SCHWEIKERT HU, 1975, J CLIN ENDOCR METAB, V40, P413, DOI 10.1210/jcem-40-3-413; SETHUMADHAVAN K, 1991, MOL CELL ENDOCRINOL, V78, P25, DOI 10.1016/0303-7207(91)90182-R; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; [No title captured]	31	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4781	4785						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371509				2022-12-25	WOS:A1992HF64200075
J	BURNS, DL; KESSEL, M; ARCINIEGA, JL; KARPAS, A; GOULDKOSTKA, J				BURNS, DL; KESSEL, M; ARCINIEGA, JL; KARPAS, A; GOULDKOSTKA, J			IMMUNOCHEMICAL LOCALIZATION OF A REGION OF CHAPERONIN-60 IMPORTANT FOR PRODUCTIVE INTERACTION WITH CHAPERONIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; PROTEIN; GROE; PURIFICATION; ATP	An IgG, monoclonal antibody (mAb 54G8) which binds to both Bordetella pertussis chaperonin-60 (cpn60) and Escherichia coli cpn60 (GroEL) was produced. mAb 54G8 as well as Fab fragments prepared from this antibody were found to abolish the ability of chaperonin-10 (cpn10, GroES) to inhibit the ATPase activity of both B. pertussis cpn60 and E. coli cpn60. Electron microscopy was used to localize the binding site of the monoclonal antibody on the B. pertussis cpn60 molecule. In the absence of the antibody, the B. pertussis molecule exhibited the tetradecameric structure typical of cpn60. Both end views (showing 7-fold symmetry of the face of the molecule) and side views were evident. When mAb 54G8 was bound, B. pertussis cpn60 molecules appeared to be cross-linked so that they formed long chains. Only side views of the molecules were seen in these long chains. When B. pertussis cpn60 complexed with Fab fragments of mAb 54G8 was examined, chains were no longer observed. Instead, side views of B. pertussis cpn60 were often seen with Fab fragments extending from the ends of the molecule. These data indicate that mAb 54G8 appears to bind at or near the end of the B. pertussis cpn60 molecule and that binding of mAb 54G8 at this location affects the ability of cpn10 to productively interact with cpn60, most likely either by sterically blocking the binding of cpn10, by affecting the conformation of cpn60 in such a way that it no longer binds cpn10, or by inhibiting proper transduction of the effects of cpn10 binding.	UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park	BURNS, DL (corresponding author), US FDA,DIV BACTERIAL PROD,CBER,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURNS DL, 1991, INFECT IMMUN, V59, P1417, DOI 10.1128/IAI.59.4.1417-1422.1991; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; ROUSE DA, 1990, INFECT IMMUN, V58, P1445, DOI 10.1128/IAI.58.5.1445-1449.1990; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	21	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25632	25635						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361184				2022-12-25	WOS:A1992KD07300004
J	KOBAYASHI, S; HIGASHI, N; SUZUKI, K; GOTO, S; YUMOTO, K; ANZAI, K				KOBAYASHI, S; HIGASHI, N; SUZUKI, K; GOTO, S; YUMOTO, K; ANZAI, K			THE 10-S BC-1 RIBONUCLEOPROTEIN PARTICLE CONTAINS IDENTIFIER SEQUENCE-BINDING PROTEINS THAT INTERACT WITH AN ARRAY OF GCAAG/CTTGC MOTIFS BETWEEN SPLIT PROMOTER SEQUENCES FOR RNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL BC1 RNA; TRANSCRIPTION FACTOR; 5S RNA; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; MESSENGER-RNA; BRAIN; ELEMENTS; REPEAT; CDNA	BC-1 RNA is a brain-specific small RNA transcript of identifier sequences present in the somas and dendrites of neurons. We recently reported that the RNA is complexed with a protein(s) to form a 10 S ribonucleoprotein particle (Kobayashi, S., Goto, S., and Anzai, K. (1991) J. Biol. Chem. 266, 4726-4730). We demonstrate here that this 10 S BC-1 ribonucleoprotein particle contains a DNA-binding protein(s) (Bp-1 protein) capable of interacting with a region between split promoter sequences for RNA polymerase III within the identifier sequences. The region has short inverted repeats: a perfect octanucleotide repeat (GCGCTTGCCTAGCAAGCGC) and an imperfect heptanucleotide repeat (GCCTAGCAAGCGCAAGGC), each of which contains a GCAAG/CTTGC motif. We also demonstrate that the binding of this protein either to the array of pentamer motifs or to BC-1 RNA is mutually exclusive. The molecular masses of photo-cross-linking adducts of Bp-1 protein to a P-32-labeled GCAAG/CTTGC motif-specific probe were estimated to be about 31 and 36 kDa, indicating that two species of Bp-1 proteins may be present in the brain.	NIHON UNIV,COLL PHARM,DIV BIOCHEM,FUNABASHI,CHIBA 274,JAPAN; TOHO UNIV,SCH PHARMACEUT SCI,DEPT BIOCHEM,MIYAMA,JAPAN	Nihon University; Toho University								ANZAI K, 1987, MECH AGEING DEV, V39, P129, DOI 10.1016/0047-6374(87)90004-2; ANZAI K, 1986, J NEUROCHEM, V47, P673; ANZAI K, 1988, MOL BRAIN RES, V4, P273, DOI 10.1016/0169-328X(88)90036-8; ANZAI K, 1987, MOL BRAIN RES, V2, P43, DOI 10.1016/0169-328X(87)90019-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1987, CURRENT PROTOCOL MOL; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DECHIARA TM, 1987, P NATL ACAD SCI USA, V84, P2624, DOI 10.1073/pnas.84.9.2624; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FUNG WP, 1988, J BIOL CHEM, V263, P480; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KOBAYASHI S, 1991, J BIOL CHEM, V266, P4726; LAWRENCE CB, 1985, NUCLEIC ACIDS RES, V13, P4239, DOI 10.1093/nar/13.12.4239; LIAO XB, 1989, P NATL ACAD SCI USA, V86, P4137, DOI 10.1073/pnas.86.11.4137; Maniatis T, 1989, DECONTAMINATION DILU; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; SAKAMOTO K, 1985, J MOL EVOL, V22, P134, DOI 10.1007/BF02101691; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPIENZA C, 1986, NATURE, V319, P418, DOI 10.1038/319418a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; SUTCLIFFE JG, 1982, P NATL ACAD SCI-BIOL, V79, P4942, DOI 10.1073/pnas.79.16.4942; SUTCLIFFE JG, 1984, NATURE, V308, P237, DOI 10.1038/308237a0; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0	43	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18291	18297						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382053				2022-12-25	WOS:A1992JN50200010
J	LEVY, H; GOKHMAN, I; ZAMIR, A				LEVY, H; GOKHMAN, I; ZAMIR, A			REGULATION AND LIGHT-HARVESTING COMPLEX-II ASSOCIATION OF A DUNALIELLA PROTEIN HOMOLOGOUS TO EARLY LIGHT-INDUCED PROTEINS IN HIGHER-PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTOLERANT ALGA DUNALIELLA; BETA-CAROTENE ACCUMULATION; PHOTOSYSTEM-II; BARDAWIL; BIOSYNTHESIS; SYSTEM; GENE; EXPRESSION	The unicellular green alga Dunaliella bardawil responds to high light, nutrient deprivation, and several other types of stress by massive accumulation of beta-carotene. We have previously cloned a nuclear gene, cbr, that is co-induced with accelerated carotenogenesis. The predicted product of cbr is closely related to early light-induced proteins (Elips) of higher plants, and also shows resemblance to chlorophyll a/b-binding proteins. In the present study, the determination of the cbr transcription start site supported the previously proposed site of translation initiation. Antibodies raised against a synthetic oligopeptide matching the predicted sequence of Cbr recognized two polypeptides of apparently 17 and 19 kDa that were induced in parallel to cbr transcript accumulation in highly illuminated or sulfate-starved D. bardawil cells. The antibodies also cross-reacted with an approximately 20-kDa polypeptide in sulfate-starved Dunaliella salina. In both D. bardawil and D. salina, Cbr was found exclusively in the thylakoid membranes. After mild solubilization, Cbr co-fractionated with light-harvesting complex II (LHCII) in sucrose gradient centrifugation and gel electrophoresis and was specifically associated with a minor LHCII complex. An occasionally observed, faster mobility Cbr form, free of LHCII, was probably released from the larger complex. These results support the conclusion that Cbr belongs to a class of stress-induced proteins transiently associated with antennae complexes.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALLEN KD, 1991, ANAL BIOCHEM, V194, P214, DOI 10.1016/0003-2697(91)90170-X; BENAMOTZ A, 1981, TRENDS BIOCHEM SCI, V6, P297, DOI 10.1016/0968-0004(81)90106-7; BENAMOTZ A, 1983, PLANT PHYSIOL, V72, P593, DOI 10.1104/pp.72.3.593; BERMAN J, 1985, J BIOL CHEM, V260, P5240; BRAMLEY PM, 1988, CURR TOP CELL REGUL, V29, P291; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREEN BR, 1988, PHOTOSYNTH RES, V15, P3, DOI 10.1007/BF00054985; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V167, P493, DOI 10.1111/j.1432-1033.1987.tb13364.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P75; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; LERS A, 1990, PLANT PHYSIOL, V93, P389, DOI 10.1104/pp.93.2.389; LERS A, 1989, MOL GEN GENET, V216, P138, DOI 10.1007/BF00332242; LIVEANU V, 1986, J BIOL CHEM, V261, P5296; Maxam A M, 1980, Methods Enzymol, V65, P499; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICK U, 1987, PLANT PHYSIOL, V85, P194, DOI 10.1104/pp.85.1.194; SHAISH A, 1991, J PHYCOL, V27, P652, DOI 10.1111/j.0022-3646.1991.00652.x; YOUNG A, 1990, STRESS RESPONSES PLA, P87	25	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18831	18836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382063				2022-12-25	WOS:A1992JN50200088
J	FACKLER, MJ; CIVIN, CI; MAY, WS				FACKLER, MJ; CIVIN, CI; MAY, WS			UP-REGULATION OF SURFACE CD34 IS ASSOCIATED WITH PROTEIN-KINASE C-MEDIATED HYPERPHOSPHORYLATION OF CD34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGENITOR CELLS; ANTIGENIC ANALYSIS; PHORBOL ESTER; BONE-MARROW; PHOSPHORYLATION; RECEPTOR; ANTIBODY; INTERNALIZATION; IDENTIFICATION; HEMATOPOIESIS	CD34 is a transmembrane sialoglycoprotein expressed by early hematopoietic progenitor cells as well as endothelial cells. Previously we found that CD34 is rapidly and stoichiometrically phosphorylated by activated protein kinase C (PKC) (Fackler, M. J., Civin, C. I., Sutherland, D. R., Baker, M. A., and May, W. S. (1990) J. Biol. Chem. 265, 11056-11061). In the present study, we find dose-dependent up-regulation of CD34 surface expression following treatment of normal human CD34+ bone marrow progenitor cells, cord blood-derived KMT-2, or KG1a myeloid leukemia cells with the PKC activator 12-O-tetradecanoylphorbol-13-acetate. Up-regulation begins within 1 min of treatment, is maximal by 30 min, is maintained for at least 3 h, and is associated with CD34 hyperphosphorylation. A specific inhibitor of PKC, 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexan-amide (NPC 15437), blocks both up-regulation and hyperphosphorylation of CD34. CD34 up-regulation is independent of transcription and/or translation and results from the recruitment of preformed intracellular CD34. The endocytosis rate of surface CD34 is unaltered by 12-O-tetradecanoylphorbol-13-acetate. Thus, activation of PKC mediates increased surface expression of the CD34 molecule possibly as a result of phosphorylation of CD34.	JOHNS HOPKINS ONCOL CTR, 424 N BOND ST, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R01CA047993, R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA47993, CA44649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHM JL, 1981, BLOOD, V58, P1119; ANDREWS RG, 1986, BLOOD, V67, P842; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; CHATILA TA, 1988, J IMMUNOL, V140, P4308; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Civin C. L., 1989, LEUKOCYTE TYPING, P818; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CIVIN CI, 1990, PROG CLIN BIOL RES, V333, P387; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; FACKLER MJ, 1990, J BIOL CHEM, V265, P11056; FERRERO D, 1983, BLOOD, V61, P171; FINA L, 1990, BLOOD, V75, P2417; KATAYAMA N, 1989, BLOOD, V73, P123; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MAY WS, 1987, J BIOL CHEM, V262, P16710; MERRILL JT, 1990, J IMMUNOL, V145, P2608; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SHOJI M, 1987, CANCER RES, V47, P6363; SIMMONS DL, 1992, J IMMUNOL, V148, P267; STEVENS DA, 1991, J BIOL CHEM, V266, P4151; STRAUSS LC, 1991, AM J PEDIAT HEMATOL, V13, P217; SULLIVAN JP, 1991, FEBS LETT, V285, P120, DOI 10.1016/0014-5793(91)80739-P; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAMURA S, 1990, BLOOD, V76, P501; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	32	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17540	17546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381351				2022-12-25	WOS:A1992JM22300013
J	GRASSL, SM				GRASSL, SM			HUMAN PLACENTAL BRUSH-BORDER MEMBRANE NA+-BIOTIN COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL CORTEX; VESICLES; TRANSPORT; KIDNEY	Membrane transport pathways for transplacental transfer of the water-soluble vitamin biotin were investigated by assessing the possible presence of a Na+-biotin cotransport mechanism in the maternal-facing membrane of human placental epithelial cells. The presence of Na+-biotin cotransport was determined from radiolabeled tracer flux measurements of biotin uptake using preparations of purified brush-border membrane vesicles. The imposition of an inwardly directed Na+ gradient stimulated vesicle uptake of biotin to levels approximately 25-fold greater than those observed at equilibrium. The voltage sensitivity of Na+ gradient-driven biotin uptake suggested Na+-biotin cotransport is electrogenic occurring with net transfer of positive charge. A kinetic analysis of the activation of biotin uptake by increasing Na+ was most consistent with an interaction of Na+ at 2 sites in the transport protein. Static head determinations used to identify the magnitude of opposing driving forces bringing flux through the cotransport mechanism to equilibrium indicated a coupling ratio of 2 Na+ per biotin. Substrate specificity studies using chemical analogues of biotin suggested both the terminal carboxylic acid of the valeric acid side chain and a second nucleus of anionic charge were important determinants for substrate interaction with the cotransport protein. Initial rate determinations of biotin uptake indicate biotin interacts with a single saturable site (K(m) = 21-mu-M) with a maximal transport rate of 4.5 nmol/mg/min. The results of this study provide evidence for an electrogenic Na+-biotin cotransport mechanism in the maternal-facing membrane of human placental epithelial cells.			GRASSL, SM (corresponding author), SUNY SYRACUSE,HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210, USA.				NIDDK NIH HHS [DK37907] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK037907] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1981, AM J PHYSIOL, V240, pF1, DOI 10.1152/ajprenal.1981.240.1.F1; BAUR B, 1990, AM J PHYSIOL, V258, pF840, DOI 10.1152/ajprenal.1990.258.4.F840; BOWERS GN, 1966, CLIN CHEM, V12, P70; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; GRASSL SM, 1989, J BIOL CHEM, V264, P11103; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; JORGENSEN PL, 1968, BIOCHIM BIOPHYS ACTA, V151, P212, DOI 10.1016/0005-2744(68)90176-9; KELLY LK, 1987, AM J PHYSIOL, V252, pC38; Machlin, 1991, HDB VITAMINS; OGIN C, 1989, BIOCHIM BIOPHYS ACTA, V980, P248, DOI 10.1016/0005-2736(89)90406-9; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PODEVIN RA, 1986, BIOCHIM BIOPHYS ACTA, V856, P471, DOI 10.1016/0005-2736(86)90138-0; SAID HM, 1987, AM J PHYSIOL, V253, pG631, DOI 10.1152/ajpgi.1987.253.5.G631; SAID HM, 1991, AM J PHYSIOL, V261, pR94, DOI 10.1152/ajpregu.1991.261.1.R94; SAID HM, 1988, BIOCHIM BIOPHYS ACTA, V945, P195, DOI 10.1016/0005-2736(88)90482-8; Segel I. H., 1975, ENZYME KINETICS, P360; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SPENCER PD, 1988, BIOCHEM MED METAB B, V40, P95, DOI 10.1016/0885-4505(88)90109-0; TRUMAN P, 1984, BIOCHIM BIOPHYS ACTA, V779, P129; TURNER RJ, 1983, J MEMBRANE BIOL, V76, P1, DOI 10.1007/BF01871450; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; WALLACH DFH, 1966, METHOD ENZYMOL, V8, P165; WATANABE T, 1990, TERATOLOGY, V42, P295, DOI 10.1002/tera.1420420313	24	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17760	17765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381353				2022-12-25	WOS:A1992JM22300046
J	BARGON, J; TRAPNELL, BC; YOSHIMURA, K; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				BARGON, J; TRAPNELL, BC; YOSHIMURA, K; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE CAN BE REGULATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; EPITHELIAL-CELLS; MESSENGER-RNA; NONSENSE MUTATIONS; AIRWAY EPITHELIA; XENOPUS OOCYTES; PHORBOL ESTER; CAMP; IDENTIFICATION; CALCIUM	Epithelial cells utilize at least two types of apical Cl- channels, the cAMP-activated cystic fibrosis transmembrane conductance regulator (CFTR) and the Ca2+/calmodulin-dependent Cl- channel. While phorbol ester (PMA) activates only CFTR-dependent Cl- secretion and the Ca2+ ionophore A23187 only the Ca2+/calmodulin-dependent Cl- secretion, PMA and A23187 share the ability to down-regulate expression of the CFTR gene at the transcriptional level. Since both PMA and A23187 can activate protein kinases, we hypothesized that protein kinase pathways may be involved in the regulation of CFTR gene expression. Exposure of HT-29 human colon carcinoma cells to the protein kinase C activator SC9 down-regulated CFTR mRNA levels in a dose-dependent fashion, similar to that seen with PMA. The reduction in CFTR transcript levels by SC9 and PMA was blocked by H7, an inhibitor of protein kinases. In a similar fashion, the down-regulation of CFTR transcript levels by A23187 was blocked by H7 as well as staurosporine, another protein kinase inhibitor. Interestingly, both H7 and staurosporine themselves increased CFTR mRNA levels. Quantification of CFTR gene transcription rate showed a reduction by SC9 (similar to that with PMA and A23187) that was prevented by H7 and that H7 by itself increased CFTR transcription. Together, these observations suggest that protein kinase pathways, likely including protein kinase C, are involved in the regulation of CFTR gene expression, with activation or inhibition of protein kinase activity down-regulating or up-regulating CFTR gene expression, respectively.	NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA; TRANSGENE SA, F-67082 STRASBOURG, FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Transgene SA								ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BLUMBERG PM, 1988, CANCER RES, V48, P1; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CUPPENS H, 1990, J MED GENET, V27, P717, DOI 10.1136/jmg.27.11.717; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG K-P, 1990, Biofactors, V2, P171; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ITO M, 1986, BIOCHEMISTRY-US, V25, P4179, DOI 10.1021/bi00363a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; NISHINO H, 1986, BIOCHIM BIOPHYS ACTA, V889, P236, DOI 10.1016/0167-4889(86)90109-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHUTTE J, 1988, P NATL ACAD SCI USA, V85, P2257; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TIEMEIER DC, 1977, GENE, V2, P173, DOI 10.1016/0378-1119(77)90016-6; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1990, FASEB J, V4, P2717; WHITE FL, 1987, J FUTURES MARKETS, V7, P109, DOI 10.1002/fut.3990070111; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	52	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16056	16060						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379589				2022-12-25	WOS:A1992JJ45800013
J	ARMENDARIZBORUNDA, J; KATAYAMA, K; SEYER, JM				ARMENDARIZBORUNDA, J; KATAYAMA, K; SEYER, JM			TRANSCRIPTIONAL MECHANISMS OF TYPE-I COLLAGEN GENE-EXPRESSION ARE DIFFERENTIALLY REGULATED BY INTERLEUKIN-1-BETA, TUMOR-NECROSIS-FACTOR-ALPHA, AND TRANSFORMING GROWTH-FACTOR-BETA IN ITO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; EXPERIMENTAL HEPATIC-FIBROSIS; ALCOHOLIC LIVER-DISEASE; VITAMIN-A; DISSE SPACE; FIBROBLASTS; MATRIX; RAT; RESPONSIVENESS; FACTOR-BETA-1	Regulation of the procollagen type I (Pro-alpha-1) gene in cultured Ito cells by diverse cytokines was studied. Specifically, we have examined the effect of interleukin-1-beta (IL-1-beta), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta) on collagen biosynthesis, levels of Pro-alpha-1(I) mRNA, and rate of transcription of Pro-alpha-1(I) gene. TGF-beta stimulated procollagen synthesis at least 2-fold at every concentration tested (5-20 ng/ml), whereas TNF-alpha inhibited it at the same concentrations. In contrast to what occurs in dermal fibroblasts, IL-1-beta (5-20 units/ml) preferentially inhibited procollagen production as measured by [H-3]proline incorporation. A similar pattern was obtained when total protein synthesis was analyzed by [25S]methionine radiolabeling. Interestingly, while TGF-beta-treated cells exhibited greater than 3-fold increase in steady-state levels of Pro-alpha-1(I) mRNA, the treatment with IL-1 had no effect on procollagen mRNA levels. TNF-alpha treatment resulted in a 2-fold decrease in the amount of collagen mRNA. The treatment with combinations of cytokines indicated that collagen gene expression in Ito cells is differentially regulated by these cytokines. Furthermore, nuclear run-off transcription experiments were performed. The results obtained suggest that TGF-beta regulates increasing collagen type I gene expression at transcriptional levels, and TNF-alpha inhibits the transcriptional rate of Pro-alpha-1 (I) gene. It is noteworthy that IL-1-beta acts on collagen type I gene regulation by a separate mechanism at a posttranscriptional level.	ASAHIKAWA RED CROSS HOSP,DEPT ORTHOPED,HOKKAIDO 070,JAPAN; VET AFFAIRS MED CTR,RES SERV,MEMPHIS,TN 38014; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center	ARMENDARIZBORUNDA, J (corresponding author), UNIV TENNESSEE,DEPT MED,MEMPHIS,TN 38103, USA.		Armendáriz-Borunda, Juan/AAU-1471-2021		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM016505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039166, R01AR026034] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM16505] Funding Source: Medline; NIAMS NIH HHS [AR39166, AR26034] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; ARMENDARIZBORUNDA J, 1989, MATRIX, V9, P150, DOI 10.1016/S0934-8832(89)80034-4; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1990, SEMIN LIVER DIS, V10, P1; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P1233; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENWEL P, 1991, LAB INVEST, V65, P644; KENT G, 1976, P NATL ACAD SCI USA, V73, P3719, DOI 10.1073/pnas.73.10.3719; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZHERNANDEZ A, 1991, HEPATOLOGY, V14, P864, DOI 10.1002/hep.1840140519; MATSUOKA M, 1989, LIVER, V9, P71; MINATO Y, 1983, HEPATOLOGY, V3, P559; NAKAGAWA S, 1989, EXP CELL RES, V182, P572, DOI 10.1016/0014-4827(89)90260-7; OHYAMA K, 1990, J LAB CLIN MED, V116, P219; ORREGO H, 1979, GUT, V20, P673, DOI 10.1136/gut.20.8.673; PIQUET PF, 1989, 2ND P INT C TUM NECR, P63; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; RAGHOW R, 1987, J BIOL CHEM, V262, P8409; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; SCHAFFNER F, 1963, GASTROENTEROLOGY, V44, P239; SENOO H, 1985, LAB INVEST, V52, P182; SHIRATORI Y, 1987, DIGEST DIS SCI, V32, P1281, DOI 10.1007/BF01296379; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAKASE S, 1988, J HEPATOL, V6, P267, DOI 10.1016/S0168-8278(88)80042-4; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; YOKOI Y, 1988, LIVER, V8, P48; [No title captured]	36	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14316	14321						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352775				2022-12-25	WOS:A1992JD32500081
J	FERLINI, A; FINI, S; SALVI, F; PATROSSO, MC; VEZZONI, P; FORABOSCO, A				FERLINI, A; FINI, S; SALVI, F; PATROSSO, MC; VEZZONI, P; FORABOSCO, A			MOLECULAR STRATEGIES IN GENETIC DIAGNOSIS OF TRANSTHYRETIN-RELATED HEREDITARY AMYLOIDOSIS	FASEB JOURNAL			English	Article						TRANSTHYRETIN GENE; HEREDITARY AMYLOIDOSIS; RG-PCR SEQUENCE ANALYSIS	PRE-ALBUMIN; DNA	Transthyretin-related hereditary (TTR) amyloidoses represent a clinically heterogeneous group of diseases associated with various point mutations of the TTR gene. We propose a molecular strategy for the diagnosis of this group of disorders.	BELLARIA HOSP, DEPT NEUROL, BOLOGNA, ITALY; CNR, IST TECNOL BIOMED AVANZATE, I-20133 MILAN, ITALY	AUSL di Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	FERLINI, A (corresponding author), UNIV MODENA, IST ANAT UMANA NORMALE, CATTEDRA ISTOL & EMBRIOL GEN, POLICLIN VIA POZZO 71, I-41100 MODENA, ITALY.		Vezzoni, Paolo/R-3416-2019; Salvi, Fabrizio/AAC-1956-2020; Vezzoni, Paolo/K-3197-2018	FERLINI, ALESSANDRA/0000-0001-8385-9870; Vezzoni, Paolo/0000-0002-6382-3923	Telethon [146] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMEIDA MR, 1991, AMYLOID AMYLOIDOSIS, P559; ALMEIDA MR, 1992, IN PRESS HUMAN MUTAT; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BENSON MD, 1991, J MED GENET, V28, P73, DOI 10.1136/jmg.28.2.73; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; COSTA PP, 1978, P NATL ACAD SCI USA, V75, P4499, DOI 10.1073/pnas.75.9.4499; FERLINI A, 1991, CYTOGENET CELL GENET, V55, P2026; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; II S, 1991, NEUROLOGY, V41, P893, DOI 10.1212/WNL.41.6.893; JONES LA, 1991, AM J HUM GENET, V48, P979; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; SARAIVA MJM, 1991, AM J HUM GENET, V48, P1004	12	38	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2864	2866		10.1096/fasebj.6.10.1353040	http://dx.doi.org/10.1096/fasebj.6.10.1353040			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1353040				2022-12-25	WOS:A1992JD95400017
J	WERTHEIMER, SJ; MYERS, CL; WALLACE, RW; PARKS, TP				WERTHEIMER, SJ; MYERS, CL; WALLACE, RW; PARKS, TP			INTERCELLULAR-ADHESION MOLECULE-1 GENE-EXPRESSION IN HUMAN ENDOTHELIAL-CELLS - DIFFERENTIAL REGULATION BY TUMOR-NECROSIS-FACTOR-ALPHA AND PHORBOL-MYRISTATE ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MESSENGER-RNA; TRANSENDOTHELIAL MIGRATION; INTERFERON-GAMMA; ICAM-1; LFA-1; ACTIVATION; IDENTIFICATION; ADHERENCE; SEQUENCE	Intercellular adhesion molecule-1 (ICAM-1) is an inducible glycoprotein expressed on the surface of inflamed endothelium which mediates in part the extravasation of granulocytes into sites of infection or injury. ICAM-1 mRNA is not detected in unstimulated human umbilical vein endothelial cells (HUVECs), but accumulates transiently following tumor necrosis factor-alpha (TNF-alpha) or phorbol myristate acetate (PMA) treatment with maximal steady state levels occurring at 2 or 4 h, respectively. Pretreating HUVECs with PMA for 72 h down-regulates protein kinase C and inhibits the subsequent induction of ICAM-1 mRNA by PMA, but does not affect TNF-alpha-induced message accumulation. Nuclear run-on assays showed that the ICAM-1 gene is transcribed under basal conditions in HUVECs, and that TNF-alpha stimulates transcriptional activity 3- to 4-fold within 30 min of treatment. In contrast, PMA has little effect on ICAM-1 gene transcription up to 4 h following stimulation. Message stability studies established that ICAM-1 mRNA induced by PMA has a longer half-life than the TNF-alpha-induced message. These results suggest that PMA acts through protein kinase C to up-regulate ICAM-1 expression primarily at a post-transcriptional level by stabilizing ICAM-1 mRNA, whereas TNF-alpha transcriptionally regulates ICAM-1 gene expression through an undefined, protein kinase C-independent pathway.			WERTHEIMER, SJ (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT BIOCHEM,RIDGEFIELD,CT 06877, USA.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTON RW, 1989, J IMMUNOL, V143, P1278; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; COSIMI AB, 1990, J IMMUNOL, V144, P4604; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9722; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLAVIN T, 1991, TRANSPLANT P, V23, P533; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARLAN JM, 1985, BLOOD, V65, P513; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNRO JM, 1989, AM J PATHOL, V135, P121; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; POBER JS, 1987, J IMMUNOL, V138, P3319; POBER JS, 1986, J IMMUNOL, V137, P1893; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4282; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YAMOTO K, 1989, J CELL PHYSL, V139, P610	54	257	258	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12030	12035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351055				2022-12-25	WOS:A1992HY94700059
J	PARK, S; MARSHALL, MS; GIBBS, JB; JOVE, R				PARK, S; MARSHALL, MS; GIBBS, JB; JOVE, R			RECONSTITUTION OF INTERACTIONS BETWEEN THE SRC TYROSINE KINASES AND RAS GTPASE-ACTIVATING PROTEIN USING A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; SARCOMA-VIRUS; GROWTH-FACTOR; P21 GTPASE; GAP; BINDING; PHOSPHORYLATION; TRANSFORMATION; PP60C-SRC; ONCOGENE	Ras GTPase-activating protein (GAP) has been implicated in mitogenic signal transduction downstream of oncogenic and receptor tyrosine kinases. Previous studies have suggested that GAP is phosphorylated by oncogenic viral Src (v-Src) and that GAP is associated with a complex containing normal cellular Src (c-Src) in vertebrate fibroblasts. To investigate molecular interactions between the Src kinases and GAP, we developed an in vitro system for reconstituting Src-GAP complexes. For this purpose, we constructed recombinant baculovirus vectors that direct expression of Rous sarcoma virus v-Src, chicken c-Src, and bovine GAP in infected Sf9 insect cells. In vitro reconstitution experiments using baculovirus-expressed proteins demonstrate that both v-Src and c-Src associate in complexes with GAP. In addition, in vitro and in vivo phosphorylation analyses indicate that GAP serves as a substrate for both the v-Src and c-Src tyrosine kinases. To determine which structural features of GAP are involved in interactions with the Src kinases, we constructed recombinant baculoviruses that encode deletion mutants of bovine GAP. Deletion of the GAP amino-terminal portion containing Src homology 2 regions, which are highly conserved structural motifs postulated to mediate interactions among proteins, diminishes GAP phosphorylation and association with Src. This reconstitution system should facilitate further studies of molecular interactions between the Src kinases and GAP.	UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, 6606 MED SCI 2, ANN ARBOR, MI 48109 USA; INDIANA UNIV, MED CTR, DEPT MED, HEMATOL ONCOL SECT, INDIANAPOLIS, IN 46202 USA; MERCK SHARP & DOHME LTD, DEPT CANC RES, W POINT, PA 19486 USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company				Park, Soochul/0000-0002-7029-3414	NCI NIH HHS [CA47809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1990, ADP RIBOSYLATING TOX, P381; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1988, CURRENT PROTOCOLS MO, pCH16; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUDOL M, 1992, IN PRESS MOL BASIS H; SUMMERS MD, 1988, MANUAL METHODS BACUL; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	51	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11612	11618						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375945				2022-12-25	WOS:A1992HX16900103
J	SALUJA, AK; DAWRA, RK; LERCH, MM; STEER, ML				SALUJA, AK; DAWRA, RK; LERCH, MM; STEER, ML			CCK-JMV-180, AN ANALOG OF CHOLECYSTOKININ, RELEASES INTRACELLULAR CALCIUM FROM AN INOSITOL TRISPHOSPHATE-INDEPENDENT POOL IN RAT PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; AMYLASE SECRETION; EXOCRINE PANCREAS; ENZYME-SECRETION; NEOMYCIN; BINDING; CA-2+; PHOSPHATES; RECEPTORS; INVITRO	In pancreatic acinar cells cholecystokinin and its analogs, caerulein and CCK-JMV-180, stimulate an increase in intracellular free [Ca2+] by releasing Ca2+ from non-mitochondrial intracellular pools. It is generally believed that the caerulein-induced release of Ca2+ is mediated by phospholipase C-catalyzed production of 1,4,5-inositol trisphosphate (IP3). In this study we have investigated the source and mechanism of Ca2+ release induced by CCK-JMV-180 using streptolysin O-permeabilized pancreatic acinar cells. Caerulein-stimulated release of Ca2+ was completely blocked by either neomycin, an inhibitor of phospholipase C, or by heparin, an IP3 receptor antagonist. These observations are compatible with the conclusion that caerulein releases Ca2+ from an IP3-sensitive pool. In contrast to caerulein, however, CCK-JMV-180-stimulated release of Ca2+ was not blocked by either neomycin or by heparin, indicating that CCK-JMV-180 releases Ca2+ by mechanisms which do not involve the generation or action of IP3. CCK-JMV-180 stimulated the release of Ca2+ even after the IP3-sensitive pool had been completely emptied by prior exposure to a supramaximally stimulating concentration of IP3 (40-mu-M). Prestimulation of permeabilized acini with 20 mM caffeine did not abolish the CCK-JMV-180-induced Ca2+ release. These results indicate that CCK-JMV-180 stimulates release of Ca2+ from a hitherto uncharacterized intracellular storage pool which is insensitive to either IP3 or caffeine.	BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, HARVARD DIGEST DIS CTR, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263	PHS HHS [31396] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADOR E, 1963, CLIN CHEM, V9, P391; BERRIDGE MJ, 1988, PHOSPHOINOSITIDES RE, P25; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUZZONE R, 1990, GASTROENTEROLOGY, V99, P1157, DOI 10.1016/0016-5085(90)90640-M; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LIGNON MF, 1987, GASTRIN CHOLECYSTOKI, P57; MARCHE P, 1983, J PHARMACOL EXP THER, V227, P415; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; OHSHIO G, 1989, PANCREAS, V4, P739, DOI 10.1097/00006676-198912000-00013; ORSULAKOVA A, 1976, J NEUROCHEM, V26, P285, DOI 10.1111/j.1471-4159.1976.tb04478.x; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PIERRE KJ, 1976, CLIN CHEM, V22, P1219; POWERS RE, 1985, BIOCHEM BIOPH RES CO, V131, P284, DOI 10.1016/0006-291X(85)91800-5; POWERS RE, 1986, J CLIN INVEST, V77, P1668, DOI 10.1172/JCI112484; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; PUTNEY JW, 1983, BIOCHEM J, V212, P483, DOI 10.1042/bj2120483; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; RUBIN RP, 1984, BIOCHEM J, V219, P655, DOI 10.1042/bj2190655; SALUJA A, 1986, AM J PHYSIOL, V250, pC413, DOI 10.1152/ajpcell.1986.250.3.C413; SALUJA AK, 1989, P NATL ACAD SCI USA, V86, P8968, DOI 10.1073/pnas.86.22.8968; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SANKARAN H, 1982, AM J PHYSIOL, V242, pG250, DOI 10.1152/ajpgi.1982.242.3.G250; SANKARAN H, 1980, J BIOL CHEM, V255, P1849; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091	34	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11202	11207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375937				2022-12-25	WOS:A1992HX16900044
J	HERRIN, DL; BATTEY, JF; GREER, K; SCHMIDT, GW				HERRIN, DL; BATTEY, JF; GREER, K; SCHMIDT, GW			REGULATION OF CHLOROPHYLL APOPROTEIN EXPRESSION AND ACCUMULATION - REQUIREMENTS FOR CAROTENOIDS AND CHLOROPHYLL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-B-PROTEIN; RIBULOSE BISPHOSPHATE CARBOXYLASE; ACTIVE PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; MESSENGER-RNA; CROSSED IMMUNOELECTROPHORESIS; DODECYL-SULFATE; CELL-CYCLE; LIGHT; MUTANT	Chlorophyll apoprotein accumulation and expression were examined in mutants of Chlamydomonas reinhardtii blocked at specific steps of carotenoid or chlorophyll synthesis. In the absence of carotenoids: 1) apoproteins of the core and light-harvesting complexes of photosystem I (CCI and LHCI, respectively) and photosystem II (CCII and LHCII, respectively) do not accumulate; 2) mRNAs for the CCI, CCII, and LHCII apoproteins accumulate to normal levels; and 3) synthesis of the chlorophyll apoproteins is differentially affected, or in some cases, not affected. In the absence of chlorophylls: 1) the apoproteins fail to accumulate; 2) mRNA levels for CCI and CCII apoproteins are relatively unchanged; 3) levels of LHCII apoprotein mRNA, but not rates of LHCII mRNA synthesis, are reduced in a light-dependent chlorophyll-synthesis mutant (ya12); and 4) synthesis of chlorophyll apoproteins is differentially affected or not affected in the case of several chloroplast-encoded apoproteins. These results demonstrate a direct role for carotenoids as well as chlorophylls in the stabilization of certain chlorophyll apoproteins and, for others, possibly in their translation. The data also indicate a role for chlorophyll synthesis in the stability of LHCII mRNA.	UNIV GEORGIA,DEPT BOT,ATHENS,GA 30602	University System of Georgia; University of Georgia			Herrin, David/M-1372-2019					ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; APEL K, 1979, EUR J BIOCHEM, V97, P183, DOI 10.1111/j.1432-1033.1979.tb13101.x; BENNETT J, 1981, EUR J BIOCHEM, V118, P61, DOI 10.1111/j.1432-1033.1981.tb05486.x; BREIDENBACH E, 1990, BIOCHIM BIOPHYS ACTA, V1048, P209, DOI 10.1016/0167-4781(90)90058-A; BRITTON G, 1986, REGULATION CHLOROPLA, P125; CHUA NH, 1979, J BIOL CHEM, V254, P215; DELEPELAIRE P, 1981, J BIOL CHEM, V256, P9300; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; EICHENBERGER W, 1986, PHYSIOL PLANTARUM, V66, P589, DOI 10.1111/j.1399-3054.1986.tb05584.x; FORD C, 1982, MOL GEN GENET, V187, P286, DOI 10.1007/BF00331130; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GREER K, 1988, WATER OXIDATION COMP; GREER KL, 1986, PLANT PHYSIOL, V82, P114, DOI 10.1104/pp.82.1.114; HAGAKI T, 1986, PLANT CELL PHYSL, V27, P1241; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRIN DL, 1986, J CELL BIOL, V103, P1837, DOI 10.1083/jcb.103.5.1837; HERRIN DL, 1987, ARCH BIOCHEM BIOPHYS, V254, P397, DOI 10.1016/0003-9861(87)90117-2; Herrin DL, 1987, PROGR PHOTOSYNTHESIS, P645; HERRIN DL, 1988, J BIOL CHEM, V263; HOOBER JK, 1990, PLANT PHYSIOL, V92, P419, DOI 10.1104/pp.92.2.419; HOOBER JK, 1982, J CELL BIOL, V95, P52; HOOBER JK, 1987, BIOCH PLANTS, V10, P1; HUMBECK K, 1989, PLANTA, V179, P242, DOI 10.1007/BF00393695; IKEUCHI M, 1987, PROGR PHOTOSYNTHESIS, V2, P805; JANERO DR, 1981, ANAL BIOCHEM, V111, P283, DOI 10.1016/0003-2697(81)90565-0; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; JOHANNINGMEIER U, 1988, EUR J BIOCHEM, V177, P417, DOI 10.1111/j.1432-1033.1988.tb14391.x; KINDLE KL, 1987, PLANT MOL BIOL, V9, P547, DOI 10.1007/BF00020532; LEVINE RP, 1970, ANNU REV GENET, V4, P397, DOI 10.1146/annurev.ge.04.120170.002145; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; Maniatis T., 1982, MOL CLONING; MARRS KA, 1991, PLANTA, V183, P327, DOI 10.1007/BF00197729; Mathis P., 1982, CAROTENOIDS CHEM BIO, P339; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MAYFIELD SP, 1986, PLANT PHYSIOL, V82, P760, DOI 10.1104/pp.82.3.760; MISHKIND ML, 1985, CURR TOP PLANT BIOCH, V4, P34; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NICHOLSONGUTHRIE CS, 1987, ARCH BIOCHEM BIOPHYS, V252, P570, DOI 10.1016/0003-9861(87)90064-6; PLUMLEY FG, 1989, P NATL ACAD SCI USA, V86, P2678, DOI 10.1073/pnas.86.8.2678; PLUMLEY FG, 1983, ANAL BIOCHEM, V134, P86, DOI 10.1016/0003-2697(83)90267-1; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PLUMLEY FG, 1986, PLANT PHYSIOL, V80, P685, DOI 10.1104/pp.80.3.685; ROMER S, 1990, PLANTA, V182, P216, DOI 10.1007/BF00197114; SIEBURTH LE, 1991, PLANT CELL, V3, P175, DOI 10.2307/3869287; SILVERTHORNE J, 1984, P NATL ACAD SCI-BIOL, V81, P1112, DOI 10.1073/pnas.81.4.1112; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9	48	81	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8260	8269						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373722				2022-12-25	WOS:A1992HQ18500047
J	IMAMURA, T; TOKITA, Y; MITSUI, Y				IMAMURA, T; TOKITA, Y; MITSUI, Y			IDENTIFICATION OF A HEPARIN-BINDING GROWTH FACTOR-I NUCLEAR TRANSLOCATION SEQUENCE BY DELETION MUTATION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; FIBROBLAST; RECEPTOR; LOCALIZATION; PURIFICATION; ONCOPROTEIN; 3T3-CELLS; PROTEINS	We have shown previously that a deletion mutant of human heparin-binding growth factor (HBGF)-1, HBGF-1U, lacking the sequence Asn-Tyr-Lys-Lys-Pro-Lys-Leu is capable of initiating c-fos mRNA expression and polypeptide phosphorylation on tyrosine residues at concentrations that do not induce either DNA synthesis or cell proliferation (1). The fact that addition of the nuclear translocation signal from the yeast histone 2B protein to the HBGF-1U mutant caused reconstitution of the biological activity of HBGF-1 indicated that nuclear translocation may be an important component of the mitogenic signal induced by HBGF-1. In order to examine the nuclear translocation potential of HBGF-1-alpha, the deletion mutant HBGF-1U, and the yeast histone 2B-HBGF-1 chimera, HBGF-1U2, we expressed these forms of HBGF1 in murine endothelial cells. Western blot and two-dimensional Western blot analysis of cytosol and nuclei demonstrate that although the three forms of HBGF-1 are readily detectable in the cytosol of the individual transfectants, HBGF-1-alpha and HBGF-1U2 but not HBGF-1U was detected in the nucleus. Furthermore, murine endothelial cells expressing HBGF-1-alpha and HBGF-1U2 exhibited an atypical cellular phenotype in vitro that was absent in the HBGF-1U transfectants. These data suggest that HBGF-1 contains a functional nuclear translocation sequence that may be responsible for the initiation of DNA synthesis, and these data further correlate the presence of the nuclear translocation sequence with an abnormal endothelial cell phenotype in vitro.			IMAMURA, T (corresponding author), FERMENTAT RES INST, DIV CELL SCI & TECHNOL, HIGASHI 1-1-3, TSUKUBA, IBARAKI 305, JAPAN.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARCIS I, 1989, ONCOGENE, V4, P335; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	30	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5676	5679						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372009				2022-12-25	WOS:A1992HH74700101
J	SCHNABEL, D; SCHRODER, M; FURST, W; KLEIN, A; HURWITZ, R; ZENK, T; WEBER, J; HARZER, K; PATON, BC; POULOS, A; SUZUKI, K; SANDHOFF, K				SCHNABEL, D; SCHRODER, M; FURST, W; KLEIN, A; HURWITZ, R; ZENK, T; WEBER, J; HARZER, K; PATON, BC; POULOS, A; SUZUKI, K; SANDHOFF, K			SIMULTANEOUS DEFICIENCY OF SPHINGOLIPID ACTIVATOR PROTEINS-1 AND PROTEINS-2 IS CAUSED BY A MUTATION IN THE INITIATION CODON OF THEIR COMMON GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO-BETA-GLUCOSIDASE; METACHROMATIC LEUKODYSTROPHY; CEREBROSIDE-SULFATASE; ENZYMATIC-HYDROLYSIS; HUMAN-FIBROBLASTS; GAUCHERS-DISEASE; MESSENGER-RNA; ACID; PURIFICATION; DEGRADATION	Sphingolipid activator proteins (SAPs) are small, nonenzymic glycoproteins that stimulate lysosomal degradation of various sphingolipids. SAP-1, SAP-2, and two additional potential activator proteins are derived from a common precursor by proteolytic processing. A severe case of sphingolipid storage disease that led to death within 16 weeks was attributed to a possible total deficiency of the SAPs generated by this gene (Harzer, K., Paton, B. C., Poulos, A., Kustermann-Kuhn, B., Roggendorf, W., Grisar, T., and Popp, M. (1989) Eur. J. Pediatr. 149, 31-39). Analysis of the SAP precursor cDNA from the patient and his fetal sibling showed an A to T transversion in the initiation codon. Allele-specific oligonucleotide hybridization revealed that both parents are heterozygous carriers for this mutation. In pulse-chase experiments using antisera raised against SAP-1 or SAP-2, no cross-reacting material could be detected in the patients' fibroblasts.	UNIV BONN, INST ORGAN CHEM & BIOCHEM, GERHARD DOMAGK STR 1, W-5300 BONN 1, GERMANY; UNIV BONN, INST CLIN BIOCHEM, W-5300 BONN, GERMANY; UNIV TUBINGEN, INST BRAIN RES, W-7400 TUBINGEN 1, GERMANY; ADELAIDE MED CTR WOMEN & CHILDREN, DEPT CHEM PATHOL, ADELAIDE, SA 5006, AUSTRALIA; UNIV N CAROLINA, SCH MED, BRAIN & DEV RES CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT NEUROL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PSYCHIAT, CHAPEL HILL, NC 27599 USA	University of Bonn; University of Bonn; Eberhard Karls University of Tubingen; Womens & Childrens Hospital Australia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Schnabel, Dirk/0000-0002-7944-7790	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289, R01NS028997] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [R01-NS28997, R01-NS24289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P491; BANKS MN, 1987, GLYCOCONJUGATE J, V4, P157, DOI 10.1007/BF01049453; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG J, 1985, BIOL CHEM H-S, V366, P887, DOI 10.1515/bchm3.1985.366.2.887; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; CHRISTOMANOU H, 1980, H-S Z PHYSIOL CHEM, V361, P1489, DOI 10.1515/bchm2.1980.361.2.1489; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; CONZELMANN E, 1987, METHOD ENZYMOL, V138, P792; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; CONZELMANN E, 1989, MOL BASIS MEMBRANE A, P379; FISCHER G, 1978, BIOCHIM BIOPHYS ACTA, V528, P69, DOI 10.1016/0005-2760(78)90053-X; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1991, BIOCHEM BIOPH RES CO, V177, P1211, DOI 10.1016/0006-291X(91)90670-3; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1988, J BIOL CHEM, V263, P6588; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PETERS SP, 1977, J BIOL CHEM, V252, P563; POTIER M, 1990, BIOCHEM BIOPH RES CO, V173, P449, DOI 10.1016/S0006-291X(05)81079-4; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; STEVENS RL, 1981, AM J HUM GENET, V33, P900; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	45	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3312	3315						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371116				2022-12-25	WOS:A1992HD15400078
J	ERBAN, JK; WAGNER, DD				ERBAN, JK; WAGNER, DD			A 130-KDA PROTEIN ON ENDOTHELIAL-CELLS BINDS TO AMINO-ACIDS 15-42 OF THE B-BETA CHAIN OF FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; VONWILLEBRAND-FACTOR; ADHESION MOLECULE-1; ACTIVATED PLATELETS; GLYCOPROTEIN-IIB; HUMAN-BLOOD; FRAGMENT-D; RECEPTOR; RELEASE	Factors which stimulate the release of von Willebrand factor (vWf) from endothelial cell Weibel-Palade bodies and which induce the expression of the leukocyte-binding adhesion molecule P-selectin (PADGEM, GMP-140, CD62) on the endothelial cell surface remain incompletely characterized. Fibrin but not fibrinogen is a potent stimulus for the release of stored von Willebrand factor from endothelial cells. Removal of fibrinopeptides A and B from fibrinogen occurs during the formation of fibrin, and the removal of fibrinopeptide B is a requirement for fibrin to induce vWf secretion. The cleavage of fibrinopeptide A by reptilase enzyme forms a fibrin gel yet it is incapable of stimulating Weibel-Palade body degranulation. As a consequence of removing fibrinopeptide B, B-beta-15-42 becomes the new NH2 terminus of the beta-chain of fibrin. We have shown that the peptide B-beta-15-42 in solution inhibits the release of vWf stimulated by fibrin. In addition, B-beta-15-42 coupled to ovalbumin supports the binding and spreading of endothelial cells, while a scrambled form of this peptide coupled to the same carrier does not. We investigated whether these determinants near the amino terminus of the beta-chain of fibrin bind to a specific protein on the surface of endothelial cells. A 130-kDa protein was isolated from surface-labeled human umbilical vein endothelial cells by specific binding to B-beta-15-42 immobilized on Sepharose. This glycoprotein was eluted with the B-beta-15-42 peptide in solution but not with the scrambled form of this peptide. The fibrin-derived peptides B-beta-19-26 and B-beta-37-56-cysteine were also incapable of eluting the 130-kDa protein bound to immobilized B-beta-15-42 as were the arginine-glycine-aspartic acid-serine RGDS tetrapeptide and EDTA. The 130-kDa protein is recognized neither by antibodies to the known integrins found on endothelial cells nor by antibodies to CD31(endoCAM, PECAM-1), a member of the immunoglobulin family of receptors found on endothelial cells. The beta-chain of fibrin thus contains a sequence near its amino terminus which specifically binds to what is likely a novel endothelial cell surface protein. This glycoprotein may promote endothelial cell adhesion to fibrin during the wound healing process and is a candidate for a receptor involved in fibrin-mediated release of Weibel-Palade bodies from endothelial cells.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University	ERBAN, JK (corresponding author), NEW ENGLAND MED CTR HOSP,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.				NHLBI NIH HHS [HL08188, P01 HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443, F32HL008188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA S, 1990, J CELL BIOL, V220, P1227; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLOMBACK B, 1958, ARK KEMI, V12, P321; BONFANTI R, 1989, BLOOD, V73, P1109; BUNCE LA, 1991, THROMB HAEMOSTASIS, V65, P1225; CHEN CS, 1988, BIOCHEMISTRY-US, V27, P6121, DOI 10.1021/bi00416a044; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CONFORTI G, 1989, BLOOD, V73, P1576; DANG CV, 1985, SCIENCE, V227, P1487, DOI 10.1126/science.4038818; DAYHOFF M, 1973, ATLAS PROTEIN SEQUEN, V5, pS29; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DELVOS U, 1988, HAEMOSTASIS, V18, P99; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GIMBRONE M, 1984, J CELL BIOL, V60, P673; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KADISH JL, 1979, TISSUE CELL, V11, P99, DOI 10.1016/0040-8166(79)90010-7; KAPLAN K, 1987, THROMB HAEMOSTASIS, V58, P939; KAPLAN KL, 1989, ARTERIOSCLEROSIS, V9, P43, DOI 10.1161/01.ATV.9.1.43; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KOPEC M, 1978, HDB EXP PHARMACOL, V46, P81; KUDRYK B, 1982, THROMB RES, V25, P277, DOI 10.1016/0049-3848(82)90247-X; KWANN H, 1971, THROMB DIATH HAEMO, V47, P361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVINE JD, 1982, BLOOD, V60, P531; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MURANO G, 1971, FEBS LETT, V14, P37, DOI 10.1016/0014-5793(71)80269-7; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NUEWUARIWSJU S, 1970, BIOCHIM BIOPHYS ACTA, V221, P326; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PLOW EF, 1984, J BIOL CHEM, V259, P5388; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; REINDERS JH, 1987, J CELL PHYSIOL, V133, P79, DOI 10.1002/jcp.1041330110; RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROWLAND FN, 1984, AM J PATHOL, V117, P418; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SHAINOFF JR, 1990, THROMB HAEMOSTASIS, V63, P193; SHEN LL, 1977, AM J PHYSIOL, V232, P629; SKOGEN WF, 1988, BLOOD, V71, P1475; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; WAGNER D, 1982, J CELL BIOL, V99, P2123; WEIMAR B, 1985, ARTERIOSCLEROSIS, V6, P139; WRIGHT S, 1988, P NATL ACAD SCI USA, V80, P5699	65	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2451	2458						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370821				2022-12-25	WOS:A1992HB53200053
J	ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH				ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH			THE AMINO-TERMINAL HALF OF PP59C-FYN CONTAINS SEQUENCES NECESSARY FOR FORMATION OF A 75KDA FORM AND ALSO REPRESSIVE ELEMENTS ABSENT IN PP60C-SRC	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; MIDDLE-T-ANTIGEN; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; COMPLEX-FORMATION; CARBOXY TERMINUS; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; PHOSPHORYLATION	Members of the src family of tyrosine kinases are composed of amino acid sequences which can be divided into three regions: the unique amino-terminal 80 residues; the next 180 residues of conserved but non-catalytic sequence; and the catalytic carboxy-terminal half of the molecule. To characterize the elements that regulate the catalytic and transforming activities of two members of this family, pp59c-fyn and pp60c-src, we generated six chimeric proteins by interchanging the three regions of the 531F mutant of pp59c-fyn and of the 527F mutant of pp60c-src. Our data indicate that substituting all or part of the amino-terminal 263 residues of pp59c-fyn for those of 527F inhibited the kinase and transforming activities of 527F. Conversely, substituting the amino-terminal half of pp60c-src for that of 531F resulted in an increase in the transforming potential of 531F. These results suggest that the amino-terminal half of pp59c-fyn contains elements which act to suppress the catalytic and transforming activities of the enzyme and that these suppressive elements are either absent or inactive in pp60c-src. These differences argue that the src family of tyrosine kinases are regulated differently in the cell. In vitro translation of some of the chimeras in rabbit reticulocyte lysates generated a 75kDa protein in addition to the expected 59kDa product. This 75kDa species is analogous to the p75 protein previously detected in wild-type pp59c-fyn translation products. Interestingly, formation of p75 required the presence of DNA sequences encoding the unique amino-terminal residues of pp59c-fyn.			ESPINO, PC (corresponding author), GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022		NATIONAL CANCER INSTITUTE [P01CA050661, R01CA043186] Funding Source: NIH RePORTER; NCI NIH HHS [CA43186, CA50661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; ESPINO PC, 1990, ONCOGENE, V5, P283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POTTER H, 1991, ALZHEIMERS DISEASE B, P276; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	33	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					317	322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1372400				2022-12-25	WOS:A1992HG98200017
J	LOWE, DG; FENDLY, BM				LOWE, DG; FENDLY, BM			HUMAN NATRIURETIC PEPTIDE RECEPTOR-A GUANYLYL CYCLASE - HORMONE CROSS-LINKING AND ANTIBODY REACTIVITY DISTINGUISH RECEPTOR GLYCOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL ZONA GLOMERULOSA; HEAT-STABLE ENTEROTOXIN; SIGNAL TRANSDUCTION; PORCINE BRAIN; GENE-PRODUCT; ATRIAL; EXPRESSION; ACTIVATION; PROTEIN; DOMAIN	Most of the physiological actions of atrial natriuretic peptide (ANP) may be attributed to activation of the natriuretic peptide receptor-A (NPR-A) guanylyl cyclase. We report here that truncation of the NPR-A cytoplasmic domain results in increased expression of cell surface ANP binding sites. The truncated receptor exhibited a hyperbolic time course for ANP binding and had a high affinity for [I-125]hANP, K(d) = 8 pM. Cells expressing truncated NPR-A were used as an immunogen to obtain monoclonal antibodies against the native conformation of the extracellular domain. These antibodies were used to select for high levels of stable NPR-A expression in 293 cells, by fluorescence-activated cell sorting. Disuccinimidyl suberate cross-linked [I-125]ANP to 135-kDa NPR-A on intact cells. Monoclonal antibody immunoprecipitation of S-35-labeled proteins revealed NPR-A size heterogeneity, with 135- and 125-kDa species. A synthetic peptide antibody directed against the extracellular domain immunoprecipitated 125-kDa NPR-A, but recognized both sizes of receptor by Western blotting. The 125-kDa NPR-A did not bind to or cross-link ANP. NPR-A size variants were expressed on the cell surface, and heterogeneity was removed by deglycosylation with protein:N-glycosidase F. Our results suggest that the degree of N-linked glycosylation of the NPR-A extracellular domain influences the ability to bind ANP.	GENENTECH INC,DEPT MEDICINAL & ANALYT CHEM,SAN FRANCISCO,CA 94080	Roche Holding; Genentech	LOWE, DG (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,SAN FRANCISCO,CA 94080, USA.							ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DAYANITHI G, 1990, J ENDOCRINOL, V125, P39, DOI 10.1677/joe.0.1250039; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; FENDLY BM, 1990, CANCER RES, V50, P1550; FULLER F, 1988, J BIOL CHEM, V263, P9395; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KAMBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P599, DOI 10.1016/S0006-291X(05)80077-4; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LARAGH JH, 1985, NEW ENGL J MED, V313, P1330; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MELOCHE S, 1987, J BIOL CHEM, V262, P10252; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; Oi V.T., 1980, SELECTED METHODS CEL, P351; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TAWARAGI Y, 1991, BIOCHEM BIOPH RES CO, V175, P645, DOI 10.1016/0006-291X(91)91614-I; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	39	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21691	21697						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356991				2022-12-25	WOS:A1992JV01100068
J	YANG, JM; LONDON, IM; CHEN, JJ				YANG, JM; LONDON, IM; CHEN, JJ			EFFECTS OF HEMIN AND PORPHYRIN COMPOUNDS ON INTERSUBUNIT DISULFIDE FORMATION OF HEME-REGULATED EIF-2-ALPHA KINASE AND THE REGULATION OF PROTEIN-SYNTHESIS IN RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 2-ALPHA; DOUBLE-STRANDED-RNA; HEAT-SHOCK PROTEIN; CONTROLLED TRANSLATIONAL REPRESSOR; RABBIT RETICULOCYTE; ALPHA-SUBUNIT; GLOBIN SYNTHESIS; BINDING FACTOR; FACTOR EIF-2; FACTOR-II	To study the mechanism by which heme regulates the heme-regulated eIF-2alpha kinase (HRI), the effects of various protoporphyrin IX (PP) compounds on the kinase activities and intersubunit disulfide formation of HRI and on protein synthesis in reticulocyte lysates were examined. Hemin and cobalt protoporphyrin (CoPP) are more effective than ZnPP, NiPP, SnPP, and metal-free PP in promoting intersubunit disulfide bond formation in HRI, in inhibiting the autokinase and eIF-2alpha kinase activities of HRI, in inhibiting phosphorylation of eIF-2alpha in rabbit reticulocytes, in maintaining protein synthesis, and in reversing the inhibition of protein synthesis in heme deficiency. There is an apparent correlation of in vitro intersubunit disulfide formation of HRI and the regulation of HRI kinase activities and protein synthesis by these porphyrin compounds. HRI in the reticulocyte lysate can be cross-linked by 1,6-bismaleimidohexane (bis-NEM). The formation of bis-NEM cross-linked dimers in lysates is prevented completely by N-ethylmaleimide (NEM) which alkylates free sulfhydryl groups and is diminished by hemin and CoPP. These results support the view that HRI in hemin-supplemented lysates is in equilibrium between the noncovalently linked dimer and the disulfide-linked dimer. The molecular size of HRI in control, hemin-supplemented, or NEM-treated hemin-supplemented lysates is identical to that of purified HRI; activation of HRI and changes in its thiol status do not significantly affect its molecular size.	HARVARD MASSACHUSETTS INST TECHNOL,DIV HLTH SCI & TECHNOL,E25-537,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)					NIDDK NIH HHS [DK-16272, R01 DK016272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016272, R01DK016272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON SD, 1969, J MOL BIOL, V42, P247, DOI 10.1016/0022-2836(69)90041-2; BONANOUTZEDAKI SA, 1978, EUR J BIOCHEM, V84, P601, DOI 10.1111/j.1432-1033.1978.tb12203.x; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; ERNST V, 1980, P NATL ACAD SCI-BIOL, V77, P1286, DOI 10.1073/pnas.77.3.1286; ERNST V, 1979, P NATL ACAD SCI USA, V76, P2118, DOI 10.1073/pnas.76.5.2118; ERNST V, 1982, HEAT SHOCK BACTERIA, P215; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; FARRELL PJ, 1978, EUR J BIOCHEM, V89, P517, DOI 10.1111/j.1432-1033.1978.tb12556.x; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1987, BIOCHIM BIOPHYS ACTA, V908, P123, DOI 10.1016/0167-4781(87)90051-0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HRONIS TS, 1981, J BIOL CHEM, V256, P1409; HRONIS TS, 1986, J BIOL CHEM, V2611, P6234; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; HURST R, 1987, J BIOL CHEM, V262, P15939; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX A, 1982, P NATL ACAD SCI-BIOL, V79, P2147, DOI 10.1073/pnas.79.7.2147; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MAXWELL CR, 1969, BIOCHEM BIOPH RES CO, V35, P79, DOI 10.1016/0006-291X(69)90485-9; MAXWELL CR, 1971, J MOL BIOL, V58, P317, DOI 10.1016/0022-2836(71)90249-X; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; RANU RS, 1976, P NATL ACAD SCI USA, V73, P4349, DOI 10.1073/pnas.73.12.4349; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	38	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20519	20524						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356981				2022-12-25	WOS:A1992JR85800119
J	IWAMOTO, T; HAGIWARA, M; HIDAKA, H; ISOMURA, T; KIOUSSIS, D; NAKASHIMA, I				IWAMOTO, T; HAGIWARA, M; HIDAKA, H; ISOMURA, T; KIOUSSIS, D; NAKASHIMA, I			ACCELERATED PROLIFERATION AND INTERLEUKIN-2 PRODUCTION OF THYMOCYTES BY STIMULATION OF SOLUBLE ANTI-CD3 MONOCLONAL-ANTIBODY IN TRANSGENIC MICE CARRYING A RABBIT PROTEIN KINASE-C-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; HUMAN LYMPHOCYTES-T; TYROSINE KINASE; ANTIGEN RECEPTOR; MOLECULAR-CLONING; GENE-EXPRESSION; FAMILY; ISOZYMES; COMPLEX; CD2	Protein kinase C (PKC) has been believed to play an important role in the differentiation/proliferation of various kinds of mammalian cells. To analyze its function in living animals, we have established a transgenic mouse line carrying rabbit protein kinase C-alpha cDNA under the control of the regulatory element of human CD2. Thymocytes of these transgenic mice overexpressed PKC-alpha. Interestingly, the increase of PKC-alpha was detected mainly in membrane fractions of transgenic thymocytes. Although the transgenic thymocytes did not show any distinct proliferative features in vivo, they displayed a unique property to extensively proliferate and produce interleukin-2 (IL-2) in response to the stimulation by a soluble form of anti-CD3 monoclonal antibody (mAb), an incomplete agonist for proliferation of normal thymocytes. Furthermore, costimulation of the phorbol 12-myristate 13-acetate and anti-CD3 mAb intensely provoked the transgenic thymocytes to release IL-2. For the first time this result provided the direct evidence that PKC-alpha translocated to the cell membrane of thymocytes works as an active second messenger of the T cell receptor-CD3 complex-delivered signal for proliferation and IL-2 production.	NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT RADIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Nagoya University; Nagoya University; Nagoya University; MRC National Institute for Medical Research								ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; ANDERSON MLM, 1985, NUCLEIC ACID HYBRIDI, P73; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BERRY N, 1989, J IMMUNOL, V143, P1407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FINN OJ, 1991, J IMMUNOL, V146, P1099; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; GILLIS S, 1978, J IMMUNOL, V120, P2027; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA M, 1990, CANCER RES, V50, P5515; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOGAN B, 1986, MANIPULATING MOUSE E, P79; IWAMOTO T, 1990, ONCOGENE, V5, P535; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MANGER B, 1987, J IMMUNOL, V139, P2755; NAKASHIMA I, 1991, J IMMUNOL, V147, P1153; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHEARMAN MS, 1988, FEBS LETT, V234, P387, DOI 10.1016/0014-5793(88)80122-4; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YAGITA H, 1988, J IMMUNOL, V140, P1321; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V100, P333, DOI 10.1093/oxfordjournals.jbchem.a121719; ZHANG YH, 1992, IMMUNOL LETT, V32, P147, DOI 10.1016/0165-2478(92)90107-Y	38	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18644	18648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382058				2022-12-25	WOS:A1992JN50200061
J	MUKAI, H; MUNEKATA, E; HIGASHIJIMA, T				MUKAI, H; MUNEKATA, E; HIGASHIJIMA, T			G-PROTEIN ANTAGONISTS - A NOVEL HYDROPHOBIC PEPTIDE COMPETES WITH RECEPTOR FOR G-PROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; RECONSTITUTED PHOSPHOLIPID-VESICLES; BETA-ADRENERGIC-RECEPTOR; SUBSTANCE-P; REGULATORY PROTEINS; WASP VENOM; STRUCTURAL DETERMINANTS; SYNTHETIC PEPTIDES; COUPLED RECEPTORS; DIRECT ACTIVATION	A substance P (SP) analog, [D-Pro4,D-Trp7,9,10] SP4-11, is known to inhibit the actions of various structurally unrelated messenger molecules as well as SP. Our studies on the effects of this peptide on the regulation of purified G proteins by receptor showed that at least some of the biological effects of the peptide can be explained by the ability of the peptide to block the activation of G proteins by receptors. Here we report that a novel truncated SP-related peptide, pGlu-Gln-D-Trp-Phe-D-Trp-D-Trp-Met-NH2, inhibited the activation of G(i) or G(o) by M2 muscarinic cholinergic receptor (M2 mAChR) or of G(s) by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis. The inhibition by the peptide was apparently reversible and competitive with respect to receptor binding to G proteins; the inhibition could be overcome by increasing the concentration of receptor in the vesicles and was not altered by changes in the concentration of G protein. The competing effects of the peptide were used to analyze the effect of agonist on receptor-G protein interaction. The concentration change of muscarinic agonist did not alter the inhibitory effects of the peptide on M2 mAChR-promoted GTPase by G(o), which is consistent with the idea that agonist increases the regulatory efficiency of the receptor but does not alter its affinity for G proteins. This new group of compounds (G protein antagonists) is a promising tool to study receptor-G protein interaction quantitatively.	UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	MUKAI, H (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P173; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BUTLER SJ, 1988, BIOCHEM J, V251, P201, DOI 10.1042/bj2510201; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FABREGAT I, 1990, J CELL PHYSIOL, V145, P88, DOI 10.1002/jcp.1041450113; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FOLKERS K, 1984, BRIT J PHARMACOL, V83, P449, DOI 10.1111/j.1476-5381.1984.tb16506.x; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, PEPTIDE CHEM 1986, P75; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1945; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUKAI H, 1987, AM J PHYSIOL, V252, pE765, DOI 10.1152/ajpendo.1987.252.6.E765; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; ORLOWSKA A, 1987, INT J PEPT PROT RES, V30, P141; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERIANIN A, 1989, J IMMUNOL, V143, P1669; PIOTROWSKI W, 1984, AGENTS ACTIONS, V14, P420, DOI 10.1007/BF01973842; PIOTROWSKI W, 1985, N-S ARCH PHARMACOL, V331, P364, DOI 10.1007/BF00500821; READ GW, 1979, J PHARMACOL EXP THER, V211, P711; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P400, DOI 10.1016/0165-6147(90)90144-W; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; TOMITA U, 1991, BIOCHEM BIOPH RES CO, V178, P400, DOI 10.1016/0006-291X(91)91827-Y; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; WILLUWEIT B, 1988, BIOCHEM J, V249, P857, DOI 10.1042/bj2490857; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; ZHANG L, 1988, BIOCHIM BIOPHYS ACTA, V972, P37, DOI 10.1016/0167-4889(88)90100-0	47	124	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16237	16243						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379592				2022-12-25	WOS:A1992JJ45800040
J	LACEY, SF; REARDON, JE; FURFINE, ES; KUNKEL, TA; BEBENEK, K; ECKERT, KA; KEMP, SD; LARDER, BA				LACEY, SF; REARDON, JE; FURFINE, ES; KUNKEL, TA; BEBENEK, K; ECKERT, KA; KEMP, SD; LARDER, BA			BIOCHEMICAL-STUDIES ON THE REVERSE-TRANSCRIPTASE AND RNASE-H ACTIVITIES FROM HUMAN-IMMUNODEFICIENCY-VIRUS STRAINS RESISTANT TO 3'-AZIDO-3'-DEOXYTHYMIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACEBO-CONTROLLED TRIAL; ZIDOVUDINE AZT; DNA-POLYMERASE; DOUBLE-BLIND; HIV; 5'-TRIPHOSPHATE; SENSITIVITY; SPECIFICITY; MUTATIONS; EFFICACY	A series of biochemical investigations to compare the DNA polymerase and RNase H functions of the reverse transcriptases (RTs) corresponding to azidothymidine (AZT)-sensitive and -resistant human immunodeficiency virus (HIV) strains are described. Steady-state kinetic studies with purified recombinant enzymes utilizing several templates and three inhibitors, 3'azido-3'deoxythymidine triphosphate (AZTTP), 3-aminothymidine 5'-triphosphate, and 2',3'-didehydro-2',3'-dideoxythymidine 5'-triphosphate, found consistent 2-4-fold differences between the enzymes from the two strains over a wide pH range. A strong pH dependence for all three inhibitors was found at pH values below 7.4 and suggested an ionizable group on the enzyme with a pK of about 7. The sensitivities of the RNase H activities of the two enzymes to AZTTP and AZTMP were also compared and found to be similar. The nucleotide incorporation fidelities of recombinant RTs corresponding to AZT-sensitive and -resistant clinical isolates were compared and the error specificities determined. No significant differences were found. Both enzymes were equally able to incorporate AZTTP into an elongating M13 DNA strand with concomitant chain termination. Purified wild-type and mutant virions from cell-culture supernatants were compared in "endogenous" DNA synthesis reactions, and the sensitivities of this activity to AZTTP were found to be similar. The contrast between the small differences found in this study and the high level of viral resistance in tissue culture presumably reflects an incomplete understanding of AZT inhibition of HIV in the cell.	WELLCOME RES LABS,DEPT EXPTL THERAPY,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	LACEY, SF (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURFINE ES, 1991, J BIOL CHEM, V266, P406; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HANDLON AL, 1988, PHARMACEUT RES, V5, P297, DOI 10.1023/A:1015926720740; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; WAINBERG MA, 1990, ANN NY ACAD SCI, V616, P346	23	127	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15789	15794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379238				2022-12-25	WOS:A1992JG11300081
J	REINES, D; GHANOUNI, P; LI, QQ; MOTE, J				REINES, D; GHANOUNI, P; LI, QQ; MOTE, J			THE RNA POLYMERASE-II ELONGATION COMPLEX - FACTOR-DEPENDENT TRANSCRIPTION ELONGATION INVOLVES NASCENT RNA CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-S-II; FACTOR-SII; PREMATURE TERMINATION; TERNARY COMPLEXES; DNA-SEQUENCE; GENE; PURIFICATION; INVITRO; INVIVO; TFIIS	Regulation of transcription elongation is an important mechanism in controlling eukaryotic gene expression. SII is an RNA polymerase II-binding protein that stimulates transcription elongation and also activates nascent transcript cleavage by RNA polymerase II in elongation complexes in vitro (Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). Here we show that SII-dependent in vitro transcription through an arrest site in a human gene is preceded by nascent transcript cleavage. RNA cleavage appeared to be an obligatory step in the SII activation process. Recombinant SII activated cleavage while a truncated derivative lacking polymerase binding activity did not. Cleavage was not restricted to an elongation complex arrested at this particular site, showing that nascent RNA hydrolysis is a general property of RNA polymerase II elongation complexes. These data support a model whereby SII stimulates elongation via a ribonuclease activity of the elongation complex.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	REINES, D (corresponding author), EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NIGMS NIH HHS [GM-46331, R01 GM046331] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ATKINSON MR, 1969, BIOCHEMISTRY-US, V8, P4897, DOI 10.1021/bi00840a037; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; DEUTSCHER MP, 1969, J BIOL CHEM, V244, P3019; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; HUET J, 1976, NATURE, V261, P431, DOI 10.1038/261431a0; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIPLING D, 1991, NATURE, V353, P509, DOI 10.1038/353509a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1991, ANAL BIOCHEM, V196, P367, DOI 10.1016/0003-2697(91)90480-H; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1991, J BIOL CHEM, V266, P10510; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; SPINDLER SR, 1979, BIOCHEMISTRY-US, V18, P4042, DOI 10.1021/bi00585a031; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TABOR S, 1990, J BIOL CHEM, V265, P8322; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	48	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15516	15522						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379232				2022-12-25	WOS:A1992JG11300042
J	OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M				OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M			MULTIPLE SRC-RELATED KINASE GENES, SRK1-4, IN THE FRESH-WATER SPONGE SPONGILLA-LACUSTRIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-ACID SEQUENCE; ONCOGENE C-SRC; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; EXPRESSION; PP60C-SRC; CELLS; PRODUCT; DNA	In one of the simplest metazoan organisms, the sponge Spongilla lacustris, at least four different src-related kinase genes (srk1-4) are expressed, all of which show a high degree of similarity to the c-src genes of vertebrates. Whereas srk2 and srk3 are clearly unrelated at the nucleic acid level, srk1 and srk4 share identical sequences in the 5' parts of their cDNAs. The cloning of several primer extension clones and genomic polymerase chain reaction experiments confirmed the hypothesis of an alternative splicing of tandemly arranged carboxy-terminal parts of srk1 and srk4. The genomic sequence encoding both proteins was found to be interrupted at the splice point by an intron which is located in the same position as one of the introns in the chicken src gene, which is the only gene conserved in invertebrates and vertebrates. All four srk genes are expressed in adult sponges as mRNA transcripts of about 2.2 kb. Tyrosine kinase activity of a src-related kinase could be detected in adult sponges but not in their resting form (gemmulae), and may reflect the activity of the srk protein products. Spongilla lacustris is the simplest organism from which a protein tyrosine kinase gene has been isolated. The presence of at least four such genes in the evolutionary ancient and primitive phylum Porifera suggests that tyrosine kinase genes arose concomitantly with or shortly after the appearance of multicellular organisms and that their activity may be involved in aggregation and cell-cell recognition.	MAX PLANCK INST BIOCHEM, GENECTR, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; UNIV MUNSTER, DEPT EXPTL TUMORBIOL, W-4400 MUNSTER, GERMANY	Max Planck Society; University of Munster				Schartl, Manfred/0000-0001-9882-5948				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BARNEKOW A, 1989, Critical Reviews in Oncogenesis, V1, P277; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DAVIS LG, 1986, BASIC METHODS MOL BI, P133; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIG G, 1991, ONCOGENE, V6, P361; HIRSCHBEHNAM A, 1988, COMP BIOCHEM PHYS B, V91, P125, DOI 10.1016/0305-0491(88)90123-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MULLER WEG, 1976, EXP CELL RES, V98, P31, DOI 10.1016/0014-4827(76)90459-6; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rasmont R., 1975, Transactions Congr int Un Game Biol, V10, P141; RAULF F, 1989, ONCOGENE RES, V5, P39; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WANG LH, 1987, ONCOGENE RES, V1, P43; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	48	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1625	1630						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1378585				2022-12-25	WOS:A1992JE81300019
J	BEPPU, M; MIZUKAMI, A; ANDO, K; KIKUGAWA, K				BEPPU, M; MIZUKAMI, A; ANDO, K; KIKUGAWA, K			ANTIGENIC DETERMINANTS OF SENESCENT ANTIGEN OF HUMAN ERYTHROCYTES ARE LOCATED IN SIALYLATED CARBOHYDRATE CHAINS OF BAND-3 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-GALACTOSIDASE; BLOOD-GROUP I; STRUCTURAL REQUIREMENTS; MEMBRANE-PROTEIN; BINDING; CELLS; OLIGOSACCHARIDES; SURFACE; MOIETY; LACTOSAMINOGLYCAN	Naturally occurring IgG autoantibody against Band 3 glycoprotein of human erythrocyte membrane (anti-Band 3) recognizes the erythrocytes modified with oxidizing or SH-blocking agents as well as senescent erythrocytes. Location of the antigenic determinants of Band 3 this autoantibody recognizes was investigated by competitive inhibition studies of the antibody binding to the modified cells. Autologous IgG binds to the modified erythrocytes, and purified Band 3 totally inhibits the binding. This inhibitory activity of Band 3 was not affected by digestion of Band 3 with various proteases. Treatment of Band 3 with endo-beta-galactosidase that destroys the poly-N-acetyllactosaminyl sugar chain of Band 3 or with neuraminidase resulted in loss of the inhibitory activity. Oligosaccharides released from Band 3 by hydrazinolysis effectively inhibited the binding of autologous IgG and I-125-labeled purified anti-Band 3 to the modified cells, whereas the oligosaccharides depleted of acidic components did not. Endo-beta-galactosidase and neuraminidase destroyed the activity of the oligosaccharides, but alpha-L-fucosidase did not. Furthermore, human lactoferrin that contains sialylated two N-acetyllactosaminyl units also exhibited potent inhibitory activity, and the activity was destroyed by endo-beta-galactosidase and neuraminidase. These results indicate that the antigenic determinants of Band 3 are located in sialylated poly-N-acetyllactosaminyl sugar chains. Based on this finding, mechanism of appearance of the antigen on senescent erythrocytes recognized by anti-Band 3 (senescent antigen) was discussed.	TOKYO COLL PHARM,1432-1 HORINOUCHI,HACHIOJI,TOKYO 19203,JAPAN	Tokyo University of Pharmacy & Life Sciences								ALDERMAN EM, 1980, BLOOD, V55, P817; AMINOFF D, 1985, CELLULAR MOL ASPECTS, P279; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BEPPU M, IN PRESS J PHARMACOB; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; FUKUDA M, 1980, P NATL ACAD SCI-BIOL, V77, P3474, DOI 10.1073/pnas.77.6.3474; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1978, J BIOL CHEM, V253, P2419; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; FURTHMAYR H, 1975, BIOCHEM BIOPH RES CO, V65, P113, DOI 10.1016/S0006-291X(75)80068-4; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; JAY DG, 1986, BIOCHEMISTRY-US, V25, P554, DOI 10.1021/bi00351a006; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P1631, DOI 10.1073/pnas.80.6.1631; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; KHANSARI N, 1983, MECH AGEING DEV, V21, P49, DOI 10.1016/0047-6374(83)90015-5; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LUTS HU, 1983, BIOMED BIOCHIM ACTA, V402, pS117; LUTS HU, 1984, J IMMUNOL, V133, P2610; MARCHESI VT, 1971, SCIENCE, V174, P1247, DOI 10.1126/science.174.4015.1247; MATSUMOTO A, 1982, J BIOCHEM-TOKYO, V91, P143, DOI 10.1093/oxfordjournals.jbchem.a133671; NIEMANN H, 1978, BIOCHEM BIOPH RES CO, V81, P1286, DOI 10.1016/0006-291X(78)91275-5; PRUZANSKI W, 1977, NEW ENGL J MED, V297, P583, DOI 10.1056/NEJM197709152971105; SCHLEPPERSCHAFER J, 1983, BIOCHEM BIOPH RES CO, V115, P551, DOI 10.1016/S0006-291X(83)80180-6; SCHLUTER K, 1986, P NATL ACAD SCI USA, V83, P6137, DOI 10.1073/pnas.83.16.6137; Spiro R G, 1973, Adv Protein Chem, V27, P349, DOI 10.1016/S0065-3233(08)60451-9; THOMAS DB, 1974, EUR J IMMUNOL, V4, P819, DOI 10.1002/eji.1830041210; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; TSUJI T, 1981, J BIOL CHEM, V256, P497; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VAYSSE J, 1986, P NATL ACAD SCI USA, V83, P1339, DOI 10.1073/pnas.83.5.1339; WATANABE K, 1979, J BIOL CHEM, V254, P3221; YAMAMOTO K, 1987, AGR BIOL CHEM TOKYO, V51, P1995, DOI 10.1080/00021369.1987.10868324	39	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14691	14696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378838				2022-12-25	WOS:A1992JF08800032
J	CELANO, P; BERCHTOLD, CM; KIZER, DL; WEERARATNA, A; NELKIN, BD; BAYLIN, SB; CASERO, RA				CELANO, P; BERCHTOLD, CM; KIZER, DL; WEERARATNA, A; NELKIN, BD; BAYLIN, SB; CASERO, RA			CHARACTERIZATION OF AN ENDOGENOUS RNA TRANSCRIPT WITH HOMOLOGY TO THE ANTISENSE STRAND OF THE HUMAN C-MYC GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON CARCINOMA-CELLS; MESSENGER-RNA; ALU SEQUENCE; EXPRESSION; COMPLEMENTARY; POLYAMINES; PROMOTER; ELEMENT; CHROMATOGRAPHY; BACTERIOPHAGE	In addition to being regulated by a complex array of cis- and trans-acting factors, c-myc protooncogene expression may be modulated by antisense RNA transcripts. Our previous studies have determined that depletion of intracellular polyamines by alpha-difluoromethylornithine results in a marked decrease in the transcription of the human c-myc gene. Because of reports that antisense transcription occurs in the 5' and 3' regions of this gene, we used a genomic clone of the human c-myc gene to ascertain whether polyamine depletion might induce an antisense RNA transcript. These studies demonstrate that polyamine depletion of the human colon cancer cell line COLO 320 results in induction of an endogenous RNA transcript with high homology to the antisense strand of the second intervening sequence (PvuII-RsaI) of the c-myc gene. Furthermore, during such depletion, steady state levels of this transcript vary inversely to the sense direction c-myc RNA. RNase protection studies suggest that the antisense transcript may arise from a different gene locus than the c-myc gene. To further identify the origins of this RNA, a cDNA library was generated from size-selected RNA and screened with c-myc sequences. A 438-base pair cDNA was isolated with almost-equal-to 85% homology, to a 285-base region in the second intron of the c-myc gene. Computer homology analysis further reveals that a 120-base region within this cDNA also has almost-equal-to 85% homology to the antisense strands of a number of genes, including the growth-related genes, N-myc, p53, and thymidine kinase. These studies provide the initial characterization of an endogenous antisense RNA transcript which could influence cell growth by modulating the expression of c-myc and other genes.			CELANO, P (corresponding author), JOHNS HOPKINS ONCOL CTR LABS,424 N BOND ST,BALTIMORE,MD 21231, USA.			Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA051085, R29CA047492, R29CA051068] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA47492, CA 51068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CALABRETTA B, 1991, CANCER RES, V51, P4505; CELANO P, 1989, J BIOL CHEM, V264, P8922; CELANO P, 1988, J BIOL CHEM, V263, P5491; CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; MCCARTHY TL, 1983, BIOCHEMISTRY-US, V22, P935, DOI 10.1021/bi00273a035; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; VILIJN F, 1989, J BIOL CHEM, V264, P11901; WEIKKILA R, 1987, NATURE, V328, P445; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	49	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15092	15096						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378845				2022-12-25	WOS:A1992JF08800086
J	NYKJAER, A; PETERSEN, CM; MOLLER, B; JENSEN, PH; MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; MUNCH, M; ANDREASEN, PA; GLIEMANN, J				NYKJAER, A; PETERSEN, CM; MOLLER, B; JENSEN, PH; MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; MUNCH, M; ANDREASEN, PA; GLIEMANN, J			PURIFIED ALPHA-2-MACROGLOBULIN RECEPTOR LDL RECEPTOR-RELATED PROTEIN BINDS UROKINASE-BULLET-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX - EVIDENCE THAT THE ALPHA-2-MACROGLOBULIN RECEPTOR MEDIATES CELLULAR DEGRADATION OF UROKINASE RECEPTOR-BOUND COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; PURIFICATION; IDENTIFICATION; EXPRESSION; SEQUENCE; CONFORMATION; MOLECULE; FRAGMENT; SURFACE	Complexes between I-125-labeled urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) bound to purified alpha-2-macroglobulin (alpha-2M) receptor (alpha-2MR)/low density lipoprotein receptor-related protein (LRP). No binding was observed when using uPA. The magnitude of uPA . PAI-1 binding was comparable with that of the alpha-2MR-associated protein (alpha-2MRAP). Binding of uPA . PAI-1 was blocked by natural and recombinant alpha-2MRAP, and about 80% inhibited by complexes between tissue-type plasminogen activator (tPA) and PAI-1, and by a monoclonal anti-PAI-1 antibody. In human monocytes, uPA . PAI-1, like uPA and its amino-terminal fragment, bound to the urokinase receptor (uPAR). Degradation of uPAR-bound I-125 uPA . PAI-1 was 3-4-fold enhanced as compared with uncomplexed uPAR-bound uPA. The inhibitor-enhanced uPA degradation was blocked by r-alpha-2MRAP and inhibited by polyclonal anti-alpha-2MR/LRP antibodies. This is taken as evidence for mediation of internalization and degradation of uPAR-bound uPA . PAI-1 by alpha-2MR/LRP.	AARHUS UNIV,DEPT CLIN IMMUNOL,DK-8000 AARHUS,DENMARK; AARHUS UNIV,GENE EXPRESS LAB,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University; Aarhus University	NYKJAER, A (corresponding author), AARHUS UNIV,INST MED BIOCHEM,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS,DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736; Jensen, Poul Henning/0000-0002-4439-9020				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GRONDAHLHANSEN J, 1987, J INVEST DERMATOL, V88, P28, DOI 10.1111/1523-1747.ep12464827; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; PETERSEN CM, 1987, SCAND J CLIN LAB INV, V47, P55; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	36	460	472	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14543	14546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378833				2022-12-25	WOS:A1992JF08800008
J	OKUMA, Y; REISINE, T				OKUMA, Y; REISINE, T			IMMUNOPRECIPITATION OF ALPHA-2A-ADRENERGIC RECEPTOR-GTP-BINDING PROTEIN COMPLEXES USING GTP-BINDING PROTEIN SELECTIVE ANTISERA - CHANGES IN RECEPTOR/GTP-BINDING PROTEIN-INTERACTION FOLLOWING AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ADENYLYL CYCLASE; IDENTIFICATION; SUBTYPES; EXPRESSION; ANTIBODIES; INHIBITION; PLATELETS; CELLS	The nature of the interaction of cloned alpha-2a-adrenergic receptors from LLC-PK1-O clone cells with G proteins was investigated using an immunoprecipitation approach. Following solubilization of the alpha-2a receptors, antiserum 8730, which is directed against the C-terminal region of G(i-alpha), immunoprecipitated alpha-2a receptor-G(i)alpha complexes. The immunoprecipitation was specific since it could be blocked by the peptide to which antiserum 8730 was generated. Antisera 3646 (anti-G(i-alpha-1), 1521 (anti-G(i-alpha-2) and 1518 (anti-G(i-alpha-3) immunoprecipitated solubilized alpha-2a receptor-G(i-alpha) complexes, indicating that all three G(i-alpha) subtypes couple with the alpha-2a receptor. Antiserum 9072, which is directed against the C-terminal region of G(o-alpha), immunoprecipitated solubilized alpha-2a receptor-G(alpha) complexes indicating that these receptors are also coupled to G(o-alpha). Antiserum 8132, which is directed against G(beta-36), immunoprecipitated solubilized alpha-2a receptors while the G(beta-35) antiserum 8129, did not, indicating that alpha-2a receptors selectively associate with G(beta-36). The binding of the partial agonist p-aminoclonidine to the solubilized alpha-2a receptor alters the association of the receptor with G proteins. Following p-aminoclonidine binding to the solubilized alpha-2a receptor, the ability of the C-terminal directed G(alpha) antisera 8730 and 9072 to coimmunoprecipitate the alpha-2a receptor-G(alpha) complex was greatly reduced. The effect of p-aminoclonidine was concentration dependent, mimicked by the full agonist UK 14304 and blocked by the alpha-2 receptor antagonist yohimbine. In contrast, antisera directed against internal regions of G(i-alpha) and G(o-alpha), immunoprecipitated the agonist-bound and agonist-free alpha-2a receptor equally well. These findings indicate that following the binding of agonists to the alpha-2a receptor, G(i-alpha) and G(o-alpha), remain physically associated with the receptor but either the conformation of G(alpha) linked to the receptor or the conformation of the receptor itself is modified such that the epitope for the C-terminal directed anti-G(i-alpha) and anti-G(o-alpha) antisera are not accessible. These agonist-induced conformational changes in the alpha-2a receptor-G(alpha) complex may be important for the activation of the G protein and the stimulation of the alpha-2a receptor signal transduction pathway.	UNIV PENN,SCH MED,DEPT PHARMACOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104	University of Pennsylvania					PHS HHS [48158, 34781, 45533] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; HSU WH, 1990, J BIOL CHEM, V265, P11220; JONES DT, 1987, J BIOL CHEM, V262, P14241; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIMBIRD LE, 1988, ALPHA2 ADRENERGIC RE; LIMBIRD LL, 1980, P NATL ACAD SCI USA, V77, P7754; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; NORTH RA, 1985, J PHYSIOL-LONDON, V358, P17, DOI 10.1113/jphysiol.1985.sp015537; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLIAMS AG, 1990, BLOOD, V76, P721; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	22	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14826	14831						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353077				2022-12-25	WOS:A1992JF08800050
J	KUNKEL, GR; DANZEISER, DA				KUNKEL, GR; DANZEISER, DA			FORMATION OF A TEMPLATE COMMITTED COMPLEX ON THE PROMOTER OF A GENE FOR THE U6 SMALL NUCLEAR-RNA FROM THE HUMAN REQUIRES MULTIPLE SEQUENCE ELEMENTS, INCLUDING THE DISTAL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; UPSTREAM PROMOTER; EFFICIENT TRANSCRIPTION; FUNCTIONAL ELEMENTS; U2 SNRNA; ENHANCER; INITIATION; INVITRO; U1; INTERMEDIATE	Vertebrate U6 small nuclear RNA (snRNA) loci exemplify a novel class of polymerase III-transcribed genes that lack an intragenic control region (ICR). Instead important transcriptional control elements are located in the 5'-flanking region and resemble those found in promoters and enhancers of polymerase II-transcribed genes. These include a proximal sequence element (PSE), a TATA element, and a distal region containing, at least, an octamer motif. We have used Sarkosyl to characterize steps in U6 promoter transcription in vitro in an unfractionated S100 extract and find very similar properties to those of the adenovirus VA1 gene that contains an ICR. Preformed preinitiation complexes are stable to 0.015% Sarkosyl and can undergo multiple rounds of initiation upon addition of nucleoside triphosphates. A higher concentration (0.075%) prevents reinitiation. In addition, we have investigated the formation of transcription complexes on this promoter in a S100 extract using a template competition assay. No stable complexes are detected with plasmid templates that contain clustered point mutations in the PSE nor with DNAs lacking the U6 5'-flanking region. A plasmid template containing mutations in the TATA element is partially deficient in competitive ability. Furthermore, the distal region upstream of position -148 is necessary for efficient stable complex formation. Within this region, the consensus octamer motif is one component needed to form complexes that withstand competition by a wild-type U6 promoter. The human U2 gene enhancer ligated to the U6 proximal region supports formation of a complex that competes at an intermediate level.			KUNKEL, GR (corresponding author), TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843, USA.			Kunkel, Gary/0000-0002-4199-369X				ACH RA, 1991, NUCLEIC ACIDS RES, V19, P4209, DOI 10.1093/nar/19.15.4209; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUNDERSON SI, 1988, J BIOL CHEM, V263, P17603; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; JANSON L, 1987, NUCLEIC ACIDS RES, V15, P4997, DOI 10.1093/nar/15.13.4997; KELEKAR A, 1990, MOL BIOL REP, V14, P173, DOI 10.1007/BF00360463; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LASSAR AB, 1983, SCIENCE, V222, P760; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MCNAMARA KJ, 1987, NUCLEIC ACIDS RES, V15, P9239, DOI 10.1093/nar/15.22.9239; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REDDY R, 1988, J BIOL CHEM, V263, P15980; REDDY R, 1987, J BIOL CHEM, V262, P75; ROEBUCK KA, 1987, MOL CELL BIOL, V7, P4185, DOI 10.1128/MCB.7.12.4185; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; TEBB G, 1988, EMBO J, V7, P3785, DOI 10.1002/j.1460-2075.1988.tb03263.x; TEBB G, 1989, MOL CELL BIOL, V9, P1682, DOI 10.1128/MCB.9.4.1682; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WIEBEN ED, 1991, NUCLEIC ACIDS RES, V19, P2869, DOI 10.1093/nar/19.11.2869; WILLIAMS JB, 1990, METHOD ENZYMOL, V181, P451; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323	61	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14250	14258						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378440				2022-12-25	WOS:A1992JD32500072
J	HUMPHRIES, DE; NICODEMUS, CF; SCHILLER, V; STEVENS, RL				HUMPHRIES, DE; NICODEMUS, CF; SCHILLER, V; STEVENS, RL			THE HUMAN SERGLYCIN GENE - NUCLEOTIDE-SEQUENCE AND METHYLATION PATTERN IN HUMAN PROMYELOCYTIC LEUKEMIA HL-60 CELLS AND T-LYMPHOBLAST MOLT-4 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SECRETORY GRANULE PROTEOGLYCANS; HUMAN-PLATELET PROTEOGLYCAN; MOUSE MAST-CELL; PEPTIDE CORE; DNA METHYLATION; MOLECULAR-CLONING; HEPARIN PROTEOGLYCANS; MESSENGER-RNA; ALU FAMILY	The complete nucleotide sequence of the 16.7-kb human gene that encodes the peptide core (serglycin) of a secretory granule proteoglycan was determined, thus representing the first proteoglycan peptide core gene to be sequenced in its entirety. The exons, intron 1, and intron 2 comprised 7, 53, and 40% of the gene, respectively. Nineteen Alu-repetitive DNA sequences were interspersed in the gene, accounting for 28% of the total nucleotides in intron 1 and 40% of the nucleotides in intron 2. The nucleotide sequence was then used in an examination of the methylation pattern of the human serglycin gene in human promyelocytic leukemia HL-60 cells that contain serglycin mRNA and in T-lymphoblast Molt-4 cells that do not. With polymerase chain reaction methodology, 13 DNA probes of 250-880 base pairs in length were generated that corresponded to unique, non-Alu sequences spaced throughout the entire human serglycin gene. When blots containing genomic DNA digested with HpaII or MspI were examined with these genomic probes, it was discovered that the 5'-flanking region and intron 1 of the serglycin gene in HL-60 cells were both substantially less methylated than intron 2. In contrast, the entire serglycin gene in Molt-4 cells was highly methylated. Because hypomethylated genes generally are transcribed more efficiently than hypermethylated genes, the high level of serglycin mRNA in HL-60 cells probably is a consequence of the low level of methylation of intron 1 and the 5'-flanking region of the serglycin gene in these cells.	HARVARD UNIV,SCH MED,DEPT VET AFFAIRS OUTPATIENT CLIN,SEELEY MUDD BLDG,RM 617,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005950] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05950] Funding Source: Medline; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; ANGERTH T, 1990, GENE, V93, P235, DOI 10.1016/0378-1119(90)90230-O; ARIGA T, 1990, GENOMICS, V8, P607, DOI 10.1016/0888-7543(90)90246-Q; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1987, MOL CELL BIOL, V7, P33, DOI 10.1128/MCB.7.1.33; BOURDON MA, 1986, J BIOL CHEM, V261, P12253; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONEHOWER LA, 1989, NUCLEIC ACIDS RES, V17, P699, DOI 10.1093/nar/17.2.699; FORSBERG LS, 1988, BIOCHIM BIOPHYS ACTA, V967, P416, DOI 10.1016/0304-4165(88)90105-5; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KRILIS SA, 1992, BLOOD, V79, P144, DOI 10.1182/blood.V79.1.144.bloodjournal791144; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; LOHMANDER LS, 1990, J BIOL CHEM, V265, P5802; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MATTEI MG, 1989, HUM GENET, V82, P87, DOI 10.1007/BF00288281; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; METCALFE DD, 1980, J BIOL CHEM, V255, P1753; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; RHODES C, 1939, NUCLEIC ACIDS RES, V19, P1933; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING, P916; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, P323; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SLAGEL V, 1987, MOL BIOL EVOL, V4, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STELLRECHT CM, 1989, NUCLEIC ACIDS RES, V17, P7523, DOI 10.1093/nar/17.18.7523; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1986, J IMMUNOL, V137, P291; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WILLARD C, 1987, J MOL EVOL, V26, P180, DOI 10.1007/BF02099850; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2; YURT RW, 1977, J BIOL CHEM, V252, P518; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	63	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13558	13563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377686				2022-12-25	WOS:A1992JB74600073
J	LOHSE, P; RADER, DJ; BREWER, HB				LOHSE, P; RADER, DJ; BREWER, HB			HETEROZYGOSITY FOR APOLIPOPROTEIN-E-4(PHILADELPHIA)(GLU(13)-]LYS, ARG(145)-]CYS) IS ASSOCIATED WITH INCOMPLETE DOMINANCE OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; RECEPTOR-BINDING ACTIVITY; AMINO-ACID-SEQUENCE; HUMAN-E APOPROTEIN; FAMILIAL DYSBETALIPOPROTEINEMIA; VARIANT; HETEROGENEITY; PATIENT; GENE; E2(LYS146->GLN)	Apolipoprotein (apo) E-4Philadelphia is a double mutant of apoE in which residue 13 of the mature protein, glutamic acid (GAG), is replaced by lysine (AAG) and amino acid 145, arginine (CGT), is converted to cysteine (TGT). These mutations result in two restriction fragment length polymorphisms for the enzymes AvaI and BbvI, a smaller apparent molecular weight of apoE-4Philadelphia on sodium dodecyl polyacrylamide gels, and severe type III hyperlipoproteinemia (HLP) in a 24-year-old homozygous female (Lohse, P., Mann, W. A., Stein, E. A., and Brewer, H. B., Jr. (1991) J. Biol. Chem. 266, 10479-10484). In the current study, we have extended our analysis to include nine additional family members of the Philadelphia kindred spanning four generations. DNA and protein analysis demonstrated that the originally described propositus is a true homozygote for the epsilon-4Philadelphia allele and that six of the nine family members are heterozygous for the mutated allele and the normal-epsilon-3 allele or, in one case, the epsilon-4 allele. Heterozygosity for apoE-4Philadelphia leads to the expression of a moderate form of type III HLP without clinical manifestations. These results are consistent with a dominant mode of inheritance of this dyslipoproteinemia. The simultaneous presence of unaffected individuals, heterozygotes, and a homozygote in the Philadelphia kindred makes it possible for the first time to demonstrate that the mutant apoE exhibits an incomplete or partial dominance of type III HLP. Heterozygosity for the normal epsilon-3 allele appears to have an influence on the expression of type III HLP, resulting in a phenotype intermediate between that of the two homozygous states.			LOHSE, P (corresponding author), NHLBI, MOLEC DIS BRANCH, 9000 ROCKVILLE PIKE, BLDG 10, RM 7N117, BETHESDA, MD 20892 USA.							BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; GHISELLI G, 1982, J CLIN INVEST, V70, P474, DOI 10.1172/JCI110638; GREGG RE, 1988, CLIN CHEM, V34, pB28; GREGG RE, 1983, NIH831266 PUBL, P383; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1982, MED CLIN N AM, V66, P441, DOI 10.1016/S0025-7125(16)31429-8; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; LEWIN B, 1987, GENES, V3, P20; LOHSE P, 1991, J BIOL CHEM, V266, P10479; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MAILLY F, 1991, J LIPID RES, V32, P613; MANN AW, 1989, CLIN RES, V37, pA520; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; RALL SC, 1983, J CLIN INVEST, V72, P1288, DOI 10.1172/JCI111085; RALL SC, 1982, J BIOL CHEM, V257, P4171; SMIT M, 1990, J LIPID RES, V31, P45; TAJIMA S, 1989, J BIOCHEM-TOKYO, V105, P249, DOI 10.1093/oxfordjournals.jbchem.a122648; TAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P48, DOI 10.1093/oxfordjournals.jbchem.a122420; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P1; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1990, J LIPID RES, V31, P535; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEISGRABER KH, 1984, J CLIN INVEST, V73, P1024, DOI 10.1172/JCI111287; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; ZANNIS VI, 1989, ADV LIPID RES, V23, P1; 1974, DHEW75628 NAT HEART	39	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13642	13646						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352296				2022-12-25	WOS:A1992JB74600086
J	WYNN, RM; DAVIE, JR; COX, RP; CHUANG, DT				WYNN, RM; DAVIE, JR; COX, RP; CHUANG, DT			CHAPERONINS GROEL AND GROES PROMOTE ASSEMBLY OF HETEROTETRAMERS (ALPHA-2-BETA-2) OF MAMMALIAN MITOCHONDRIAL BRANCHED-CHAIN ALPHA-KETO ACID DECARBOXYLASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEHYDROGENASE COMPLEX; PROTEIN; IDENTIFICATION; EXPRESSION	We have investigated the possible role of chaperonins groEL and groES in the folding and assembly of heterotetramers (alpha-2-beta-2) of Mammalian mitochondrial branched-chain alpha-keto acid decarboxylase (E1) in Escherichia coli. The mature E1-alpha subunit fused to maltose-binding protein (MBP) was coexpressed with mature E1-beta on the same vector in ES- and EL- mutant strains. Only small or trace amounts of active E1 component were obtained. Cotransformation of the ES- mutant host with a second vector overexpressing groEL and groES resulted in a greater than 500-fold increase in E1-specific activity. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the content of both MBP-E1-alpha and E1-beta polypeptides was markedly increased in the presence of overexpressed chaperonin proteins. The time course studies showed that the increase in E1-specific activity and subunit levels correlated with the increase in groEL and groES until the concentration of the chaperonins reached a saturating level in the cell. The functional MBP-E1 fusion protein from ES- double transformants were purified by amylose resin affinity chromatography. The MBP moiety was removed by subsequent digestion with Factor Xa endoprotease, followed by Sephacryl S-300HR chromatography. It was found that E1-alpha and E1-beta assembled into an active 160-kDa species, which was consistent with the alpha-2-beta-2 structure of E1. The present results demonstrate that chaperonins groEL and groES promote folding and assembly of heterotetrameric proteins of mammalian mitochondrial origin.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wynn, Richard/0000-0002-1879-2136; Davie, James/0000-0002-0420-6888	NIDDK NIH HHS [DK-37373, DK-26758] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; Ellis R J, 1990, Semin Cell Biol, V1, P1; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HU CWC, 1988, J BIOL CHEM, V263, P9007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Sambrook J, 1989, MOL CLONING LABORATO; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; WYNN RM, 1992, J BIOL CHEM, V267, P1881; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHI W, 1992, IN PRESS PROTEIN SCI	18	77	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12400	12403						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352285				2022-12-25	WOS:A1992HZ48300003
J	MCDONOUGH, PM; GLEMBOTSKI, CC				MCDONOUGH, PM; GLEMBOTSKI, CC			INDUCTION OF ATRIAL-NATRIURETIC-FACTOR AND MYOSIN LIGHT CHAIN-2 GENE-EXPRESSION IN CULTURED VENTRICULAR MYOCYTES BY ELECTRICAL-STIMULATION OF CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEART-CELLS; ALPHA-1-ADRENERGIC RECEPTOR; MEMBRANE DEPOLARIZATION; CARDIAC MYOCYTES; RAT; HYPERTROPHY; GROWTH; TRANSCRIPTION; SEQUENCES; PATHWAYS	While hormonal stimuli and mechanical stretch can induce cardiac-specific gene expression and in some cases cellular hypertrophy, the relationship between myocyte contraction frequency, gene expression, and myocyte growth has not been well characterized. In this study a new model system was developed in which cultures of neonatal rat ventricular myocytes were subjected to long term pacing of contractions with pulsatile electrical stimulation. Myocytes submitted to electrical stimulation for 3 days displayed dramatic increases in cellular size and myofibrillar organization, and a 5-10-fold increase in the expression of the cardiac genes atrial natriuretic factor and myosin light chain-2. Atrial natriuretic factor expression induced by electrical stimulation of contractions was inhibited by nifedipine or W7, indicating a dependence on calcium influx and calmodulin activity. Phosphoinositide hydrolysis and cAMP formation were not affected by electrical stimulation suggesting that gene induction occurred independently of the activation of protein kinases C or A above basal levels. These findings show that the cellular events associated with contraction, such as changes in cytoplasmic free calcium levels and/or cellular stretch, may serve as important determinants of myocyte growth and cardiac gene expression.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NINDS NIH HHS [NS-25037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; BROWNSON C, 1988, MUSCLE NERVE, V11, P1183, DOI 10.1002/mus.880111113; DESNOS C, 1990, DEV BRAIN RES, V52, P161, DOI 10.1016/0165-3806(90)90231-M; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; LEE HR, 1988, J BIOL CHEM, V263, P7352; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MCDERMOTT P, 1985, AM J PHYSIOL, V249, pH763, DOI 10.1152/ajpheart.1985.249.4.H763; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; UNDERWOOD LE, 1987, AM J PHYSIOL, V252, pC450, DOI 10.1152/ajpcell.1987.252.4.C450; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WIER G, 1990, ANNU REV PHYSIOL, V52, P467; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	37	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11665	11668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376309				2022-12-25	WOS:A1992HY94700002
J	FAHIEN, LA; TELLER, JK				FAHIEN, LA; TELLER, JK			GLUTAMATE-MALATE METABOLISM IN LIVER-MITOCHONDRIA - A MODEL CONSTRUCTED ON THE BASIS OF MITOCHONDRIAL LEVELS OF ENZYMES, SPECIFICITY, DISSOCIATION-CONSTANTS, AND STOICHIOMETRY OF HETERO-ENZYME COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; KETOGLUTARATE DEHYDROGENASE COMPLEX; CARBAMOYL-PHOSPHATE SYNTHETASE; HEART CITRATE SYNTHASE; RAT-LIVER; ORNITHINE TRANSCARBAMYLASE; ISOCITRATE DEHYDROGENASE; ALPHA-KETOGLUTARATE; SUBUNIT STRUCTURE; ASPARTATE-AMINOTRANSFERASE	The level of aspartate aminotransferase in liver mitochondria was found to be approximately 140-mu-M, or 2-3 orders of magnitude higher than its dissociation constant in complexes with the inner mitochondrial membrane and the high molecular weight enzymes (M(r) = 1.6 x 10(5) to 2.7 x 10(6)) carbamyl-phosphate synthase I, glutamate dehydrogenase, and the alpha-ketoglutarate dehydrogenase complex. The total concentration of aminotransferase-binding sites on these structures in liver mitochondria was more than sufficient to accommodate all of the aminotransferase. Therefore, in liver mitochondria, the aminotransferase could be associated with the inner mitochondrial membrane and/or these high molecular weight enzymes. The aminotransferase in these hetero-enzyme complexes could be supplied with oxalacetate because binding of aminotransferase to the high molecular weight enzymes can enhance binding of malate dehydrogenase, and binding of both malate dehydrogenase and the aminotransferase facilitated binding of fumarase. The level of malate dehydrogenase was found to be so high (140-mu-M) in liver mitochondria, compared with that of citrate synthase (25-mu-M) and the pyruvate dehydrogenase complex (0.3-mu-M), that there would also be a sufficient supply of oxalacetate to citrate synthase-pyruvate dehydrogenase.			FAHIEN, LA (corresponding author), UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, 1300 UNIV AVE, MADISON, WI 53706 USA.				NATIONAL CANCER INSTITUTE [R01CA040445] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD F, 1986, BIOCHEM J, V236, P527, DOI 10.1042/bj2360527; BALL DJ, 1980, J BIOL CHEM, V255, P805; BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; BLOXHAM DP, 1981, P NATL ACAD SCI-BIOL, V78, P5381, DOI 10.1073/pnas.78.9.5381; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; BUSTAMANTE E, 1977, ANAL BIOCHEM, V80, P401, DOI 10.1016/0003-2697(77)90661-3; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CASSMAN M, 1971, BIOCHEMISTRY-US, V10, P1015; CHARLES R, 1980, BIOCHIM BIOPHYS ACTA, V629, P36, DOI 10.1016/0304-4165(80)90262-7; CHAZOTTE B, 1991, J BIOL CHEM, V266, P5973; CHURCHICH JE, 1978, BIOCHEM BIOPH RES CO, V83, P1105, DOI 10.1016/0006-291X(78)91509-7; CHURCHICH JE, 1976, BIOCHEM BIOPH RES CO, V68, P409, DOI 10.1016/0006-291X(76)91160-8; DATTA A, 1985, J BIOL CHEM, V260, P5008; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; DEROSA G, 1979, BIOCHIM BIOPHYS ACTA, V567, P116, DOI 10.1016/0005-2744(79)90178-5; DSOUZA SF, 1983, J BIOL CHEM, V258, P4706; DUSZYNSKI J, 1978, J BIOL CHEM, V253, P6149; EGAN RR, 1971, BIOCHIM BIOPHYS ACTA, V250, P47, DOI 10.1016/0005-2744(71)90118-5; EHRLICH RS, 1987, BIOCHEM J, V248, P269, DOI 10.1042/bj2480269; EHRLICH RS, 1976, BIOCHEMISTRY-US, V15, P4034, DOI 10.1021/bi00663a018; FAHIEN LA, 1978, J BIOL CHEM, V253, P5745; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P478, DOI 10.1016/0003-9861(69)90060-5; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P449, DOI 10.1016/0003-9861(69)90057-5; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FAHIEN LA, 1985, J BIOL CHEM, V260, P6069; FAHIEN LA, 1983, ARCH BIOCHEM BIOPHYS, V220, P386, DOI 10.1016/0003-9861(83)90428-9; FAHIEN LA, 1979, ARCH BIOCHEM BIOPHYS, V192, P33, DOI 10.1016/0003-9861(79)90069-9; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FAHIEN LA, 1979, J BIOL CHEM, V254, P5983; FAHIEN LA, 1984, ARCH BIOCHEM BIOPHYS, V230, P213, DOI 10.1016/0003-9861(84)90102-4; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P468, DOI 10.1016/0003-9861(69)90059-9; FAHIEN LA, 1977, J BIOL CHEM, V252, P1250; FAHIEN LA, 1988, J BIOL CHEM, V263, P10687; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P456, DOI 10.1016/0003-9861(69)90058-7; FAHIEN LA, 1976, ARCH BIOCHEM BIOPHYS, V176, P298, DOI 10.1016/0003-9861(76)90168-5; FELISS N, 1970, BIOCHEM BIOPH RES CO, V40, P932, DOI 10.1016/0006-291X(70)90993-9; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; GITOMER WL, 1987, BIOCHEM J, V248, P997, DOI 10.1042/bj2480997; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; HAYAKAWA T, 1969, J BIOL CHEM, V244, P3660; HIRASHIMA M, 1967, J BIOL CHEM, V242, P902; KANAREK L, 1964, J BIOL CHEM, V239, P4202; KANAREK L, 1964, J BIOL CHEM, V239, P4207; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KISPAL G, 1986, J BIOL CHEM, V261, P14209; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEE YH, 1975, J BIOL CHEM, V250, P5604; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LOPES C, 1970, EUR J BIOCHEM, V83, P635; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1981, BIOCHEMISTRY-US, V20, P3665, DOI 10.1021/bi00516a001; LUSTY CJ, 1979, J BIOL CHEM, V254, P30; MARSHALL M, 1980, J BIOL CHEM, V255, P7301; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MARTINEZCARRION M, 1967, BIOCHEMISTRY-US, V6, P1715, DOI 10.1021/bi00858a021; MERZ JM, 1987, ARCH BIOCHEM BIOPHYS, V258, P132, DOI 10.1016/0003-9861(87)90330-4; MORIYAMA T, 1971, J BIOL CHEM, V246, P3217; MULLINAX TR, 1982, J BIOL CHEM, V257, P13233; NOYES B E, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1334, DOI 10.1073/pnas.71.4.1334; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; RUOHO A, 1975, BIOCHEM BIOPH RES CO, V63, P417, DOI 10.1016/0006-291X(75)90704-4; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; SIEBERT G, 1957, J BIOL CHEM, V226, P965; SINGH M, 1970, J BIOL CHEM, V245, P4636; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; SMITH EL, 1970, P NATL ACAD SCI USA, V67, P724, DOI 10.1073/pnas.67.2.724; Sols A., 1970, CURRENT TOPICS CELLU, V2, P227; SPIVEY HO, 1989, BIOESSAYS, V10, P127, DOI 10.1002/bies.950100409; Srere P. A., 1972, ENERGY METABOLISM RE, P79; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; SUMEGI B, 1983, BIOCHIM BIOPHYS ACTA, V749, P163, DOI 10.1016/0167-4838(83)90248-0; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; SWICK RW, 1965, J BIOL CHEM, V240, P3334; TELLER JK, 1990, J BIOL CHEM, V265, P19486; VIRDEN R, 1972, BIOCHEM J, V127, P503, DOI 10.1042/bj1270503; WANDERS RJA, 1983, EUR J BIOCHEM, V133, P245, DOI 10.1111/j.1432-1033.1983.tb07455.x; WILLSON VJC, 1981, EUR J BIOCHEM, V113, P477, DOI 10.1111/j.1432-1033.1981.tb05088.x; WIMMER MJ, 1975, J BIOL CHEM, V250, P710	92	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10411	10422						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350279				2022-12-25	WOS:A1992HV09000035
J	NTAMBI, JM				NTAMBI, JM			DIETARY-REGULATION OF STEAROYL-COA DESATURASE-1 GENE-EXPRESSION IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; MESSENGER-RNA; RAT-LIVER; THYROID-HORMONE; S14 GENE; TRANSCRIPTIONAL ACTIVATION; 3T3-L1 PREADIPOCYTES; CHROMATIN STRUCTURE; TERMINAL ENZYME	Expression of the murine liver stearoyl-CoA desaturase gene (SCD1) is induced upon feeding fasted mice a fat-free, high carbohydrate diet (Ntambi, J. M., Buhrow, S. A., Kaestner, K. H., Christy, R. J., Sibley, E., Kelly, T. J., and Lane, M. D. (1988) J. Biol. Chem. 263, 17291-17300). In the present study, SCD1-specific RNA riboprobes and cDNA probes were used to study the mechanism for the induction of SCD1 mRNA. Based on the time course of induction, the SCD1 mRNA increased from 2-fold within 6 h to 45-fold within 36 h. Nuclear run-on transcription studies showed that the accumulation of SCD1 mRNA after refeeding starved mice a fat-free, high carbohydrate diet was a consequence of the transcriptional activation of the SCD1 gene. The SCD1 mRNA level decreased rapidly (t1/2 = approximately 4 h) within 24 h when mice fed the fat-free, high carbohydrate diet were switched to a regular chow diet. Furthermore, when the fat-free diet was supplemented with triacylglycerides containing polyunsaturated fatty acids, the transcription of the SCD1 gene and the induction of the SCD1 mRNA were significantly blunted. Triacylglycerides containing saturated and monounsaturated fatty acids were without dramatic effects. In contrast, synthesis of liver albumin mRNA was little affected by any of these dietary variations, indicating that the observed changes in the transcription of the SCD1 gene and mRNA levels were specific. These data demonstrate that both dietary carbohydrates and polyunsaturated fatty acids or their metabolites directly or indirectly regulate the expression of the SCD1 gene in mouse liver.			NTAMBI, JM (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,3900 RESERVOIR RD,WASHINGTON,DC 20007, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; ESNER M, 1982, BIOCHEM J, V206, P561; GOODRIDGE AG, 1983, ARCH BIOPHYS, V227, P54; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JEFFCOAT R, 1979, EUR J BIOCHEM, V101, P439, DOI 10.1111/j.1432-1033.1979.tb19737.x; JOSHI VC, 1979, J BIOL CHEM, V254, P1779; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1987, J BIOL CHEM, V262, P778; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KASTURI R, 1984, ARCH BIOCHEM BIOPHYS, V233, P530, DOI 10.1016/0003-9861(84)90476-4; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PRASAD MR, 1979, J BIOL CHEM, V254, P6362; SONG MKH, 1988, J BIOL CHEM, V263, P17970; THIEDE MA, 1985, J BIOL CHEM, V260, P4459; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; TOMLINSON JE, 1988, J NUTR, V118, P408, DOI 10.1093/jn/118.3.408; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	31	240	252	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10925	10930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350282				2022-12-25	WOS:A1992HV09000107
J	COUPRY, I; DUZIC, E; LANIER, SM				COUPRY, I; DUZIC, E; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .2. PREFERENTIAL COUPLING OF THE ALPHA-2C-ADRENERGIC RECEPTOR TO THE GUANINE NUCLEOTIDE-BINDING PROTEIN, GO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED MUSCARINIC RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; HIGH-AFFINITY; REGULATORY PROTEINS; FUNCTIONAL RECONSTITUTION; PHOSPHOLIPID-VESICLES; MOLECULAR-CLONING; CALCIUM CHANNELS; ALPHA-SUBUNIT; HYBRID-CELLS	Cell to cell communication by many hormones and neurotransmitters involves three major entities: receptor (R), G-protein (G), and effector molecule (E). Plasticity in this system is conferred by the existence of each entity as isoforms or closely related subtypes that are expressed in a tissue-specific and developmentally regulated manner. Factors that determine signal specificity in this system are poorly understood. Such factors include the relative affinity and stoichiometry of R-G or G-E and the possible colocalization of R-G-E in cellular microdomains. Utilizing the alpha-2-adrenergic receptor (alpha-2-AR) system as a representative subfamily of this class of signal transducers, we determined the relative importance of these factors. By analysis of R-G coupling in mammalian cells cotransfected With alpha-2-AR genes and G(alpha) cDNA, we demonstrate preferential coupling between an alpha-2-AR subtype and G(o). Our data implicate R-G affinity as an important determinant of signal transduction specificity and indicate that a critical level of G(o-alpha) is required for coupling. This report indicates the utility of R-G cotransfection in mammalian cells as a "natural environment model" to characterize events occurring at the R-G and G-E interface.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CELLULAR & MOLEC RES LAB,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital			COUPRY, Isabelle/L-4900-2014	Lanier, Stephen/0000-0002-2740-7607	FOGARTY INTERNATIONAL CENTER [F05TW004313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; FIC NIH HHS [3 FO5 TW4313] Funding Source: Medline; NINDS NIH HHS [NS-24821] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, FASEB J, V4, P3068; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DUZIC E, 1992, J BIOL CHEM, V267, P9844; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1986, J BIOL CHEM, V261, P133; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1985, J BIOL CHEM, V260, P864; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KUROSE H, 1986, J BIOL CHEM, V261, P6423; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LONGABAUGH JP, 1988, J CLIN INVEST, V81, P420, DOI 10.1172/JCI113335; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MILLIGAN G, 1990, BIOCHEM J, V270, P521; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEGISHI M, 1988, J BIOL CHEM, V263, P6893; OHARA K, 1988, MOL PHARMACOL, V33, P290; PARKER EM, 1991, J BIOL CHEM, V266, P519; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P187; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRASSHEIM D, 1990, BIOCHEM J, V266, P521, DOI 10.1042/bj2660521; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SUSANNI EE, 1989, CIRC RES, V65, P1145, DOI 10.1161/01.RES.65.4.1145; THOMSEN WJ, 1988, MOL PHARMACOL, V34, P6301; UEDA H, 1989, J BIOL CHEM, V264, P3732; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9852	9857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349607				2022-12-25	WOS:A1992HT96500065
J	WHITE, RT; DAMM, D; HANCOCK, N; ROSEN, BS; LOWELL, BB; USHER, P; FLIER, JS; SPIEGELMAN, BM				WHITE, RT; DAMM, D; HANCOCK, N; ROSEN, BS; LOWELL, BB; USHER, P; FLIER, JS; SPIEGELMAN, BM			HUMAN ADIPSIN IS IDENTICAL TO COMPLEMENT FACTOR-D AND IS EXPRESSED AT HIGH-LEVELS IN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE HOMOLOG; AMINO-ACID-SEQUENCE; INSULIN-RECEPTOR; MESSENGER-RNA; FACTOR-B; BIOSYNTHESIS; PROTEINS; MONOCYTES; PATHWAY; CELLS	A cDNA for human adipsin was isolated and shown to encode a protein sharing 98% amino acid sequence similarity with the protein sequence previously determined for purified natural human complement factor D. Like mouse adipsin, recombinant human adipsin displays the enzymatic activity of human complement factor D, cleaving complement factor B only when B is complexed with activated complement component C3. We conclude that human adipsin is equivalent to complement factor D and that adipsin is the homologue of factor D in rodents. Adipose tissue is a major site of synthesis of human adipsin/complement factor D mRNA, but unlike the case in rodents, human adipsin mRNA is also expressed in monocytes/macrophages. The data presented here, demonstrating the equivalence of human adipsin to complement factor D and its high level of expression in fat, suggest a previously unsuspected role for adipose tissue in immune system biology.	UNIV EDINBURGH,AGR & FOOD RES COUNCIL,CTR GENOME RES,EDINBURGH EH9 3JQ,SCOTLAND; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of Edinburgh; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	WHITE, RT (corresponding author), CALIF BIOTECHNOL INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043, USA.		Flier, jeffrey/AAG-6223-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405, R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405, DK42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNUM SR, 1985, J IMMUNOL, V134, P1799; BEATTY DW, 1981, CLIN IMMUNOL IMMUNOP, V18, P334, DOI 10.1016/0090-1229(81)90126-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DECEULAER C, 1980, IMMUNOLOGY, V41, P37; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GROSSO LE, 1985, CANCER RES, V45, P847; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4471; KING GL, 1980, J CLIN INVEST, V66, P130, DOI 10.1172/JCI109826; LESAVRE PH, 1979, J IMMUNOL, V123, P529; Maniatis T., 1982, MOL CLONING; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; NIEMANN MA, 1984, BIOCHEMISTRY-US, V23, P2482, DOI 10.1021/bi00306a025; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TAYLOR SI, 1981, P NATL ACAD SCI-BIOL, V78, P7157, DOI 10.1073/pnas.78.11.7157; TOMANA M, 1985, MOL IMMUNOL, V22, P107, DOI 10.1016/S0161-5890(85)80004-3; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	26	300	323	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9210	9213						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374388				2022-12-25	WOS:A1992HR85400077
J	LICHTENBERG, U; QUINTRELL, N; BISHOP, JM				LICHTENBERG, U; QUINTRELL, N; BISHOP, JM			HUMAN PROTEIN-TYROSINE KINASE GENE HCK - EXPRESSION AND STRUCTURAL-ANALYSIS OF THE PROMOTER REGION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; SV40 T-ANTIGEN; HEMATOPOIETIC-CELLS; FGR PROTOONCOGENE; MAMMALIAN-CELLS; LCK GENE; DIFFERENTIATION; LINE; SEQUENCE; HL-60	The vertebrate gene HCK encodes a protein-tyrosine kinase that is closely related to the product of the proto-oncogene SRC. HCK is expressed principally in monocytic and granulocytic hematopoietic cells, in coordination with differentiation of these cells. Here we report an initial description of the mechanisms by which expression of human HCK is controlled. Induction of the gene during differentiation was manifested by an increase in the steady-state levels of HCK RNA and protein product. The accumulation of RNA apparently resulted from modulation of transcription itself, since no change occurred in the stability of the transcripts. Transcription initiated at multiple sites, clustered c. 145 nucleotides upstream of the first intron of HCK. The sequence of 660 bp upstream of the major initiation site was determined, revealing candidate binding sites for Sp1 and AP-2 transcription factors, but neither TATA nor CAAT elements. Comparison to the same region of the mouse hck locus showed five small regions of similarity, only two of which were topographically analogous between the two sequences. It appears that expression of HCK is regulated primarily through control of transcription, but the mechanisms by which tissue-specific expression and increase of transcription during differentiation are achieved remain to be explored.	UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	LICHTENBERG, U (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DALTON WT, 1988, BLOOD, V71, P242; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GALLAGHER R, 1979, BLOOD, V54, P713; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIKKO J, 1979, NATURE, V279, P605; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TARELLA C, 1982, CANCER RES, V42, P445; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, 1991, BLOOD, V77, P726; ZIEGLER SF, 1991, ONCOGENE, V6, P283; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	62	32	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					849	858						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373873				2022-12-25	WOS:A1992HP64200003
J	SHARIF, M; PRIVALSKY, ML				SHARIF, M; PRIVALSKY, ML			V-ERBA AND C-ERBA PROTEINS ENHANCE TRANSCRIPTIONAL ACTIVATION BY C-JUN	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; THYROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; NEGATIVE REGULATION; ONCOGENE PROTEIN; OSTEOCALCIN GENE; BINDING DOMAIN; BETA-GENE; TATA BOX	The ability of different transcription factors to interact with one another is an important means by which the eucaryotic cell can integrate separate growth and differentiation signals into a coherent response. We report here an analysis of the interactions of transcription factors that are also the products of oncogenes: the erbA, jun and fos proteins. We demonstrate that the c-jun polypeptide can functionally interact with the c-erbA protein (thyroid hormone receptor) to yield an enhanced activity greater than that of either factor individually. Although the avian erythroblastosis v-erbA allele is generally thought to act as a transcriptional repressor in vertebrate cells, we also report the existence of promoter contexts where v-erbA, as well as c-erbA, can serve as 'co-activators' of c-jun function. V-erbA appears to augment retinoic acid receptor function in the same context. Our results suggest that v-erbA may have unanticipated positive effect on transcription in the neoplastic cell in addition to the repressor functions previously characterized.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis					NCI NIH HHS [CA53394, CA38823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, R01CA053394, R01CA038823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOUCHER P, 1990, ONCOGENE, V5, P1303; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FORREST D, 1990, ONCOGENE, V5, P309; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STEIN GS, 1989, CONNECT TISSUE RES, V20, P3, DOI 10.3109/03008208909049996; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					953	960						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349165				2022-12-25	WOS:A1992HP64200015
J	OTSU, K; KINSELLA, JL; KOH, E; FROEHLICH, JP				OTSU, K; KINSELLA, JL; KOH, E; FROEHLICH, JP			PROTON DEPENDENCE OF THE PARTIAL REACTIONS OF THE SODIUM-PROTON EXCHANGER IN RENAL BRUSH-BORDER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; INTRACELLULAR PH REGULATION; PRESTEADY-STATE KINETICS; FROG SKIN; VESICLES; AMILORIDE; ANTIPORT; KIDNEY; MECHANISM; TRANSPORT	The pre-steady state time dependence of Na+ accumulation by the Na+-H+ exchanger in renal brush border membrane vesicles was investigated at 0-degrees-C by a manual mixing technique using amiloride to quench the reaction. Dilution of acid-loaded (pH(i) 5.7) vesicles into an alkaline medium (pH(o) 7.7) containing 1 mM Na-22(+) produced a time course of amiloride-sensitive Na+ uptake that consisted of three distinct phases: 1) a lag, 2) a monoexponential "burst," and 3) a linear or steady state phase. Experiments testing for the presence of Na-22(+) backflux, residual Na+ binding to the membrane, and hysteresis were negative, lending support to the hypothesis that the burst phase corresponds to Na+ translocation during the initial turnover of Na+-H+ exchanger. Lowering the internal pH increased the amount of Na+ uptake in each of the phases without affecting the apparent burst rate, whereas lowering the external pH inhibited Na+ uptake while increasing the duration of the lag phase. The pattern of inhibition produced by external H+ was of the simple competitive type, indicating that Na+ and H+ share a common binding site. Steady state Na+ uptake showed a sigmoidal dependence on internal pH (Hill coefficient = 1.67), consistent with the presence of an internal allosteric H+ activation site. Alkaline loading conditions (pH(i) 7.7), which favor desaturation of the internal H+ binding sites, completely abolished Na+ uptake in the steady state. In contrast, Na+ accumulation during the burst phase was reduced to 25% of an acid-loaded (pH(i) 5.7) control. The persistence of the burst phase and the disappearance of steady state Na+ uptake under alkaline loading conditions suggest that recycling of the H+-loaded exchanger is a late event in the transport cycle that follows Na+ translocation (ping-pong mechanism) and controls the steady state rate of Na+ accumulation. Activation of the recycling step involves sequential binding of H+ to the allosteric and transport sites, thus accounting for the cooperative dependence of steady state Na+ uptake on the internal [H+].	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; NIA,CARDIOVASC SCI LAB,BALTIMORE,MD 21224	University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								ARONSON PS, 1983, J BIOL CHEM, V258, P6767; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Booth A G, 1974, Biochem J, V142, P575; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CHOEN J, 1988, J BIOL CHEM, V263, P2309; CUTHBERT AW, 1974, MOL PHARMACOL, V10, P880; CUTHBERT AW, 1978, BRIT J PHARMACOL, V63, P139, DOI 10.1111/j.1476-5381.1978.tb07783.x; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; FROEHLICH O, 1986, BIOCHIM BIOPHYS ACTA, V864, P169; Frost AA, 1961, KINETICS MECHANISM, P166; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1982, BIOCHIM BIOPHYS ACTA, V689, P161, DOI 10.1016/0005-2736(82)90200-0; KINSELLA JL, 1979, BIOCHIM BIOPHYS ACTA, V552, P468, DOI 10.1016/0005-2736(79)90191-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOODY WJ, 1981, J PHYSIOL-LONDON, V316, P293, DOI 10.1113/jphysiol.1981.sp013788; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; Neet K E, 1980, Methods Enzymol, V64, P192; OTSU K, 1989, P NATL ACAD SCI USA, V86, P4818, DOI 10.1073/pnas.86.13.4818; OTSU K, 1986, BIOPHYS J, V49, pA553; OTSU K, 1988, BIOPHYS J, V53, pA341; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PARIS S, 1983, J BIOL CHEM, V258, P3503; RINDLER MJ, 1981, J BIOL CHEM, V256, P820; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Segel I.H., 1975, ENZYME KINETICS, P353; VIGNE P, 1985, J BIOL CHEM, V260, P4120; VIGNE P, 1982, J BIOL CHEM, V257, P9394; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF733, DOI 10.1152/ajprenal.1982.242.6.F733; WIERZBICKI W, 1990, J MEMBRANE BIOL, V117, P11, DOI 10.1007/BF01871562	35	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8089	8096						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373720				2022-12-25	WOS:A1992HQ18500022
J	SIGURSKJOLD, BW; BUNDLE, DR				SIGURSKJOLD, BW; BUNDLE, DR			THERMODYNAMICS OF OLIGOSACCHARIDE BINDING TO A MONOCLONAL-ANTIBODY SPECIFIC FOR A SALMONELLA O-ANTIGEN POINT TO HYDROPHOBIC INTERACTIONS IN THE BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOL-WATER INTERACTIONS; HEAT-CAPACITY; CARBOHYDRATE INTERACTIONS; MAGNETIC-RESONANCE; PROTEIN-STRUCTURE; AQUEOUS-SOLUTIONS; COMBINING SITES; SEROGROUP-A; STABILITY; MONOSACCHARIDES	The thermodynamic characteristics of oligosaccharide binding to an antibody binding site that is dominated by aromatic amino acids suggest that the hydrophobic effect contributes substantially to complex formation as well as hydrogen bonding and van der Waals interactions. A detailed titration microcalorimetric study on the temperature dependence of the binding of a trisaccharide, representing the epitope of a Salmonella O-antigen, showed that its maximum binding to the monoclonal antibody Se155-4 occurs just below room temperature and both enthalpy and entropy changes are strongly dependent on temperature in a mutually compensating manner. The heat capacity change also shows an unusually strong temperature dependence being large and negative above room temperature and positive below. van't Hoff analysis of the temperature dependence of the binding constant yielded a biphasic curve with two apparent intrinsic enthalpy estimations (approximately -100 kJ mol-1 above 18-degrees-C and approximately +100 kJ mol-1 below), each very different from the calorimetrically determined enthalpies (ranging from about -60 kJ mol-1 to -20 kJ mol-1). This was interpreted as being due to large enthalpy contributions from concomitant reactions, most notably changes in solvation. Linear plots, -DELTA-H0 versus -T-DELTA-S0, observed for temperature-dependent measurements mirror the behavior seen for a series of functional group replacements, suggesting that the molecular and physical origin of these phenomena are closely related and linked to the role of water in complex formation. The thermodynamic results are compared to the mode of binding determined from a 2.05-angstrom resolution structure of the Fab-oligosaccharide complex, and with literature data for the heat capacities of sugars in aqueous solution and for the thermodynamics of carbohydrate binding to transport proteins and lectins.			SIGURSKJOLD, BW (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA.							ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; ANAND NN, 1990, PROTEIN ENG, V3, P541, DOI 10.1093/protein/3.6.541; ANAND NN, 1991, J BIOL CHEM, V266, P21874; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BOCK K, 1987, PURE APPL CHEM, V59, P1447, DOI 10.1351/pac198759111447; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; BOCK K, 1990, STUDIES NATURAL PROD, V7, P29; BONNER OD, 1976, J CHEM THERMODYN, V8, P105, DOI 10.1016/0021-9614(76)90082-3; BUNDLE DR, 1989, PURE APPL CHEM, V61, P1171, DOI 10.1351/pac198961071171; CABANI S, 1981, J SOLUTION CHEM, V10, P563, DOI 10.1007/BF00646936; CARVER JP, 1989, CIBA F SYMP, V145, P6; Cesaro A., 1986, THERMODYNAMIC DATA B, P177; CYGLER M, 1991, SCIENCE, V215, P489; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DIPAOLA G, 1977, CAN J CHEM, V55, P3825, DOI 10.1139/v77-540; FRANKS F, 1991, PURE APPL CHEM, V63, P1367, DOI 10.1351/pac199163101367; FRANKS F, 1987, PURE APPL CHEM, V59, P1189, DOI 10.1351/pac198759091189; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GILL SJ, 1985, J PHYS CHEM-US, V89, P3758, DOI 10.1021/j100263a034; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HEARN RP, 1971, BIOCHEMISTRY-US, V10, P806; HINDSGAUL O, 1985, CAN J CHEM, V63, P2653, DOI 10.1139/v85-440; HINZ HJ, 1979, BIOCHEMISTRY-US, V18, P3084, DOI 10.1021/bi00581a027; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; KAWAIZUMI F, 1981, B CHEM SOC JPN, V54, P2282, DOI 10.1246/bcsj.54.2282; KAWAIZUMI F, 1981, J CHEM THERMODYN, V13, P89, DOI 10.1016/S0021-9614(81)80013-4; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; LEMIEUX RU, 1978, NOUV J CHIM, V2, P321; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LEMIEUX RU, 1985, 8TH P INT S MED CHEM, P329; LIAN YN, 1982, ACTA CHEM SCAND A, V36, P735, DOI 10.3891/acta.chem.scand.36a-0735; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAHANTA SK, 1990, BIOCHEM J, V265, P831, DOI 10.1042/bj2650831; MIYAJIMA K, 1983, B CHEM SOC JPN, V56, P1620, DOI 10.1246/bcsj.56.1620; MIYAJIMA K, 1985, B CHEM SOC JPN, V58, P2595, DOI 10.1246/bcsj.58.2595; MORIN PE, 1991, BIOCHEMISTRY-US, V30, P8494, DOI 10.1021/bi00098a030; MUKKUR TKS, 1984, CRC CR REV BIOCH MOL, V16, P133, DOI 10.3109/10409238409102301; MULLER N, 1990, ACCOUNTS CHEM RES, V23, P23, DOI 10.1021/ar00169a005; NEUROHR KJ, 1982, BIOCHEMISTRY-US, V21, P498, DOI 10.1021/bi00532a013; NICHOLS N, 1976, J CHEM THERMODYN, V8, P1081, DOI 10.1016/0021-9614(76)90139-7; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; TANFORD C, 1980, HYDROPHOBIC EFFECT; WIESINGER H, 1986, THERMODYNAMIC DATA B, P211; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOOD RH, 1990, P NATL ACAD SCI USA, V87, P946, DOI 10.1073/pnas.87.3.946; ZIDOVETZKI R, 1988, MOL IMMUNOL, V25, P379, DOI 10.1016/0161-5890(88)90032-6	57	106	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8371	8376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373726				2022-12-25	WOS:A1992HQ18500065
J	YIN, TG; MIYAZAWA, K; YANG, YC				YIN, TG; MIYAZAWA, K; YANG, YC			CHARACTERIZATION OF INTERLEUKIN-11 RECEPTOR AND PROTEIN TYROSINE PHOSPHORYLATION INDUCED BY INTERLEUKIN-11 IN MOUSE 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING; GENE-EXPRESSION; CACHECTIN; FIBROBLASTS; ADIPOCYTES; CACHEXIA; INVITRO; SIGNAL	In this study, we have characterized the biochemical nature of interleukin (IL)-11 receptors (IL-11R) and determined the possible signal transduction pathways mediated by IL-11 in 3T3-L1 mouse preadipocytes. The results show that IL-11 strongly inhibited lipoprotein lipase activity and adipogenesis in 3T3-L1 cells, and the suppression of lipoprotein lipase activity by IL-11 was controlled at the post-transcriptional level. The ability of IL-11 to inhibit lipoprotein lipase activity and adipogenesis therefore reflected the expression of functional IL-11R on the cell surface. Scatchard plot analysis according to specific binding data revealed the existence of a single class of high affinity IL-11R with a K(d) of 3.49 x 10(-10) M and a receptor density of 5140 sites/cell on 3T3-L1 cells. Affinity cross-linking studies with I-125-IL-11 indicated that IL-11R consists of a single polypeptide chain of 151 kDa in size. Furthermore, we have studied the role of protein tyrosine phosphorylation in the IL-11R-linked signal transduction pathways. The results show that IL-11R ligation rapidly and transiently stimulated tyrosine phosphorylation of 152-, 94-, 47-, and 44-kDa proteins. This effect is specific for IL-11 since neutralizing antibody to IL-11 abrogated IL-11-induced tyrosine phosphorylation, and other cytokines such as IL-6 and IL-1-alpha did not change the tyrosine phosphorylation pattern in 3T3-L1 cells. These results suggest that IL-11R is closely linked to a functional protein-tyrosine kinase pathway, and tyrosine phosphorylation may be a key step in the initiation of the IL-11R-mediated transmembrane signaling.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,975 W WALNUT ST,IB 540,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis								BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRUNO E, 1991, EXP HEMATOL, V19, P378; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; GIMBLE JM, 1989, MOL CELL BIOL, V9, P4587, DOI 10.1128/MCB.9.11.4587; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PRICE SR, 1986, BIOCHIM BIOPHYS ACTA, V889, P374, DOI 10.1016/0167-4889(86)90201-6; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	33	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8347	8351						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373723				2022-12-25	WOS:A1992HQ18500061
J	BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA				BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA			LIPOPOLYSACCHARIDE-GAMMA-INDUCED AND INTERFERON-GAMMA-INDUCED EXPRESSION OF HCK AND LYN TYROSINE KINASES IN MURINE BONE MARROW-DERIVED MACROPHAGES	ONCOGENE			English	Article							RESPIRATORY BURST; GENE HCK; HUMAN NEUTROPHIL; CELLS; PHOSPHORYLATION; ACTIVATION; PHAGOCYTES; RECEPTOR; OXIDASE; CD4	We have examined the role of tyrosine phosphorylation during the course of macrophage activation. Initial experiments indicated that vanadate, a known phosphotyrosine phosphatase inhibitor, enhanced the phorbol 12-myristate 13-acetate (PMA)-triggered respiratory burst and potentiated the priming effects of bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma), suggesting that tyrosine phosphorylation may be important in these end cell functions. As src-related kinases have been implicated in the activation of cells of other haemopoietic lineages, we examined the relationship between the activity of two such kinases, hck and lyn, and priming of the respiratory burst. We found that the level of hck and lyn is increased following exposure of bone marrow-derived macrophages (BMM) to LPS or IFN-gamma. The induction of both of these kinases follows similar kinetics with maximal activity occurring at 24-48 h. Interestingly, the kinetics of induction of hck and lyn kinase activity in BMM demonstrated a close temporal relationship with the priming effects of LPS and IFN-gamma on the macrophage respiratory burst. Collectively, these observations raise the possibility that modulation of expression of hck and lyn is involved in the regulation of the respiratory burst.	LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne			Stanley, Ed G/A-2985-2013; Phillips, Wayne A/H-8070-2013	Stanley, Ed G/0000-0002-6389-3665; Phillips, Wayne A/0000-0002-7961-638X; Lock, Peter/0000-0003-4421-3609; Ralph, Stephen/0000-0002-4335-092X				CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; JOHNSTON RB, 1990, PEDIATRIC RES S, V27, P544; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; PHILLIPS WA, 1990, J CELL PHYSIOL, V144, P190, DOI 10.1002/jcp.1041440203; PHILLIPS WA, 1989, J IMMUNOL, V142, P2445; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	26	116	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					703	710						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373483				2022-12-25	WOS:A1992HQ68200012
J	BAJT, ML; GINSBERG, MH; FRELINGER, AL; BERNDT, MC; LOFTUS, JC				BAJT, ML; GINSBERG, MH; FRELINGER, AL; BERNDT, MC; LOFTUS, JC			A SPONTANEOUS MUTATION OF INTEGRIN-ALPHA-IIB-BETA-3 (PLATELET GLYCOPROTEIN-IIB-IIIA) HELPS DEFINE A LIGAND-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN GAMMA-CHAIN; GPIIB-IIIA; GLANZMANNS THROMBASTHENIA; MONOCLONAL-ANTIBODIES; ADHESION RECEPTOR; RECOGNITION SITE; CELL-SURFACE; EXPRESSION; COMPLEX; LOCALIZATION	This work characterizes a mutant integrin alpha(IIb)beta-3 (glycoprotein (GP) IIb-IIIa) from a thrombasthenic patient, ET, whose platelets fail to aggregate in response to stimuli. The nature of the defect was defined by the reduced ability of synthetic peptide ligands, corresponding to the carboxyl terminus of the fibrinogen-gamma chain (gamma-402-411) and Arg-Gly-Asp (RGD), to increase the binding of the occupancy-dependent anti-LIBS1 antibody to mutant alpha(IIb)beta-3 and the reduced binding of mutant alpha(IIb)beta-3 to an immobilized RGD peptide. In addition, ET's platelets failed to bind the ligand-mimetic monoclonal anti-alpha(IIb)beta-3, PAC1. DNA sequence analysis of amplified ET genomic DNA revealed a single G --> A base change which encoded substitution of R214 by Q in mature beta-3. Introduction of this point mutation into recombinant wild type alpha(IIb)beta-3 expressed in Chinese hamster ovary cells reproduced the ET platelet alpha(IIb)beta-3 deficits in binding of fibrinogen, mAb PAC1, and synthetic peptide ligands. Furthermore, substitution of R214 by Q in the synthetic peptide containing the sequence of beta-3(211-222) resulted in decreased ability of this peptide to block fibrinogen binding to purified alpha(IIb)beta-3. These findings suggest that substitution of beta-3 R214 by Q is responsible for the functional defect in alpha-(IIb)beta-3 and that R214 is proximal to or part of a ligand binding domain in alpha-(IIb)beta-3.	UNIV SYDNEY, WESTMEAD HOSP, DEPT MED, THROMBOSIS & CARDIOVASC DIS RES CTR, WESTMEAD, NSW 2145, AUSTRALIA	University of Sydney	BAJT, ML (corresponding author), Scripps Clinic, COMM VASCULAR BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Berndt, Michael C/D-5580-2012	Frelinger, Andrew/0000-0002-6871-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042977, R29HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008172] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42977] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [T32GM08172-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN ML, 1987, SEMIN THROMB HEMOST, V13, P307, DOI 10.1055/s-2007-1003506; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COURTOIS G, 1986, EUR J BIOCHEM, V159, P61, DOI 10.1111/j.1432-1033.1986.tb09833.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1990, BLOOD, V76, P2017; GINSBERG MH, 1980, BLOOD, V55, P661; HERRMANN BG, 1987, GUIDE MOL CLONING TE, P180; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1986, BLOOD, V68, P1224; TAUB R, 1989, J BIOL CHEM, V264, P259; XIAOPING D, 1991, CELL, V65, P409; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	35	157	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3789	3794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371279				2022-12-25	WOS:A1992HE60700040
J	SZABO, I; BERNARDI, P; ZORATTI, M				SZABO, I; BERNARDI, P; ZORATTI, M			MODULATION OF THE MITOCHONDRIAL MEGACHANNEL BY DIVALENT-CATIONS AND PROTONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; INNER MEMBRANE; PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; SULFHYDRYL-GROUPS; CYCLOSPORINE-A; CHANNEL; INHIBITION; CONDUCTANCE	In patch-clamp experiments on rat liver mitoplasts, the 1.3 nanosiemens (in 150 mM KCl) mitochondrial mega-channel was activated by Ca'' and competitively inhibited by Mg2+, Mn2+, Ba2+, and Sr2+. Cyclosporin A, which inhibits the mega-channel, also showed a competitive behavior versus Ca2+. The pore is regulated by pH in the physiological range; lower pH values cause its closure in a Ca2+-reversible manner. The modulating sites involved in these effects are located on the matrix side of the membrane. As illustrated in the companion paper (Bernardi, P., Vassanelli, S., Veronese, P., Colonna, R., Szabo, I., and Zoratti, M. (1992) J. Biol. Chem. 267, 2934-2939), the calcium-induced permeability transition of mitochondria is affected by these various agents in a similar manner. The results support the identification of the mega-channel with the pore believed to be involved in the permeabilization process. The kinetic characteristics of the single channel events support the idea that the mega-channel is composed of cooperating subunits.	CNR, CTR STUDI FISIOL MITOCONDRI, IST PATOL GEN, VIA TRIESTE 75, I-35121 PADUA, ITALY	Consiglio Nazionale delle Ricerche (CNR)			Padova, Ildiko/K-5344-2016; Szabo, Ildiko/AAW-5972-2021; Bernardi, Paolo/C-3656-2008	Szabo, Ildiko/0000-0002-3637-3947; Bernardi, Paolo/0000-0001-9187-3736				ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V113, P438, DOI 10.1016/S0926-6593(66)80002-4; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, MECHANICS SWELLING C; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; HILLERED L, 1983, FEBS LETT, V154, P247, DOI 10.1016/0014-5793(83)80158-6; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IGBAVBOA U, 1989, BIOCHEM BIOPH RES CO, V161, P619, DOI 10.1016/0006-291X(89)92644-2; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LEQUOC K, 1982, ARCH BIOCHEM BIOPHYS, V216, P639, DOI 10.1016/0003-9861(82)90254-5; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; OSHEA PS, 1984, BIOCHEM J, V219, P719, DOI 10.1042/bj2190719; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1990, J BIOENERG BIOMEMBR, V22, P663, DOI 10.1007/BF00809070; SARIS NEL, 1988, J BIOENERG BIOMEMBR, V20, P749, DOI 10.1007/BF00762551; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; TONINELLO A, 1982, FEBS LETT, V142, P63, DOI 10.1016/0014-5793(82)80220-2; ZOCCARATO F, 1981, EUR J BIOCHEM, V114, P195, DOI 10.1111/j.1432-1033.1981.tb05136.x; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1991, TRENDS BIOMEMBRANES, P263	40	205	210	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2940	2946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371109				2022-12-25	WOS:A1992HD15400022
J	GEISER, AG; BURMESTER, JK; WEBBINK, R; ROBERTS, AB; SPORN, MB				GEISER, AG; BURMESTER, JK; WEBBINK, R; ROBERTS, AB; SPORN, MB			INHIBITION OF GROWTH BY TRANSFORMING GROWTH-FACTOR-BETA FOLLOWING FUSION OF 2 NONRESPONSIVE HUMAN CARCINOMA CELL-LINES - IMPLICATION OF THE TYPE-II RECEPTOR IN GROWTH INHIBITORY RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; HUMAN-LUNG FIBROBLASTS; PLASMINOGEN-ACTIVATOR INHIBITOR; MESSENGER-RNA EXPRESSION; TGF-BETA; REVERSIBLE INHIBITION; IV COLLAGENASE; PROLIFERATION; FACTOR-BETA-1; BINDING	Loss of growth regulation by transforming growth factor-beta (TGF-beta) may be an important step in carcinogenesis. We have used a cell fusion system to show that inhibition of growth by TGF-beta can be restored to carcinoma cell lines that are unresponsive to the inhibitory effects of TGF-beta. In a previous study, the EJ bladder carcinoma line was fused to the SW480 colon adenocarcinoma line and found to produce nontumorigenic hybrid cells along with one hybrid cell clone of low tumorigenicity. Here we show that the capacity of the nontumorigenic hybrid cells to respond to either TGF-beta-1 or TGF-beta-2 has been restored, while the parental or tumorigenic hybrid cells show little or no inhibition of growth following TGF-beta treatment. Crosslinking analyses with labeled TGF-beta-1 demonstrated much higher levels of the type II (85 kDa) receptor in the hybrid cells compared with the parental tumor lines. Both the parental and tumorigenic hybrid cell lines were capable of responding to TGF-beta as evidenced by increased levels of mRNA for fibronectin, type IV collagenase, and plasminogen activator inhibitor after treatment with TGF-beta-1. These results suggest that the type II receptor is necessary for mediating the effects of TGF-beta on inhibition of growth but not on gene activation of the hybrid cells.			GEISER, AG (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.							ARTEAGA CL, 1988, CANCER RES, V48, P3898; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BROWN PD, 1990, CANCER RES, V50, P6184; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; FAFEUR V, 1991, J CELL BIOCH B, V15, P172; Fafeur V, 1990, GROWTH FACTORS, V3, P237, DOI 10.3109/08977199009043908; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEISER AG, 1989, CANCER RES, V49, P1572; GEISER A G, 1989, Critical Reviews in Oncogenesis, V1, P261; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUGGETT AC, 1990, CANCER RES, V50, P7468; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINASK KK, 1991, EXP CELL RES, V192, P1, DOI 10.1016/0014-4827(91)90149-O; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1977, J NATL CANCER I, V58, P1743, DOI 10.1093/jnci/58.6.1743; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCMAHON JB, 1986, CANCER RES, V46, P4665; MULDER KM, 1990, CANCER RES, V50, P7581; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAHL SM, 1988, J IMMUNOL, V140, P3026; Wakefield L. M., 1990, TUMOR SUPPRESSOR GEN, P217; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOLLENBERG GK, 1987, CANCER RES, V47, P6595	48	177	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2588	2593						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370826				2022-12-25	WOS:A1992HB53200074
J	KURODA, S; OTAKA, S; MIYAZAKI, T; NAKAO, M; FUJISAWA, Y				KURODA, S; OTAKA, S; MIYAZAKI, T; NAKAO, M; FUJISAWA, Y			HEPATITIS-B VIRUS ENVELOPE L-PROTEIN PARTICLES - SYNTHESIS AND ASSEMBLY IN SACCHAROMYCES-CEREVISIAE, PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-ANTIGEN PARTICLES; HUMAN-LYSOZYME; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SIGNAL SEQUENCE; P-31 GENE; YEAST; EXPRESSION; SECRETION; ACID	The hepatitis B virus envelope gene encodes three transmembrane proteins in frame; S, the product of S gene; M, the product of M (pre-S2 + S) gene; and L, the product of L (pre-S1 + pre-S2 + S) gene. Unlike the S and M proteins, attempts to efficiently synthesize L proteins and assemble them into L protein particles in various eukaryotic cells have been unsuccessful, probably because of the presence of the pre-S1 peptide with an unknown function which appears to be inhibitory to the host secretory apparatus. To investigate the role of the pre-S1 peptide, we constructed an L gene fused with a synthetic gene for chicken-lysozyme signal peptide (C-SIG) at the 5'-terminal and placed the resultant gene under the control of the yeast glyceraldehyde-3-phosphate dehydrogenase gene promoter. After the fused-C-SIG peptide was correctly processed by the yeast secretory apparatus, a yeast transformant synthesized a protein with a molecular mass of approximately 52 kDa at a level of 42% of the total soluble protein. Electron micrographic observation showed that the gene products assembled into 23-nm spherical and filamentous particles. The pre-S peptide of the gene product was deposited into the endoplasmic reticulum (ER) lumen and well-glycosylated. It seemed that the gene products were accumulated as particles in certain specific membrane structures of the yeast secretory apparatus. Moreover, both the amount of mRNAs specific for the L gene and the in vivo stability of the synthesized L proteins did not change significantly by the addition of the C-SIG gene. These findings indicated that, if the pre-S1 peptide penetrates the ER membrane efficiently, the L proteins can be synthesized cotranslationally, translocate across the ER membrane with its S region, and then assemble by themselves into the particle form. Therefore, the pre-S1 peptide may involve weak or reduced signal peptide activity for recognition by the secretory apparatus and/or for the transport of the pre-S peptide into the ER lumen.	TAKEDA CHEM IND LTD, BIOL RES LABS, OSAKA 532, JAPAN	Takeda Chemical Industries	KURODA, S (corresponding author), TAKEDA CHEM IND LTD, BIOTECHNOL RES LABS, OSAKA 532, JAPAN.							BACH ML, 1979, P NATL ACAD SCI USA, V76, P386, DOI 10.1073/pnas.76.1.386; BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BUDKOWSKA A, 1982, J IMMUNOL METHODS, V51, P341, DOI 10.1016/0022-1759(82)90401-X; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1986, MOL CELL BIOL, V6, P1454, DOI 10.1128/MCB.6.5.1454; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUJISAWA Y, 1985, GENE, V40, P23, DOI 10.1016/0378-1119(85)90020-4; FUJISAWA Y, 1990, VACCINE, V8, P192, DOI 10.1016/0264-410X(90)90044-M; GERBER MA, 1974, AM J PATHOL, V75, P489; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; HAZAMA M, 1989, VACCINE, V7, P567, DOI 10.1016/0264-410X(89)90285-5; HEERMANN KH, 1987, INTERVIROLOGY, V28, P14, DOI 10.1159/000149993; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HITZEMAN RA, 1983, NUCLEIC ACIDS RES, V11, P2745, DOI 10.1093/nar/11.9.2745; IMAMURA T, 1987, J VIROL, V61, P3543, DOI 10.1128/JVI.61.11.3543-3549.1987; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V138, P268, DOI 10.1016/0006-291X(86)90275-5; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V141, P942, DOI 10.1016/S0006-291X(86)80134-6; JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0; JIGAMI Y, 1986, GENE, V43, P273, DOI 10.1016/0378-1119(86)90216-7; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURODA S, 1991, VACCINE, V9, P163, DOI 10.1016/0264-410X(91)90148-Y; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; KUROKI K, 1990, VIROLOGY, V78, P297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1988, GENE, V67, P229, DOI 10.1016/0378-1119(88)90400-3; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILICH DR, 1986, J IMMUNOL, V137, P313; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; NARITA K, 1966, J BIOCHEM-TOKYO, V59, P170, DOI 10.1093/oxfordjournals.jbchem.a128278; Neurath A R, 1988, Adv Virus Res, V34, P65, DOI 10.1016/S0065-3527(08)60516-3; NEURATH AR, 1989, VACCINE, V7, P234; OBERTO J, 1985, GENE, V40, P57, DOI 10.1016/0378-1119(85)90024-1; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PATZER EJ, 1986, J VIROL, V58, P884, DOI 10.1128/JVI.58.3.884-892.1986; PERSING DH, 1987, J VIROL, V61, P1672, DOI 10.1128/JVI.61.5.1672-1677.1987; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIMON K, 1988, J CELL BIOL, V107, P2163, DOI 10.1083/jcb.107.6.2163; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSUGITA A, 1982, EUR J BIOCHEM, V124, P585, DOI 10.1111/j.1432-1033.1982.tb06634.x; VALENZUELA P, 1985, BIO-TECHNOL, V3, P317, DOI 10.1038/nbt0485-317; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; WINGFIELD PT, 1987, YEAST, V3, P43, DOI 10.1002/yea.320030107; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0; [No title captured]	53	86	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1953	1961						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370486				2022-12-25	WOS:A1992HA48500085
J	ROYCHOUDHURY, S; CHAKRABARTY, K; HO, YK; CHAKRABARTY, AM				ROYCHOUDHURY, S; CHAKRABARTY, K; HO, YK; CHAKRABARTY, AM			CHARACTERIZATION OF GUANOSINE DIPHOSPHO-D-MANNOSE DEHYDROGENASE FROM PSEUDOMONAS-AERUGINOSA - STRUCTURAL-ANALYSIS BY LIMITED PROTEOLYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; ALGINATE SYNTHESIS; RAS ONCOGENE; BINDING; GENE; PROTEIN; INFECTION; SEQUENCE; DOMAIN; TU	Alginate is believed to be a major virulence factor in the pathogenicity of Pseudomonas aeruginosa in the lungs of patients suffering from cystic fibrosis. Guanosine diphospho-D-mannose dehydrogenase (GDPmannose dehydrogenase, EC 1.1.1.132) is a key enzyme in the alginate biosynthetic pathway which catalyzes the oxidation of guanosine diphospho-D-mannose (GDP-D-mannose) to GDP-D-mannuronic acid. In this paper, we report the structural analysis of GMD by limited proteolyses using three different proteases, trypsin, submaxillary Arg-C protease, and chymotrypsin. Treatment of GMD with these proteases indicated that the amino-terminal part of this enzyme may fold into a structural domain with an apparent molecular mass of 25-26 kDa. Multiple proteolytic cleavage sites existed at the carboxyl-terminal end of this domain, indicating that this segment may represent an exposed region of the protein. Initial proteolysis also generated a carboxyl-terminal fragment with an apparent molecular mass of 16-17 kDa which was further digested into smaller fragments by trypsin and chymotrypsin. The proteolytic cleavage sites were localized by partial amino-terminal sequencing of the peptide fragments. Arg-295 was identified as the initial cleavage site for trypsin and Tyr-278 for chymotrypsin. Catalytic activity of GMD was totally abolished by the initial cleavage. However, binding of the substrate, GDP-D-mannose, increased stability toward proteolysis and inhibited the loss of enzyme activity. GMP and GDP (guanosine 5'-mono- and diphosphates) also blocked the initial cleavage, but NAD and mannose showed no effect. These results suggest that binding of the guanosine moiety at the catalytic site of GMD may induce a conformational change that reduces the accessibility of the cleavage sites to proteases. Binding of [C-14]GDP-D-mannose to the amino-terminal domain was not affected by the removal of the carboxyl-terminal 16-kDa fragment. Furthermore, photoaffinity labeling of GMD with [P-32]arylazido-beta-alanine-NAD followed by proteolysis demonstrated that the radioactive NAD was covalently linked to the amino-terminal domain. These observations imply that the amino-terminal domain (25-26 kDa) contains both the substrate and cofactor binding sites. However, the carboxyl-terminal fragment (16-17 kDa) may possess amino acid residues essential for catalysis. Thus, proteolysis had little effect on substrate binding, but totally eliminated catalysis. These biochemical data are in complete agreement with amino acid sequence analysis for the existence of substrate and cofactor sites of GMD. A linear peptide map of GMD was constructed for future structure/functional studies.	UNIV ILLINOIS,COLL MED,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NEI NIH HHS [EY-05788] Funding Source: Medline; NIAID NIH HHS [AI-16790] Funding Source: Medline; NATIONAL EYE INSTITUTE [R23EY005788, R01EY005788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI016790, R01AI016790] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRY A, 1989, J BACTERIOL, V171, P2313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN S, 1977, J BIOL CHEM, V252, P8990; DERETIC V, 1987, J BACTERIOL, V169, P351, DOI 10.1128/jb.169.1.351-358.1987; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DEVAULT JD, 1990, MOL MICROBIOL, V4, P737, DOI 10.1111/j.1365-2958.1990.tb00644.x; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; EVANS LR, 1973, J BACTERIOL, V116, P9115; HOIBY N, 1974, ACTA PATH MICRO IM B, VB 82, P551; JENG SJ, 1975, J SUPRAMOL STR CELL, V3, P448, DOI 10.1002/jss.400030506; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; KIMBARA K, 1989, BIOCHEM BIOPH RES CO, V164, P601, DOI 10.1016/0006-291X(89)91502-7; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; REYNOLDS HY, 1975, ANN INTERN MED, V82, P819, DOI 10.7326/0003-4819-82-6-819; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUSSELL NJ, 1988, MOL ASPECTS MED, V10, P1, DOI 10.1016/0098-2997(88)90002-7; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZIELINSKI NA, 1991, J BIOL CHEM, V266, P9754	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					990	996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370473				2022-12-25	WOS:A1992GY96000051
J	DUEWEKE, TJ; KEZDY, FJ; WASZAK, GA; DEIBEL, MR; TARPLEY, WG				DUEWEKE, TJ; KEZDY, FJ; WASZAK, GA; DEIBEL, MR; TARPLEY, WG			THE BINDING OF A NOVEL BISHETEROARYLPIPERAZINE MEDIATES INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; ZIDOVUDINE AZT; DOUBLE-BLIND; HIV; 3'-AZIDO-3'-DEOXYTHYMIDINE; REPLICATION; EFFICACY	The bisheteroarylpiperazines (BHAPs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and specifically block HIV-1 replication (Romero, D. L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J. R., Poppe, S. M., Aristoff, P. A., Downey, K. M., So, A. G., Resnick, L., and Tarpley, W. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8806-8810). Here we show that the radiolabeled BHAP [H-3]U-88204 binds specifically to HIV-1 RT with high affinity (K(D) of 50 nm) and a stoichiometry of 1 mol of U-88204 per 1 mol of p66/p51 RT heterodimer. Binding of [H-3]U-88204 to RT is unaffected by the presence of saturating poly(rC).oligo (dG)12-18 template-primer. Direct measurement of competition between [H-3]U-88204 and other RT inhibitors for binding to RT reveals mutually exclusive competition between [H-3]U-88204 and the non-nucleoside RT inhibitor BI-RG-587 (Kopp, E. B., Miglietta, J. J., Shrutkowski, A. G., Shih, C.-K., Grob, P. M. and Skoog, M.T. (1991) Nucleic Acids Res. 19, 3035-3039), indicating that both share the same binding site. Phosphonoformate in concentrations up to 50-mu-M shows no competition with [H-3]U-88204 for binding to RT either alone or in the presence of template-primer. Dideoxynucleotide RT inhibitors affect the binding of [H-3]U-88204 to RT when complementary template-primer is present. [H-3]U-88204 and the dideoxynucleotide ddGTP can bind RT simultaneously, but the presence of one ligand decreases the affinity of RT for the second. Inasmuch as ddGTP approximates the nucleotide substrate of RT, the direct demonstration of an RT-dideoxynucleotide-[H-3]U-88204 complex validates the use of indirect kinetic methods to assess the strength of BHAP interaction with RT and suggests that RT inhibition by U-88204 is achieved via effects on nucleotide substrate binding.			DUEWEKE, TJ (corresponding author), UPJOHN CO,KALAMAZOO,MI 49001, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CH, 1989, J BIOL CHEM, V264, P11934; COHEN KA, 1991, J BIOL CHEM, V266, P14670; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1989, ANTIVIR RES, V12, P1, DOI 10.1016/0166-3542(89)90064-8; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRANK KB, 1991, J BIOL CHEM, V266, P14232; HAO Z, 1988, MOL PHARMACOL, V34, P431; HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045; JACOBS S, 1975, J PHARM COMMUN, V66, P687; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SARIN PS, 1985, BIOCHEM PHARMACOL, V34, P4075, DOI 10.1016/0006-2952(85)90392-2; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	26	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					27	30						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370445				2022-12-25	WOS:A1992GY43900008
J	WALAJTYSRHODE, E; ZAPATERO, J; MOEHREN, G; HOEK, JB				WALAJTYSRHODE, E; ZAPATERO, J; MOEHREN, G; HOEK, JB			THE ROLE OF THE MATRIX CALCIUM LEVEL IN THE ENHANCEMENT OF MITOCHONDRIAL PYRUVATE CARBOXYLATION BY GLUCAGON PRETREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; DEHYDROGENASE PHOSPHATE PHOSPHATASE; FREE CA-2+ CONCENTRATION; ISOLATED HEPATOCYTES; PHOSPHORYLATION-DEPHOSPHORYLATION; 2-OXOGLUTARATE DEHYDROGENASE; OXOGLUTARATE DEHYDROGENASE; INORGANIC PYROPHOSPHATE; HORMONAL-STIMULATION; ADENINE-NUCLEOTIDES	The effect of Ca2+ on the rate of pyruvate carboxylation was studied in liver mitochondria from control and glucagon-treated rats, prepared under conditions that maintain low Ca2+ levels (1-3 nmol/mg of protein). When the matrix-free [Ca2+] was low (< 100 nM), the rate of pyruvate carboxylation was not significantly different in mitochondria from control and glucagon-treated rats. Accumulation of 5-8 nmol of Ca2+/mg, which increased the matrix [Ca2+] to 2-5-mu-M in both preparations, significantly enhanced pyruvate carboxylase flux by 20-30% in the mitochondria from glucagon-treated rats, but had little effect in control preparations. Higher levels of Ca2+ (up to 75 nmol/mg) inhibited pyruvate carboxylation in both preparations, but the difference between the mitochondria from control and glucagon-treated animals was maintained. The enhancement of pyruvate dehydrogenase flux by mitochondrial Ca2+ uptake was also significantly greater in mitochondria from glucagon-treated rats. These differential effects of Ca2+ uptake on enzyme fluxes did not correlate with changes in the mitochondrial ATP/ADP ratio, the pyrophosphate level, or the matrix volume. Arsenite completely prevented (CO2)-C-14 incorporation when pyruvate was the only substrate, but caused only partial inhibition when succinate and acetyl carnitine were present as alternative sources of energy and acetyl-CoA. Under these conditions, mitochondria from glucagon-treated rats were less sensitive to arsenite than the control preparations, even at low Ca2+ levels. We conclude that the Ca2+-dependent enhancement of pyruvate carboxylation in mitochondria from glucagon-treated rats is a secondary consequence of pyruvate dehydrogenase activation; glucagon treatment is suggested to affect the conditions in the mitochondria that change the sensitivity of the pyruvate dehydrogenase complex to dephosphorylation by the Ca2+-sensitive pyruvate dehydrogenase phosphatase.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38461] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM PAJ, 1969, J BIOL CHEM, V244, P6444; AGIUS L, 1985, EUR J BIOCHEM, V152, P699, DOI 10.1111/j.1432-1033.1985.tb09250.x; ALLAN EH, 1983, BIOCHEM J, V212, P417, DOI 10.1042/bj2120417; ALTIN JG, 1986, BIOCHEM J, V238, P653, DOI 10.1042/bj2380653; ASSIMACOPOULOSJEANNET F, 1986, J BIOL CHEM, V261, P8799; ASSIMACOPOULOSJEANNET F, 1983, FEBS LETT, V159, P83, DOI 10.1016/0014-5793(83)80421-9; BABCOCK DF, 1979, J BIOL CHEM, V254, P8117; BADDAMS HM, 1983, BIOCHEM J, V210, P73, DOI 10.1042/bj2100073; BLACKMORE PF, 1979, J BIOL CHEM, V254, P6945; BOND M, 1987, J BIOL CHEM, V262, P15630; BRYTE J, 1977, FEBS LETT, V80, P443; CHAN TM, 1979, J BIOL CHEM, V254, P8730; COOK GA, 1978, ANAL BIOCHEM, V91, P557, DOI 10.1016/0003-2697(78)90543-2; DAVIDSON AM, 1988, BIOCHEM J, V254, P379, DOI 10.1042/bj2540379; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; FOLDES M, 1977, J BIOL CHEM, V252, P5372; GARRISON JC, 1975, J BIOL CHEM, V250, P2769; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1984, BIOCHEM J, V223, P677, DOI 10.1042/bj2230677; HANSON RL, 1969, J BIOL CHEM, V244, P4351; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; HAYNES RC, 1986, HORMONAL CONTROL GLU, P19; HOEK JB, 1983, J BIOL CHEM, V258, P54; KIMMICH GA, 1969, J BIOL CHEM, V244, P190; KRAUSFRIEDMANN N, 1986, TRENDS BIOCHEM SCI, V11, P276, DOI 10.1016/0968-0004(86)90023-X; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; LUKACS GL, 1988, FEBS LETT, V229, P219, DOI 10.1016/0014-5793(88)80831-7; MCCLURE WR, 1971, J BIOL CHEM, V246, P3591; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1985, BIOCHEM J, V231, P597, DOI 10.1042/bj2310597; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; MCCORMACK JG, 1985, AM J PHYSIOL, V249, pE543; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; MORGAN NG, 1983, J BIOL CHEM, V258, P5110; MORIKOFE.S, 1973, J BIOL CHEM, V248, P7588; MURPHY E, 1980, J BIOL CHEM, V255, P6600; Perrin D. D., 2012, BUFFERS PH METAL ION; RASHED HM, 1988, J BIOL CHEM, V263, P5700; Reed L J, 1981, Curr Top Cell Regul, V18, P95; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; SAAVEDRAMOLINA A, 1990, BIOCHEM BIOPH RES CO, V167, P148, DOI 10.1016/0006-291X(90)91743-C; SCRUTTON MC, 1976, FEBS LETT, V62, P220, DOI 10.1016/0014-5793(76)80057-9; SCRUTTON MC, 1981, SHORT TERM REGULATIO, P175; SIESS EA, 1988, EUR J BIOCHEM, V173, P369, DOI 10.1111/j.1432-1033.1988.tb14007.x; SIESS EA, 1977, BIOCHEM J, V166, P225, DOI 10.1042/bj1660225; SIESS EA, 1985, EUR J BIOCHEM, V52, P131; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; STADDON JM, 1985, BIOCHEM J, V225, P327, DOI 10.1042/bj2250327; STADDON JM, 1986, BIOCHEM J, V238, P737, DOI 10.1042/bj2380737; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; TAYLOR WM, 1980, BIOCHEM J, V188, P443, DOI 10.1042/bj1880443; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2376; VANTHIENEN WD, 1981, J BIOL CHEM, V256, P8371; VONGLUTZ G, 1976, FEBS LETT, V72, P299, DOI 10.1016/0014-5793(76)80991-X; WALAJTYS EI, 1974, J BIOL CHEM, V249, P1857; WAN B, 1989, J BIOL CHEM, V264, P13430; WEBB JL, 1966, ENZYMES METABOL INH, V111, P121; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; YAMAZAKI RK, 1975, ARCH BIOCHEM BIOPHYS, V166, P575, DOI 10.1016/0003-9861(75)90422-1	67	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					370	379						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370447				2022-12-25	WOS:A1992GY43900061
J	GANTZ, I; DELVALLE, J; WANG, LD; TASHIRO, T; MUNZERT, G; GUO, YJ; KONDA, Y; YAMADA, T				GANTZ, I; DELVALLE, J; WANG, LD; TASHIRO, T; MUNZERT, G; GUO, YJ; KONDA, Y; YAMADA, T			MOLECULAR-BASIS FOR THE INTERACTION OF HISTAMINE WITH THE HISTAMINE-H2-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; CLONING; IDENTIFICATION; GENE; ACTIVATION; EXPRESSION; AGONISTS; ROLES	We undertook these studies to characterize the molecular basis of the interaction of histamine with the H2 receptor. Key areas of homology in the structures of the histamine H2 and beta2 adrenergic receptor suggested specific transmembrane amino acids that might be important for binding of histamine. A third transmembrane aspartic acid of the histamine receptor (Asp98), thought to serve as a counter anion that interacts with the cationic amine moiety of histamine, was mutated to Asn98, and the mutated receptor was expressed in Hepa cells. Removal of the negatively charged amino acid abolished both binding of the H2 receptor antagonist [methyl-H-3]tiotidine and histamine stimulated increases in cellular cAMP content. Mutation of a fifth transmembrane aspartic acid (Asp186) to Ala186 or Asn186 by itself or in conjunction with mutation of another fifth transmembrane amino acid (Thr190 to Ala190 ) resulted in a loss of [methyl-H-3] tiotidine binding, although the generation of cAMP in response to histamine was maintained. The histamine receptor with only a Thr190 to Ala190 or Cys190 mutation retained the ability to bind [methyl-H-3]tiotidine, but both the affinity and efficacy of binding were reduced. These data lead us to propose a model for histamine binding in which Asp98 is essential for histamine binding and action, Asp186 defines H2 selectivity, and Thr190 is important in establishing the kinetics of histamine binding, but is not essential for H2 selectivity.	UNIV MICHIGAN,MED CTR,DEPT SURG,3101 TAUBMAN CTR,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIDDK NIH HHS [P30DK34933, R01DK33500, R01DK34306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK033500, R01DK034306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DURANT GJ, 1975, J MED CHEM, V18, P905, DOI 10.1021/jm00243a009; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANTIATIS T, 1989, MOL CLONING LABORATO; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RISING TJ, 1985, FRONTIERS HISTAMINE, V51, P61; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; WANG CD, 1991, MOL PHARMACOL, V40, P168; WEINSTEIN H, 1976, MOL PHARMACOL, V12, P738; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	17	122	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20840	20843						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356984				2022-12-25	WOS:A1992JT97800053
J	MUTHUCHAMY, M; PAJAK, L; WIECZOREK, DF				MUTHUCHAMY, M; PAJAK, L; WIECZOREK, DF			INDUCTION OF ENDOGENOUS MYOSIN LIGHT CHAIN-1 AND CARDIAC ALPHA-ACTIN EXPRESSION IN L6E9 CELLS BY MYOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; MYOGENIC DETERMINATION FACTORS; CREATINE-KINASE GENE; SKELETAL-MUSCLE; REGULATORY FACTORS; DNA-BINDING; FUNCTIONAL-ACTIVITY; XENOPUS-EMBRYOS; MYC HOMOLOGY; DIFFERENTIATION	Rat L6E9 muscle cells commit to terminal differentiation by forming a large muscle syncitia complete with the expression of a large number of muscle-specific contractile protein genes. To determine whether these cells, which fail to synthesize MLC (myosin light chain) 1 and cardiac alpha-actin, exhibit a deficiency in the expression of muscle determination genes, we measured expression of MyoD1, myogenin, Myf-5, and MRF-4. Results show these cells do not synthesize MyoD1, yet express the other myogenic determination genes. Transient expression of exogenous MyoD1 in these cells is sufficient to activate endogenous MLC 1 and cardiac alpha-actin mRNA synthesis during muscle differentiation. Previously undetected myosin heavy chain (MHC) isoforms (beta-MHC and perinatal MHC) are also transcribed at low levels in L6E9 muscle cells, and in MyoD1-transfected L6E9 cells no change occurs in their expression. Furthermore, treatment with the demethylating agent 5-azacytidine activates expression of the endogenous MyoD1 gene in L6E9 cells and, subsequently, rescues deficiencies in their myogenic biochemical program. These results demonstrate that the endogenous MyoD1 gene in L6E9 cells is not defective and can be functionally activated. Also, the MyoD1 protein plays an essential role, which cannot be compensated by other known muscle determination proteins, in the induction of MLC 1 and cardiac alpha-actin expression.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46826] Funding Source: Medline; NIAMS NIH HHS [AR 39423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; COHEN A, 1988, NUCLEIC ACIDS RES, V16, P10037, DOI 10.1093/nar/16.21.10037; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Favaloro J, 1980, Methods Enzymol, V65, P718; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; HICKEY R, 1986, MOL CELL BIOL, V6, P3287, DOI 10.1128/MCB.6.9.3287; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAJAK L, 1991, DEV BIOL, V145, P28, DOI 10.1016/0012-1606(91)90210-T; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR MV, 1991, GENE DEV, V5, P1149, DOI 10.1101/gad.5.7.1149; TAYLOR SM, 1982, J CELL PHYSIOL, V111, P187, DOI 10.1002/jcp.1041110210; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	58	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18728	18734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382061				2022-12-25	WOS:A1992JN50200074
J	MENDOZA, JA; LORIMER, GH; HOROWITZ, PM				MENDOZA, JA; LORIMER, GH; HOROWITZ, PM			CHAPERONIN CPN60 FROM ESCHERICHIA-COLI PROTECTS THE MITOCHONDRIAL ENZYME RHODANESE AGAINST HEAT INACTIVATION AND SUPPORTS FOLDING AT ELEVATED-TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; SMALL STOICHIOMETRY; PROTEINS; GROEL; SHOW; ATP	The chaperonin protein cpn60 from Escherichia coli protects the monomeric, mitochondrial enzyme rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) against heat inactivation. The thermal inactivation of rhodanese was studied for four different states of the enzyme: native, refolded, bound to cpn60 in the form of a binary complex formed from unfolded rhodanese, and a thermally perturbed state. Thermal stabilization is observed in a range of temperatures from 25 to 48-degrees-C. Rhodanese that had been inactivated by incubation at 48-degrees-C, in the presence of cpn60 can be reactivated at 25-degrees-C, upon addition of cpn10, K+, and MgATP. A recovery of about 80% was achieved after 1 h of the addition of those components. Thus, the enzyme is protected against heat inactivation and kept in a reactivable form if inactivation is attempted using the binary complex formed between rhodanese folding intermediate(s) and cpn60. The chaperonin-assisted refolding of urea-denatured rhodanese is dependent on the temperature of the refolding reaction. However, optimal chaperonin assisted refolding of rhodanese observed at 25-degrees-C, which is achieved upon addition of cpn10 and ATP to the cpn60-rhodanese complex, is independent of the temperature of preincubation of the complex, that was formed previously at low temperature. The results are in agreement with a model in which the chaperonin cpn60 interacts with partly folded intermediates by forming a binary complex which is stable to elevated temperatures. In addition, it appears that native rhodanese can be thermally perturbed to produce a state different from that achieved by denaturation that can interact with cpn60.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880	University of Texas System; University of Texas Health San Antonio; DuPont					NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HOROWITZ P, 1987, J BIOL CHEM, V262, P5587; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KLIBANOV AM, 1983, ADV APPL MICROBIOL, V29, P1, DOI 10.1016/S0065-2164(08)70352-6; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1991, J CELL BIOCH SG, V15, P160; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Ploegman J.H., 1978, NATURE, V273, P1245; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	23	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17631	17634						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355476				2022-12-25	WOS:A1992JM22300026
J	CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ				CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ			TRANSFORMATION MEDIATED BY THE HUMAN HER-2 GENE INDEPENDENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CANCER; NEU ONCOGENE; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; POINT MUTATION; OVARIAN-CANCER; CELL-GROWTH; 3T3 CELLS	Amplification of the HER-2 (c-erbB-2) gene and overexpression of the p185HER-2 gene product is found in approximately one-third of primary human breast and ovarian cancers and is associated with a poor clinical outcome of early relapse and death. The HER-2 gene encodes a cell-surface growth factor receptor with intrinsic tyrosine kinase activity. Wild-type human HER-2 has been shown to act as a potent oncogene when overexpressed in mouse fibroblasts. Recent data suggest that the mechanism by which HER-2 mediates transformation requires the interaction of the epidermal growth factor (EGF) receptor. To test whether overexpression of normal human HER-2 can transform cells independently of the EGF receptor, we have introduced multiple copies of HER-2 into the EGF receptor-negative cell line, NR6, and have performed assays for both transformation and tumorigenicity. Engineered NR6 cells that overexpress the HER-2 gene product display a highly transformed and tumorigenic phenotype as compared with control cells. Additionally, a monoclonal antibody to the extracellular domain of the HER-2 receptor is able to inhibit the proliferation of the overexpressing cells in vitro as well as tumor growth in vivo. This study provides clear evidence that HER-2-mediated transformation can be achieved independently of the EGF receptor.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Fred Hutchinson Cancer Center				Miller, Dusty/0000-0002-3736-3660	NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36827] Funding Source: Medline; NIGMS NIH HHS [GM-07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; Chen E, 1986, Biochem Soc Symp, V52, P65; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KUMAR R, 1991, MOL CELL BIOL, V11, P976; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PRESS MF, 1984, LAB INVEST, V50, P480; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	47	164	179	2	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354348				2022-12-25	WOS:A1992JJ37600023
J	BORCHELT, DR; TARABOULOS, A; PRUSINER, SB				BORCHELT, DR; TARABOULOS, A; PRUSINER, SB			EVIDENCE FOR SYNTHESIS OF SCRAPIE PRION PROTEINS IN THE ENDOCYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; ASPARAGINE-LINKED GLYCOSYLATION; INFECTED CULTURED-CELLS; INCUBATION PERIOD MICE; SEMLIKI FOREST VIRUS; BREFELDIN-A; TRANSGENIC MICE; RAT HEPATOCYTES; EARLY ENDOSOMES; GOLGI PROTEINS	Infectious scrapie prions are composed largely, if not entirely, of an abnormal isoform of the prion protein (PrP) which is designated PrP(Sc). A chromosomal gene encodes both the cellular prion protein (PrP(C)) as well as PrP(Sc). Pulse-chase experiments with scrapie-infected cultured cells indicate that PrP(Sc) is formed by a post-translational process. PrP is translated in the endoplasmic reticulum, modified as it passes through the (Golgi, and is transported to the cell surface. Release of nascent PrP from the cell surface by phosphatidylinositol-specific phospholipase C or hydrolysis with dispase prevented PrP(Sc) synthesis. At 18-degrees-C, the synthesis of PrP(Sc) was inhibited under conditions that other investigators report a blockage of endosomal fusion with lysosomes. Our results suggest that PrP(Sc) synthesis occurs after PrP transits from the cell surface. Whether all of the PrP molecules have an equal likelihood to be converted into PrP(Sc) or only a distinct subset is eligible for conversion remains to be established. Identifying the subcellular compartment(s) of PrP(Sc) synthesis should be of considerable importance in defining the molecular changes that distinguish PrP(Sc) from PrP(C).	UNIV CALIF SAN FRANCISCO, DEPT NEUROL, HSE-781, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132, R35AG008967] Funding Source: NIH RePORTER; NIA NIH HHS [AG08967, AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RG, 1991, SCIENCE, V255, P410; BARRY RA, 1988, J IMMUNOL, V140, P1188; BARRY RA, 1986, J INFECT DIS, V153, P848, DOI 10.1093/infdis/153.5.848; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHANDLER RL, 1961, LANCET, V1, P1378; CLARKE MC, 1979, SLOW TRANSMISSIBLE D, V2, P225; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUNN WA, 1980, J BIOL CHEM, V255, P5971; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARE JF, 1984, ARCH BIOCHEM BIOPHYS, V233, P547, DOI 10.1016/0003-9861(84)90478-8; HARE JF, 1988, J BIOL CHEM, V263, P8759; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARKOVITS P, 1981, CR ACAD SCI III-VIE, V293, P413; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MCKINLEY MP, 1991, J VIROL, V65, P1440; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1990, CELL, V1, P101; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1991, FASEB J, V5, pA1177; TARABOULOS A, 1991, 1991 PRION DIS HUM A; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; WEIGEL PH, 1981, J BIOL CHEM, V256, P2615; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	64	436	447	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16188	16199						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1353761				2022-12-25	WOS:A1992JJ45800034
J	THEROUX, SJ; LATOUR, DA; STANLEY, K; RADEN, DL; DAVIS, RJ				THEROUX, SJ; LATOUR, DA; STANLEY, K; RADEN, DL; DAVIS, RJ			SIGNAL TRANSDUCTION BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR IS ATTENUATED BY A COOH-TERMINAL DOMAIN SERINE PHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; LIGAND-INDUCED INTERNALIZATION; TISSUE-SPECIFIC TRANSFORMATION; TYROSINE KINASE; EGF RECEPTOR; HUMAN-FIBROBLASTS; A431 CELLS; ERBB; THREONINE; BINDING	It has been proposed that the acute desensitization of epidermal growth factor receptor (EGF-R) function can be accounted for, in part, by the effect of EGF to increase phosphorylation of the receptor at Ser1046/7 (Countaway, J. L., Nairn, A. C., and Davis, R. J. (1992) J. Biol. Chem. 267, 1129-1140). Here, we show that the mutational removal of this phosphorylation site causes an activation of EGF-R function and a potentiation of signal transduction. The mechanism of potentiation results from 1) defective down-regulation of the EGF-R when cells are incubated with high concentrations of EGF; and 2) increased EGF-stimulated tyrosine phosphorylation. The increased EGF-stimulated phosphorylation is associated with an alteration of the apparent specificity of tyrosine phosphorylation and is independent of the down-regulation defect. Together, these data strongly support the hypothesis that Ser1046/7 is a biologically significant site of regulatory phosphorylation of the EGF-R.	UNIV MASSACHUSETTS, SCH MED,DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED,HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R03CA053396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA53396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LEISTER KJ, 1989, P NATL ACAD SCI USA, V86, P783, DOI 10.1073/pnas.86.3.783; LUND KA, 1990, J BIOL CHEM, V265, P20517; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MATRISIAN LM, 1982, ANAL BIOCHEM, V125, P339, DOI 10.1016/0003-2697(82)90015-X; MCCUNE BK, 1990, J BIOL CHEM, V265, P9715; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1982, J BIOL CHEM, V257, P4222	45	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16620	16626						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379601				2022-12-25	WOS:A1992JJ45800097
J	JIA, S; VANDUSEN, WJ; DIEHL, RE; KOHL, NE; DIXON, RAF; ELLISTON, KO; STERN, AM; FRIEDMAN, PA				JIA, S; VANDUSEN, WJ; DIEHL, RE; KOHL, NE; DIXON, RAF; ELLISTON, KO; STERN, AM; FRIEDMAN, PA			CDNA CLONING AND EXPRESSION OF BOVINE ASPARTYL (ASPARAGINYL) BETA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FACTOR-LIKE DOMAIN; HUMAN FACTOR-IX; HYDROXYASPARTIC ACID; PROLYL 4-HYDROXYLASE; MOLECULAR-CLONING; RNA TRANSCRIPTS; POINT MUTATIONS; DNA-POLYMERASE; ALPHA-SUBUNIT	Aspartyl (asparaginyl) beta-hydroxylase which specifically hydroxylates 1 Asp or Asn residue in certain epidermal growth factor-like domains of a number of proteins, has been previously purified to apparent homogeneity from detergent-solubilized bovine liver microsomes (Wang, Q., VanDusen, W. J., Petroski, C. J., Garsky, V. M., Stern, A. M., and Friedman, P. A. (1991) J. Biol. Chem. 266, 14004-14010). Three oligonucleotides, corresponding to three amino acid sequences of the purified hydroxylase, were used to screen bovine cDNA libraries. Several overlapping positive cDNA clones containing a full length open reading frame of 754 amino acids encoding a 85-kDa protein were isolated, and a cDNA, containing the full length open reading frame, was constructed from two of these clones. The resulting clone was then transcribed and translated in vitro to produce recombinant protein which possessed Asp beta-hydroxylase activity. These results constitute proof that the protein purified from bovine liver is an Asp beta-hydroxylase. Comparisons of deduced amino acid sequences of two other alpha-ketoglutarate-dependent dioxygenases, prolyl-4-hydroxylase and lysyl hydroxylase, with that of Asp beta-hydroxylase showed no significant homologies. Indeed, Asp beta-hydroxylase appears to be unique as no striking homology was found with known protein sequences. Furthermore, structural predictions derived from the deduced amino acid sequence are in accord with earlier Stokes' radius and sedimentation coefficient determinations of the enzyme, suggesting that the enzyme contains a relatively compact carboxyl-terminal catalytic domain and an extended amino terminus. This amino-terminal region has a potential transmembrane type II signal-anchor domain that could direct the catalytic domain into the lumen of the endoplasmic reticulum.	MERCK SHARP & DOHME LTD,WP44-204,W POINT,PA 19486	Merck & Company				Stern, Andrew/0000-0002-8437-2957; Elliston, Keith/0000-0002-9110-9233				ARLAUD GJ, 1987, FEBS LETT, V222, P129, DOI 10.1016/0014-5793(87)80205-3; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BERG RA, 1979, J BIOL CHEM, V254, P3111; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNLUND P, 1983, J BIOL CHEM, V258, P12059; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; GRONKE RS, 1988, J CELL BIOL, V107, P4689; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; MORITA T, 1984, J BIOL CHEM, V259, P5689; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; SUGO T, 1984, J BIOL CHEM, V259, P5705; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; TURPEENNIEMIHUJANEN TM, 1981, COLLAGEN REL RES, V1, P355; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG QP, 1991, J BIOL CHEM, V266, P14004	41	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14322	14327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378441				2022-12-25	WOS:A1992JD32500082
J	SPRINGHORN, JP; ELLINGSEN, O; BERGER, HJ; KELLY, RA; SMITH, TW				SPRINGHORN, JP; ELLINGSEN, O; BERGER, HJ; KELLY, RA; SMITH, TW			TRANSCRIPTIONAL REGULATION IN CARDIAC-MUSCLE - COORDINATE EXPRESSION OF ID WITH A NEONATAL PHENOTYPE DURING DEVELOPMENT AND FOLLOWING A HYPERTROPHIC STIMULUS IN ADULT-RAT VENTRICULAR MYOCYTES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ALPHA-ACTIN; CELLS; DIFFERENTIATION; SKELETAL; CULTURE; HEART; GROWTH; GENE; ACCUMULATION	The transcriptional regulatory mechanisms in heart muscle that direct cardiac development and allow for a flexible, adaptive response to physiologic stress are not well understood. We demonstrate that a negative regulator of gene transcription termed Id that has been described predominantly in proliferating cell lines and in undifferentiated tissue during growth, is expressed in freshly isolated terminally differentiated adult rat ventricular myocytes, in contrast to most other tissues in the adult rat. Id mRNA expression is regulated in ventricular myocytes during post-natal development, peaking at the transition from hyperplastic to hypertrophic growth at day 17 in the rat, declining subsequently to lower, stable levels in adult myocytes. Although Id mRNA becomes undetectable in adult ventricular myocytes 48 h following isolation in the absence of serum, it can be rapidly reinduced by an alpha-adrenergic agonist, accompanied by increased protein synthesis and the reexpression, in defined media, of the neonatal genes prepro-ANP and skeletal muscle alpha-actin. Thus, the differential regulation of Id during cardiac development, the presence of Id mRNA in normal cardiac myocytes, and its increased expression following a hypertrophic stimulus all suggest a role for this transcriptional regulator in the control of cardiac muscle cell phenotype.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SPRINGHORN, JP (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036141, R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLAYCOMB WC, 1980, DEV BIOL, V80, P466, DOI 10.1016/0012-1606(80)90419-4; CLAYCOMB WC, 1988, BIOCHEM J, V255, P617; CLAYCOMB WC, 1977, BIOCHEM J, V168, P599, DOI 10.1042/bj1680599; CLAYCOMB WC, 1983, ADV EXP MED BIOL, V161, P249; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EID H, 1992, IN PRESS CIRC RES; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; IKEDA U, 1990, CARDIOSCIENCE, V1, P225; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAG AC, 1981, TISSUE CELL, V13, P515, DOI 10.1016/0040-8166(81)90023-9; NAG AC, 1985, CARDIAC MORPHOGENESI, P24; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Piper H, 1990, CELL CULTURE TECHNIQ, P36; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SMITH WR, 1989, CELLULAR MOL BIOL MU, P359; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZAK R, 1984, GROWTH HEART HLTH DI, P169	45	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14360	14365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378442				2022-12-25	WOS:A1992JD32500087
J	POPOV, KM; ZHAO, Y; SHIMOMURA, Y; KUNTZ, MJ; HARRIS, RA				POPOV, KM; ZHAO, Y; SHIMOMURA, Y; KUNTZ, MJ; HARRIS, RA			BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE - MOLECULAR-CLONING, EXPRESSION, AND SEQUENCE SIMILARITY WITH HISTIDINE PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BOVINE KIDNEY; COMPLEX; HEART; PHOSPHORYLATION; FAMILY; GENES; LOCUS	A cDNA for branched-chain alpha-ketoacid dehydrogenase kinase was cloned from a rat heart cDNA library. The cDNA had an open reading frame encoding a protein of 382 amino acid residues with a calculated molecular weight of 43,280. The clone codes for the branched-chain alpha-ketoacid dehydrogenase kinase based on the following: 1) the deduced amino acid sequence contained the partial sequence of the kinase determined by direct sequencing; 2) expression of the cDNA in Escherichia coli resulted in synthesis of a 43,000-Da protein that was recognized specifically by kinase antibodies; and 3) enzyme activity that phosphorylated and inactivated the branched-chain alpha-ketoacid dehydrogenase complex was found in extracts of E. coli expressing the protein. Northern blot analysis indicated the mRNA for the branched-chain alpha-ketoacid dehydrogenase kinase was more abundant in rat heart than in rat liver, as expected from the relative amounts of kinase activity expressed in these tissues. The deduced sequence of the kinase aligned with a high degree of similarity within subdomains characteristic of procaryotic histidine protein kinases. This first mitochondrial protein kinase to be cloned appears more closely related in sequence to procaryotic histidine protein kinases than to eucaryotic serine/threonine protein kinases.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIADDK NIH HHS [AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 19259] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEGGS M, 1987, FEBS LETT, V215, P13, DOI 10.1016/0014-5793(87)80104-7; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; COOK KG, 1984, EUR J BIOCHEM, V145, P587, DOI 10.1111/j.1432-1033.1984.tb08597.x; ESPINAL J, 1986, BIOCHEM J, V237, P285, DOI 10.1042/bj2370285; GILLIM SE, 1983, BIOCHEM BIOPH RES CO, V111, P74, DOI 10.1016/S0006-291X(83)80119-3; GOETTFERT M, 1990, P NATL ACAD SCI USA, V87, P2680; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MCFARLANE SA, 1985, NUCLEIC ACIDS RES, V13, P7591; PAXTON R, 1986, ARCH BIOCHEM BIOPHYS, V244, P187, DOI 10.1016/0003-9861(86)90108-6; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; Reed LJ, 1987, ENZYMES, P77; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOMURA Y, 1991, FEBS LETT, V288, P95, DOI 10.1016/0014-5793(91)81010-6; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WIRTZ E, 1991, MOL BIOCHEM PARASIT, V47, P119, DOI 10.1016/0166-6851(91)90154-X	29	152	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13127	13130						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377677				2022-12-25	WOS:A1992JB74600004
J	BIRCHMACHIN, MA; FARNSWORTH, L; ACKRELL, BAC; COCHRAN, B; JACKSON, S; BINDOFF, LA; AITKEN, A; DIAMOND, AG; TURNBULL, DM				BIRCHMACHIN, MA; FARNSWORTH, L; ACKRELL, BAC; COCHRAN, B; JACKSON, S; BINDOFF, LA; AITKEN, A; DIAMOND, AG; TURNBULL, DM			THE SEQUENCE OF THE FLAVOPROTEIN SUBUNIT OF BOVINE HEART SUCCINATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; AMINO-ACID-SEQUENCE; FUMARATE REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; COMPLEX-II; UBIQUINONE OXIDOREDUCTASE; MITOCHONDRIAL PROTEIN; BINDING-SITE; ACTIVE-SITE	The cDNA sequence of the flavoprotein subunit of bovine heart succinate dehydrogenase is reported. This is the first complete eukaryotic sequence of the flavoprotein subunit to be characterized, and it encodes a 665-amino acid protein that consists of a presequence and a 621-residue mature protein. The deduced bovine sequence shows homology to the corresponding peptides of prokaryotic succinate dehydrogenase and the related fumarate reductases; in particular, there is good overall homology (48%) to the flavoprotein subunit of Escherichia coli succinate dehydrogenase. The conserved sequences comprising the active site and those involved in FAD binding are also found in the bovine protein. The active site of the bovine polypeptide contains a cysteine that confers sensitivity of the enzyme to sulfhydryl reagents; this cysteine is only present in some sequences and thus provides a discriminatory biochemical marker. A putative flavoprotein subunit of human placental succinate dehydrogenase (partial sequence) that lacks this critical cysteine (Malcovati, M., Marchetti, T., Zanelli, T., and Tenchini, M. L. (1991) in Flavins and Flavoproteins 1990 (Curti, B., Ronchi, S., and Zanetti, G., eds) pp. 727-730, Walter de Gruyter & Co., Berlin) has only 16% homology to the bovine heart flavoprotein subunit. However, we show that the enzyme from human placenta is as sensitive to N-ethylmaleimide as that from bovine tissues. In addition, a transcript in human placenta and muscle hybridizes to the bovine heart flavoprotein cDNA and is the same size as that in bovine tissues.	UNIV NEWCASTLE UPON TYNE, DEPT MED, Newcastle Upon Tyne NE2 4HH, ENGLAND; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; NATL INST MED RES, DIV GENES & CELLULAR CONTROLS, PROT STRUCT LAB, LONDON NW7 1AA, ENGLAND	Newcastle University - UK; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); MRC National Institute for Medical Research	BIRCHMACHIN, MA (corresponding author), UNIV NEWCASTLE UPON TYNE, DIV CLIN NEUROSCI, Newcastle Upon Tyne NE2 4HH, ENGLAND.			Bindoff, Laurence/0000-0003-0988-276X	NHLBI NIH HHS [HL-16251, HL-22050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022050, P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B A, 1978, Methods Enzymol, V53, P466; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; ACKRELL BAC, 1977, J BIOL CHEM, V252, P6963; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; AITKEN A, 1989, PROTEIN SEQUENCING P, P43; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLAY VJ, 1988, BIOCHEM BIOPH RES CO, V157, P1423, DOI 10.1016/S0006-291X(88)81034-9; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; DESNUELLE C, 1989, BIOCHEM BIOPH RES CO, V163, P695, DOI 10.1016/0006-291X(89)92279-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KENNEY WC, 1976, J BIOL CHEM, V251, P2369; KENNEY WC, 1975, J BIOL CHEM, V250, P3089; KENNEY WC, 1972, J BIOL CHEM, V247, P4510; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; KITA K, 1990, BIOCHEM BIOPH RES CO, V166, P101, DOI 10.1016/0006-291X(90)91916-G; KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7; KOTLYAR AB, 1984, BIOCHEM INT, V8, P545; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; MALCOVATI M, 1991, FLAVINS AND FLAVOPROTEINS 1990, P727; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICE DW, 1984, J MOL BIOL, V174, P483, DOI 10.1016/0022-2836(84)90332-2; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; SALACH JI, 1987, METHOD ENZYMOL, V142, P627; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; VINOGRAD.AD, 1972, BIOCHEM BIOPH RES CO, V49, P441, DOI 10.1016/0006-291X(72)90430-5; VINOGRADOV A D, 1986, Biokhimiya, V51, P1944; VINOGRADOV AD, 1976, EUR J BIOCHEM, V63, P365, DOI 10.1111/j.1432-1033.1976.tb10238.x; WALKER WH, 1970, J BIOL CHEM, V245, P4224; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025	55	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11553	11558						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375942				2022-12-25	WOS:A1992HX16900094
J	BIRGE, RB; FAJARDO, JE; MAYER, BJ; HANAFUSA, H				BIRGE, RB; FAJARDO, JE; MAYER, BJ; HANAFUSA, H			TYROSINE-PHOSPHORYLATED EPIDERMAL GROWTH-FACTOR RECEPTOR AND CELLULAR P130 PROVIDE HIGH-AFFINITY BINDING SUBSTRATES TO ANALYZE CRK-PHOSPHOTYROSINE-DEPENDENT INTERACTIONS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; PROTEIN-KINASE; PDGF RECEPTOR; EGF RECEPTOR; SEQUENCE SIMILARITY; ONCOGENE PRODUCT; HUMAN-PLACENTA; ASSOCIATION; DOMAINS	The genome of CT10 avian sarcoma virus encodes a 47-kDa fusion protein that consists of viral gag sequences fused to a cell-derived sequence containing SH2 and SH3 domains (v-crk). Genetic and biochemical evidence suggests that v-Crk can induce transformation of chicken embryo fibroblasts by influencing the activity of cellular proteins involved in growth regulation. In this report, we have developed an in vitro microtiter assay to study the binding of bacterially expressed glutathione S-transferase-fusion proteins of v-Crk and its cellular homolog, c-Crk, to the phosphorylated epidermal growth factor receptor (EGFR). Competitive binding data are presented that compare the abilities of heterologous glutathione S-transferase-fusion proteins containing GAPSH2[N], AblSH2, SrcSH2, and PLC-gamma-SH2[N] sequences to inhibit Crk binding. Results indicate that both full-length Crk and GAPSH2[N] bind the phosphorylated EGFR with high affinity and can quantitatively compete the binding of each other by competitive enzyme-linked immunosorbent assay. Binding of full-length Crk or the isolated SH2 domains of GAP or Abl resulted in a significant protection of phosphorylated EGFR against dephosphorylation by cellular phosphatase activity, but did not appear to stimulate the intrinsic tyrosine kinase activity of the EGFR. To extend these findings to p130, the major phosphotyrosine-containing protein in CT10-transformed cells, we utilized a nitrocellulose filter binding assay. Results demonstrate high affinity binding of Crk toward denatured p130 and, as is the case for phosphorylated EGFR, Crk binding can partially protect p130 from phosphatase activity. However, no apparent competition of Crk binding was noted with heterologous SH2-containing proteins including GAPSH2[N], suggesting a possible specificity of Crk-p130 binding. These data are consistent with a direct role of SH2 in the modulation of cellular phosphotyrosine status in vivo.	ROCKEFELLER UNIV,DEPT MOLEC ONCOL,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356, R01CA051462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007233] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462, CA44356-03] Funding Source: Medline; NIAID NIH HHS [AI-07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4380; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; PIGA A, 1985, EXP CELL RES, V159, P103, DOI 10.1016/S0014-4827(85)80041-0; SHEU SH, 1991, NATURE, V352, P736; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640	37	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10588	10595						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375224				2022-12-25	WOS:A1992HV09000057
J	YU, DH; MATIN, A; HUNG, MC				YU, DH; MATIN, A; HUNG, MC			THE RETINOBLASTOMA GENE-PRODUCT SUPPRESSES NEU ONCOGENE-INDUCED TRANSFORMATION VIA TRANSCRIPTIONAL REPRESSION OF NEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUSCEPTIBILITY GENE; CELL-CYCLE; EXPRESSION; ELEMENTS; PROTEIN; CANCER; SEQUENCE; ENCODES; BINDING; CLONING	The retinoblastoma susceptibility gene (Rb) is a tumor suppressor gene involved in the etiology of many types of human cancers. However, the molecular mechanisms involved in tumor suppression by Rb are largely unknown. The neu gene is a dominant transforming oncogene and a member of the growth factor receptor tyrosine kinase gene family. Both inactivation of the Rb gene and overexpression of the neu gene are involved in human breast and lung cancers. Therefore, it is of interest and importance to investigate the potential interactions between Rb and neu. Here we show that Rb suppresses neu-induced transformation by focus formation assays. This transformation suppression by Rb was further shown to be due to transcriptional repression of neu using Rb expressing effector plasmid and neu promoter-chloramphenicol acetyltransferase reporter gene. The cis-acting element conferring Rb-mediated repression was mapped to a recently identified novel enhancer in the neu promoter. The data indicate that the growth factor receptor neu is a target for the Rb gene product and transcriptional repression of a dominant oncogene expression may be one of the molecular mechanisms of Rb-mediated tumor suppression.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R03CA054989] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CA-54989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUPE R, 1990, SCIENCE, V249, P1552; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHAO XY, 1992, IN PRESS MOL CELL BI	30	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10203	10206						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350277				2022-12-25	WOS:A1992HV09000002
J	WONG, M; LAWTON, T; GOETINCK, PF; KUHN, JL; GOLDSTEIN, SA; BONADIO, J				WONG, M; LAWTON, T; GOETINCK, PF; KUHN, JL; GOLDSTEIN, SA; BONADIO, J			AGGRECAN CORE PROTEIN IS EXPRESSED IN MEMBRANOUS BONE OF THE CHICK-EMBRYO - MOLECULAR AND BIOMECHANICAL STUDIES OF NORMAL AND NANOMELIA EMBRYOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; MESSENGER-RNA; CARTILAGE; COLLAGEN; SULFATE; PROTEOGLYCANS; GENE; CHONDROCYTES; SYNTHESIZE; SEQUENCE	The recessive mutation nanomelia blocks the synthesis of a large aggregating proteoglycan (aggrecan) by avian embryo chondrocytes. Lack of aggrecan is associated with short stature, multiple morphological defects in cartilage, and embryo lethality. Bony defects have also been described, but were assumed to be a secondary consequence of the cartilage defect. However, two lines of evidence presented in this paper indicate that the aggrecan deficiency directly affects intramembranous bone. First, the morphology (i.e. projected area and shape) of certain membranous bones of nanomelia embryos was abnormal. Second, membranous bone from nanomelia embryos proved to be significantly stiffer in biomechanical tests that measured functional properties of the extracellular matrix. These findings were unexpected because intramembranous bones normally develop from mesenchyme and not from a cartilage intermediate, and they prompted a search for evidence of aggrecan expression in the bone of normal chick embryos. We report that: 1) aggrecan mRNA was identified by PCR analysis of total RNA isolated from day- 13 chick embryo calvarium, 2) the PCR method successfully amplified aggrecan mRNA from primary chick embryo osteoblasts in culture, 3) in situ hybridization of membranous bone tissue sections demonstrated aggrecan expression by chick embryo osteoblasts in vivo, and 4) the aggrecan message was identified in Northern blots of calvarial mRNA probed at high stringency. The results of the molecular and biomechanical studies provide evidence that aggrecan is indeed expressed in membranous bone as well as cartilage. Altogether, these results suggest that aggrecan may contribute to the functional properties and the normal growth and development of avian membranous bone.	UNIV MICHIGAN,DEPT SURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,PROGRAM BIOENGN,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	WONG, M (corresponding author), UNIV MICHIGAN,ORTHOPAED RES LABS,ORTHOPAED SURG SECT,ANN ARBOR,MI 48109, USA.		Zenobi-Wong, Marcy/J-5398-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557, R29AR038473] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20557, AR-38473] Funding Source: Medline; NICHD NIH HHS [HD-22016] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1979, STEREOLOGICAL METHOD; BARRY F, 1990, BIOCHEM SOC T, V18, P197, DOI 10.1042/bst0180197; BERESFORD JN, 1987, J BIOL CHEM, V262, P17164; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; CHOI K, 1990, J BIOMECH, V23, P1103, DOI 10.1016/0021-9290(90)90003-L; CHOI K, 1992, IN PRESS J BIOMECH; CHRISTNER JE, 1978, ANAL BIOCHEM, V90, P22, DOI 10.1016/0003-2697(78)90004-0; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FITCH JM, 1989, DEVELOPMENT, V105, P85; GOETINCK PF, 1988, PATHOL IMMUNOPATH R, V7, P73, DOI 10.1159/000157097; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; KOSHER RA, 1986, DEV BIOL, V118, P112, DOI 10.1016/0012-1606(86)90078-3; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KUHN JL, 1989, J ORTHOPAED RES, V7, P876, DOI 10.1002/jor.1100070614; LANDAUER W, 1965, J HERED, V56, P131, DOI 10.1093/oxfordjournals.jhered.a107392; MAJMUDAR G, 1991, J BONE MINER RES, V6, P869; Maroudas, 1979, ADULT ARTICULAR CART, P219; MARTIN RB, 1989, STRUCTURE FUNCTION A; Mow V.C., 1989, BASIC BIOMECHANICS M, V2nd, P31; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; ODONNELL CM, 1988, J BIOL CHEM, V263, P17749; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PENNYPACKER JP, 1976, DEV BIOL, V50, P35, DOI 10.1016/0012-1606(76)90065-8; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; STIRPE NS, 1987, DEV BIOL, V124, P77, DOI 10.1016/0012-1606(87)90461-1; STIRPE NS, 1990, DEV BIOL, V137, P419, DOI 10.1016/0012-1606(90)90266-L; STIRPE NS, 1989, DEVELOPMENT, V107, P22; TANAKA T, 1988, J BIOL CHEM, V263, P15831	33	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5592	5598						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372006				2022-12-25	WOS:A1992HH74700088
J	EBERLEIN, GA; EYSSELEIN, VE; DAVIS, MT; LEE, TD; SHIVELY, JE; GRANDT, D; NIEBEL, W; WILLIAMS, R; MOESSNER, J; ZEEH, J; MEYER, HE; GOEBELL, H; REEVE, JR				EBERLEIN, GA; EYSSELEIN, VE; DAVIS, MT; LEE, TD; SHIVELY, JE; GRANDT, D; NIEBEL, W; WILLIAMS, R; MOESSNER, J; ZEEH, J; MEYER, HE; GOEBELL, H; REEVE, JR			PATTERNS OF PROHORMONE PROCESSING - ORDER REVEALED BY A NEW PROCHOLECYSTOKININ-DERIVED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLECYSTOKININ MESSENGER-RNA; CANINE CHOLECYSTOKININ; MOLECULAR-FORMS; SEQUENCE; BRAIN; PREPROCHOLECYSTOKININ; CLONING; PLASMA; CDNA; GASTRINOMA	An 83-amino acid cholecystokinin peptide with a sulfated tyrosine and an amidated carboxyl terminus (CCK-83) was purified from human intestinal mucosa. The purified peptide was chemically characterized, and its bioactivity was compared to CCK-8. Several post-translational processing steps such as cleavage at basic residues, sulfation, and amidation are necessary to form biologically active cholecystokinin from its nascent prepropeptide. The discovery of CCK-83 gives new insight into the order of preprohormone processing. The processing of prepro-CCK appears to be in the order of: 1) signal peptidase cleavage, 2) tyrosine sulfation, 3) cleavage after a carboxyl-terminal pair of basic residues, 4) carboxypeptidase B-like cleavage of these basic residues, 5) amidation (which results in the formation of CCK-83), and 6) cleavage at monobasic residues by endopeptidases (which results in the smaller molecular forms of cholecystokinin). The characterization of biologically active CCK-83 with a sulfated tyrosine and an amidated carboxyl terminus establishes the site of signal peptidase action and suggests an order of post-translational modifications that give rise to the various molecular forms of cholecystokinin.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,CTR INFLAMMATORY BOWEL DIS,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,CTR INFLAMMATORY BOWEL DIS,DEPT SURG,TORRANCE,CA 90509; UNIV ESSEN GESAMTHSCH,DEPT GASTROENTEROL & SURG,W-4300 ESSEN 1,GERMANY; CITY HOPE NATL MED CTR,BECKMAN RES INT,DUARTE,CA 91010; UNIV WURZBURG,MED POLIKLIN,W-8700 WURZBURG,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM 1,W-4630 BOCHUM,GERMANY; VET ADM MED CTR BRENTWOOD,CTR ULCER RES & EDUC,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Duisburg Essen; City of Hope; Beckman Research Institute of City of Hope; University of Wurzburg; Ruhr University Bochum; University of California System; University of California Los Angeles	EBERLEIN, GA (corresponding author), CALIF BIOTECHNOL INST,MT VIEW,CA 94043, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036200, R01DK033850] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33850, DK 36200, DK 41031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; DEPAUW E, 1984, BIOCHEM BIOPH RES CO, V123, P27, DOI 10.1016/0006-291X(84)90375-9; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DESMOND H, 1987, FEBS LETT, V210, P185, DOI 10.1016/0014-5793(87)81334-0; EBERLEIN GA, 1987, AM J PHYSIOL, V253, pG477, DOI 10.1152/ajpgi.1987.253.4.G477; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ENG J, 1984, PEPTIDES, V5, P1203, DOI 10.1016/0196-9781(84)90188-8; EYSSELEIN VE, 1988, REGUL PEPTIDES, V22, P205, DOI 10.1016/0167-0115(88)90033-X; EYSSELEIN VE, 1984, REGUL PEPTIDES, V9, P173, DOI 10.1016/0167-0115(84)90070-3; EYSSELEIN VE, 1990, AM J PHYSIOL, V258, pG253, DOI 10.1152/ajpgi.1990.258.2.G253; EYSSELEIN VE, 1982, PEPTIDES, V3, P687, DOI 10.1016/0196-9781(82)90171-1; EYSSELEIN VE, 1987, J BIOL CHEM, V262, P214; GUBLER U, 1987, J BIOL CHEM, V262, P15242; GUBLER U, 1984, P NATL ACAD SCI-BIOL, V81, P4307, DOI 10.1073/pnas.81.14.4307; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUEBNER VD, 1991, J BIOL CHEM, V266, P12223; JUNG DH, 1980, CLIN CHIM ACTA, V100, P7, DOI 10.1016/0009-8981(80)90179-5; KREIL G, 1973, EUR J BIOCHEM, V33, P556; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; MOESSNER J, 1989, Z GASTROENTEROL, V27, P94; MUTT V, 1976, CLIN ENDOCRINOL, V5, pS175, DOI 10.1111/j.1365-2265.1976.tb03825.x; REEVE JR, 1983, J BIOL CHEM, V258, P5582; REEVE JR, 1984, BIOCHEM BIOPH RES CO, V123, P404, DOI 10.1016/0006-291X(84)90428-5; REEVE JR, 1991, J BIOL CHEM, V266, P13770; REEVE JR, 1986, J BIOL CHEM, V261, P6392; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; REHFELD JF, 1972, BIOCHIM BIOPHYS ACTA, V285, P364, DOI 10.1016/0005-2795(72)90321-2; RODRIGUEZ C, 1989, J BIOL CHEM, V264, P5988; STEINER DF, 1975, PROTEASES BIOL CONTR, P531; TAKAHASHI Y, 1985, P NATL ACAD SCI USA, V82, P1931, DOI 10.1073/pnas.82.7.1931; TATEMOTO K, 1984, FEBS LETT, V174, P289, DOI 10.1016/0014-5793(84)81175-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITTEN JL, 1984, BIOCHEM BIOPH RES CO, V124, P350, DOI 10.1016/0006-291X(84)91560-2	35	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1517	1521						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370477				2022-12-25	WOS:A1992HA48500022
J	KREIDER, BL; ROVERA, G				KREIDER, BL; ROVERA, G			THE IMMEDIATE EARLY GENE RESPONSE TO A DIFFERENTIATIVE STIMULUS IS DISRUPTED BY THE V-ABL AND V-RAS ONCOGENES	ONCOGENE			English	Article							SERUM GROWTH-FACTORS; PROGENITOR-CELL LINE; C-FOS; PROTO-ONCOGENE; GRANULOCYTIC DIFFERENTIATION; FACTORS ENCODES; 3T3 CELLS; JUN; INDUCTION; TRANSCRIPTION	The immediate early gene activation in response to a differentiative stimulus was investigated in the hematopoietic progenitor cell line 32DC13(G). A transient and coordinated increase in mRNA levels for c-fos, c-jun, jun-B, TIS-7/PC-4, TIS-8/egr-1, and TIS-11 occurred during the first 2 h of treatment with granulocyte colony stimulating factor (G-CSF), which ultimately induces the 32DC13(G) cells to terminally differentiate into neutrophilic granulocytes. This pattern of mRNA induction was disrupted by v-abl and v-ras, two oncogenes known to interfere with G-CSF-induced differentiation of 32DC13(G) cells. Induction of the mRNAs for c-jun and TIS-7/PC-4 was blocked by the presence of v-abl, whereas v-ras caused constitutive expression of c-fos mRNA and blocked the c-jun, jun-B and TIS-7/PC-4 mRNA response. Release of the differentiation block in the ras-transformed 32DC13(G) cells by co-treatment with retinoic acid and G-CSF partially restored the normal c-fos and c-jun mRNA induction pattern, suggesting that the proper activation of these genes may be important for myeloid differentiation.	WISTAR INST,36TH & SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NCI NIH HHS [CA 52009, CA 10815, CA 09171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815, P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, ONCOGENE HDB; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MAVILIO F, 1989, ONCOGENE, V4, P301; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROVERA G, 1987, ONCOGENE, V1, P29; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213	34	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					135	140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371335				2022-12-25	WOS:A1992HC22700018
J	YOKOTA, I; SAIJO, T; VOCKLEY, J; TANAKA, K				YOKOTA, I; SAIJO, T; VOCKLEY, J; TANAKA, K			IMPAIRED TETRAMER ASSEMBLY OF VARIANT MEDIUM-CHAIN ACYL-COENZYME-A DEHYDROGENASE WITH A GLUTAMATE OR ASPARTATE SUBSTITUTION FOR LYSINE-304 CAUSING INSTABILITY OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COA DEHYDROGENASE; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PREVALENT MUTATION; ESCHERICHIA-COLI; MCAD DEFICIENCY; GENE; IDENTIFICATION; BIOSYNTHESIS	Ninety percent of variant medium-chain acyl-CoA dehydrogenase (MCAD) alleles in patients with MCAD deficiency carry a 985A-->G transition which causes glutamate substitution for lysine 329 in precursor (p) MCAD (K-304 in mature MCAD). We have used site-directed mutagenesis to produce three variant cDNAs encoding variant pMCAD with glutamate (Kp329E2), aspartate (Kp329D), or arginine (Kp329R) substitution for Kp329. We carried out in vitro expression of cDNAs, and incubated the translation products with isolated rat liver mitochondria. Kp329E was imported into mitochondria and processed into the mature subunit as efficiently as wild-type. Gel filtration analysis of the mitochondria revealed that at 10 min after import, markedly more K304E eluted as a monomer than did wild-type, and the amount of K304E tetramer formed was distinctly less than wild-type at any point up to 60 min after import, indicating that the assembly of K304E is defective. After further incubation, K304E decayed more rapidly than did wild-type, indicating a reduced stability. In similar studies, K304R behaved like the wild-type, while K304D closely resembled K304E, indicating that the presence of a basic residue at 304 is essential for tetramer formation and intramitochondrial stability of mature MCAD.	YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, POB 3333, NEW HAVEN, CT 06510 USA	Yale University	TANAKA, K (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, POB 3333, NEW HAVEN, CT 06510 USA.		Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [DK38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAKEMORE AIF, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90907-7; BROSS P, 1992, PROG CLIN BIOL RES, V375, P473; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COATES PM, 1992, PEDIATR RES, V31, P34, DOI 10.1203/00006450-199201000-00006; CONBOY JG, 1981, P NATL ACAD SCI-BIOL, V78, P3073, DOI 10.1073/pnas.78.5.3073; GREGERSEN N, 1991, HUM GENET, V86, P545; GREGERSEN N, 1992, PROG CLIN BIOL RES, V375, P441; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA Y, 1986, PEDIATR RES, V20, P843, DOI 10.1203/00006450-198609000-00007; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; INAGAKI T, 1990, J CLIN BIOCHEM NUTR, V8, P1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; KIM JJP, 1992, NEW DEV FATTY ACID O, V111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWENSTEIN J, 1970, Biochimica et Biophysica Acta, V223, P432, DOI 10.1016/0005-2728(70)90201-X; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MATSUBARA Y, 1991, LANCET, V338, P552, DOI 10.1016/0140-6736(91)91110-G; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MATSUBARA Y, 1986, P NATL ACAD SCI USA, V83, P6543, DOI 10.1073/pnas.83.17.6543; OGILVIE I, 1991, BIOCHEM MED METAB B, V46, P373, DOI 10.1016/0885-4505(91)90085-Y; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROE CR, 1988, METABOLIC BASIS INHE, P889; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4530; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALDINGER D, 1988, BIOL CHEM H-S, V369, P1185, DOI 10.1515/bchm3.1988.369.2.1185; YOKOTA I, 1991, AM J HUM GENET, V49, P1280; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; 1992, NEW DEV FATTY ACID O, P499	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26004	26010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361190				2022-12-25	WOS:A1992KD07300063
J	HOYERHANSEN, G; RONNE, E; SOLBERG, H; BEHRENDT, N; PLOUG, M; LUND, LR; ELLIS, V; DANO, K				HOYERHANSEN, G; RONNE, E; SOLBERG, H; BEHRENDT, N; PLOUG, M; LUND, LR; ELLIS, V; DANO, K			UROKINASE PLASMINOGEN-ACTIVATOR CLEAVES ITS CELL-SURFACE RECEPTOR RELEASING THE LIGAND-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ONCOGENIC VIRUS; U937 MONOCYTES; SYSTEM; ENZYME; DEGRADATION; POTENTIATION; INHIBITORS; EXPRESSION; ANTIBODIES	The cellular receptor for urokinase-type plasminogen activator (uPAR) is a glycolipid-anchored three-domain membrane protein playing a central role in pericellular plasminogen activation. We have found that urokinase (uPA) can cleave its receptor between domains 1 and 2 generating a cell-associated uPAR variant without ligand-binding properties. In extracts of U937 cells there are two uPAR variants which after complete deglycosylation have apparent molecular masses of 35,000 and 27,000. Analysis with monoclonal antibodies showed that these variants represented the intact uPAR and a two-domain form, uPAR(2+3), lacking ligand-binding domain 1. Trypsin treatment showed that both variants are present on the outside of the cells. Addition to the culture medium of an anticatalytic monoclonal antibody to uPA inhibited the formation of the uPAR(2+3), indicating that uPA is involved in its generation. Purified uPAR can be cleaved directly by uPA as well as by plasmin. The uPA-catalyzed cleavage does not require binding of the protease to the receptor through its epidermal growth factor-like receptor-binding domain, since low molecular weight uPA that lacks this domain also cleaves uPAR. This unusual reaction in which a specific binding protein is proteolytically inactivated by its own ligand may represent a regulatory step in the plasminogen activation cascade.			HOYERHANSEN, G (corresponding author), RIGSHOSP, FINSEN INST, STRANDBLVD 49, DK-2100 COPENHAGEN, DENMARK.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Ploug, Michael/0000-0003-2215-4265; Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARON-VAN EVERCOOREN A, 1987, DEV BRAIN RES, V36, P101, DOI 10.1016/0165-3806(87)90068-X; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; COHEN SD, 1981, J IMMUNOL, V126, P1415; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1990, UCLA SYM BI, V131, P173; DANO K, 1979, BIOCHIM BIOPHYS ACTA, V566, P138, DOI 10.1016/0005-2744(79)90256-0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V630, P146, DOI 10.1016/0304-4165(80)90146-4; DANO K, 1989, CANCER METASTASIS, P98; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; KALTOFT K, 1982, P NATL ACAD SCI-BIOL, V79, P3720, DOI 10.1073/pnas.79.12.3720; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND LR, 1991, J BIOL CHEM, V266, P5177; NIELSEN LS, 1986, J IMMUNOASSAY, V7, P209, DOI 10.1080/01971528608060467; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OLSON D, 1992, J BIOL CHEM, V267, P9129; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHALLER J, 1985, EUR J BIOCHEM, V149, P267, DOI 10.1111/j.1432-1033.1985.tb08921.x; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; SUMMARIA L, 1975, J BIOL CHEM, V250, P3988; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	38	230	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18224	18229						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381366				2022-12-25	WOS:A1992JM22300113
J	BIRNBERG, NC; STORK, PJS; HEMMICK, LM				BIRNBERG, NC; STORK, PJS; HEMMICK, LM			EXPRESSION OF THE C-HARVEY RAS ONCOGENE ALTERS PEPTIDE-SYNTHESIS IN THE NEUROSECRETORY CELL-LINE ATT20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PITUITARY-CELLS; PC12 CELLS; NEURONAL DIFFERENTIATION; GROWTH-FACTOR; GENE; ADRENOCORTICOTROPIN; TRANSCRIPTION; INHIBITION; PROTEINS; FOS	Ras proteins are enriched in neurosecretory cells suggesting that ras may play an important role in regulating the differentiated properties of such cells. We introduced the human H-ras oncogene, EJ-ras, into the model secretory cell line AtT20 to determine the effects of ras oncogene expression on neuropeptide synthesis and release. We report here that both of these processes are changed in ras-transfected AtT20 cells. Stimulated release of the pituitary hormone corticotropin is reduced, and transcription of the gene encoding its precursor, proopiomelanocortin, is down-regulated. At the same time, expression of other genes, both housekeeping and neural-specific, remain relatively unchanged. The alteration of proopiomelanocortin expression in AtT20 cells following ras oncogene transformation supports the hypothesis that ras may play a role in the determination of the differentiated phenotype of neurosecretory cells.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University	BIRNBERG, NC (corresponding author), YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510, USA.							ADLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2086, DOI 10.1073/pnas.80.7.2086; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Battey, 1986, BASIC METHODS MOL BI; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARNEY WP, 1988, CLIN CHEM, V34, P1696; CHERA PG, 1987, P NATL ACAD SCI USA, V84, P3234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLAMM RE, 1990, PFLUG ARCH EUR J PHY, V416, P120, DOI 10.1007/BF00370232; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HANLEY MR, 1987, NATURE, V328, P668, DOI 10.1038/328668a0; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; HERBERT E, 1978, ENDOCRINOLOGY, V102, P218, DOI 10.1210/endo-102-1-218; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PHILLIPS M, 1982, ENDOCRINOLOGY, V110, P892; ROBERTS JL, 1978, BIOCHEMISTRY-US, V17, P3609, DOI 10.1021/bi00610a030; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; STORK P, 1991, ONCOGENE, V6, P857; SUPRENANT A, 1982, J CELL BIOL, V95, P559; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; UHLER M, 1983, J BIOL CHEM, V258, P257	32	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15464	15468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379231				2022-12-25	WOS:A1992JG11300034
J	MAGAGNIN, S; BERTRAN, J; WERNER, A; MARKOVICH, D; BIBER, J; PALACIN, M; MURER, H				MAGAGNIN, S; BERTRAN, J; WERNER, A; MARKOVICH, D; BIBER, J; PALACIN, M; MURER, H			POLY(A)(+) RNA FROM RABBIT INTESTINAL-MUCOSA INDUCES B(0,+) AND Y(+) AMINO-ACID-TRANSPORT ACTIVITIES IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER VESICLES; ECOTROPIC RETROVIRUS RECEPTOR; CULTURED ANIMAL-CELLS; EXPRESSION CLONING; COTRANSPORT SYSTEM; MEMBRANE-VESICLES; MOUSE BLASTOCYSTS; CYSTINE UPTAKE; PROTEIN; KIDNEY	Injection of poly(A)+ RNA (mRNA) isolated from rabbit intestinal mucosa into Xenopus laevis oocytes results in an increase in sodium-independent uptake of L-[H-3]leucine, L-[S-35]cystine, and L-[H-3]arginine. This uptake activity is related to an mRNA species corresponding to the recently isolated rabbit kidney cortex cDNA clone rBAT (related to b0,+ amino acid transporter; Bertran, J., Werner, A., Stange, G., Markovich, D., Moore, M. L., Biber, J., Testar, X., Zorzano, A., Palacin, M., and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 281, 717-723) and to a protein involved in amino acid transport via system y+. This conclusion is based on the following observations: 1) mRNA isolated from mucosa of duodenum, jejunum, and ileum, but not from colon, induces sodium-independent uptake of L-leucine, L-cystine, and L-arginine. 2) In Northern blot analysis, mRNA isolated from mucosa of duodenum, jejunum, and ileum, but not from colon, hybridizes to an rBAT cDNA probe, with signals of 2.2-2.3 kilobases and 3.7-3.9 kilobases. 3) mRNA isolated from mucosa of jejunum induces sodium-independent uptake of L-leucine and L-cystine which shows an inhibition pattern corresponding to system b0,+; the inhibition pattern of mRNA-induced uptake of L-arginine is compatible with the contribution of system b0,+ and y+. 4) Hybrid depletion with an rBAT antisense oligonucleotide greatly prevents the mRNA-dependent induction of uptake of L-cystine (>90%) and of L-leucine (approximately 75%); it reduces to about 50% the induction of L-arginine uptake. 5) After separation of mRNA on a sucrose density gradient, the fractions resulting in expression of b0,+ transport activity were also those hybridizing with rBAT cDNA; induction of transport activity from these fractions was also sensitive to hybrid depletion. 6) The mRNA-induced component Of L-arginine uptake which is resistant to rBAT hybrid depletion is inhibited by L-homoserine, only in the presence of sodium; thus, it is related to a system y+-like activity.	UNIV ZURICH,INST PHYSIOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Palacín, Manuel/G-9786-2015; Markovich, Daniel/F-7884-2012	Palacin, Manuel/0000-0002-8670-293X				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AOSHIMA H, 1988, ARCH BIOCHEM BIOPHYS, V265, P73, DOI 10.1016/0003-9861(88)90372-4; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BERTRAN J, 1992, IN PRESS P NATL ACAD; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1497; COADY MJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P130, DOI 10.1016/0003-9861(90)90622-6; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FURESZ TC, 1991, AM J PHYSIOL, V261, pC246, DOI 10.1152/ajpcell.1991.261.2.C246; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MIRCHEFF AK, 1982, J MEMBRANE BIOL, V64, P113, DOI 10.1007/BF01870773; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NCMANARA PD, 1991, J BIOL CHEM, V266, P986; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PALACIN M, 1990, BIOCHEM J, V270, P189, DOI 10.1042/bj2700189; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; TARNUZZER RW, 1990, J BIOL CHEM, V265, P13914; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TATE SS, 1989, ARCH BIOCHEM BIOPHYS, V275, P591, DOI 10.1016/0003-9861(89)90405-0; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443	38	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15384	15390						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379228				2022-12-25	WOS:A1992JG11300022
J	ARYSTARKHOVA, E; GASPARIAN, M; MODYANOV, NN; SWEADNER, KJ				ARYSTARKHOVA, E; GASPARIAN, M; MODYANOV, NN; SWEADNER, KJ			NA,K-ATPASE EXTRACELLULAR SURFACE PROBED WITH A MONOCLONAL-ANTIBODY THAT ENHANCES OUABAIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SODIUM DODECYL-SULFATE; ALPHA-SUBUNIT; CATALYTIC SUBUNIT; GEL-ELECTROPHORESIS; NA+/K+-ATPASE; NA+,K+-ATPASE; PROTEINS; RAT; IDENTIFICATION	The Na,K-stimulated ATPase is inhibited by extracellular cardiac glycosides, which bind to the enzyme's alpha-subunit. We used a monoclonal antibody, VG4, as a probe of the extracellular surface. The antibody was specific for Na,K-ATPase and bound to intact cells. The epitope was mapped to the first extracellular loop (H1-H2) of alpha, using a combination of techniques including trypsinolysis, N-terminal sequence of a fragment containing the determinant, and analysis of the effects of species-specific sequence differences. The antibody inhibited Na,K-ATPase activity under certain circumstances, indicating that the H1-H2 loop participates in conformational changes that are transmitted to the active site. Mutations in the H1-H2 loop have been shown by others to affect ouabain affinity. Ouabain and the antibody acted synergistically to inhibit the enzyme, which seemingly supported the hypothesis that the H1-H2 loop is an essential part of the cardiac glycoside binding site. Direct measurements of the binding of [H-3]ouabain, however, indicated that VG, enhanced rather than inhibited binding, presumably by promoting favorable conformation changes. The data suggest the possibility that the cardiac glycoside binding site may be intramembrane rather than extracellular.	MASSACHUSETTS GEN HOSP, DEPT NEUROSURG RES, WELLMAN 4, FRUIT ST, BOSTON, MA 02114 USA; MM SHEMYAKIN BIOORGAN CHEM INST, MOSCOW 117871, USSR; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Harvard University; Harvard Medical School			Gasparian, Marine/J-6725-2018; Chernyak, Boris V/D-9917-2012	Chernyak, Boris V/0000-0003-1523-0864; Gasparian, Marine/0000-0003-2308-2574	NHLBI NIH HHS [HL 36271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALL WJ, 1987, BIOCHEM BIOPH RES CO, V148, P246, DOI 10.1016/0006-291X(87)91102-8; BALL WJ, 1984, BIOCHEMISTRY-US, V23, P2275, DOI 10.1021/bi00305a029; BALL WJ, 1986, BIOCHEMISTRY-US, V25, P7155, DOI 10.1021/bi00370a058; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GLYNN IM, 1964, PHARMACOL REV, V16, P381; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; NOGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1237, DOI 10.1016/S0006-291X(88)81272-5; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROSSI B, 1988, METHOD ENZYMOL, V156, P323; SATOH K, 1989, BIOCHIM BIOPHYS ACTA, V994, P104, DOI 10.1016/0167-4838(89)90149-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK DB, 1983, P NATL ACAD SCI-BIOL, V80, P5281, DOI 10.1073/pnas.80.17.5281; STAHL WL, 1990, J HISTOCHEM CYTOCHEM, V38, P1099, DOI 10.1177/38.8.2164057; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; Thomas R., 1990, ADV DRUG RES, P311; URAYAMA O, 1985, J BIOCHEM-TOKYO, V98, P209, DOI 10.1093/oxfordjournals.jbchem.a135260; URAYAMA O, 1990, BIOCHIM BIOPHYS ACTA, V1040, P267, DOI 10.1016/0167-4838(90)90086-U; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201	41	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13694	13701						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377691				2022-12-25	WOS:A1992JB74600094
J	BREUER, W; KARTNER, N; RIORDAN, JR; CABANTCHIK, ZI				BREUER, W; KARTNER, N; RIORDAN, JR; CABANTCHIK, ZI			INDUCTION OF EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) was studied in HT-29 human colonic carcinoma cells with the aim of assessing possible mechanisms of up-regulation of its expression. CFTR was identified and quantified in total cell extracts by Western immunoblots using a monoclonal anti-CFTR antibody and was functionally assessed by tracer Cl- efflux from intact cells. It was found that various stimuli that lead to a sustained (greater-than-or-equal-to 8 h) elevation of intracellular cyclic AMP elicited a marked and specific increase in CFTR expression in cell membranes and concomitant activation of Cl- secretion. Further activation of Cl- secretion was obtained by additional short term activation by cyclic AMP analogues or cyclic AMP-inducing agents. Blockers of transcription or translation largely depressed the cAMP-mediated induction of CFTR levels and associated function, indicating that the inductive phenomenon was at the transcriptional level. The results imply the involvement of putative cyclic AMP responsive (and related) elements that are present in the CFTR gene promoter and that are known to modulate eukaryotic gene expression. Activation of these elements by various stimuli might provide pharmacological tools for up-regulation of CFTR expression at both biochemical and physiological levels.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NHLBI NIH HHS [HL 40158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040158] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEULEMANS J, 1991, PED PULM S, V6, P251; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; LOHRMANN E, 1990, PFLUG ARCH EUR J PHY, V418, pR236; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1059; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SOOD RC, 1991, PEDIATR PULM S, V6, pA226; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	23	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10465	10469						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375221				2022-12-25	WOS:A1992HV09000041
J	DUZIC, E; COUPRY, I; DOWNING, S; LANIER, SM				DUZIC, E; COUPRY, I; DOWNING, S; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .1. COUPLING OF ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES TO DISTINCT G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; HIGH-AFFINITY; ALPHA-2B-ADRENERGIC RECEPTOR; CELL LINE; EXPRESSION; CLONING; IDENTIFICATION; SYSTEMS; BRAIN	Alpha-2-adrenergic receptor (alpha-2-AR) subtypes couple to pertussis toxin (PT)-sensitive G-proteins to elicit both stimulatory and inhibitory cell responses. Signal specificity may be generated by the ability of the receptor subtypes to "recognize" distinct G-proteins with different affinity. To address this issue we stably expressed three alpha-2-AR subtypes, RNG-alpha-2 (alpha-2B-AR), RG10 (alpha-2C-AR), and RG20 (alpha-2D-AR), in NIH-3T3 fibroblasts, which express two PT-sensitive G-proteins (G(i-alpha-2), G(i-alpha-3), and analyzed receptor/G-protein interactions by determining: 1) functional coupling to adenylylcyclase and 2) the ability of the receptors to exist in a high affinity state for agonist. In alpha-2D-AR transfectants expressing 200 or 2,200 fmol of receptor/mg of protein, epinephrine (10-mu-M) inhibited forskolin-induced elevation of cellular cAMP by 26 +/- 4.8% and 72 +/- 6.2%, respectively. Similar results were obtained in alpha-2B-AR transfectants. However, in alpha-2C-AR transfectants (200 fmol/mg) the forskolin-induced elevation of cellular cAMP was not altered by agonist treatment. In alpha-2C-AR transfectants expressing higher receptor densities (650-1,200 fmol/mg), epinephrine inhibited the effect of forskolin by 30 +/- 3.2%. This difference in functional coupling among the alpha-2-AR subtypes is reflected at the receptor/G-protein interface. In membrane preparations of alpha-2B and alpha-2D-AR but not alpha-2c-AR transfectants, agonist competition curves were biphasic, indicating high and low affinity states of the receptor for agonist. The high affinity state was guanyl-5'-yl imidodiphosphate- and PT-sensitive, indicative of receptor/G-protein coupling. These data suggest that the alpha-2c-AR differs from the alpha-2B and alpha-2D-AR subtypes in its ability to recognize PT-sensitive G-proteins expressed in NIH-3T3 fibroblasts. The alpha-2c-AR may couple preferentially to PT-sensitive G-proteins (G(i1), G(o1,2) not expressed in NIH-3T3 fibroblasts and thereby elicit different cellular responses.	MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CELLULAR & MOLEC RES LAB,BOSTON,MA 02114	Medical University of South Carolina; Harvard University; Harvard Medical School; Massachusetts General Hospital			COUPRY, Isabelle/L-4900-2014	Lanier, Stephen/0000-0002-2740-7607	FIC NIH HHS [3 FO5 TW4313-02] Funding Source: Medline; NINDS NIH HHS [NS-24821] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CALTABIANO MM, 1990, GENE AMST, V85, P479; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CARPENE C, 1990, BIOCHEM PHARMACOL, V40, P437, DOI 10.1016/0006-2952(90)90541-R; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COUPRY I, 1992, J BIOL CHEM, V267, P9852; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN C, 1986, DNA CLONING PRACTICA, V2, P152; GRAHAM RM, 1986, HEART CARDIOVASCULAR, V2, P1059; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LANIER SM, 1988, J BIOL CHEM, V263, P14491; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LORENZ W, 1990, MOL PHARMACOL, V38, P599; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MCKENZIE FR, 1990, BIOCHEM J, V267, P371; MICHEL AD, 1989, BRIT J PHARMACOL, V98, P890, DOI 10.1111/j.1476-5381.1989.tb14618.x; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; PARIS H, 1990, J PHARMACOL EXP THER, V254, P888; REGAN JW, 1986, J BIOL CHEM, V261, P3894; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P187; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMMONEAUX V, 1991, MOL PHARMACOL, V40, P235; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STARKE K, 1989, PHYSIOL REV, V69, P900; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; THOMSEN WJ, 1988, MOL PHARMACOL, V34, P814; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	51	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9844	9851						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349606				2022-12-25	WOS:A1992HT96500064
J	KWON, HM; YAMAUCHI, A; UCHIDA, S; PRESTON, AS; GARCIAPEREZ, A; BURG, MB; HANDLER, JS				KWON, HM; YAMAUCHI, A; UCHIDA, S; PRESTON, AS; GARCIAPEREZ, A; BURG, MB; HANDLER, JS			CLONING OF THE CDNA FOR A NA+/MYO-INOSITOL COTRANSPORTER, A HYPERTONICITY STRESS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL TRANSPORT; NUCLEOTIDE-SEQUENCE; SYMPORT CARRIER; NA+/GLUCOSE; GLUCOSE; CELLS; GENE	Kidney medullary cells in situ, as well as kidney-derived Madin-Darby canine kidney (MDCK) cells accumulate nonperturbing, small organic solutes (osmolytes), including myo-inositol, when bathed in hypertonic media. Accumulation of osmolytes balances the osmolality of extracellular fluid without raising intracellular salts that would perturb cellular functions. In hypertonic media, increased myo-inositol accumulation is the result of increased activity of a Na+/myo-inositol cotransporter. We have isolated a cDNA encoding a Na+/myo-inositol cotransporter from MDCK cells using expression in Xenopus oocytes. The cDNA sequence predicts a protein of 718 amino acids with a significant amino acid sequence similarity to the Na+/D-glucose cotransporters of absorbing epithelia. Transporter mRNA is present in kidney and brain and is markedly induced in MDCK cells by medium hypertonicity, demonstrating that adaptation to hypertonic stress involves up-regulation of transporter mRNA accumulation.	JOHNS HOPKINS UNIV, SCH MED,DIV NEPHROL,ROSS BLDG,9TH FLOOR S, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA; NHLBI, KIDNEY & ELECTROLYTE METAB LAB, BETHESDA, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Uchida, Shinichi/D-1111-2013; Lee-Kwon, Whaseon/D-6021-2011		NIDDK NIH HHS [DK42479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGNASCO S, 1986, J BIOL CHEM, V261, P5872; CASPARY WF, 1970, BIOCHIM BIOPHYS ACTA, V203, P308, DOI 10.1016/0005-2736(70)90145-8; COADY MJ, 1990, AM J PHYSIOL, V259, pC605, DOI 10.1152/ajpcell.1990.259.4.C605; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; HAMMERMAN MR, 1980, AM J PHYSIOL, V239, pF113, DOI 10.1152/ajprenal.1980.239.2.F113; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEILIG CW, 1989, AM J PHYSIOL, V257, pF1108, DOI 10.1152/ajprenal.1989.257.6.F1108; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KWON HM, 1991, AM J PHYSIOL, V260, pF258, DOI 10.1152/ajprenal.1991.260.2.F258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; MORIYAMA T, 1991, AM J PHYSIOL, V260, pF494, DOI 10.1152/ajprenal.1991.260.4.F494; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; STRANGE K, 1991, AM J PHYSIOL, V260, pC784, DOI 10.1152/ajpcell.1991.260.4.C784; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; UCHIDA S, 1991, J CLIN INVEST, V88, P656, DOI 10.1172/JCI115350; VEIS JH, 1991, AM J PHYSIOL, V260, pF619, DOI 10.1152/ajprenal.1991.260.5.F619; WHITESIDE CI, 1991, AM J PHYSIOL, V260, pF138, DOI 10.1152/ajprenal.1991.260.1.F138; YAMATO I, 1990, J BIOL CHEM, V265, P2450; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	27	323	327	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6297	6301						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372904				2022-12-25	WOS:A1992HK31800087
J	OGATA, Y; ENGHILD, JJ; NAGASE, H				OGATA, Y; ENGHILD, JJ; NAGASE, H			MATRIX METALLOPROTEINASE-3 (STROMELYSIN) ACTIVATES THE PRECURSOR FOR THE HUMAN MATRIX METALLOPROTEINASE-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RHEUMATOID SYNOVIAL FIBROBLASTS; IV COLLAGENASE; DEGRADING METALLOPROTEINASE; ALVEOLAR MACROPHAGES; V COLLAGEN; GELATINASE; PURIFICATION; TISSUE; CELLS	Matrix metalloproteinase 9 (MMP-9), also known as 92-kDa gelatinase/type IV collagenase, is secreted from neutrophils, macrophages, and a number of transformed cells in zymogen form. Here we report that matrix metalloproteinase 3 (MMP-3/stromelysin) is an activator of the precursor of matrix metalloproteinase 9 (proMMP-9). MMP-3 initially cleaves proMMP-9 at the Glu40-Met41 bond located in the middle of the propeptide to generate an 86-kDa intermediate. Cleavage of this bond triggers a change in proMMP-9 that renders the Arg87-Phe88 bond susceptible to the second cleavage by MMP-3, resulting in conversion to an 82-kDa form alpha-2-Macroglobulin binding studies of partially activated MMP-9 demonstrate that the 82-kDa species is proteolytically active, but not the initial intermediate of 86 kDa. This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. The results imply that MMP-3 may be an effective activator of proMMP-9 in vivo.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,3901 RAINBOW BLVD,KANSAS CITY,KS 66103; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	University of Kansas; University of Kansas Medical Center; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; DAVIS GE, 1990, CANCER RES, V50, P1113; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; LYONS IG, 1991, BIOCHEMISTRY-US, V30, P1449; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1989, J CELL SCI, V92, P487; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1989, FEBS LETT, V249, P353, DOI 10.1016/0014-5793(89)80657-X; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SALAMONSEN LA, 1991, J CELL SCI, V100, P381; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SOPATA I, 1974, BIOCHIM BIOPHYS ACTA, V370, P510, DOI 10.1016/0005-2744(74)90112-0; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	42	585	603	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3581	3584						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371271				2022-12-25	WOS:A1992HE60700008
J	PARK, DJ; MIN, HK; RHEE, SG				PARK, DJ; MIN, HK; RHEE, SG			INHIBITION OF CD3-LINKED PHOSPHOLIPASE-C BY PHORBOL ESTER AND BY CAMP IS ASSOCIATED WITH DECREASED PHOSPHOTYROSINE AND INCREASED PHOSPHOSERINE CONTENTS OF PLC-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CALCIUM; COMPLEX; PATHWAY; TURNOVER	The mechanisms by which phorbol 12-myristate 13-acetate (PMA) and cAMP attenuate the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P2) induced by ligation of the T-cell antigen receptor complex (TCR) was studied in the human Jurkat T-cell line. It has previously been shown that stimulation of Jurkat cells with antibodies to CD3, components of the TCR, elicits a rapid and transient phosphorylation of phospholipase C (PLC)-gamma-1, the predominant PLC isozyme in Jurkat cells, at multiple tyrosine residues and that such tyrosine phosphorylation leads to activation of PLC-gamma-1. Prior incubation of Jurkat cells with PMA or forskolin, which increases intracellular cAMP concentrations, prevented tyrosine phosphorylation of PLC-gamma-1 as well as the hydrolysis of PtdIns 4,5-P2 induced by ligation of CD3. Dose-response curves of PMA and of forskolin for the inhibition of PLC-gamma-1 tyrosine phosphorylation and of PtdIns 4,5-P2 hydrolysis were similar. These results suggest that the inhibition of PtdIns 4,5-P2 hydrolysis by PMA and cAMP is attributable to reduced tyrosine phosphorylation of PLC-gamma-1. Treatment of Jurkat cells with PMA or forskolin stimulated the phosphorylation of PLC-gamma-1 at serine 1248. PMA treatment also elicited the phosphorylation of PLC-gamma-1 at an unidentified serine site. Phosphopeptide map analysis indicated that the sites of PLC-gamma-1 phosphorylated in Jurkat cells treated with PMA and forskolin are the same as those phosphorylated in vitro by protein kinase C (PKC) and cAMP-dependent protein kinase (PKA), respectively. Stimulation of Jurkat cells with antibodies to CD3 also elicited phosphorylation of PLC-gamma-1 at serine 1248 and at the unidentified serine site phosphorylated in PLC-gamma-1 from PMA-treated cells. Thus, phosphorylation of PLC-gamma-1 by PKC or PKA at serine 1248 may modulate the interaction of PLC-gamma-1 with the protein tyrosine kinase or the protein tyrosine phosphatase; this altered interaction may, at least in part, be responsible for the decreased tyrosine phosphorylation of PLC-gamma-1 seen in PMA- and forskolin-treated Jurkat cells. Furthermore, in the absence of PMA, activation of PKC by diacylglycerol provides a negative feedback signal responsible for reducing the phosphotyrosine contents of PLC-gamma-1.	NHLBI,BIOCHEM LAB,BLDG 3,RM 122,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Park, Do-Joon/J-2736-2012					ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; ALBERT F, 1985, J IMMUNOL, V134, P3649; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHOUAIB S, 1987, J CLIN INVEST, V80, P333, DOI 10.1172/JCI113077; DOSREIS GA, 1986, CELL IMMUNOL, V101, P213, DOI 10.1016/0008-8749(86)90199-1; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HIS ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; ISAKOV N, 1987, J IMMUNOL, V138, P3100; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1989, J BIOL CHEM, V264, P20167; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LERNER A, 1988, J IMMUNOL, V140, P936; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MCATEE P, 1989, J BIOL CHEM, V264, P11193; MEISENHELDER J, 1989, CELL, V57, P1108; MILLS GB, 1989, J IMMUNOL, V142, P1995; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; SOMMERMEYER H, 1990, EUR J IMMUNOL, V20, P1881, DOI 10.1002/eji.1830200902; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TOMITAYAMAGUCHI M, 1990, J IMMUNOL, V144, P3946; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG T, 1978, SCIENCE, V201, P155, DOI 10.1126/science.208147; WARD SG, 1990, J IMMUNOL, V144, P3523; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	43	146	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1496	1501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370476				2022-12-25	WOS:A1992HA48500019
J	MONNIER, D; COLAS, JF; ROSAY, P; HEN, R; BORRELLI, E; MAROTEAUX, L				MONNIER, D; COLAS, JF; ROSAY, P; HEN, R; BORRELLI, E; MAROTEAUX, L			NKD, A DEVELOPMENTALLY REGULATED TACHYKININ RECEPTOR IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SUBSTANCE-P-LIKE; IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; FMRFAMIDE-LIKE; NEUROPEPTIDES; EXPRESSION; CLONING; GENE; LOCALIZATION	A number of neuropeptides have been described which are present in the insect nervous system. The physiological role of these neuropeptides has not yet been clarified. We have characterized a Drosophila melanogaster cDNA coding for a protein, NKD, whose sequence resembles that of mammalian G protein-coupled neuropeptide receptors. This protein shows 38% homology with the mammalian tachykinin NK3 receptor within the transmembrane domain region. Stable cell lines expressing this cDNA are responsive to Locusta migratoria tachykinin but not to other peptides of the tachykinin family. The expression of this gene is detected principally in adult fly heads, but also in the adult body and in embryos. Interestingly, NKD mRNA is detected at very early stages of Drosophila embryonic development (3 h) and reaches the highest level of expression at 12-16 h, a time which correlates with the period of major neuronal development. In situ hybridization experiments demonstrate that NKD is expressed in the central nervous system, as well as in subsets of neurons in each segment of the developing ventral ganglia. The cytological localization of this gene is at position 86C on the Drosophila third chromosome.	FAC MED STRASBOURG,CNRS,GENET EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Maroteaux, Luc/H-4585-2019	Maroteaux, Luc/0000-0002-9499-8603				ARAKAWA S, 1990, NEURON, V4, P343, DOI 10.1016/0896-6273(90)90047-J; BROADIE KS, 1990, DEVELOPMENT, V108, P59; COPENHAVER PF, 1989, DEV BIOL, V131, P70, DOI 10.1016/S0012-1606(89)80039-9; FOLKERS K, 1984, BRIT J PHARMACOL, V83, P449, DOI 10.1111/j.1476-5381.1984.tb16506.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P396; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HOFFMANN JA, 1991, NEW BIOL, V3, P336; KESHISHIAN H, 1985, J NEUROSCI, V5, P1005; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MUDGE AW, 1989, NATURE, V339, P663, DOI 10.1038/339663a0; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; NASSEL DR, 1990, BRAIN RES, V507, P225, DOI 10.1016/0006-8993(90)90276-H; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONAI T, 1989, FEBS LETT, V255, P219, DOI 10.1016/0014-5793(89)81095-6; Sambrook J, 1989, MOL CLONING LABORATO; SAUDOU F, 1990, EMBO J, V9, P3611, DOI 10.1002/j.1460-2075.1990.tb07572.x; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1990, FEBS LETT, V261, P397, DOI 10.1016/0014-5793(90)80601-E; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANBRUNT J, 1987, BIO-TECHNOL, V5, P31; VERHAERT P, 1985, HISTOCHEMISTRY, V86, P501; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	29	125	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1298	1302						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370464				2022-12-25	WOS:A1992GY96000096
J	FOUFELLE, F; GOUHOT, B; PEGORIER, JP; PERDEREAU, D; GIRARD, J; FERRE, P				FOUFELLE, F; GOUHOT, B; PEGORIER, JP; PERDEREAU, D; GIRARD, J; FERRE, P			GLUCOSE STIMULATION OF LIPOGENIC ENZYME GENE-EXPRESSION IN CULTURED WHITE ADIPOSE-TISSUE - A ROLE FOR GLUCOSE-6-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYL-COA CARBOXYLASE; FATTY-ACID SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PYRUVATE-KINASE GENE; RAT HEPATOCYTES; MESSENGER-RNA; DEPENDENT INDUCTION; POSTTRANSCRIPTIONAL REGULATION; INSULIN; LIVER	The expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) is low in the adipose tissue of suckling rats and increases markedly at weaning to a high carbohydrate diet. We have studied in vitro the factors regulating this phenomenon. Inguinal adipose tissue pieces from 19-day-old suckling rats were cultured for 6 or 24 h in minimal essential medium. Insulin (100 nM) added in the presence of lactate and pyruvate did not stimulate the expression of FAS and ACC. Glucose (20 mM) alone resulted in a 5-7-fold increase of FAS and ACC mRNA. Insulin potentiated the effect of glucose. 3-O-Methylglucose, a glucose analog that is transported into the cell but not metabolized, had no effect on FAS and ACC mRNA accumulation. However, 2-deoxyglucose (1 mM), a glucose analog which is phosphorylated to 2-deoxyglucose 6-phosphate, stimulated the expression of FAS and ACC to the same extent as 20 mM glucose. Glucose 6-phosphate concentrations in adipose tissue pieces cultured in various conditions changed in parallel with the FAS and ACC mRNA levels. We conclude that glucose 6-phosphate could be the metabolite involved in the stimulation of lipogenic enzyme gene expression in response to glucose.	HOP ST VINCENT DE PAUL,INSERM,U342,82 AV DENFERT ROCHEREAU,F-75674 PARIS 14,FRANCE; CNRS,CTR RECH ENDOCRINOL MOLEC & DEV,F-92190 MEUDON,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)			Ferré, Pascal/K-1250-2013	Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; GIFFHORN S, 1984, BIOCHEM J, V221, P343, DOI 10.1042/bj2210343; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; Girard J., 1977, GLUCAGON ITS ROLE PH, P563, DOI DOI 10.1007/978-1-4612-6366-1-36; GOODRIDGE AG, 1986, FASEB J, V45, P2399; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KATZ NR, 1983, BIOCHEM J, V212, P65, DOI 10.1042/bj2120065; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LETURQUE A, 1991, AM J PHYSIOL, V260, pE588, DOI 10.1152/ajpendo.1991.260.4.E588; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1983, METABOLISM, V33, P545; MEYER S, 1991, EUR J BIOCHEM, V202, P985, DOI 10.1111/j.1432-1033.1991.tb16460.x; MEYUHAS O, 1976, BIOCHEM J, V158, P9, DOI 10.1042/bj1580009; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; NEPOKROEFF CM, 1984, EUR J BIOCHEM, V140, P441, DOI 10.1111/j.1432-1033.1984.tb08122.x; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Romsos D R, 1974, Adv Lipid Res, V12, P97; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; SPENCE JT, 1985, BIOCHEM J, V227, P939, DOI 10.1042/bj2270939; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; TSUJIKAWA M, 1980, J NUTR SCI VITAMINOL, V26, P367, DOI 10.3177/jnsv.26.367; VERNON RG, 1981, BIOCHEM J, V200, P307, DOI 10.1042/bj2000307; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	36	168	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20543	20546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356982				2022-12-25	WOS:A1992JT97800006
J	SUN, XC; GARLID, KD				SUN, XC; GARLID, KD			ON THE MECHANISM BY WHICH BUPIVACAINE CONDUCTS PROTONS ACROSS THE MEMBRANES OF MITOCHONDRIA AND LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; LOCAL-ANESTHETICS; LIGHT-SCATTERING; K+-TRANSPORT; RECONSTITUTION; CONTRACTION; EXCHANGER; MATRIX; ACIDS	Bupivacaine and etidocaine possess the remarkable property of stimulating mitochondrial respiration to levels comparable with those observed with classical anionic protonophores (Dabadie, P., Bendriss, P., Erny, P., and Mazat, J. P. (1987) FEBS Lett. 226, 77-82). We show that these amphiphilic amines conduct protons across the membranes of mitochondria and liposomes and stimulate respiration by a true proton-ophoretic mechanism. The kinetics of drug-induced H+ flux exhibited integer Hill coefficients that were greater than two under all conditions, suggesting that multimers are required for H+ transport. When the energy barrier for ion transport was lowered in mitochondria, by increasing the membrane potential, or in liposomes, by adding phloretin, the Hill coefficients decreased to lower integer numbers. Protonophoretic activity depended exclusively on medium concentration of free base, leading us to conclude that bupivacaine and etidocaine conduct protons as associated, intramembrane multimers of the free base. Bupivacaine-induced H+ leak was ohmic rather than nonohmic, as would be expected of a mobile charged carrier. This kinetic behavior seems improbable for a multimeric mobile carrier mechanism and suggests a channel mechanism, in which ohmicity results from splitting of the energy barrier by energy wells along the transport pathway (Garlid, K. D., Beavis, A. D., and Ratkje, S. K. (1989) Biochim. Biophys. Acta 976, 109-120). We hypothesize that bupivacaine and etidocaine act by a novel "flickering channel" mechanism, in which transient linear complexes of free base molecules provide weak binding sites (energy wells) for protons within lipid bilayer membranes.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699					Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 31086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN OS, 1976, J GEN PHYSIOL, V67, P749, DOI 10.1085/jgp.67.6.749; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; DABADIE P, 1987, FEBS LETT, V226, P77, DOI 10.1016/0014-5793(87)80554-9; DORDICK RS, 1980, J BIOL CHEM, V255, P299; ELEDJAM JJ, 1989, ANESTH ANALG, V69, P732; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1979, BIOCHEM BIOPH RES CO, V87, P842, DOI 10.1016/0006-291X(79)92034-5; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, J BIOL CHEM, V261, P1529; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SEEMAN P, 1972, PHARMACOL REV, V24, P583; STRICHARTZ GR, 1990, ANESTH ANALG, V71, P158; TERADA H, 1990, J BIOL CHEM, V265, P7837; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; TONINELLO A, 1988, J BIOL CHEM, V263, P19407	24	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19147	19154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382068				2022-12-25	WOS:A1992JP59300024
J	WADZINSKI, BE; EISFELDER, BJ; PERUSKI, LF; MUMBY, MC; JOHNSON, GL				WADZINSKI, BE; EISFELDER, BJ; PERUSKI, LF; MUMBY, MC; JOHNSON, GL			NH2-TERMINAL MODIFICATION OF THE PHOSPHATASE-2A CATALYTIC SUBUNIT ALLOWS FUNCTIONAL EXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; PROTEIN-KINASE-C; TRANSFORMATION; ACTIVATION; INHIBITION; SEQUENCE; FORM	Functional expression of recombinant wild-type phosphatase 2A catalytic subunit has been unsuccessful in the past. A nine-amino-acid peptide sequence (YPYDVPDYA) derived from the influenza hemagglutinin protein was used to modify the NH2 and/or COOH terminus of the phosphatase 2A catalytic subunit. Addition of the nine-amino-acid sequence at the NH2 terminus allowed recombinant phosphatase 2A expression as a predominantly cytosolic phosphatase 2A enzyme. The 12CA5 monoclonal antibody that recognizes the nine-amino-acid hemagglutinin peptide sequence was used to immunoprecipitate the epitope-tagged phosphatase 2A catalytic subunit. Assay of the immunoprecipitated epitope-tagged phosphatase 2A demonstrated an okadaic acid-sensitive dephosphorylation of [P-32] histone H1 and [P-32]myelin basic protein similar to that measured with the wild-type enzyme. Functional phosphatase activity could be demonstrated for the NH2-terminal modified phosphatase 2A catalytic subunit following transient expression in COS cells or stable expression in Rat1a cells. In contrast, the COOH-terminal-modified phosphatase 2A catalytic subunit was very poorly expressed. The NH2-, COOH-modified subunit, having the nine-amino-acid hemagglutinin peptide sequence encoded at both termini of the polypeptide, was also expressed as a functional phosphatase 2A enzyme. Thus, NH2-terminal modification of the phosphatase 2A catalytic subunit results in a functional plasmid-expressed enzyme. The unique nine-amino-acid epitope-tag sequence also provides a method to easily resolve the recombinant phosphatase 2A from the endogenous wild-type gene product and related phosphatases expressed in cells.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	National Jewish Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31107] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEE WW, 1989, J BIOL CHEM, V264, P5687; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAKES S, 1988, BIOCHIM BIOPHYS ACTA, V967, P11, DOI 10.1016/0304-4165(88)90182-1; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	24	63	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16883	16888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380955				2022-12-25	WOS:A1992JL05300027
J	BARRUECO, JR; OLEARY, DF; SIROTNAK, FM				BARRUECO, JR; OLEARY, DF; SIROTNAK, FM			METABOLIC TURNOVER OF METHOTREXATE POLYGLUTAMATES IN LYSOSOMES DERIVED FROM S180 CELLS - DEFINITION OF A 2-STEP PROCESS LIMITED BY MEDIATED LYSOSOMAL PERMEATION OF POLYGLUTAMATES AND ACTIVATING REDUCED SULFHYDRYL COMPOUNDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST LYSOSOMES; GAMMA-GLUTAMYL; TRANSPORT-SYSTEM; CYTO-TOXICITY; HYDROLASE; INVITRO; POLYGLUTAMYLATION; PROTEOLYSIS; CYSTEINE; TUMOR	Transport and metabolic turnover of methotrexate (MTX) polyglutamates were examined in lysosomes derived from S180 cells. These studies extend prior work from this laboratory (Barrueco, J. R., and Sirotnak, F. M. (1991) J. Biol. Chem 266, 11732-11737) which described basic properties of a facilitative transport system in lysosomes capable of mediating intralysosomal accumulation of MTX polyglutamates. In the present report, we show that the rate of turnover of MTX polyglutamates in lysosomes, which releases MTX in the extralysosomal space, is limited by the extent of mediated intralysosomal accumulation of the polyglutamate and reduced sulfhydryls that activate the enzyme folylpolyglutamate hydrolase. Evidence is presented that cysteine functions as the naturally occurring reduced sulfhydryl compound in lysosomes being equipotent to 2-mercaptoethanol as an activator of folylpolyglutamate hydrolase. Folylpolyglutamate hydrolase in permeabilized lysosomes from S180 cells exhibited a low pH optimum characteristic of a lysosomal enzyme, was activated at concentrations of reduced sulfhydryl at 0.1 mM and above, and exhibited K(m) values in the range of 0.2-3-mu-M that decreased with increase in polyglutamate chain length. Values for K(m) for MTX polyglutamates of folylpolyglutamate hydrolase activity were 100-200-fold lower than values for K(m) or K(i) for facilitated intralysosomal transport, whereas capacities for both processes were similar. This relationship between the kinetic properties of each process ensures efficient hydrolysis of MTX polyglutamates within the lysosome.	MEM SLOAN KETTERING CANC CTR,MOLEC THERAPEUT LAB,PROGRAM MOLEC PHARMACOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 08748, CA 22764, CA 18856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA018856, R01CA022764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; CHABNER BA, 1982, PHARM PRINCIPLES CAN, P229; COOPER AJL, 1983, ANN REV BIOCH, V52, P189; ELSENHANS B, 1984, J BIOL CHEM, V259, P6364; FABRE I, 1984, CANCER RES, V44, P3190; Hall C W, 1978, Methods Enzymol, V50, P439; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; LLOYD JB, 1986, BIOCHEM J, V237, P271, DOI 10.1042/bj2370271; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MEGO JL, 1985, BIOCHIM BIOPHYS ACTA, V841, P139, DOI 10.1016/0304-4165(85)90014-5; MEGO JL, 1984, BIOCHEM J, V218, P775, DOI 10.1042/bj2180775; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1987, J BIOL CHEM, V262, P6010; POSER RG, 1981, CANCER RES, V41, P4441; PRIEST DG, 1982, MOL CELL BIOCHEM, V43, P81, DOI 10.1007/BF00423095; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SILINK M, 1975, J BIOL CHEM, V250, P5982; SIROTNAK FM, 1978, BIOCHEM PHARMACOL, V27, P1821, DOI 10.1016/0006-2952(78)90025-4; SMITH ML, 1987, J BIOL CHEM, V262, P1244; WANG TTY, 1986, J BIOL CHEM, V261, P3551	24	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15356	15361						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379226				2022-12-25	WOS:A1992JG11300018
J	HARWERTH, IM; WELS, W; MARTE, BM; HYNES, NE				HARWERTH, IM; WELS, W; MARTE, BM; HYNES, NE			MONOCLONAL-ANTIBODIES AGAINST THE EXTRACELLULAR DOMAIN OF THE ERBB-2 RECEPTOR FUNCTION AS PARTIAL LIGAND AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST CANCER; NEU ONCOGENE PRODUCT; BETA-CASEIN GENE; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; PROTEIN EXPRESSION; C-ERBB-2 PROTEIN; CELL-LINE; KINASE	In this paper we describe the isolation and characterization of four monoclonal antibodies (FRP5, FSP16, FWP51, and FSP77) which specifically recognize the human erbB-2 protein. All of the antibodies recognize epitopes on the extracellular domain of the receptor protein. FRP5 and FSP16 compete with one another for binding while FWP51 and FSP77 each recognize a different epitope. The effects of the antibodies on the erbB-2 receptor protein have been analyzed. Two different erbB-2-expressing cell lines, SKBR3 breast tumor cells and HC11 R111 cells, were examined. The SKBR3 cells express approximately 1 x 10(6) molecules of the erbB-2 protein/cell; HC11 R111 cells, a clone of mouse mammary epithelial cells derived by transfection of a human erbB-2 expression plasmid, contain 10-fold less erbB-2 protein than the SKBR3 cells. Treatment of the two cell lines with FRP5, FSP16, and FWP51 led to a rapid increase in the phosphotyrosine content of the erbB-2 protein. Three of the antibodies, FRP5, FSP16, and FSP77, stimulated the turnover of the erbB-2 protein. Binding of the antibodies did not stimulate DNA synthesis in HC11 R111 cells. Thus, the erbB-2-specific monoclonal antibodies behave as partial ligand agonists. The antibodies were examined for their effects upon the growth of SKBR3 and HC11 R111 cells. The growth of SKBR3 cells was inhibited by 90% following long term treatment of the cells with FSP77.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Wels, Winfried/0000-0001-9858-3643				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BERGER MS, 1988, CANCER RES, V48, P1238; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DREBIN JA, 1988, ONCOGENE, V2, P387; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FERNANDEZPOL JA, 1985, J BIOL CHEM, V260, P5003; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HARLOW E, 1988, ANTIBODIES LABORATOR, P330; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOEHLER G, 1975, NATURE, V256, P495; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LANGTON BC, 1991, CANCER RES, V51, P2593; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATO JD, 1987, METHOD ENZYMOL, V146, P63; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; VARLEY JM, 1987, ONCOGENE, V1, P423; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	51	120	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15160	15167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353079				2022-12-25	WOS:A1992JF08800096
J	BONNER, JC; GOODELL, AL; LASKY, JA; HOFFMAN, MR				BONNER, JC; GOODELL, AL; LASKY, JA; HOFFMAN, MR			REVERSIBLE BINDING OF PLATELET-DERIVED GROWTH FACTOR-AA, FACTOR-AB, AND FACTOR-BB ISOFORMS TO A SIMILAR SITE ON THE SLOW AND FAST CONFORMATIONS OF ALPHA-2-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC PULMONARY FIBROSIS; ALPHA-MACROGLOBULIN; ALVEOLAR MACROPHAGES; HUMAN-FIBROBLASTS; FACTOR-BETA; PROTEASE COMPLEXES; SURFACE-RECEPTORS; FAST FORMS; PDGF; CELLS	The mechanism by which the platelet-derived growth factor (PDGF)-binding protein, alpha-2-macroglobulin (alpha-2M), modulates PDGF bioactivity is unknown, but could involve reversible PDGF-alpha-2M binding. Herein we report that >70% of I-125-PDGF-BB or -AB complexed to alpha-2M was dissociated by SDS-denaturation followed by SDS-polyacrylamide gel electrophoresis, i.e. most of the binding was noncovalent. Reduction of the PDGF.alpha-2M complex following denaturation dissociated the cytokine from alpha-2M by >90%, suggesting covalent disulfide bond formation. Approximately 50% of the growth factor was dissociated by lowering the pH from 7.5 to 4.0. I-125-PDGF-BB bound alpha-2M in a time-dependent manner (t1/2 = approximately 1 h), reaching equilibrium after 4 h. The I-125-pDGF.BB/alpha-2M complex dissociated more slowly (t1/2 = approximately 2.5 h). "Slow" and "fast" alpha-2M bound nearly equal amounts of PDGF-AB or -BB. Trypsin treatment converted PDGF-BB/alpha-2M complex to the fast conformation but did not release bound I-125-PDGF-BB. All PDGF-isoforms (AA, -AB, and -BB) competed for binding with I-125-PDGF-BB binding to slow alpha-2M and fast alpha-2M-methylamine by 65-80%. Other cytokines that bind alpha-2M (transforming growth factor-beta-1 and -beta-2, tumor necrosis factor-alpha, basic fibroblast growth factor, interleukin-1-beta, and -6) did not compete for I-125-PDGF-BB binding slow alpha-2M, but transforming growth factor-beta-1 and basic fibroblast growth factor inhibited I-125-PDGF-BB binding alpha-2M-methylamine by 30-50%. The reversible nature of the PDGF.alpha-2M complex could allow for targeted PDGF release near mesenchymal cells which possess PDGF receptors.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	BONNER, JC (corresponding author), NIEHS, PULM PATHOBIOL LAB, POB 12233, RES TRIANGLE PK, NC 27709 USA.			Hoffman, Maureane/0000-0001-7123-0100				ADHAM NF, 1969, ARCH BIOCHEM BIOPHYS, V132, P175, DOI 10.1016/0003-9861(69)90351-8; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BONNER JC, 1991, AM J RESP CELL MOL, V5, P539, DOI 10.1165/ajrcmb/5.6.539; BONNER JC, 1989, AM J RESP CELL MOL, V1, P171, DOI 10.1165/ajrcmb/1.3.171; BORTH W, 1989, J BIOL CHEM, V264, P5818; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; GANROT PO, 1966, CLIN CHIM ACTA, V14, P493, DOI 10.1016/0009-8981(66)90037-4; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, J CELL SCI, V96, P193; HOFFMAN MR, 1987, J IMMUNOL, V139, P1885; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAMES K, 1980, TRENDS BIOCHEM SCI, V5, P43, DOI 10.1016/S0968-0004(80)80094-6; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARYNEN P, 1983, ANN NY ACAD SCI, V421, P401, DOI 10.1111/j.1749-6632.1983.tb18133.x; MATSUDA T, 1989, J IMMUNOL, V142, P148; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MOSHER DF, 1976, J EXP MED, V143, P462, DOI 10.1084/jem.143.2.462; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NELLES LP, 1980, BIOCHIM BIOPHYS ACTA, V623, P46, DOI 10.1016/0005-2795(80)90006-9; NEY KA, 1985, BIOCHEMISTRY-US, V24, P4586, DOI 10.1021/bi00338a016; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSORNIOVARGAS AR, 1990, AM J RESP CELL MOL, V3, P595, DOI 10.1165/ajrcmb/3.6.595; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RAINES EW, 1990, PEPTIDE GROWTH FACTO, P173; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SOTTRUPJENSEN L, 1987, PLASMA PROTEINS, P192; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WHITE R, 1980, LUNG, V158, P9, DOI 10.1007/BF02713697; WILLINGHAM MC, 1979, J CELL BIOL, V82, P614, DOI 10.1083/jcb.82.3.614; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265	54	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12837	12844						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377675				2022-12-25	WOS:A1992HZ48300069
J	BATEN, A; SAKAMOTO, K; SHAMSUDDIN, AM				BATEN, A; SAKAMOTO, K; SHAMSUDDIN, AM			LONG-TERM CULTURE OF NORMAL HUMAN COLONIC EPITHELIAL-CELLS INVITRO	FASEB JOURNAL			English	Note						CYTOKERATIN; ELECTRON MICROSCOPY; IMMUNOCYTOCHEMISTRY; LARGE INTESTINE	EPIDERMAL GROWTH-FACTOR; SERUM-FREE MEDIUM; EXPLANT CULTURE; ORGAN-CULTURE; CLONAL GROWTH; RAT COLON; KERATINOCYTES; METABOLISM; TISSUE; TUMORS	Studies of normal cellular function as well as the understanding of cellular mechanisms of carcinogenesis and other diseases of the large intestine have been limited, particularly due to the lack of long-term culture of normal human large intestinal epithelial cells (NHLIEC). Using the epithelia from surgically resected human colon, we have dissociated a sufficient number of viable NHLIEC and maintained them in in vitro culture for up to 5 months. Normal-appearing human large intestinal mucosal fragments (1 mm2) were treated with 0.01 mg/ml trypsin, 0.2 mg/ml collagenase + 0.1 mm EGTA or 0.1 mg/ml trypsin + 0.1 mm EGTA in a Stomacher laboratory blender to isolate the cells. Compared with other methods, the use of the Stomacher blender combined with low concentrations of proteolytic enzymes yielded greater numbers of cells per gram of tissue, with up to 84% viable cells. Primary and serially passaged NHLIEC were cultured in CMRL-1066, MEM with 5% serum, and serum-free KGM. These media were all supplemented with insulin, hydrocortisone, epithelial growth factor, and bovine pituitary extract. CMRL-1066 was found to be the best medium for NHLIEC. Contaminating fibroblasts were selectively removed by briefly allowing the cells to adhere to the culture vessel and adding 25 U/ml collagenase to the culture media at the first subculture treatment. The epithelial nature and secretory function of the established cells were confirmed by morphological criteria (light microscopy, phase contrast microscopy and electron microscopy), immunoreactivity to cytokeratin, and positive mucin cytochemistry. We propose that using this methodology for the culture and maintenance of NHLIEC for an extended period of time would serve as a valuable model for a variety of investigations.	UNIV MARYLAND,SCH MED,DEPT PATHOL,ROOM 600-C,MSTF,10 S PINE ST,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore								AUTRUP H, 1978, IN VITRO CELL DEV B, V14, P868; AUTRUP H, 1978, CANCER RES, V38, P3689; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BUSET M, 1987, IN VITRO CELL DEV B, V23, P403; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; DANES BS, 1982, J NATL CANCER I, V69, P1271; DEOCA HM, 1973, TISSUE CULTURE METHO, P8; FRIEDMAN EA, 1981, IN VITRO CELL DEV B, V17, P632; GIBSONDAMBROSIO RE, 1986, IN VITRO CELL DEV B, V22, P529; HAY RJ, 1984, TISSUE CULTURE, P331; IYENGAR V, 1991, FASEB J, V5, P2856, DOI 10.1096/fasebj.5.13.1655550; JANSING R, 1984, TISSUE CELL, V16, P157, DOI 10.1016/0040-8166(84)90040-5; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOYER MP, 1983, P SOC EXP BIOL MED, V174, P12; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; SHAMSUDDIN AKM, 1978, PATHOL RES PRACT, V163, P362, DOI 10.1016/S0344-0338(78)80033-8; SHAMSUDDIN AKM, 1981, J NATL CANCER I, V66, P403; SHAMSUDDIN AKM, 1986, GANO MONOGR, V31, P59; SHAMSUDDIN AM, 1982, ARCH PATHOL LAB MED, V106, P140; SHAMSUDDIN AM, 1982, HUM PATHOL, V13, P790, DOI 10.1016/S0046-8177(82)80075-0; SHAMSUDDIN AM, 1990, COLON CANCER CELLS, P137; SHAMSUDDIN AM, 1991, DIAGNOSTIC ASSAYS CO; SHAMSUDDIN AM, 1989, GASTROINTESTINAL OES, P41; SIDDIQUI KM, 1984, IN VITRO CELL DEV B, V20, P859; SPICER SS, 1965, J HISTOCHEM CYTOCHEM, V13, P211, DOI 10.1177/13.3.211; SUN TT, 1981, VISION RES, V21, P55, DOI 10.1016/0042-6989(81)90137-1; TSAO MC, 1982, J CELL PHYSIOL, V110, P219, DOI 10.1002/jcp.1041100217; VIDRICH A, 1985, ANN NY ACAD SCI, V455, P354, DOI 10.1111/j.1749-6632.1985.tb50422.x; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; YU QC, 1990, PATHOBIOLOGY, V58, P138, DOI 10.1159/000163575	33	39	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2726	2734		10.1096/fasebj.6.9.1377141	http://dx.doi.org/10.1096/fasebj.6.9.1377141			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1377141				2022-12-25	WOS:A1992HZ48100015
J	MENETSKI, JP; VARGHESE, A; KOWALCZYKOWSKI, SC				MENETSKI, JP; VARGHESE, A; KOWALCZYKOWSKI, SC			THE PHYSICAL AND ENZYMATIC-PROPERTIES OF ESCHERICHIA-COLI RECA PROTEIN DISPLAY ANION-SPECIFIC INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POTASSIUM GLUTAMATE; NUCLEIC-ACIDS; BINDING; POLYNUCLEOTIDE; BACTERIA; EXCHANGE; LIGANDS; INVITRO; ATPASE	The enzymatic activities of Escherichia coli recA protein are sensitive to ionic composition. Here we report that sodium glutamate (NaGlu) is much less inhibitory to the DNA strand exchange, DNA-dependent ATPase, and DNA binding activities of the recA protein than is NaCl. Both joint molecule formation and complete exchange of DNA strands occur (albeit at reduced rates) at NaGlu concentrations as high as 0.5 M whereas concentrations of NaCl greater than 0.2 M are sufficient for complete inhibition. The single-stranded DNA (ssDNA)-dependent ATPase activity is even less sensitive to inhibition by NaGlu; ATP hydrolysis stimulated by M13 ssDNA is unaffected by 0.5 M NaGlu and is further stimulated by E. coli ssDNA binding protein approximately 2-fold. Finally, NaGlu has essentially no effect on the stability of recA protein-epsilon-M13 DNA complexes, with concentrations of NaGlu as high as 1.5 m failing to dissociate the complexes. Surprisingly, NaGlu also has little effect on the concentration of NaCl required to disrupt the recA protein-epsilon-EM13 DNA complex, demonstrating that destabilization is dependent on both the concentration and type of anionic rather than cationic species. Quantitative analysis of DNA binding isotherms establishes that the intrinsic binding affinity of recA protein is affected by the anionic species present and that the cooperativity parameter is relatively unaffected. Consequently, the sensitivity of recA protein-ssDNA complexes to disruption by NaCl does not result from the competitive effects associated with cation displacement from the ssDNA upon protein binding but rather results from anion displacement upon complex formation. The magnitude of this anion-specific effect on ssDNA binding is large relative to that of other nucleic acid binding proteins.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611; UNIV CALIF DAVIS,DIV BIOL SCI,MICROBIOL SECT,DAVIS,CA 95616	Northwestern University; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN D, V1, P244; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEBOWITZ JH, 1985, THESIS J HOPKINS U; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; PUGH BF, 1988, J BIOL CHEM, V263, P76; Record M T Jr, 1985, Adv Biophys, V20, P109; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	32	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10400	10404						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350278				2022-12-25	WOS:A1992HV09000033
J	BANGS, JD; CRAIN, PF; HASHIZUME, T; MCCLOSKEY, JA; BOOTHROYD, JC				BANGS, JD; CRAIN, PF; HASHIZUME, T; MCCLOSKEY, JA; BOOTHROYD, JC			MASS-SPECTROMETRY OF MESSENGER-RNA CAP-4 FROM TRYPANOSOMATIDS REVEALS 2 NOVEL NUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; DISCONTINUOUS TRANSCRIPTION; LIQUID-CHROMATOGRAPHY; SPLICED LEADER; BRUCEI; DERIVATIVES; CONTAINS; SEQUENCE; DNA	Synthesis of mRNA in kinetoplastid protozoa involves the process of trans-splicing, in which an identical 39-41-nucleotide (depending on the species) mini-exon is placed at the 5' end of mature mRNAs. The mini-exon sequence is highly conserved among all members of the Kinetoplastida, nucleotides 1-6 being identical in the four genera so far examined. Prior to trans-splicing, the mini-exon donor RNA is capped by the addition of a (5'-5') triphosphate-linked 7-methylguanosine, followed by modification of the first four transcribed nucleotides. Partial structures have been Previously deduced for this cap 4 moiety from Trypanosoma brucei and Leptomonas collosoma. We have Purified enough cap 4 from T. brucei and Crithidia fasciculata to allow definitive structural analysis by combined liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry. The results, together with the known mini-exon sequence, show that cap 4 in both species has the structure m7G(5')ppp(5')m2(6)AmpAmpCmpm3Ump. The presence of N6,N6,2'-O-trimethyladenosine and 3,2'-O-dimethyluridine, nucleosides previously unknown in nature, were confirmed by rigorous comparison with synthetic standards. The conservation of cap 4 between these divergent genera suggests that this structure may be common to most if not all Kinetoplastida.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Stanford University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Boothroyd, John C./0000-0001-9719-745X	NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [2T32CA09302-13] Funding Source: Medline; NIAID NIH HHS [AI21025] Funding Source: Medline; NIGMS NIH HHS [GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1990, TETRAHEDRON LETT, V31, P5507, DOI 10.1016/S0040-4039(00)97884-5; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BJORK GR, 1984, PROCESSING RNA, P291; BOOTHROYD JC, 1989, NUCL ACIDS MOL BIOL, V3, P216; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CORDINGLEY JS, 1980, MOL BIOCHEM PARASIT, V1, P91, DOI 10.1016/0166-6851(80)90003-1; CRAIN PF, 1983, ANAL BIOCHEM, V132, P124, DOI 10.1016/0003-2697(83)90434-7; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DUNN DB, 1975, HDB BIOCH MOL BIOL, P127; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; GABRIEL A, 1987, J BIOL CHEM, V262, P16192; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, pA3; GREENBERG JR, 1988, NUCLEIC ACIDS RES, V16, P3437, DOI 10.1093/nar/16.8.3437; HALL R, 1971, MODIFIED NUCLEOSIDES, P96; HALL RH, 1971, MODIFIED NUCLEOSIDES, P160; HOLMES JL, 1985, ORG MASS SPECTROM, V20, P169, DOI 10.1002/oms.1210200302; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Maniatis T, 1989, DECONTAMINATION DILU; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P825, DOI 10.1016/0076-6879(90)93453-R; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P771, DOI 10.1016/0076-6879(90)93449-U; MCCLOSKEY JA, 1974, BASIC PRINCIPLES NUC, V1, pCH3; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MUHICH ML, 1987, NUCLEIC ACIDS RES, V15, P3141, DOI 10.1093/nar/15.7.3141; PANG H, 1982, J ORG CHEM, V47, P3923, DOI 10.1021/jo00141a023; PANG H, 1982, J ORG CHEM S, V47; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; ROTTMAN FM, 1978, INT REV BIOCH BIOCH, V17, P45; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TAKEDA N, 1991, J CHROMATOGR-BIOMED, V562, P225, DOI 10.1016/0378-4347(91)80580-6; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VESTAL ML, 1990, METHOD ENZYMOL, V193, P107, DOI 10.1016/0076-6879(90)93413-F; VONMINDEN DL, 1974, J ORG CHEM, V39, P285; WAGNER D, 1974, J ORG CHEM, V39, P24, DOI 10.1021/jo00915a005	42	150	154	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9805	9815						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349605				2022-12-25	WOS:A1992HT96500058
J	BURGESS, JW; WADA, I; LING, N; KHAN, MN; BERGERON, JJM; POSNER, BI				BURGESS, JW; WADA, I; LING, N; KHAN, MN; BERGERON, JJM; POSNER, BI			DECREASE IN BETA-SUBUNIT PHOSPHOTYROSINE CORRELATES WITH INTERNALIZATION AND ACTIVATION OF THE ENDOSOMAL INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; RAT ADIPOCYTES; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; HEPATOMA-CELLS; INTACT-CELLS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; LIVER; ENDOCYTOSIS	In a previous study, we showed that the rat hepatic insulin receptor (IR) kinase of endosomes (ENs) was transiently activated to levels exceeding those of plasma membrane (PM) receptors following insulin injection. Phosphatase treatment of EN receptors abolished IR kinase activation implicating beta-subunit autophosphorylation as a mediator of the activation process (Khan, M. N., Baquiran, G., Brule, C., Burgess, J., Foster, B., Bergeron, J. J. M., and Posner, B. I. (1989) J. Biol. Chem. 264, 12931-12940). In the present study, the phosphotyrosine (PY) content of the IR beta-subunit in PM and ENs was estimated by two different methods. In one method, direct in vivo labeling with P-32(i) followed by receptor immunoprecipitation was carried out. In the second method, immunoblotting with antibodies against the submembrane domain of the IR beta-subunit, encompassing residue 960 (alpha-960), and with antibodies against PY (alpha-PY) was used to determine the content of PY/beta-subunit in PM and ENs following injection of insulin. By both methods, it was round that the PY content of PM IR was significantly greater than that of IR in ENs. With doses of 1.5-mu-g of insulin/100 g body weight (50% receptor occupancy) or 15-mu-g/100 g body weight (receptor saturation), the PY/beta-subunit of PM IR attained a level 2.0 to 2.5-fold of that observed for the IR of ENs. Surprisingly, the IR of ENs incorporated 3 to 5 times more PY/beta-subunit than those of PM consequent to autophosphorylation. Exogenous IR kinase activity (poly(Glu:Tyr)) in PM changed only slightly with insulin dose. In contrast, EN receptors exhibited a dose-dependent increase in kinase activity coincident with the decrease in PY/beta-subunit levels. A comparison of the proportion of receptor and kinase activity immunoprecipitated by alpha-PY both before and after autophosphorylation indicated that ENs but not PM contained a small population of lightly phosphorylated but highly activated receptors. Since Thr12-Lys (IR kinase residues 1142-1153) efficiently inhibited IR autophosphorylation of both PM and EN receptors, Tris phosphorylation of beta-subunit regulatory tyrosines was unlikely. These results may be explicable by a dephosphorylation-dependent activation of IR kinase, as seen with the src family of tyrosine kinases.	WHITTIER INST DIABET & ENDOCRINOL,LA JOLLA,CA 92093; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital	BURGESS, JW (corresponding author), ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA.		Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021	Wada, Ikuo/0000-0001-5668-6994	PHS HHS [R01-DI 19573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AZUMA K, 1991, J BIOL CHEM, V266, P4831; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BALLOTTI R, 1987, BIOCHEM J, V241, P99, DOI 10.1042/bj2410099; BENOIT R, 1987, NEUROMETHODS, V6; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; FEHLMANN M, 1982, J CELL BIOL, V93, P82, DOI 10.1083/jcb.93.1.82; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GREEN A, 1982, P NATL ACAD SCI-BIOL, V79, P427, DOI 10.1073/pnas.79.2.427; HARI J, 1987, J BIOL CHEM, V262, P15341; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MORRISON BD, 1987, J BIOL CHEM, V262, P2861; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OKADA M, 1989, J BIOL CHEM, V264, P20886; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PANG DT, 1985, J BIOL CHEM, V260, P7131; PILCH PF, 1979, J BIOL CHEM, V254, P3375; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; POSNER BI, 1987, INSULIN INSULIN LIKE, P1; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1989, J BIOL CHEM, V264, P12820; THIES RS, 1990, J BIOL CHEM, V265, P10132; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1986, ENZYMES, V17, P247; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YIP CC, 1978, J BIOL CHEM, V253, P1743; YU KT, 1986, J BIOL CHEM, V261, P4715	61	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10077	10086						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374397				2022-12-25	WOS:A1992HT96500095
J	THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB				THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB			IDENTIFICATION OF DISTINCT POPULATIONS OF PI-3 KINASE-ACTIVITY FOLLOWING T-CELL ACTIVATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; HUMAN PLATELETS; ANTIGEN RECEPTOR; CD4 RECEPTOR; PDGF RECEPTOR; RAT-LIVER; ASSOCIATION	Activation of mature CD4+ T lymphocytes by antigen-presenting cells involves engagement of the CD3/T-cell antigen receptor complex along with the CD4 surface glycoprotein and the phosphorylation of cellular proteins on tyrosine residues leading to stimulation of a variety of cellular second-messenger systems. Several recent studies have implicated non-receptor protein tyrosine kinases of the src family, especially p56lck and p59fyn, in mediating at least a portion of these tyrosine phosphorylation events. In the present study we have examined the involvement of one type of second-messenger system, phosphatidylinositol-3 kinase (PI-3 kinase), in signal transduction during antibody-induced activation of normal resting human CD4+ T cells. We demonstrate that PI-3 kinase activity is increased following co-approximation of CD4 with the T-cell receptor and that PI-3 kinase activity co-precipitates with the CD4-p56lck complex. We also show that following T-cell activation a complex containing PI-3 kinase activity can be demonstrated in CD3-epsilon-immunoprecipitates which is distinct from that which interacts with p56lck.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, NATURE, V312, P312; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HORAK ID, 1990, ONCOGENE, V5, P597; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	59	61	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373484				2022-12-25	WOS:A1992HQ68200014
J	ALAM, T; AN, MR; PAPACONSTANTINOU, J				ALAM, T; AN, MR; PAPACONSTANTINOU, J			DIFFERENTIAL EXPRESSION OF 3 C/EBP ISOFORMS IN MULTIPLE TISSUES DURING THE ACUTE PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENHANCER-BINDING-PROTEIN; SERUM-ALBUMIN GENE; HEPATOMA-CELLS; RAT-LIVER; TRANSCRIPTIONAL REGULATION; ANGIOTENSINOGEN GENE; LEUCINE ZIPPER; FAMILY; GLUCOCORTICOIDS; TRANSACTIVATION	Eucaryotic organisms possess natural defense processes triggered by stress factors such as injury, infection, and inflammation. The acute phase response is an early defense mechanism during which striking changes in protein synthesis occur in the liver and other tissues. The altered expression of many acute phase protein genes is at the transcriptional level. Some of these genes have DNA binding sites for the CCAAT/enhancer binding protein (C/EBP) family of transcription factors. We report here that in vivo expression of three isoforms of C/EBP is dramatically changed during the acute phase response. The steady-state mRNA levels of C/EBP-alpha decreased significantly in the liver, lung, and fat tissues of lipopolysaccharide (LPS)-treated mice; moreover, nuclear run-off transcription assays indicated a decrease in the rate of C/EBP-alpha gene transcription in isolated liver nuclei. The steady-state levels of C/EBP-beta and a new isoform, C/EBP-delta, were dramatically increased in many tissues within 4 h following LPS treatment. The rates of transcription of these two genes were only minimally altered in liver but significantly increased in kidney nuclei isolated from stimulated animals. Thus, the C/EBP isoforms exhibit differential mechanisms in their responses to LPS in various tissues and are likely to play an important role in mediating the transcriptional activation of genes involved in the acute phase response.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,613 BASIC SCI BLDG,RT F-43,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, IN PRESS BIOCHEMISTR; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTER KC, 1989, J BIOL CHEM, V264, P4112; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EVERS BM, 1991, SURGERY, V110, P247; FEY G, 1990, PROGR LIVER DIS, P89; FEY GH, 1987, MOL BIOL MED, V4, P323; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOJ A, 1974, STRUCTURE FUNCTION P, V1, P73; KOJ A, 1985, ACUTE PHASE RESPONSE, P00145; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T, 1982, MOL CLONING LABORATO; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NORTHEMANN W, 1989, BIOCHEMISTRY-US, V28, P84, DOI 10.1021/bi00427a013; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SCHREIBER G, 1987, PLASMA PROTEINS STRU, V5, P293; THOMAS T, 1989, J BIOL CHEM, V264, P5784; THOMPSON WL, 1976, BIOCHEM J, V156, P25, DOI 10.1042/bj1560025; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	38	289	290	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5021	5024						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371993				2022-12-25	WOS:A1992HH74700002
J	HUANG, MM; INDIK, Z; BRASS, LF; HOXIE, JA; SCHREIBER, AD; BRUGGE, JS				HUANG, MM; INDIK, Z; BRASS, LF; HOXIE, JA; SCHREIBER, AD; BRUGGE, JS			ACTIVATION OF FC-GAMMA-RII INDUCES TYROSINE PHOSPHORYLATION OF MULTIPLE PROTEINS INCLUDING FC-GAMMA-RII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN-PLATELETS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; GLYCOPROTEIN-IIB; IMMUNOGLOBULIN-G; EXPRESSION; THROMBIN; KINASE; CLONING	Platelets provide a useful system for studying Fc-gamma receptor-mediated signaling events because these cells express only a single class of Fc-gamma receptors and because platelet aggregation and secretion can be activated through Fc-gamma receptor stimulation. We report here that stimulation of platelets by cross-linking antibodies to Fc-gamma-RII or by treatment with an anti-CD9 monoclonal antibody, which acts through Fc-gamma-RII, causes an induction of tyrosine phosphorylation of multiple platelet proteins. Although the profile of tyrosine-phosphorylated proteins induced by stimulation of this Fc receptor was similar to that induced by thrombin, an additional 40-kDa phosphorylated protein was also detected. This protein co-migrated with Fc-gamma-RII and was immunoprecipitated with a monoclonal antibody to Fc-gamma-RII. In addition, after the cross-linking of Fc-gamma-RII in HEL cells or in COS-1 cells transfected with Fc-gamma-RII cDNA, the 40-kDa protein immunoprecipitated with anti-Fc-gamma-RII was also phosphorylated on tyrosine. These data strongly suggest that Fc-gamma-RII itself is a substrate for a tyrosine kinase(s) activated when Fc-gamma-RII is stimulated. Fc-gamma-RII was phosphorylated by the Src protein in vitro, suggesting that this kinase may be responsible for phosphorylation of Fc-gamma-RII in vivo. These studies establish that activation of platelets and human erythroleukemia cells through Fc-gamma-RII and CD9 involves an induction of tyrosine phosphorylation of multiple proteins including Fc-gamma-RII itself and suggest that these phosphorylation events may be involved in Fc-gamma-RII-mediated cell signaling.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA27951] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NIAID NIH HHS [AI22193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027951, R01CA027951] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON GP, 1990, BLOOD, V76, P1165; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014-5793(83)81027-8; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRASS LF, 1991, J BIOL CHEM, V266, P958; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EISENMAN E, 1992, IN PRESS NATURE; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3606; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GORMAN DJ, 1985, NOUV REV FR HEMATOL, V27, P255; HENSON PM, 1973, J CLIN INVEST, V52, P1282, DOI 10.1172/JCI107296; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HORSEWOOD P, 1991, BLOOD, V78, P1019; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; ISRAELS ED, 1973, THROMB DIATH HAEMOST, V29, P434; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KARAS SP, 1982, BLOOD, V60, P1277; KELTON JG, 1988, BLOOD, V72, P925; KELTON JG, 1987, AM J HEMATOL, V25, P299, DOI 10.1002/ajh.2830250310; KING M, 1990, CELL IMMUNOL, V128, P462, DOI 10.1016/0008-8749(90)90041-O; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MODDERMAN PW, 1988, THROMB HAEMOSTASIS, V60, P68; MOREL MC, 1989, BRIT J HAEMATOL, V71, P57, DOI 10.1111/j.1365-2141.1989.tb06275.x; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PAOLINI R, 1992, IN PRESS NATURE; RAPPAPORT EF, 1991, CLIN RES, V39, P151; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RENDU F, 1987, BIOCHEM BIOPH RES CO, V146, P1397, DOI 10.1016/0006-291X(87)90805-9; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIVIER E, 1991, J IMMUNOL, V146, P206; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x	51	185	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5467	5473						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372004				2022-12-25	WOS:A1992HH74700071
J	ADAN, RAH; COX, JJ; VANKATS, JP; BURBACH, JPH				ADAN, RAH; COX, JJ; VANKATS, JP; BURBACH, JPH			THYROID-HORMONE REGULATES THE OXYTOCIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; CANCER CELL-LINE; VASOPRESSIN GENE; RESPONSE ELEMENT; MESSENGER-RNA; EXPRESSION; RAT; PROMOTER; IDENTIFICATION; LACTATION	Endocrine factors involved in the transcriptional regulation of the oxytocin (OT) gene were investigated in heterologous expression systems. Plasmids having a 5'-flanking region of the rat OT gene (-363/+16) or the human OT gene (-382/+41) cloned in front of the firefly luciferase gene were co-transfected with an expression vector for the rat thyroid hormone receptor-alpha in P19 embryonal carcinoma (EC) cells. Thyroid hormone (T3) stimulated the activity of the rat and human OT promoters about 10-fold. In MCF-7 breast tumor cells transfected with the human OT promoter-luciferase fusion gene, T3 stimulation through endogenous thyroid hormone receptors was about 5-fold. Co-transfection experiments in P19EC cells using 5' deletion mutants of the rat OT gene showed that thyroid hormone responsiveness was located in two regions, one located between nucleotides -195 and -172, the other between nucleotides -172 and -148. Each region accounted for about 3-fold T3 stimulation. Gel retardation analysis using extracts from HeLa cells overproducing the c-erbA/TR-alpha protein showed specific binding to the -172/-148 element, while no binding occurred on the -195/-172 element. The -172/-148 element which contains the imperfect estrogen response element, GGTGACCTTGACC, has inverted as well as direct repeats of the TGACC motif. Mutagenesis of TGACC motifs separately reduced thyroid hormone responsiveness by about 50%. However, simultaneous mutation of two TGACC motifs abolished the responsiveness to T3 completely. There was no cooperativity between the activated thyroid hormone and estrogen receptors in transfected MCF-7 cells nor in thyroid hormone receptor and estrogen receptor co-transfected P19EC cells. Negative interactions between these two receptors were observed and gel retardation assays showed interaction between the two receptors proteins. It was shown in an in vivo experiment that treatment of rats with thyroid hormone increased hypothalamic OT mRNA levels, the pituitary OT content, as well as OT levels in blood. The results reveal thyroid hormone as a physiological regulator of OT gene expression, which stimulates OT promoter activity directly through interaction with a thyroid hormone-response element in the OT gene.	UNIV UTRECHT, FAC MED,DEPT PHARMACOL,RUDOLF MAGNUS INST, VONDELLAAN 6, 3521 GD UTRECHT, NETHERLANDS	Utrecht University			van Kats, Jorge/A-8284-2008					ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ALMAZAN G, 1989, DEV BRAIN RES, V45, P69, DOI 10.1016/0165-3806(89)90008-4; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURBACH JPH, 1990, J NEUROENDOCRINOL, V2, P633; BURBACH JPH, 1989, METHOD ENZYMOL, V168, P385; DALMAN FC, 1990, J BIOL CHEM, V265, P1615; DAY RN, 1989, MOL ENDOCRINOL, V3, P931, DOI 10.1210/mend-3-6-931; DELEAUNOIT Y, 1989, IN VITRO CELL DEV, V25, P585; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6882; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUCHS AR, 1986, OXYTOCIN CLIN LABORA, P207; FUKUDA T, 1988, ENDOCRINOLOGY, V123, P2646, DOI 10.1210/endo-123-6-2646; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RICHARD S, 1990, J BIOL CHEM, V265, P6098; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554, DOI 10.1210/endo-119-2-554; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SOLOFF MS, 1985, OXYTOCIN CLIN LABORA, P259; TALANTI S, 1972, LIFE SCI, V11, P49, DOI 10.1016/0024-3205(72)90162-2; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDEHEIJNING BJM, 1991, J NEUROENDOCRINOL, V3, P57, DOI 10.1111/j.1365-2826.1991.tb00239.x; VANTOL HHM, 1988, MOL BRAIN RES, V4, P303, DOI 10.1016/0169-328X(88)90039-3; VANTOL HHM, 1987, ENDOCRINOLOGY, V120, P71, DOI 10.1210/endo-120-1-71; VANTOL HHM, 1988, ENDOCRINOLOGY, V122, P945, DOI 10.1210/endo-122-3-945; VANTOL HHM, 1990, NEUROSCI RES COMMUN, V7, P25; VANTOL HHM, 1987, METHOD ENZYMOL, V168, P398; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; ZINGG HH, 1988, MOL BRAIN RES, V4, P1, DOI 10.1016/0169-328X(88)90011-3	48	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3771	3777						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371278				2022-12-25	WOS:A1992HE60700037
J	KIM, YK; LEE, AS				KIM, YK; LEE, AS			IDENTIFICATION OF A PROTEIN-BINDING SITE IN THE PROMOTER OF THE HUMAN THYMIDINE KINASE GENE REQUIRED FOR THE G1-S-REGULATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; CYCLE; GROWTH	When quiescent cells are stimulated to enter the cell cycle, the thymidine kinase (TK) gene is transcriptionally activated at the border of G1 and S. In this report we show that the human TK promoter contains multiple protein-binding sites. By site-directed mutagenesis, we identified a protein-binding site on the human TK promoter required for conferring G1-S-regulated transcription to a heterologous promoter and dissociated it functionally from an adjacent protein-binding domain containing an inverted CCAAT motif required for high basal level expression. Substitution-mutation of this site results in constitutive expression of the neo reporter gene in serum-stimulated fibroblasts, as well as in cells arrested in mid-G1 by a temperature-sensitive mutation. The regulatory domains for the human TK promoter exhibit interesting symmetrical features, including a set of CCAAT motifs and sites similar to the novel Yi protein-binding site recently discovered in the mouse TK promoter.	UNIV SO CALIF, SCH MED, NORRIS CANC RES INST, LOS ANGELES, CA 90033 USA	University of Southern California	KIM, YK (corresponding author), UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA.			Lee, Amy/0000-0002-0378-5443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCOT SS, 1989, J BIOL CHEM, V264, P2343; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BASERGA R, 1985, BIOL CELL REPRODUCTI, P134; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; ITO M, 1990, J BIOL CHEM, V265, P6954; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MELERO JA, 1978, J CELL PHYSIOL, V95, P295, DOI 10.1002/jcp.1040950307; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUDZINSKI GP, 1989, CELL TISSUE KINET, V22, P405, DOI 10.1111/j.1365-2184.1989.tb00226.x; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; YONG KK, 1988, P NATL ACAD SCI USA, V85, P5894, DOI 10.1073/pnas.85.16.5894	27	42	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2723	2727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370831				2022-12-25	WOS:A1992HB53200092
J	STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J				STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J			CHARACTERIZATION OF LYSYL RESIDUES OF NADH-CYTOCHROME-B5 REDUCTASE IMPLICATED IN CHARGE-PAIRING WITH ACTIVE-SITE CARBOXYL RESIDUES OF CYTOCHROME-B5 BY SITE-DIRECTED MUTAGENESIS OF AN EXPRESSION VECTOR FOR THE FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; LECITHIN LIPOSOMES; B5 REDUCTASE; ACID; PARTICIPATION; DESATURATION; INVOLVEMENT; SEQUENCE; FORM	An expression vector for bovine NADH-cytochrome b5, reductase was constructed from two DNA fragments that were derived from beef liver poly(A+) RNA using the polymerase chain reaction. Site-directed mutagenesis of the 3 lysine residues of the reductase, previously implicated in the formation of active-site charge pairs with carboxylate residues of cytochrome b5, was then used to obtain the purified catalytic domains of flavoproteins modified at each of these sites. The observed marked decreases in catalytic efficiencies of substitutions of a negative charge at the normally positively charged residues with the catalytic domain of cytochrome b5, are consistent with their participation in the formation of charge pairs with carboxylate groups of the hemeprotein to optimize rapid electron transfer from the reductase flavin to the heme of the cytochrome.			STRITTMATTER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015924] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15924] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAILEY HA, 1979, J BIOL CHEM, V254, P5388; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KEYES SR, 1979, J BIOL CHEM, V254, P7778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVERDE A, 1968, J BIOL CHEM, V243, P5779; MATHEWS FS, 1976, ENZYMES BIOL MEMBR, V4, P143; MIKI K, 1987, J BIOL CHEM, V262, P11801; OKAYASU T, 1977, LIPIDS, V12, P267, DOI 10.1007/BF02533345; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; ROGERS MJ, 1975, J BIOL CHEM, V250, P5713; ROGERS MJ, 1973, J BIOL CHEM, V248, P800; ROGERS MJ, 1974, J BIOL CHEM, V249, P895; SALEMME FR, 1976, J MOL BIOL, V102, P563, DOI 10.1016/0022-2836(76)90334-X; Sambrook J, 1989, MOL CLONING, V3; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; SPATZ L, 1973, J BIOL CHEM, V248, P793; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2661; Strittmatter P, 1978, Methods Enzymol, V52, P97; STRITTMATTER P, 1958, J BIOL CHEM, V233, P748; STRITTMATTER P, 1975, P NATL ACAD SCI USA, V72, P2658, DOI 10.1073/pnas.72.7.2658; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; STRITTMATTER P, 1962, J BIOL CHEM, V237, P3250; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1991, J BIOL CHEM, V266, P66	32	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2519	2523						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370824				2022-12-25	WOS:A1992HB53200063
J	MACKIE, GA				MACKIE, GA			SECONDARY STRUCTURE OF THE MESSENGER-RNA FOR RIBOSOMAL-PROTEIN S20 - IMPLICATIONS FOR CLEAVAGE BY RIBONUCLEASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; POLYNUCLEOTIDE PHOSPHORYLASE; PROCESSING ENZYME; SEQUENCE; GENE; STABILIZATION; STABILITY; MUTANTS; DECAY	A synthetic RNA transcript containing the entire sequence of one of the two natural mRNAs for Escherichia richia coli ribosomal protein S20 is a substrate for specific cleavage by an endonuclease which is or depends on ribonuclease E (Mackie, G. A. (1991) J. Bacteriol. 173, 2488-2497). Partial cleavage with ribonucleases T1 or CL3 and limited modification with dimethyl sulfate have been employed to identify residues that are likely to be single stranded in the S20 mRNA's native state. The data show that the 5' one-third of the mRNA is relatively unstructured whereas the 3' one-third is extensively folded. The latter property can account for the previously observed accumulation of a 147-residue product co-terminal with the 3' end of the S20 mRNA (Mackie, G. A. (1989) J. Bacteriol. 171, 4112-4120). Sites of cleavage by the ribonuclease E-dependent activity map to single-stranded regions of the RNA. In addition, denaturation of the RNA substrate results in loss of susceptibility to the ribonuclease E-dependent activity and simultaneous loss of the single-stranded character of the two most prominent cleavage sites. It is proposed that ribonuclease E is a single-strand-specific enzyme with few primary structural constraints but a preference for an AU dinucleotide 3' to the site of cleavage.			MACKIE, GA (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ARRAIANO CM, 1988, J BACTERIOL, V170, P4625, DOI 10.1128/jb.170.10.4625-4633.1988; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRAY PN, 1973, EUR J BIOCHEM, V28, P412; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLMES WM, 1983, CELL, V32, P1029; KING TC, 1986, MICROBIOL REV, V50, P428, DOI 10.1128/MMBR.50.4.428-451.1986; KOKOSKA RJ, 1990, BIOCHIMIE, V72, P803, DOI 10.1016/0300-9084(90)90189-N; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1981, J BIOL CHEM, V256, P8177; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MACKIE GA, 1986, NUCLEIC ACIDS RES, V14, P6965, DOI 10.1093/nar/14.17.6965; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PARSONS GD, 1988, J BACTERIOL, V170, P2485, DOI 10.1128/jb.170.6.2485-2492.1988; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1054	1061						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370457				2022-12-25	WOS:A1992GY96000061
J	RAO, PV; KRISHNA, CM; ZIGLER, JS				RAO, PV; KRISHNA, CM; ZIGLER, JS			IDENTIFICATION AND CHARACTERIZATION OF THE ENZYMATIC-ACTIVITY OF ZETA-CRYSTALLIN FROM GUINEA-PIG LENS - A NOVEL NADPH-QUINONE OXIDOREDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; CARBONYL REDUCTASE; DT-DIAPHORASE; SEMI-QUINONE; PROTEIN; DEHYDROGENASES; EVOLUTION; SYSTEMS; GENE	Zeta-crystallin is a major protein in the lens of certain mammals. In guinea pigs it comprises 10% of the total lens protein, and it has been shown that a mutation in the zeta-crystallin gene is associated with autosomal dominant congenital cataract. As with several other lens crystallins of limited phylogenetic distribution, zeta-crystallin has been characterized as an "enzyme/crystallin" based on its ability to reduce catalytically the electron acceptor 2,6-dichlorophenolindophenol. We report here that certain naturally occurring quinones are good substrates for the enzymatic activity of zeta-crystallin. Among the various quinones tested, the orthoquinones 1,2-naphthoquinone and 9,10-phenanthrenequinone were the best substrates whereas menadione, ubiquinone, 9,10-anthraquinone, vitamins K1 and K2 were inactive as substrates. This quinone reductase activity was NADPH specific and exhibited typical Michaelis-Menten kinetics. Activity was sensitive to heat and sulfhydryl reagents but was very stable on freezing. Dicumarol (K(i) = 1.3 x 10(-5) M) and nitrofurantoin (K(i) = 1.4 x 10(-5) M) inhibited the activity competitively with respect to the electron acceptor, quinone. NADPH protected the enzyme against inactivation caused by heat, N-ethylmaleimide, or H2O2. Electron paramagnetic resonance spectroscopy of the reaction products showed formation of a semiquinone radical. The enzyme activity was associated with O2 consumption, generation of O2- and H2O2, and reduction of ferricytochrome c. These properties indicate that the enzyme acts through a one-electron transfer process. The substrate specificity, reaction characteristics, and physicochemical properties of zeta-crystallin demonstrate that it is an active NADPH:quinone oxidoreductase distinct from quinone reductases described previously.	NEI,MECHANISMS OCULAR DIS LAB,BETHESDA,MD 20892; NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLEN AO, 1952, J PHYS CHEM-US, V56, P576; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENAS NK, 1991, BIOCHIM BIOPHYS ACTA, V1073, P195, DOI 10.1016/0304-4165(91)90201-Q; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Estabrook R W, 1978, Methods Enzymol, V52, P43; Fridovich, 1977, SUPEROXIDE SUPEROXID, P11; GARLAND D, 1991, ARCH BIOCHEM BIOPHYS, V285, P134, DOI 10.1016/0003-9861(91)90339-K; Harding JJ, 1984, EYE B, V1b, P207; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HENDERSON GB, 1988, P NATL ACAD SCI USA, V85, P5374, DOI 10.1073/pnas.85.15.5374; HUANG QL, 1987, CURR EYE RES, V6, P725, DOI 10.3109/02713688709034836; HUANG QL, 1990, EXP EYE RES, V50, P317, DOI 10.1016/0014-4835(90)90217-I; IYANAGI T, 1987, CHEM SCRIPTA, V27A, P31; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; KEDDERIS GL, 1988, DRUG METAB REV, V19, P33, DOI 10.3109/03602538809049618; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LIND C, 1990, METHOD ENZYMOL, V186, P287; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MORENO SNJ, 1984, J BIOL CHEM, V259, P6298; PAZ MA, 1991, J BIOL CHEM, V266, P689; PEDERSEN JA, 1985, CRC HDB EPR SPECTRA, P18; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RAO PV, 1991, ARCH BIOCHEM BIOPHYS, V284, P181, DOI 10.1016/0003-9861(91)90281-M; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; ROSEN GM, 1982, ARCH BIOCHEM BIOPHYS, V215, P367, DOI 10.1016/0003-9861(82)90097-2; STEIDER CM, 1990, BIOCHEM PHARMACOL, V40, P1849; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; WERMUTH B, 1986, BIOCHEM PHARMACOL, V35, P1277, DOI 10.1016/0006-2952(86)90271-6; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; Williams CH., 1976, ENZYMES, P89; WINTERBOURN CC, 1981, ARCH BIOCHEM BIOPHYS, V209, P159, DOI 10.1016/0003-9861(81)90268-X; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	36	162	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					96	102						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370456				2022-12-25	WOS:A1992GY43900021
J	VASSILATIS, DK; DESPOMMIER, D; MISEK, DE; POLVERE, RI; GOLD, AM; VANDERPLOEG, LHT				VASSILATIS, DK; DESPOMMIER, D; MISEK, DE; POLVERE, RI; GOLD, AM; VANDERPLOEG, LHT			ANALYSIS OF A 43-KDA GLYCOPROTEIN FROM THE INTRACELLULAR PARASITIC NEMATODE TRICHINELLA-SPIRALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-PARTICLE FRACTION; GEL-ELECTROPHORESIS; MUSCLE LARVA; DNA-BINDING; PROTEINS; ANTIGENS; EXPRESSION; INFECTION; CLONING; CELLS	The L1 larvae of the parasitic nematode Trichinella spiralis invade skeletal muscle and initiate a process that has been interpreted to represent skeletal muscle dedifferentiation. In this process, the infected region of the muscle cell is converted into a unique structure, called the Nurse cell. The nematode T. spiralis can survive for tens of years within the cytoplasm of the Nurse cell and secretes proteins into the cytoplasm that are believed to play a role in mediating the Nurse cell formation or maintenance. We have cloned a cDNA encoding the T. spiralis-derived, 43-kDa secreted protein. Structural analysis of the predicted 344-amino acid sequence revealed an N terminally located signal peptide and a potential helix-loop-helix motif in the main body of the protein. Antibodies raised against the 43-kDa recombinant protein were used in immunocytolocalizations of T. spiralis-infected skeletal muscle sections. These antibodies strongly stained the Nurse cell nuclei and the nematode itself. Specific, though slightly weaker staining also occurred in the Nurse cell cytoplasm. In Western blots, the antibodies react with the 43-kDa protein but also detected at least two other T. spiralis-secreted proteins. DNA hybridizations reveal at least one additional 43-kDa-related sequence encoded in the T. spiralis genome. We conclude that either the 43-kDa protein and/or a closely related 43-kDa family member is secreted into the muscle and translocates to the muscle-derived nuclei. This model may provide insights into the mechanisms involved in Nurse cell formation.	COLUMBIA UNIV,SCH PUBL HLTH,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,SCH PUBL HLTH,DIV TROP MED,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NIAID NIH HHS [R01-AI-10627-21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; DESPOMMIER D, 1975, AM J PATHOL, V78, P477; DESPOMMIER D, 1975, EXP PARASITOL, V37, P108, DOI 10.1016/0014-4894(75)90058-2; DESPOMMIER D, 1991, J PARASITOL, V77, P290, DOI 10.2307/3283099; DESPOMMIER DD, 1976, J PARASITOL, V62, P775, DOI 10.2307/3278960; DESPOMMIER DD, 1981, J PARASITOL, V67, P332, DOI 10.2307/3280552; DESPOMMIER DD, 1977, PARASITOLOGY, V74, P109, DOI 10.1017/S0031182000047570; DESPOMMIER DD, 1981, EXP PARASITOL, V51, P279, DOI 10.1016/0014-4894(81)90116-8; DESPOMMIER DD, 1990, EXP PARASITOL, V71, P27, DOI 10.1016/0014-4894(90)90005-W; DESPOMMIER DD, 1976, MUSCULATURE ECOLOGIC, P270; GARDINER CH, 1976, J PARASITOL, V62, P865, DOI 10.2307/3279174; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLD AM, 1990, MOL BIOCHEM PARASIT, V41, P187, DOI 10.1016/0166-6851(90)90181-K; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARBOE N, 1973, MANUAL QUANTITATIVE, P161; HARLEY JP, 1971, EXP PARASITOL, V30, P11, DOI 10.1016/0014-4894(71)90064-6; JASMER DP, 1990, EXP PARASITOL, V70, P452, DOI 10.1016/0014-4894(90)90130-5; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KHAN ZA, 1966, J PARASITOL, V52, P248, DOI 10.2307/3276480; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZEK WJ, 1971, J PARASITOL, V57, P1015, DOI 10.2307/3277858; KOZEK WJ, 1971, J PARASITOL, V57, P1029, DOI 10.2307/3277860; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MASMER DP, 1991, EXP PARASITOL, V72, P321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RIBASMUJAL D, 1968, VIRCHOWS ARCH A, V345, P154, DOI 10.1007/BF00548649; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GL, 1973, THESIS RICE U HOUSTO; SU XZ, 1991, MOL BIOCHEM PARASIT, V45, P331, DOI 10.1016/0166-6851(91)90101-B; TEPPEMA JS, 1973, PARASITOLOGY, V66, P291, DOI 10.1017/S0031182000045224; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VILLELLA JB, 1958, J PARASITOL, V44, P41	38	76	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18459	18465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382055				2022-12-25	WOS:A1992JN50200037
J	AMMENDOLA, R; MESURACA, M; RUSSO, T; CIMINO, F				AMMENDOLA, R; MESURACA, M; RUSSO, T; CIMINO, F			SP1-DNA BINDING-EFFICIENCY IS HIGHLY REDUCED IN NUCLEAR EXTRACTS FROM AGED RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-BINDING; TRANSCRIPTION FACTORS; MESSENGER-RNA; GENE-EXPRESSION; PROMOTER; PROTEIN; MOUSE; SP1; LIVER	To explore the role of transcriptional factors in the genesis of the senescent phenotype, nuclear extracts from 4- and 30-month-old rat brains were analyzed for the presence of DNA-binding proteins able to interact with double-stranded oligonucleotides containing recognition sites for sequence-specific DNA-binding factors. Gel shift assays revealed that the DNA-binding efficiency of Sp1 is significantly reduced in aged animals compared to young ones, whereas CTF/NF1 and AP1 from young and old rat nuclear extracts bind their DNA targets with the same efficiency. The quantitative analysis of Spl by immunoblotting indicated that equivalent quantities and degrees of heterogeneity of Spl protein are present in both nuclear extracts, suggesting that the observed difference is not due to a different expression of this transcriptional factor. DNase I footprinting of the heavy chain ferritin gene promoter, which contains a Sp1 binding site, demonstrated that the nuclear extract from 30-month-old rat brain does not protect the region involved in the regulation of the H ferritin gene by Sp1. This results in a reduction of about 50% of the expression of the H ferritin mRNA in aged rat brains. Furthermore, the Sp1 binding sites present in the SV40 early promoter are not protected in a DNase I footprinting assay where a nuclear extract from 30-month-old rat brain was used as a source of DNA binding proteins. Liver nuclear extracts prepared from young and aged rats demonstrated that a decrease of Sp1 binding efficiency is similarly present in this tissue.	UNIV NAPOLI FEDERICO 2, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, VIA S PANSINI 5, I-80131 NAPLES, ITALY	University of Naples Federico II			Russo, Tommaso/K-1331-2016	Russo, Tommaso/0000-0003-4426-0106; AMMENDOLA, Rosario/0000-0003-1655-8028; MESURACA, Maria/0000-0002-5455-168X				AMMENDOLA R, 1990, MOL CELL BIOL, V10, P387, DOI 10.1128/MCB.10.1.387; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHATTERJEE B, 1981, J BIOL CHEM, V256, P5939; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CINADER B, 1989, GENOME, V31, P361, DOI 10.1139/g89-055; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FLEMING JE, 1988, P NATL ACAD SCI USA, V85, P4099, DOI 10.1073/pnas.85.11.4099; FRIEDMAN V, 1990, MECH AGEING DEV, V52, P27, DOI 10.1016/0047-6374(90)90142-3; FUKUDA H, 1990, EUR J BIOCHEM, V188, P517, DOI 10.1111/j.1432-1033.1990.tb15430.x; GAUCHAT J-F, 1988, Aging Immunology and Infectious Disease, V1, P191; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYFLICK L, 1985, EXP GERONTOL, V20, P145, DOI 10.1016/0531-5565(85)90032-4; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI DD, 1988, LIFE SCI, V43, P1215; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAGEL JE, 1988, J CLIN INVEST, V81, P1096, DOI 10.1172/JCI113422; ONO T, 1985, GERONTOLOGY, V31, P362, DOI 10.1159/000212725; ONO T, 1978, P NATL ACAD SCI USA, V75, P4431, DOI 10.1073/pnas.75.9.4431; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SIERRA F, 1989, MOL CELL BIOL, V9, P5610, DOI 10.1128/MCB.9.12.5610; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITH JR, 1980, MECH AGEING DEV, V13, P387, DOI 10.1016/0047-6374(80)90080-9; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WU WT, 1986, CELL IMMUNOL, V100, P224, DOI 10.1016/0008-8749(86)90021-3; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	51	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17944	17948						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381357				2022-12-25	WOS:A1992JM22300071
J	PEPINSKY, B; HESSION, C; CHEN, LL; MOY, P; BURKLY, L; JAKUBOWSKI, A; CHOW, EP; BENJAMIN, C; CHIROSSO, G; LUHOWSKYJ, S; LOBB, R				PEPINSKY, B; HESSION, C; CHEN, LL; MOY, P; BURKLY, L; JAKUBOWSKI, A; CHOW, EP; BENJAMIN, C; CHIROSSO, G; LUHOWSKYJ, S; LOBB, R			STRUCTURE-FUNCTION STUDIES ON VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; EOSINOPHIL ADHERENCE; MONOCLONAL-ANTIBODY; ICAM-1 CD54; VCAM-1; RECEPTOR; BINDING; DOMAINS; MAC-1	Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the integrin very late antigen-4 (VLA4). The VCAM1/VLA4 interaction mediates both adhesion and signal transduction and is thought to play an important role in inflammatory and immune responses in vivo. The major form of human VCAM1 contains seven extracellular Ig-like domains, with domain 1 designated as the most N-terminal. We have examined the relationship between human VCAM1 structure and function using a combination of domain truncation mutants and proteolytic fragmentation of recombinant soluble VCAM1. We have characterized two regions of VCAM1, localized to domains 4 and 5, which are highly sensitive to proteolytic cleavage, localized the epitope of the blocking monoclonal antibody 4B9 to domain 1, and found that domains 1-3 are sufficient for both its adhesive function and its ability to initiate T cell activation.	BIOGEN INC, 14 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA	Biogen								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HESSION C, 1991, J BIOL CHEM, V266, P6682; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; HOUEN G, 1991, ANAL BIOCHEM, V193, P186, DOI 10.1016/0003-2697(91)90006-F; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LOBB RR, 1991, ADHESION ITS ROLE IN, P1; LOBB RR, 1991, CELLULAR MOL MECHANI, V2, P151; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH GM, 1991, J IMMUNOL, V146, P3419; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WELLER PF, 1991, J EXP MED, V173, P1553; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	40	78	84	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17820	17826						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381355				2022-12-25	WOS:A1992JM22300054
J	VANDIJK, MCM; KRUIJT, JK; BOERS, W; LINTHORST, C; VANBERKEL, TJC				VANDIJK, MCM; KRUIJT, JK; BOERS, W; LINTHORST, C; VANBERKEL, TJC			DISTINCT PROPERTIES OF THE RECOGNITION SITES FOR BETA-VERY LOW-DENSITY-LIPOPROTEIN (REMNANT RECEPTOR) AND ALPHA-2-MACROGLOBULIN (LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN) ON RAT PARENCHYMAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; LDL-RECEPTOR; HIGH-AFFINITY; LIVER-CELLS; BINDING; HEPATOCYTES; CLEARANCE; COMPLEX; PLASMA	The properties of the recognition sites for alpha-2-macroglobulin (alpha-2-macroglobulin receptor; low density lipoprotein receptor-related protein) and beta-migrating very low density lipoprotein (beta-VLDL) (remnant receptor) on rat parenchymal cells were directly compared to analyze whether both substrates are recognized and internalized by the same receptor system. In cholesterol-fed rats, the large circulating pool of beta-VLDL is unable to diminish the liver uptake of I-125-labeled alpha-2-macroglobulin, while liver uptake of I-125-labeled beta-VLDL in these rats is reduced by 87.3% at 10 min after injection. In vitro competition studies with isolated parenchymal liver cells demonstrate that the binding of I-125-labeled alpha-2-macroglobulin to rat parenchymal cells is not effectively competed for by beta-VLDL, whether this lipoprotein is additionally enriched in apolipoprotein E or not. Binding of alpha-2-macroglobulin to parenchymal cells requires the presence of calcium, while binding of beta-VLDL does not. Incubation of parenchymal cells for 1 h with proteinase K reduced the subsequent binding of alpha-2-macroglobulin by 90.1%, while the binding of beta-VLDL was reduced by only 20.2%. In the presence of monensin, the association of alpha-2-macroglobulin to parenchymal cells at 2 h of incubation was reduced by 64.7%, while the association of beta-VLDL was not affected. Preincubation of parenchymal cells with monensin for 60 min at 37-degrees-C reduced the subsequent binding of alpha-2-macroglobulin by 54.5%, while binding of beta-VLDL was only reduced by 14.6%. The results indicate that the recognition sites for alpha-2-macroglobulin and beta-VLDL on rat parenchymal cells do exert different properties and are therefore likely to reside on different molecules.	LEIDEN UNIV,SYLVIUS LAB,CTR BIOPHARMACEUT SCI,DIV BIOPHARMACEUT,POB 9503,2300 RA LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,VANGOOL LAB EXPTL INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam			Van Berkel, Theo/ABD-7677-2021					ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HARKES L, 1989, EUR J BIOCHEM, V180, P241, DOI 10.1111/j.1432-1033.1989.tb14639.x; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HUI DY, 1986, J BIOL CHEM, V261, P4256; HUI DY, 1981, J BIOL CHEM, V256, P5646; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17732	17737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381352				2022-12-25	WOS:A1992JM22300041
J	WOOD, JN; LILLYCROP, KA; DENT, CL; NINKINA, NN; BEECH, MM; WILLOUGHBY, JJ; WINTER, J; LATCHMAN, DS				WOOD, JN; LILLYCROP, KA; DENT, CL; NINKINA, NN; BEECH, MM; WILLOUGHBY, JJ; WINTER, J; LATCHMAN, DS			REGULATION OF EXPRESSION OF THE NEURONAL POU PROTEIN OCT-2 BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SIMPLEX VIRUS LATENCY; NEUROTROPHIC FACTOR; SENSORY NEURONS; B-CELL; GENE; RECEPTOR; TRANSCRIPTION; ENCODES; INVITRO	POU proteins are a class of homeobox-containing transcription factors that regulate tissue-specific gene expression and influence cell differentiation and function. We have investigated the possible role of such factors in mediating the actions of nerve growth factor (NGF) on sensory neurons. NGF has been found to have differential effects on the levels of three POU protein transcription factors that are expressed in adult rat sensory neurons. A sensory neuron octamer-binding protein with the properties of the transcription factor Oct-2 is up-regulated 3-4-fold by NGF, as measured by mobility shift assays using nuclear extracts from adult rat dorsal root ganglion neurons grown in the presence or absence of NGF. Quantitation of Oct-2 mRNA by polymerase chain reaction amplification of RNA from such cells shows a parallel increase in Oct-2 mRNA levels. In contrast, the levels of mRNA encoding the ubiquitous POU protein Oct-1 or the neuron-specific POU protein Brn-3, also present in sensory neurons, are unaffected by NGF. These observations suggest a role for Oct-2 in mediating transcriptional effects induced by NGF. In particular, as Oct-2 is known to inhibit herpes simplex virus immediate-early gene expression in neuronal cells, these findings provide a mechanism for the known action of NGF in the maintenance of latent herpes virus infections in sensory neurons.	SANDOZ INST MED RES, LONDON WC1E 6BN, ENGLAND	Novartis; Sandoz	WOOD, JN (corresponding author), UNIV COLL & MIDDLESEX HOSP SCH MED, MED MOLEC BIOL UNIT, WINDEYER BLDG, CLEVELAND ST, LONDON W1P 6DB, ENGLAND.		Ninkina, Natalia N/A-1732-2011					BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BROAD PM, 1989, NUCLEIC ACIDS RES, V17, P6999, DOI 10.1093/nar/17.17.6999; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DENT CL, 1991, BIOCHEM J, V277, P541, DOI 10.1042/bj2770541; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; FALKNER FG, 1986, NUCLEIC ACIDS RES, V14, P8819, DOI 10.1093/nar/14.22.8819; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LATCHMAN DS, 1992, IN PRESS BIOCH SOC T; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WILCOX CL, 1988, J VIROL, V62, P393, DOI 10.1128/JVI.62.2.393-399.1988; WILCOX CL, 1990, J NEUROSCI, V10, P1268; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	35	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17787	17791						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381354				2022-12-25	WOS:A1992JM22300050
J	WILLIAMS, SF; PALMER, MAJ; PEOPLES, OP; WALSH, CT; SINSKEY, AJ; MASAMUNE, S				WILLIAMS, SF; PALMER, MAJ; PEOPLES, OP; WALSH, CT; SINSKEY, AJ; MASAMUNE, S			BIOSYNTHETIC THIOLASE FROM ZOOGLOEA-RAMIGERA - MUTAGENESIS OF THE PUTATIVE ACTIVE-SITE BASE CYS-378 TO SER-378 CHANGES THE PARTITIONING OF THE ACETYL S-ENZYME INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-KETOACYL THIOLASE; PROTON-TRANSFER	The proposed active-site base Cys-378 of thiolase, responsible for deprotonation of acetyl-CoA, has been converted to a less acidic residue Ser-378 by mutagenesis. Comparison of the CD spectra and dimethyl suberimidate cross-linking experiments of the wild type, mutant Ser-378, and Gly-378 enzymes indicated that there have been no major conformational changes. The Ser-378 enzyme retains 0.1% of the V(max) of wild type in the direction of acetoacetyl-CoA thiolytic cleavage and 0.07% of the V(max) in the Claisen condensation direction. Analysis of the acetyl S-enzyme intermediate partitioning, that is capture of the acetyl enzyme by 1) the thiolate of coenzyme A relative to 2) the C-2 carbanion of acetyl-CoA, is changed to favor reaction 2 in the case of the Ser-378 mutant enzyme.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	WILLIAMS, SF (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DAVIS JT, 1987, J BIOL CHEM, V262, P82; GEHRING U, 1972, ENZYMES, V7, P391; GILBERT HF, 1981, BIOCHEMISTRY-US, V20, P5643, DOI 10.1021/bi00523a001; HILLEL Z, 1977, BIOCHEMISTRY-US, V16, P3334, DOI 10.1021/bi00634a008; MASAMUNE S, 1989, J AM CHEM SOC, V111, P1879, DOI 10.1021/ja00187a053; MASAMUNE S, 1989, PURE APPL CHEM, V61, P303, DOI 10.1351/pac198961030303; PALMER MAJ, 1991, J BIOL CHEM, V266, P8369; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006	9	36	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16041	16043						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1353760				2022-12-25	WOS:A1992JJ45800010
J	TOKI, S; TSUKUDA, E; NOZAWA, M; NONAKA, H; YOSHIDA, M; MATSUDA, Y				TOKI, S; TSUKUDA, E; NOZAWA, M; NONAKA, H; YOSHIDA, M; MATSUDA, Y			THE ES-242S, NOVEL N-METHYL-D-ASPARTATE ANTAGONISTS OF MICROBIAL ORIGIN, INTERACT WITH BOTH THE NEUROTRANSMITTER RECOGNITION SITE AND THE ION CHANNEL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE MODULATORY SITE; EXCITATORY AMINO-ACIDS; RAT-BRAIN MEMBRANES; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; L-GLUTAMATE; TRICYCLIC ANTIDEPRESSANTS; SELECTIVE ANTAGONIST; SYNAPTIC PLASTICITY; HIGHER AFFINITY	ES-242-1 approximately 5 are novel microbial bioxanthracenes which do not contain nitrogen. The ES-242s inhibited the binding of [H-3]TCP and [H-3]CGS19755 to the N-methyl-D-aspartate (NMDA) receptor complex. They had no effect on the binding of the specific ligands for the non-NMDA receptor. The biochemical and pharmacological properties of ES-242-1 were fully examined since it is the most potent of the five compounds. ES-242-1 is highly specific for the NMDA receptor; it has no effect on other receptors. Kinetic analyses indicated that ES-242-1 inhibited the binding of [H-3] TCP and [H-3]CGS19755 in a competitive manner, respectively, suggesting that ES-242-1 interacts with both the transmitter recognition site and the channel domain. ES-242-1 selectively inhibited NMDA-induced Ca2+ influx in primary cultures of mouse hippocampal neurons. ES-242-1 also specifically blocked the increase in cyclic GMP accumulation induced by NMDA or L-glutamate in rat cerebellar slices. In a concentration range of 0.1-1.0-mu-M, ES-242-1 was as potent as MK-801 in preventing glutamate-induced neurotoxicity in primary cultures of mouse hippocampal neurons. These results show that ES-242-1 is a potent and specific antagonist for the NMDA receptor. The antagonistic properties of the ES-242s appear to be due to a novel mechanism of action at the NMDA receptor.	KYOWA HAKKO KOGYO CO LTD,PHARMACEUT RES LABS,NAGAIZUMI,SHIZUOKA 411,JAPAN	Kyowa Kirin Ltd	TOKI, S (corresponding author), KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,3-6-6 ASAHIMACHI,MACHIDA,TOKYO 194,JAPAN.							BAUD J, 1989, NEUROSCI LETT, V107, P184, DOI 10.1016/0304-3940(89)90814-8; BILLARD W, 1984, LIFE SCI, V35, P1885, DOI 10.1016/0024-3205(84)90540-X; BLOOM JW, 1987, LIFE SCI, V41, P491, DOI 10.1016/0024-3205(87)90226-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; BRUNS RF, 1980, P NATL ACAD SCI-BIOL, V77, P5547, DOI 10.1073/pnas.77.9.5547; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHANG RSL, 1978, EUR J PHARMACOL, V48, P463, DOI 10.1016/0014-2999(78)90177-2; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FOSTER AC, 1989, J NEUROSCI, V9, P2191; GAITKOWSKI GA, 1983, NATURE, V304, P65; GARTHWAITE J, 1978, NATURE, V275, P328, DOI 10.1038/275328a0; GOZLAN H, 1983, NATURE, V305, P140, DOI 10.1038/305140a0; GREENBERG DA, 1976, LIFE SCI, V19, P69, DOI 10.1016/0024-3205(76)90375-1; HONEY CR, 1985, NEUROSCI LETT, V61, P135, DOI 10.1016/0304-3940(85)90414-8; KEANA JFW, 1989, P NATL ACAD SCI USA, V86, P5631, DOI 10.1073/pnas.86.14.5631; KEMP JA, 1987, TRENDS PHARMACOL SCI, V8, P414, DOI 10.1016/0165-6147(87)90223-9; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KOE BK, 1989, EUR J PHARMACOL, V161, P263; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LONDON ED, 1979, MOL PHARMACOL, V15, P492; MACDERMOTT AB, 1987, TRENDS NEUROSCI, V10, P280, DOI 10.1016/0166-2236(87)90173-1; MARVIZON JCG, 1988, EUR J PHARMACOL, V151, P157, DOI 10.1016/0014-2999(88)90709-1; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY DE, 1987, NEUROCHEM RES, V12, P775, DOI 10.1007/BF00971514; MURPHY DE, 1987, J PHARMACOL EXP THER, V240, P778; MURPHY DE, 1988, BRIT J PHARMACOL, V95, P932, DOI 10.1111/j.1476-5381.1988.tb11723.x; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; PEROUTKA SJ, 1988, EUR J PHARMACOL, V148, P297, DOI 10.1016/0014-2999(88)90579-1; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PETERSON C, 1989, DEV BRAIN RES, V48, P187, DOI 10.1016/0165-3806(89)90075-8; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SERNAGOR E, 1989, NEURON, V2, P1221, DOI 10.1016/0896-6273(89)90306-1; SILLS MA, 1989, MOL PHARMACOL, V36, P160; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SONDERS MS, 1988, TRENDS NEUROSCI, V11, P37, DOI 10.1016/0166-2236(88)90048-3; THOMSON AM, 1989, TRENDS NEUROSCI, V12, P349, DOI 10.1016/0166-2236(89)90042-8; TOKI S, 1992, J ANTIBIOT, V45, P88, DOI 10.7164/antibiotics.45.88; TOKI S, 1992, IN PRESS J ANTIBIOT; VIGNON J, 1983, BRAIN RES, V280, P194, DOI 10.1016/0006-8993(83)91193-9; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YUZAKI M, 1990, BRAIN RES, V517, P51, DOI 10.1016/0006-8993(90)91006-3	50	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14884	14892						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378842				2022-12-25	WOS:A1992JF08800059
J	HOFFMAN, P; YAFFE, MB; HOFFMAN, BL; YEI, SP; WOLD, WSM; CARLIN, C				HOFFMAN, P; YAFFE, MB; HOFFMAN, BL; YEI, SP; WOLD, WSM; CARLIN, C			CHARACTERIZATION OF THE ADENOVIRUS-E3 PROTEIN THAT DOWN-REGULATES THE EPIDERMAL GROWTH-FACTOR RECEPTOR - EVIDENCE FOR INTERMOLECULAR DISULFIDE BONDING AND PLASMA-MEMBRANE LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION E3; CELL-SURFACE; INTRACELLULAR-TRANSPORT; TRANSFERRIN RECEPTOR; SIGNAL PEPTIDASE; BREFELDIN-A; A431 CELLS; SEQUENCE; BIOSYNTHESIS; GLYCOPROTEIN	We have characterized the biosynthesis and processing of a 91 amino acid hydrophobic integral membrane protein encoded by human group C adenoviruses which down-regulates the EGF receptor (Carlin, C. R., Tollefson, A. E., Brady, H. A., Hoffman, B. L., and Wold, W. S. M. (1989) Cell 57, 135-144). Previous studies have shown that two immunologically related proteins are produced in vivo, a 13.7-kDa protein encoded by E3 message f and a 11.3-kDa protein derived from 13.7 kDa by proteolysis (Hoffman, B. L., Ullrich, A., Wold, W. S. M., and Carlin, C. R. (1990) Mol. Cell. Biol. 10, 5521-5524; Tollefson, A. E., Krajcsi, P., Yei, S., Carlin, C. R., and Wold, W. S. M. (1990) J. Virol. 64, 794-801). We report here that the 13.7- and 11.3-kDa proteins form intermolecular disulfide bonds cotranslationally at Cys-31 and tend to migrate as high molecular weight aggregates under nonreducing conditions. Both proteins are also present at the cell surface, as evidenced by specific immunoprecipitation from intact monolayers enzymatically labeled with I-125. Moreover, an antiserum specific for a putative extracellular epitope recognizes the same viral proteins as antibodies directed against a C-terminal synthetic 15-mer. The 13.7- and 11.3-kDa proteins are detected at early time points during pulse-chase radiolabeling of infected cells, do not undergo any further changes in molecular weight, and focus at their predicted isoelectric points (7.4 and 7.2, respectively). Identical results are obtained in stable transfectants constitutively expressing only 13.7 and 11.3 kDa, suggesting that biosynthesis and processing is not dependent on other viral proteins. These results have been incorporated into a computer-based model to predict the orientation of 13.7 and 11.3 kDa in the lipid bilayer. This model provides a basis for testing predictions regarding the topology of the viral proteins, as well as putative interactions with heterologous proteins in the microenvironment of the plasma membrane that cause down-regulation of the epidermal growth factor receptor.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; ST LOUIS UNIV,SCH MED,INST MOLEC VIROL,ST LOUIS,MO 63110	Case Western Reserve University; Saint Louis University				Hoffman, Brian/0000-0003-2576-9345	NCI NIH HHS [CA-49540] Funding Source: Medline; NHLBI NIH HHS [HL07653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049540] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1976, IMMUNOGENETICS, V3, P209, DOI 10.1007/BF01576954; ADEN DP, 1978, NATURE, V271, P375, DOI 10.1038/271375a0; ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BRADY HA, 1988, MOL CELL BIOL, V8, P3291, DOI 10.1128/MCB.8.8.3291; BRADY HA, 1987, NUCLEIC ACIDS RES, V15, P9397, DOI 10.1093/nar/15.22.9397; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CARLIN CR, 1982, P NATL ACAD SCI-BIOL, V79, P5026, DOI 10.1073/pnas.79.16.5026; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; CLADARAS C, 1985, VIROLOGY, V140, P28, DOI 10.1016/0042-6822(85)90443-X; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Flint S. J, 1981, DNA TUMOR VIRUSES; FLOMENBERG PR, 1988, J VIROL, V62, P4431, DOI 10.1128/JVI.62.11.4431-4437.1988; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Green M, 1979, Methods Enzymol, V58, P425; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5876; HERISSE J, 1980, NUCLEIC ACIDS RES, V8, P2173, DOI 10.1093/nar/8.10.2173; HOFFMAN BL, 1990, MOL CELL BIOL, V10, P5521, DOI 10.1128/MCB.10.10.5521; HOFFMAN P, 1992, J VIROL, V66, P197, DOI 10.1128/JVI.66.1.197-203.1992; HONG JS, 1988, VIROLOGY, V167, P545, DOI 10.1016/S0042-6822(88)90117-1; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KELLY TJ, 1973, J VIROL, V12, P643, DOI 10.1128/JVI.12.3.643-652.1973; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRAJCSI P, 1992, VIROLOGY, V187, P131, DOI 10.1016/0042-6822(92)90302-6; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIGNAS C, 1986, GENE, V50, P173, DOI 10.1016/0378-1119(86)90322-7; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOLLEFSON AE, 1990, J VIROL, V64, P794, DOI 10.1128/JVI.64.2.794-801.1990; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; WOLD WSM, 1985, J BIOL CHEM, V260, P2424	64	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13480	13487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377684				2022-12-25	WOS:A1992JB74600062
J	HO, KC; QUARMBY, VE; FRENCH, FS; WILSON, EM				HO, KC; QUARMBY, VE; FRENCH, FS; WILSON, EM			MOLECULAR-CLONING OF RAT PROSTATE TRANSGLUTAMINASE COMPLEMENTARY-DNA - THE MAJOR ANDROGEN-REGULATED PROTEIN-DP1 OF RAT DORSAL PROSTATE AND COAGULATING GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; STEROID-BINDING PROTEIN; VENTRAL PROSTATE; ERYTHROCYTE-MEMBRANE; MR=14,000 SUBUNIT; C-MYC; RNA; SEQUENCES; GENES; TRANSCRIPTION	Complementary DNA (cDNA) that codes for a major androgen-dependent secretory protein of rat coagulating gland and dorsal prostate, dorsal protein 1 (DP1), was isolated by molecular cloning. Recombinant DP1 cDNA clones were identified from a bacteriophage lambda-gt11 rat coagulating gland expression library using an affinity purified polyclonal antibody. Amino acid sequence deduced from DNA contained sequences identical with several DP1 cyanogen bromide cleavage fragments. Northern blot hybridization of poly(A) RNA isolated from intact rat dorsal prostate and coagulating gland revealed a predominant messenger RNA (mRNA) species of approximately 3200 nucleotides. Tissue-specific expression of DP1 mRNA was indicated by the absence of DP1 mRNA in ventral prostate and other tissues of the rat. Expression of DP1 mRNA was androgen-dependent, decreasing approximately 80% 7 days after castration and increasing rapidly following androgen replacement. Southern blot analysis of restriction enzyme-digested rat DNA indicated that DP1 is encoded by a single gene and that no major genomic rearrangements accounted for its lack of expression in the dorsal prostate-derived rat Dunning tumor. Sequence comparisons revealed that rat prostate DP1 shares sequence identity with Factor XIIIa and tissue transglutaminase, including the active center, GQCWVF, indicating that DP1 is a member of the transglutaminase gene family.	UNIV N CAROLINA,REPROD BIOL LABS,CB 7500 MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004466, R37HD016910, R37HD004466, P30HD018968, R01HD016910] Funding Source: NIH RePORTER; NICHD NIH HHS [HD04466, HD16910, P30-HD18968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT RJ, 1984, PROSTATE, V5, P75, DOI 10.1002/pros.2990050108; BLATTNER FR, 1978, SCIENCE, V202, P1279, DOI 10.1126/science.725603; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHAN SJ, 1979, P NATL ACAD SCI USA, V76, P5036, DOI 10.1073/pnas.76.10.5036; CHEN C, 1979, J STEROID BIOCHEM, V11, P401, DOI 10.1016/0022-4731(79)90058-X; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FORSGREN B, 1979, P NATL ACAD SCI USA, V76, P3149, DOI 10.1073/pnas.76.7.3149; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOTTERER GS, 1957, P SOC EXP BIOL MED, V94, P60, DOI 10.3181/00379727-94-22855; GRANDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAYASHI N, 1991, BIOL REPROD, V45, P308, DOI 10.1095/biolreprod45.2.308; HEYNS W, 1977, BIOCHEM BIOPH RES CO, V77, P1492, DOI 10.1016/S0006-291X(77)80147-2; HEYNS W, 1977, EUR J BIOCHEM, V78, P221, DOI 10.1111/j.1432-1033.1977.tb11733.x; HO KC, 1985, GENE, V39, P49, DOI 10.1016/0378-1119(85)90106-4; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; ISAACS JT, 1982, CANCER RES, V42, P2352; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEA OA, 1979, J BIOL CHEM, V254, P6196; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OHARE K, 1979, NUCLEIC ACIDS RES, V7, P321, DOI 10.1093/nar/7.2.321; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8818; PARKER MG, 1983, J BIOL CHEM, V258, P12; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PARKER MG, 1978, EUR J BIOCHEM, V85, P399, DOI 10.1111/j.1432-1033.1978.tb12252.x; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PORTA R, 1990, INT J PEPT PROT RES, V35, P117; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; SAMBROOK J, 1989, MOL CLONING LAB MANU, P779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P173; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEERS E, 1965, J BIOL CHEM, V240, P2478; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; THOMAS P, 1980, P NATL ACAD SCI USA, V74, P5201; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEAVER CA, 1981, P NATL ACAD SCI-BIOL, V78, P4073, DOI 10.1073/pnas.78.7.4073; Williams-Ashman H G, 1980, Adv Enzyme Regul, V18, P239, DOI 10.1016/0065-2571(80)90018-7; WILLIAMSASHMAN HG, 1977, BIOCHEM BIOPH RES CO, V79, P1192, DOI 10.1016/0006-291X(77)91132-9; WILLIAMSASHMAN HG, 1984, MOL CELL BIOCHEM, V58, P51, DOI 10.1007/BF00240604; WILSON EM, 1980, J BIOL CHEM, V255, P946; WILSON EM, 1981, PROSTATIC CELL STR A, P351; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZKURA K, 1987, AGR BIOL CHEM TOKYO, V51, P957; [No title captured]	57	87	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12660	12667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352290				2022-12-25	WOS:A1992HZ48300045
J	CHEN, L; MAO, SJT; LARSEN, WJ				CHEN, L; MAO, SJT; LARSEN, WJ			IDENTIFICATION OF A FACTOR IN FETAL BOVINE SERUM THAT STABILIZES THE CUMULUS EXTRACELLULAR-MATRIX - A ROLE FOR A MEMBER OF THE INTER-ALPHA-TRYPSIN INHIBITOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID SYNTHESIS; PROTEINASE-INHIBITORS; HUMAN-PLASMA; LIMITED PROTEOLYSIS; RELEASED INHIBITOR; GLYCOPROTEIN EDC1; FOLLICULAR-FLUID; CELL COMPLEXES; EXPANSION; SEQUENCE	Fetal bovine serum (FBS) has been widely used in the culture of cumulus-oocyte complexes, since it is believed that FBS stabilizes the expanding cumulus extracellular matrix. In this study, we have identified a factor in FBS that is responsible for this effect. FBS was first fractionated by stepwise precipitation with ammonium sulfate followed by high performance liquid chromatography (HPLC) on a gel filtration column. Active fractions, as determined by their ability to stabilize the cumulus extracellular matrix in a bioassay system, were further purified by HPLC on DEAE ion-exchange and gel filtration columns. The purified factor was exhibited as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an apparent M(r) 150,000 and a single peak on a C-8 reverse-phase HPLC. The sequence of the first 14 NH2-terminal amino acids was determined by Edman degradation, revealing significant sequence identity of the bovine serum factor with the light chain shared by members of the inter-alpha-trypsin inhibitor family. Western blot analysis using anti-human I-alpha-I IgG shows that the antibody reacts positively with the purified factor, and immunodepletion of FBS with anti-I-alpha-I antibody agarose eliminated its ability to stabilize the extracellular matrix. This factor is found in mouse follicular fluid collected 6 h following human chorionic gonadotropin injection to stimulate ovulation, but not in unstimulated mice. Anti-I-alpha-I-positive epitopes were also localized within the cumulus extracellular matrix of mouse preovulatory follicles in immunocytochemical preparations using anti-human I-alpha-I IgG, supporting the possibility that this molecule or molecules may diffuse into follicular fluid after an ovulatory stimulus to act as structural linkers that ensure normal cumulus expansion, through stabilization of the cumulus extracellular matrix thus supporting the process of ovulation.	UNIV CINCINNATI,COLL MED,DEPT ANAT & CELL BIOL,MAIL LOCATION 521,CINCINNATI,OH 45267; MARION MERRELL DOW RES INST,CINCINNATI,OH 45215	University System of Ohio; University of Cincinnati; Dow Chemical Company								BLANDAU RL, 1971, PATHWAYS CONCEPTION; CARDIN AD, 1986, J BIOL CHEM, V261, P6744; CHAWLA RK, 1978, J IMMUNOL, V121, P1636; CHAWLA RK, 1990, J CELL BIOCHEM, V42, P207, DOI 10.1002/jcb.240420404; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; CRAN DG, 1976, ACTA ENDOCRINOL-COP, V82, P631, DOI 10.1530/acta.0.0820631; DEKEL N, 1978, GAMETE RES, V1, P47, DOI 10.1002/mrd.1120010108; DEKEL N, 1979, BIOL REPROD, V23, P9; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DOWNS SM, 1986, GAMETE RES, V15, P115, DOI 10.1002/mrd.1120150203; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; EPPIG JJ, 1980, BIOL REPROD, V22, P629, DOI 10.1093/biolreprod/22.3.629; EPPIG JJ, 1979, J EXP ZOOL, V208, P111, DOI 10.1002/jez.1402080112; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; FRANCK C, 1983, SCAND J CLIN LAB INV, V43, P151; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; GWATKIN RBL, 1977, FERTILIZATION MAN MA; HOCHSTRASSER K, 1983, H-S Z PHYSIOL CHEM, V364, P1679, DOI 10.1515/bchm2.1983.364.2.1679; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN WJ, 1989, FOLLICULAR DEV OVULA, P87; Larsen WJ, 1991, ULTRASTRUCTURE OVARY, P45; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MAO SJT, 1987, ANAL BIOCHEM, V161, P514, DOI 10.1016/0003-2697(87)90482-9; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; MORII M, 1985, BIOL CHEM H-S, V366, P19, DOI 10.1515/bchm3.1985.366.1.19; ODUM L, 1990, BIOL CHEM H-S, V371, P1153, DOI 10.1515/bchm3.1990.371.2.1153; PIKO L, 1969, FERTILIZATION, V2, P325; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; RASP G, 1987, BIOL CHEM H-S, V368, P727, DOI 10.1515/bchm3.1987.368.1.727; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; SALIER JP, 1983, ANAL BIOCHEM, V133, P336, DOI 10.1016/0003-2697(83)90093-3; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SATO E, 1978, J REPROD FERTIL, V54, P263, DOI 10.1530/jrf.0.0540263; SCHREITMULLER T, 1987, BIOL CHEM H-S, V368, P963, DOI 10.1515/bchm3.1987.368.2.963; SHALGI R, 1973, FERTIL STERIL, V24, P429; SLUSS PM, 1987, ENDOCRINOLOGY, V120, P1477, DOI 10.1210/endo-120-4-1477; Steinbuch M, 1976, Methods Enzymol, V45, P760; TADANO Y, 1978, HISTOCHEMISTRY, V57, P203, DOI 10.1007/BF00492080; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VETR H, 1989, FEBS LETT, V245, P137, DOI 10.1016/0014-5793(89)80207-8; YOSHIMURA Y, 1987, FERTIL STERIL, V47, P22	47	207	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12380	12386						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376324				2022-12-25	WOS:A1992HY94700109
J	KLATT, P; HEINZEL, B; JOHN, M; KASTNER, M; BOHME, E; MAYER, B				KLATT, P; HEINZEL, B; JOHN, M; KASTNER, M; BOHME, E; MAYER, B			CA2+/CALMODULIN-DEPENDENT CYTOCHROME-C REDUCTASE-ACTIVITY OF BRAIN NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLYL CYCLASE; RAT-LIVER MICROSOMES; L-ARGININE; P-450 REDUCTASE; BOVINE LUNG; PURIFICATION; CALMODULIN; ACTIVATOR; OXIDATION; COFACTOR	Nitric oxide acts as a widespread signal molecule and represents the endogenous activator of soluble guanylyl cyclase. In endothelial cells and brain tissue, NO is enzymatically formed from L-arginine by Ca2+/calmodulin-regulated NO synthases which require NADPH, tetrahydrobiopterin, and molecular oxygen as cofactors. Here we show that purified brain NO synthase binds to cytochrome c-agarose and exhibits superoxide dismutase-insensitive cytochrome c reductase activity with a V(max) of 10.2-mu-mol x mg-1 x min-1 and a K(m) of 34.1-mu-M. Cytochrome c reduction was largely dependent on Ca2+/calmodulin and cochromatographed with L-citrulline formation during gel filtration. When reconstituted with cytochrome P450, NO synthase induced a moderate Ca2+-independent hydroxylation of N-ethylmorphine. NO synthase also reduced the artificial electron acceptors nitro blue tetrazolium and 2,6-dichlorophenolindophenol. Cytochrome c, 2,6-dichlorophenolindophenol, and nitro blue tetrazolium inhibited NO synthase activity determined as formation Of L-citrulline from 0.1 mM L-arginine in a concentration-dependent manner with half-maximal effects at 166, 41, and 7.3-mu-M, respectively. These results suggest that NO synthase may participate in cellular electron transfer processes and that a variety of electron-acceptors may interfere with NO formation due to the broad substrate specificity of the reductase domain of NO synthase.	GRAZ UNIV,INST PHARMACOL & TOXICOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA; FREE UNIV BERLIN,INST PHARMACOL,W-1000 BERLIN 33,GERMANY; FREE UNIV BERLIN,INST TOXICOL & EMBRYOPHARMACOL,W-1000 BERLIN 33,GERMANY	University of Graz; Free University of Berlin; Free University of Berlin			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				BENVENISTE I, 1991, BIOCHEM BIOPH RES CO, V177, P105, DOI 10.1016/0006-291X(91)91954-B; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; COCHIN J, 1959, J PHARMACOL EXP THER, V125, P105; Estabrook R W, 1978, Methods Enzymol, V52, P43; ESTABROOK RW, 1982, OXYGENASES OXYGEN ME, P371; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KOJIMA H, 1987, J BIOCHEM-TOKYO, V102, P1083, DOI 10.1093/oxfordjournals.jbchem.a122146; KUONEN DR, 1988, J NEUROCHEM, V50, P1017, DOI 10.1111/j.1471-4159.1988.tb10567.x; KUWADA M, 1985, BIOCHIM BIOPHYS ACTA, V830, P45; KUWAHARA T, 1984, BIOCHEM BIOPH RES CO, V124, P121, DOI 10.1016/0006-291X(84)90925-2; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER B, 1989, FEBS LETT, V256, P211, DOI 10.1016/0014-5793(89)81750-8; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1974, BIOCHEM BIOPH RES CO, V60, P1315, DOI 10.1016/0006-291X(74)90341-6; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369	42	206	207	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11374	11378						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375940				2022-12-25	WOS:A1992HX16900068
J	STENMARK, H; ARIANSEN, S; AFANASIEV, BN; OLSNES, S				STENMARK, H; ARIANSEN, S; AFANASIEV, BN; OLSNES, S			INTERACTIONS OF DIPHTHERIA-TOXIN B-FRAGMENT WITH CELLS - ROLE OF AMINO-TERMINAL AND CARBOXYL-TERMINAL REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; ENTRY; MEMBRANE; MOLECULE; MUTANTS	The B-fragment of diphtheria toxin binds to cell surface receptors and facilitates entry of the enzymatically active A-fragment into the cytosol. The roles of the amino- and carboxyl-terminal regions of the B-fragment in interactions with the cell membrane were studied by measuring specific binding, insertion into membranes at low pH, and formation of cation-selective channels, as well as by toxicity measurements after association with active A-fragment. Deletion of the amino-terminal 12 amino acids of the B-fragment did not affect its ability to bind to receptors and to form ion channels at low pH, whereas both abilities were strongly impaired when one more amino acid (Trp206) was removed. Replacement of the amino-terminal 31 residues with an amphipathic sequence from human apolipoprotein A1 restored receptor binding but not ion channel formation. The binding to cells was virtually abolished when 9 residues were deleted from the carboxyl terminus. Deletion of only 4 residues or extension by 12 residues did not prevent specific binding, but reduced insertion, channel formation, and toxicity. Those deletions that reduced receptor binding ability increased the trypsin sensitivity of the B-fragment. The results indicate that the amino- and carboxyl-terminal regions of diphtheria toxin B-fragment are important for receptor binding, possibly because they contribute to keep the B-fragment in a binding-competent conformation. Small alterations in the carboxyl-terminal end reduced insertion, channel formation, and toxicity more than the ability of the B-fragment to bind to cells.	WA ENGELHARDT MOLEC BIOL INST,MOSCOW,USSR	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	STENMARK, H (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,OSLO 3,NORWAY.		Stenmark, Harald/B-8868-2008					BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; Frankel A. E., 1988, IMMUNOTOXINS; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOTTE P, 1980, J CELL BIOL, V87, P837, DOI 10.1083/jcb.87.3.837; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; OLSNES S, 1989, J BIOL CHEM, V264, P12749; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S, 1991, Semin Cell Biol, V2, P7; PAPPENHEIMER AM, 1972, IMMUNOCHEMISTRY, V9, P891, DOI 10.1016/0019-2791(72)90163-2; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; ROGNE S, 1986, HUM GENET, V72, P68, DOI 10.1007/BF00278820; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; STENMARK H, 1991, MOL MICROBIOL, V5, P595, DOI 10.1111/j.1365-2958.1991.tb00730.x; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021	23	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8957	8962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374382				2022-12-25	WOS:A1992HR85400041
J	BALDWIN, AN; BITLER, CM; WELCHER, AA; SHOOTER, EM				BALDWIN, AN; BITLER, CM; WELCHER, AA; SHOOTER, EM			STUDIES ON THE STRUCTURE AND BINDING-PROPERTIES OF THE CYSTEINE-RICH DOMAIN OF RAT LOW AFFINITY NERVE GROWTH-FACTOR RECEPTOR (P75NGFR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; GLOBULAR-PROTEINS; CRYSTAL-STRUCTURE; BLOOD-COAGULATION; DISTANCE GEOMETRY; EXPRESSION; CELLS; GENE	The binding domain of p75NGFR contains four "repeats" of a 6-cysteine pattern. To test whether these repeats have any structural or functional independence, each repeat has been separately deleted. In each case, deletion led to the loss of most nerve growth factor (NGF) binding activity. The epitopes of two monoclonal antibodies, MC 192 and 271c, could be distinguished, however. Repeat IV was found to be unnecessary for binding MC192, whereas Repeat I was not required for binding 217c. This suggests that either terminal repeat can be removed without loss of native-like structure in the remaining repeats. Trp155 in the fourth repeat forms an essential part of the 217c epitope but is not required for either MC192 or NGF binding. Deletion of the linker region between the membrane-spanning domain and the cysteine-rich domain does not affect the binding of NGF or MC192, and has only a slight, if any, effect on 217c binding. Cyclic permutation of the four repeats failed to yield protein capable of binding NGF or MC192.			BALDWIN, AN (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NINDS NIH HHS [NS042270] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDOERFER KL, 1990, P NATL ACAD SCI USA, V87, P187, DOI 10.1073/pnas.87.1.187; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FERRARI G, 1991, EXP NEUROL, V112, P183, DOI 10.1016/0014-4886(91)90068-N; GOLDENBERG DP, 1983, J MOL BIOL, V165, P407, DOI 10.1016/S0022-2836(83)80265-4; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAX I, 1991, J BIOL CHEM, V266, P13828; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEASE JHB, 1988, BIOCHEMISTRY-US, V27, P8491, DOI 10.1021/bi00422a029; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SQUINTO SP, 1991, CELL, V65, P1; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WRIGHT CS, 1977, J MOL BIOL, V111, P439, DOI 10.1016/S0022-2836(77)80063-6; YAN H, 1991, J BIOL CHEM, V266, P12099; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	53	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8352	8359						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373724				2022-12-25	WOS:A1992HQ18500062
J	LEROUX, C; MAZURE, N; MARTIN, P				LEROUX, C; MAZURE, N; MARTIN, P			MUTATIONS AWAY FROM SPLICE SITE RECOGNITION SEQUENCES MIGHT CIS-MODULATE ALTERNATIVE SPLICING OF GOAT ALPHA-S1-CASEIN TRANSCRIPTS - STRUCTURAL ORGANIZATION OF THE RELEVANT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN MULTIGENE FAMILY; PRE-MESSENGER RNA; COMPLETE NUCLEOTIDE-SEQUENCE; BETA-TROPOMYOSIN GENE; SECONDARY STRUCTURE; NONSENSE MUTATIONS; EXON SEQUENCES; KAPPA-CASEIN; CDNAS; ACID	Alpha(s1)-casein variants F and D, synthesized in goat milk at lower levels than variant A, essentially differ from it by internal deletions of 37 and 11 amino acid residues, respectively. Northern blot analysis of mRNAs encoding alpha(s1)-casein F and A and sequencing of the relevant cloned cDNAs, as well as sequencing of in vitro amplified genomic fragments, revealed multiple alternatively processed transcripts, from the F allele. Although correctly spliced messengers were identified, most of the FmRNAs lacked three exons. There exons, further identified as exons 9, 10, and 11, together encode the 37 amino acid residues present in alpha(s1)-casein variant A but missing in variant F. Exon 9 codes for the sequence present in variant A but deleted in variant D. A single nucleotide deletion in exon 9 and two insertions, 11 and 3 base pairs in length, in the downstream intron, were identified as mutations potentially responsible for the alternative skipping of these 3 exons. From a computer-predicted secondary structure it appeared that the 11-base pair insertion might be involved in base-pairing interactions with the intron 5' splice site which might consequently be less accessible to U1 snRNA. We also report here the complete structural organization of the goat alpha(s1)-casein transcription unit, deduced from polymerase chain reaction experiments. It contains 19 exons scattered within a nucleotide stretch nearly 17-kilobase pairs long.	INRA, GENET BIOCHIM LAB, DOMAINE VILVERT, F-78350 JOUY EN JOSAS, FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Mazure, Nathalie/0000-0003-1350-7161; Leroux, Christine/0000-0001-6835-3978				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BOISNARD M, 1991, EUR J BIOCHEM, V201, P633, DOI 10.1111/j.1432-1033.1991.tb16324.x; BOISNARD M, 1985, BIOCHIMIE, V67, P1043, DOI 10.1016/S0300-9084(85)80299-6; BONSING J, 1988, AUST J BIOL SCI, V41, P527, DOI 10.1071/BI9880527; BRIGNON G, 1989, Protein Sequences and Data Analysis, V2, P181; BRIGNON G, 1990, EUR J BIOCHEM, V193, P237, DOI 10.1111/j.1432-1033.1990.tb19328.x; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; ERSTER SH, 1988, NUCLEIC ACIDS RES, V16, P5999, DOI 10.1093/nar/16.13.5999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAYE P, 1977, BIOCHEM BIOPH RES CO, V79, P903, DOI 10.1016/0006-291X(77)91196-2; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GROSCLAUDE F, 1987, GENET SEL EVOL, V19, P399, DOI 10.1186/1297-9686-19-4-399; GROSCLAUDE F, 1978, ANN GENET SEL ANIM, V10, P313, DOI 10.1186/1297-9686-10-3-313; GRUSBY MJ, 1990, P NATL ACAD SCI USA, V87, P6897, DOI 10.1073/pnas.87.17.6897; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOBBS AA, 1982, NUCLEIC ACIDS RES, V10, P8079, DOI 10.1093/nar/10.24.8079; JONES WK, 1985, J BIOL CHEM, V260, P7042; LEROUX C, 1990, ANIM GENET, V21, P341, DOI 10.1111/j.1365-2052.1990.tb01979.x; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; MAHE MF, 1989, GENET SEL EVOL, V21, P127, DOI 10.1051/gse:19890202; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MCKNIGHT RA, 1989, J DAIRY SCI, V72, P2464, DOI 10.3168/jds.S0022-0302(89)79386-3; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERCIER JC, 1990, GENOME ANALYSIS IN DOMESTIC ANIMALS, P233; MERCIER JC, 1971, EUR J BIOCHEM, V23, P41, DOI 10.1111/j.1432-1033.1971.tb01590.x; MERCIER JC, 1985, BIOCHIMIE, V67, P959, DOI 10.1016/S0300-9084(85)80291-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PROVOT C, 1989, BIOCHIMIE, V71, P827, DOI 10.1016/0300-9084(89)90046-1; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Rosen J. M., 1987, The mammary gland. Development, regulation, and function., P301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART AF, 1984, NUCLEIC ACIDS RES, V12, P3895, DOI 10.1093/nar/12.9.3895; STEWART AF, 1987, MOL BIOL EVOL, V4, P231; Swaisgood H. E., 1982, Developments in Dairy Chemistry, V1, P1; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; YULEE LY, 1986, NUCLEIC ACIDS RES, V14, P1883, DOI 10.1093/nar/14.4.1883; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	50	116	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6147	6157						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372900				2022-12-25	WOS:A1992HK31800066
J	XU, RX; ANTHOLINE, WE; PETERING, DH				XU, RX; ANTHOLINE, WE; PETERING, DH			REACTION OF CO(II)BLEOMYCIN WITH DIOXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BLEOMYCIN; DEOXYRIBONUCLEIC-ACID; ACTIVATED BLEOMYCIN; OXYGEN; DNA; COBALT; SYSTEM; DRUG; O2	The reaction of Co(II)bleomycin with dioxygen has been investigated. Dioxygen binds to the Co(II) complex within the time of mixing according to electron spin resonance and uv-visible spectroscopy and dioxygen analysis. Then, two dioxygenated cobalt centers react, releasing 1 mol of O2 and forming an intermediate characterized by a few highly shifted H-1 NMR resonances and loss of the ESR spectrum. This is thought to be a dioxygen-bridged dimer of cobalt bleomycin molecules. Time-dependent absorbance and dioxygen measurements yield the same second order rate constant for this step of the reaction. According to uv-visible and NMR spectral analysis, the intermediate decays into diamagnetic products in a first order rate process. High performance liquid chromatography and H-1 NMR studies demonstrate that the product contains two bleomycin species of equal concentration. One component is Co(III)bleomycin, designated Form II. The other is the peroxide adduct of Co(III)bleomycin, Form 1, as determined by direct determination of hydrogen peroxide, which is slowly released from the product at low pH. In contrast, hydrogen peroxide is readily detected during the reaction of Co(II)Blm with O2. In isolation, Form I is unstable at pH 7 and is converted within 24 h into a mixture of Form I and Form II.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201; MED COLL WISCONSIN,DEPT RADIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,NATL BIOMED ESR CTR,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Milwaukee; Medical College of Wisconsin; Medical College of Wisconsin					NCI NIH HHS [CA-22184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBEN JO, 1968, BIOCHEMISTRY-US, V7, P624, DOI 10.1021/bi00842a018; ALBERTINI JP, 1982, BIOCHEMISTRY-US, V21, P6777, DOI 10.1021/bi00269a025; BARHAM D, 1972, ANALYST, V97, P142, DOI 10.1039/an9729700142; BARR JR, 1990, J AM CHEM SOC, V112, P4058, DOI 10.1021/ja00166a064; BASOLO F, 1967, MECHANISMS INORGANIC, P158; BURGER RM, 1983, J BIOL CHEM, V258, P1559; BURGER RM, 1979, J BIOL CHEM, V254, P2299; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; BYRNES RW, 1990, CANCER RES, V50, P5275; CHANG CH, 1982, BIOCHEMISTRY-US, V21, P6332, DOI 10.1021/bi00268a001; CHANG CH, 1983, BIOCHEM BIOPH RES CO, V110, P959; CHIKIRA M, 1989, J BIOL CHEM, V264, P21478; FUJII A, 1973, J ANTIBIOT, V26, P396, DOI 10.7164/antibiotics.26.396; JONES RD, 1979, CHEM REV, V79, P139, DOI 10.1021/cr60318a002; NAKAMURA M, 1988, J ANTIBIOT, V41, P638, DOI 10.7164/antibiotics.41.638; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2740, DOI 10.1021/bi00607a007; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2476; SUGIURA Y, 1978, J ANTIBIOT, V31, P1206, DOI 10.7164/antibiotics.31.1206; VOS CM, 1981, J INORG BIOCHEM, V12, P45; 1972, WORTHINGTON ENZYME M, P43	23	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					944	949						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370470				2022-12-25	WOS:A1992GY96000043
J	PIPAON, C; SANTOS, A; PEREZCASTILLO, A				PIPAON, C; SANTOS, A; PEREZCASTILLO, A			Thyroid Hormone Up-regulates NGFI-A Gene Expression in Rat Brain during Development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAINS; GROWTH-FACTORS; RECEPTOR; TRANSCRIPTION; ENCODES; TRIIODOTHYRONINE; PROTEIN	NGFI-A is an immediate-early response gene induced by signals that initiate growth and differentiation. Its mRNA encodes a sequence-specific transcriptional activator possibly implicated in the control of brain developmental processes. Due to the essential role of thyroid hormone for a correct brain development, we have now investigated the possible regulation by 3,5,3'-triiodo-L-thyronine (T3) of NGFI-A gene expression during maturation of the central nervous system. Our results indicate that expression of mRNA encoding NGFI-A transcription factor is about 8-fold decreased in the brain of neonatal hypothyroid rats. No changes were seen when hypothyroidism was induced in adult life. T3 treatment increased NGFI-A mRNA within 1 h, suggesting that thyroid hormone effect is likely to be a direct one. These data indicate a strong regulation by thyroid hormone of the expression of the growth factor inducible gene NGFI-A during brain development, making this gene a suitable model to study T3 action in the early developing nervous system.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC MED,DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid			Santos, Angel/K-3744-2014; Pipaon, Carlos/L-4922-2014; Perez-Castillo, Ana/A-9505-2015	Santos, Angel/0000-0002-7551-8483; Pipaon, Carlos/0000-0002-3851-6710; Perez-Castillo, Ana/0000-0002-2632-5853				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HAN EB, 1976, AM J OBSTET GYNECOL, V125, P949; JUMP DB, 1984, J BIOL CHEM, V259, P2789; Klein RZ., 1980, NEONATAL THYROID SCR, P51; KOENIG MP, 1981, FETAL BRAIN DISORDER, P229; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MELLSTROM B, 1991, IN PRESS MOL ENDOCRI; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; RABIE A, 1973, BRAIN RES, V61, P267, DOI 10.1016/0006-8993(73)90532-5; SAMUELS HH, 1983, MOL BASIS THYROID HO, P35; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; WOLFF EC, 1964, THYROID GLAND, V1, P237; YAFFE BM, 1984, J BIOL CHEM, V259, P6284	27	56	57	2	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					21	23		10.1016/S0021-9258(18)48449-9	http://dx.doi.org/10.1016/S0021-9258(18)48449-9			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370444	hybrid			2022-12-25	WOS:A1992GY43900006
J	DUZIC, E; LANIER, SM				DUZIC, E; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .3. COUPLING OF ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES IN A CELL TYPE-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENYLATE-CYCLASE; CYCLIC-AMP ACCUMULATION; HAMSTER OVARY CELLS; RAT-BRAIN; PHOSPHOLIPASE-C; ADRENERGIC-RECEPTORS; GENERATING SYSTEMS; CALCIUM CHANNELS; ACTIVATION; STIMULATION	A number of diverse signaling pathways can be activated by G-protein coupled receptors. However, the factors involved in selection of a particular transduction pathway by a single receptor are not well understood. We are attempting to address this issue utilizing the alpha2-adrenergic receptor (alpha2-AR) subfamily as a representative model system. In this report, we demonstrate that the cellular response mediated by an alpha2-AR subtype is cell-specific and thus depends on its environment. Receptor coupling to adenylylcyclase was determined following stable expression of the rat alpha2B- and alpha2D-AR subtypes in three functionally distinct cell types (NIH-3T3 fibroblasts, DDT1 MF-2 smooth muscle cells, and the pheochromocytoma cell line PC-12). When the receptor subtype gene is expressed in NIH-3T3 and DDT1 MF-2 cells, receptor activation inhibits basal and forskolin-induced increases in cellular cAMP. However, in PC-12 transfectants the same receptor subtype actually increases basal cAMP and augments the effect of forskolin. Potentiation of the forskolin effect in PC-12 cells is insensitive to pertussis toxin but is blocked by loading the cells with BAPTA (bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid) which minimizes changes in Ca2+i by calcium chelation. These data and the functional demonstration of a Ca2+/calmodulin-sensitive adenylylcyclase in PC-12 but not NIH-3T3 and DDT1MF-2 cells, suggests that the cell-specific effects of epinephrine are due to receptor coupling to both different G-proteins and types of adenylylcyclase.	MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425	Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NINDS NIH HHS [NS-24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROSTROM CO, 1977, J BIOL CHEM, V252, P5677; BROSTROM MA, 1982, BIOCHIM BIOPHYS ACTA, V721, P227, DOI 10.1016/0167-4889(82)90073-8; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CALTABIANO MM, 1990, GENE AMST, V85, P479; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COUPRY I, 1992, J BIOL CHEM, V267, P9852; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; DALY JW, 1982, J NEUROCHEM, V38, P532, DOI 10.1111/j.1471-4159.1982.tb08660.x; DALY JW, 1981, J NEUROSCI, V1, P49, DOI 10.1523/JNEUROSCI.01-01-00049.1981; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P9844; Exton J H, 1987, Kidney Int Suppl, V23, pS68; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GRAHAM RM, 1986, HEART CARDIOVASCULAR, V2, P1059; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES SB, 1991, MOL PHARMACOL, V39, P239; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUBALAK S, 1992, IN PRESS AM J PHYSL; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LeDonne N C Jr, 1980, Ann N Y Acad Sci, V356, P402, DOI 10.1111/j.1749-6632.1980.tb29647.x; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Longenecker GL., 1985, PLATELETS PHYSL PHAR, P159; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL S, 1984, BIOCHEM J, V224, P453, DOI 10.1042/bj2240453; MACNEIL S, 1985, CELL CALCIUM, V6, P213; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MALNOE A, 1982, BIOCHIM BIOPHYS ACTA, V714, P84, DOI 10.1016/0304-4165(82)90129-5; MCCLUE SJ, 1991, MOL PHARMACOL, V40, P627; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MINOCHERHOMJEE AM, 1988, CALMODULIN, P249; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PILC A, 1986, J PHARMACOL EXP THER, V237, P725; PINKASKRAMARSKI R, 1988, FEBS LETT, V239, P174, DOI 10.1016/0014-5793(88)80911-6; POBBINER BF, 1991, MOL PHARMACOL, V40, P156; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TIMMERMANS PBMWM, 1987, CAN J PHYSIOL PHARM, V65, P1649, DOI 10.1139/y87-259; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	69	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24045	24052						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358886				2022-12-25	WOS:A1992JZ23900092
J	BRANDSCH, R; BICHLER, V; SCHMIDT, M; BUCHNER, J				BRANDSCH, R; BICHLER, V; SCHMIDT, M; BUCHNER, J			GROE DEPENDENCE OF REFOLDING AND HOLOENZYME FORMATION OF 6-HYDROXY-D-NICOTINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; ARTHROBACTER-OXIDANS; D-6-HYDROXYNICOTINE OXIDASE; PROTEINS; BINDING; CATALYSTS; PURIFICATION; APOENZYME; FAD	In Escherichia coli cells expressing 6-hydroxy-D-nicotine oxidase (6-HDNO), a flavoprotein with covalently bound FAD, approximately 40% of the polypeptide is in its apoform. We investigated whether in vivo holoenzyme formation was influenced by the association of the apoenzyme with cellular chaperones. Immunoprecipitation of apoenzyme-containing cell extract with protein-A-Separose-bound 6-HDNO- or GroEL-specific antibodies failed to reveal the formation of complexes between these proteins. The limiting factor in holoenzyme formation in vivo appeared to be the intracellular supply of phosphorylated tricarbon compounds (e.g. glycerol-3-P) acting as allosteric effectors in the flavinylation reaction. When holoenzyme formation from purified apo6-HDNO was investigated in vitro, addition of GroEL and GroES to the reaction assays increased the yield of holoenzyme formation. The observed increase in apoenzyme to holoenzyme transition was ATP independent, and the effect of GroE could be simulated by high concentrations of glycerol (40%). Apparently, a nonspecific protein-protein interaction between the GroE proteins and the apo6-HDNO favored holoenzyme formation. The refolding of guanidinium hydrochloride-unfolded holoenzyme, however, was catalyzed by GroEL and GroES in an ATP-dependent reaction. Recovery of the native, enzymatically active, conformation ranged from 30 to 40%. When apo6-HDNO was denatured and refolded, the same dependence on GroE and ATP was observed in the recovery of a conformation able to incorporate FAD and to yield holoenzyme. [C-14] FAD in the refolding assay yielded radioactively labeled 6-HDNO demonstrating the autocatalytical covalent incorporation of FAD into the polypeptide during the folding process.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	University of Regensburg	BRANDSCH, R (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,W-7800 FREIBURG,GERMANY.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BRUHMULLER M, 1972, EUR J BIOCHEM, V29, P143, DOI 10.1111/j.1432-1033.1972.tb01968.x; BRUHMULLER M, 1978, EUR J BIOCHEM, V37, P256; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GODSELL DS, 1991, TRENDS BIOCHS CI, V16, P203; HAMM HH, 1978, EUR J BIOCHEM, V93, P449; HARLOW E, 1988, ANTIBODIES, P425; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAROSSA RA, 1991, MOL MICROBIOL, V5, P529, DOI 10.1111/j.1365-2958.1991.tb00724.x; Maniatis T., 1982, MOL CLONING; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAUCH L, 1990, MOL GEN GENET, V221, P427, DOI 10.1007/BF00259408; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; NAGURSKY H, 1988, EUR J BIOCHEM, V177, P319, DOI 10.1111/j.1432-1033.1988.tb14379.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8	25	21	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20844	20849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356985				2022-12-25	WOS:A1992JT97800054
J	HAINES, DS; SUHADOLNIK, RJ; HUBBELL, HR; GILLESPIE, DH				HAINES, DS; SUHADOLNIK, RJ; HUBBELL, HR; GILLESPIE, DH			CELLULAR AND ENZYMATIC-ACTIVITIES OF A SYNTHETIC HETEROPOLYMER DOUBLE-STRANDED-RNA OF DEFINED SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREATED HELA-CELLS; PROTEIN-SYNTHESIS; 2',5'-OLIGO(A) POLYMERASE; INTERFERON; ACTIVATION; KINASE; PPPA2'P5'A2'P5'A; EXPRESSION; INFECTION; INDUCTION	We have synthesized a novel heteropolymer double-stranded RNA (dsRNA) molecule of defined length and strandedness (dsRNA309) and evaluated its ability to induce cytokine gene expression, activate dsRNA-dependent enzymes, and inhibit both tumor cell growth and virus replication. Unlike the conventionally studied synthetic homopolymer dsRNAs, polyinosinic acid:polycytidylic acid (poly(I-C)) and its mismatched analogue polyinosinic:polycytidylic, uridylic acid (poly(I-C-12,U), dsRNA309 possessed restricted biological activity. dsRNA309 was unable to inhibit tumor cell growth or efficiently induce cytokine (i.e. interferon-beta and interleukin-1-alpha) gene expression. However, dsRNA309 was able to inhibit virus replication and activate dsRNA-dependent intracellular enzymes, 2'-5' oligoadenylate synthetase (2'-5'A synthetase) and the dsRNA-activated inhibitor kinase in in vitro assay systems. Overall, dsRNA309 provided a means for examining the mechanisms governing the dsRNA-regulated antiviral and antiproliferative responses, and studies with dsRNA309 demonstrated that the ability of a synthetic dsRNA to activate dsRNA-dependent intracellular enzymes does not necessarily predict the same gene inducing capacity.	TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	HAINES, DS (corresponding author), HAHNEMANN UNIV, DEPT NEOPLAST DIS, BROAD & VINE ST, PHILADELPHIA, PA 19102 USA.							BAGLIONI C, 1978, NATURE, V273, P684, DOI 10.1038/273684a0; CARTER WA, 1974, SCIENCE, V186, P1172, DOI 10.1126/science.186.4170.1172; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; CORY JG, 1965, BIOCHIM BIOPHYS ACTA, V103, P646, DOI 10.1016/0005-2787(65)90085-7; FARRELL PJ, 1978, P NATL ACAD SCI USA, V75, P5893, DOI 10.1073/pnas.75.12.5893; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GOLDFELD AE, 1989, P NATL ACAD SCI USA, V86, P1490, DOI 10.1073/pnas.86.5.1490; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HUBBELL HR, 1984, CANCER RES, V44, P3252; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MARCUS PI, 1977, NATURE, V266, P815, DOI 10.1038/266815a0; MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401; MINKS MA, 1980, J BIOL CHEM, V255, P6403; MINKS MA, 1979, J BIOL CHEM, V254, P180; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; TORRENCE PF, 1984, HDB EXP PHARM, V71, P233; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	29	7	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18315	18319						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356106				2022-12-25	WOS:A1992JN50200014
J	KRIKOS, A; LAHERTY, CD; DIXIT, VM				KRIKOS, A; LAHERTY, CD; DIXIT, VM			TRANSCRIPTIONAL ACTIVATION OF THE TUMOR-NECROSIS-FACTOR ALPHA-INDUCIBLE ZINC FINGER PROTEIN, A20, IS MEDIATED BY KAPPA-B ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NUCLEAR FACTOR BINDING; LONG TERMINAL REPEAT; THROMBOSPONDIN GENE; ENHANCER ELEMENTS; HUMAN FIBROBLASTS; DNA METHYLATION; INDUCTION; EXPRESSION; SEQUENCE	A20 was first identified as a tumor necrosis factor (TNF) primary response transcript encoding a 790-amino acid protein with a unique zinc finger motif. Recently, A20 was shown to protect cells from TNF-induced cytotoxicity in a variety of cell lines. Nuclear run-on studies previously established that TNF activates A20 at the transcriptional level. To further characterize the mechanism by which TNF activates the A20 gene, we have cloned the A20 5'-flanking sequences and identified TNF-responsive elements within the promoter. The transcription initiation site was mapped by both primer extension and S1 nuclease protection experiments to a position 4.2 kilobases kB upstream of the initiator methionine; the first and second exon were separated by a 3.9-kb intron. Sequences upstream of the transcription start site were 76% GC-rich and contained six Sp1 binding sites and a TATA-like sequence at -29 but lacked a consensus CCAAT site. Transfection of Jurkat T-cells with an array of A20 promoter CAT constructs showed that two kappa-B elements residing at -54 and -66 were required for induction by TNF. Supporting this notion, DNA electrophoretic mobility shift assays using nuclear extracts from unstimulated and TNF-stimulated Jurkat cells demonstrated kappa-B-specific binding of a TNF-activated factor to an end-labeled probe containing the two A20 kappa-B sequences. Finally, evidence obtained from cotransfection experiments showed that A20 negatively regulated its own expression.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE ST,POB 0602,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CELLULAR & MOLEC BIOL PROGRAM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45351] Funding Source: Medline; NIAMS NIH HHS [AR-20557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANISOWICZ A, 1991, J IMMUNOL, V147, P520; ASUBEL FM, 1989, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRUNFELD C, 1990, ADV INTERNAL MED, V35, P44; HERR W, 1991, HORMONAL CONTROL GEN, P25; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KRASNOW SW, 1991, CYTOKINE, V3, P1; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Sambrook J, 1989, MOL CLONING LABORATO; SARMA V, 1992, J IMMUNOL, V148, P3302; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WOLF FW, 1992, J BIOL CHEM, V267, P1317; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	46	373	386	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17971	17976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381359				2022-12-25	WOS:A1992JM22300075
J	WANG, S; DENG, LP; MILNE, RW; TALL, AR				WANG, S; DENG, LP; MILNE, RW; TALL, AR			IDENTIFICATION OF A SEQUENCE WITHIN THE C-TERMINAL-26 AMINO-ACIDS OF CHOLESTERYL ESTER TRANSFER PROTEIN RESPONSIBLE FOR BINDING A NEUTRALIZING MONOCLONAL-ANTIBODY AND NECESSARY FOR NEUTRAL LIPID TRANSFER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-DENSITY LIPOPROTEINS; HUMAN-PLASMA; MUTAGENESIS; CLONING	The cholesteryl ester transfer protein (CETP; 476 amino acids) mediates the transfer of neutral lipids and phospholipids between plasma lipoproteins. Previous studies showed that the epitope of a neutralizing monoclonal antibody (TP2) was located within the C-terminal 26 amino acids (aa) of CETP. To determine possible involvement of this region in lipid transfer activities, we generated six deletion mutants between Arg-451 and Leu-475 by in vitro mutagenesis and expressed mutant proteins in mammalian cells. Only deletion mutants between aa Phe-463 and Leu-475 failed to bind TP2; these mutant proteins were well secreted by cells but showed markedly reduced cholesteryl ester transfer activity. One of the deletion mutants (DELTA-470-475) showed similar reductions in cholesteryl ester and triglyceride transfer activities but normal or increased phospholipid transfer activity. Limited proteolysis of this mutant protein indicated a similar overall folding pattern to the wild-type protein. Thus, aa between Phe-463 and Leu-475 are necessary for binding TP2. Deletions within this sequence selectively impair neutral lipid transfer activity, suggesting a direct involvement in neutral lipid transfer.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV MOLEC MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	Columbia University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022682, R37HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1980, J LIPID RES, V21, P238; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GLOMSET JA, 1968, J LIPID RES, V9, P155; HESLER CB, 1988, J BIOL CHEM, V263, P5020; IHM J, 1982, J LIPID RES, V23, P1328; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON RE, 1982, J LIPID RES, V23, P1058; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; SWENSON TL, 1989, J BIOL CHEM, V264; TALL AR, 1986, J LIPID RES, V27, P361; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019	20	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17487	17490						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381349				2022-12-25	WOS:A1992JM22300003
J	BROOKS, SF; HERGET, T; BROAD, S; ROZENGURT, E				BROOKS, SF; HERGET, T; BROAD, S; ROZENGURT, E			THE EXPRESSION OF 80K/MARCKS, A MAJOR SUBSTRATE OF PROTEIN-KINASE-C (PKC), IS DOWN-REGULATED THROUGH BOTH PKC-DEPENDENT AND PKC-INDEPENDENT PATHWAYS - EFFECTS OF BOMBESIN, PLATELET-DERIVED GROWTH-FACTOR, AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; AMINO-ACID-SEQUENCE; STRUCTURALLY RELATED PEPTIDES; AFFINITY CROSS-LINKING; PHORBOL ESTERS; CYCLIC-AMP; DNA-SYNTHESIS; RAPIDLY STIMULATE; QUIESCENT FIBROBLASTS; CELLULAR SUBSTRATE	We have examined the regulation of expression of 80K/MARCKS, a major and specific protein kinase C (PKC) substrate of Swiss 3T3 fibroblasts. Addition of bombesin (10 nm) to confluent quiescent cultures of these cells induced a dramatic and sustained down-regulation of 80-kDa mRNA and protein levels to a minimum of 5% of control within 8 and 48 h, respectively, without depletion of PKC activity. In contrast, the effect of phorbol 12,13-dibutyrate on 80K/MARCKS mRNA levels was transient, and recovery of these transcripts correlated with the loss of PKC activity. The ability of bombesin to down-regulate 80K/MARCKS mRNA levels was dose-dependent (ED50 0.5 nm) and was abolished by both the specific bombesin antagonist [Leu13-psi(CH2NH),Leu14]bombesin and by prior depletion of PKC. Of a range of agents tested, platelet-derived growth factor (PDGF), but not insulin or Ca2+ ionophore, also down-regulated 80K/MARCKS mRNA to 24% of control within 5 h. Prior down-regulation of PKC abolished the effect of PDGF at a concentration of 7 ng/ml. Surprisingly, at higher doses (25 ng/ml), PDGF induced the down-regulation of 80K/MARCKS mRNA in a PKC-independent manner. Furthermore, elevation of cAMP, either through receptor-mediated mechanisms (e.g. prostaglandin E1) or by direct stimulation of adenylate cyclase (e.g. forskolin), also caused a marked dose-dependent depletion of 80K/MARCKS mRNA levels, which were further reduced by co-administration with cAMP-phosphodiesterase inhibitors. The rate of transcription of the 80K/MARCKS gene was unaltered by treatment of cells with either bombesin, PDGF, or forskolin/1-methyl-3-isobutylxanthine. These results indicate a role for both PKC-dependent and -independent pathways in growth factor-induced down-regulation of 80K/MARCKS expression, through a post-transcriptional mechanism.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BROOKS SF, 1990, FEBS LETT, V268, P291, DOI 10.1016/0014-5793(90)81030-R; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, FEBS LETT, V255, P149, DOI 10.1016/0014-5793(89)81079-8; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HERGET T, 1986, EMBO J, V5, P659, DOI 10.1002/j.1460-2075.1986.tb04264.x; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HIRAI M, 1989, J CELL PHYSIOL, V139, P9, DOI 10.1002/jcp.1041390103; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LINDNER D, 1992, J BIOL CHEM, V267, P24; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, J CELL PHYSIOL, V112, P243, DOI 10.1002/jcp.1041120213; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	64	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14212	14218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378435				2022-12-25	WOS:A1992JD32500066
J	BANEYX, F; GATENBY, AA				BANEYX, F; GATENBY, AA			A MUTATION IN GROEL INTERFERES WITH PROTEIN FOLDING BY REDUCING THE RATE OF DISCHARGE OF SEQUESTERED POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; GENE-PRODUCTS; PURIFICATION; SUPPRESSION; EXPRESSION; EXPORT; ATP	GroEL140, a mutant Escherichia coli chaperonin unable to support bacteriophage lambda-head assembly, was purified to near homogeneity and compared to wild type GroEL (cpn60). GroEL140 exhibited a 1.5-fold lower ATPase activity relative to the wild type protein. The hydrolysis of ATP by both polypeptides was fully inhibited by an excess of ATP-gamma-S and partially inhibited by ADP and 5'-adenylylimidodiphosphate, suggesting that adenine nucleotides display different affinities for the ATP binding site of chaperonins. GroEL140 was more sensitive to trypsin digestion compared to wild type GroEL indicating that the mutation destabilized the conformation of the mutant. The proteolytic susceptibility of both chaperonins was similarly enhanced upon addition of ATP, ADP or non-hydrolyzable ATP analogs, providing evidence (i) of a conformational change in the chaperonin structure which is likely to drive the protein discharge process, and (ii) that hydrolysis of ATP is not required to achieve topological modifications. GroEL140 retained its ability to bind non-native ribulose bisphosphate carboxylase/oxygenase (Rbu-P2-carboxylase), but released bound proteins upon addition of ATP and GroES (cpn10) 6-7-fold less efficiently compared to GroEL. This functional defect was shown to be related to a suboptimal, but not an absence of, interaction with GroES since (i) GroEL140 and GroES were unable to form a complex isolatable by size exclusion chromatography, and (ii) increasing the incubation time or the concentration of GroES enhanced the amount of refolded Rbu-P2-carboxylase discharged from GroEL140-Rbu-P2-carboxylase binary complexes. Pulse-chase experiments involving a double immunoabsorption technique confirmed that Rbu-P2-carboxylase remained associated two times longer with GroEL140 than with GroEL in vivo.	DUPONT CO,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont								BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GATENBY AA, 1981, NATURE, V291, P117, DOI 10.1038/291117a0; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1977, ANAL BIOCHEM, V78, P66, DOI 10.1016/0003-2697(77)90009-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIKI T, 1988, J MOL BIOL, V201, P327, DOI 10.1016/0022-2836(88)90141-6; MORIMOTO R I, 1990, P1; NEIDHARDT FC, 1981, J BACTERIOL, V145, P513, DOI 10.1128/JB.145.1.513-520.1981; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SOMERVILLE CR, 1984, MOL GEN GENET, V193, P214, DOI 10.1007/BF00330670; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1992, IN PRESS BIOCHEMISTR; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VIITANEN PV, 1992, IN PRESS PROTEIN SCI; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	41	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11637	11644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350786				2022-12-25	WOS:A1992HX16900107
J	BANO, M; WORLAND, P; KIDWELL, WR; LIPPMAN, ME; DICKSON, RB				BANO, M; WORLAND, P; KIDWELL, WR; LIPPMAN, ME; DICKSON, RB			RECEPTOR-INDUCED PHOSPHORYLATION BY MAMMARY-DERIVED GROWTH FACTOR-I IN MAMMARY EPITHELIAL-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; HUMAN-MILK; PROLIFERATION; PURIFICATION; FIBROBLASTS; SERUM	Previous work has shown that a mammary-derived growth factor (MDGF1), a human milk-derived, acidic, 62-kDa, N-glycosylated growth factor binds to cell surface receptors and stimulates proliferation of mammary epithelial cells. An 18-amino acid N-terminal partial sequence of the factor did not show any homology to other known growth factors or proteins. Using polyclonal antiserum raised against the synthetic peptide, we demonstrated that conditioned medium prepared from human breast cancer cell lines contains the factor. The antibody could adsorb the biological activity of the factor present in the conditioned medium. Earlier experiments on receptor cross-linking indicated that the receptor was approximately 120-140 kDa. Since tyrosine phosphorylation plays a crucial role in cell proliferation and cell transformation, experiments were conducted to find out whether MDGF1 induces the appearance of phosphotyrosine in MDGF1-receptor-positive MDA-MB 468, MCF-7, and 184A1N4 cell lines compared to receptor-negative lines. Western blot analysis using monoclonal antiphosphotyrosine indicated that MDGF1 induces phosphotyrosine in a 180-185-kDa protein in MDGF1 receptor-positive cell lines. Phosphorylation was not blocked and phosphorylated proteins were not immunoprecipitated by an antibody directed against the binding site of the EGF receptor. Cell membrane fractionation demonstrated that phosphorylation induced by MDGF1 was membrane-associated. The nature of this 180-185-kDa protein and its possible relationship to the MDGF1 receptor are under investigation.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; CELLCO ADV BIOREACTORS INC,GERMANTOWN,MD 20874	Georgetown University								BANO M, 1992, BIOCHEMISTRY-US, V31, P610, DOI 10.1021/bi00117a044; BANO M, 1990, J BIOL CHEM, V265, P1874; BANO M, 1985, J BIOL CHEM, V260, P5745; BANO M, 1983, J BIOL CHEM, V258, P2729; HOLLENBERG MD, 1979, VITAM HORM, V37, P69; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JAMES R, 1984, ANNU REV BIOCHEM, V53, P259; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; Kidwell W. R., 1985, Human lactation. Milk components and methodologies, P209; KIDWELL WR, 1984, CELL CULTURE METHODS, V2, P105; KIDWELL WR, 1980, CONTROL MECHANISMS A, P333; Klagsbrun M., 1984, Growth Maturation Factors, V2, P161; KLAGSBRUN M, 1980, J CELL BIOL, V84, P808, DOI 10.1083/jcb.84.3.808; KLAGSBRUN M, 1978, P NATL ACAD SCI USA, V75, P5057, DOI 10.1073/pnas.75.10.5057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWKO WM, 1981, CANCER RES, V42, P2855; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SERENI A, 1981, CELL BIOL INT REP, V5, P339, DOI 10.1016/0309-1651(81)90003-5; SHING YW, 1984, CELL CULTURE METHODS, V1, P159; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICHA MS, 1979, EXP CELL RES, V124, P181, DOI 10.1016/0014-4827(79)90268-4; WICHA MS, 1980, DEV BIOL, V80, P253, DOI 10.1016/0012-1606(80)90402-9; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10389	10392						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375220				2022-12-25	WOS:A1992HV09000031
J	ZHANG, DE; RABEK, JP; HSIEH, CC; TORRESRAMOS, C; PAPACONSTANTINOU, J				ZHANG, DE; RABEK, JP; HSIEH, CC; TORRESRAMOS, C; PAPACONSTANTINOU, J			FUNCTIONAL-ANALYSIS OF THE MOUSE ALPHA-FETOPROTEIN ENHANCERS AND THEIR SUBFRAGMENTS IN PRIMARY MOUSE HEPATOCYTE CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING SITES; GENE-EXPRESSION; NUCLEAR FACTOR; ALPHA-1-FETOPROTEIN GENE; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; ALBUMIN GENES; C/EBP FAMILY; ELEMENTS; LIVER	We have compared the activities of mouse alpha-fetoprotein (AFP) enhancers I, II, and III with their minimal enhancer fragments (Mers) I, II, and III and with the entire 7-kilobase pair enhancer domain by transient expression assay in primary fetal mouse liver cells. The level of expression directed by the AFP promoter [p(-1009)AFPcat] alone is stimulated at least 10-fold by the entire AFP enhancer domain (-1009 to -6983). Enhancer I can drive the level of chloramphenicol acetyltransferase activity equivalent to that of the entire enhancer domain, whereas the increase in activity by enhancers II and III is significantly lower (1.5-fold). MersI, II, and III all mediate a greater increase in activity than their corresponding enhancer regions. The increase with MerI is 16-fold. Using DNase I protection analyses we identified 3 protein-binding regions in MerI; site Ia binds liver and brain nuclear proteins; site Ib binds liver, kidney, and brain nuclear proteins as well as purified C/EBP; site Ic binds liver and kidney nuclear proteins. Site-specific mutation of Ia, Ib, or Ic showed a 10-25% reduction in chloramphenicol acetyltransferase expression; deletion of the C/EBP-binding site in Ib showed a 45% reduction in activity and mutation of all 3 sites (Ia, Ib, and Ic) resulted in a 75% reduction in activity. Our studies indicate no single trans-acting factor is absolutely essential for enhancer activity, and that the enhancer activity of Merl is mediated via a combinatorial and additive mechanism.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010		NATIONAL CANCER INSTITUTE [R01CA031472] Funding Source: NIH RePORTER; NCI NIH HHS [CA31472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KRUMLAUF R, 1985, MOL CELL BIOL, V5, P1639, DOI 10.1128/MCB.5.7.1639; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MOLNE M, 1989, NUCLEIC ACIDS RES, V17, P3447, DOI 10.1093/nar/17.9.3447; POLIARD A, 1990, J BIOL CHEM, V265, P2137; RABEK JP, 1992, IN PRESS BOCH BIOPHY; Sambrook J, 1989, MOL CLONING LABORATO; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG DE, 1991, J BIOL CHEM, V266, P21179; ZHANG DE, 1990, J CELL BIOL, V11, pA121	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10676	10682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375227				2022-12-25	WOS:A1992HV09000071
J	SILVERMAN, TA; NOGUCHI, M; SAFER, B				SILVERMAN, TA; NOGUCHI, M; SAFER, B			ROLE OF SEQUENCES WITHIN THE 1ST INTRON IN THE REGULATION OF EXPRESSION OF EUKARYOTIC INITIATION FACTOR-2-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIREFLY LUCIFERASE; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSCRIPTION; DNA; IDENTIFICATION; LYMPHOCYTES; ACTIVATION; PROMOTER	Resting human peripheral blood T cells synthesize proteins at very low rates and contain very low levels of eukaryotic initiation factor (eIF) 2-alpha mRNA. Daring mitogenic activation, the level of eIF-2-alpha mRNA increases at least 50-fold, an effect thought to be due primarily to intranuclear stabilization of the primary transcript (Cohen, R. B., Boal, T. R., and Safer, B. (1990) EMBO J. 9, 3831-3837). Analysis of sequences within the first intron revealed a region with homology to the "initiator" (Inr) sequence first described by Smale and Baltimore (Smale, S. T., and Baltimore, D. (1989) Cell 57, 103-113). This Inr element is positioned 450 bases downstream of the eIF-2-alpha promoter and is oriented to generate an overlapping antisense transcript. Deletion or mutation of the Inr element results in a reproducible 5-8-fold increase in the activity of an eIF-2-alpha promoter-driven CAT reporter gene and a corresponding 2.5-fold decrease in activity of an antisense driven luciferase reporter gene in vivo in 293 cells. In vitro transcription analysis also reveals antisense transcripts which depend on an intact Inr element and whose 5' ends map to sequences surrounding the Inr consensus sequence. A potential role for double-stranded RNA generated by these overlapping divergent transcription units in the regulation of eIF-2-alpha gene expression in T cells is suggested.	NHLBI,PROT & RNA BIOSYNTH SECT,MOLEC HEMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BOAL TR, 1991, THESIS G WASHINGTON; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG S, 1989, MOL CELL BIOL, V9, P3679, DOI 10.1128/MCB.9.9.3679; HUMBELIN M, 1989, GENE AMST, V8, P315; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; Sambrook J, 1989, MOL CLONING LABORATO; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; UDEY MC, 1981, J IMMUNOL, V126, P1106; WETTENHALL REH, 1979, BIOCHIM BIOPHYS ACTA, V432, P312; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; [No title captured]	27	37	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9738	9742						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374407				2022-12-25	WOS:A1992HT96500047
J	BERNARDI, P				BERNARDI, P			MODULATION OF THE MITOCHONDRIAL CYCLOSPORINE-A-SENSITIVE PERMEABILITY TRANSITION PORE BY THE PROTON ELECTROCHEMICAL GRADIENT - EVIDENCE THAT THE PORE CAN BE OPENED BY MEMBRANE DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE STRESS; HEART-MITOCHONDRIA; INNER MEMBRANE; CA-2+-DEPENDENT PORE; RUTHENIUM RED; CALCIUM; PHOSPHOLIPASE-A2; PURIFICATION; INHIBITION	This paper reports an investigation on the relationship between the proton electrochemical gradient (DELTA-mu(H+)) and the cyclosporin A-sensitive permeability transition pore (PTP) in rat liver mitochondria. Using the SH group cross-linker phenylarsine oxide as the inducer, we show that both matrix pH and the membrane potential can modulate the process of PTP induction independently of Ca2+. We find that membrane depolarization induces the PTP per se when pH(i) is above 7.0, while at acidic matrix pH values PTP induction is effectively prevented. Since Ca2+ uptake leads to major modifications of the DELTA-mu(H+) (i.e. matrix alkalinization and membrane depolarization), we have explored the possibility that the Ca2+-induced changes of the DELTA-mu(H+) may contribute to PTP induction by Ca2+. Our data in mitochondria treated with Ca2+ plus N-ethylmaleimide and Ca2+ plus phosphate show that membrane depolarization is a powerful inducer of the PTP. Taken together, our observations indicate that the PTP can be controlled directly by the DELTA-mu(H+) both in the absence and presence of Ca2+, and suggest that a collapse of the membrane potential may be the cause rather than the consequence of PTP induction under many experimental conditions. Thus, many inducers may converge on dissipation of the membrane potential component of the DELTA-mu(H+) by a variety of mechanisms.	UNIV PADUA, INST GEN PATHOL, BIOPHYS & MEMBRANE BIOL, I-35121 PADUA, ITALY	University of Padua	BERNARDI, P (corresponding author), UNIV PADUA, SCH MED, CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736				ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; AZZONE GF, 1984, CURR TOP BIOENERG, V13, P1; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V936, P139, DOI 10.1016/0005-2728(88)90261-7; CHAVEZ E, 1988, J BIOL CHEM, V263, P3582; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FLETCHER JM, 1961, J CHEM SOC, P2000, DOI 10.1039/jr9610002000; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; HUNTER FE, 1955, J BIOL CHEM, V216, P357; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LEQUOC K, 1982, ARCH BIOCHEM BIOPHYS, V216, P639, DOI 10.1016/0003-9861(82)90254-5; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; Siliprandi N, 1978, FUNCTIONS GLUTATHION, P139; STONER HB, 1973, J PHYSIOL-LONDON, V232, P285, DOI 10.1113/jphysiol.1973.sp010270; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZURINI M, 1981, EUR J BIOCHEM, V119, P517, DOI 10.1111/j.1432-1033.1981.tb05638.x	42	397	406	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8834	8839						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374381				2022-12-25	WOS:A1992HR85400023
J	THOMPSON, DB; SOMMERCORN, J				THOMPSON, DB; SOMMERCORN, J			USE OF A MULTIPLE S1 NUCLEASE PROTECTION ASSAY TO MONITOR CHANGES IN RNA LEVELS FOR TYPE-1 PHOSPHATASE AND SEVERAL PROTOONCOGENES IN RESPONSE TO INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; GENE-EXPRESSION; MESSENGER-RNA; OLIGONUCLEOTIDE PROBES; NUCLEOTIDE-SEQUENCE; HEPATOMA-CELLS; FOS-PROTEIN; TRANSCRIPTION; LOCALIZATION; CLONING	Changes in insulin-regulated gene expression occur in a time- and tissue-dependent fashion. To monitor these changes we have adapted the S1 nuclease protection assay to allow simultaneous estimation of multiple RNA species in a single sample by using synthetic oligonucleotides of various lengths as probes for specific RNA species, which can then be resolved by electrophoresis. The multiple S1 nuclease protection assay was used to assess the influence of insulin on the RNA concentrations of 12 different genes in human skeletal muscle. Estimates obtained by this assay were comparable with those obtained by Northern analysis. RNA levels for proto-oncogene c-src displayed a transient 4-fold increase, whereas RNA levels for type 1 protein phosphatase were suppressed by 50% during the same time period. RNAs corresponding to known insulin-responsive genes such as c-fos, c-myc, c-Ha-ras, and c-src displayed rapid and transient 2-4-fold increases between 30 and 60 min as detected by either Northern analysis or the multiple S1 nuclease protection assay. In addition, RNA levels for the insulin receptor, Glut-4, Glut-3, and c-jun were apparently unaffected by exposure of the cells to insulin.			THOMPSON, DB (corresponding author), NIDDKD,CLIN DIABET & NUTR SECT,PHOENIX,AZ 85016, USA.							BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BECK AJ, 1977, CELL, V12, P721; BECKER-ANDRE M, 1991, Methods in Molecular and Cellular Biology, V2, P189; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1989, J BIOL CHEM, V264, P21435; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COUTLEE F, 1990, J BIOL CHEM, V265, P11601; COVERA S, 1991, J BIOL CHEM, V266, P9271; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GAI XX, 1989, ONCOGENE RES, V5, P111; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HANES BD, 1985, NUCLEIC ACID HYBRIDI; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HENDERSON GS, 1991, BIOTECHNIQUES, V10, P190; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KELLER GH, 1989, DNA PROBES, P1; KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MOORE PS, 1989, ARCH BIOCHEM BIOPHYS, V275, P486, DOI 10.1016/0003-9861(89)90395-0; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; Nei M., 1983, P165; Nei M, 1987, MOL EVOLUTIONARY GEN, P254, DOI [10.7312/nei-92038, DOI 10.7312/NEI-92038]; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Sharp P A, 1980, Methods Enzymol, V65, P750; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TORCZYNSKI RM, 1985, DNA-J MOLEC CELL BIO, V4, P283, DOI 10.1089/dna.1985.4.283; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Vogt V M, 1980, Methods Enzymol, V65, P248; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WOOD WI, 1987, METHOD ENZYMOL, V152, P443	53	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5921	5926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372896				2022-12-25	WOS:A1992HK31800034
J	FESCHENKO, MS; ZVARITCH, EI; HOFMANN, F; SHAKHPARONOV, MI; MODYANOV, NN; VORHERR, T; CARAFOLI, E				FESCHENKO, MS; ZVARITCH, EI; HOFMANN, F; SHAKHPARONOV, MI; MODYANOV, NN; VORHERR, T; CARAFOLI, E			A MONOCLONAL-ANTIBODY RECOGNIZES AN EPITOPE IN THE 1ST EXTRACELLULAR LOOP OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; AMINO-ACID SEQUENCE; CA-2+ PUMP; SARCOPLASMIC-RETICULUM; ERYTHROCYTE-MEMBRANE; FUNCTIONAL DOMAINS; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; CALCIUM-PUMP	A monoclonal antibody against the human erythrocyte Ca2+ pump (1E4) reacted with the enzyme in intact erythrocytes. Using trypsinized preparations of the pump the antibody only reacted with the N-terminal fragments of 33.5 and 35 kDa. The fragments span from the N terminus (35 kDa) or from residue 19 (33.5 kDa) to residue 314 of the hPMCA4 isoform of the pump. Exhaustive degradation with a number of agents produced smaller peptides which reacted with the antibody. Sequencing analysis on two chymotryptic fragments of 8.8 and 13.5 kDa identified the epitope in an approximately 80-residue domain beginning with Gly-81. Two peptides corresponding to the putative extramembrane portions of this region of the pump were synthesized. The antibody reacted with one of them, spanning residues Phe-121 to Gly-152 and containing the first putative external loop of the pump. Peptides corresponding to overlapping portions of this peptide were synthesized, leading to the location of the epitope in a 13-residue sequence (Glu-130 to Glu-142) in the first predicted extracellular loop (Verma, A. K., Filoteo, A. G., Stanford, D. R., Wieben, E. D., Strehler, E. E., Fischer, R., Heim, R., Vogel, G., Mathews, S., Strehler-Page, M-A., James, P., Vorherr, T., Krebs, J., Penniston, J. T., and Carafoli, E. (1988) J. Biol. Chem. 263, 14152-14159).	SWISS FED INST TECHNOL,BIOCHEM LAB,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND; MM SHEMYAKIN BIOORGAN CHEM INST,MOSCOW 117871,USSR	ETH Zurich; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BEATTY JD, 1987, J IMMUNOL METHODS, V100, P161, DOI 10.1016/0022-1759(87)90186-4; BEATTY JD, 1987, J IMMUNOL METHODS, V100, P173, DOI 10.1016/0022-1759(87)90187-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARIDE AJ, 1988, BIOCHEM J, V255, P663; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DESRGROTH SF, 1970, J IMMUNOL METHODS, V35, P1; DIANO M, 1987, ANAL BIOCHEM, V166, P224, DOI 10.1016/0003-2697(87)90568-9; ENGVALL E, 1972, J IMMUNOL, V109, P129; FESCHENKO MS, 1991, IN PRESS BIOL MEMBRA; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; GREEB J, 1989, J BIOL CHEM, V264, P18569; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHLER G, 1981, IMMUNOLOGICAL METHOD, P296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NIGGLI V, 1981, J BIOL CHEM, V256, P395; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; SACHS G, 1989, J BIOENERG BIOMEMBR, V21, P573, DOI 10.1007/BF00808114; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; VRMA AK, 1988, J BIOL CHEM, V263, P14152; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4097	4101						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371283				2022-12-25	WOS:A1992HE60700079
J	NAKAJIMA, Y; TSUCHIDA, K; NEGISHI, M; ITO, S; NAKANISHI, S				NAKAJIMA, Y; TSUCHIDA, K; NEGISHI, M; ITO, S; NAKANISHI, S			DIRECT LINKAGE OF 3 TACHYKININ RECEPTORS TO STIMULATION OF BOTH PHOSPHATIDYLINOSITOL HYDROLYSIS AND CYCLIC-AMP CASCADES IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; MOLECULAR CHARACTERIZATION; ADENYLATE-CYCLASE; PHOSPHOINOSITIDE METABOLISM; INOSITOL PHOSPHOLIPIDS; MAMMALIAN TACHYKININ; FUNCTIONAL CDNA; MESSENGER-RNAS; P RECEPTOR; FIBROBLASTS	The mammalian tachykinin system consists of three distinct peptides, substance P, substance K, and neuromedin K, and possesses three corresponding receptors. In this investigation we examined intracellular signal transduction of the individual tachykinin receptors by transfection and stable expression of these receptor cDNAs in Chinese hamster ovary cells. The three receptors commonly showed a rapid and marked stimulation in both phosphatidylinositol (PI) hydrolysis and cyclic AMP formation in response to tachykinin interaction. Direct linkage of the three receptors to both phospholipase C and adenylate cyclase was evidenced by the finding that tachykinin, added together with GTP, activated these enzyme activities in membrane preparations derived from tachykinin receptor-expressing cells. The stimulation of cyclic AMP formation was less efficient than that of PI hydrolysis in receptor-expressing cells as well as their membrane preparations (about 1 order of magnitude difference in the effective peptide concentrations). However, the stimulatory responses of the PI hydrolysis and cyclic AMP formation in both receptor-expressing cells and their membrane preparations were induced in complete agreement with the tachykinin binding selectivity of each subtype of the receptors. This investigation demonstrated unequivocally that the tachykinin receptors have the potential to couple directly to both phospholipase C and adenylate cyclase and to stimulate PI hydrolysis and cyclic AMP formation.	OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA,OSAKA 565,JAPAN		NAKAJIMA, Y (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; ERSPAMER CF, 1980, N-S ARCH PHARMACOL, V311, P61; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEY MR, 1980, MOL PHARMACOL, V18, P78; HENDERSON AK, 1990, LIFE SCI, V47, pPL7, DOI 10.1016/0024-3205(90)90329-P; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; LANIYONU A, 1988, FEBS LETT, V240, P186, DOI 10.1016/0014-5793(88)80365-X; LIPSKY JJ, 1982, J PHARMACOL EXP THER, V220, P287; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NAWA H, 1984, LIFE SCI, V34, P1153, DOI 10.1016/0024-3205(84)90087-0; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; SASAI Y, 1989, BIOCHEM BIOPH RES CO, V165, P695, DOI 10.1016/S0006-291X(89)80022-1; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SUGAMA K, 1989, BIOCHIM BIOPHYS ACTA, V1011, P75, DOI 10.1016/0167-4889(89)90081-5; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; UHING RJ, 1986, J BIOL CHEM, V261, P2140; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANGIERSBERGEN PLM, 1991, P NATL ACAD SCI USA, V88, P1661, DOI 10.1073/pnas.88.5.1661; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WATSON SP, 1984, BIOCHEM PHARMACOL, V33, P3733, DOI 10.1016/0006-2952(84)90033-9; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMASHITA K, 1983, LIFE SCI, V32, P2163, DOI 10.1016/0024-3205(83)90106-6; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	34	271	284	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2437	2442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370820				2022-12-25	WOS:A1992HB53200051
J	SUGAWARA, E; NIKAIDO, H				SUGAWARA, E; NIKAIDO, H			PORE-FORMING ACTIVITY OF OMPA PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE-PROTEIN; CELL-ENVELOPE MEMBRANE; PSEUDOMONAS-AERUGINOSA; TRANSPORT MUTANTS; DODECYL-SULFATE; MAJOR PROTEINS; K-12; CHANNELS; PERMEABILITY; PURIFICATION	Escherichia coli outer membrane protein OmpA was purified to homogeneity, as a monomer, from a K12 derivative deficient in both OmpF and OmpC porins. When proteoliposomes reconstituted from the purified OmpA, phospholipids, and lithium dodecyl sulfate were tested for permeability to small molecules by osmotic swelling, it was found that OmpA produced apparently nonspecific diffusion channels that allowed the penetration of various solutes. The pore-forming activity was destroyed by the heat denaturation of the OmpA protein, and the use of an OmpA-deficient mutant showed that the activity was not caused by copurifying contaminants. The size of the OmpA channel, estimated by comparison of diffusion rates of solutes of different sizes, was rather similar to that of E. coli OmpF and OmpC porins, i.e. about 1 nm in diameter. The rate of penetration of L-arabinose caused by a given amount of OmpA protein, however, was about a hundredfold lower than the rate produced by the same amount of E. coli OmpF porin. The addition of large amounts of lithium dodecyl sulfate to the reconstitution mixture increased the permeability through the OmpA channel, apparently by facilitating the correct insertion of OmpA into the bilayer.			SUGAWARA, E (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS JC, 1985, J BACTERIOL, V161, P484, DOI 10.1128/JB.161.2.484-492.1985; BAVOIL P, 1977, MOL GEN GENET, V158, P23, DOI 10.1007/BF00455116; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; DUCHENE M, 1988, J BACTERIOL, V170, P155, DOI 10.1128/jb.170.1.155-162.1988; EYTAN GD, 1976, J BIOL CHEM, V251, P6831; FLAMMANN HT, 1984, J BACTERIOL, V159, P410, DOI 10.1128/JB.159.1.410-412.1984; GOTOH N, 1989, J BACTERIOL, V171, P983, DOI 10.1128/jb.171.2.983-990.1989; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; KLOSE M, 1988, J BIOL CHEM, V263, P13297; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MANNING PA, 1977, J MOL BIOL, V116, P285, DOI 10.1016/0022-2836(77)90217-0; MANNING PA, 1976, J BACTERIOL, V127, P1081; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; NAKAE T, 1976, J BIOL CHEM, V251, P2176; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; NIKAIDO H, 1977, BIOCHEM BIOPH RES CO, V76, P324, DOI 10.1016/0006-291X(77)90728-8; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Nikaido H., 1986, BACTERIA, V10, P145; SCHNAITMAN CA, 1984, J BACTERIOL, V159, P555, DOI 10.1128/JB.159.2.555-563.1984; SCHWEIZER M, 1977, J BACTERIOL, V129, P1651, DOI 10.1128/JB.129.3.1651-1652.1977; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SONNTAG I, 1978, J BACTERIOL, V136, P280, DOI 10.1128/JB.136.1.280-285.1978; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; VANALPHEN L, 1977, FEBS LETT, V75, P285, DOI 10.1016/0014-5793(77)80104-X; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WOODRUFF WA, 1989, J BACTERIOL, V171, P3304, DOI 10.1128/jb.171.6.3304-3309.1989; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	32	189	196	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2507	2511						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370823				2022-12-25	WOS:A1992HB53200061
J	DIJESO, B; LIGUORO, D; FERRANTI, P; MARINACCIO, M; ACQUAVIVA, R; FORMISANO, S; CONSIGLIO, E				DIJESO, B; LIGUORO, D; FERRANTI, P; MARINACCIO, M; ACQUAVIVA, R; FORMISANO, S; CONSIGLIO, E			MODULATION OF THE CARBOHYDRATE MOIETY OF THYROGLOBULIN BY THYROTROPIN AND CALCIUM IN FISHER RAT-THYROID LINE-5 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI FOREST VIRUS; CHLORIDE SLOWS TRANSPORT; YEAST SECRETORY PATHWAY; VIRAL MEMBRANE-PROTEINS; GOLGI-COMPLEX; KIDNEY-CELLS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; FOLLICLES; MONENSIN	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days. Such a TSH effect is much less or not evident when secreted thyroglobulin is digested with peptide N-glycohydrolase F or when intracellular thyroglobulin is compared. Intracellular thyroglobulin migrates faster than thyroglobulin secreted either in the presence or in the absence of TSH. Evaluation of the mannose and galactose content of thyroglobulin demonstrates that intracellular thyroglobulin has more mannose and less galactose than extracellular thyroglobulin; it also shows that TSH decreases the mannose content of thyroglobulin while increasing its galactose content. Bio-Gel P6 chromatography shows that TSH increases the complex type carbohydrate chains while decreasing the high mannose chains in the secreted thyroglobulin. High mannose type oligosaccarides were characterized by fast atom bombardment-mass spectrometry analysis. Treatment with the calcium ionophore A23187 (5-mu-M) of FRTL-5 cells cultured with or without TSH causes the appearance of a "fast" migrating form of thyroglobulinin in the culture medium. Bio-Gel P6 chromatography shows that A23187 causes a dramatic decrease of the complex carbohydrate chains of the secreted thyroglobulin.	CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC LUIGI CALIFANO,I-80131 NAPLES,ITALY; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; CNR,SERV SPETTROMETRIA,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			Ferranti, Pasquale/ABF-8111-2021	di jeso, bruno/0000-0001-8713-5984; FERRANTI, Pasquale/0000-0002-6250-6512				Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATLA CAD SCI US, V77, P4355; ARIMA T, 1972, J BIOL CHEM, V247, P1825; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1987, J BIOL CHEM, V262, P10304; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORTESE F, 1976, EUR J BIOCHEM, V68, P121, DOI 10.1111/j.1432-1033.1976.tb10770.x; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DUNN JT, 1975, J BIOL CHEM, V250, P5801; EGGO MC, 1982, ENDOCRINOLOGY, V111, P1663, DOI 10.1210/endo-111-5-1663; EKHLOM R, 1981, MOL CELL ENDOCRINOL, V24, P141; FONTANA S, 1980, AUTOIMMUNE ASPECTS E, P147; FRANC JL, 1984, BIOCHEM BIOPH RES CO, V118, P910, DOI 10.1016/0006-291X(84)91481-5; FUKUDA M, 1971, BIOCHEM J, V123, P407, DOI 10.1042/bj1230407; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLIN KS, 1988, J BIOL CHEM, V263, P11478; MATLIN KS, 1986, J BIOL CHEM, V261, P5172; MULLIN BR, 1977, ENDOCRINOLOGY, V100, P351, DOI 10.1210/endo-100-2-351; NITSCH L, 1980, P NATL ACAD SCI-BIOL, V77, P472, DOI 10.1073/pnas.77.1.472; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ODA K, 1988, J BIOL CHEM, V263, P12576; RANI CSS, 1985, BIOCHEM BIOPH RES CO, V131, P1041, DOI 10.1016/0006-291X(85)90195-0; RING P, 1987, CELL TISSUE RES, V250, P149, DOI 10.1007/BF00214666; RING P, 1987, CELL TISSUE RES, V248, P153, DOI 10.1007/BF01239976; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; RONIN C, 1986, J BIOL CHEM, V261, P7287; RONIN C, 1976, BIOCHIM BIOPHYS ACTA, V428, P445, DOI 10.1016/0304-4165(76)90053-2; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHNEIDE.AB, 1971, J BIOL CHEM, V246, P6592; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SHIFRIN S, 1983, J BIOL CHEM, V258, P3780; SPIRO MJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P35, DOI 10.1016/0003-9861(80)90403-8; SPIRO RG, 1965, J BIOL CHEM, V240, P1603; THORENS B, 1986, NATURE, V321, P618, DOI 10.1038/321618a0	46	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1938	1944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370485				2022-12-25	WOS:A1992HA48500083
J	MORLEY, GP; CALLAGHAN, JM; ROSE, JB; TOH, BH; GLEESON, PA; VANDRIEL, IR				MORLEY, GP; CALLAGHAN, JM; ROSE, JB; TOH, BH; GLEESON, PA; VANDRIEL, IR			THE MOUSE GASTRIC H,K-ATPASE BETA-SUBUNIT - GENE STRUCTURE AND COORDINATE EXPRESSION WITH THE ALPHA-SUBUNIT DURING ONTOGENY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE GASTRITIS; H+/K+-ATPASE; ADHESION MOLECULE; PERNICIOUS-ANEMIA; GLIA AMOG; NA,K-ATPASE; RAT; CLONING; STOMACH; DNA	The gastric H,K-ATPase (EC 3.6.1.3) is responsible for acid secretion into the stomach and is composed of two subunits, alpha and beta. The structure of the gene encoding the mouse beta-subunit and the expression of both subunits during ontogeny are reported. The gene spans approximately 12 kilobase pairs and contains 7 exons. The positions at which introns interrupt the coding regions of the mouse H,K-ATPase beta-subunit and mouse Na,K-ATPase (EC 3.6.1.37) beta-2 subunit genes are identical. The alternative beta-subunit isoform of the Na,K-ATPase, beta-1, has a similar but not identical gene structure. Primer extension and S1 nuclease analysis of RNA isolated from mouse stomachs aged between 2 and 25 days indicated that major transcription-initiation sites are between 22 and 25 base pairs 5' of the translation initiation site at all ages. The expression of the H,K-ATPase alpha and beta-subunit genes during ontogeny (day 1-40) was found to be co-ordinated. Protein levels of both the ATPase alpha and beta-subunits were very low until day 15 and then increased to adult levels by day 30. In any mucosal cell throughout ontogeny, expression. of the beta-subunit gene invariably coincided with the expression of the alpha-subunit gene. Cells detected by anti-H,K-ATPase beta-subunit antibodies in sections from 10- and 30-day-old mice all had typical morphology of parietal cells and were arranged in glandular structures. Co-ordinate expression of the two subunit genes suggest that the regulatory mechanisms will be similar and that the beta-subunit may be required for localization and function of the catalytic alpha-subunit.	MONASH UNIV, ALFRED HOSP, SCH MED, DEPT PATHOL & IMMUNOL, MELBOURNE, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503; van Driel, Ian/0000-0001-5371-120X				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; CALLAGHAN JM, 1990, J CELL SCI, V95, P563; CROTHERS JM, 1990, AM J PJHYSL, V259, pG918; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALLER LD, 1985, ENZYMES BIOL MEMBR, V3, P431; FORTE JG, 1989, HDB PHYSL, V3, P207; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLEESON PA, 1991, IMMUNOL TODAY, V12, P233, DOI 10.1016/0167-5699(91)90036-S; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GOLDKORN I, 1989, J BIOL CHEM, V264, P18768; HELANDER HF, 1969, GASTROENTEROLOGY, V56, P35; HELANDER HF, 1989, SCAND J GASTROENTERO, V24, P863, DOI 10.3109/00365528909089227; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HERVATIN F, 1989, BIOCHIM BIOPHYS ACTA, V985, P320, DOI 10.1016/0005-2736(89)90419-7; HERVATIN F, 1987, AM J PHYSIOL, V252, pG28, DOI 10.1152/ajpgi.1987.252.1.G28; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JOHNSON LR, 1985, ANNU REV PHYSIOL, V47, P199; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES CM, 1991, GASTROENTEROLOGY, V101, P287, DOI 10.1016/0016-5085(91)90002-3; JONES CM, 1991, EUR J BIOCHEM, V197, P49, DOI 10.1111/j.1432-1033.1991.tb15881.x; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAGYAR JP, 1990, NUCLEIC ACIDS RES, V18, P6695, DOI 10.1093/nar/18.22.6695; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MORI Y, 1989, GASTROENTEROLOGY, V97, P364, DOI 10.1016/0016-5085(89)90072-3; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Sambrook J, 1989, MOL CLONING LABORATO; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; THEAN ET, 1989, IMMUNOL CELL BIOL, V67, P41, DOI 10.1038/icb.1989.5; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	51	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1165	1174						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370459				2022-12-25	WOS:A1992GY96000077
J	REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW				REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW			VARIABLE PATTERN OF JUN AND FOS GENE-EXPRESSION IN DIFFERENT HEMATOPOIETIC-CELL LINES DURING INTERLEUKIN 3-INDUCED ENTRY INTO THE CELL-CYCLE	ONCOGENE			English	Article								Jun (c-jun, jun-B and jun-D) and fos (c-fos, fos-B and fra) proteins dimerize to form the family of AP-1 transcriptional activators. If each dimer exhibits unique transactivating properties, then any phenotypic change should show a characteristic pattern of jun and fos expression. To test this hypothesis we have assessed jun and fos RNA expression after stimulation of the factor-dependent cell lines 32D and FDCP1. These hematopoietic progenitor lines become quiescent in G0/G1 after interleukin 3 (IL-3) deprivation, and upon stimulation synchronously enter the cell cycle. 32D cells respond to IL-3 with rapid induction of jun-B and c-fos, followed by induction of jun-D and fra-1, but no rise in c-jun expression. FDCP1 cells show a very different pattern, with induction of c-jun, jun-D and fra-1. To investigate the response of a single cell line to different physiological stimuli we used a 32D subclone engineered to respond to colony stimulating factor 1 (CSF-1). This subclone showed identical induction of jun and fos after stimulation with either CSF-1 or IL-3. The conservation of response of a single cell line, but the disparate patterns demonstrated by different cells, suggest a fundamental difference in both the regulation and function of the fos/jun complexes in these cells.	NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HASTHORPE S, 1988, INT J CELL CLONING, V6, P30, DOI 10.1002/stem.5530060105; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO JY, 1990, BLOOD, V75, P1780; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MATSUI M, 1990, ONCOGENE, V5, P249; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					43	50						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371337				2022-12-25	WOS:A1992HC22700006
J	MCMAHON, HT; FORAN, P; DOLLY, JO; VERHAGE, M; WIEGANT, VM; NICHOLLS, DG				MCMAHON, HT; FORAN, P; DOLLY, JO; VERHAGE, M; WIEGANT, VM; NICHOLLS, DG			TETANUS TOXIN AND BOTULINUM TOXINS TYPE-A AND TYPE-B INHIBIT GLUTAMATE, GAMMA-AMINOBUTYRIC-ACID, ASPARTATE, AND MET-ENKEPHALIN RELEASE FROM SYNAPTOSOMES - CLUES TO THE LOCUS OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; NEUROTOXIN TYPE-A; PROTEIN KINASE-C; PERMEABILIZED CHROMAFFIN CELLS; CEREBRAL CORTICAL SYNAPTOSOMES; CYTOSOLIC FREE CA-2+; LIGHT CHAIN; CLOSTRIDIAL NEUROTOXINS; ACETYLCHOLINE-RELEASE; TRANSMITTER RELEASE	Tetanus toxin (100 nM) when preincubated with guinea pig cerebrocortical synaptosomes for 45 min reduces the final extent of the KCl-evoked, Ca2+-dependent, glutamate transmitter release to 30% of non-intoxicated controls. Similarly, 100 nM Botulinum neurotoxins, types A and B, preincubated for 90 min inhibit release to 45-60% of non-intoxicated controls. The toxins preferentially attenuate a slow phase of KCl-evoked glutamate release which may be associated with synaptic vesicle mobilization. Tetanus toxin additionally inhibits the release of aspartate, gamma-aminobutyric acid and met-enkephalin from the same preparation. Since amino acids and neuropeptides are released by distinct mechanisms, this indicates that the toxin affects a step common to both exocytotic pathways. When Ba2+ (which does not interact with calmodulin) is substituted for Ca2+, the control KCl-evoked release of each transmitter is unaffected and tetanus toxin is still inhibitory. Taken together these results implicate a calmodulin-independent locus (or loci) of action common to small- and large-dense-core vesicles and associated with vesicle transport.	UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; UNIV UTRECHT, RUDOLF MAGNUS INST PHARMACOL, 3508 TC UTRECHT, NETHERLANDS	University of Dundee; Imperial College London; Utrecht University			NICHOLLS, DAVID G/K-4300-2012; Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; verhage, matthijs/0000-0002-6085-7503	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILERA J, 1990, FEBS LETT, V263, P61, DOI 10.1016/0014-5793(90)80705-N; AGUILERA J, 1990, J NEUROCHEM, V54, P339, DOI 10.1111/j.1471-4159.1990.tb13319.x; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ASHTON AC, 1990, TOXICON, V28, P963, DOI 10.1016/0041-0101(90)90025-3; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; ASHTON AC, 1991, J NEUROCHEM, V56, P827, DOI 10.1111/j.1471-4159.1991.tb01998.x; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CONSIDINE RV, 1990, TOXICON, V28, P13, DOI 10.1016/0041-0101(90)90002-O; DASGUPTA BR, 1988, BIOCHIMIE, V70, P811, DOI 10.1016/0300-9084(88)90111-3; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EVANS DM, 1986, EUR J BIOCHEM, V154, P409, DOI 10.1111/j.1432-1033.1986.tb09413.x; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; FISHMAN PS, 1987, BRAIN RES, V406, P275, DOI 10.1016/0006-8993(87)90792-X; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT, P1; GREENGARD P, 1987, MOL NEUROBIOL, V1, P82; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HALPERN JL, 1990, J NEUROCHEM, V55, P2072, DOI 10.1111/j.1471-4159.1990.tb05797.x; HILGER GA, 1989, FEBS LETT, V242, P245; JANICKI PK, 1983, J NEUROCHEM, V41, P395, DOI 10.1111/j.1471-4159.1983.tb04755.x; KAUPPINEN RA, 1986, EUR J BIOCHEM, V158, P159, DOI 10.1111/j.1432-1033.1986.tb09733.x; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LAZAROVICI P, 1989, FEBS LETT, V253, P121, DOI 10.1016/0014-5793(89)80943-3; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; MATTEOLI M, 1989, CELL BIOL INT REP, V13, P981, DOI 10.1016/0309-1651(89)90014-3; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; PARTON RG, 1987, J NEUROCHEM, V49, P1057; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; POULAIN B, 1991, J BIOL CHEM, V266, P9580; RABASSEDA X, 1988, TOXICON, V26, P329, DOI 10.1016/0041-0101(88)90001-3; SANCHEZPRIETO J, 1987, J NEUROCHEM, V49, P58, DOI 10.1111/j.1471-4159.1987.tb03394.x; SANCHEZPRIETO J, 1987, EUR J BIOCHEM, V165, P675, DOI 10.1111/j.1432-1033.1987.tb11494.x; SANDBERG K, 1989, J NEUROSCI, V9, P3946; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TSE CK, 1982, EUR J BIOCHEM, V122, P493; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; VERHAGE M, 1992, IN PRESS BRAIN RES; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]	60	237	239	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21338	21343						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356988				2022-12-25	WOS:A1992JV01100015
J	BRUGGEMANN, EP; CURRIER, SJ; GOTTESMAN, MM; PASTAN, I				BRUGGEMANN, EP; CURRIER, SJ; GOTTESMAN, MM; PASTAN, I			CHARACTERIZATION OF THE AZIDOPINE AND VINBLASTINE BINDING-SITE OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; BACTERIAL TRANSPORT PROTEINS; DEPENDENT TRANSPORT; PHOTOAFFINITY PROBE; MEMBRANE-VESICLES; CYSTIC-FIBROSIS; H-3 AZIDOPINE; DRUG-BINDING; TUMOR-CELLS; KB CELLS	To determine the number of drug binding sites that exist on the multidrug transporter, P-glycoprotein, we used azidopine, a dihydropyridine photoaffinity compound that reverses multidrug resistance and labels P-glycoprotein. Azidopine labels P-glycoprotein in two distinct locations: one labeled site is within the amino half of P-glycoprotein between amino acid residues 198 and 440, and the other site is within the carboxy half of the protein. Vinblastine is a cytotoxic drug that is used in cancer chemotherapy and is a substrate for transport by P-glycoprotein. We found that vinblastine inhibits azidopine labeling to approximately the same extent at each labeled site on P-glycoprotein. Because several studies have shown that amino acid residue 185 of P-glycoprotein plays a critical role in some aspects of drug binding and transport, we also studied the effect that amino acid residue 185 has on azidopine labeling. These studies show that azidopine labels both sites equivalently in both wild-type (G185) and mutant (V185) P-glycoproteins. We conclude from our results that the two halves of P-glycoprotein approach each other to form a single binding site for these drugs.	NCI,MOLEC BIOL LAB,BLDG 37,RM 4E16,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144; AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CASTILLO G, 1990, P NATL ACAD SCI USA, V87, P4737, DOI 10.1073/pnas.87.12.4737; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; CROOP JM, 1987, CANCER RES, V47, P5982; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERRY DR, 1984, FEBS LETT, V169, P112, DOI 10.1016/0014-5793(84)80299-9; FERRY DR, 1985, EMBO J, V4, P1933, DOI 10.1002/j.1460-2075.1985.tb03873.x; FOJO A, 1985, CANCER RES, V45, P3002; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FORD JM, 1990, CANCER RES, V50, P1748; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KOIKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAFA AR, 1990, BIOCHEM BIOPH RES CO, V166, P259; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SHEN DW, 1986, J BIOL CHEM, V261, P7762; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLINGHAM MC, 1986, CANCER RES, V46, P5941; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	50	202	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21020	21026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356986				2022-12-25	WOS:A1992JT97800080
J	VAIRO, G; COCKS, BG; CRAGOE, EJ; HAMILTON, JA				VAIRO, G; COCKS, BG; CRAGOE, EJ; HAMILTON, JA			SELECTIVE SUPPRESSION OF GROWTH FACTOR-INDUCED CELL-CYCLE GENE-EXPRESSION BY NA+/H+ ANTIPORT INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MARROW-DERIVED MACROPHAGES; PROLIFERATION SIGNALS; MURINE MACROPHAGES; S-PHASE; ACTIVATION; AGENTS; CSF-1; STIMULATION; AMILORIDE; EXCHANGE	Activation of Na+/H+ exchange activity is a ubiquitous response to growth factors and has been implicated in the mitogenic response. Little is known of how the antiport influences events in the nucleus which ultimately control the cell cycle. Using potent Na+/H+ exchange inhibitors we show for normal mouse bone marrow-derived macrophages that this activity is required for the colony-stimulating factor-1-induced gene expression of the M1 and M2 subunits of ribonucleotide reductase, an enzyme critical for DNA synthesis. Suppression of M1 and M2 mRNA levels occurred when the inhibitors were added up to 8 h after the growth factor, mirroring their ability to prevent entry into S phase at similar times. Antiport activity was not required for the induction of other genes associated with cell cycle progression including proliferating cell nuclear antigen and the G1 cyclin, CYL1. These results highlight the differential expression of various cell cycle-associated genes and demonstrates that non-coordinate regulation of CYL1 cyclin and DNA synthesis gene expression can occur. The selective dependence of ribonucleotide reductase subunit gene expression on Na+/H+ exchange activity may provide a biochemical basis for the requirement of persistent antiporter activity during G1 for subsequent entry into S phase.			VAIRO, G (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; HAMILTON JA, 1991, BLOOD, V77, P616; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KNIGHT KR, 1992, J LEUKOCYTE BIOL, V51, P350, DOI 10.1002/jlb.51.4.350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN GJ, 1988, CANCER RES, V48, P5151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METCALF D, 1984, HEMOPOIETIC COLONIES; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VAIRO G, 1988, J CELL PHYSIOL, V134, P13, DOI 10.1002/jcp.1041340103; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19043	19046						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382066				2022-12-25	WOS:A1992JP59300006
J	BELUNIS, CJ; MDLULI, KE; RAETZ, CRH; NANO, FE				BELUNIS, CJ; MDLULI, KE; RAETZ, CRH; NANO, FE			A NOVEL 3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE FROM CHLAMYDIA-TRACHOMATIS REQUIRED FOR EXPRESSION OF THE GENUS-SPECIFIC EPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE EPITOPE; ANTIGEN; IDENTIFICATION; BIOSYNTHESIS; PSITTACI	DNA cloned from Chlamydia trachomatis is able to direct the formation of the genus-specific lipopolysaccharide epitope of chlamydiae in enteric Gram-negative bacteria. We now demonstrate that a single C. trachomatis gene (gseA) is sufficient to impart this trait to Escherichia coli. The deduced amino acid sequence of gseA shows 23% identity (66% similarity) to kdtA, an E. coli gene that codes for a bifunctional enzyme catalyzing the addition of two 3-deoxy-D-manno-octulosonic acid (Kdo) residues to lipid A precursors (Clementz, T., and Raetz, C. R. H. (1991) J. Biol. Chem. 266, 9687-9696). Extracts of E. coli expressing gseA transfer at least one additional Kdo unit from CMP-Kdo to precursors already bearing the two Kdo residues attached by the kdtA gene product. Introduction of gseA into an E. coli mutant with a thermolabile kdtA gene product endows cell extracts with the ability to transfer not only the third but also the first two Kdos to lipid A precursors, demonstrating that the C. trachomatis enzyme is at least trifunctional. Given the similarities of these two Kdo transferases and the essentiality of Kdo in Gram-negative bacteria, lipopolysaccharide biosynthesis may be a target for development of novel drugs effective against chlamydiae.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000,RAHWAY,NJ 07065; UNIV VICTORIA,CANADIAN BACTERIAL DIS NETWORK,VICTORIA V8W 3P6,BC,CANADA; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA	Merck & Company; University of Victoria; University of Victoria				Nano, Francis/0000-0002-9363-7830				BAVOIL P, 1984, INFECT IMMUN, V44, P479, DOI 10.1128/IAI.44.2.479-485.1984; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; BRADE L, 1987, INFECT IMMUN, V55, P482, DOI 10.1128/IAI.55.2.482-486.1987; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CALDWELL HD, 1984, INFECT IMMUN, V44, P306, DOI 10.1128/IAI.44.2.306-314.1984; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COLLINS J, 1979, GENE, V6, P29, DOI 10.1016/0378-1119(79)90083-0; Dawson CR, 1981, GUIDE TRACHOMA CONTR, P8; DHIR SP, 1971, INFECT IMMUN, V4, P725, DOI 10.1128/IAI.4.6.725-730.1971; DREYFUSS G, 1984, MOL CELL BIOL, V4, P414; FRIIS RR, 1972, J BACTERIOL, V110, P706, DOI 10.1128/JB.110.2.706-721.1972; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HATCH TP, 1984, J BACTERIOL, V157, P13, DOI 10.1128/JB.157.1.13-20.1984; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; NANO FE, 1985, SCIENCE, V228, P742, DOI 10.1126/science.2581315; NANO FE, 1986, CHLAMYDIAL INFECTION, P129; NEWHALL WJ, 1983, J BACTERIOL, V154, P998, DOI 10.1128/JB.154.2.998-1001.1983; NURMINEN M, 1983, SCIENCE, V220, P1279, DOI 10.1126/science.6344216; PEREZMARTINEZ JA, 1985, INFECT IMMUN, V50, P905, DOI 10.1128/IAI.50.3.905-910.1985; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDINIA LM, 1989, J BACTERIOL, V171, P335, DOI 10.1128/jb.171.1.335-341.1989; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	31	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18702	18707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382060				2022-12-25	WOS:A1992JN50200070
J	PENG, M; LUNDGREN, E				PENG, M; LUNDGREN, E			TRANSIENT EXPRESSION OF THE EPSTEIN-BARR-VIRUS LMP1 GENE IN HUMAN PRIMARY B-CELLS INDUCES CELLULAR ACTIVATION AND DNA-SYNTHESIS	ONCOGENE			English	Article							MEMBRANE-PROTEIN LMP1; HUMAN LYMPHOCYTES-B; NUCLEAR ANTIGEN-2; SURFACE-ANTIGEN; GROWTH-FACTOR; RODENT CELLS; 3T3 CELLS; TRANSFORMATION; INFECTION; IMMORTALIZATION	The Epstein- Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) and Epstein-Barr virus nuclear antigen 2 (EBNA2) are expressed in EBV-immortalized human B cells. It has previously been shown that transfection of the LMP1 and EBNA2 genes into Burkitt's lymphoma cell lines results in the up-regulation of CD23, CD21, ICAM-1 and LFA-1 cell-surface proteins. In the present study, the effects of transient expression of the LMP1 and EBNA2 genes were studied in normal primary human B cells pretreated with UV-inactivated EBV particles. To identify and purify cells which express the transfected DNA we used a gene encoding a surface molecule, CD2, as a co-transfection marker. We show that transient expression of the LMP1 gene, from heterologous promoters, is sufficient to induce cellular enlargement and up-regulation of surface expression of the activation markers CD23, CD21, ICAM-1 and LFA-1 in primary B cells. Most importantly, we show that transient expression of the LMP1 gene is sufficient to induce DNA synthesis in human primary B cells. Transient EBNA2 expression enhanced the effect of transient LMP1 expression on CD21 and CD23 cell-surface expression but, under our experimental conditions, inhibited the induction of DNA synthesis by LMP1. We conclude that activation of primary B cells with inactivated EBV particles, followed by transient expression of only two viral genes, EBNA2 and LMP1, is sufficient to reconstitute some of the early events of B-cell immortalization by EBV.			PENG, M (corresponding author), UMEA UNIV,UNIT APPL CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN.		Pilon, Marc/AAY-4082-2020; Pilon, Marc/B-9955-2008	Pilon, Marc/0000-0003-3919-2882; Pilon, Marc/0000-0003-3919-2882				ABBOTT SD, 1900, J VIROL, V64, P2126; ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOOS H, 1990, J GEN VIROL, V71, P1811, DOI 10.1099/0022-1317-71-8-1811; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; CUOMO L, 1990, EUR J IMMUNOL, V20, P2293, DOI 10.1002/eji.1830201019; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GORDON J, 1986, IMMUNOLOGY, V58, P591; GORDON J, 1984, J EXP MED, V159, P1554, DOI 10.1084/jem.159.5.1554; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HAUER CA, 1989, NUCLEIC ACIDS RES, V17, P1989, DOI 10.1093/nar/17.5.1989; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUTTFLETCHER LM, 1987, J VIROL, V61, P774, DOI 10.1128/JVI.61.3.774-781.1987; KIEFF E, 1990, VIROLOGY, P1889; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MASUCCI MG, 1987, EUR J IMMUNOL, V17, P815, DOI 10.1002/eji.1830170613; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MONROE JG, 1985, J IMMUNOL, V135, P1674; OHNO H, 1991, J IMMUNOL, V147, P2100; PILON M, 1991, J IMMUNOL, V146, P1047; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; TOSATO G, 1990, J VIROL, V64, P3033, DOI 10.1128/JVI.64.6.3033-3041.1990; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	53	103	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354347				2022-12-25	WOS:A1992JJ37600014
J	LEE, SW; WULFKUHLE, JD; OTTO, JJ				LEE, SW; WULFKUHLE, JD; OTTO, JJ			VINCULIN BINDING-SITE MAPPED ON TALIN WITH AN ANTIIDIOTYPIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; OVERLAY TECHNIQUE; IDENTIFICATION; PURIFICATION; CLEAVAGE; SEQUENCE; DOMAIN; MUSCLE	Vinculin and talin are major adhesion plaque components which interact in vitro and presumably in vivo. The amino acid sequence of talin is now known so details of its domain structure can be mapped. We localized vinculin binding sites in the talin sequence by overlaying peptide maps of talin with an anti-idiotypic vinculin antibody that recognizes talin and with I-125-vinculin. A rabbit injected only twice with vinculin and producing anti-vinculin antibodies spontaneously generated a second antibody that recognizes talin. Vinculin and anti-vinculin antibodies specifically compete with this second antibody for binding to talin as determined by solid-phase binding and overlay assays. The antibody is thus most likely an anti-idiotypic antibody which mimics a region of vinculin that interacts with talin. The binding site of the anti-idiotypic antibody on talin was mapped to the 196 amino acids spanning residues 1653 to 1848. A second vinculin binding site identified with an I-125-vinculin blot overlay technique was located between residues 483 and 1652. The observation that talin has two immunologically distinct vinculin binding sites suggests that vinculin may have two different talin binding sites or one "complex" site with two interacting regions.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus								BECKERLE MC, 1990, CELL MOTIL CYTOSKEL, V16, P7, DOI 10.1002/cm.970160103; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KILIC F, 1991, J BIOL CHEM, V266, P8734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHALLORAN T, 1986, BIOCHIM BIOPHYS ACTA, V869, P337, DOI 10.1016/0167-4838(86)90074-9; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	16	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16355	16358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379597				2022-12-25	WOS:A1992JJ45800058
J	TABB, JS; KISH, PE; VANDYKE, R; UEDA, T				TABB, JS; KISH, PE; VANDYKE, R; UEDA, T			GLUTAMATE TRANSPORT INTO SYNAPTIC VESICLES - ROLES OF MEMBRANE-POTENTIAL, PH GRADIENT, AND INTRAVESICULAR PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; BOVINE CEREBRAL-CORTEX; FUNCTIONAL RECONSTITUTION; CATECHOLAMINE TRANSPORT; CHROMAFFIN VESICLES; ENERGY-DEPENDENCE; DELTA-PH; PROTON; GLYCINE; ATPASE	Glutamate, the major excitatory neurotransmitter in the mammalian central nervous system, is transported into bovine synaptic vesicles in a manner that is ATP dependent and requires a vesicular electrochemical proton gradient. We studied the electrical and chemical elements of this driving force and evaluated the effects of chloride on transport. Increasing concentrations of Cl- were found to increase the steady-state ATP-dependent vesicular pH gradient (DELTA-pH) and were found to concomitantly decrease the vesicular membrane potential (DELTA-PSI). Low millimolar chloride concentrations, which cause 3-6-fold stimulation of vesicular glutamate uptake, caused small but measurable increases in DELTA-pH and decreases in DELTA-PSI, when compared to control vesicles in the absence of chloride. Nigericin in potassium buffers was used to alter the relative proportions of DELTA-pH and DELTA-PSI. Compared to controls, at all chloride concentrations tested, nigericin virtually abolished DELTA-pH and increased the vesicle interior positive DELTA-PSI. Concomitantly, nigericin increased ATP-dependent glutamate uptake in 0-1 mM chloride but decreased glutamate uptake in 4 mM (45%), 20 mM (80%), and 140 mM (75%) Cl- (where DELTA-pH in the absence of nigericin was large). These findings suggest that either DELTA-PSI, DELTA-pH, or a combination can drive glutamate uptake, but to different degrees. In the presence of 4 mM Cl-, where uptake is optimal, both DELTA-PSI and DELTA-pH contribute to the driving force for uptake. When the extravesicular pH was increased from 7.4 to 8.0, more Cl- was required to stimulate vesicular glutamate uptake. In the absence of Cl-, as extravesicular pH was lowered to 6.8, uptake was over 3-fold greater than it was at pH 7.4. As extravesicular pH was reduced from 8.0 toward 6.8, less Cl- was required for maximal stimulation. Decreasing the extravesicular pH from 8.0 to 6.8 in the absence of Cl- significantly increased glutamate uptake activity, even though proton-pumping ATPase activity actually decreased about 45% under identical conditions. In the absence of chloride, nigericin increased glutamate uptake at all the pH values tested except pH 8.0. Glutamate uptake at pH 6.8 in the presence of nigericin was over 6-fold greater than uptake at pH 7.4 in the absence of nigericin. We conclude from these experiments that optimal ATP-dependent glutamate uptake requires a large DELTA-PSI and a small DELTA-pH. Chloride stimulates glutamate uptake by increasing the vesicle DELTA-pH, and we suggest that the resulting decrease in intravesicular pH at low Cl- concentrations plays an important role in stimulating vesicular glutamate uptake.	UNIV MICHIGAN,MENTAL HLTH RES INST,205 ZINA PITCHER PL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PSYCHIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Kish, Phil E/H-6051-2011		NIMH NIH HHS [MH 15794-12] Funding Source: Medline; NINDS NIH HHS [NS 26884] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026884] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; CIDON S, 1989, J BIOL CHEM, V264, P8281; FLOOR E, 1988, J NEUROCHEM, V55, P1663; FONNUM F, 1989, J NEUROCHEM, V52, P946; FYSKE EM, 1988, J NEUROCHEM, V50, P1237; HELL JW, 1990, J BIOL CHEM, V265, P2111; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOLZ RW, 1978, P NATL ACAD SCI USA, V75, P5190, DOI 10.1073/pnas.75.10.5190; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; JOHNSON RG, 1979, J BIOL CHEM, V254, P963; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KISH PE, 1989, METHOD ENZYMOL, V174, P10; LOH YP, 1984, J BIOL CHEM, V259, P8238; MAYCOX PR, 1990, EMBO J, V9, P1465, DOI 10.1002/j.1460-2075.1990.tb08263.x; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SHIOI J, 1989, BIOCHEM J, V258, P499, DOI 10.1042/bj2580499; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; TABB JS, 1991, 3RD IBRO WORLD C NEU; TOLL L, 1978, BIOCHEMISTRY-US, V17, P2517, DOI 10.1021/bi00606a010; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603	30	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15412	15418						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353494				2022-12-25	WOS:A1992JG11300026
J	KIEFER, MC; SCHMID, C; WALDVOGEL, M; SCHLAPFER, I; FUTO, E; MASIARZ, FR; GREEN, K; BARR, PJ; ZAPF, J				KIEFER, MC; SCHMID, C; WALDVOGEL, M; SCHLAPFER, I; FUTO, E; MASIARZ, FR; GREEN, K; BARR, PJ; ZAPF, J			CHARACTERIZATION OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-4, PROTEIN-5, AND PROTEIN-6 PRODUCED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAPANCREATIC TUMOR HYPOGLYCEMIA; SARCOMA CELL-LINE; IGF-I; CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; HUMAN-SERUM; EXPRESSION; CLONING; SEQUENCE; DNA	The insulin-like growth factor binding protein (IGFBP) family comprises six structurally distinct, but highly homologous proteins. They have been identified in serum and other biological fluids, tissue extracts, and cell culture media. We have recently cloned cDNAs encoding human IGFBP-4, -5, and -6 and have now expressed these BPs in yeast as ubiquitin (Ub)-IGFBP fusion proteins. Western ligand blotting with I-125-IGF II under nonreducing conditions of recombinant human (rh) IGFBP-containing yeast lysates revealed specific binding bands for IGFBP-4, -5, and -6 at apparent molecular masses of 24-26, 30-32, and 24-26 kDa, respectively, indicating processing of the fusion proteins. High-performance liquid chromatography-purified rhIGFBPs had virually the same amino acid composition, amino acid number, and NH2-terminal sequences as the native BPs. Except for the affinity of rhIGFBP-6 for IGF I (K(a) = 8.5 x 10(8) M-1), the affinity constants of the three IGFBPs for IGF I and II lie between 1.7 and 3.3 x 10(10) M-1, i.e. 25-100 times higher than the IGF I and II affinities of the type I IGF receptor. When present in excess, rhIGFBP-4, -5, and -6 inhibited IGF I- and II-stimulated DNA and glycogen synthesis in human osteoblastic cells, but rhIGFBP-6 had only a weak inhibitory effect on IGF I in agreement with its relatively lower IGF I affinity constant. The results of this study show that the primary effect of the three rhIGFBPs is the attenuation of IGF activity and suggest that IGFBPs contribute to the control of IGF-mediated cell growth and metabolism.	UNIV HOSP ZURICH,DEPT MED,METAB UNIT,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	KIEFER, MC (corresponding author), CHIRON CORP,EMERYVILLE,CA 94608, USA.			Schmid, Christoph/0000-0003-2080-4439				ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; BARR PJ, 1991, EXPRESSION SYSTEMS P, P51; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BICSAK TA, 1991, BIOL REPROD, V44, P599, DOI 10.1095/biolreprod44.4.599; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BROWN AL, 1989, J BIOL CHEM, V264, P5148; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CULOUSCOU JM, 1991, J CANCER RES, V51, P2813; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1919; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHMAN H, 1989, EUR J BIOCHEM, V180, P259, DOI 10.1111/j.1432-1033.1989.tb14641.x; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MEULI C, 1978, DIABETOLOGIA, V14, P255, DOI 10.1007/BF01219425; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; NILSON BL, 1984, ANAL BIOCHEM, V141, P311; NISSLEY SP, 1991, MODERN CONCEPTS INSU; RECHLER MM, 1991, PEPTIDE GROWTH FACTO, V1; RINAS U, 1990, BIO-TECHNOL, V8, P543, DOI 10.1038/nbt0690-543; RODAN SB, 1989, J ENDOCRINOL, V122, P219, DOI 10.1677/joe.0.1220219; RODAN SB, 1987, CANCER RES, V47, P4961; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; SCHMID C, 1984, FEBS LETT, V173, P48, DOI 10.1016/0014-5793(84)81015-7; SCHMID C, 1983, CALCIFIED TISSUE INT, V35, P578, DOI 10.1007/BF02405097; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SHUSTER JR, 1989, YEAST GENETIC ENG, P83; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZAPF J, 1977, CLIN CHEM, V23, P677; ZAPF J, 1979, J CLIN INVEST, V63, P1077, DOI 10.1172/JCI109377; ZAPF J, 1989, P NATL ACAD SCI USA, V86, P3813, DOI 10.1073/pnas.86.10.3813; ZAPF J, 1990, J BIOL CHEM, V265, P14892	66	186	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12692	12699						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377672				2022-12-25	WOS:A1992HZ48300049
J	VALLEJO, M; MILLER, CP; HABENER, JF				VALLEJO, M; MILLER, CP; HABENER, JF			SOMATOSTATIN GENE-TRANSCRIPTION REGULATED BY A BIPARTITE PANCREATIC-ISLET D-CELL-SPECIFIC ENHANCER COUPLED SYNERGETICALLY TO A CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; PROTEIN-BINDING DOMAINS; CYCLIC-AMP; PROMOTER ELEMENT; CONTROL REGION; MESSENGER-RNA; GLUCAGON GENE; MAMMALIAN-CELLS; DNA ELEMENTS; EXPRESSION	The insulin-, glucagon-, and somatostatin-producing cells in the pancreatic islets derive from a common precursor stem cell and differentiate sequentially during embryonic development, thereby providing an informative model for the study of the transcriptional mechanisms involved in the control of cell-specific gene expression. Relative to the early expression of the glucagon and insulin genes on embryonic days 10 and 12, respectively, the expression of the somatostatin gene is delayed (day 17). The relatively late expression of the somatostatin gene indicates the involvement of both negative and positive transcriptional control mechanisms. We show that the expression of the somatostatin gene in pancreatic islet cells is accomplished by the interplay of both positive and negative cis-regulatory DNA elements. We have characterized the functional properties of one of these positive control elements, the somatostatin gene upstream enhancer element (SMS-UE). The SMS-UE is a pancreatic islet D-cell-specific transcriptional regulator that acts synergistically with the cyclic AMP response element. Mutation-expression and cell-free transcription analyses show that the SMS-UE is a bipartite element with two interdependent functional domains. Our results indicate that the SMS-UE is part of a functional unit that includes other transcriptional control elements of the somatostatin gene proximal promoter, and that they act together to regulate the D-cell-specific transcription of the somatostatin gene in the islet cells of the pancreas.			VALLEJO, M (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, HOWARD HUGHES MED INST, MOLEC ENDOCRINOL LAB, BOSTON, MA 02114 USA.		Vallejo, Mario/ABG-4610-2020	Vallejo, Mario/0000-0002-6422-0323	NIDDK NIH HHS [DK30457, DK30834] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030457, R01DK030834, R01DK030457] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDEK RW, 1991, DIABETES, V40, P1041, DOI 10.2337/diabetes.40.8.1041; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MONTMINY MR, 1984, P NATL ACAD SCI-BIOL, V81, P3337, DOI 10.1073/pnas.81.11.3337; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; PATEL YC, 1991, ENDOCRINOLOGY, V128, P1754, DOI 10.1210/endo-128-4-1754; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; POWERS AC, 1989, J BIOL CHEM, V264, P10048; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEAQUIST ER, 1989, DIABETES, V38, P1439, DOI 10.2337/diabetes.38.11.1439; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SINGLETON CK, 1984, J BIOL CHEM, V259, P1963; STRATOWA C, 1986, P NATL ACAD SCI USA, V83, P4292, DOI 10.1073/pnas.83.12.4292; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TAVIANINI MA, 1984, J BIOL CHEM, V259, P1798; WANG TC, 1990, J BIOL CHEM, V265, P8908; WERNER H, 1988, J BIOL CHEM, V263, P7666; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	59	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12868	12875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352291				2022-12-25	WOS:A1992HZ48300073
J	DEBYSER, Z; VANDAMME, AM; PAUWELS, R; BABA, M; DESMYTER, J; DE CLERCQ, E				DEBYSER, Z; VANDAMME, AM; PAUWELS, R; BABA, M; DESMYTER, J; DE CLERCQ, E			KINETICS OF INHIBITION OF ENDOGENOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTION BY 2',3'-DIDEOXYNUCLEOSIDE 5'-TRIPHOSPHATE, TETRAHYDROIMIDAZO-[4,5,1-JK][1,4]-BENZODIAZEPIN-2(1H)-THIONE, AND 1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REPLICATION; SUBSTRATE; AGENTS	Recently, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H-)-one and -thione (TIBO) and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) compounds have been shown to be potent, selective, and specific inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in vitro. They interact with the reverse transcriptase of HIV-1 in a way different from that of previously studied reverse transcriptase (RT) inhibitors. We established an endogenous RT assay, starting from intact HIV-1 virions. This assay mimics the reverse transcription process in the HIV-infected cell more closely than RT assays with artificial templates. We investigated the inhibition of endogenous HIV-I reverse transcription by the TIBO derivative (+)-(S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo [4,5,1-jk]-[1,4]-benzodiazepin-2(1H)-thione (R-82150) in comparison with the HEPT derivative 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and 2',3'-dideoxyguanosine 5'-triphosphate. The kinetics and characteristics of RT inhibition by TIBO in the endogenous RT assay were similar to those found previously for the exogenous RT assay (following addition of exogenous template/primer); thus, RT inhibition by TIBO was specific for HIV-1 and the extent of RT inhibition was dependent on which of the four substrates (dATP, dTTP, dGTP, and dCTP) was present in limited concentrations. Of the three enzymatic activities, RNA-dependent DNA polymerization was preferentially inhibited, and inhibition was not competitive with respect to the natural substrates. HIV-1 RT behaved as an allosteric enzyme, which means that positive cooperativity for binding of the substrate was observed. TIBO behaved as an allosteric inhibitor by causing a concentration-dependent decrease in this cooperativity.	FUKUSHIMA MED SCH, DEPT MICROBIOL, FUKUSHIMA 96012, JAPAN	Fukushima Medical University	DEBYSER, Z (corresponding author), CATHOLIC UNIV LEUVEN, REGA INST MED RES, MINDERBROEDERSSTR 10, B-3000 LOUVAIN, BELGIUM.		Vandamme, Anne-Mieke/I-4127-2012; Baba, Masanori/G-3867-2011	Vandamme, Anne-Mieke/0000-0002-6594-2766; De Clercq, Erik/0000-0002-2985-8890				BABA M, 1991, MOL PHARMACOL, V39, P805; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BASU A, 1989, J BIOL CHEM, V264, P8746; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BERTAZZONI U, 1989, CLIN CHIM ACTA, V183, P101, DOI 10.1016/0009-8981(89)90280-5; BORROTOESODA K, 1991, J VIROL, V65, P1952, DOI 10.1128/JVI.65.4.1952-1959.1991; BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DEBYSER Z, 1992, MOL PHARMACOL, V41, P203; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GONTIJO NF, 1990, FOCUS, V12, P55; HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; KUKLA MJ, 1991, J MED CHEM, V34, P746, DOI 10.1021/jm00106a040; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002; MYERS G, 1990, HUMAN RETROVIRUSES A; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; VARMUS H, 1982, MOL BIOL TUMOR VIRUS, V5, P414; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YONG WH, 1990, AIDS, V4, P199, DOI 10.1097/00002030-199003000-00004	27	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11769	11776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376311				2022-12-25	WOS:A1992HY94700022
J	FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S				FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S			REPLACEMENT OF NEGATIVE BY POSITIVE CHARGES IN THE PRESUMED MEMBRANE-INSERTED PART OF DIPHTHERIA TOXIN-B FRAGMENT - EFFECT ON MEMBRANE TRANSLOCATION AND ON FORMATION OF CATION CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; CELLS; ENTRY; MUTANTS; MOLECULE; CYTOSOL	Diphtheria toxin B fragment is capable of forming cation-selective channels in the plasma membrane. Such channels may be involved in the translocation of the toxin A fragment to the cytosol. Seven negatively charged amino acids in the B fragment were replaced one by one by lysines, followed by studies of cytotoxicity and channel-forming ability of the different mutants. The mutant D392K showed a strong reduction in binding to cell surface receptors. Of the six mutants that showed wild-type binding affinity, the two mutants D295K and D318K were very inefficient in forming channels. These two mutants had the lowest ability to mediate A fragment translocation. The mutant E362K was able both to induce cation channel formation and to mediate A fragment translocation at a higher pH value than the wild-type B fragment. The results support the notion that formation of cation channels is of importance for the translocation of the A fragment across the plasma membrane, and they indicate that the pH requirement for translocation of the A fragment to the cytosol is partly determined by the B fragment.			FALNES, PO (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1989, J BIOL CHEM, V264, P11367; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; OLSNES S, 1980, J BIOL CHEM, V255, P284; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; STENMARK H, 1991, MOL MICROBIOL, V5, P595, DOI 10.1111/j.1365-2958.1991.tb00730.x; UCHIDA T, 1972, SCIENCE, V175, P901, DOI 10.1126/science.175.4024.901; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	25	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12284	12290						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376320				2022-12-25	WOS:A1992HY94700094
J	THOMAS, PM; SAMELSON, LE				THOMAS, PM; SAMELSON, LE			THE GLYCOPHOSPHATIDYLINOSITOL-ANCHORED THY-1 MOLECULE INTERACTS WITH THE P60FYN PROTEIN TYROSINE KINASE IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; CO-EXPRESSION; ACTIVATION; PHOSPHORYLATION; MEMBRANE; COMPLEX; ASSOCIATION; CHAIN	Stimulation of murine T cells by engagement of the multi-component T cell antigen receptor or by cross-linking the Thy-1 molecule leads to a similar response characterized by lymphocyte activation and lymphokine production. The early biochemical events induced by engaging these molecules also are similar and begin with activation of a tyrosine kinase pathway and tyrosine phosphorylation of a comparable set of substrates. Previous work demonstrates that the protein tyrosine kinase p60(fyn) is associated with the antigen receptor and therefore it may participate in the tyrosine phosphorylations that are observed with antigen receptor signaling. In this study we demonstrate that the Thy-1 molecule is also associated with p60(fyn) in a murine T cell hybridoma and in murine thymocytes. The interaction is independent of antigen receptor expression. Thy-1 is a member of the class of molecules anchored to the plasma membrane by a glycophosphatidylinositol (GPI) group. The association of Thy-1 with p60(fyn) is dependent on the GPI linkage, since cleavage of the GPI anchor disrupts the interaction. The association of Thy-1 and p60(fyn) suggests a means by which Thy-1 cross-linking leads to tyrosine phosphorylation and T cell activation.			THOMAS, PM (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ANDERSON GW, 1991, SCIENCE, V255, P410; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALAFAT J, 1983, J GEN VIROL, V64, P1241, DOI 10.1099/0022-1317-64-6-1241; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; NARDELLI B, 1989, J IMMUNOL METHODS, V120, P233, DOI 10.1016/0022-1759(89)90247-0; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2	31	210	215	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12317	12322						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351058				2022-12-25	WOS:A1992HY94700099
J	ZHELEZNYAK, A; BROWN, EJ				ZHELEZNYAK, A; BROWN, EJ			IMMUNOGLOBULIN-MEDIATED PHAGOCYTOSIS BY HUMAN MONOCYTES REQUIRES PROTEIN-KINASE-C ACTIVATION - EVIDENCE FOR PROTEIN-KINASE-C TRANSLOCATION TO PHAGOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE PLASMA-MEMBRANE; SIGNAL TRANSDUCTION; RESPIRATORY BURST; RECEPTORS; MECHANISM; POTENT; DIFFERENTIATION; NEUTROPHILS; INHIBITORS; ANTIGEN	This study has investigated the role of protein kinase C (PKC) activation in IgG-mediated phagocytosis by human monocytes. Incubation of monocytes with IgG-opsonized targets increased membrane-associated PKC approximately 2-fold. Kinetic studies showed that the translocation of PKC to membrane occurred before significant ingestion took place. The pharmacologic PKC inhibitor H7 inhibited IgG-dependent ingestion with ID50 of 20-mu-M, while the structurally related isoquinoline sulfonamide HA1004 had no effect at this concentration. Staurosporine and calphostin C, PKC inhibitors which have different mechanisms of actions than H7, also inhibited ingestion. Depletion of PKC by prolonged incubation with phorbol esters also inhibited phagocytosis, and dose-response curves showed a strong correlation between the extent of PKC depletion and the extent of inhibition of ingestion. Finally, phagosomes were isolated by sucrose density centrifugation of cells disrupted 5 min after the initiation of phagocytosis. Measurement of PKC activity and immunoreactivity in the phagosomes showed that PKC was concentrated in the phagosome membrane approximately 5-fold compared to the uninvolved plasma membrane. Together, these data suggest that PKC activation is an early, essential step in the efficient ingestion of IgG-opsonized targets by monocytes.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,CAMPUS BOX 8051,660 S EUCLID ST,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BROWN EJ, 1987, J IMMUNOL, V139, P3777; BROZNA JP, 1988, J IMMUNOL, V141, P1642; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EPPELL BA, 1989, J IMMUNOL, V143, P4141; GRAHAM IL, 1991, J IMMUNOL, V146, P685; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; GRIFFIN FM, 1974, J EXP MED, V139, P323, DOI 10.1084/jem.139.2.323; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LENNARTZ MR, 1990, J CELL BIOL, V111, P214; LORENZ RG, 1990, J IMMUNOL, V144, P1600; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; METCALF JA, 1986, LABORATORY MANUAL NE; Metchnikoff ME., 1884, VIRCHOWS ARCH PATH A, V9, P177, DOI [10.1007/BF02361555, DOI 10.1007/BF02361555]; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; ROSALES C, 1992, J BIOL CHEM, V267, P5265; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703	29	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12042	12048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376316				2022-12-25	WOS:A1992HY94700061
J	WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F				WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F			FUNCTIONAL HOMOLOGY BETWEEN N-MYC AND C-MYC IN MURINE PLASMACYTOMAGENESIS - PLASMACYTOMA DEVELOPMENT IN N-MYC TRANSGENIC MICE	ONCOGENE			English	Article							LEUKEMIA-VIRUS; V-ABL; CHROMOSOMAL TRANSLOCATIONS; CELLULAR ONCOGENES; KINASE-ACTIVITY; BALB/C MICE; B-CELLS; GENE; EXPRESSION; AMPLIFICATION	Mouse plasmacytomas induced by pristane oil alone, or in combination with Abelson murine leukemia virus (A-MuLV), regularly carry one of three alternative chromosomal translocations that juxtapose c-myc to immunoglobulin heavy- or light-chain loci. E-mu-c-myc transgenic mice develop translocation-free plasmacytomas after induction by pristane oil and/or A-MuLV [Sugiyama, H., Silva, S., Wang, Y., Weber, G., Babonits, M., Rosen, A., Wiener, F. & Klein, G. (1990). Int. J. Cancer, 46, 845-8521. In order to test whether another member of the myc family, N-myc, could play a similar role as c-myc, we treated E-mu- N -myc transgenic mice with pristane and helper-free A-MuLV. Of 20 mice that received a single pristane injection followed by A-MuLV, 17 developed plasmacytomas with a mean latency period of 54 +/- 20 days. In a corresponding group that only received a single pristane injection, five out of six transgenic mice developed plasmacytomas with a mean latency period of 142 +/- 32 days. However, after three monthly injections of pristane, all 15 transgenic mice developed plasmacytomas with a mean latency period of 128 +/- 20 days. All plasmacytomas expressed the N-myc transgene, while none of them expressed either c-myc or endogenous N-myc. None of the tumors carried the usual plasmacytoma-associated translocations.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; NCI,GENET LAB,BETHESDA,MD 20892	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 14054-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; POTTER M, 1984, ADV VIRAL ONCOL, V4, P139; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSEN A, 1979, J IMMUNOL METHODS, V28, P1, DOI 10.1016/0022-1759(79)90322-3; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J, 1989, MOL CLONING LABORATO; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUGIYAMA H, 1990, INT J CANCER, V46, P845, DOI 10.1002/ijc.2910460516; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375720				2022-12-25	WOS:A1992HU64200023
J	THOMIS, DC; FLOYDSMITH, G; SAMUEL, CE				THOMIS, DC; FLOYDSMITH, G; SAMUEL, CE			MECHANISM OF INTERFERON ACTION - CDNA STRUCTURE AND REGULATION OF A NOVEL SPLICE-SITE VARIANT OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE-A FROM INTERFERON-TREATED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-2; MOLECULAR-CLONING; MOUSE FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; C-ALPHA; PHOSPHORYLATION; FAMILY; SEQUENCES; ISOFORMS	A molecular cDNA clone (KIN27) was isolated that encodes a novel variant of the catalytic subunit C-alpha of the human cyclic AMP-dependent protein kinase (PKA). Analysis of PKA genomic sequence data revealed that the KIN27 variant transcripts likely result from alternative splice-site selection of the C-alpha gene transcripts. The KIN27 cDNA has therefore been designated C-alpha-2. RNA amplification by polymerase chain reaction revealed that KIN27 C-alpha-2 splice-site variant RNA and PKA C-alpha RNA were both expressed in the amnion U and HeLa human cell lines. C-alpha RNA was about 3- to 5-fold more abundant than C-alpha-2 RNA. Interferon treatment decreased the steady-state amount of the C-alpha-2 RNA relative to C-alpha RNA. These results suggest that alternative splicing may contribute to the structural heterogeneity of C subunits expressed in human cells and that interferon may affect this process.	UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DIV MOLEC & CELLULAR BIOL,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,GRAD PROGRAM BIOCHEM & MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara					NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012520, R01AI020611, R37AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATWATER JA, 1987, VIROLOGY, V159, P350, DOI 10.1016/0042-6822(87)90473-9; ATWATER JA, 1982, VIROLOGY, V123, P206, DOI 10.1016/0042-6822(82)90306-3; BANERJEE DK, 1983, VIROLOGY, V129, P230, DOI 10.1016/0042-6822(83)90411-7; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BERRY MJ, 1985, J BIOL CHEM, V260, P1240; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; CHEN U, 1990, MOL IMMUNOL, V27, P1249; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; KARATHANASIS SK, 1983, NATURE, V301, P718, DOI 10.1038/301718a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LASKY SR, 1982, J BIOL CHEM, V257, P1087; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1983, VIROLOGY, V130, P474, DOI 10.1016/0042-6822(83)90101-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPERLING J, 1991, P NATL ACAD SCI USA, V88, P10377, DOI 10.1073/pnas.88.23.10377; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; THOMIS DC, 1992, J VIROL, V66, P2519, DOI 10.1128/JVI.66.4.2519-2522.1992; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WANG AM, 1990, PCR PROTOCOLS GUIDE, P70; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9; [No title captured]	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10723	10728						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375229				2022-12-25	WOS:A1992HV09000078
J	COGHLAN, VM; VICKERY, LE				COGHLAN, VM; VICKERY, LE			ELECTROSTATIC INTERACTIONS STABILIZING FERREDOXIN ELECTRON-TRANSFER COMPLEXES - DISRUPTION BY CONSERVATIVE MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; AMINO-ACID SEQUENCE; HUMAN PLACENTAL FERREDOXIN; ADRENODOXIN REDUCTASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; SALT BRIDGE; PROTEIN; RECOGNITION; REPLACEMENTS	Mitochondrial ferredoxins mediate electron transfer from NADPH:ferredoxin oxidoreductase to cytochrome P450 enzymes. Previous studies on human ferredoxin, in which acidic residues were replaced with neutral amino acids, established that Asp-76 and Asp-79 are are important for binding to both reductase and P450 (Coghlan, V. M., and Vickery, L. E. (1991) J. Biol. Chem. 266, 18606-18612). Here we report that replacement of Asp --> Glu at position 76 or 79, whereas maintaining negative charge at these positions also results in dramatic decreases in binding affinity for both electron transfer partners (5-100-fold, DELTA(DELTA-G) almost-equal-to 1.0-2.8 kcal/mol). These results imply that the active electron transfer complexes in these systems are dominated by a stable form which requires specific pairwise electrostatic interactions of fixed geometry for recognition and binding. This mechanism contrasts with that proposed for other electron transfer systems (as exemplified by cytochrome c) in which electrostatic interactions are believed to function primarily in precollisional orientation leading to "encounter complexes" having multiple geometries of similar free energy.	UNIV CALIF IRVINE, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM43548] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM GE, 1973, J CLIN ENDOCR METAB, V37, P40, DOI 10.1210/jcem-37-1-40; AKHREM AA, 1978, BIOORG KHIM+, V4, P462; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BAGBY S, 1990, EUR J BIOCHEM, V188, P413, DOI 10.1111/j.1432-1033.1990.tb15418.x; BURCH AM, 1990, SCIENCE, V247, P831, DOI 10.1126/science.2154849; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1988, ARCH BIOCHEM BIOPHYS, V264, P376, DOI 10.1016/0003-9861(88)90302-5; DAS G, 1988, J BIOL CHEM, V263, P18290; DUVAL JF, 1980, STEROIDS, V36, P473, DOI 10.1016/0039-128X(80)90034-3; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P4445, DOI 10.1021/bi00412a035; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; Kraut J, 1981, BIOCHEM SOC T, V9, P197, DOI 10.1042/bst0090197; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MATTHEW JB, 1983, NATURE, V301, P169, DOI 10.1038/301169a0; MAUK MR, 1982, BIOCHEMISTRY-US, V21, P1843, DOI 10.1021/bi00537a021; MCLENDON G, 1991, STRUCT BOND, V75, P159; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMURA T, 1964, J BIOL CHEM, V239, P2379; ORMEJOHNSON NR, 1979, J BIOL CHEM, V254, P2103; POULOS TL, 1987, J BIOL CHEM, V262, P13881; ROBERTS VA, 1991, J BIOL CHEM, V266, P13431; RODGERS KK, 1988, SCIENCE, V240, P1657, DOI 10.1126/science.2837825; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WEBER PC, 1985, J BIOL CHEM, V260, P5568; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387	39	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8932	8935						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1349603				2022-12-25	WOS:A1992HR85400037
J	PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A				PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A			THE PROMOTER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE DIRECTING SV40 T-ANTIGEN EXPRESSION INDUCES MALIGNANT PROLIFERATION OF EPENDYMAL CELLS IN TRANSGENIC MICE	ONCOGENE			English	Note							IDENTIFICATION; MUTATIONS; PROTEIN; TUMORS; LINES; DEFECT	Transgenic mice bearing a human cystic fibrosis transmembrane conductance regulator (CFTR) promoter-SV40 T antigen fusion transgene were generated in order to localize in vivo the potential oncogenesis linked to the tissue-specific activity of the promoter for the CFTR gene. Surprisingly, the only site of tumors resulting from expression of the reporter onc gene was ependymal cells lining the brain ventricles. SV40 T antigen expression in these cells led to a consistent pathology in the first weeks of age: ependymoma and consequent hydrocephaly. Tumor-derived cell lines were established, characterized and shown to originate from SV40 T antigen-induced ependymoma. No pathological alterations were found in other organs, such as lungs and pancreas, in which cystic fibrosis is pathologically manifest in humans. Such transgenic mice and derived cell lines may represent valid models for analysing (1) the role of SV40 T antigen in ependymoma formation and (2) CFTR function in ependymal cells.	TRANSGENE SA,DEPT ANIM SYST,11 RUE MOLSHEIM,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892; HOP HAUTE PIERRE,SERV ANAT PATHOL GEN,F-67200 STRASBOURG,FRANCE	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); CHU Strasbourg								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARAKI M, 1983, ARCH HISTOL JAPON, V46, P191, DOI 10.1679/aohc.46.191; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BECKER LE, 1983, HUM PATHOL, V14, P538, DOI 10.1016/S0046-8177(83)80006-9; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1990, BIOLOGICALS, V18, P191, DOI 10.1016/1045-1056(90)90006-L; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Flint S. J, 1981, DNA TUMOR VIRUSES; GABRION J, 1988, NEUROSCIENCE, V24, P993, DOI 10.1016/0306-4522(88)90082-6; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOGAN B, 1986, MANIPULATING MOUSE E; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LEVITAN IB, 1989, SCIENCE, V244, P1423, DOI 10.1126/science.2544028; MANTHORPE CM, 1977, BRAIN RES, V134, P407, DOI 10.1016/0006-8993(77)90818-6; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAVIRANI A, 1989, BIO-TECHNOL, V7, P1049; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROESSMANN U, 1980, BRAIN RES, V200, P13, DOI 10.1016/0006-8993(80)91090-2; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	46	13	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					993	997						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373882				2022-12-25	WOS:A1992HP64200020
J	RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW				RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW			MOLECULAR-CLONING AND CHARACTERIZATION OF THE T(2 14) TRANSLOCATION ASSOCIATED WITH CHILDHOOD CHRONIC LYMPHOCYTIC-LEUKEMIA	ONCOGENE			English	Article							C-MYC ONCOGENE; GAMMA-GENES; B-CELL; PSEUDOAUTOSOMAL REGION; T(2-14) TRANSLOCATION; GENOMIC SEQUENCES; BURKITT-LYMPHOMA; RESTRICTION MAP; CHAIN; SWITCH	Two rare cases of chronic lymphocytic leukemia (CLL) in children, patients AS and LH, have been found to be associated with a unique chromosomal translocation, t(2;14)(p13;q32). Previous studies have shown the breakpoints of this translocation to be in the gamma-2 switch region of the Ig heavy-chain locus on chromosome 14 and in an uncharacterized region of chromosome 2. We have cloned and characterized the translocation breakpoints to examine the possibility that an oncogene contributed to the pathogenesis of these cases of CLL. Sequence analysis of AS and LH breakpoints established that the chromosome 2 breakage in the two patients occurred only 38 bp apart and within a strong non-methylated CpG island. Furthermore, human probes from the region cross-hybridized to other species, indicating strong evolutionary conservation. Northern analysis using the chromosome 2 probes detected a 2.85-kb transcript in the tumor cells and in a CD5+ B-cell line. These data suggest that a potential oncogene located near the 2p13 breakpoint may have been activated by the t(2;14) translocation in these two cases of chronic lymphocytic leukemia.			RICHARDSON, AL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD AP, 1986, NATURE, V321, P9; BOUMSELL L, 1980, J EXP MED, V151, P1539; BRISSENDEN JE, 1985, CANCER RES, V45, P5593; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; DUNN IS, 1987, NUCLEIC ACIDS RES, V15, P2677; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FULTON TR, 1989, NUCLEIC ACIDS RES, V17, P271, DOI 10.1093/nar/17.1.271; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; KAMOUN M, 1981, J IMMUNOL, V127, P987; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; LEVINE EG, 1986, CANCER RES, V46, P6481; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maniatis T., 1982, MOL CLONING; MARCU KB, 1982, NATURE, V298, P87, DOI 10.1038/298087a0; MITELMAN F, 1988, CANCER RES, V48, P7115; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NISHIDA K, 1989, CANCER RES, V49, P1275; NOWELL PC, 1986, CANCER GENET CYTOGEN, V19, P219, DOI 10.1016/0165-4608(86)90050-6; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRICOLI JV, 1985, CYTOGENET CELL GENET, V40, P762; VESHIMA Y, 1985, INT J CANCER, V36, P287; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0	43	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					961	970						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373880				2022-12-25	WOS:A1992HP64200016
J	DALTON, SL; MARCANTONIO, EE; ASSOIAN, RK				DALTON, SL; MARCANTONIO, EE; ASSOIAN, RK			CELL ATTACHMENT CONTROLS FIBRONECTIN AND ALPHA-5-BETA-1 INTEGRIN LEVELS IN FIBROBLASTS - IMPLICATIONS FOR ANCHORAGE-DEPENDENT AND ANCHORAGE-INDEPENDENT GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO FIBROBLASTS; VIRUS-TRANSFORMED CELLS; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; SURFACE PROTEIN; RECEPTORS; ADHESION; COLLAGENASE; TRANSLATION; DOMAIN	We have examined the effect of cell attachment on fibronectin and alpha-5-beta-1 integrin levels in three distinct anchorage-dependent fibroblast cell lines. Analysis of long-term biosynthetically labeled proteins from parallel cultures of adherent and nonadherent cells showed that the steady-state level of extracellular fibronectin is decreased upon loss of attachment. Pulse labeling studies and Northern blot analyses showed that the decrease occurs post-synthetically. A combined approach of surface radioiodination and biosynthetic labeling also demonstrated a selective post-synthetic decrease in cell-surface expression of the alpha-5-beta-1 integrin upon loss of cell attachment. Overall, we estimate that extracellular fibronectin and cell surface alpha-5-beta-1 integrin levels are reduced 5-7-fold in NIH-3T3, 15-20-fold in AKR-2B, and 50-fold in NRK fibroblasts. Finally, we find decreased total (serum- and cell-derived) fibronectin bound to the surface of nonadherent cells consistent with the reduced expression of alpha-5-beta-1 integrin. These results demonstrate a systematic down-regulation of fibronectin and its major receptor upon loss of attachment and suggest a potential mechanism involved in maintenance of the anchorage-dependent phenotype.	COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR REPROD SCI, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NICHD NIH HHS [HD05077] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CAYANIS E, 1990, J BIOL CHEM, V265, P10829; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; HYNES RO, 1990, FIBRONECTINS, P301; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KESKIOJA J, 1980, CANCER RES, V40, P4722; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MOSES HL, 1985, CANCER CELL, V3, P65; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SPORN MB, 1984, CANCER CELL, V1, P1; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WERB Z, 1986, J CELL BIOL, V102, P697, DOI 10.1083/jcb.102.3.697; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	44	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8186	8191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373721				2022-12-25	WOS:A1992HQ18500036
J	KANAYA, S; NAKAI, C; KONISHI, A; INOUE, H; OHTSUKA, E; IKEHARA, M				KANAYA, S; NAKAI, C; KONISHI, A; INOUE, H; OHTSUKA, E; IKEHARA, M			A HYBRID RIBONUCLEASE-H - A NOVEL RNA CLEAVING ENZYME WITH SEQUENCE-SPECIFIC RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SELECTIVE CLEAVAGE; DNA-SEQUENCE; OLIGONUCLEOTIDES; GENE; OLIGORIBONUCLEOTIDES; IDENTIFICATION; TRANSLATION; RESIDUES	A hybrid enzyme which site-specifically hydrolyzes RNA was created by covalently linking an oligodeoxyribonucleotide to Escherichia coli ribonuclease HI, an enzyme which specifically cleaves RNA moiety of DNA/RNA hybrids. A cysteine residue was substituted for Glu135 by site-directed mutagenesis in the mutant enzyme, in which all 3 free cysteine residues were replaced by alanine (Kanaya, S., Kimura, S., Katsuda, C., and Ikehara, M. (1990) Biochem. J. 271, 59-66), and coupled with a maleimide group, which is attached to the 5' terminus of the nonadeoxyribonucleotide (5'-GTCATCTCC-3') with a flexible tether. The resulting hybrid enzyme, d9-C135/RNase H, cleaved the phosphodiester bond between the fifth and sixth residues of the complementary nonaribonucleotide, without addition of the oligodeoxyribonucleotide. The nonaribonucleotide is cleaved by the wild-type or unmodified mutant enzyme only when the complementary oligodeoxyribonucleotide is present. When the kinetic parameters of the hybrid enzyme for the hydrolysis of the nonaribonucleotide were compared with those of the unmodified mutant enzyme for the hydrolysis of the nonanucleotide duplex, the hybrid enzyme exhibited a 7- and 4-fold decreases in the K(m) and k(cat) values, respectively, indicating that it performs multiple turnovers and has a sufficiently high hydrolytic activity. Hybrid ribonucleases H with various oligodeoxyribonucleotides in size and sequence, therefore, might be used as excellent tools for structural and functional studies of RNA.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	KANAYA, S (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ATABEKOV KJ, 1988, FEBS LETT, V232, P96, DOI 10.1016/0014-5793(88)80393-4; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; COREY DR, 1987, SCIENCE, V238, P1401, DOI 10.1126/science.3685986; CROUCH R J, 1990, New Biologist, V2, P771; Crouch RJ, 1985, NUCLEASES, P211; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P580; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HAYASE Y, 1990, BIOCHEMISTRY-US, V29, P8793, DOI 10.1021/bi00489a041; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; IWAI S, 1990, TETRAHEDRON, V46, P6673, DOI 10.1016/S0040-4020(01)87858-3; JAY E, 1974, NUCLEIC ACIDS RES, V1, P331, DOI 10.1093/nar/1.3.331; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KITAGAWA T, 1981, CHEM PHARM BULL, V29, P1130; KOIZUMI M, 1989, NUCLEIC ACIDS RES, V17, P7059, DOI 10.1093/nar/17.17.7059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METELEV VG, 1988, FEBS LETT, V226, P232, DOI 10.1016/0014-5793(88)81429-7; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7179, DOI 10.1093/nar/17.18.7179; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHIBAHARA S, 1987, NUCLEIC ACIDS RES, V15, P4403, DOI 10.1093/nar/15.11.4403; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZUCKERMANN RN, 1988, J AM CHEM SOC, V110, P1614, DOI 10.1021/ja00213a040; ZUCKERMANN RN, 1988, J AM CHEM SOC, V110, P6592, DOI 10.1021/ja00227a066; ZUCKERMANN RN, 1989, P NATL ACAD SCI USA, V86, P1766, DOI 10.1073/pnas.86.6.1766	43	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8492	8498						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373729				2022-12-25	WOS:A1992HQ18500083
J	NEGISHI, M; HASHIMOTO, H; ICHIKAWA, A				NEGISHI, M; HASHIMOTO, H; ICHIKAWA, A			TRANSLOCATION OF ALPHA-SUBUNITS OF STIMULATORY GUANINE NUCLEOTIDE-BINDING PROTEINS THROUGH STIMULATION OF THE PROSTACYCLIN RECEPTOR IN MOUSE MASTOCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DECAPEPTIDE; ADENYLATE-CYCLASE SYSTEM; PLASMA-MEMBRANE; PLATELET MEMBRANES; GS-ALPHA; ACTIVATION; MYRISTOYLATION; IDENTIFICATION; PROSTAGLANDIN; TRANSDUCERS	The translocation of the alpha-subunits of Gs from the membrane to the cytosol by iloprost, a stable prostacyclin analogue, was studied in mouse mastocytoma P-815 cells. In the presence of guanosine 5'-O-(thiotriphosphate) (GTP-gamma-S), iloprost stimulated the adenylate cyclase activity, caused the release of both 42- and 45-kDa proteins reactive with the anti Gs-alpha carboxyl-terminal antibody, RM/1, from the membrane and attenuated cholera toxin-catalyzed ADP-ribosylation of the 42- and 45-kDa proteins in the membrane. The iloprost-stimulated adenylate cyclase activity and release of Gs-alpha from the membrane were markedly suppressed by RM/1. Cholera toxin treatment also stimulated the adenylate cyclase activity and release of Gs-alpha from the membrane, and iloprost synergistically potentiated these actions of cholera toxin. In mastocytoma cells, iloprost induced the translocation of both 42- and 45-kDa Gs-alpha from the membrane to the cytosol, 45-kDa Gs-alpha remaining in the cytosol for a longer time than 42-kDa Gs-alpha. Whereas 42-kDa Gs-alpha in the cytosol was eluted at the position of M(r) = approximately 40,000, 45-kDa Gs-alpha was eluted at the position of M(r) = approximately 120,000 from a Superose 12 gel filtration column. In contrast, both 42- and 45-kDa Gs-alpha released in vitro from the membrane by iloprost plus GTP-gamma-S were eluted at the position of M(r) = approximately 40,000, but only 45-kDa Gs-alpha was eluted at the position of M(r) = approximately 120,000 when it was incubated with cytosol. These results taken together demonstrate that iloprost induces the translocation of both 42- and 45-kDa Gs-alpha from the membrane to the cytosol and that only the 45-kDa Gs-alpha released exists in the cytosol as a soluble complex with unidentified component(s) in mastocytoma cells.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN	Kyoto University			Hashimoto, Hitoshi/D-1209-2010	Hashimoto, Hitoshi/0000-0001-6548-4016				BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHANG FH, 1989, J BIOL CHEM, V264, P5352; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; JOHNSON AR, 1970, J PHARMACOL EXP THER, V175, P632; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KADOWITZ PJ, 1978, J APPL PHYSIOL, V45, P408, DOI 10.1152/jappl.1978.45.3.408; LOMBROSO M, 1984, PROSTAGLANDINS, V27, P321, DOI 10.1016/0090-6980(84)90083-2; LYNCH CJ, 1986, FEBS LETT, V200, P333, DOI 10.1016/0014-5793(86)81163-2; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLIGAN G, 1989, BIOCHEM J, V260, P837, DOI 10.1042/bj2600837; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEGISHI M, 1991, BIOCHEM BIOPH RES CO, V176, P102, DOI 10.1016/0006-291X(91)90895-E; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135	27	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2364	2369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370818				2022-12-25	WOS:A1992HB53200040
J	NUTTER, LM; NGO, EO; FISHER, GR; GUTIERREZ, PL				NUTTER, LM; NGO, EO; FISHER, GR; GUTIERREZ, PL			DNA STRAND SCISSION AND FREE-RADICAL PRODUCTION IN MENADIONE-TREATED CELLS - CORRELATION WITH CYTOTOXICITY AND ROLE OF NADPH QUINONE ACCEPTOR OXIDOREDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXICITY; INTERCALATING AGENTS; ISOLATED HEPATOCYTES; HYDROGEN-PEROXIDE; RAT HEPATOCYTES; MAMMALIAN-CELLS; TUMOR-CELLS; METABOLISM; DAMAGE; THIOL	Menadione (MD; 2-methyl-1,4-naphthoquinone), a redox cycling quinone was shown to induce single (ss)- and double (ds)-strand DNA breaks in human MCF-7 cells. This DNA damage was mediated via the hydroxyl radical as evidenced by electron spin resonance spectroscopy (ESR) studies utilizing the spin- trap, 5,5-dimethyl-1-pyrroline-1-oxide. The free radical production and DNA damage were shown to play a role in MD cytotoxicity as revealed by the reversal of MD toxicity and inhibition of hydroxyl radical production by exogeneously added catalase. The role of NADPH quinone acceptor oxidoreductase in the metabolism of MD was evaluated. Purified quinone acceptor oxidoreductase in combination with MD resulted in the production of significant levels of the hydroxyl radical as measured by ESR. Dicumarol, an inhibitor of quinone acceptor oxidoreductase, decreased the production of the hydroxyl radical and attenuated DNA strand breaks in MCF-7 cells treated with MD.	UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore	NUTTER, LM (corresponding author), UNIV MINNESOTA,DEPT PHARMACOL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NCI NIH HHS [CA33861, 1R29CA52618-O1A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1985, CANCER RES, V45, P5257; AKMAN SA, 1987, J PHARMACOL EXP THER, V240, P486; BEGLEITER A, 1988, CANCER RES, V48, P1727; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; Buettner G.R, 1982, SUPEROXIDE DISMUTASE, V2, P63; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; CHLEBOWSKI RT, 1985, CANCER TREAT REV, V12, P49, DOI 10.1016/0305-7372(85)90012-X; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4513; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FISHER GR, 1991, FREE RADICAL BIO MED, V10, P359, DOI 10.1016/0891-5849(91)90044-4; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GOLD J, 1986, CANCER TREAT REP, V70, P1433; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KEYES SR, 1985, CANCER RES, V45, P213; KOHN KW, 1979, METHOD CANCER RES, V16, P291; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; MARTINS EAL, 1990, FREE RADICAL BIO MED, V8, P433, DOI 10.1016/0891-5849(90)90056-O; MIRABELLI F, 1988, BIOCHEM PHARMACOL, V37, P3423, DOI 10.1016/0006-2952(88)90691-0; MORRISON H, 1984, BIOCHEM PHARMACOL, V33, P1763, DOI 10.1016/0006-2952(84)90347-2; MORRISON H, 1985, TOXICOL LETT, V28, P37, DOI 10.1016/0378-4274(85)90007-4; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NUTTER L M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P5; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; OLLINGER K, 1990, CHEM-BIOL INTERACT, V73, P53, DOI 10.1016/0009-2797(90)90108-Y; POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; SIEGEL D, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P558; SINHA BK, 1987, BIOCHEMISTRY-US, V26, P3776, DOI 10.1021/bi00387a006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SU YZ, 1987, CANCER TREAT REP, V71, P619; THOR H, 1982, J BIOL CHEM, V257, P2419; TSUDA H, 1990, CANCER LETT, V55, P195, DOI 10.1016/0304-3835(90)90119-I; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006	38	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2474	2479						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370822				2022-12-25	WOS:A1992HB53200056
J	YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC				YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC			MECHANISMS OF C-ERBB2/NEU ONCOGENE-INDUCED METASTASIS AND REPRESSION OF METASTATIC PROPERTIES BY ADENOVIRUS 5 E1A GENE-PRODUCTS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; RAT EMBRYO CELLS; TUMOR-CELLS; PROTO-ONCOGENE; C-ERBB-2 GENE; NEU ONCOGENE; CANCER METASTASIS; CARCINOMA-CELLS; OVARIAN-CANCER; INVITRO ASSAY	c-erbB2/neu is a transforming oncogene that encodes a 185-kDa transmembrane glycoprotein. In many but not all studies, amplification and/or overexpression of the human c-erbB2/neu oncogene has been correlated with poor prognosis and the number of lymph node metastases in node-positive breast cancer patients. We have shown that expression of the activated rat c-erbB2/neu oncogene in mouse embryo fibroblast 3T3 cells is sufficient to induce experimental metastases in nude mice. Important steps in the metastatic event are tumor cell adhesion to endothelial cells and invasion of basement membranes. Therefore, we further examined the ability of c-erbB2/neu oncogene-transformed 3T3 cells to adhere to microvessel endothelial cells and secrete basement membrane-degradative enzymes. The c-erbB2/neu oncogene-transformed 3T3 cells were shown to be more adherent and have higher gelatinase activities. Since we had previously shown that the adenovirus 5 E1A gene product can suppress c-erbB2/neu-induced transformation of 3T3 cells, we examined the possibility that E1A can abrogate the metastatic properties of c-erbB2/neu-transformed 3T3 cells. We found that introduction of the EIA gene into c-erbB2/neu-transformed 3T3 cells reduced the formation of experimental metastatic tumors and inhibited metastasis-associated properties, such as adhesion to microvessel endothelial cells, migration through a layer of reconstituted basement membrane (Matrigel) and secretion of basement membrane-degradative enzymes. The results indicate that the mechanism by which the c-erbB2/neu gene induces higher metastatic potential is to promote adhesion and invasion steps of the metastatic cascade. The EIA gene, which functions by inhibiting these steps, is thus a suppressor gene for c-erbB2/neu-induced experimental metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [R35-CA 44352, R03-CA54989, R01-CA41524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA054989, R35CA044352, R01CA041524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; AUERBACH R, 1987, CANCER RES, V47, P1492; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; DEMILIA J, 1989, ONCOGENE, V4, P1233; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMADA JI, 1992, IN PRESS BR J CANCER; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INOKUCHI J, 1990, CANCER RES, V50, P6731; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, CANCER RES, V46, P1; LIOTTA LA, 1989, MECHANISMS CANCER IN; MENSING H, 1983, EUR J CELL BIOL, V29, P268; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAJIMA M, 1989, CANCER RES, V49, P1698; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1989, INVAS METAST, V9, P102; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; REPESH LA, 1989, INVAS METAST, V9, P192; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P77; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WEINER DB, 1990, CANCER RES, V50, P421; WEXLER DH, 1986, J NATL CANCER I, V36, P641; YAN DH, 1991, ONCOGENE, V6, P343; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG X, 1989, ONCOGENE, V4, P985	55	105	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359495				2022-12-25	WOS:A1992JW66500019
J	BERNDT, JA; KIM, JG; HUDSON, LD				BERNDT, JA; KIM, JG; HUDSON, LD			IDENTIFICATION OF CIS-REGULATORY ELEMENTS IN THE MYELIN PROTEOLIPID PROTEIN (PLP) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-SPECIFIC TRANSCRIPTION; BASIC-PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; MAMMALIAN-CELLS; INVITRO TRANSCRIPTION; BINDING-PROTEINS; RAPID ASSAY; GLIAL-CELLS; JC VIRUS; EXPRESSION	Regulatory elements of the proteolipid protein (PLP) gene were identified physically by footprinting and gel mobility shift assays and functionally by transfecting glial cell lines with PLP-chloramphenicol acetyltransferase chimeric genes. In both human and rat glial cells, only several hundred base pairs of upstream sequence were sufficient for high level activity of the human PLP promoter. This region contains five sites that contact nuclear proteins in vitro. More distal recognition sites may exist, as regions upstream of -524 displayed silencing activity indicative of a negative regulatory element. A series of site directed mutations revealed one essential positive element (ATGGA at -118) which is found in other genes encoding myelin proteins. Our combined biochemical and functional analyses indicate that the key cis sites for maximal tissue-specific expression of PLP in cultured glial cells are clustered near the promoter. Within this cluster are several conserved motifs that may coordinate the regulation of myelin-specific genes.	NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BLDG 36, RM 5D04, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRITTEN RJ, 1971, Q REV BIOL, V46, P111, DOI 10.1086/406830; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GARDINIER MV, 1988, J NEUROCHEM, V51, P360; GENCIC S, 1990, J NEUROSCI, V10, P117; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOUT O, 1991, Society for Neuroscience Abstracts, V17, P375; HOLTER W, 1989, EXP CELL RES, V184, P546, DOI 10.1016/0014-4827(89)90353-4; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; HUDSON LD, 1990, SEMIN NEUROSCI, V2, P483; Hudson Lynn D., 1992, P677; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR D, 1991, J BIOL CHEM, V266, P15876; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LASHGARI MS, 1990, J CLIN INVEST, V86, P1671, DOI 10.1172/JCI114890; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1990, SEMIN NEUROSCI, V2, P437; LEVINE SM, 1990, DEV NEUROSCI-BASEL, V12, P235, DOI 10.1159/000111853; MACKLIN WB, 1987, J NEUROSCI RES, V18, P383, DOI 10.1002/jnr.490180302; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MATTHIEU J-M, 1991, Journal of Neurochemistry, V57, pS13; MATTHIEU JM, 1990, NEUROL NEUR, V59, P109; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MCKINNON RD, 1986, MICROINJECTION ORGAN, P199; MIRKSY R, 1990, SEMIN NEUROSCI, V2, P423; MIURA M, 1989, GENE, V75, P31; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NADON N, 1989, J CELL BIOCH B S, V13, P181; NAVA KA, 1991, J NEUROSCI, V11, P3060; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Richardson WD, 1990, SEMIN NEUROSCI, V2, P445; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHINDLER P, 1990, J NEUROCHEM, V55, P2079, DOI 10.1111/j.1471-4159.1990.tb05798.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUBERT D, 1986, J NEUROSCI, V6, P2829; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VERDI JM, 1989, J NEUROCHEM, V52, P321, DOI 10.1111/j.1471-4159.1989.tb10935.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	55	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14730	14737						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378839				2022-12-25	WOS:A1992JF08800037
J	GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF				GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF			CLONAL CHARACTERISTICS OF ACUTE LYMPHOBLASTIC CELLS DERIVED FROM BCR ABL-P190 TRANSGENIC MICE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; ABL ONCOGENE; BONE-MARROW; GENE; REARRANGEMENT; STIMULATION; EXPRESSION; INVITRO; TRANSLOCATION	The clonal and immunophenotypic characteristics of blood leukemic cells from BCR/ABL p190 transgenic mice were investigated. All cell populations evaluated in vivo and in vitro had B-lymphocyte progenitor immunophenotypes. Immunoglobulin (J(H)) rearrangement patterns provided evidence for clonal diversification at different sites in vivo. Multiple clones were established in vitro from two of these mice (nos. 730 and 753). These cells expressed BCR/ABL p190 protein tyrosine kinase (PTK) and were highly malignant on transfer to secondary recipients. Cells independently cloned in vitro shared identical immunophenotypes and clonal IgH rearrangements, but these were distinct from those of the dominant clones in the mouse from which they were derived. Nevertheless, in vitro clones from mouse no. 753 had an abnormal karyotype (chromosome 14 trisomy) in common with the dominant clone in blood, providing evidence for a hierarchy or clonal selection in vivo and in vitro. Two sets of in vitro clones proliferated independently of exogenous growth factors and stroma and released autocrine interleukin 7 growth factor activity. These data provide evidence for rapid divergent clonal evolution and selection of B-cell progenitors initiated by BCR/ABL p190, followed by other, secondary genetic events mirroring similar changes in the equivalent, highly malignant human leukemia Philadelphia (Ph)-positive/B-precursor acute lymphoblastic leukemia (ALL).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90054	Children's Hospital Los Angeles	GRIFFITHS, SD (corresponding author), INST CANC RES,CTR LEUKAEMIA RES FUND,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Healy, Lyn/0000-0002-7044-8789	NATIONAL CANCER INSTITUTE [R01CA050248, R01CA047073] Funding Source: NIH RePORTER; NCI NIH HHS [CA47073, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BLOOMFIELD CD, 1989, CANCER GENET CYTOGEN, V40, P171, DOI 10.1016/0165-4608(89)90023-X; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOPER MD, 1986, NATURE, V321, P616, DOI 10.1038/321616a0; COWLING GJ, 1985, MODERN TRENDS HUMAN, V6, P385; DEKLEIN A, 1986, BLOOD, V68, P1369; DHUT S, 1991, LEUKEMIA, V5, P49; DOW LW, 1989, BLOOD, V73, P1291; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GIMBLE JM, 1989, BLOOD, V74, P303; GREAVES MF, 1986, CLIN HAEMATOL, V15, P621; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HIRSCHGINSBERG C, 1988, BLOOD, V71, P186; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; KALOUSEK DK, 1988, BRIT J HAEMATOL, V70, P5, DOI 10.1111/j.1365-2141.1988.tb02426.x; Kincade P W, 1990, Adv Cancer Res, V54, P235, DOI 10.1016/S0065-230X(08)60813-1; KITANO K, 1988, BRIT J HAEMATOL, V70, P21, DOI 10.1111/j.1365-2141.1988.tb02428.x; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE G, 1989, J IMMUNOL, V142, P3875; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCNAGNY KM, 1988, J IMMUNOL, V141, P2551; MINOWADA J, 1980, S NEW TRENDS HUMAN I, P188; NAEME PB, 1985, BLOOD, V65, P142; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OCONNOR R, 1991, BLOOD, V77, P1534; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PALUMBO GJ, 1990, CANCER RES, V90, P1917; RIBEIRO RC, 1987, BLOOD, V70, P948; RIEDER H, 1991, CANCER GENET CYTOGEN, V53, P139; RUSSO C, 1991, BLOOD, V77, P1050; Sambrook J, 1989, MOL CLONING LABORATO; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TURHAN AG, 1988, BLOOD, V71, P1495; VONCKEN JW, 1992, BLOOD, V79, P1029; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1391	1399						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377812				2022-12-25	WOS:A1992HZ97100018
J	VALLEJO, M; PENCHUK, L; HABENER, JF				VALLEJO, M; PENCHUK, L; HABENER, JF			SOMATOSTATIN GENE UPSTREAM ENHANCER ELEMENT ACTIVATED BY A PROTEIN COMPLEX CONSISTING OF CREB, ISL-1-LIKE, AND ALPHA-CBF-LIKE TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; DNA-BINDING PROTEIN; CAMP RESPONSE ELEMENTS; CYCLIC-AMP; INSULIN GENE; PROMOTER ELEMENT; NUCLEAR FACTORS; GLUCAGON GENE; SUBUNIT GENE; SEQUENCE	The expression of the genes encoding the hormones glucagon, insulin, somatostatin, and pancreatic polypeptide in the endocrine islets of the pancreas is regulated in a cell-specific manner, defining four distinct cellular phenotypes (A-, B-, D-, and F-cells, respectively). Binding of nuclear proteins to cognate DNA sequences within cis-acting regulatory elements mediates the transcriptional events that result in the cell-specific activation or repression of gene expression. In a parallel study, we describe the functional properties of the SMS-UE, a pancreatic islet D-cell specific enhancer element that regulates the expression of the somatostatin gene and contains two interdependent domains, A and B. In the studies described herein, we have characterized the nuclear proteins that recognize the SMS-UE. Domain A of the SMS-UE is a DNA enhancer sequence that is identical to that bound by the ubiquitously distributed CCAAT box-binding protein alpha-CBF, a transcription factor that regulates the expression of the human chorionic gonadotrophin alpha-subunit gene. The B-domain, on the other hand, binds an islet cell-specific protein with characteristics similar to those of Isl-1, a transcriptional activator protein that binds to the E2 enhancer of the rat insulin-1 gene. In addition, the SMS-UE binds transcription factor CREB but not CREM, the close homolog of CREB, on a site adjacent to, or overlapping, the 3' end of domain B. We show that the carboxyl-terminal bZIP domain of CREB binds to the cAMP response element of the somatostatin gene but is not sufficient for binding to the SMS-UE, and we present evidence suggesting that CREB.SMS-UE binding requires stabilization by a region of the protein located within the transactivation domain.			VALLEJO, M (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114, USA.		Vallejo, Mario/ABG-4610-2020	Vallejo, Mario/0000-0002-6422-0323	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030457, R37DK030457] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30457] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUDEK RW, 1991, DIABETES, V40, P1041, DOI 10.2337/diabetes.40.8.1041; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUHRMANN G, 1990, NUCLEIC ACIDS RES, V18, P1287, DOI 10.1093/nar/18.5.1287; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1089; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANAK R, 1991, MOL CELL BIOL, V11, P3652; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON E, 1991, MOL ENDOCRINOL, V5, P879; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; POWERS AC, 1989, J BIOL CHEM, V264, P10048; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN LP, 1984, SCIENCE, V224, P168, DOI 10.1126/science.6142531; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STRATOWA C, 1986, P NATL ACAD SCI USA, V83, P4292, DOI 10.1073/pnas.83.12.4292; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931	73	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12876	12884						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352292				2022-12-25	WOS:A1992HZ48300074
J	NINOMIYA, H; STEWART, BH; ROLLINS, SA; ZHAO, J; BOTHWELL, ALM; SIMS, PJ				NINOMIYA, H; STEWART, BH; ROLLINS, SA; ZHAO, J; BOTHWELL, ALM; SIMS, PJ			CONTRIBUTION OF THE N-LINKED CARBOHYDRATE OF ERYTHROCYTE ANTIGEN CD59 TO ITS COMPLEMENT-INHIBITORY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID LATERAL DIFFUSION; MEMBRANE ATTACK COMPLEX; BIOLOGICAL-ACTIVITY; REGULATORY CONTROL; BLOOD-PLATELETS; LYMPHOID-CELLS; PROTEIN; C5B-9; SURFACE; SPECIFICITY	The contribution of N-linked carbohydrate to the complement-inhibitory function of the human erythrocyte membrane glycoprotein, CD59, was investigated. Amino acid sequence analysis of tryptic peptides labeled with [H-3]borohydride revealed an N-linked carbohydrate moiety at the Asn18 residue. No O-linked carbohydrate was detected, as judged by the failure of asialo-CD59 to bind peanut agglutinin and by its resistance to digestion by O-glycanase. The apparent molecular mass of CD59 was reduced from 18-20 to 14 kDa upon complete digestion with N-glycanase, with no detectable proteolysis. N-glycanase digestion of CD59 was associated with an 88 +/- 4% loss of the complement-inhibitory activity of the protein, as assessed by its capacity to protect chicken erythrocytes from lysis by the human C5b-9 proteins. By contrast, no change in function was observed after digestion of CD59 with neuraminidase, under conditions that removed > 60% of [H-3]sialic acid residues. Despite loss of functional activity after N-glycanase digestion, we detected no change in the capacity of the deglycosylated CD59 to incorporate into erythrocyte membranes or to bind specifically and with species selectivity to the C8 and C9 components of the membrane attack complex. In order to alter the branched-chain structure of the N-linked carbohydrate of CD59 without enzymatic digestion, Chinese hamster ovary (CHO) cells transfected with cDNA for human CD59 were grown in the alpha-mannosidase inhibitor, 1-deoxymannojirimycin, resulting in conversion of approximately 70% of the membrane glycoprotein to a high mannose. When grown in the presence of 1-deoxymannojirimycin, the C5b-9-inhibitory activity of CD59 expressed on the surface of the transfected CHO cells was reduced by an amount comparable to that observed for the N-glycanase digested protein. Taken together, these data suggest that normal glycosylation of Asn18 in CD59 is required for the normal expression of its complement-inhibitory activity on membrane surfaces, although these N-linked sugar residues do not contribute to CD59's affinity for the C8 and C9 components of the C5b-9 complex.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R37HL036061, R01HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946, HL36061] Funding Source: Medline; NIGMS NIH HHS [GM40924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; HAMILTON KK, 1990, BLOOD, V76, P2572; HARADA R, 1990, J IMMUNOL, V144, P1823; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MERI S, 1990, IMMUNOLOGY, V71, P1; NODA K, 1991, Complement and Inflammation, V8, P199; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; OKADA H, 1983, EUR J IMMUNOL, V13, P340, DOI 10.1002/eji.1830130413; OKADA N, 1989, J IMMUNOL, V143, P2262; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PHILBRICK WM, 1990, EUR J IMMUNOL, V20, P87, DOI 10.1002/eji.1830200113; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P589, DOI 10.1093/oxfordjournals.jbchem.a122900; SUTTAJIT M, 1971, J BIOL CHEM, V246, P3405; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	27	70	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8404	8410						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373727				2022-12-25	WOS:A1992HQ18500070
J	MURPHY, PM; OZCELIK, T; KENNEY, RT; TIFFANY, HL; MCDERMOTT, D; FRANCKE, U				MURPHY, PM; OZCELIK, T; KENNEY, RT; TIFFANY, HL; MCDERMOTT, D; FRANCKE, U			A STRUCTURAL HOMOLOG OF THE N-FORMYL PEPTIDE RECEPTOR - CHARACTERIZATION AND CHROMOSOME MAPPING OF A PEPTIDE CHEMOATTRACTANT RECEPTOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; XENOPUS OOCYTES; WASP VENOM; CDNA; CLONING; EXPRESSION; MASTOPARAN; SEQUENCE; BINDING; GENES	Phagocytic cells of many higher species express calcium mobilizing G protein-coupled receptors for bacterial N-formyl peptides which mediate chemotaxis, degranulation, and the respiratory burst. cDNA encoding an N-formyl peptide receptor (FPR) has been reported. We now report the isolation of a closely related cDNA, 2.6 kilobase pairs in length, which we have designated as the FPRL1 receptor cDNA (FPRL1 = formyl peptide receptor like-1). FPR and the FPRL1 receptor derive from small, single-copy genes, both of which are located on human chromosome 19. The gene loci are designated FPR1 and FPRL1, respectively. Both FPR and FPRL1 cDNA cross-hybridize under high stringency conditions with a third gene, designated as FPRL2, which does not appear to be expressed in neutrophils. In contrast, transcripts for both the FPRL1 receptor and FPR are detected only in differentiated myeloid cells; the distribution of N-formyl peptide binding sites is also restricted to mature myeloid cells. FPRL1 cDNA encodes a 351-amino acid polypeptide whose sequence is 69% identical to that of FPR. G protein-coupled receptors that exhibit this degree of structural similarity typically possess a conserved ligand specificity. However, the FPRL1 receptor does not bind prototype N-formyl peptide ligands when expressed in heterologous cell types. These results suggest that FPR1 may be the only gene that is expressed by neutrophils that encodes a receptor capable of binding prototype N-formyl peptides. Moreover, discovery of the FPRL1 receptor indicates the existence of another as yet unidentified peptide that may recruit neutrophils to sites of inflammation.	HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	MURPHY, PM (corresponding author), NIAID, HOST DEF LAB, BLDG 10, RM 11N113, BETHESDA, MD 20892 USA.		McDermott, David/AAP-2459-2021	McDermott, David/0000-0001-6978-0867	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUGHMAN JA, 1986, J CRAN GENET DEV BIO, V6, P341; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN IM, 1988, INFLAMMATION BASIC P, P55; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MIYAKE Y, 1983, BIOCHIM BIOPHYS ACTA, V758, P181, DOI 10.1016/0304-4165(83)90300-8; MURPHY PM, 1990, FEBS LETT, V261, P353, DOI 10.1016/0014-5793(90)80590-F; MURPHY PM, 1990, NUCLEIC ACIDS RES, V18, P1896, DOI 10.1093/nar/18.7.1896; MURPHY PM, 1991, J BIOL CHEM, V266, P12560; MURPHY PM, 1990, J IMMUNOL, V145, P2227; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; ODOWD BF, 1991, ENCY HUM BIOL, V1, P81; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; ROT A, 1987, P NATL ACAD SCI USA, V84, P7967, DOI 10.1073/pnas.84.22.7967; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHIFFER M, 1967, BIOPHYS J, V7, P121; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; WANG CR, 1991, CELL, V66, P1; WESS J, 1990, MOL PHARMACOL, V38, P517; WILSON SP, 1989, FEBS LETT, V247, P239, DOI 10.1016/0014-5793(89)81343-2; YAKOTA Y, 1989, J BIOL CHEM, V264, P17649	47	203	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7637	7643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373134				2022-12-25	WOS:A1992HN48500063
J	GUADAGNO, SN; BORNER, C; WEINSTEIN, IB				GUADAGNO, SN; BORNER, C; WEINSTEIN, IB			ALTERED REGULATION OF A MAJOR SUBSTRATE OF PROTEIN-KINASE-C IN RAT 6 FIBROBLASTS OVERPRODUCING PKC-BETA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; PROMINENT CELLULAR SUBSTRATE; SUBCELLULAR-DISTRIBUTION; TRANSFORMED FIBROBLASTS; POLYACRYLAMIDE GELS; CALMODULIN-BINDING; MOLECULAR-CLONING; GENE-EXPRESSION; DOWN-REGULATION; 87-KDA PROTEIN	We have shown previously that the stable overproduction of protein kinase C beta-I (cPKC-beta-I) in rat 6 (R6) embryo fibroblasts results in multiple cellular growth abnormalities. To characterize the pathways through which cPKC-beta-I acts to exert its effects, we have undertaken a biochemical analysis of the cell line R6-PKC3. The subcellular distribution of cPKC-beta-I in unstimulated R6-PKC3 cells was approximately 80% cytosolic and approximately 20% membrane bound, and treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in translocation and down-regulation of an appreciable fraction of the cPKC-beta-I enzyme. However, long term TPA treatment was not sufficient to down-regulate all of the overproduced enzyme from both the cytosolic and membrane fractions. Two-dimensional gel analysis of P-32-labeled cellular phosphoproteins from either untreated or TPA-treated cultures revealed only minor qualitative differences between R6-PKC3 cells and a vector control cell line, R6-C1. On the other hand, several quantitative differences in the level of phosphorylation of discrete protein spots were seen. The most prominent phosphoprotein was a previously described 80/87-kDa protein designated MARCKS (myr-istoylated alanine-rich C kinase substrate). Compared with R6-C1 cells, R6-PKC3 cells exhibited a 2-3-fold increase in the basal level of phosphorylation of MARCKS and after treatment with TPA, displayed a dramatic prolongation in phosphorylation of this protein. Additionally, treatment of R6-PKC3 cells with TPA led to a prolonged increase in both the cytosolic and total cellular level of the MARCKS protein and a pronounced decrease in the level of MARCKS mRNA. Taken together, these results indicate that overproduction of cPKC-beta-I markedly alters several parameters of the MARCKS protein which may be responsible, at least in part, for the altered phenotype of these cells.	COLUMBIA UNIV,CTR COMPREHENS CANC,701 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					PHS HHS [02656] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENZEEV A, 1986, TRENDS BIOCHEM SCI, V11, P478, DOI 10.1016/0968-0004(86)90251-3; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1991, IN PRESS NATURE; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIEH LL, 1989, J CELL BIOCHEM, V41, P179, DOI 10.1002/jcb.240410403; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1989, J BIOL CHEM, V264, P20928; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAUSS RS, 1989, ONCOGENE, V4, P991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1990, J BIOL CHEM, V265, P22434; PATEL J, 1987, J BIOL CHEM, V262, P16686; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; RODRIGUEZPENA A, 1986, BIOCHEM BIOPH RES CO, V140, P379, DOI 10.1016/0006-291X(86)91101-0; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WOODGETT JR, 1987, CELL MEMBRANES METHO, V3, P215; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	69	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2697	2707						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370830				2022-12-25	WOS:A1992HB53200089
J	LUTFALLA, G; GARDINER, K; PROUDHON, D; VIELH, E; UZE, G				LUTFALLA, G; GARDINER, K; PROUDHON, D; VIELH, E; UZE, G			THE STRUCTURE OF THE HUMAN INTERFERON ALPHA-BETA-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSIGNMENT; SEQUENCE; PROTEIN; GAMMA; CHROMOSOME-21; ORGANIZATION; SUPERFAMILY; EXPRESSION; CLONING; GENOME	Using the cDNA coding for the human interferon alpha/beta-receptor (IFNAR), the IFNAR gene has been physically mapped relative to the other loci of the chromosome 21q22.1 region. 32,906 base pairs covering the IFNAR gene have been cloned and sequenced. Primer extension and solution hybridization-ribonuclease protection have been used to determine that the transcription of the gene is initiated in a broad region of 20 base pairs. Some aspects of the polymorphism of the gene, including noncoding sequences, have been analyzed; some are allelic differences in the coding sequence that induce amino acid variations in the resulting protein. The exon structure of the IFNAR gene and of that of the available genes for the receptors of the cytokine/growth hormone/prolactin/interferon receptor family have been compared with the predictions for the secondary structure of those receptors. From this analysis, we postulate a common origin and propose an hypothesis for the divergence from the immunoglobulin superfamily.	ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA		LUTFALLA, G (corresponding author), INST RECH SCI CANC, CNRS, VIRAL ONCOL LAB, 7 RUE GUY MOQUET, BP 8, F-94801 VILLEJUIF, FRANCE.		Lutfalla, Georges/AAW-9386-2021; Uzé, Gilles/O-6383-2019	Uze, Gilles/0000-0002-4150-5772; LUTFALLA, Georges/0000-0002-6591-7894	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NHGRI NIH HHS [KO1 HG00001] Funding Source: Medline; NICHD NIH HHS [P01 HD17449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX DR, 1990, CYTOGENET CELL GENET, V55, P235, DOI 10.1159/000133017; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GABORIAUD C, 1990, FEBS LETT, V269, P1, DOI 10.1016/0014-5793(90)81103-U; GARDINER K, 1990, J CELL SCI, V96, P5; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCINNIS MG, 1991, GENOMICS, V11, P573, DOI 10.1016/0888-7543(91)90064-L; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; Sambrook J, 1989, MOL CLONING LABORATO; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VIELH E, 1990, NUCLEIC ACIDS RES, V18, P5580, DOI 10.1093/nar/18.18.5580; WATKINS PC, 1987, CYTOGENET CELL GENET, V46, P712; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	30	88	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2802	2809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370833				2022-12-25	WOS:A1992HB53200103
J	PORT, JD; HUANG, LY; MALBON, CC				PORT, JD; HUANG, LY; MALBON, CC			BETA-ADRENERGIC AGONISTS THAT DOWN-REGULATE RECEPTOR MESSENGER-RNA UP-REGULATE A M(R) 35,000 PROTEIN(S) THAT SELECTIVELY BINDS TO BETA-ADRENERGIC-RECEPTOR MESSENGER-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; STABILITY INVITRO; BETA-2-ADRENERGIC RECEPTORS; ALPHA-1-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; GM-CSF; GENE	In an effort to explore the molecular basis for agonist-induced destabilization of beta-adrenergic receptor mRNA, we investigated the nature of RNA-binding proteins both in untreated and agonist-treated DDT1-MF2 smooth muscle cells. Messenger RNAs for the alpha1b-, beta1, and beta2-adrenergic receptors as well as for beta-globin were transcribed in vitro, incubated with cytosolic fractions, covalently cross-linked by short-wave UV light, and analyzed by SDS-polyacrylamide gel electrophoresis. A prominent M(r) 35,000 radiolabeled protein(s) with the following characteristics was identified: (i) binds selectively to beta1- and beta2-adrenergic receptor mRNAs, both of which undergo agonist-induced down-regulation; (ii) does not bind to either alpha1b-adrenergic receptor mRNA, which does not undergo agonist induced down-regulation, or to beta-globin mRNA; (iii) displays binding to beta2-adrenergic receptor mRNA that is selectively competed by poly(U) RNA, but not poly(A), -(C), or -(G) RNA; and (iv) displays binding to receptor mRNA that can be competed by RNA harboring destabilizer sequences that are AU-rich and AUUUA pentamer-rich. The abundance of the M(r) 35,000 RNA-binding protein selective for beta-adrenergic receptor message, a factor we term betaARB protein, varies inversely with the level of receptor mRNA, being induced by agonists that down-regulate receptor mRNA.	SUNY STONY BROOK, HLTH SCI CTR,SCH MED,DEPT PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020	Port, Jonathan D./0000-0001-7048-3544	NHLBI NIH HHS [R01 HL051239] Funding Source: Medline; NIADDK NIH HHS [K04 AM00786] Funding Source: Medline; NIDDK NIH HHS [DK25410, DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111, R01DK025410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1991, CRIT REV EUKAR GENE, V1, P99; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1988, MOL BIOL MED, V5, P1; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	48	116	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24103	24108						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358887				2022-12-25	WOS:A1992JZ23900101
J	SILBERRING, J; CASTELLO, ME; NYBERG, F				SILBERRING, J; CASTELLO, ME; NYBERG, F			CHARACTERIZATION OF DYNORPHIN-A-CONVERTING ENZYME IN HUMAN SPINAL-CORD - AN ENDOPROTEASE RELATED TO A DISTINCT CONVERSION PATHWAY FOR THE OPIOID HEPTADECAPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; MET-ENKEPHALIN; SPECIFICITY; PEPTIDES; NEUROPEPTIDES; BRAIN	A highly specific proteinase, converting dynorphin A (1-17) to enkephalins, was isolated from the human spinal cord and subjected to further characterization. The enzyme was found to be a thiol-dependent protein with a relative molecular mass of 50 kDa and a pH optimum between 5.0 and 5.5. This proteinase appears to exclusively convert dynorphin A (1-17) to Leu-enkephalin and its COOH-terminal extensions Leu-enkephalin-Arg6 (which was a major conversion product) and Leu-enkephalin-Arg6-Arg7 but not the other prodynorphin- or proenkephalin-derived peptides. This high specificity toward a single structure is suggested to be involved in a distinct processing pathway associated with the generation of the opioid peptides with selectivity for delta-opioid receptors.	UNIV UPPSALA,DEPT PHARMACOL,POB 591,S-75124 UPPSALA,SWEDEN	Uppsala University			Castelló, María/GRX-6490-2022; Silberring, Jerzy/AGA-5631-2022; Castelló, María/AGO-5653-2022	Silberring, Jerzy/0000-0002-4362-8362; Castelló, María/0000-0001-8669-4805				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ANDREWS PC, 1989, REGUL PEPTIDES, P193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMARGO ACM, 1987, J NEUROCHEM, V48, P1258, DOI 10.1111/j.1471-4159.1987.tb05655.x; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; FUJIMOTO JM, 1989, J PHARMACOL EXP THER, V251, P1045; FUJIMOTO JM, 1990, NEUROPHARMACOLOGY, V29, P609, DOI 10.1016/0028-3908(90)90021-I; FUJIMOTO JM, 1990, PHARMACOLOGIST, V32, P138; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; Hope D B, 1974, Methods Enzymol, V31, P403; KUMAGAI A, 1982, METHOD ENZYMOL, V86, P17; LYRENAS S, 1988, OBSTET GYNECOL, V72, P54; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NYBERG F, 1985, BIOCHEM BIOPH RES CO, V131, P1069, DOI 10.1016/0006-291X(85)90199-8; NYBERG F, 1991, BRAIN RES, V552, P129, DOI 10.1016/0006-8993(91)90670-Q; NYBERG F, 1987, HDB EXPT PHARM, V82, P227; Nyberg F, 1991, DEGRADATION BIOACTIV, P189; NYBERG F, 1990, J PROGR CLIN BIOL RE, V20, P261; PRZEWLOCKI R, 1983, BRAIN RES, V280, P95, DOI 10.1016/0006-8993(83)91177-0; ROOS P, 1979, BIOCHIM BIOPHYS ACTA, V588, P368, DOI 10.1016/0304-4165(79)90345-3; SATOH M, 1989, J NEUROCHEM, V52, P61, DOI 10.1111/j.1471-4159.1989.tb10898.x; SILBERRING J, 1991, J CHROMATOGR, V554, P83, DOI 10.1016/S0021-9673(01)88439-9; SILBERRING J, 1992, LIFE SCI, V50, P839, DOI 10.1016/0024-3205(92)90202-Z; SILBERRING J, 1990, ANAL CHIM ACTA, V238, P331, DOI 10.1016/S0003-2670(00)80555-3; SILBERRING J, 1989, BIOMED CHROMATOGR, V3, P203, DOI 10.1002/bmc.1130030506; SILBERRING J, 1989, J BIOL CHEM, V264, P11082; SILBERRING J, 1990, BIOMED ENVIRON MASS, V19, P819, DOI 10.1002/bms.1200191305; SILBERRING J, 1992, J CHROMATOGR, V50, P839; SUPATTAPONE S, 1988, MOL BRAIN RES, V3, P173, DOI 10.1016/0169-328X(88)90063-0; TURNER AJ, 1986, ESSAYS BIOCHEM, V22, P69	32	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21324	21328						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356987				2022-12-25	WOS:A1992JV01100013
J	IKEDA, RA; BAILEY, PA				IKEDA, RA; BAILEY, PA			INHIBITION OF T7 RNA-POLYMERASE BY T7 LYSOZYME INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 LYSOZYME; ESCHERICHIA-COLI; TRANSCRIPTION; EXPRESSION; DNA; PROMOTER; SYSTEM; GENES	The in vivo observation that the expression of bacteriophage T7 gene 3.5 (T7 lysozyme) inactivates T7 class II transcription and the in vitro observation that T7 lysozyme inhibits T7 RNA polymerase lead to the hypothesis that T7 lysozyme might preferentially inhibit transcription from T7 class II promoters. T7 lysozyme was cloned into a lambdap(L) expression vector, overproduced in Escherichia coli, and purified. The ability of purified T7 lysozyme to inhibit transcription from T7 DNA, the cloned T7 class II promoters, phi2.5 and phi4.7, and the cloned class III promoter, phi10, was measured in vitro. It was observed that the effectiveness of T7 lysozyme as an inhibitor of T7 RNA polymerase is inversely related to the concentration of Mg2+; T7 lysozyme inhibits T7 RNA polymerase most effectively at low Mg2+ concentrations. In addition, no preferential inhibition of transcription from cloned T7 class II promoters was observed, nor was a strong T7 class III promoter preferred when transcriptional capacity was reduced by T7 lysozyme. These observations contradict the hypotheses that the temporal control of T7 gene expression is either due to direct and selective inhibition of the T7 class II promoters by T7 lysozyme or to preferential transcription of the strong T7 class III promoters when transcriptional capacity is reduced by T7 lysozyme. It appears that alternative mechanisms such as the involvement of additional proteins and/or cellular conditions to enhance transcription from T7 class III promoters or to inhibit transcription from T7 class II promoter are necessary to explain the temporal control of transcription of bacteriophage T7.			IKEDA, RA (corresponding author), GEORGIA INST TECHNOL, SCH CHEM & BIOCHEM, ATLANTA, GA 30332 USA.			Ikeda, Richard/0000-0003-4015-5528	NIAID NIH HHS [AI-24905] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024905] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; IKEDA RA, 1992, J BIOL CHEM, V267, P11322; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; INOUYE M, 1973, J BIOL CHEM, V248, P7247; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SILBERSTEIN S, 1975, J MOL BIOL, V96, P1, DOI 10.1016/0022-2836(75)90178-3; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1982, COLD SPRING HARB SYM, V47, P999, DOI 10.1101/SQB.1983.047.01.114; SUMMERS WC, 1969, VIROLOGY, V39, P175, DOI 10.1016/0042-6822(69)90037-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAVRIEV SK, 1982, NUCLEIC ACIDS RES, V10, P1635, DOI 10.1093/nar/10.5.1635	23	12	14	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20153	20158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356974				2022-12-25	WOS:A1992JR85800065
J	TATSUTA, T; NAITO, M; OHHARA, T; SUGAWARA, I; TSURUO, T				TATSUTA, T; NAITO, M; OHHARA, T; SUGAWARA, I; TSURUO, T			FUNCTIONAL INVOLVEMENT OF P-GLYCOPROTEIN IN BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODIES; MOLECULAR-WEIGHT; ENZYME-ACTIVITY; MDR1 GENE; EXPRESSION; TRANSPORT; MEMBRANE	P-glycoprotein, an active efflux pump of antitumor agents in multidrug-resistant tumor cells, exists in various normal tissues, including brain capillaries. To study the physiological function of P-glycoprotein expressed in brain capillary endothelium, we established nine mouse brain capillary endothelial cell (MBEC) lines and examined the transport of antitumor agents across the monolayer of MBEC epithelia. In the MBECs, the activities of alkaline phosphatase and gamma-glutamyl transpeptidase, specific markers for brain capillary endothelial cells, were about three times higher than those in other cells including human umbilical vein endothelial cells. By immunoblot analysis, P-glycoprotein was detected in all of the nine MBEC clones. The P-glycoprotein expressed in MBECs specifically bound [I-125]iodoaryl azidoprazosin as that in multidrug-resistant cells, and efflux of vincristine was observed in the MBECs. When MBECs were grown on a porous filter membrane, they formed a monolayer of epithelium. By immunoelectron microscopic analysis, P-glycoprotein in MBEC epithelia was shown to be localized to the apical surface of the cells. Moreover, the unidirectional transepithelial transport of vincristine from basal side to apical side was demonstrated in vitro. These observations indicate that P-glycoprotein in brain capillary endothelium prevents vincristine from entering the central nervous system and thus may be one of the functional components of the blood-brain barrier.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA MED COLL,DEPT PATHOL,KAWAGOE,SAITAMA 350,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Saitama Medical University; Japanese Foundation for Cancer Research								ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; AUERBACH R, 1982, P NATL ACAD SCI-BIOL, V79, P7891, DOI 10.1073/pnas.79.24.7891; BECK DW, 1986, BRAIN RES, V381, P131, DOI 10.1016/0006-8993(86)90700-6; BETZ AL, 1975, AM J PHYSIOL, V228, P895, DOI 10.1152/ajplegacy.1975.228.3.895; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; COOMBER BL, 1985, MICROVASC RES, V30, P99, DOI 10.1016/0026-2862(85)90042-1; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNFORD EM, 1992, CANCER CHEMOTH PHARM, V29, P439, DOI 10.1007/BF00684844; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEBAULT LE, 1980, SCIENCE, V207, P653, DOI 10.1126/science.6101511; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GARLACH JH, 1986, NATURE, V324, P485; GOLDSTEIN GW, 1986, SCI AM, V254, P74; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREIG NH, 1990, J CONTROL RELEASE, V11, P61, DOI 10.1016/0168-3659(90)90121-9; GREIG NH, 1984, CANCER TREAT REV, V11, P157, DOI 10.1016/0305-7372(84)90006-9; GREIG NH, 1990, CANCER CHEMOTH PHARM, V26, P263, DOI 10.1007/BF02897227; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, CANCER RES, V48, P3173; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HORIO M, 1989, J BIOL CHEM, V264, P14880; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; LISE D, 1991, BIOCHEM J, V276, P745; Maniatis T., 1982, MOL CLONING; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MOMMA S, 1987, J NEUROCHEM, V48, P1291, DOI 10.1111/j.1471-4159.1987.tb05660.x; NAITO M, 1987, CANCER IMMUNOL IMMUN, V24, P158; NAITO M, 1989, BIOCHEM BIOPH RES CO, V158, P1066, DOI 10.1016/0006-291X(89)92830-1; NAITO M, 1988, J BIOL CHEM, V263, P11887; NAKAMURA H, 1990, Japanese Journal of Clinical Electron Microscopy, V23, P393; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; SPECTOR R, 1980, J NEUROCHEM, V35, P1092, DOI 10.1111/j.1471-4159.1980.tb07863.x; SPECTOR R, 1982, J NEUROCHEM, V39, P837, DOI 10.1111/j.1471-4159.1982.tb07968.x; SUGAWARA I, 1990, JPN J CANCER RES, V81, P727, DOI 10.1111/j.1349-7006.1990.tb02636.x; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; SUGIMOTO Y, 1987, CANCER RES, V47, P2620; SUGIYAMA Y, 1990, PHARM TECH JAPAN, V6, P519; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TSURUO T, 1983, CANCER RES, V43, P5437; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLIAM FNG, 1989, MOL CELL BIOL, V9, P1224; WILLIAMS SK, 1980, J NEUROCHEM, V35, P374, DOI 10.1111/j.1471-4159.1980.tb06274.x; YANG CPH, 1989, J BIOL CHEM, V264, P782	51	324	328	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20383	20391						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356979				2022-12-25	WOS:A1992JR85800099
J	GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; DELAMARTER, JF				GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; DELAMARTER, JF			LABILE PROTEINS PLAY A DUAL ROLE IN THE CONTROL OF ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 (ELAM-1) GENE-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR NECROSIS FACTOR; HISTONE MESSENGER-RNA; GROWTH-FACTOR; C-FOS; ACTIN GENE; SYNTHESIS INHIBITORS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; TISSUE FACTOR	Endothelial leukocyte adhesion molecule-1 (ELAM-1) is a membrane protein exclusively expressed on endothelial cells, where it plays a key role in the inflammatory response by adhering to a subset of leukocytes. The expression of the ELAM-1 gene is very tightly regulated. ELAM-1 is undetectable in uninduced cells, and it is transiently expressed following cytokine induction. Treatment of resting endothelial cells with three different protein synthesis inhibitors, cycloheximide (CHX), anisomycin, and emetine, caused an increase in the steady-state level of ELAM-1 mRNA above that observed with IL (interleukin)-l alone. Furthermore, ELAM-1 mRNA was found in the presence of all three protein synthesis inhibitors without IL-1 treatment. Analysis of the mRNA half-life indicated that the protein synthesis inhibitors act, in part, by stabilizing ELAM-1 mRNA. In addition, protein synthesis inhibitors potentiate the effect of IL-1beta at the level of transcription initiation as shown by nuclear run-on experiments. The NFkappaB-like binding activity to the ELAM-1 promoter sequence induced by IL-1beta is augmented by inhibitors of protein synthesis. The NFkappaB binding sequence was found to be necessary and sufficient for superinduction of the ELAM-1 gene by CHX. These results show that regulation at the level of protein synthesis is implicated in the overall regulation of ELAM-1 gene expression. Mechanisms which could explain these effects are discussed.			GHERSA, P (corresponding author), GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		Hooft van Huijsduijnen, Rob/B-3653-2009	Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAKER EJ, 1986, MOL CELL BIOL, V6, P54, DOI 10.1128/MCB.6.1.54; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; COX GS, 1990, J BIOL CHEM, V265, P13190; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONG ZY, 1988, MOL CELL BIOL, V8, P3518, DOI 10.1128/MCB.8.8.3518; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RUCO LP, 1990, AM J PATHOL, V137, P1163; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIVE HL, 1984, MOL CELL BIOL, V4, P2723, DOI 10.1128/MCB.4.12.2723; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	50	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19226	19232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382069				2022-12-25	WOS:A1992JP59300035
J	FEVE, B; BAUDE, B; KRIEF, S; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ				FEVE, B; BAUDE, B; KRIEF, S; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ			INHIBITION BY DEXAMETHASONE OF BETA-3-ADRENERGIC RECEPTOR RESPONSIVENESS IN 3T3-F442A ADIPOCYTES - EVIDENCE FOR A TRANSCRIPTIONAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HAMSTER BETA-2-ADRENERGIC RECEPTOR; BROWN ADIPOSE-TISSUE; MESSENGER-RNA LEVELS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; MOLECULAR CHARACTERIZATION; 3T3-L1 PREADIPOCYTES; DNA-BINDING; C-JUN	Modulation of beta-3-adrenergic receptor (beta-3AR) expression by dexamethasone was investigated in the murine 3T3-F442A adipocytic cell line. In untreated cells, a major population of binding sites (62,000-114,000 sites/cell) of low affinity for (-)-[H-3] CGP12177 and (-)-[I-125]iodocyanopindolol (corresponding to the beta-3AR subtype) was present along with a minor population (6,500-8,000 sites/cell) of sites of high affinity for the radioligands (corresponding to a mixture of the beta-1 and beta-2AR subtypes). Long-term exposure of the cells to 250 nM dexamethasone led to a sharp decrease in beta-3AR density (less than 5,000 sites/cell) which paralleled a diminished potency of the beta-3AR-selective agonists BRL37344 and CGP12177 to stimulate the production of intracellular cAMP. Analysis of RNA by polymerase chain reaction and nuclear run-on assays indicated that dexamethasone inhibited the synthesis of beta-3AR mRNA, resulting in 4-8-fold decrease in the steady-state levels of this mRNA. The down-regulation of beta-3AR protein and cellular mRNA appeared to be mediated by the receptor for glucocorticoids as assessed by the antagonistic action of the anti-glucocorticoid RU38486.	HOP HENRI MONDOR,CNRS,INSERM,U282,F-94010 CRETEIL,FRANCE; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75221 PARIS 05,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Gustave-Eiffel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Feve, Bruno/0000-0001-6577-9009; Krief, Stephane/0000-0002-5543-731X				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARCH JRS, 1989, P NUTR SOC, V48, P215, DOI 10.1079/PNS19890032; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAUN T, 1970, P NATL ACAD SCI USA, V66, P995, DOI 10.1073/pnas.66.3.995; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHALLISS RAJ, 1988, BIOCHEM PHARMACOL, V37, P947, DOI 10.1016/0006-2952(88)90186-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; EMORINE LJ, 1991, BIOCHEM PHARMACOL, V41, P853, DOI 10.1016/0006-2952(91)90188-B; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; EXTON J H, 1987, Diabetes Metabolism Reviews, V3, P163; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUEST SJ, 1990, J BIOL CHEM, V265, P5370; HAINQUE B, 1987, BIOCHIM BIOPHYS ACTA, V931, P347, DOI 10.1016/0167-4889(87)90226-6; HOLLENGA C, 1990, HORM METAB RES, V22, P17, DOI 10.1055/s-2007-1004839; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LAI E, 1982, J BIOL CHEM, V257, P6691; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUZIN P, 1991, J BIOL CHEM, V266, P24053; MUZZIN P, 1988, BIOCHEM BIOPH RES CO, V156, P375, DOI 10.1016/S0006-291X(88)80851-9; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; PAIRAULT J, 1982, EUR J BIOCHEM, V127, P351, DOI 10.1111/j.1432-1033.1982.tb06879.x; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SKALA J, 1971, CAN J PHYSIOL PHARM, V49, P501, DOI 10.1139/y71-064; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P1083; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; VANDERTUIG JG, 1984, LIFE SCI, V34, P1423, DOI 10.1016/0024-3205(84)90056-0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YORK DA, 1985, AM J PHYSIOL, V249, pE299, DOI 10.1152/ajpendo.1985.249.3.E299; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4	56	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15909	15915						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379241				2022-12-25	WOS:A1992JG11300097
J	LEV, S; YARDEN, Y; GIVOL, D				LEV, S; YARDEN, Y; GIVOL, D			DIMERIZATION AND ACTIVATION OF THE KIT RECEPTOR BY MONOVALENT AND BIVALENT BINDING OF THE STEM-CELL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; PDGF BETA-RECEPTOR; SPOTTING W LOCUS; ONCOGENE C-KIT; EGF RECEPTOR; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; LIGAND-BINDING; CDNA CLONING	The protooncogene c-kit encodes a tyrosine kinase receptor for the stem cell factor (SCF). Mutants of c-kit were shown to confer a pleiotropic defective phenotype and often display negative dominance in heterozygous mice. To explore the involvement of receptor dimerization in this genetic phenomenon, we employed both a human ligand, which does not recognize the murine receptor, and a rodent SCF, which binds to the human receptor with 100-fold reduced affinity as compared with human SCF. SCF binding to living cells was found to induce rapid and complete receptor dimerization that involved activation of the catalytic tyrosine kinase function. Although receptor dimerization can be attributed to the dimeric nature of the ligand, no dissociation of Kit dimers occurred at high excess of SCF, suggesting that receptor-receptor interactions are also involved in dimer stabilization. This was supported by in vitro formation of heterodimers between the human and murine Kit proteins through monovalent binding of species-specific human SCF. By coexpression of human and mouse Kit in murine fibroblasts, we found that receptor heterodimerization in living cells involved an increase in the affinity of human Kit for rat SCF and also an accelerated rate of receptor down-regulation. When a human Kit mutant lacking the kinase insert domain was coexpressed with the murine wild-type receptor, we observed a significant decrease in both the activation of the intact tyrosine kinase and its coupling to an effector protein, namely phosphatidylinositol 3'-kinase. Our results favor a receptor activation model that assumes an initial step of monovalent ligand binding, followed by an intermediate receptor dimer bound by one arm of the ligand molecule. This model predicts the existence of an intrinsic receptor dimerization site and provides a structural basis for genetic dominance of mutant SCF receptors.			LEV, S (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Lev, Sima/AAP-7880-2020; YARDEN, YOSEF/K-1467-2012	Lev, Sima/0000-0002-2108-3330; 	NCI NIH HHS [CA 53120] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BLUMEJENSEN P, 1991, EMBO J, V10, P4124; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HERBST R, 1991, J BIOL CHEM, V266, P19908; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P924; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARNAKARA P, 1991, BIOCHEMISTRY-US, V30, P1761; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, J BIOL CHEM, V266, P13828; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Silvers W.K., 1979, COAT COLORS MICE, P206; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	54	131	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15970	15977						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379243				2022-12-25	WOS:A1992JG11300106
J	RESTLE, T; PAWLITA, M; SCZAKIEL, G; MULLER, B; GOODY, RS				RESTLE, T; PAWLITA, M; SCZAKIEL, G; MULLER, B; GOODY, RS			STRUCTURE-FUNCTION-RELATIONSHIPS OF HIV-1 REVERSE-TRANSCRIPTASE DETERMINED USING MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ESCHERICHIA-COLI; HTLV-III; RNASE-H; MUTATIONAL ANALYSIS; DOMAIN-STRUCTURE; CELL-LINE; VIRUS; EXPRESSION; AIDS	The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is one of the main targets in approaches to the chemotherapy of AIDS. A detailed knowledge of structure-function relationships of this enzyme is a prerequisite for rational drug design. We have used monoclonal antibodies as tools to identify functionally important regions of the protein. The preparation of 23 murine monoclonal antibodies (mAb) against HIV-1 reverse transcriptase and their different effects on the enzyme are described. The interaction of purified mAbs with HIV-1 RT was demonstrated by enzyme-linked immunosorbent assay (ELISA), Western blots, and high performance liquid chromatography size exclusion chromatography. One of the antibodies also recognized recombinant HIV-2 RT. Antibody binding epitopes on HIV-1 RT were analyzed by immunoblotting using cyanogen bromide fragmented RT, C-terminally truncated mutants, and a peptide ELISA employing 15-mer synthetic overlapping peptides spanning nearly the complete polypeptide chain. The epitopes were mapped within three domains corresponding to amino acids 200-230, 300-428, and 528-560. Two mAbs show neutralizing properties on enzymatic functions of RT. One affects the polymerase activity and to a certain degree the RNase H activity of the enzyme, whereas the other inhibits the latter activity exclusively. mAb 28, which blocks the polymerase activity, interferes with the nucleotide binding region of RT, as shown by fluorescence spectroscopy using a labeled template/primer complex. By investigating the antibody effects on dimer formation of the heterodimeric enzyme, three domains corresponding to amino acids 230-300, 350-428, and residues around amino acid 540 involved in protein-protein interactions were localized.	DEUTSCH KREBSFORSCHUNGSZENTRUM,FORSCH SCHWERPUNKT ANGEW TUMORVIROL,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	RESTLE, T (corresponding author), MAX PLANCK INST MED RES,BIOPHYS ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.		Pawlita, Labor/C-9720-2011; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Muller, Barbara/0000-0001-5726-5585; Pawlita, Michael/0000-0002-4720-8306				BAILLON JG, 1991, NEW BIOL, V3, P1015; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEVICO A, 1991, VIROLOGY, V185, P387, DOI 10.1016/0042-6822(91)90786-B; DEVICO AL, 1989, AIDS RES HUM RETROV, V5, P51, DOI 10.1089/aid.1989.5.51; DEVICO AL, 1991, J BIOL CHEM, V266, P6774; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FERNS RB, 1991, AIDS RES HUM RETROV, V7, P307, DOI 10.1089/aid.1991.7.307; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; IKUTA K, 1989, VIROLOGY, V170, P408, DOI 10.1016/0042-6822(89)90431-5; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KRAUS G, 1990, EUR J BIOCHEM, V192, P207, DOI 10.1111/j.1432-1033.1990.tb19216.x; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; LUKE W, 1990, BIOCHEMISTRY-US, V29, P1764; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MORRIS GE, 1987, BIOCHEM J, V248, P53, DOI 10.1042/bj2480053; MOUS J, 1988, J VIROL, V62, P1433, DOI 10.1128/JVI.62.4.1433-1436.1988; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; MULLER B, 1991, J BIOL CHEM, V266, P14709; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NORTH TW, 1990, J BIOL CHEM, V265, P5121; ORVELL C, 1991, J GEN VIROL, V72, P1913, DOI 10.1099/0022-1317-72-8-1913; PADBERG C, 1989, AIDS RES HUM RETROV, V5, P61, DOI 10.1089/aid.1989.5.61; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; PWALITA M, 1981, J EXP MED, V154, P1946; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; TANESE N, 1986, J VIROL, V59, P743, DOI 10.1128/JVI.59.3.743-745.1986; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERMA IM, 1981, ENZYMES, V14, P87; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	52	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14654	14661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378837				2022-12-25	WOS:A1992JF08800027
J	GIESELMANN, V; SCHMIDT, B; VONFIGURA, K				GIESELMANN, V; SCHMIDT, B; VONFIGURA, K			INVITRO MUTAGENESIS OF POTENTIAL N-GLYCOSYLATION SITES OF ARYLSULFATASE-A - EFFECTS ON GLYCOSYLATION, PHOSPHORYLATION, AND INTRACELLULAR SORTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE SPECIFIC RECEPTOR; LYSOSOMAL-ENZYMES; OLIGOSACCHARIDES; FIBROBLASTS; EXPRESSION	The correct intracellular sorting of lysosomal enzymes such as arylsulfatase A depends on the presence of mannose 6-phosphate residues on high mannose type oligosaccharides. The arylsulfatase A cDNA contains three potential N-glycosylation sites, two of which are utilized. We have mutated one or two of the N-glycosylation sites and analyzed the glycosylation, phosphorylation, and intracellular sorting of the mutant arylsulfatase A polypeptides. The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive. In mutants with one oligosaccharide side chain at positions I, II, or III all side chains can acquire mannose 6-phosphate residues irrespective of their location. This demonstrates spatial flexibility of the phosphotransferase, which specifically recognizes lysosomal enzymes and initiates the addition of mannose 6-phosphate residues on oligosaccharide side chains. However, these mutants have different intracellular sorting efficiencies and seem to use different (mannose 6-phosphate receptor-dependent and -independent) sorting pathways.			GIESELMANN, V (corresponding author), UNIV GOTTINGEN,BIOCHEM ABT 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.							ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; ISIDORO C, 1990, EUR J BIOCHEM, V191, P591, DOI 10.1111/j.1432-1033.1990.tb19162.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN C, 1989, J BIOL CHEM, V264, P1252; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, H-S Z PHYSIOL CHEM, V363, P425, DOI 10.1515/bchm2.1982.363.1.425; WAHEED A, 1983, AM J HUM GENET, V35, P228	15	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13262	13266						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352293				2022-12-25	WOS:A1992JB74600029
J	MEINKOTH, JL; GOLDSMITH, PK; SPIEGEL, AM; FERAMISCO, JR; BURROW, GN				MEINKOTH, JL; GOLDSMITH, PK; SPIEGEL, AM; FERAMISCO, JR; BURROW, GN			INHIBITION OF THYROTROPIN-INDUCED DNA-SYNTHESIS IN THYROID FOLLICULAR CELLS BY MICROINJECTION OF AN ANTIBODY TO THE STIMULATORY G-PROTEIN OF ADENYLATE-CYCLASE, G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; DIBUTYRYL-CYCLIC-AMP; FOS MESSENGER-RNAS; C-FOS; FRTL5 CELLS; THYROGLOBULIN GENE; INCREASE LEVELS; INSULIN; EXPRESSION; CULTURE	Thyrotropin (TSH) is an important regulator of thyroid follicular cells. While its-role in the maintenance of differentiated functions is undisputed, its role as a mitogen is less clear. TSH induces DNA synthesis and cell proliferation in some cells, while in others, TSH is mitogenic only in the presence of additional growth factors such as insulin-like growth factor-1. TSH causes elevations in intracellular cAMP and is thought to utilize this second messenger system in its mitogenic action. We studied TSH as a mitogen in Wistar rat thyroid cells (WRT) (Brandi, M. L., Rotella, C. M., Mavilia, C., Franceschelli, F., Tanini, A., and Toccafondi, R. (1987) Mol. Cell. Endocrinol. 54, 91-103) and examined the role of the guanine nucleotide binding protein, G(s), in its mitogenic action. WRT cells synthesized DNA in response to TSH and elevations in cAMP. In addition, TSH caused a rapid stimulation of an indicator gene whose expression is regulated by cAMP response elements. Following microinjection of an inhibitory polyclonal antibody raised against the G(s) protein, both TSH-induced changes in gene expression and DNA synthesis were significantly reduced. These results demonstrate that virtually all of the mitogenic action of TSH is transduced through the G(s) protein in WRT cells, presumably through the regulation of adenylate cyclase. Whether all or only part of TSH action is mediated by cAMP and the cAMP-dependent protein kinase remains to be determined.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; NIDDKD, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MEINKOTH, JL (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0613K, LA JOLLA, CA 92093 USA.		Meinkoth, Judy L/G-2900-2010					ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BRANDI ML, 1987, MOL CELL ENDOCRINOL, V54, P91, DOI 10.1016/0303-7207(87)90142-0; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; DAMANTE G, 1988, BIOCHEM BIOPH RES CO, V151, P1194, DOI 10.1016/S0006-291X(88)80492-3; DERE WH, 1985, ENDOCRINOLOGY, V117, P2249, DOI 10.1210/endo-117-5-2249; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Eggo MC, 1990, GROWTH FACTORS, V2, P99, DOI 10.3109/08977199009071497; GERARD C, 1982, BIOCHIM BIOPHYS ACTA, V710, P359, DOI 10.1016/0005-2760(82)90119-9; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE NT, 1991, ENDOCRINOLOGY, V128, P111, DOI 10.1210/endo-128-1-111; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, HORM METAB RES, V23, P51; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOSES AC, 1989, ENDOCRINOLOGY, V125, P2758, DOI 10.1210/endo-125-5-2758; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; REUSE S, 1986, BIOCHEM BIOPH RES CO, V141, P1066, DOI 10.1016/S0006-291X(86)80152-8; REUSE S, 1990, EXP CELL RES, V189, P33, DOI 10.1016/0014-4827(90)90253-7; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROGER PP, 1983, J ENDOCRINOL, V96, P241, DOI 10.1677/joe.0.0960241; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROTELLA CM, 1989, MOL CELL ENDOCRINOL, V65, P63, DOI 10.1016/0303-7207(89)90166-4; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1986, J BIOL CHEM, V261, P3919; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; YATANI A, 1988, J BIOL CHEM, V263, P9887; ZAKARIJA M, 1989, ENDOCRINOLOGY, V125, P1253, DOI 10.1210/endo-125-3-1253	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13239	13245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377681				2022-12-25	WOS:A1992JB74600025
J	YAMADA, K; GONCALVES, E; KAHN, CR; SHOELSON, SE				YAMADA, K; GONCALVES, E; KAHN, CR; SHOELSON, SE			SUBSTITUTION OF THE INSULIN-RECEPTOR TRANSMEMBRANE DOMAIN WITH THE C-NEU/ERBB2 TRANSMEMBRANE DOMAIN CONSTITUTIVELY ACTIVATES THE INSULIN-RECEPTOR KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MIMICS LIGAND INDUCTION; FMS PROTO-ONCOGENE; POINT MUTATION; CYTOPLASMIC DOMAIN; TYROSINE KINASE; NEU ONCOGENE; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; BETA-SUBUNIT	To examine the role of the transmembrane domain (TM) of the insulin receptor in insulin-induced receptor kinase activation, we prepared four mutated insulin receptors: 1) a Val938 --> Asp substitution (IR/TM(V-->D)), 2) insertion of a 3-amino acid repeat (Val938-Phe939-Leu940) (IR/TM+3), or the entire TM was replaced by the corresponding domain of either the 3) platelet-derived growth factor (PDGF) receptor (IR/TM(PDGFR)) or 4) c-neu/erbB2 proto-oncogene product (IR/TM(c-neu)). Each mutant receptor was stably expressed in Chinese hamster ovary cells, assessed by fluorescence-activated cell sorting, insulin binding, and biosynthetic labeling. All mutant receptors exhibited normal affinity for insulin. Pulse-chase experiments showed that each proreceptor was processed into alpha- and beta-subunits, although the rate of IR/TM(V-->D) conversion was reduced almost-equal-to 3-fold. With IR/TM(PDGFR), IR/TM(V-->D), and IR/TM+3 basal and insulin-stimulated levels of autophosphorylation and tyrosine kinase activation were normal, both in wheat germ agglutinin (WGA)-purified receptor preparations and intact cells. By contrast, following WGA purification or isolation of crude membranes, IR/TM(c-neu) was a constitutively active autokinase and substrate kinase in vitro. However, in intact cells insulin-stimulated autophosphorylation and kinase activity appeared normal. We conclude that although there is considerable latitude in acceptable structure, residues within the insulin receptor transmembrane domain can play a functional role in regulation of insulin receptor tyrosine kinase activity.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.			Goncalves, Edison/AAR-3280-2020; Kahn, Ronald/AAY-2435-2021	Goncalves, Edison/0000-0002-7887-1231; Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031036, R37DK031036, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836, DK31036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P1; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COBB MH, 1989, J BIOL CHEM, V264, P18701; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUNNILL P, 1968, BIOPHYS J, V8, P865, DOI 10.1016/S0006-3495(68)86525-7; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FRITZ HJ, 1978, BIOCHEMISTRY-US, V17, P1257, DOI 10.1021/bi00600a020; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; GANDERTON RH, 1989, THESIS U CAMBRIDGE; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAISER ET, 1987, TRENDS BIOCHEM SCI, V12, P305, DOI 10.1016/0968-0004(87)90147-2; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEEF JW, 1987, J BIOL CHEM, V262, P14837; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	62	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12452	12461						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352286				2022-12-25	WOS:A1992HZ48300015
J	KIM, YA; SHRIVER, B; QUAY, T; HERSH, LB				KIM, YA; SHRIVER, B; QUAY, T; HERSH, LB			ANALYSIS OF THE IMPORTANCE OF ARGININE-102 IN NEUTRAL ENDOPEPTIDASE (ENKEPHALINASE) CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; SITE-DIRECTED MUTAGENESIS; 24.11 ENKEPHALINASE; ACTIVE-SITE; METALLOENDOPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE ACTIVITY; LEUKEMIA ANTIGEN; EC 3.4.24.11; RAT-KIDNEY; THERMOLYSIN	Neutral endopeptidase 24.11 contains an active site arginine believed to function in substrate binding. This arginine is thought to form an ionic interaction with the COOH-terminal carboxylate of NEP substrates. The functionality of arginine 102 has been investigated by using site-directed mutagenesis to produce mutants in which this residue was converted to a lysine, glycine, glutamine, or glutamate. All of the mutants exhibited essentially full activity as determined with a synthetic peptide amide, glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide. In contrast, activity was detected only with the wild-type enzyme and the lysine mutant using a synthetic substrate containing a free COOH-terminal carboxylate, dansyl-Gly-Trp-Gly. Inhibition studies with the physiologically active peptide substrates substance P, endothelin, and angiotensin 1, as well as substance P free acid, [D-Ala2,Leu5]enkephalin, and [D-Ala2,Leu5]enkephalinamide indicated a lack of importance of arginine 102 in substrate binding. With [D-Ala2,Met5]enkephalin and the chemotactic peptide, N-formyl-Met-Leu-Phe, a significant decrease in affinity is observed with the arginine 102 mutants. These results suggest that the contribution of arginine 102 to substrate binding is dependent upon the strength of other subsite interactions. Examination of dipeptides as inhibitors indicates that the nature and orientation of the P'2 residue is important in determining the strength of the interaction of arginine 102 with its substrates.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02243] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BEAUMONT A, 1986, BIOCHEM BIOPH RES CO, V139, P733, DOI 10.1016/S0006-291X(86)80052-3; BEAUMONT A, 1991, J BIOL CHEM, V266, P214; BRALET J, 1990, EUR J PHARMACOL, V179, P57, DOI 10.1016/0014-2999(90)90401-Q; CASEY ML, 1991, J BIOL CHEM, V266, P23041; CHIPKIN R E, 1986, Drugs of the Future, V11, P593; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HELIN K, 1991, EUR J PHARMACOL, V198, P23, DOI 10.1016/0014-2999(91)90557-7; HERSH LB, 1986, LIFE SCI, V38, P1151, DOI 10.1016/0024-3205(86)90168-2; HERSH LB, 1986, J BIOL CHEM, V261, P6433; JACKSON DG, 1986, J BIOL CHEM, V261, P8649; KAHN JC, 1990, LANCET, V335, P118, DOI 10.1016/0140-6736(90)90595-V; KERR MA, 1974, BIOCHEM J, V137, P489, DOI 10.1042/bj1370489; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KOEHN JA, 1987, J BIOL CHEM, V262, P11623; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECOMTE JM, 1990, EUR J PHARMACOL, V179, P65, DOI 10.1016/0014-2999(90)90402-R; LEFRANCOIS P, 1990, LANCET, V336, P307, DOI 10.1016/0140-6736(90)91837-Z; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LLORENS C, 1981, EUR J PHARMACOL, V69, P113, DOI 10.1016/0014-2999(81)90609-9; MALFROY B, 1982, BIOCHEM BIOPH RES CO, V106, P276, DOI 10.1016/0006-291X(82)91106-8; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V143, P58, DOI 10.1016/0006-291X(87)90629-2; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; NORTHRIDGE DB, 1989, LANCET, V2, P591; POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015; RONCO P, 1988, LAB INVEST, V58, P210; SCHWARTZ JC, 1985, TRENDS PHARMACOL SCI, V6, P472, DOI 10.1016/0165-6147(85)90226-3; SEYMOUR AA, 1989, HYPERTENSION, V14, P87, DOI 10.1161/01.HYP.14.1.87; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; SONNENBERG JL, 1988, PEPTIDES, V9, P173, DOI 10.1016/0196-9781(88)90024-1; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SYBERTZ EJ, 1989, J PHARMACOL EXP THER, V250, P624; SYBERTZ EJ, 1990, HYPERTENSION, V15, P152, DOI 10.1161/01.HYP.15.2.152; TRAPANI AJ, 1989, J CARDIOVASC PHARM, V14, P419, DOI 10.1097/00005344-198909000-00010; VEMULAPALLI S, 1988, AM J HYPERTENS, V1, pA106; VIJAYARAGHAVAN J, 1990, BIOCHEMISTRY-US, V29, P8052, DOI 10.1021/bi00487a009; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150	44	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12330	12335						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376321				2022-12-25	WOS:A1992HY94700101
J	AHLUWALIA, N; BERGERON, JJM; WADA, I; DEGEN, E; WILLIAMS, DB				AHLUWALIA, N; BERGERON, JJM; WADA, I; DEGEN, E; WILLIAMS, DB			THE P88 MOLECULAR CHAPERONE IS IDENTICAL TO THE ENDOPLASMIC-RETICULUM MEMBRANE-PROTEIN, CALNEXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; SIGNAL-SEQUENCE RECEPTOR; CELL-SURFACE EXPRESSION; HLA-B ANTIGENS; INTRACELLULAR-TRANSPORT; LIGHT-CHAINS; BETA-2-MICROGLOBULIN; ASSOCIATION; PEPTIDE; HEAVY	We previously described a novel molecular chaperone (designated p88) that participates in the assembly of murine class I histocompatibility molecules (Degen, E., and Williams, D. B. (1991) J. Cell Biol. 112, 1099-1115). Our findings suggest that p88 may either promote proper assembly of class I molecules or retain them, probably within the endoplasmic reticulum (ER), until assembly of the ternary complex of heavy chain, beta-2-microglobulin, and peptide ligand is complete. In this report, we compare p88 to calnexin, a calcium-binding 90-kDa phosphoprotein of the ER membrane (Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J.-J., 11, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). We show that p88 and calnexin share antigenic epitopes defined by a polyclonal anti-calnexin antiserum. Furthermore, both proteins were immunoprecipitated in association with an intracellularly retained variant of the class I H-2K(b) molecule. Since p88 and calnexin were also indistinguishable by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, were resistant to digestion with endoglycosidase H, and exhibited virtually identical patterns of peptide fragments following digestion with either V8 protease or trypsin, we conclude that p88 and calnexin represent the same protein. The identification of the p88 chaperone as a phosphorylated, calcium-binding protein of the ER membrane suggests possible means whereby its interaction with class I molecules may be regulated.	UNIV TORONTO,DEPT BIOCHEM,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; BETH ISRAEL HOSP,BOSTON,MA 02215; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 2B2,QUEBEC,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; McGill University; Harvard University; Harvard Medical School			Bergeron, John/AAW-1893-2021	Wada, Ikuo/0000-0001-5668-6994				ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BECK JC, 1986, J IMMUNOL, V137, P916; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HOCHSTENBACH F, 1992, IN PRESS P NATL ACAD; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOCH GLE, 1987, J CELL SCI, V87, P491; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NUCHTERN JG, 1989, NATURE, V339, P2223; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; SWIEDLER SJ, 1983, J BIOL CHEM, V258, P1515; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; WADA I, 1991, J BIOL CHEM, V266, P19599; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	36	112	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10914	10918						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350281				2022-12-25	WOS:A1992HV09000105
J	MOSS, J; STANLEY, SJ; NIGHTINGALE, MS; MURTAGH, JJ; MONACO, L; MISHIMA, K; CHEN, HC; WILLIAMSON, KC; TSAI, SC				MOSS, J; STANLEY, SJ; NIGHTINGALE, MS; MURTAGH, JJ; MONACO, L; MISHIMA, K; CHEN, HC; WILLIAMSON, KC; TSAI, SC			MOLECULAR AND IMMUNOLOGICAL CHARACTERIZATION OF ADP-RIBOSYLARGININE HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; TURKEY ERYTHROCYTES; RIBOSYLTRANSFERASE ACTIVITY; SUBSTRATE-SPECIFICITY; RIBOSYLATION FACTOR; CHOLERA-TOXIN; PROTEIN; NUCLEOTIDE; IDENTIFICATION	Mono-ADP-ribosylation is a reversible modification of proteins with NAD:arginine ADP-ribosyltransferases and ADP-ribosylarginine hydrolases catalyzing the forward and reverse reactions, respectively. Hydrolase activities were present in a variety of animal species, with the highest specific activities found in rat and mouse brain, spleen, and testis. Rat and mouse hydrolases were dithiothreitol- and Mg2+-dependent, whereas the bovine and guinea pig enzymes were dithiothreitol-independent. A rat brain hydrolase was purified approximately 20,000-fold and represented the major approximately 39-kDa protein on denaturing gels. Immunoaffinity-purified rabbit polyclonal antibodies reacted with 39-kDa proteins from turkey erythrocytes and rat, mouse, and calf brains. A rat brain cDNA library was screened using oligonucleotide and polymerase chain reaction-generated cDNA probes. Inserts from two overlapping clones yielded a composite sequence that included a 1086-base pair open reading frame, which contained amino acid sequences found in the purified hydrolase. A hydrolase fusion protein, synthesized in Escherichia coli, reacted with anti-39-kDa polyclonal antibodies and exhibited Mg2+- and dithiothreitol-dependent hydrolase activity. A coding region cDNA hybridized readily to a 1.7-kilobase band in rat and mouse poly(A)+ RNA, but poorly to bovine, chicken, rabbit, and human poly(A)+ RNA. The immunological and molecular biological data are consistent with partial conservation of hydrolase structure across animal species.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MOSS, J (corresponding author), NHLBI, CELLULAR METAB LAB, ROOM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.		Monaco, Lucia/A-4031-2010					Aktories K, 1990, ADP RIBOSYLATING TOX, P79; BIRNBAUMER L, 1990, ADP RIBOSYLATING TOX, P225; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BODLEY JW, 1990, ADP RIBOSYLATING TOX, P21; CHANG YC, 1986, BIOCHEM BIOPH RES CO, V139, P932, DOI 10.1016/S0006-291X(86)80267-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEW AM, 1989, NUCLEIC ACIDS RES, V17, P5859, DOI 10.1093/nar/17.14.5859; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1979, J BIOL CHEM, V254, P8891; MOSS J, 1988, BIOCHEMISTRY-US, V27, P5819, DOI 10.1021/bi00415a063; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1986, BIOCHEMISTRY-US, V25, P5408, DOI 10.1021/bi00367a010; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; ROSENTHAL A, 1990, NUCLEIC ACIDS RES, V18, P3095, DOI 10.1093/nar/18.10.3095; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANUMA S, 1990, FEBS LETT, V261, P381, DOI 10.1016/0014-5793(90)80597-C; TANUMA S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P246, DOI 10.1016/0167-4889(89)90168-7; TANUMA S, 1987, J BIOCHEM-TOKYO, V101, P821, DOI 10.1093/jb/101.3.821; TANUMA S, 1988, J BIOL CHEM, V263, P5485; UHLEN M, 1989, NATURE, V340, P733, DOI 10.1038/340733a0; UI M, 1990, ADP RIBOSYLATING TOX, P45; WEST RE, 1985, J BIOL CHEM, V260, P4428; WICK MJ, 1990, ADP RIBOSYLATING TOX, P31; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493	39	106	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10481	10488						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375222				2022-12-25	WOS:A1992HV09000043
J	TILLY, BC; WINTER, MC; OSTEDGAARD, LS; ORIORDAN, C; SMITH, AE; WELSH, MJ				TILLY, BC; WINTER, MC; OSTEDGAARD, LS; ORIORDAN, C; SMITH, AE; WELSH, MJ			CYCLIC AMP-DEPENDENT PROTEIN-KINASE ACTIVATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CHLORIDE CHANNELS IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPORT; GENE; IDENTIFICATION; RECONSTITUTION; MEMBRANES	Membrane vesicles, prepared from mouse NIH-3T3 fibroblasts and Chinese hamster ovary cells expressing high levels of cystic fibrosis transmembrane conductance regulator (CFTR), were fused with Mueller-Rudin planar lipid bilayers. Upon addition of the catalytic subunit of cAMP-dependent protein kinase and ATP, low conductance Cl--selective ion channels were observed in 10 of 16 experiments. The channels had a linear current-voltage relationship and a unitary conductance of approximately 6.5 pS. The channels were more permeable to Cl- than to I- and showed no appreciable time-dependent voltage activation. In contrast, addition of cAMP-dependent protein kinase and ATP to lipid bilayers fused with vesicles prepared from mock transfected (n = 14) cells failed to activate Cl-channels. These data support the conclusion that CFTR is a Cl- channel. They indicate that it can be reconstituted in a planar lipid bilayer and that the biophysical and regulatory properties are very similar to those observed in the native cell membrane. These data also argue against the requirement for loosely associated factors for regulation or function of the channel.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,500 EMRB,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation				Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; ANDERSEN OS, 1986, ION CHANNEL RECONSTI, P385; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORONADO R, 1992, IN PRESS METHODS ENZ; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINHARDT R, 1987, J MEMBRANE BIOL, V95, P47, DOI 10.1007/BF01869629; REINHART PH, 1991, J NEUROSCI, V11, P1627; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280	28	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9470	9473						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374403				2022-12-25	WOS:A1992HT96500006
J	KUNZ, D; GERARD, NP; GERARD, C				KUNZ, D; GERARD, NP; GERARD, C			THE HUMAN-LEUKOCYTE PLATELET-ACTIVATING-FACTOR RECEPTOR - CDNA CLONING, CELL-SURFACE EXPRESSION, AND CONSTRUCTION OF A NOVEL EPITOPE-BEARING ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; RABBIT PLATELETS; CHROMOSOME LOCALIZATION; MOLECULAR-CLONING; GASTRIC TISSUES; MEMBRANES; BINDING; GENE; TRACHEAL; ACID	A human myeloid transcript of approximately 4 kilobases was cloned as a cDNA from an expression library based on homology with the guinea pig cDNA recently described by Honda et al. (Honda, Z-1., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Tok, H., Ito, K., Miyamato, T., and Shimizu, T. (1991) Nature 349, 342-346) as a receptor for platelet-activating factor (PAF). The cloned DNA confers high affinity binding sites for platelet-activating factor when transfected into COS-7 cells and has binding and desensitization properties similar to the human leukocyte receptor. Southern analysis using this cDNA indicates that the PAF receptor gene is present as a single copy in the human genome. The deduced protein sequence predicts seven hydrophobic regions for the PAF receptor, characteristic of the rhodopsin gene family, and is 83% identical to the deduced protein sequence of the corresponding guinea pig molecule. A modified human PAF receptor cDNA was constructed by inserting an additional 30 nucleotides after the 5'-ATG, encoding the amino acid sequence MDYKDDDDKEF, which is specifically recognized by a monoclonal antibody. The modified cDNA encodes a functional PAF receptor and is detected by antibody on the membrane of transfected COS-7 cells. The use of this construct supports the structural model for the rhodopsin-like superfamily of receptors which places the NH2-terminal sequence on the extracellular side of the membrane, and should additionally be useful for affinity purification of the receptor protein.	CHILDRENS HOSP MED CTR, DEPT PEDIAT, DIV PULM, 320 LONGWOOD AVE, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER LAB, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, THORNDIKE LAB, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAAS F, 1984, HUM GENET, V67, P301, DOI 10.1007/BF00291357; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1057; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOMMA H, 1987, J BIOL CHEM, V262, P10582; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1986, J BIOL CHEM, V261, P532; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NG DS, 1988, EUR J PHARMACOL, V154, P47, DOI 10.1016/0014-2999(88)90361-5; PAULSON SK, 1990, P SOC EXP BIOL MED, V195, P247; PINKARD RN, 1979, J IMMUNOL, V123, P1847; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNYDER F, 1987, PLATELET ACTIVATING; STIMLER NP, 1981, AM J PATHOL, V105, P64; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TOKUMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P91, DOI 10.1016/0005-2760(90)90223-K; WANG HY, 1989, J BIOL CHEM, V264, P14424; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	33	181	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9101	9106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374385				2022-12-25	WOS:A1992HR85400062
J	BERKOWITZ, EA; EVANS, MI				BERKOWITZ, EA; EVANS, MI			FUNCTIONAL-ANALYSIS OF REGULATORY REGIONS UPSTREAM AND IN THE 1ST INTRON OF THE ESTROGEN-RESPONSIVE CHICKEN VERY LOW-DENSITY APOLIPOPROTEIN-II GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-DEPENDENT INTERACTION; GROWTH-HORMONE GENE; VITELLOGENIN GENE; AVIAN LIVER; DEVELOPMENTAL REGULATION; TRANSCRIPTION FACTORS; RECEPTOR-BINDING; MESSENGER-RNA; YOLK PROTEIN; CELL-LINE	Estrogen regulates the expression of the yolk protein genes in the chicken liver during periods of egg laying. While all five of these genes, vitellogenins I, II, and III, very low density apolipoprotein II (apoVLDLII), and apolipoprotein B, respond to estrogen, individual controls are superimposed on their coordinate regulation with respect to the kinetics of induction, magnitude of response, and developmental expression. The estrogen-responsive Leghorn strain M hepatoma (LMH) cell line provides a model system for studying the molecular basis of the similarities and differences in the regulation of these genes. The apoVLDLII gene is regulated by estrogen in LMH cells in an appropriate time- and dose-dependent manner. Regulatory regions of the apoVLDLII gene have been identified by transient transfection studies in LMH cells. All four of the sequences previously shown to bind protein between the TAATA motif at -26 and proximal estrogen response element at -171 are essential in regulation of the apoVLDLII gene. Mutation, of any single binding region reduces expression by more than 80%, indicating cooperative interactions of proteins across the entire region. While these sequences will direct assembly of a functional transcription complex, we demonstrate that addition of the first intron of the apoVLDLII gene to the promoter construct results in a 4-fold increase in estrogen-dependent expression following transient transfection into LMH cells. Results of deletion analyses indicate that two distinct regions of the intron contribute to this regulation.	W VIRGINIA UNIV,MED CTR,SCH MED,DEPT BIOCHEM,MORGANTOWN,WV 26506	West Virginia University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026339, R01HD026339] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26339] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERKOWITZ EA, 1992, IN PRESS IN VITRO CE; BINDER R, 1990, MOL ENDOCRINOL, V4, P201, DOI 10.1210/mend-4-2-201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUHAT A, 1990, NUCLEIC ACIDS RES, V18, P2861, DOI 10.1093/nar/18.10.2861; BURCH JBE, 1984, NUCLEIC ACIDS RES, V12, P1117, DOI 10.1093/nar/12.2.1117; BURCH JBE, 1990, NUCLEIC ACIDS RES, V18, P4157, DOI 10.1093/nar/18.14.4157; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CATO ACB, 1988, MOL CELL BIOL, V8, P5323, DOI 10.1128/MCB.8.12.5323; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; COCHRANE AW, 1988, J MOL BIOL, V203, P555, DOI 10.1016/0022-2836(88)90192-1; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EVANS MI, 1987, P NATL ACAD SCI USA, V84, P8493, DOI 10.1073/pnas.84.23.8493; EVANS MI, 1988, GENE DEV, V2, P116, DOI 10.1101/gad.2.1.116; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KOK K, 1985, NUCLEIC ACIDS RES, V13, P5189, DOI 10.1093/nar/13.14.5189; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LIN CT, 1986, ENDOCRINOLOGY, V118, P538, DOI 10.1210/endo-118-2-538; LOWNDES NF, 1990, MOL CELL BIOL, V10, P4990, DOI 10.1128/MCB.10.9.4990; MATHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93, DOI 10.1016/0003-9861(89)90090-8; MOORE DD, 1985, P NATL ACAD SCI USA, V82, P699, DOI 10.1073/pnas.82.3.699; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PTASHNE M, 1981, NATURE, V16, P249; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RAYNAUD JP, 1973, MOL PHARMACOL, V9, P520; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHIP ADVH, 1983, NUCLEIC ACIDS RES, V11, P2529; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILKS A, 1981, GENE, V16, P249, DOI 10.1016/0378-1119(81)90081-0; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	51	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7134	7138						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372608				2022-12-25	WOS:A1992HM05300104
J	DISTEL, RJ; ROBINSON, GS; SPIEGELMAN, BM				DISTEL, RJ; ROBINSON, GS; SPIEGELMAN, BM			FATTY-ACID REGULATION OF GENE-EXPRESSION - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; BINDING-PROTEIN; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; SODIUM-BUTYRATE; C-FOS; 3T3-ADIPOCYTES; COMPLEXES; ENHANCER; INSULIN	Fatty acids are important metabolic substrates and may also be involved in pathological syndromes such as the insulin resistance of diabetes and obesity. We demonstrate here that fatty acids can regulate specific gene expression; mRNAs encoding the fatty acid binding protein adipocyte P2 (aP2) and the Fos-related transcription factor Fra1 are specifically induced at least 20-fold upon treatment of preadipocytes with oleate. For aP2, the effect requires long chain fatty acids and occurs without a generalized activation of the genes linked to adipocyte differentiation. Other fibroblastic cells without preadipocyte characteristics do not induce aP2 mRNA in response to fatty acids. Unlike aP2, Fra1 induction by fatty acids also can be detected in NIH 3T3 and 3T3-C2 fibroblasts. Nuclear transcription assays in 3T3-F442A preadipocytes demonstrate that fatty acids elicit no transcriptional increase in the aP2 gene. Fra1, on the other hand, shows a 3-4-fold increase in transcription. These results demonstrate at least two distinct mechanisms by which fatty acids may influence gene expression.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MAYER 813,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013033] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405] Funding Source: Medline; NIGMS NIH HHS [GM13033] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMRI EZ, 1991, J LIPID RES, V32, P1457; BAKER N, 1978, CANCER RES, V38, P2372; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BOND JF, 1984, MOL CELL BIOL, V4, P1313, DOI 10.1128/MCB.4.7.1313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P46; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; MATARESE V, 1988, J BIOL CHEM, V263, P14544; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TOSCANI A, 1988, ONCOGENE RES, V3, P223; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117	25	197	202	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5937	5941						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372897				2022-12-25	WOS:A1992HK31800037
J	MORRIS, AP; CUNNINGHAM, SA; BENOS, DJ; FRIZZELL, RA				MORRIS, AP; CUNNINGHAM, SA; BENOS, DJ; FRIZZELL, RA			CELLULAR-DIFFERENTIATION IS REQUIRED FOR CAMP BUT NOT CA2+-DEPENDENT CL- SECRETION IN COLONIC EPITHELIAL-CELLS EXPRESSING HIGH-LEVELS OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCYTIC DIFFERENTIATION; ELECTROLYTE TRANSPORT; CANCER-CELLS; CHLORIDE; MEMBRANE; CHANNELS; INVITRO; MOUSE; CA-2+; HT-29	The gene responsible for cystic fibrosis (CF) has recently been cloned and sequenced. When transfected into CF epithelial cells, normal transcripts of this gene correct the underlying defect in CF, i.e. cAMP-dependent Cl- secretion is restored. Thus, the protein encoded by this gene, designated "cystic fibrosis transmembrane conductance regulator" (CFTR), somehow participates in the Cl- secretory response. In this paper we have correlated CFTR gene expression with cAMP and Ca2+-dependent Cl- secretion in unpolarized (parental) and polarized (Cl.19A) clones of the human colonic adenocarcinoma cell line HT-29. These cell lines were found to express equally high levels of CFTR mRNA at 4 days post-passage. In addition, protein expression (determined by immunoprecipitation) was also identical. The cAMP-generating agonist forskolin had little effect on I-125 efflux from the unpolarized cells. In contrast, this agonist increased I-125 efflux 3-fold in polarized cells. The lack of response in the unpolarized cells was not due to the inability of forskolin to raise cAMP levels. Neurotensin, a Ca2+-mobilizing agonist, stimulated I-125 efflux from both cell lines. In the polarized cells, the magnitude of this response was attenuated at 8 days post-seeding. At this time, the undifferentiated line attained some cAMP responsiveness. This latter effect was paralleled by the appearance of monolayers within areas of the multicell layer. Cell-attached patch-clamp recording from apical membrane patches of polarized cells revealed the presence of a forskolin-stimulated 8-pS Cl- channel; no channel activity was observed in forskolin-stimulated unpolarized cells. Ca2+-activated Cl- channels were found in both cell lines. In agreement with the I-125 efflux data, the single-channel activation response to [Ca2+]i was smaller in the polarized cell line. From these studies, we can conclude that CFTR expression, measured both at the mRNA and protein level, does not correlate with the colonocyte's ability to secrete chloride ions in response to a cAMP-generating agonist. Cyclic AMP-dependent Cl- secretion requires cellular polarization; specifically, the delineation of an apical membrane. Differences in the cellular location of CFTR during differentiation are likely to explain our results. In contrast, Ca2+-stimulated Cl- secretion occurred independently of cellular polarization but was reduced when the cells formed tight junctions.			MORRIS, AP (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031091, P50DK042017, P01DK038518] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31091, DK 38518, DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUGERON C, 1984, CANCER RES, V44, P3961; AUGERON C, 1986, ION GRADIENT COUPLED, P363; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; BRINKLEY BR, 1973, TISSUE CULTURE METHO, P438; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLONY PC, 1990, CELL MOL BIOL COLON, P1; DENNING G, 1991, FASEB J, V5, pA8069; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FRIZZELL RA, 1977, J MEMBRANE BIOL, V35, P175, DOI 10.1007/BF01869948; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GREY MA, 1988, J MEMBRANE BIOL, V105, P131; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOOGEVEEN AT, 1991, EXP CELL RES, V193, P435, DOI 10.1016/0014-4827(91)90118-E; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; LABOISSE CL, 1990, MOL BIOL COLON CANCE, P27; LEBIVIC A, 1988, EUR J CELL BIOL, V46, P113; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; MORRIS AP, 1990, CELL REGUL, V1, P951, DOI 10.1091/mbc.1.12.951; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; OLOUGHLIN EV, 1991, AM J PHYSIOL, V260, P758; PHILLIPS TE, 1984, AM J PHYSIOL, V247, pG674, DOI 10.1152/ajpgi.1984.247.6.G674; PINTO M, 1982, BIOL CELL, V44, P193; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; SUNTER JP, 1979, J ANAT, V129, P833; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAYLOR CJ, 1987, LANCET, V2, P107, DOI 10.1016/S0140-6736(87)92781-4; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; ZIMMERMAN TW, 1982, AM J PHYSIOL, V242, pG116, DOI 10.1152/ajpgi.1982.242.2.G116	42	81	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5575	5583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372005				2022-12-25	WOS:A1992HH74700086
J	JURANKA, P; ZHANG, F; KULPA, J; ENDICOTT, J; BLIGHT, M; HOLLAND, IB; LING, V				JURANKA, P; ZHANG, F; KULPA, J; ENDICOTT, J; BLIGHT, M; HOLLAND, IB; LING, V			CHARACTERIZATION OF THE HEMOLYSIN TRANSPORTER, HLYB, USING AN EPITOPE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CHROMOSOMAL HEMOLYSIN; NUCLEOTIDE-SEQUENCE; PROTEIN; SECRETION; MUTAGENESIS; SIGNAL; EXPORT	The prokaryotic hlyB gene product is a member of a superfamily of ATP-binding transport proteins that include the eukaryotic multidrug-resistance P-glycoprotein, the yeast STE6, and the cystic fibrosis CFTR gene products (Juranka, P. F., Zastawny, R. L., and Ling, V. (1989) FASEB J. 3, 2583-2592). Previous genetic studies have indicated that HlyB is involved in the transport of the 107-kDa HlyA protein from Escherichia coli; however, the HlyB protein has not been purified for biochemical studies due to its low abundance. In this study, we have engineered a monoclonal antibody epitope into the C-terminal end of HlyB that did not destroy its function. This has allowed us to use immunological methods to identify and localize various molecular forms of the HlyB protein present in vivo.	ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV PARIS 11,DEPT GENET & MICROBIOL,CNRS,URA D1354,F-91405 ORSAY,FRANCE	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Endicott, Jane/0000-0003-4868-0116				CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KORONAKIS V, 1988, MOL GEN GENET, V213, P551, DOI 10.1007/BF00339631; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1988, MECHANISMS DRUG RESI, V9, P197; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKMAN N, 1986, CURR TOP MICROBIOL, V125, P159; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; MACKMAN N, 1985, MOL GEN GENET, V201, P529, DOI 10.1007/BF00331351; MACKMAN N, 1984, MOL GEN GENET, V196, P123; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER W, 1980, J BACTERIOL, V144, P53, DOI 10.1128/JB.144.1.53-59.1980; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U	29	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3764	3770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371277				2022-12-25	WOS:A1992HE60700036
J	KO, K; BORNEMISZA, O; KOURTZ, L; KO, ZW; PLAXTON, WC; CASHMORE, AR				KO, K; BORNEMISZA, O; KOURTZ, L; KO, ZW; PLAXTON, WC; CASHMORE, AR			ISOLATION AND CHARACTERIZATION OF A CDNA CLONE ENCODING A COGNATE 70-KDA HEAT-SHOCK PROTEIN OF THE CHLOROPLAST ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; TRANSIT PEPTIDE; MESSENGER-RNA; HSP70; TRANSLOCATION; POLYPEPTIDES; BINDING; IMPORT; GENES; MEMBRANES	The translocation of proteins into the endoplasmic reticulum, the mitochondrion, and the chloroplast has recently been shown to involve homologues of the highly conserved 70-kDa heat shock protein (HSP70) family. In this study, we have isolated and sequenced a full-length cDNA clone encoding a cognate 70-kDa heat shock protein of the spinach chloroplast envelope (SCE70). The cDNA insert is 2,535 base pairs long and codes for 653 amino acid residues of a protein with a predicted molecular mass of 71,731 daltons. The deduced amino acid sequence shows a high degree of homology with HSP70 proteins from other organisms. Southern genomic and RNA analyses reveal different hybridization patterns than that observed for a heat-inducible 70-kDa protein gene. The protein synthesized from the SCE70 cDNA insert co-migrates with a 70-kDa polypeptide of the chloroplast envelope following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis and import studies indicate that SCE70 is associated with the chloroplast outer envelope. The import data suggest that SCE70 is targeted to the envelope membrane via a pathway different from other plastidic precursors but similar to that recently reported for outer envelope proteins SOE1 and OM14.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	KO, K (corresponding author), QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA.		Plaxton, William C/O-3353-2013	Plaxton, William C/0000-0002-8447-7249				ALTANO C, 1989, J BIOL CHEM, V264, P10709; AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BARTLETT SG, 1982, METHODS CHLOROPLAST; BIENZ M, 1984, P NATL ACAD SCI-BIOL, V81, P3138, DOI 10.1073/pnas.81.10.3138; BIGGIN MO, 1984, P NATL ACAD SCI USA, V80, P3963; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; CASHMORE AR, 1982, METHODS CHLOROPLAST; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUA NH, 1982, METHODS CHLOROPLAST; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1985, J BIOL CHEM, V260, P3691; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; HUNYH TV, 1985, DNA CLONING PRACTICA, V1, P49; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LIN TY, 1991, PLANT MOL BIOL, V16, P475, DOI 10.1007/BF00023998; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANIATIS T, 1981, MOL CLONING; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; POWELL MJ, 1990, GENE, V95, P105, DOI 10.1016/0378-1119(90)90420-V; ROBERTS JK, 1991, PLANT MOL BIOL, V16, P671, DOI 10.1007/BF00023431; ROCHESTER DE, 1986, EMBO J, V5, P451, DOI 10.1002/j.1460-2075.1986.tb04233.x; ROGERS SG, 1988, PLANT MOL BIOL METHO; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA M, 1986, J BACTERIOL, V168, P213, DOI 10.1128/jb.168.1.213-220.1986; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WILKINSON MC, 1990, PHYTOCHEMISTRY, V10, P3073; WINTER J, 1988, MOL GEN GENET, V211, P315, DOI 10.1007/BF00330609	58	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2986	2993						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371110				2022-12-25	WOS:A1992HD15400029
J	JOSEPH, CK; QURESHI, SA; WALLACE, DJ; FOSTER, DA				JOSEPH, CK; QURESHI, SA; WALLACE, DJ; FOSTER, DA			MARCKS PROTEIN IS TRANSCRIPTIONALLY DOWN-REGULATED IN V-SRC-TRANSFORMED BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; HERBIMYCIN-A; FPS GENE; PHOSPHORYLATION; EXPRESSION; 80-KDA; HETEROGENEITY; FIBROBLASTS	Activation of protein kinase C (PKC) by tumor-promoting phorbol esters leads to the phosphorylation of an 80-kilodalton PKC substrate (known as MARCKS) in murine fibroblasts. In BALB/c 3T3 cells stably transformed by v-Src, phorbol esters were unable to induce phosphorylation of MARCKS. Western blot analysis and in vitro kinase assays showed that both PKC protein levels and kinase activity were unchanged in v-Src-transformed relative to the parental nontransformed BALB/c 3T3 cells. However, MARCKS protein levels were reduced in v-Src-transformed cells relative to nontransformed cells. MARCKS RNA levels were also correspondingly reduced in v-Src-transformed cells. Nuclear "run-on" assays showed decreased transcription of MARCKS in v-Src-transformed cells. Thus, the absence of MARCKS in v-Src-transformed cells could be explained by a down-regulation of MARCKS transcription. Inhibiting the protein tyrosine kinase activity of v-Src with herbimycin A restored MARCKS RNA levels, MARCKS transcription, and MARCKS protein, suggesting that down-regulation of MARCKS in v-Src-transformed BALB/c 3T3 cells is a direct effect of v-Src.	CUNY HUNTER COLL,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021; CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)					NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BIEMANN HPN, 1990, MOL CELL BIOL, V10, P2122, DOI 10.1128/MCB.10.5.2122; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; NIEDEL JE, 1986, RECEPTORS PHOSPHOINO, P47; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P306; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UNGER ER, 1986, AM J SURG PATHOL, V10, P1, DOI 10.1097/00000478-198601000-00001; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YANG HC, 1987, J CELL PHYSIOL, V133, P377, DOI 10.1002/jcp.1041330224	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1327	1330						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370466				2022-12-25	WOS:A1992GY96000100
J	YANG, ZH; WENSEL, TG				YANG, ZH; WENSEL, TG			INORGANIC PYROPHOSPHATASE FROM BOVINE RETINAL ROD OUTER SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; CGMP PHOSPHODIESTERASE; FREE CALCIUM; LIGHT ADAPTATION; CYCLIC-GMP; RAT-LIVER; PURIFICATION; CA-2+; PHOTORECEPTORS; ACTIVATION	Rod outer segments from bovine retina contain a higher level of intracellular inorganic pyrophosphatase (EC 3.6.1.1) activity than has been found in any other mammalian tissue; the specific activity in extracts of soluble outer segment proteins is more than 6-fold higher than in extracts from bovine liver and more than 24-fold higher than in skeletal muscle extracts. This high activity may be necessary to keep inorganic pyrophosphate concentrations low in the face of the high rates of pyrophosphate production that accompany the cGMP flux driving phototransduction. We have begun to explore the role of inorganic pyrophosphatase in photoreceptor cGMP metabolism by 1) studying the kinetic properties of this enzyme and its interactions with divalent metal ions and anionic inhibitors, 2) purifying it and studying its size and subunit composition, and 3) examining the effects of pyrophosphate on rod outer segment guanylyl cyclase. K(m) for magnesium pyrophosphate was 0.9-1.5 muM, and the purified enzyme hydrolyzed >885 mumol of PP(i) min-1 mg-1. The enzyme appears to be a homodimer of 36-kilodalton subunits when analyzed by gel electrophoresis and density gradient centrifugation, implying that k(cat) = 10(3) s-1, and k(cat)/K(m) = 0.7-1 x 10(9) M-1 s-1. The enzyme was inhibited by Ca2+ at submicromolar levels: 28% inhibition was observed at 138 nM [Ca2+], and 53% inhibition at 700 nM [Ca2+]. Imidodiphosphate acted as a competitive inhibitor, with K(i) = 1.2 muM, and fluoride inhibited half-maximally approximately 20 muM. Inhibition studies on rod outer segment guanylyl cyclase confirmed previous reports that pyrophosphate inhibits guanylyl cyclase, suggesting an essential role for inorganic pyrophosphatase in maintaining cGMP metabolism.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1986, J BIOL CHEM, V261, P3034; ANG Z, 1991, BIOPHYS J, V59, pA535; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAYKOV AA, 1989, ARCH BIOCHEM BIOPHYS, V273, P287, DOI 10.1016/0003-9861(89)90486-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER LG, 1977, BIOINORG CHEM, V7, P141; CHEN M, 1973, P SOC EXP BIOL MED, V143, P44, DOI 10.3181/00379727-143-37249; CHEUNG WY, 1966, BIOCHEM BIOPH RES CO, V23, P214, DOI 10.1016/0006-291X(66)90530-4; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; DAVIDSON AM, 1989, BIOCHEM J, V258, P817, DOI 10.1042/bj2580817; DETWILER P B, 1989, Investigative Ophthalmology and Visual Science, V30, P162; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FELIX R, 1975, BIOCHEM J, V147, P111, DOI 10.1042/bj1470111; FISHER RA, 1974, ANN HUM GENET, V37, P341, DOI 10.1111/j.1469-1809.1974.tb01841.x; FISHER RA, 1974, ANN HUM GENET, V38, P171, DOI 10.1111/j.1469-1809.1974.tb01948.x; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HACHIMORI A, 1983, J BIOCHEM, V93, P257, DOI 10.1093/oxfordjournals.jbchem.a134161; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; IRIE M, 1970, J BIOCHEM, V67, P47, DOI 10.1093/oxfordjournals.jbchem.a129233; JANSON CA, 1979, J BIOL CHEM, V254, P3743; JOHNSONRA, 1990, J BIOL CHEM, V265, P11595; KHANDELWAL RL, 1980, BIOCHIM BIOPHYS ACTA, V613, P95, DOI 10.1016/0005-2744(80)90196-5; KLEMME JH, 1976, Z NATURFORSCH C, V31, P544; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB TD, 1986, J PHYSIOL-LONDON, V372, P315, DOI 10.1113/jphysiol.1986.sp016011; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MOE OA, 1972, J BIOL CHEM, V247, P7315; MOE OA, 1972, J BIOL CHEM, V247, P7308; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PEPE IM, 1986, FEBS LETT, V203, P73, DOI 10.1016/0014-5793(86)81439-9; PRITZKER KPH, 1986, HUM PATHOL, V17, P543, DOI 10.1016/S0046-8177(86)80124-1; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; PYNES GD, 1967, J BIOL CHEM, V242, P2119; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RATTO GM, 1988, J NEUROSCI, V8, P3240; RIDLINGTON JW, 1972, J BIOL CHEM, V247, P7303; SHATTON JB, 1981, CANCER RES, V41, P1866; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; STETTEN D, 1960, AM J MED, V28, P867, DOI 10.1016/0002-9343(60)90195-9; STRYER L, 1991, J BIOL CHEM, V266, P10711; THUILLIER L, 1978, BIOCHIM BIOPHYS ACTA, V524, P198, DOI 10.1016/0005-2744(78)90118-3; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHEELER TJ, 1980, BIOCHEMISTRY-US, V19, P4564, DOI 10.1021/bi00561a004; YANG Z, 1990, Investigative Ophthalmology and Visual Science, V31, P216; YANG ZH, 1992, J BIOL CHEM, V267, P24641; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YOSHIDA C, 1982, CANCER RES, V42, P3526	61	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24634	24640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360011				2022-12-25	WOS:A1992KA26300073
J	ZU, YL; TAKAMATSU, Y; ZHAO, MJ; MAEKAWA, T; HANDA, H; ISHII, S				ZU, YL; TAKAMATSU, Y; ZHAO, MJ; MAEKAWA, T; HANDA, H; ISHII, S			TRANSCRIPTIONAL REGULATION BY A POINT MUTANT OF ADENOVIRUS-2 E1A PRODUCT LACKING DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; AMP RESPONSE ELEMENT; CYCLIC-AMP; ACTIVATES TRANSCRIPTION; FUNCTIONAL DOMAINS; ESCHERICHIA-COLI; MESSENGER-RNAS; EARLY PROMOTER; PROTEIN; TRANSFORMATION	The adenovirus E1a protein (E1A) regulates transcription through interaction with transcription factors bound to DNA, like cAMP response element BP1/ATF2, or through dissociating E2F transcription factor complex. However, it was also reported that E1A can bind to DNA (Chatterjee, P. K., Bruner, M., Flint, S. J., and Harter, M. L. (1988) EMBO J. 7, 835-841), and it is not clear whether DNA binding of E1A is involved in a part of the process of transcriptional regulation by E1A. In this paper, the small region of E1A that is responsible for DNA binding was identified and a point mutant lacking DNA binding activity was constructed. Analysis of deletion mutants of E1A proteins expressed in bacteria showed that a basic region between amino acids 201 and 216 of E1A is essential for DNA binding. Point mutation of arginines at amino acid numbers 205 and 206 to aspartic acids completely abolished the DNA binding activity of E1A. Using this mutant, the requirement of the E1A DNA binding for E1A-dependent transcriptional regulation was examined. trans-Activation of the adenovirus E4 promoter and trans-repression of the human c-erbB-2 promoter by this point mutant were examined by cotransfection experiments. Mutations of the E1A DNA-binding domain affected neither the E1A-induced trans-activation nor trans-repression at all. These results give complete proof that the DNA binding activity of E1A is not required for transcriptional regulation by E1A.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA 236,JAPAN; TOKYO INST TECHNOL,FAC LIFE SCI & TECHNOL,DEPT BIOSYST,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	RIKEN; Yokohama City University; Tokyo Institute of Technology			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANAKA S, 1987, MOL CELL BIOL, V7, P2578, DOI 10.1128/MCB.7.7.2578; HANDA H, 1987, GENE, V58, P127; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KATO HT, 1983, MOL CELL BIOL, V3, P2058; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERRICAUDET M, 1979, NATURE, V218, P649; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZU YL, 1991, J BIOL CHEM, V266, P24134	55	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20181	20187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356975				2022-12-25	WOS:A1992JR85800070
J	MONTROSERAFIZADEH, C; BLACKMON, DL; HAMOSH, A; OLIVA, MM; HAWKINS, AL; CURRISTIN, SM; GRIFFIN, CA; YANG, VW; GUGGINO, WB; CUTTING, GR; MONTROSE, MH				MONTROSERAFIZADEH, C; BLACKMON, DL; HAMOSH, A; OLIVA, MM; HAWKINS, AL; CURRISTIN, SM; GRIFFIN, CA; YANG, VW; GUGGINO, WB; CUTTING, GR; MONTROSE, MH			REGULATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE-TRANSCRIPTION AND ALTERNATIVE RNA SPLICING IN A MODEL OF DEVELOPING INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; RIBONUCLEIC-ACID; CELL POLARITY; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; GENERATION; TRANSPORT	Transcriptional and post-transcriptional regulation of CFTR (cystic fibrosis transmembrane conductance regulator) gene expression was studied in HT29 cells. It is known that the abundance of CFTR mRNA increases during differentiation of pluripotent HT29-18 cells and is maintained at high levels in the stably differentiated HT29-18-C1 subclone. Nuclear run-on assays suggest that increased transcription of the CFTR gene explains the increased abundance of total CFTR mRNA in differentiated HT29 cells. The increased transcription cannot be ascribed to cell cycle-dependent expression of the CFTR gene or to changes in CFTR gene copy number between subcloned cells. Similar to native tissue cells, differentiated HT29 cells contain low copy numbers of CFTR transcripts (1-5/cell), and a portion of the CFTR transcripts are alternatively spliced to remove exon 9 (and make 9- mRNA). During differentiation of HT29-18 cells, the absolute amount of full-length CFTR mRNA increases 8-fold, whereas the amount of 9- mRNA increases 18-fold. The fraction of 9- mRNA in the CFTR mRNA pool is increased in differentiated HT29 cells. The results show that gene transcription regulates the abundance of CFTR transcripts and that regulatory control of alternative RNA splicing may also be a cellular mechanism to modulate CFTR function.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,ROSS RES BLDG,RM 930,720 RUTLAND ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)				Oliva-Hemker, Maria/0000-0002-4054-7372	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM041015] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47122] Funding Source: Medline; NIGMS NIH HHS [GM41015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1989, MOL BIOL CELL, P727; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AUSBEL FM, 1991, CURRENT PROTOCOLS MO; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BLACKMON DL, 1982, ANAL BIOCHEM, V200, P352; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUPPENS H, 1990, J MED GENET, V27, P717, DOI 10.1136/jmg.27.11.717; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAWKINS AL, 1991, CANCER GENET CYTOGEN, V54, P11, DOI 10.1016/0165-4608(91)90024-O; HAY R, 1988, AM TYPE CULTURE COLL; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LEBIVIC A, 1987, BIOL CELL, V60, P209; LEBIVIC A, 1988, P NATL ACAD SCI USA, V85, P136; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MONTROSE MH, 1989, J MEMBRANE BIOL, V108, P31, DOI 10.1007/BF01870423; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; NEUTRA M, 1989, DIFFERENTIATION INTE, P363; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRONG TV, 1990, PEDIATR PULMON S, V5, P195; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344	47	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19299	19305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382071				2022-12-25	WOS:A1992JP59300044
J	HUETTINGER, M; RETZEK, H; HERMANN, M; GOLDENBERG, H				HUETTINGER, M; RETZEK, H; HERMANN, M; GOLDENBERG, H			LACTOFERRIN SPECIFICALLY INHIBITS ENDOCYTOSIS OF CHYLOMICRON REMNANTS BUT NOT ALPHA-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; RAT-LIVER; APOLIPOPROTEIN-E; ALPHA-2-MACROGLOBULIN RECEPTOR; PARENCHYMAL-CELLS; CULTURED-CELLS; LDL RECEPTOR; PLASMA; CLEARANCE	Our recently found nonlipoprotein inhibitor of chylomicron remnant uptake, lactoferrin, has been investigated in vivo and in vitro. Lipoprotein lipase extracted triglycerides from chylomicrons, doubly labeled with [H-3]retinol/[C-14]oleate, in the presence of lactoferrin normally. The subsequent uptake of remnants into liver was retarded considerably. In the intact rat, chylomicron remnants (CRs), predominantly labeled in the apoB48 moiety by I-125, were excluded from the hepatic endosomal compartment in the presence of lactoferrin as shown in subcellular fractionation studies of rat livers. In tissue culture, internalization of [I-125]chylomicron remnants was inhibited in the presence of 14 pM lactoferrin by 70%. Upon removal of lactoferrin, internalization was rapidly restored. Protease digestion eliminated the inhibitory effect completely. Modification of arginine residues with cyclohexanedione reversibly removed the inhibitory potency of lactoferrin. We located by molecular modeling an alpha-helical segment in lactoferrin on the exposed surface of the molecule containing the sequence Arg-X-X-Arg-Lys-X-Arg, which resembles the receptor recognition structure in apolipoprotein E (apoE). This firmly established ligand correspondence with apoE, the candidate ligand for CR recognition by the receptor. Finally, the postulated second function of low density lipoprotein receptor-related protein, uptake of alpha-2-macroglobulin (alpha-2M) was found to be distinct from lipoprotein binding, since lactoferrin inhibited CR but not alpha-2M internalization. In addition, CR uptake was not affected by alpha-2M. We conclude that if a bifunctional receptor were to operate, its diverse functions were exerted by independently operating substructures. The results of our in vivo and cell culture experiments are, however, entirely compatible with the existence of two receptors as well.			HUETTINGER, M (corresponding author), UNIV VIENNA,DEPT MED CHEM,WAHRINGERSTR 10,A-1090 VIENNA,AUSTRIA.			Retzek, Helmut/0000-0002-2256-7687; Hermann, Marcela/0000-0003-2298-4269				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3566; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DYER CA, 1991, J BIOL CHEM, V266, P22803; EVANS WH, 1985, METHOD ENZYMOL, V109, P246; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GMEINER BM, 1985, BIOCHIM BIOPHYS ACTA, V829, P76, DOI 10.1016/0167-4838(85)90070-6; GOLDENBERG H, 1988, BIOCHIM BIOPHYS ACTA, V968, P331, DOI 10.1016/0167-4889(88)90024-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MAHLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P225, DOI 10.1073/pnas.77.1.225; REGOECZI E, 1985, AM J PHYSIOL, V248, pG8, DOI 10.1152/ajpgi.1985.248.1.G8; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; Smith E L, 1977, Methods Enzymol, V47, P156; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; VANBERKEL TJC, 1983, BIOCHEM J, V216, P71, DOI 10.1042/bj2160071; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDYKE RW, 1984, P NATL ACAD SCI-BIOL, V81, P3108; WATTIAUX R, 1986, BIOCHEM BIOPH RES CO, V136, P504, DOI 10.1016/0006-291X(86)90469-9	32	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18551	18557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382056				2022-12-25	WOS:A1992JN50200049
J	ULRICH, MJ; GRAY, WJ; LEY, TJ				ULRICH, MJ; GRAY, WJ; LEY, TJ			AN INTRAMOLECULAR DNA TRIPLEX IS DISRUPTED BY POINT MUTATIONS ASSOCIATED WITH HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLOBIN-GENE; INCREASES PROMOTER STRENGTH; SUPERCOILED PLASMIDS; BINDING-SITES; H-DNA; NUCLEAR PROTEINS; ERYTHROID-CELLS; HELIX FORMATION; MIRROR REPEATS; BRITISH FORM	Several investigators have suggested that secondary structures in DNA may be involved with physiologic gene regulatory processes in higher organisms. This hypothesis has been difficult to prove, however, since naturally occurring mutations that alter secondary DNA structures have not yet been identified. In this report, we describe a secondary DNA structure upstream from the human gamma-globin genes; this structure is formed in a homopyrimidine-homopurine tract and is stabilized by acidic pH and negative supercoiling of plasmid DNA. Since this structure is asymmetrically cleaved by S1 nuclease, it probably contains a single-stranded region and an intramolecular triplex. The single-stranded region is actually accessible for Watson-Crick base pairing with exogenous oligomers, a characteristic that permitted us to directly map the secondary DNA structure without additional chemical modifications of the supercoiled DNA. Five different point mutations just downstream from the single-stranded region are associated with hereditary persistence of fetal hemoglobin; four of these mutations dramatically reduce the stability of the secondary DNA structure, suggesting that these mutations alter formation of the intramolecular triplex by destabilizing critical Hoogsteen (triple-stranded) base pairs. These mutations may therefore represent a novel class of genetic defects that alter gene expression by changing the interaction of a critical regulatory molecule with a secondary DNA structure.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCI NIH HHS [CA-49712] Funding Source: Medline; NIDDK NIH HHS [DK-38682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COCKERILL PN, 1983, BIOCHEM BIOPH RES CO, V112, P547, DOI 10.1016/0006-291X(83)91499-7; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COLLINS FS, 1984, BLOOD, V64, P1292; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; COOK PR, 1975, J CELL SCI, V19, P261; COSTA FF, 1991, BLOOD, V76, P1896; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; ECONOMOU EP, 1991, BLOOD, V77, P174; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FOURCADEPERONNET F, 1992, J VIROL, V66, P1682, DOI 10.1128/JVI.66.3.1682-1687.1992; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GELINAS R, 1986, BLOOD, V67, P1777; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GILMAN JG, 1988, BLOOD, V72, P78; GILMAN JG, 1988, BRIT J HAEMATOL, V68, P455; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLIKIN GC, 1983, NATURE, V303, P770, DOI 10.1038/303770a0; GLOVER JNM, 1990, BIOCHEMISTRY-US, V29, P11110, DOI 10.1021/bi00502a014; GRAY WJ, 1985, BLOOD, V66, pA71; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1990, BLOOD, V75, P756; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1991, JH S CONT M, P277; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEY TJ, 1991, BLOOD, V77, P1146; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MARGOT JB, 1985, J MOL BIOL, V184, P195, DOI 10.1016/0022-2836(85)90373-0; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; METHERALL JE, 1988, AM J HUM GENET, V42, P476; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; NICOLIS S, 1989, NUCLEIC ACIDS RES, V17, P5509, DOI 10.1093/nar/17.14.5509; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; OTTOLENGHI S, 1988, BLOOD, V71, P815; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RIXON MW, 1990, BIOCHEMISTRY-US, V29, P4393, DOI 10.1021/bi00470a019; RIXON MW, 1988, MOL CELL BIOL, V8, P713, DOI 10.1128/MCB.8.2.713; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; RUNKEL L, 1986, NUCLEIC ACIDS RES, V14, P7143, DOI 10.1093/nar/14.18.7143; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; STOMING TA, 1989, BLOOD, V73, P329; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SURREY S, 1988, BLOOD, V71, P807; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TANAKA M, 1990, ANN NY ACAD SCI, V612, P167; TATE VE, 1986, BLOOD, V68, P1389; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; ULRICH MJ, 1990, BLOOD, V75, P990; WABER PG, 1986, BLOOD, V67, P551; WANG JNC, 1985, J BIOL CHEM, V260, P8194; WANG ZY, 1992, J BIOL CHEM, V267, P13669; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YANG KG, 1988, BLOOD, V71, P1414; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	90	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18649	18658						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382059				2022-12-25	WOS:A1992JN50200062
J	LEUNG, LLK; LI, WX; MCGREGOR, JL; ALBRECHT, G; HOWARD, RJ				LEUNG, LLK; LI, WX; MCGREGOR, JL; ALBRECHT, G; HOWARD, RJ			CD36 PEPTIDES ENHANCE OR INHIBIT CD36-THROMBOSPONDIN BINDING - A 2-STEP PROCESS OF LIGAND-RECEPTOR INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; MEMBRANE GLYCOPROTEIN; CELL-ADHESION; GPIIB-IIIA; PARASITIZED ERYTHROCYTES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS	CD36 (glycoprotein IV or IIIB) is an integral plasma membrane protein of wide cellular distribution and functions as a receptor site for thrombospondin (TSP), an adhesive protein important in cell-cell and cell-matrix interactions. OKM5, a monoclonal anti-CD36 antibody, has been reported to block CD36 cell adhesive functions suggesting that the OKM5 epitope on CD36 is functionally important. A panel of 10 synthetic CD36 peptides was made. One peptide, P139-155, specifically inhibited the immunoadsorption of CD36 by OKM5, and P139-155 was directly immunoadsorbed by OKM5, indicating that CD36 sequence 139-155 represents part of the OKM5 epitope. TSP bound to immobilized P139-155 in a dose-dependent and saturable manner. Surprisingly, P139-155 significantly augmented, instead of inhibited, binding of CD36 to TSP. This peptide did not induce platelet aggregation but augmented ADP- and collagen-induced aggregation in platelet-rich plasma. Another CD36 peptide, P93-110, which had no effect on OKM5 immunoadsorption, blocked binding of CD36 to immobilized TSP and partially inhibited collagen-induced platelet aggregation. P93-110 by itself did not bind to TSP; however, in the presence of P139-155, there was a marked enhancement of P93-110 binding to TSP, with a stoichiometry consistent with the trimeric nature of TSP. The data suggest that CD36-TSP interaction is a two-step process; the sequence 139-155 region of CD36 binds first to TSP, triggering a change in TSP to reveal a second site, which binds the 93-110 region of CD36 with high affinity. CD36 peptides can be used as stimulators or inhibitors in cellular adhesive events involving TSP-CD36 interaction. Conformational changes leading to the exposure or activation of high affinity binding sites may occur in both the receptor and the ligand upon cell-cell and cell-matrix adhesion.	STANFORD UNIV,MED CTR,SCH MED,DIV HEMATOL,STANFORD,CA 94305; INSERM,F-69008 LYON,FRANCE; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL42943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BEISO P, 1990, BIOCHIM BIOPHYS ACTA, V1033, P7, DOI 10.1016/0304-4165(90)90186-Z; CLEZARDIN P, 1986, EUR J BIOCHEM, V154, P95, DOI 10.1111/j.1432-1033.1986.tb09363.x; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HOWARD RJ, 1989, BLOOD, V74, P2603; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KIEFFER N, 1991, BIOCHIM BIOPHYS ACTA, V77, P2649; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OCKENHOUSE CF, 1991, SCIENCE, V88, P3175; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SILVERSTEIN RL, 1986, ARTERIOSCLEROSIS, V6, P245, DOI 10.1161/01.ATV.6.3.245; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; WIKNER NE, 1987, J INVEST DERMATOL, V88, P207, DOI 10.1111/1523-1747.ep12525350; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	46	82	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18244	18250						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381367				2022-12-25	WOS:A1992JM22300116
J	SCHMIDT, M; BUCHNER, J				SCHMIDT, M; BUCHNER, J			INTERACTION OF GROE WITH AN ALL-BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT CHAIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CONSTANT FRAGMENT; BINDING; RECONSTITUTION; PURIFICATION; INTERMEDIATE; AGGREGATION; POLYPEPTIDE	Molecular chaperones are involved in protein folding both in vivo and in vitro. The Escherichia coli chaperone GroEL interacts with a number of nonnative proteins. A common structural motif of nonnative proteins, which is recognized by GroEL, has not yet been identified. In order to study the role of beta-sheet secondary structure on the interaction of nonnative proteins with GroEL, we used the F(ab) fragment of a monoclonal antibody as a model substrate protein. Here we show that GroEL interacts functionally with this all-beta-protein during reactivation. Antibody fragments refold spontaneously in good yield from the guanidine-denatured state. Functional refolding to the native state is inhibited transiently by GroEL, but there is no complete folding arrest in the absence of Mg-ATP and GroES. The yield of these unspecifically released GroEL-bound F(ab) fragments corresponds to that of the spontaneous reactivation in the absence of chaperones. However, the refolding kinetics in the presence of GroEL are considerably slower. The addition of Mg-ATP to the GroEL.F(ab) complex results in an immediate release of bound substrate protein and a significant increase in the amount of reconstituted antibody fragments compared to spontaneous reactivation. GroES is not essential for functional GroEL-mediated refolding of the F(ab) fragment but affects the reactivation yield to a small extent. Interestingly, stimulation of the GroEL-mediated F(ab) refolding depends primarily on the binding and not on hydrolysis of adenosine triphosphates. Previous results indicate the binding of alpha-helices to GroEL. The results presented in this paper suggest that beta-sheet secondary structural elements are recognized by GroEL. We therefore conclude that the interaction of a nonnative protein with GroEL depends mainly on the nature of the early folding intermediate but not on a specific element of secondary structure.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BALDWIN RL, 1991, CIBA F SYMP, V161, P190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY JS, 1992, NATURE, V355, P455; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	38	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16829	16833						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1355088				2022-12-25	WOS:A1992JL05300018
J	BRECHLER, V; PAVOINE, C; HANF, R; GARBARZ, E; FISCHMEISTER, R; PECKER, F				BRECHLER, V; PAVOINE, C; HANF, R; GARBARZ, E; FISCHMEISTER, R; PECKER, F			INHIBITION BY GLUCAGON OF THE CGMP-INHIBITED LOW-K(M) CAMP PHOSPHODIESTERASE IN HEART IS MEDIATED BY A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LIVER PLASMA-MEMBRANE; ADENYLATE-CYCLASE; AMP PHOSPHODIESTERASES; CALCIUM CURRENT; CA-2+ PUMP; SELECTIVE INHIBITORS; HORMONAL-REGULATION; CARDIAC-CELLS; ACTIVATION	We have recently reported that glucagon activated the L-type Ca2+ channel current in frog ventricular myocytes and showed that this was linked to the inhibition of a membrane-bound low-K(m) cAMP phosphodiesterase (PDE) (Mery, P. F., Brechler, V., Pavoine, C., Pecker, F., and Fischmeister, R. (1990) Nature 345, 158-161). We show here that the inhibition of membrane-bound PDE activity by glucagon depends on guanine nucleotides, a reproducible inhibition of 40% being obtained with 0.1-mu-M glucagon in the presence of 10-mu-M GTP, with GTP > GTP-gamma-S, while GDP and ATP-gamma-S were without effect. Glucagon had no effect on the cytosolic low-K(m) cAMP PDE, assayed with or without 10-mu-M GTP. Glucagon inhibition of membrane-bound PDE activity was not affected by pretreatment of the ventricle particulate fraction with cholera toxin. However, it was abolished after pertussis toxin pretreatment. Mastoparan, a wasp venom peptide known to activate G(i)/G(o) proteins directly, mimicked the effect of glucagon. PDE inhibition by glucagon was additive with the inhibition induced by Ro 20-1724, but was prevented by milrinone. This was correlated with an increase by glucagon of cAMP levels in frog ventricular cells which was not additive with the increase in cAMP due to milrinone. We conclude that glucagon specifically inhibits the cGMP-inhibited, milrinone-sensitive PDE (CGI-PDE). Insensitivity of adenylylcyclase to glucagon and inhibition by the peptide of a low-K(m) cAMP PDE were not restricted to frog heart, but also occurred in mouse and guinea pig heart. These results confirm that two mechanisms mediate the action of glucagon in heart: one is the activation of adenylylcyclase through G(s), and the other relies on the inhibition of the membrane-bound low-K(m) CGI-PDE, via a pertussis toxin-sensitive G-protein.	UNIV PARIS 11, INSERM, U241, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	BRECHLER, V (corresponding author), HOP HENRI MONDOR, INSERM, U99, F-94010 CRETEIL, FRANCE.		Pavoine, Catherine/N-4405-2018; Fischmeister, Rodolphe/L-6061-2018	Pavoine, Catherine/0000-0002-0598-5545; Fischmeister, Rodolphe/0000-0003-2086-9865				ARRIODUPONT M, 1985, BIOL CELL, V54, P163; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BLACHE P, 1990, J BIOL CHEM, V265, P21514; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; BUXTON ILO, 1986, AM J PHYSIOL, V251, pH307, DOI 10.1152/ajpheart.1986.251.2.H307; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHATELAIN P, 1983, PFLUG ARCH EUR J PHY, V397, P100, DOI 10.1007/BF00582046; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; GANZ MB, 1990, J BIOL CHEM, V265, P8989; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HEYWORTH CM, 1983, BIOCHEM J, V214, P99, DOI 10.1042/bj2140099; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOLMER SR, 1991, CIRCULATION, V84, P1891, DOI 10.1161/01.CIR.84.5.1891; HUGHES AR, 1984, P NATL ACAD SCI-BIOL, V81, P5680, DOI 10.1073/pnas.81.18.5680; KISS Z, 1984, EUR J BIOCHEM, V142, P323, DOI 10.1111/j.1432-1033.1984.tb08289.x; LACOMBE ML, 1979, J BIOL CHEM, V254, P3697; LOTEN EG, 1978, J BIOL CHEM, V253, P746; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MASTERS SB, 1984, MOL PHARMACOL, V26, P149; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; MERY PF, 1990, NATURE, V345, P158, DOI 10.1038/345158a0; MIOT F, 1983, FEBS LETT, V151, P273, DOI 10.1016/0014-5793(83)80085-4; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; MULLER B, 1990, J CARDIOVASC PHARM, V16, P796, DOI 10.1097/00005344-199011000-00016; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; PYNE NJ, 1989, BIOCHEM J, V261, P897, DOI 10.1042/bj2610897; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SIMMONS MA, 1988, MOL PHARMACOL, V33, P664; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISHAAR RE, 1988, DRUG DEVELOP RES, V12, P119, DOI 10.1002/ddr.430120206; WILDENTHAL K, 1976, J CLIN INVEST, V57, P551, DOI 10.1172/JCI108310	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15496	15501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353495				2022-12-25	WOS:A1992JG11300039
J	CAMACHOHUBNER, C; BUSBY, WH; MCCUSKER, RH; WRIGHT, G; CLEMMONS, DR				CAMACHOHUBNER, C; BUSBY, WH; MCCUSKER, RH; WRIGHT, G; CLEMMONS, DR			IDENTIFICATION OF THE FORMS OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS PRODUCED BY HUMAN FIBROBLASTS AND THE MECHANISMS THAT REGULATE THEIR SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; CULTURED HUMAN-FIBROBLASTS; HUMAN-SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; FACTOR-I; SOMATOMEDIN-C; DNA-SYNTHESIS; PURIFICATION; RELEASE; PLASMA	Human fibroblasts secrete insulin-like growth factor-binding proteins (IGFBPs) that can modify insulin-like growth factor (IGF) I action. We have determined the molecular identities of three forms of IGFBPs that are secreted by human fibroblasts in vitro. Ligand blot analysis of fibroblast conditioned media revealed that the M(r) 43,000 and 39,000 forms were the most abundant, but that M(r) 31,000 and 24,000 forms were also present. An antiserum that was specific for IGFBP-5 reacted with the M(r) 31,000 form, and an IGFBP-4-specific antiserum recognized only the M(r) 24,000 form. The M(r) 39,000 and 43,000 forms were detected by IGFBP-3 antiserum. Further proof that fibroblasts synthesized these forms of IGFBPs was obtained by Northern blotting. A cDNA probe for IGFBP-3 hybridized with a 2.4-kilobase (kb) transcript, whereas a cDNA probe for IGFBP-5 recognized a single 6.0-kb transcript, and an IGFBP-4 cDNA probe recognized 2.2- and 2.0-kb transcripts. IGF-I and -II caused a minimal (<43%) increase in IGFBP-5 mRNA abundance and had no effect on IGFBP-4 mRNA abundance. IGF-I and -II (100 ng/ml) stimulated 6-8-fold increases in IGFBP-5 levels, whereas IGFBP-4 was inhibited. Insulin failed to elicit any change in IGFBP-5, suggesting that binding of the IGFs to IGFBPs was required to detect the increase. Immunoblotting for IGFBP-5 revealed an M(r) 23,000 (non-IGF-I-binding) fragment. To determine if the IGFs were influencing proteolytic degradation of IGFBP-5, pure IGFBP-5 was added to fibroblast cultures and incubated for 4 h at 37-degrees-C. The amount of fragment formation was attenuated by the presence of IGF-I and -II, but not insulin, suggesting that this is a mechanism by which the IGFs act to modulate IGFBP-5 concentration. In contrast to the IGFs, forskolin, which increased IGFBP-4 and -5 mRNA abundance and secretion, had no effect on fragment formation. The results show that human fibroblasts synthesize and secrete IGFBP-3, -4, and -5 and that changes in intracellular cAMP regulate synthesis, whereas the IGFs regulate IGFBP-4 and -5 levels by post-transcriptional mechanisms.			CAMACHOHUBNER, C (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS SO, 1984, ENDOCRINOLOGY, V115, P520, DOI 10.1210/endo-115-2-520; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ATKISON PR, 1980, ENDOCRINOLOGY, V106, P2006, DOI 10.1210/endo-106-6-2006; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMMONS DR, 1984, J CLIN ENDOCR METAB, V58, P850, DOI 10.1210/jcem-58-5-850; CLEMMONS DR, 1990, J BIOL CHEM, V265, P12210; CLEMMONS DR, 1986, J BIOL CHEM, V261, P293; CLEMMONS DR, 1987, MOL ENDOCRINOL, V1, P339, DOI 10.1210/mend-1-5-339; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P643, DOI 10.1210/endo-127-2-643; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAWKE D, 1987, USER B; HILL DJ, 1989, J ENDOCRINOL, V122, P87, DOI 10.1677/joe.0.1220087; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MCCUSKER RH, 1988, ENDOCRINOLOGY, V122, P2071, DOI 10.1210/endo-122-5-2071; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SVOBODA ME, 1980, BIOCHEMISTRY-US, V19, P790, DOI 10.1021/bi00545a027; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	35	295	299	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11949	11956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376315				2022-12-25	WOS:A1992HY94700046
J	VANDERHOORN, FA				VANDERHOORN, FA			IDENTIFICATION OF THE TESTIS C-MOS PROMOTER - SPECIFIC ACTIVITY IN A SEMINIFEROUS TUBULE-DERIVED EXTRACT AND BINDING OF A TESTIS-SPECIFIC NUCLEAR FACTOR	ONCOGENE			English	Article							PROTO-ONCOGENE; INVITRO TRANSCRIPTION; MOUSE PROTAMINE-1; TRANSGENIC MICE; GERM-CELLS; EXPRESSION; GENE; PRODUCT; RNA; ENHANCER	The c-mos proto-oncogene is predominantly expressed in male and female germ cells and is involved in the regulation of meiosis. To investigate the mechanism of testis-specific regulation of c-mos transcription, I set out to identify the rat testis c-mos promoter. This was achieved by characterization of the rat testis c-mos transcription start site by primer extension and sequence analysis of cDNAs obtained by polymerase chain reaction amplification of 5' ends of c-mos RNA. The rat testis c-mos transcription start site is located 0.56 kb upstream of the coding region. A fragment containing the rat testis c-mos promoter directs transcription in a nuclear extract derived from rat seminiferous tubules, but not in a liver nuclear extract. DNAase I footprint analysis and gel-retardation assays showed binding of a novel testis-specific nuclear factor to the rat testis c-mos promoter at a site homologous to the testis-specific cis-acting element identified in the promoter of the RT7 gene, which is specifically expressed in haploid male germ cells.			VANDERHOORN, FA (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, 3330 HOSP DR NW, CALGARY T2N 4N1, ALBERTA, CANADA.							BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERZOG NK, 1988, ONCOGENE, V3, P225; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAMBROOK J, 1988, MOL CLONING LABORATO; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VANDERHOORN FA, 1989, BIOCHEM BIOPH RES CO, V161, P8, DOI 10.1016/0006-291X(89)91552-0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	29	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1093	1099						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375715				2022-12-25	WOS:A1992HU64200006
J	OEHM, A; BEHRMANN, I; FALK, W; PAWLITA, M; MAIER, G; KLAS, C; LIWEBER, M; RICHARDS, S; DHEIN, J; TRAUTH, BC; PONSTINGL, H; KRAMMER, PH				OEHM, A; BEHRMANN, I; FALK, W; PAWLITA, M; MAIER, G; KLAS, C; LIWEBER, M; RICHARDS, S; DHEIN, J; TRAUTH, BC; PONSTINGL, H; KRAMMER, PH			PURIFICATION AND MOLECULAR-CLONING OF THE APO-1 CELL-SURFACE ANTIGEN, A MEMBER OF THE TUMOR-NECROSIS-FACTOR NERVE GROWTH-FACTOR RECEPTOR SUPERFAMILY - SEQUENCE IDENTITY WITH THE FAS ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; EXPRESSION; PROTEINS; APOPTOSIS; LYMPHOCYTES; CLEAVAGE; GENES	The APO-1 antigen as defined by the mouse monoclonal antibody anti-APO-1 was previously found to be expressed on the cell surface of activated human T and B lymphocytes and a variety of malignant human lymphoid cell lines. Cross-linking of the APO-1 antigen by anti-APO-1 induced programmed cell death, apoptosis, of APO-1 positive cells. To characterize the APO-1 cell surface molecule and to better understand its role in induction of apoptosis, the APO-1 protein was purified to homogeneity from membranes of SKW6.4 B lymphoblastoid cells by solubilization with sodium deoxycholate, affinity chromatography with anti-APO-1 antibody, and reversed phase high performance liquid chromatography. Each purification step was followed by an APO-1-specific solid phase enzyme-linked immunosorbent assay using the monoclonal antibody anti-APO-1. In sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the APO-1 antigen was found to be a membrane glycoprotein of 48-kDa. Endoproteinase-cleaved peptides of the APO-1 protein were subjected to amino acid sequencing, and corresponding oligonucleotides were used to identify a full-length APO-1 cDNA clone from an SKW6.4 cDNA library. The deduced amino acid sequence of APO-1 showed sequence identity with the Fas antigen, a cysteine-rich transmembrane protein of 335 amino acids with significant similarity to the members of the tumor necrosis factor/nerve growth factor receptor superfamily. The APO-1 antigen was expressed upon transfection of APO-1 cDNA into BL60-P7 Burkitt's lymphoma cells and conferred sensitivity towards anti-APO-1-induced apoptosis to the transfectants.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST APPL TUMOR VIROL,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST CELL & TUMOR BIOL,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Pawlita, Labor/C-9720-2011	Dhein, Jens/0000-0002-7200-2967; Pawlita, Michael/0000-0002-4720-8306; Behrmann, Iris/0000-0003-3688-3645				ARVIEUX J, 1988, PRACTICAL APPROACH S, P113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; INUI S, 1989, LEUCOCYTE TYPING, V4, P93; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KOHLER HR, 1990, ULTRASTRUCT PATHOL, V14, P513; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMMER PH, 1991, APOPTOSIS MOL BASIS, P87; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOLF J, 1990, CANCER RES, V50, P3095; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	29	881	932	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10709	10715						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375228				2022-12-25	WOS:A1992HV09000076
J	NAKAGAWA, Y; RIVERA, V; LARNER, AC				NAKAGAWA, Y; RIVERA, V; LARNER, AC			A ROLE FOR THE NA/K-ATPASE IN THE CONTROL OF HUMAN C-FOS AND C-JUN TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; EPIDERMAL GROWTH-FACTOR; PROTO-ONCOGENE FOS; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MEDIATE INDUCTION; GENE-EXPRESSION; INTERFERON; DNA; SEQUENCES; RNA	The c-fos proto-oncogene is known to be regulated by a variety of hormones, growth factors, and other conditions that alter cellular metabolism. The regulation of c-fos RNA concentrations is known to occur both by altered RNA half-life and/or changes in the transcription rate of the gene. In most cases thus far investigated, induction of c-fos transcription by growth factors occurs very rapidly and transiently. Results presented in this paper show that ouabain, a specific inhibitor of the Na/K-ATPase increases the transcription of c-fos, as well as c-jun, in a variety of cultured cells. However, in contrast to other agents that induce c-fos and c-jun expression, the increased transcription rate of these genes in the presence of ouabain required several hours and remained elevated for at least 16 h. NIH 3T3 cells that have been transfected with deletions of the human c-fos promoter have enabled us to define at least two elements within the promotor that are regulated by ouabain. These include the serum response element and a region between 123 and 222 base pairs 5' to the start site of transcription. We speculate that regulation of the intracellular ion balance through changes in Na/K pump activity may be a general mechanism by which basal transcriptional activity of c-fos is modulated.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	US Food & Drug Administration (FDA); Harvard University; Harvard Medical School								AKAI H, 1989, J BIOL CHEM, V264, P3252; BEVEREN CV, 1983, CELL, V32, P1241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1987, BIOESSAYS, V7, P225; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GEERING K, 1986, CURR TOP MEMBR TRANS, V27, P221; GOMI K, 1986, CANCER RES, V46, P6211; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LARNER AC, 1986, J BIOL CHEM, V261, P453; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; YAMATO K, 1989, BLOOD, V74, P1314	35	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8785	8788						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374380				2022-12-25	WOS:A1992HR85400015
J	TRACKMAN, PC; BEDELLHOGAN, D; TANG, J; KAGAN, HM				TRACKMAN, PC; BEDELLHOGAN, D; TANG, J; KAGAN, HM			POSTTRANSLATIONAL GLYCOSYLATION AND PROTEOLYTIC PROCESSING OF A LYSYL OXIDASE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE; PURIFICATION; AORTA; CULTURES; ELASTIN; CELLS; DNA	The synthesis and post-translational processing of a lysyl oxidase precursor protein predicted by the cDNA sequence of rat aorta lysyl oxidase were investigated. In vitro transcription of the cloned lysyl oxidase cDNA and cell-free translation of its mRNA transcript yielded a 47-kDa protein in the absence and a 50-kDa glycosylated protein in the presence of pancreatic membranes, each of which were immunoprecipitated with antibody against the 32-kDa bovine enzyme. Similarly, an N-glycosylated, 50-kDa protein band was synthesized by and immunoprecipitated from cultured neonatal rat aorta smooth muscle cells labeled with [S-35]methionine. Pulse-chase studies of proteins newly synthesized by these cells demonstrated that the glycosylated 50-kDa precursor is secreted and that it is processed to the 32-kDa molecular form of lysyl oxidase principally in the medium. The presence of an extracellular processing enzyme activity which converts the 50-kDa precursor to the 32-kDa species was demonstrated by incubating conditioned medium of neonatal rat aorta smooth muscle cell cultures as a source of processing activity with conditioned medium containing S-35-labeled precursor synthesized but not processed by a tumorigenic cell line transfected with a lysyl oxidase expression vector. In contrast to the 50-kDa species, the 32-kDa protein does not appear to be N-glycosylated consistent with the loss of N-linked oligosaccharide units during the processing to the smaller species. The modes of biosynthesis and secretion of lysyl oxidase are discussed in terms of other nonproteolytic activities required for activation of prolysyl oxidase.			TRACKMAN, PC (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL019717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19717, HL-13262] Funding Source: Medline; NIAMS NIH HHS [R37-AR-18880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMASSIAN B, 1991, CONNECT TISSUE RES, V25, P197, DOI 10.3109/03008209109029156; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; BURBELO PD, 1986, COLLAGEN REL RES, V6, P153; CRONLUND AL, 1986, CONNECT TISSUE RES, V15, P173, DOI 10.3109/03008208609167141; DORNER AJ, 1990, METHOD ENZYMOL, V185, P557; ENWEMEKA CS, 1991, TISSUE CELL, V23, P173, DOI 10.1016/0040-8166(91)90072-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAGAN HM, 1986, J CELL BIOL, V103, P1121, DOI 10.1083/jcb.103.3.1121; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P222; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROMEROCHAPMAN N, 1991, BIOCHEM J, V275, P657, DOI 10.1042/bj2750657; SAMBROOK J, 1989, MOL CLONING APPENDIX; SHACKLETON DR, 1990, BIOCHEM J, V266, P917; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; WAKASAKI H, 1990, LAB INVEST, V63, P377; WAKASAKI H, 1990, BIOCHEM BIOPH RES CO, V166, P1201, DOI 10.1016/0006-291X(90)90993-W; WOYNAROWSKA B, 1989, CANCER RES, V49, P5598	32	144	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8666	8671						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349020				2022-12-25	WOS:A1992HQ18500105
J	STEPHAN, V; BENHAMOU, M; GUTKIND, JS; ROBBINS, KC; SIRAGANIAN, RP				STEPHAN, V; BENHAMOU, M; GUTKIND, JS; ROBBINS, KC; SIRAGANIAN, RP			FC-EPSILON-RI-INDUCED PROTEIN TYROSINE PHOSPHORYLATION OF PP72 IN RAT BASOPHILIC LEUKEMIA-CELLS (RBL-2H3) - EVIDENCE FOR A NOVEL SIGNAL TRANSDUCTION PATHWAY UNRELATED TO G-PROTEIN ACTIVATION AND PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; HISTAMINE-RELEASE; MAST-CELLS; INOSITOL TRISPHOSPHATE; SYNERGISTIC SIGNALS; MEDIATED ACTIVATION; KINASE-C; RECEPTOR; SECRETION; INHIBITION	Recently, we demonstrated that aggregation of the high affinity IgE receptor in rat basophilic leukemia (RBL-2H3) cells results in rapid tyrosine phosphorylation of a 72-kDa protein (pp72). Here we investigated the relationship of pp72 phosphorylation to guanine nucleotide-binding protein (G protein) activation and phosphatidylinositol hydrolysis. The activation of G proteins by NaF in intact cells or by guanosine 5'-O-(3-thiotriphosphate) in streptolysin 0-permeabilized cells induced both phosphatidylinositol hydrolysis and histamine release without tyrosine phosphorylation of pp72. Similarly, in RBL-2H3 cells expressing the G protein-coupled muscarinic acetylcholine receptor, carbachol activated phospholipase C and induced secretion without concomitant pp72 phosphorylation. Therefore, pp72 phosphorylation was not induced by G protein activation or as a consequence of phosphatidylinositol hydrolysis. To investigate whether pp72 tyrosine phosphorylation precedes the activation of phospholipase C, we studied the effect of the tyrosine kinase inhibitor genistein. Preincubation of cells with genistein decreased, in parallel, antigen-induced tyrosine phosphorylation of pp72 (IC50 = 34-mu-g/ml) and histamine release (IC50 = 31-mu-g/ml). However, genistein at concentrations of up to 60-mu-g/ml did not inhibit phosphatidylinositol hydrolysis nor did it change the amount of the secondary messenger inositol (1,4,5)-triphosphate. Previous observations showed that there was no pp72 tyrosine phosphorylation after activation of protein kinase C or after an increase in intracellular calcium. Taken together, these results suggest that pp72 tyrosine phosphorylation represents a distinct, independent signaling pathway induced specifically by aggregation of the Fc-epsilon-RI.	NIDR,IMMUNOL LAB,BLDG 10,RM 1N 106,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Benhamou, Marc/0000-0001-7763-3795				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P87; BALLA T, 1988, J BIOL CHEM, V263, P4083; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BEAVEN MA, 1991, FASEB J, V5, pA1676; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1986, FASEB J, V45, P2156; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANE PJL, 1991, J IMMUNOL, V146, P715; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; NARASIMHAN V, 1990, J BIOL CHEM, V264, P1459; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRIBLUDA VS, 1987, J BIOL CHEM, V262, P11449; RASHEED S, 1976, J VIROL, V19, P13, DOI 10.1128/JVI.19.1.13-18.1976; SAITO H, 1989, J IMMUNOL, V143, P250; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WILSON BS, 1989, J IMMUNOL, V143, P259	44	69	69	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5434	5441						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372002				2022-12-25	WOS:A1992HH74700066
J	EMMERICH, J; BEG, OU; PETERSON, J; PREVIATO, L; BRUNZELL, JD; BREWER, HB; SANTAMARINAFOJO, S				EMMERICH, J; BEG, OU; PETERSON, J; PREVIATO, L; BRUNZELL, JD; BREWER, HB; SANTAMARINAFOJO, S			HUMAN LIPOPROTEIN-LIPASE - ANALYSIS OF THE CATALYTIC TRIAD BY SITE-DIRECTED MUTAGENESIS OF SER-132, ASP-156, AND HIS-241	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-HEPARIN PLASMA; PANCREATIC LIPASE; MOLECULAR-CLONING; HEPATIC LIPASE; GENE FAMILY; SEQUENCE; CDNA; BINDING; INACTIVATION; DEFICIENCY	Lipoprotein lipase (LPL) plays a central role in normal lipid metabolism as the key enzyme involved in the hydrolysis of triglycerides present in chylomicrons and very low density lipoproteins. LPL is a member of a family of hydrolytic enzymes that include hepatic lipase and pancreatic lipase. Based on primary sequence homology of LPL to pancreatic lipase, Ser- 132, Asp-156, and His-241 have been proposed to be part of a domain required for normal enzymic activity. We have analyzed the role of these potential catalytic residues by site-directed mutagenesis and expression of the mutant LPL in human embryonic kidney-293 cells. Substitution of Ser- 132, Asp- 156, and His-241 by several different residues resulted in the expression of an enzyme that lacked both triolein and tributyrin esterase activities. Mutation of other conserved residues, including Ser-97, Ser-307, Asp-78, Asp-37 1, Asp-440, His-93, and His-439 resulted in the expression of active enzymes. Despite their effect on LPL activity, substitutions of Ser-132, Asp-156, and His-241 did not change either the heparin affinity or lipid binding properties of the mutant LPL. In summary, mutation of Ser-132, Asp-156, and His-241 specifically abolishes total hydrolytic activity without disrupting other important functional domains of LPL. These combined results strongly support the conclusion that Ser-132, Asp-156, and His-241 form the catalytic triad of LPL and are essential for LPL hydrolytic activity.	NHLBI,MOLEC DIS BRANCH,BLDG 10,RM 7N117,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENAVRAM CM, 1986, P NATL ACAD SCI USA, V83, P4185, DOI 10.1073/pnas.83.12.4185; BENGTSSON G, 1982, FEBS LETT, V147, P183, DOI 10.1016/0014-5793(82)81038-7; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; EMI M, 1990, J BIOL CHEM, V265, P5910; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOBAYASHI J, 1989, EUR J CLIN INVEST, V19, P424, DOI 10.1111/j.1365-2362.1989.tb00254.x; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; OSTLUNDLINDQVIST AM, 1977, FEBS LETT, V83, P231, DOI 10.1016/0014-5793(77)81011-9; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P9; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YANG CY, 1989, J BIOL CHEM, V264, P16822	35	84	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4161	4165						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371284				2022-12-25	WOS:A1992HE60700087
J	BOCHKAREVA, ES; GIRSHOVICH, AS				BOCHKAREVA, ES; GIRSHOVICH, AS			A NEWLY SYNTHESIZED PROTEIN INTERACTS WITH GROES ON THE SURFACE OF CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; ATP HYDROLYSIS; IDENTIFICATION; PURIFICATION; CARBOXYLASE; PRODUCTS; GROWTH; GENE	To facilitate folding and assembly of different proteins, chaperonin GroEL requires the presence of its helper protein GroES. Using a photochemical cross-linking approach, we show that GroES and newly synthesized pre-beta-lactamase (pre-betalac) contact with each other only within the ternary complex with GroEL. Possibly owing to this contact GroES is able to directly influence the pre-betalac/GroEL interaction. Furthermore, the cross-linking of pre-betalac to GroES suggests that the binding of the protein ligands to GroEL occurs near the GroES binding site, known to be in the central hole space of GroEL.	WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	GIRSHOVICH, AS (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							ANG D, 1991, J BIOL CHEM, V266, P24233; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	25	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25672	25675						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361186				2022-12-25	WOS:A1992KD07300014
J	FLORIO, T; PAN, MG; NEWMAN, B; HERSHBERGER, RE; CIVELLI, O; STORK, PJS				FLORIO, T; PAN, MG; NEWMAN, B; HERSHBERGER, RE; CIVELLI, O; STORK, PJS			DOPAMINERGIC INHIBITION OF DNA-SYNTHESIS IN PITUITARY-TUMOR CELLS IS ASSOCIATED WITH PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROLACTIN SECRETION; ADENYLATE-CYCLASE; GH3 CELLS; RAT; BROMOCRIPTINE; GROWTH; SOMATOSTATIN; RECEPTOR; VANADATE; PROTEINS	Dopaminergic D2 receptor agonists, such as bromocriptine, are potent anti-proliferative agents in the treatment of human pituitary adenomas. We have reproduced the anti-proliferative effect of dopamine in an established pituitary cell line stably transfected with the rat D2 dopamine receptor cDNA. We found that dopaminergic inhibition of DNA synthesis parallels the stimulation of a phosphotyrosine phosphatase activity. Both actions are blocked by pertussis toxin and by the phosphotyrosine phosphatase inhibitor, vanadate. We suggest that the anti-proliferative action of dopamine is mediated, at least in part, by the dopaminergic stimulation of a phosphotyrosine phosphatase.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; Civelli, Olivier/A-8392-2012	Florio, Tullio/0000-0002-2394-996X; Hershberger, Ray/0000-0001-5683-6526				ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BANCROFT FC, 1969, J CELL BIOL, V43, P432, DOI 10.1083/jcb.43.3.432; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FAGIN JA, 1987, ENDOCRINOLOGY, V120, P2037, DOI 10.1210/endo-120-5-2037; FAURE N, 1980, ENDOCRINOLOGY, V107, P1022, DOI 10.1210/endo-107-4-1022; HAUG E, 1976, ENDOCRINOLOGY, V99, P1482, DOI 10.1210/endo-99-6-1482; HERSHBERGER RE, 1991, CIRCULATION, V83, P1343, DOI 10.1161/01.CIR.83.4.1343; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KROWN KA, 1992, ENDOCRINOLOGY, V131, P595, DOI 10.1210/en.131.2.595; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LIU YF, 1992, IN PRESS MOL ENDOCRI; LLOYD HM, 1975, NATURE, V255, P497, DOI 10.1038/255497a0; MALARKEY WB, 1977, NATURE, V266, P640, DOI 10.1038/266640a0; MELMED S, 1986, BRAIN RES, V369, P83, DOI 10.1016/0006-8993(86)90515-9; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; PAN MG, 1992, SCIENCE, V256, P37; PRYSORJONES RA, 1981, J ENDOCRINOL, V88, P463, DOI 10.1677/joe.0.0880463; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSENFELD RG, 1989, ENDOCRINOLOGY, V124, P2867, DOI 10.1210/endo-124-6-2867; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHALLY AV, 1988, CANCER RES, V48, P6977; SICHLEY DR, 1983, MOL PHARMACOL, V23, P585; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THORNER MO, 1975, BRIT MED J, V4, P694, DOI 10.1136/bmj.4.5998.694; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5; WASS JAH, 1982, BRIT MED J, V284, P1908, DOI 10.1136/bmj.284.6333.1908; WINKELMANN W, 1983, ACTA ENDOCRINOL-COP, V102, P37; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	38	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24169	24172						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360008				2022-12-25	WOS:A1992KA26300006
J	SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC				SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC			HTLV-I AND HTLV-II TAX TRANSACTIVATE THE HUMAN EGR-1 PROMOTER THROUGH DIFFERENT CIS-ACTING SEQUENCES	ONCOGENE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; PRIMARY HUMAN-LYMPHOCYTES; LONG TERMINAL REPEAT; GENE-EXPRESSION; C-FOS; GROWTH; PROTEIN; TRANSFORMATION; IDENTIFICATION	The immediate-early response gene, EGR-1, encodes a zinc finger-containing transcription factor that is involved in growth and differentiation of a variety of cell types. EGR-1 is induced in normal T cells following mitogenic stimulation and has recently been shown to be constitutively expressed in human T-cell leukemia virus type I (HTLV-I)- and type II (HTLV-II)-transformed T-cell lines. The trans-activating protein of HTLV-I, Tax, has been demonstrated to trans-activate promoters of a number of cellular genes, some of which may be critical in regulating T-cell proliferation. In this study, we examine the effect of Tax on expression of EGR-1 in three T-cell lines and demonstrate that both HTLV-I and -II Tax are capable of trans-activating human EGR-1 recombinant promoter constructs. Interestingly, HTLV-I and -II Tax trans-activate the human EGR-1 promoter through different promoter regions in the Jurkat cell line, suggesting that HTLV-I and -II Tax may lead to constitutive expression of EGR-1 through different signaling pathways. Deregulated expression of EGR-1 may contribute to uncontrolled cell growth and transformation during early stages of T-cell activation in HTLV-I and -II-infected cells.	UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	SAKAMOTO, KM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, A2-312, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA08974, CA01314] Funding Source: Medline; NIDDK NIH HHS [DK43025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001314, F32CA008974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, ONCOGENE, V3, P123; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KUMAR A, 1972, P NATL ACAD SCI USA, V69, P681, DOI 10.1073/pnas.69.3.681; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NIMER SD, 1989, ONCOGENE, V4, P671; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takatsuki K, 1990, RETROVIRUS BIOL HUMA, P147; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATERS CM, 1990, ONCOGENE, V5, P669; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2125	2130						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359492				2022-12-25	WOS:A1992JW66500004
J	LUKACS, GL; CHANG, XB; KARTNER, N; ROTSTEIN, OD; RIORDAN, JR; GRINSTEIN, S				LUKACS, GL; CHANG, XB; KARTNER, N; ROTSTEIN, OD; RIORDAN, JR; GRINSTEIN, S			THE CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR IS PRESENT AND FUNCTIONAL IN ENDOSOMES - ROLE AS A DETERMINANT OF ENDOSOMAL PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CONDUCTANCE; CELLS; GENE; ACIDIFICATION; MEMBRANE; IDENTIFICATION; EXPRESSION; TRANSPORT; ATPASES; CAMP	Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to defective Cl- conductance in epithelial cells. While the CFTR gene product has been detected in the plasma membrane, its presence and functional role in the membranes of intracellular compartments remain to be established. The purpose of the present experiments was to functionally localize CFTR in the endosomal membrane and to test the role of the associated Cl- conductance in the regulation of endosomal pH (PH(en)). When using conductive protonophores, the net H+ flux across the endosomal membrane of Chinese hamster ovary (CHO) cells is limited by the movement of counterions. Thus, ionic permeability could be estimated indirectly, from the changes in pH(en) determined fluorimetrically. Measurements in situ and in a cell-free microsomal preparation indicate the presence of a protein kinase A (PKA)-activated anion conductance in endosomes from CHO cells transfected with CFTR, but not in endosomes from wild-type or mock-transfected cells. In endosomes isolated from CFTR-expressing cells, the stimulatory effect of PKA was diminished by a specific peptide inhibitor of PKA, by alkaline phosphatase treatment or by a monoclonal antibody against the second nucleotide binding fold of CFTR. Increasing counterion permeability by phosphorylation of CFTR or by addition of valinomycin failed to alter the rate or extent of endosomal acidification in situ. Our observations indicate that functional CFTR, susceptible to activation by PKA, is present in endosomes of transfected CHO cells. More importantly, the data suggest that factors other than counterion permeability are the major determinants of pH(en).	HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA; TORONTO GEN HOSP, DEPT SURG, TORONTO M5G 2C4, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital				Lukacs, Gergely/0000-0003-0900-0675				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS WH, 1991, J CLIN INVEST, V88, P1; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; WADE JB, 1986, ANNU REV PHYSIOL, V48, P213; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; XIE XS, 1983, J BIOL CHEM, V258, P4834; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713	34	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14568	14572						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378835				2022-12-25	WOS:A1992JF08800014
J	STEPIEN, G; TORRONI, A; CHUNG, AB; HODGE, JA; WALLACE, DC				STEPIEN, G; TORRONI, A; CHUNG, AB; HODGE, JA; WALLACE, DC			DIFFERENTIAL EXPRESSION OF ADENINE-NUCLEOTIDE TRANSLOCATOR ISOFORMS IN MAMMALIAN-TISSUES AND DURING MUSCLE-CELL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SYNTHASE BETA-SUBUNIT; ADP ATP TRANSLOCASE; MITOCHONDRIAL-DNA GENES; HUMAN SKELETAL-MUSCLE; ADP/ATP TRANSLOCATOR; SEQUENCE-ANALYSIS; MOLECULAR-CLONING; HUMAN-LYMPHOCYTES; ALPHA-SUBUNIT	The adenine nucleotide translocator (ANT) catalyzes the exchange of ADP and ATP across the mitochondrial internal membrane. Its three isoforms, ANT1, ANT2, and ANT3 are coded by differentially regulated nuclear genes. The patterns of expression of these genes in human, bovine, and mouse tissue are similar. ANT1 is highly expressed in heart and skeletal muscle and is induced during myoblast differentiation. It is coordinately regulated with the nuclear gene for the mitochondrial ATP synthase beta-subunit, with which it shares the positive muscle cis element, the OXBOX. ANT2 is either absent or weakly expressed in all tissues. ANT3 is ubiquitously expressed in all tissues, and its transcript level is proportional to the level of oxidative metabolism. The tissue-specific expression of the ANT gene family thus provides insight into the molecular basis of the differential reliance of mammalian tissues on oxidative phosphorylation.	EMORY UNIV,SCH MED,DEPT GENET & MOLEC MED,ATLANTA,GA 30322	Emory University			Torroni, Antonio/E-1557-2011	Torroni, Antonio/0000-0002-4163-4478	NHLBI NIH HHS [HL-45572] Funding Source: Medline; NINDS NIH HHS [NS-21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BREEN GAM, 1988, BIOCHEM BIOPH RES CO, V152, P264, DOI 10.1016/S0006-291X(88)80709-5; BUCKLER AJ, 1988, MOL CELL BIOL, V8, P1371, DOI 10.1128/MCB.8.3.1371; CHEN ST, 1990, SOMAT CELL MOLEC GEN, V16, P143, DOI 10.1007/BF01233044; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DICKMAN KG, 1989, AM J PHYSIOL, V257, pC333, DOI 10.1152/ajpcell.1989.257.2.C333; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KACZMAREK L, 1985, BIOCHEM BIOPH RES CO, V133, P410, DOI 10.1016/0006-291X(85)90921-0; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KU DH, 1990, J BIOL CHEM, V265, P16060; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; Li W. H., 1985, MOL EVOLUTIONARY GEN, P1; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LOMAX MI, 1989, TRENDS BIOCHEM SCI, V14, P501, DOI 10.1016/0968-0004(89)90185-0; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RASMUSSEN UB, 1986, BIOCHEM BIOPH RES CO, V138, P850, DOI 10.1016/S0006-291X(86)80574-5; SACCONE C, 1991, EUR J BIOCHEM, V195, P151, DOI 10.1111/j.1432-1033.1991.tb15688.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048	48	242	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14592	14597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378836				2022-12-25	WOS:A1992JF08800018
J	JANSSEN, OE; REFETOFF, S				JANSSEN, OE; REFETOFF, S			INVITRO EXPRESSION OF THYROXINE-BINDING GLOBULIN (TBG) VARIANTS - IMPAIRED SECRETION OF TBG(PRO-227) BUT NOT TBG(PRO-113)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; AUSTRALIAN ABORIGINES; INHERITED ABNORMALITY; ENDOPLASMIC-RETICULUM; AMERICAN BLACKS; SEQUENCE; SERUM; MUTATION; GENE; GLYCOSYLATION	Thyroxine-binding globulin (TBG) is a glycoprotein that transports thyroid hormones in blood. Of two naturally occurring variants in man that harbor single proline substitutions (TBG-CD5 and TBG-Montreal), only TBG-CD5 manifests as complete TBG deficiency. In order to determine the pathophysiology of these TBG disorders, we expressed TBG-CD5 and TBG-Montreal (TBG-M), as well as the common type TBG (TBG-C) in reticulocyte lysate and Xenopus oocytes. Vectors encoding the three TBG types were constructed, transcribed in vitro, and their products of cell-free translation and processing by canine microsomal membranes were analyzed. TBG-C and TBG-M had identical mobility on denaturing polyacrylamide gel electrophoresis but could be distinguished by differences in thyroxine (T4) binding. TBG-CD5 had altered electrophoretic mobility and did not bind T4. TBG-C and TBG-M expressed in microinjected Xenopus oocytes showed properties similar to their respective serum forms, whereas TBG-CD5 was found in small amounts only intracellularly. Our results confirm that the previously described alanine 113 to proline substitution is responsible for the altered properties of TBG-M. The substitution of leucine 227 by proline in TBG-CD5 appears to impair its cotranslational processing and secretion.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago			Refetoff, Samuel/ABB-1263-2021	Refetoff, Samuel/0000-0003-0164-8231	NIDDK NIH HHS [DK 15070] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015070, R37DK015070] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BERTENSHAW R, 1991, AM J HUM GENET, V48, P741; BERTENSHAW RH, 1992, IN PRESS BIOCH BIOPH; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; FOREMAN RC, 1987, BIOSCIENCE REP, V7, P307, DOI 10.1007/BF01121452; FRAIZER GC, 1990, J CLIN INVEST, V86, P1878; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GERSHENGORN MC, 1977, J BIOL CHEM, V252, P8713; GILLES AM, 1986, P NATL ACAD SCI USA, V83, P5798, DOI 10.1073/pnas.83.16.5798; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOCMAN G, 1981, REV PHYSL BIOCH PHAR, V81, P45; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IBRAHIMI I, 1987, J BIOL CHEM, V262, P10189; JANSSEN OE, 1991, HUM GENET, V87, P119, DOI 10.1007/BF00204164; JANSSEN OE, 1992, TRENDS ENDOCRIN MET, V3, P49, DOI 10.1016/1043-2760(92)90043-Z; KAMBE F, 1992, MOL ENDOCRINOL, V6, P443, DOI 10.1210/me.6.3.443; KESSLER SW, 1976, J IMMUNOL, V117, P1482; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI PZ, 1991, METABOLISM, V40, P1231, DOI 10.1016/0026-0495(91)90221-H; LIEBHABER SA, 1983, J CLIN INVEST, V71, P461, DOI 10.1172/JCI110790; MALLER JL, 1983, METHOD ENZYMOL, V99, P219; MORI Y, 1988, J CLIN ENDOCR METAB, V67, P727, DOI 10.1210/jcem-67-4-727; MORI Y, 1990, J CLIN ENDOCR METAB, V70, P804, DOI 10.1210/jcem-70-3-804; MORI Y, 1989, MOL ENDOCRINOL, V3, P575, DOI 10.1210/mend-3-3-575; MURATA Y, 1985, J ENDOCRINOL INVEST, V8, P225, DOI 10.1007/BF03348482; MURATA Y, 1986, ENDOCRINOLOGY, V118, P1614, DOI 10.1210/endo-118-4-1614; MURATA Y, 1986, NEW ENGL J MED, V314, P694, DOI 10.1056/NEJM198603133141107; POLLER W, 1991, HUM GENET, V86, P522; REFETOFF S, 1989, ENDOCR REV, V10, P275, DOI 10.1210/edrv-10-3-275; REFETOFF S, 1984, J CLIN ENDOCR METAB, V59, P269, DOI 10.1210/jcem-59-2-269; REFETOFF S, 1989, ENDOCRINOLOGY, P541; ROBBINS J, 1978, RECENT PROG HORM RES, V84, P477; SAIKI RK, 1988, SCIENCE, V239, P481; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNE DH, 1989, J CLIN ENDOCR METAB, V68, P114, DOI 10.1210/jcem-68-1-114; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIFERS RN, 1989, AM J RESP CELL MOL, V1, P341, DOI 10.1165/ajrcmb/1.5.341; TAKAMATSU J, 1986, J CLIN ENDOCR METAB, V63, P80, DOI 10.1210/jcem-63-1-80; TAKAMATSU J, 1987, J CLIN INVEST, V79, P833, DOI 10.1172/JCI112891; TAKEDA K, 1989, J CLIN INVEST, V83, P1344, DOI 10.1172/JCI114021; TRENT JM, 1987, AM J HUM GENET, V41, P428; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; VERBANAC KM, 1986, J BIOL CHEM, V261, P9979; WALTZ MR, 1990, J ENDOCRINOL INVEST, V13, P343, DOI 10.1007/BF03349576; WEISS R, 1989, CLIN RES, V37, pA536; YAMAMORI I, 1991, J CLIN ENDOCR METAB, V73, P262, DOI 10.1210/jcem-73-2-262; ZINN AB, 1978, J BIOL CHEM, V253, P6768	53	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13998	14004						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378434				2022-12-25	WOS:A1992JD32500036
J	CIAMBRONE, GJ; MCKEOWNLONGO, PJ				CIAMBRONE, GJ; MCKEOWNLONGO, PJ			VITRONECTIN REGULATES THE SYNTHESIS AND LOCALIZATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN HT-1080 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; AMNIOTIC MEMBRANE; INHIBITOR TYPE-1; HUMAN-MONOCYTES; SARCOMA-CELLS; INVASION; DEGRADATION; PURIFICATION	The effect of extracellular matrix composition on the location, amount, and activity of cell-associated urokinase-type plasminogen activator was tested using HT-1080 cells adherent to either fibronectin or vitronectin. Specific immunoprecipitation of newly synthesized urokinase indicated that cells adherent to fibronectin synthesized 2-3-fold more urokinase than cells adherent to vitronectin. Complexes of urokinase and plasminogen activator inhibitor type 1 (PAI-1) were detected in cell layers of vitronectin-adherent but not fibronectin-adherent cells. Inhibition of PAI-1 using a neutralizing monoclonal antibody resulted in a 3-fold increase in urokinase enzymatic activity on vitronectin adherent cells. Urokinase activity on fibronectin adherent cells was only slightly increased following PAI-1 neutralization. Examination of both HT-1080 and normal human fibroblast cells by immunofluorescent microscopy localized urokinase-type plasminogen activator to discrete; focal areas underneath cells adherent to vitronectin. Urokinase was not detectable by immunofluorescence on cells adherent to fibronectin. The addition of exogenous prourokinase to locate urokinase receptors on adherent HT-1080 cells indicated that the focal localization of cell-surface urokinase resulted from the clustering of urokinase receptors following adhesion to vitronectin but not fibronectin-coated substrates. These results suggest that vitronectin can contribute to the control of cell-surface plasmin activity by regulating the synthesis of urokinase and directing the localization of urokinase receptors.	UNION UNIV, DEPT PHYSIOL & CELL BIOL, NEIL HELLMAN MED RES BLDG, ALBANY, NY 12208 USA	Union College					NCI NIH HHS [CA-37785] Funding Source: Medline; NHLBI NIH HHS [HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037785] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; KIRCHHEIMER JC, 1990, J IMMUNOL, V145, P1518; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KOLEGA J, 1982, J CELL SCI, V54, P23; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NEWMAN E D, 1991, Journal of Cell Biology, V115, p128A; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; REICH R, 1988, CANCER RES, V48, P3307; RIFKIN DB, 1989, AM REV RESPIR DIS, V140, P1112, DOI 10.1164/ajrccm/140.4.1112; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STREULI CH, 1990, J CELL BIOL, V110, P1405; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	42	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13617	13622						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377687				2022-12-25	WOS:A1992JB74600082
J	FACCHIANO, F; LUINI, A				FACCHIANO, F; LUINI, A			TETANUS TOXIN POTENTLY STIMULATES TISSUE TRANSGLUTAMINASE - A POSSIBLE MECHANISM OF NEUROTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; INHIBITS EXOCYTOSIS; STRUCTURAL FEATURES; INSULIN RELEASE; LIGHT CHAIN; PROTEIN; GTP; SYNAPTOSOMES; HOMOLOGY; ENZYME	The observation that tetanus toxin (TT) contains two sequences that show homology to known transglutaminase (TGase) substrate sites suggested that the toxin and TGase might interact. This prediction was confirmed by two pieces of evidence. First, TT potently stimulated the enzymatic activity of TGase. The effect was maximal at physiological (micromolar) concentrations of the endogenous TGase regulators calcium and GTP. Second, TT and TGase displayed marked variations of their intrinsic fluorescence properties when they were coincubated, indicating the occurrence of binding between them. TT-TGase binding and TGase activation occurred at similar concentrations of TT and are probably causally related. The activation of TGase, an enzyme present in nerve endings that, when activated, can irreversibly cross-link cellular proteins, might mediate the neurotoxic action of TT.			FACCHIANO, F (corresponding author), CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY.		Luini, Alberto/L-1372-2013; Facchiano, Francesco/K-8716-2016	Luini, Alberto/0000-0002-8729-2549; Facchiano, Francesco/0000-0003-4313-0617				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BERGAMINI CM, 1987, BIOCHIM BIOPHYS ACTA, V916, P149, DOI 10.1016/0167-4838(87)90222-6; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; CHEN RF, 1976, BIOCH FLUORESCENCE S, V2, P410; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FACCHIANO A, 1989, COMPUT APPL BIOSCI, V5, P299; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; HAND D, 1985, BIOSCIENCE REP, V5, P1079, DOI 10.1007/BF01119629; ISRAEL M, 1987, J NEUROCHEM, V49, P975, DOI 10.1111/j.1471-4159.1987.tb00989.x; KATZ B, 1969, J PHYSIOL-LONDON, V203, P459, DOI 10.1113/jphysiol.1969.sp008875; LAZAROVICI P, 1987, J BIOL CHEM, V262, P2645; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; METAFORA S, 1987, J PROTEIN CHEM, V6, P353; NURY S, 1989, EUR J BIOCHEM, V180, P161, DOI 10.1111/j.1432-1033.1989.tb14627.x; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P203; RAGONE R, 1989, PROTEIN ENG, V2, P497, DOI 10.1093/protein/2.7.497; SENER A, 1985, ENDOCRINOLOGY, V117, P237, DOI 10.1210/endo-117-1-237; SENER A, 1985, BIOCHEM PHARMACOL, V34, P2495, DOI 10.1016/0006-2952(85)90532-5; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1983, J PHARMACOL EXP THER, V225, P546; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; UDENFRIEND S, 1962, FLUORESCENCE ASSAY B, P108	35	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13267	13271						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352294				2022-12-25	WOS:A1992JB74600030
J	DAUBNER, SC; LAURIANO, C; HAYCOCK, JW; FITZPATRICK, PF				DAUBNER, SC; LAURIANO, C; HAYCOCK, JW; FITZPATRICK, PF			SITE-DIRECTED MUTAGENESIS OF SERINE-40 OF RAT TYROSINE-HYDROXYLASE - EFFECTS OF DOPAMINE AND CAMP-DEPENDENT PHOSPHORYLATION ON ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLIC-AMP; END PRODUCT; ACTIVATION; PH; PHEOCHROMOCYTOMA; CELLS; 3-MONOOXYGENASE; PURIFICATION; MECHANISM	Rat tyrosine hydroxylase expressed with a baculovirus expression system contains covalent phosphate and has kinetic parameters consistent with those expected of phosphorylated enzyme (Fitzpatrick, P. F., Chlumsky, L. J., Daubner, S. C., and O'Malley, K. L. (1990) J. Biol. Chem. 265, 2042-2047). The phosphorylation site was identified as serine 40, by purifying the enzyme from cells grown in the presence of [P-32]phosphate. Replacement of serine 40 with alanine by site-directed mutagenesis prevented phosphorylation but had little effect on the steady-state kinetic parameters at pH 7. Both wild type and S40A tyrosine hydroxylase were expressed in Escherichia coli; the kinetic parameters of the enzymes purified from bacteria were nearly identical to those of the enzymes expressed with the baculovirus system, although the bacterially expressed enzyme contained no covalent phosphate. Treatment of this wild type enzyme with cAMP-dependent protein kinase decreased the K(BH4) value about 2-fold but had no effect on the V(max) value at pH 7. Treatment with a stoichiometric amount of dopamine decreased the V(max) value 15-fold and increased the K(BH4) value 2-3-fold. Phosphorylation of the dopamine-bound enzyme increased the V(max)value 10-fold and decreased the K(BH4)value 2-fold. The kinetic parameters of the dopamine-bound recombinant enzyme were identical to those of enzyme purified from PC12 cells. In contrast, the S40A enzyme was converted to a less active form by treatment with dopamine but was not affected by phosphorylating conditions. These results are consistent with a model in which the major effect of phosphorylation of serine 40 is to relieve tyrosine hydroxylase from the inhibitory effects of catecholamines.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70119	Texas A&M University System; Texas A&M University College Station; Louisiana State University System					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025134, R29NS025134] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25134] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1991, J MOL NEUROSCI, V2, P203; AMES MM, 1978, J BIOL CHEM, V253, P27; ANDERSSON KK, 1989, FEBS LETT, V258, P9, DOI 10.1016/0014-5793(89)81603-5; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ANDERSSON KK, 1989, J INORG BIOCHEM, V36, P323; Arnow LE, 1937, J BIOL CHEM, V118, P531; ATKINSON J, 1987, J NEUROCHEM, V49, P1241, DOI 10.1111/j.1471-4159.1987.tb10016.x; BAILEY SW, 1989, BIOCHEMISTRY-US, V28, P494, DOI 10.1021/bi00428a013; BENSON SA, 1984, BIOTECHNIQUES, V66, P64; BONNEFOY E, 1988, EUR J BIOCHEM, V174, P685, DOI 10.1111/j.1432-1033.1988.tb14152.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; Cleland W W, 1979, Methods Enzymol, V63, P103; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P3658, DOI 10.1021/bi00229a010; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; FUJISAWA H, 1982, OXYGENASES OXYGEN ME, P281; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAGIWARA T, 1991, J BIOL CHEM, V266, P16401; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1982, J BIOL CHEM, V257, P2641; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; HAYCOCK JW, 1982, J BIOL CHEM, V257, P13699; HOSS A, 1990, J VIROL, V64, P4799; JOH TH, 1978, P NATL ACAD SCI USA, V75, P4744, DOI 10.1073/pnas.75.10.4744; KATZ IR, 1976, BIOCHIM BIOPHYS ACTA, V429, P84, DOI 10.1016/0005-2744(76)90032-2; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAR MA, 1982, J NEUROCHEM, V39, P409, DOI 10.1111/j.1471-4159.1982.tb03962.x; LOVENBERG W, 1975, P NATL ACAD SCI USA, V72, P2955, DOI 10.1073/pnas.72.8.2955; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MILLER LP, 1985, NEUROCHEM INT, V7, P689, DOI 10.1016/0197-0186(85)90067-1; OKUNO S, 1985, J BIOL CHEM, V260, P2633; POLLOCK RJ, 1981, J NEUROCHEM, V37, P855, DOI 10.1111/j.1471-4159.1981.tb04471.x; RICHTAND NM, 1985, J BIOL CHEM, V260, P8465; ROSKOSKI R, 1987, J NEUROCHEM, V48, P840, DOI 10.1111/j.1471-4159.1987.tb05593.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STULL JT, 1977, J BIOL CHEM, V252, P851; TACHIKAWA E, 1986, MOL PHARMACOL, V30, P476; VIGNY A, 1982, BIOCHEM BIOPH RES CO, V106, P1, DOI 10.1016/0006-291X(82)92049-6; VIGNY A, 1981, J NEUROCHEM, V36, P483, DOI 10.1111/j.1471-4159.1981.tb01618.x; VRANA KE, 1981, J NEUROCHEM, V36, P92, DOI 10.1111/j.1471-4159.1981.tb02382.x; VULLIET PR, 1980, P NATL ACAD SCI-BIOL, V77, P92, DOI 10.1073/pnas.77.1.92; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WAYMIRE JC, 1972, J CLIN INVEST, V51, P1798, DOI 10.1172/JCI106981; YAMAUCHI T, 1979, J BIOL CHEM, V254, P503; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	55	145	147	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12639	12646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352289				2022-12-25	WOS:A1992HZ48300042
J	PICCIOTTO, MR; COHN, JA; BERTUZZI, G; GREENGARD, P; NAIRN, AC				PICCIOTTO, MR; COHN, JA; BERTUZZI, G; GREENGARD, P; NAIRN, AC			PHOSPHORYLATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNELS; AIRWAY EPITHELIA; CALCIUM; PHOSPHOPROTEIN; IDENTIFICATION; ACTIVATION; EXPRESSION; SUBSTRATE; DARPP-32	Regulation of epithelial chloride flux, which is defective in patients with cystic fibrosis, may be mediated by phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) or protein kinase C (PKC). Part of the R-domain of CFTR (termed CF-2) was expressed in and purified from Escherichia coli. CF-2 was phosphorylated on seryl residues by PKA, PKC, cyclic GMP-dependent protein kinase (PKG), and calcium/calmodulin-dependent protein kinase I (CaM kinase I). Direct amino acid sequencing and peptide mapping of CF-2 revealed that serines 660, 700, 737, and 813 as well as serine 768, serine 795, or both were phosphorylated by PKA and PKG, and serines 686 and 790 were phosphorylated by PKC. CFTR was phosphorylated in vitro by PKA, PKC, or PKG on the same sites that were phosphorylated in CF-2. Kinetic analysis of phosphorylation of CF-2 and of synthetic peptides confirmed that these sites were excellent substrates for PKA, PKC, or PKG. CFTR was immunoprecipitated from T84 cells labeled with P-32(i). Its phosphorylation was stimulated in response to agents that activated either PKA or PKC. Peptide mapping confirmed that CFTR was phosphorylated at several sites identified in vitro. Thus, regulation of CFTR is likely to occur through direct phosphorylation of the R-domain by protein kinases stimulated by different second messenger pathways.	DUKE UNIV,DEPT MED,DURHAM,NC 27706; VET ADM MED CTR,DURHAM,NC 27705	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PICCIOTTO, MR (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.		Picciotto, Marina R./F-8747-2012	Picciotto, Marina R./0000-0002-4404-1280; Nairn, Angus/0000-0002-7075-0195	NIDDK NIH HHS [DK 40701] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040701, R29DK040701] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, IN PRESS P NATL ACAD, V89; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1991, NATURE, V350, P277, DOI 10.1038/350277a0; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOLMES CFB, 1987, FEBS LETT, V215, P21, DOI 10.1016/0014-5793(87)80106-0; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN M, 1992, IN PRESS AM J PHYSL; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MORAN O, 1991, FEBS LETT, V279, P256, DOI 10.1016/0014-5793(91)80162-V; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALTER U, 1980, J BIOL CHEM, V255, P3757; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	54	279	280	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12742	12752						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377674				2022-12-25	WOS:A1992HZ48300056
J	BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD				BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD			ANGIOGENIC ACTIVITY OF THE K-FGF/HST ONCOGENE IN NEURAL TRANSPLANTS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR GENE FAMILY; NIH 3T3 CELLS; ENDOTHELIAL-CELLS; TRANSFORMING GENE; FACTOR RECEPTOR; MESODERM INDUCTION; STOMACH CANCERS; DOWN-REGULATION; MESSENGER-RNA	Using retrovirus-mediated gene transfer into neural transplants, we have expressed the human K-fgf/hst oncogene in the central nervous system. Single-cell suspensions of fetal rat brains were removed at embryonic days 13 and 14, exposed to a retroviral vector encoding the K-fgf oncogene and stereotaxically implanted into the caudate putamen of syngenic adult Fisher rats. Recipient animals were sacrificed at intervals of 6-16 months without evidence of neurological impairment. Mock-infected grafts showed the characteristic histopathological appearance of organotypically differentiated neural transplants. In contrast, grafts exposed to the K-fgf gene exhibited abundant capillary proliferation and capillary angiomas. By in situ hybridization analysis and immunohistochemistry, expression of K-fgf was detected in neural cells adjacent to vascular proliferations. Neurons and glia with abundant K-fgf transcripts were morphologically unaffected. In order to examine the transforming potential of the K-fgf gene in the nervous system, we combined retrovirus-mediated transfer of the K-fgf oncogene with a single transplacental exposure of the donor animals to the neurotropic carcinogen N-ethyl-N-nitrosourea (NEU). However, this combination of transforming agents did not result in tumor formation in the grafts. These results provide evidence for a powerful angiogenic effect of K-fgf on the developing brain in vivo.	UNIV ZURICH, DEPT PATHOL, NEUROPATHOL LAB, CH-8091 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; NYU HOSP, DEPT MICROBIOL, NEW YORK, NY 10016 USA	University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); New York University			Aguzzi, Adriano/A-3351-2008; Talarico, Daniela/AAN-5608-2020	Talarico, Daniela/0000-0001-5814-9244; Aguzzi, Adriano/0000-0002-0344-6708				ADELAIDE J, 1988, ONCOGENE, V2, P413; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGER PC, 1988, CANCER RES, V48, P2871; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CONNOLLY DT, 1987, BIOCHEM BIOPH RES CO, V144, P705, DOI 10.1016/S0006-291X(87)80022-0; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P2295, DOI 10.1073/pnas.71.6.2295; Hannan RL, 1988, GROWTH FACTORS, V1, P7, DOI 10.3109/08977198809000242; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERBERT JM, 1988, INT J TISSUE REACT, V10, P133; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HUEBNER K, 1988, ONCOGENE RES, V3, P263; KLEIHUES P, 1990, TOXICOL PATHOL, V18, P193, DOI 10.1177/019262339001800125; KLEIHUES P, 1989, IARC SCI PUBLIC, V96, P121; KNIGHTON DR, 1990, J TRAUMA, V30, pS134; KODA T, 1987, JPN J CANCER RES, V78, P325; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MILLER WH, 1990, ONCOGENE, V5, P511; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PATERNO GD, 1989, DEVELOPMENT, V106, P79; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Singer B., 1983, MOL BIOL MUTAGENS CA; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS KA, 1980, J BIOL CHEM, V255, P5517; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; TOGARI A, 1985, J NEUROSCI, V5, P307; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VELCICH A, 1989, ONCOGENE RES, V5, P31; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIESTLER OD, 1989, IARC SCI PUBL, V96, P267; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	66	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1177	1183						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375717				2022-12-25	WOS:A1992HU64200015
J	CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A				CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A			OCCURRENCE OF DISTINCT PML RAR-ALPHA FUSION GENE ISOFORMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA DETECTED BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; CELL-LINE; DIFFERENTIATION; TRANSLOCATION; EXPRESSION; BREAKPOINT	A specific 'nested' reverse transcriptase/polymerase chain reaction (RT/PCR) procedure was used to characterize the expression patterns of PML-RAR-alpha chimeric mRNAs in 32 patients with acute promyelocytic leukemia (APL). The sensitivity of the technique was such that the fusion gene transcript could be detected from as little as 2.5 pg of total leukemic cell RNA against a background of 1-mu-g of cellular RNA lacking the PML-RAR-alpha fusion gene transcript(s). In 19 cases the PML-RAR-alpha isoform referred to here as long was identified. A short isoform, which in comparison with the long form lacks three PML exons, was detected in 11 other cases. A third PML-RAR-alpha mRNA isoform, in which the most 3' PML exon present in the long-type isoform was truncated in its sequences lying immediately upstream of RAR-alpha B region, was found and characterized in a single patient. In one APL patient with a variant translocation t(11;17), the PCR product corresponding to PML-RAR-alpha chimeric mRNAs could not be amplified despite the presence of RAR-alpha gene rearrangement. Genomic and PCR analysis showed that the different PML-RAR-alpha isoforms found in APL patients arise as a result of distinct translocation breakpoints. In each case the exons encoding the B-F regions of RAR-alpha are expressed and are spliced downstream from variable PML gene exons. The 'nested' RT/PCR analysis of the PML-RAR-alpha fusion gene proved to be a rapid and sensitive tool for the diagnosis of the APL and for monitoring the residual APL chimeric mRNA expression during complete remission.	SHANGHAI MED UNIV 2, RUI JIN HOSP, SHANGHAI INST HEMATOL, 197 RUI-JIN RD II, SHANGHAI 200025, PEOPLES R CHINA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, ROCHELLE BELFER CHEMOTHERAPY FDN LAB, NEW YORK, NY 10029 USA	Shanghai Jiao Tong University; Icahn School of Medicine at Mount Sinai			Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHANG KS, 1991, LEUKEMIA, V5, P200; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN Z, 1991, LEUKEMIA, V5, P288; CHEN ZX, 1991, BLOOD, V78, P1413; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIDSON JN, 1951, J PATHOL BACTERIOL, V63, P471, DOI 10.1002/path.1700630314; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLYNN PJ, 1983, BLOOD, V62, P1211; GLASS CK, 1991, HORMONAL CONTROL GEN, P129; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUDAS LJ, 1991, PERSPECTIVES CELLULA, P121; HAUNG ME, 1988, BLOOD, V7251, P5673; HEIM S, 1987, CANCER CYTOGENETICS; HUGHES TP, 1991, BLOOD, V77, P874; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACCUMBER M, 1984, SCIENCE, V224, P402, DOI 10.1126/science.6200933; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MENTEN ML, 1953, CANCER RES, V13, P733; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLS KI, 1991, BLOOD, V78, P1155; MORGAN GJ, 1990, BRIT J HAEMATOL, V76, P33, DOI 10.1111/j.1365-2141.1990.tb07833.x; NEGRIN RS, 1991, BLOOD, V78, P255; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; RIBEIRO RC, 1987, BLOOD, V70, P948; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTH MS, 1992, BLOOD, V79, P276; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHAPIRO SS, 1985, RETINOIDS CELL DIFFE, P30; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN GL, 1992, IN PRESS BR J HAEMAT; TONG JH, 1992, ONCOGENE, V7, P311; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WAXMAN S, 1983, BLOOD S, V62, pA154; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; 1985, CYTOGENET CELL GENET, V21, P309	72	93	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1223	1232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375719				2022-12-25	WOS:A1992HU64200021
J	ATTALI, B; ROMEY, G; HONORE, E; SCHMIDALLIANA, A; MATTEI, MG; LESAGE, F; RICARD, P; BARHANIN, J; LAZDUNSKI, M				ATTALI, B; ROMEY, G; HONORE, E; SCHMIDALLIANA, A; MATTEI, MG; LESAGE, F; RICARD, P; BARHANIN, J; LAZDUNSKI, M			CLONING, FUNCTIONAL EXPRESSION, AND REGULATION OF 2 K+ CHANNELS IN HUMAN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; CELL ACTIVATION; MEMBRANE-PROTEIN; ION CHANNELS; PATCH-CLAMP; RAT UTERUS; DIVERSITY; CALCIUM; CHARYBDOTOXIN; GENE	Low stringency screening of a Jurkat cDNA library with a rat brain K+ channel (RCK1) probe has resulted in the isolation of HLK3, a voltage-gated K+ channel. In Xenopus oocytes, the HLK3 clone directs the expression of a rapidly activating transient outward K+ current similar to the type n K+ current recorded in Jurkat T cells. The HLK3 gene is located on the short arm of human chromosome 1 (p13.3). Polymerase chain reaction was used to clone HIsK from Jurkat cDNA. The HIsK clone shares the same sequence with a previously described genomic clone (Murai, T., Kazikuka, A., Takumi, T., Ohkubo, H., and Nakanishi, S. (1989) Biochem. Biophys. Res. Commun. 161, 176-181). In Xenopus oocytes, it encodes a slowly activating, noninactivating K+ channel which cannot be recorded in Jurkat cells by conventional patch-clamp techniques. Transcripts of both clones are present at a similar level before and after activation of purified human T lymphocytes and Jurkat cells, reflecting a constitutive expression of K+ channel messages. This finding is in good agreement with the electrophysiological results for type n K+ current density on the same cells. HLK3 current is very sensitive to the scorpion toxin charybdotoxin (IC50 = 0.8 nM). HIsK current is totally insensitive to this toxin but is blocked by the antiarrhythmic clofilium (IC50 = 80-mu-M). While charybdotoxin has no effect on interleukin 2 mRNA induction, clofilium potently inhibits interleukin 2 mRNA expression upon mitogen-induced T cell activation. It is concluded that the HLK3 channel is not an important component of the T cell mitogenic response. Other targets for K+ channel blockers, such as the HIsK protein, could be involved in the activation process.	SOPHIA ANTIPOLIS, INST PHARMACOL MOLEC & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE; HOP ENFANTS LA TIMONE, CTR GENET MED, INSERM, U242, F-13385 MARSEILLE 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019; SCHMID-ALLIANA, Annie/P-4366-2016	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919; SCHMID-ALLIANA, Annie/0000-0003-2321-7408				AMIGORENA S, 1990, J IMMUNOL, V144, P2038; ARENA JP, 1988, MOL PHARMACOL, V34, P60; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BREGESTOVSKI P, 1986, NATURE, V319, P776, DOI 10.1038/319776a0; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK NS, 1989, POTASSIUM CHANNELS S, P182; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DEUTSCH C, 1984, J CELL BIOL, V98, P885, DOI 10.1083/jcb.98.3.885; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HUET S, 1986, J IMMUNOL, V137, P1420; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEWIS RS, 1988, TRENDS NEUROSCI, V11, P214, DOI 10.1016/0166-2236(88)90129-4; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RANDRIAMAMPITA C, 1991, CELL CALCIUM, V12, P313, DOI 10.1016/0143-4160(91)90005-Y; REHM H, 1991, FASEB J, V5, P164, DOI 10.1096/fasebj.5.2.2004663; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; SEGEL GB, 1979, J CLIN INVEST, V64, P834, DOI 10.1172/JCI109531; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	55	131	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8650	8657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373731				2022-12-25	WOS:A1992HQ18500103
J	FOUNTOULAKIS, M				FOUNTOULAKIS, M			UNFOLDING INTERMEDIATES OF THE EXTRACELLULAR DOMAIN OF THE INTERFERON GAMMA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-BINDING; PROTEIN; THIOREDOXIN; TRANSLOCATION; MECHANISM	Reduction of proteins which require disulfide bonds to be stable in the folded state is accompanied by stepwise unfolding. A soluble human interferon gamma-receptor produced in Escherichia coli was used to investigate the kinetics of formation of unfolding intermediates. The protein includes 8 cysteine residues forming four disulfide bonds. It was reduced by using either dithiothreitol or the thioredoxin reduction system. Reduction with dithiothreitol resulted in formation of mainly four monomeric unfolding species as visualized by sodium dodecyl sulfate-polyacrylamide gels. The enzymatically catalyzed reaction produced only small amounts of two monomeric products and mostly delivered oligomeric and polymeric forms. In both cases, the ligand binding capacity of the receptor was significantly reduced immediately after appearance of the first intermediate. The intermediates involved interchange of disulfide bonds and did not show ligand binding capacity. Some of them were recognized by specific antibodies which detect conformational epitopes on the native interferon gamma-receptor. On the basis of the antibody binding, a preliminary characterization of the formed intermediates was attempted. When the soluble receptor was reduced in the presence of denaturing agents, the reduction products were different from the unfolding intermediates generated in the absence of denaturants.			FOUNTOULAKIS, M (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,BLDG 15-16,CH-4002 BASEL,SWITZERLAND.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KING J, 1989, CHEM ENG NEWS, V67, P32, DOI 10.1021/cen-v067n015.p032; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MOULT J, 1991, BIOCHEMISTRY-US, V30, P3816, DOI 10.1021/bi00230a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001	32	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7095	7100						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372607				2022-12-25	WOS:A1992HM05300098
J	MARSHALL, LB; FIGLER, NL; GONIAS, SL				MARSHALL, LB; FIGLER, NL; GONIAS, SL			IDENTIFICATION OF ALPHA-2-MACROGLOBULIN CONFORMATIONAL INTERMEDIATES BY ELECTRON-MICROSCOPY AND IMAGE-ANALYSIS - COMPARISON OF ALPHA-2-MACROGLOBULIN-THROMBIN AND ALPHA-2-MACROGLOBULIN REACTED WITH CIS-DICHLORODIAMMINEPLATINUM(II) AND TRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED HUMAN ALPHA-2-MACROGLOBULIN; HUMAN-PLASMA; FAST FORMS; PROTEINASE; METHYLAMINE; COMPLEX; MACROMOLECULES; BINDING	Human alpha-2-macroglobulin (alpha-2M) exists in two well defined, highly distinct conformations and in less well described intermediate conformations. In this study, previously characterized reactions were used to partially or completely transform the conformation of alpha-2M. Electron micrographs of each preparation were subjected to image analysis. TernarY alpha-2M-trypsin (2 mol of trypsin/mol of alpha-2M) was analyzed as a control for the fully transformed state. Correspondence analysis (CORAN) and hierarchical ascendant classification (HAC) generated five image clusters from 330 aligned alpha-2M-trypsin complexes. Average images of each cluster resembled the letter "H" with four nearly equivalent lateral arms. Abnormally shaped lateral arms were not demonstrated by HAC, using a variety of factor sets. In a native polyacrylamide gel electrophoresis system, alpha-2M-thrombin migrated in a diffuse band partially behind alpha-2M-trypsin, suggesting conformational heterogeneity. CORAN and HAC of 733 alpha-2M-thrombin complexes identified two neighboring clusters, the average images of which showed an H-like structure in which one arm was replaced by a globular stain-excluding body. The two alpha-2M-thrombin clusters included 125 images (17.1 % of image population). The complete absence of atypical lateral arm structure in the alpha-2M-trypsin clusters suggests that this variation is not the result of orientation or staining artifact. Native alpha-2M was reacted with cis-dichlorodiammineplatinum(II) and then with trypsin to form alpha-2M-Pt-trypsin, a preparation that includes partially transformed alpha-2M structures. CORAN and HAC of 580 alpha-2M-Pt-trypsin complexes generated five clusters, the average images of which showed atypical lateral arm structure equivalent to that demonstrated with alpha-2M-thrombin. The five alpha-2M-Pt-trypsin clusters accounted for 15.2% of the image population. These studies suggest that alpha-2M conformational change intermediates demonstrate common structural characteristics, permitting an elucidation of the steps involved in this complex transformation.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BOX 214,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NHLBI NIH HHS [HL-02272] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BOISSET N, 1988, BIOL CELL, V64, P45, DOI 10.1016/0248-4900(88)90092-5; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DELAIN E, 1988, J BIOL CHEM, V263, P2981; FIGLER NL, 1991, J STRUCT BIOL, V106, P237, DOI 10.1016/1047-8477(91)90073-6; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1989, ELECTRON MICROSC REV, V2, P53, DOI 10.1016/0892-0354(89)90010-5; FRANK J, 1978, ULTRAMICROSCOPY, V3, P282; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; NISHIGAI M, 1985, BIOCHIM BIOPHYS ACTA, V831, P236, DOI 10.1016/0167-4838(85)90040-8; PIZZO SV, 1984, RECEPTORS, V1, P178; POCHON F, 1983, FEBS LETT, V161, P51, DOI 10.1016/0014-5793(83)80728-5; ROCHE PA, 1988, ARCH BIOCHEM BIOPHYS, V267, P285, DOI 10.1016/0003-9861(88)90034-3; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1981, FEBS LETT, V127, P167, DOI 10.1016/0014-5793(81)80197-4; STEINER JP, 1985, BIOCHEMISTRY-US, V24, P2993, DOI 10.1021/bi00333a028; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369	31	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6347	6352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372906				2022-12-25	WOS:A1992HK31800093
J	FORD, VA; STRINGER, C; KENNEL, SJ				FORD, VA; STRINGER, C; KENNEL, SJ			THROMBOMODULIN IS PREFERENTIALLY EXPRESSED IN BALB-C LUNG MICROVESSELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY ASSAY; HUMAN-PLACENTA; PROTEIN-C; NATURAL ANTICOAGULANT; FACTOR-V; THROMBIN; ENDOTHELIUM; ANTIGEN; LOCALIZATION; ACTIVATION	Previously, two rat monoclonal antibodies where developed which bind distinct epitopes on a murine glycoprotein, P112, which is expressed primarily in lung capillary endothelium. In this paper we show that P112 is identical to the endothelial anticoagulant protein, thrombomodulin (TM). Several lines of evidence support this conclusion. First, amino acid analysis of P112 shows a high degree of homology to TM, and both molecules exhibit the same mobility in gel electrophoresis. Second, P112 and TM share reactivity for two different monoclonal antibodies. Third, purified P112, like TM, acts as a cofactor for protein C activation. Finally, two cDNA clones identified with P112 polyclonal antiserum contain sequence identity with the known TM cDNA sequence. Quantitative analysis of TM (P112) expression using a two-site monoclonal antibody assay demonstrates that significantly higher levels of TM are found in lung in comparison with other highly vascularized organs, i.e. the kidney and liver. Quantitative Northern blot data coincides with the two-site assay data and demonstrates that the high level of TM expression in lung is not due to preferential binding of the monoclonal antibodies to lung TM but rather to increased production of TM mRNA in the lung relative to other highly vascularized organs. It is suggested that expression of TM is highest in cells from continuous endothelium.	OAK RIDGE NATL LAB, DIV BIOL SCI, OAK RIDGE, TN 37831 USA; UNIV TENNESSEE, OAK RIDGE GRAD SCH BIOMED SCI, OAK RIDGE, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville					NCI NIH HHS [CA 09104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSINGT.JB, 1974, MICROVASC RES, V7, P229, DOI 10.1016/0026-2862(74)90008-9; Berlilner RW., 1973, HDB PHYSL, P185; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRONE C, 1963, P SOC EXP BIOL MED, V112, P453; CRONE C, 1984, HDB PHYSL CARDIOVASC, P435; DEBAULT LE, 1986, LAB INVEST, V54, P172; DEBAULT LE, 1986, LAB INVEST, V54, P179; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; FULCHER CA, 1984, BLOOD, V63, P486; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HUGHES BJ, 1989, CANCER RES, V49, P6214; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KENNEL SJ, 1988, LAB INVEST, V59, P692; KENNEL SJ, 1987, EXP MOL PATHOL, V47, P110, DOI 10.1016/0014-4800(87)90012-8; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; KENNEL SJ, 1981, CANCER RES, V41, P3465; KENNEL SJ, 1986, CANCER RES, V46, P707; KENNEL SJ, 1990, NUCL MED BIOL, V17, P193, DOI 10.1016/0883-2897(90)90147-S; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, V1; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOLLAR P, 1980, J CLIN INVEST, V66, P1222, DOI 10.1172/JCI109973; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; MARUYAMA K, 1990, J PHARM SCI, V79, P978, DOI 10.1002/jps.2600791107; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORELLE G, 1989, FOCUS, V11, P77; PALADE GE, 1979, ACTA PHYSIOL SCAND, P11; PAWLIK G, 1981, BRAIN RES, V208, P35, DOI 10.1016/0006-8993(81)90619-3; PINO RM, 1989, PROGR HISTOCHEMISTRY; RORVIK MC, 1988, J HISTOCHEM CYTOCHEM, V36, P741, DOI 10.1177/36.7.3290332; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SAMBROOK J, 1989, MOL CLONING LABORATO, P2118; THOMPSON EA, 1986, J CLIN INVEST, V78, P13, DOI 10.1172/JCI112541; WEIBEL ER, 1973, PHYSIOL REV, V53, P419, DOI 10.1152/physrev.1973.53.2.419; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	43	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5446	5450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372003				2022-12-25	WOS:A1992HH74700068
J	MUNDSCHAU, LJ; FALLER, DV				MUNDSCHAU, LJ; FALLER, DV			ONCOGENIC RAS INDUCES AN INHIBITOR OF DOUBLE-STRANDED RNA-DEPENDENT EUKARYOTIC INITIATION FACTOR-2-ALPHA-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							68,000-MR PROTEIN-KINASE; ADENOVIRUS VA RNA1; GROWTH-FACTOR; SIGNAL TRANSDUCTION; EIF-2-ALPHA KINASE; 3T3 CELLS; C-FOS; RECEPTOR AUTOPHOSPHORYLATION; SELECTIVELY BLOCKS; 3T3-F442A CELLS	The interferon-inducible 68-kDa dsRNA-dependent eIF2alpha-kinase (dsI) is a potent cellular antiviral enzyme which is activated by autophosphorylation in response to double-stranded RNA (dsRNA). Activated dsI has also been implicated as a second messenger for gene induction by platelet-derived growth factor (PDGF) and interferon (IFN). We have shown previously that introduction of a transforming ras gene into BALB/c-3T3 fibroblasts blocks induction of responsive genes by PDGF and IFN. We therefore investigated the effect of transforming ras genes on dsI activity in these cells. We report here that dsRNA-mediated activation of dsI is blocked in v-ras-containing cells in a manner specific to ras and not attributable to the transformed phenotype since: 1) a dexamethasone-inducible v-Haras gene produced the effect within 18 h of induction; 2) morphologic reversion of ras-transformed cells with cAMP or the Krev-1 gene restored potential for dsI activation; and 3) transformation by v-mos or v-abl had no effect on dsI activation. Latent dsI levels were unaffected by v-ras. A heat-sensitive dsI inhibitory activity could be demonstrated in v-ras-containing cells which functioned in trans when mixed with untransformed cell extracts prior to stimulation with dsRNA. The inhibitory activity, which was destroyed by phenol-chloroform extraction, did not bind dsRNA.	BOSTON UNIV,SCH MED,CANC RES CTR,80 E CONCORD ST,E124,BOSTON,MA 02118	Boston University				Kasman, Laura/0000-0002-8661-2918				ALEXANDER D R, 1990, New Biologist, V2, P1049; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEDID M, 1991, J IMMUNOL, V147, P867; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEGON S, 1974, BIOCHEM BIOPH RES CO, V56, P745, DOI 10.1016/0006-291X(74)90668-8; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; OFFERMANN MK, 1989, MOL CELL BIOL, V9, P1969, DOI 10.1128/MCB.9.5.1969; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RANSONE LJ, 1988, J VIROL, V62, P3551, DOI 10.1128/JVI.62.10.3551-3557.1988; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAMSTAG Y, 1991, J IMMUNOL, V147, P788; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	44	88	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23092	23098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358881				2022-12-25	WOS:A1992JY16300061
J	TALMAGE, DA; LACKEY, RS				TALMAGE, DA; LACKEY, RS			RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES POLYOMAVIRUS TRANSFORMATION AND C-FOS EXPRESSION IN RAT FIBROBLASTS	ONCOGENE			English	Article							MIDDLE-T-ANTIGEN; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; EMBRYONAL CARCINOMA-CELLS; MESSENGER-RNA; TRANSCRIPTION FACTOR; BINDING PROTEIN; NEGATIVE REGULATION; MOUSE FIBROBLASTS; GROWTH-FACTOR	To explore the molecular mechanisms by which retinoic acid inhibits oncogenic transformation, we have examined the effects of retinoic acid on the polyomavirus-induced transformation of rat fibroblasts. Treatment of rat F111 fibroblasts with high concentrations of retinoic acid (10(-6)M) partially inhibited the ability of polyomavirus to induce dense focus formation (50-70%). This effect was not secondary to a retinoic acid-dependent block of cellular proliferation. To address the role of the retinoic acid receptor (RAR-alpha) in mediating the transformation-inhibitory effect of retinoic acid, we have overexpressed either RAR-alpha or cellular retinoic acid-binding protein I (CRABP) cDNAs in F111 cells. Introduction of a CRABP I expression vector did not alter the responsiveness of F111 cells to retinoic acid in any detectable fashion. In contrast, overexpression of RAR-alpha increased the sensitivity of F111 cells to the transformation-inhibitory action of retinoic acid by 10- to 100-fold. At high concentrations, retinoic acid inhibited transformation of F111-RAR cells by polyomavirus by about 90%. At near physiological concentrations, retinoic acid inhibited transformation by 25-50% in F111-RAR cells but not in control cells. Retinoic acid did not inhibit either the synthesis of polyoma middle T (mT) or pp60c-src, the cellular target for mT action, or the formation of mT:pp60c-src:PI-3 kinase (phosphatidylinositol-3 kinase) complexes. Therefore, RAR-alpha was not acting as a negative regulator of expression of either the polyomavirus middle T oncogene or the cellular proto-oncogene. c-src. It seems likely that RAR-alpha regulates the expression of cellular genes whose products interact in some way with mT-regulated signaling pathways. leading to a ligand-dependent suppression of polyoma transformation. In addition, RAR-alpha overexpression selectively inhibits the serum-stimulated expression of the c-fos gene, but does not affect the expression of a number of other serum- and polyomavirus-inducible genes including c-jun, junB, c-myc and actin.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,630 W 168 ST,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	NICHD NIH HHS [HD 26854] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BLUMHOFF R, 1990, SCIENCE, V250, P399; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GEBERT JF, 1991, ONCOGENE, V6, P1858; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GROSS L, 1983, ONCOGENIC VIRUSES, P737; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATHEWS JT, 1986, J VIROL, V58, P239; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PLET A, 1982, J BIOL CHEM, V257, P889; RAJAN N, 1991, J LIPID RES, V32, P1195; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STRICKLAND S, 1980, DEV BIOL, V78, P76, DOI 10.1016/0012-1606(80)90319-X; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P851; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; [No title captured]	65	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380150				2022-12-25	WOS:A1992JJ37600020
J	ALVAREZ, J; MONTERO, M; GARCIASANCHO, J				ALVAREZ, J; MONTERO, M; GARCIASANCHO, J			HIGH-AFFINITY INHIBITION OF CA2+-DEPENDENT K+ CHANNELS BY CYTOCHROME-P-450 INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; INSIDE-OUT VESICLES; ASCITES TUMOR-CELLS; CA-2+-ACTIVATED K+; INTRACELLULAR CALCIUM; ERYTHROCYTE-MEMBRANE; POTASSIUM CHANNELS; ANTIFUNGAL AGENTS; ELECTRON-DONORS; TRANSPORT	The Ca2+-dependent K+ channel of human red cells was inhibited with high affinity by several imidazole antimycotics which are potent inhibitors of cytochrome P-450. IC50 values were (in mu-M): clotrimazole, 0.05; tioconazole, 0.3; miconazole, 1.5; econazole, 1.8. Inhibition of the channel was also found with other drugs with known cytochrome P-450 inhibitory effect. However, no inhibition was obtained with carbon monoxide (CO). This suggests that, given the high selectivity of the above inhibitors for the heme moiety, a different but closely related to cytochrome P-450 kind of hemoprotein may be involved in the regulation of the red cell Ca2+-dependent K+ channel. Clotrimazole also inhibited two other charybdotoxin-sensitive Ca2+-dependent K+ channels, those of rat thymocytes (IC50 = 0.1-0.2-mu-M) and of Ehrlich ascites tumor cells (IC50 = 0.5-mu-M). Imidazole antimycotics inhibit also receptor-operated Ca2+ channels (Montero, M., Alvarez, J. and Garcia-Sancho, J. (1991) Biochem. J. 277, 73-79). This suggests that both Ca2+ and Ca2+-dependent K+ channels might have a similar regulatory mechanism involving a cytochrome.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & BIOL MOLEC & FISIOL, E-47005 VALLADOLID, SPAIN	Universidad de Valladolid			Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653; Garcia-Sancho, Javier/0000-0003-4573-7930				ABIA A, 1986, BIOCHIM BIOPHYS ACTA, V856, P403, DOI 10.1016/0005-2736(86)90054-4; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V856, P408, DOI 10.1016/0005-2736(86)90055-6; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1984, BIOCHIM BIOPHYS ACTA, V771, P23, DOI 10.1016/0005-2736(84)90105-6; ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V860, P25, DOI 10.1016/0005-2736(86)90494-3; ALVAREZ J, 1985, J PHYSIOL-LONDON, V369, pP113; ALVAREZ J, 1989, RED CELL MEMBRANE, P201; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BARAN DT, 1973, BIOCHIM BIOPHYS ACTA, V307, P627, DOI 10.1016/0005-2736(73)90307-6; BLISARD KS, 1979, J BIOL CHEM, V254, P5104; BRUDER G, 1980, BIOCHIM BIOPHYS ACTA, V600, P739, DOI 10.1016/0005-2736(80)90477-0; BRUDER G, 1978, EXP CELL RES, V117, P207, DOI 10.1016/0014-4827(78)90443-3; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COSSUM PA, 1988, BIOPHARM DRUG DISPOS, V9, P321, DOI 10.1002/bod.2510090402; GALLIN EK, 1988, BIOPHYS J, V53, pA548; GARCIASANCHO J, 1979, BIOCHIM BIOPHYS ACTA, V556, P118, DOI 10.1016/0005-2736(79)90424-3; GARCIASANCHO J, 1989, METHOD ENZYMOL, V173, P368; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V508, P236, DOI 10.1016/0005-2736(78)90327-9; GRINSTEIN S, 1983, J CELL PHYSIOL, V116, P352, DOI 10.1002/jcp.1041160313; GRYGORCZYK R, 1983, CELL CALCIUM, V4, P499, DOI 10.1016/0143-4160(83)90025-8; HERMANN A, 1987, J GEN PHYSIOL, V90, P27, DOI 10.1085/jgp.90.1.27; HOFFMANN EK, 1985, FED PROC, V44, P2513; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; HULTQUIST DE, 1971, BIOCHIM BIOPHYS ACTA, V229, P33, DOI 10.1016/0005-2795(71)90314-X; INUI Y, 1966, J GEN PHYSIOL, V50, P203, DOI 10.1085/jgp.50.1.203; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEVINSON C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P1, DOI 10.1016/0005-2736(90)90375-X; LEW VL, 1976, NATURE, V263, P336, DOI 10.1038/263336a0; LEW VL, 1985, CELL CALCIUM, V6, P15, DOI 10.1016/0143-4160(85)90031-4; LEW VL, 1989, METHOD ENZYMOL, V173, P100; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MAHAUT-SMITH M P, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS164, DOI 10.1007/BF00582284; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; MASON JI, 1985, BIOCHEM PHARMACOL, V34, P1087, DOI 10.1016/0006-2952(85)90613-6; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MINER C, 1983, BIOCHIM BIOPHYS ACTA, V727, P266, DOI 10.1016/0005-2736(83)90412-1; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MURRAY M, 1990, PHARMACOL REV, V42, P85; OMURA T, 1964, J BIOL CHEM, V239, P2379; PAPANDREOU P, 1989, CLIN CHIM ACTA, V181, P189, DOI 10.1016/0009-8981(89)90187-3; REICHSTEIN E, 1981, J MEMBRANE BIOL, V59, P57, DOI 10.1007/BF01870821; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; ROGERSON TD, 1977, BIOCHEM PHARMACOL, V26, P1039, DOI 10.1016/0006-2952(77)90241-6; SANCHEZ A, 1986, REV ESP FISIOL, V42, P459; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SIMONS TJB, 1976, J PHYSIOL-LONDON, V288, P481; STARKE DW, 1984, MOL PHARMACOL, V25, P467; Steck T L, 1974, Methods Enzymol, V31, P172; SZE H, 1979, BIOCHIM BIOPHYS ACTA, V554, P180, DOI 10.1016/0005-2736(79)90017-8; VALDEOLMILLOS M, 1982, BIOCHIM BIOPHYS ACTA, V685, P273, DOI 10.1016/0005-2736(82)90067-0; VANDENBOSSCHE H, 1983, BIOCHEM SOC T, V11, P665, DOI 10.1042/bst0110665; WOLFF D, 1988, J MEMBRANE BIOL, V106, P243, DOI 10.1007/BF01872162; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0; YUBISUI T, 1988, BIOCHIM BIOPHYS ACTA, V936, P447, DOI 10.1016/0005-2728(88)90022-9; ZAMUDIO I, 1966, BIOCHIM BIOPHYS ACTA, V120, P165, DOI 10.1016/0926-6585(66)90290-1	61	251	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11789	11793						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376313				2022-12-25	WOS:A1992HY94700025
J	PELES, E; LAMPRECHT, R; BENLEVY, R; TZAHAR, E; YARDEN, Y				PELES, E; LAMPRECHT, R; BENLEVY, R; TZAHAR, E; YARDEN, Y			REGULATED COUPLING OF THE NEU RECEPTOR TO PHOSPHATIDYLINOSITOL 3'-KINASE AND ITS RELEASE BY ONCOGENIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; EGF RECEPTOR; MIDDLE-T; SIGNAL TRANSDUCTION; CHIMERIC RECEPTOR; POINT MUTATION; PROTEIN; TRANSFORMATION	The neu protooncogene encodes a tyrosine kinase receptor that is involved in the regulation of normal growth and malignant transformation. To circumvent the use of the incompletely characterized ligand of Neu, we constructed a chimeric protein composed of the ligand-binding domain of the epidermal growth factor receptor and the transmembrane and cytoplasmic portions of Neu. By expressing this Neu-epidermal growth factor receptor chimera (termed NEC), we found that following stimulation by the heterologous ligand, the tyrosine kinase of Neu became associated with a phosphatidylinositol (PI) kinase activity. The association was dependent on the concentration of the ligand and was almost maximal within 30 s after ligand binding. The lipid kinase was identified as a type I PI 3'-kinase on the basis of its inhibition by Nonidet P-40 and high pressure liquid chromatography of the phosphorylated product. To confirm the identification of PI 3'-kinase as an effector of Neu, we raised antibodies to the a-isoform of the regulatory subunit of PI 3'-kinase (p85). Using these antibodies, it was possible to directly demonstrate ligand-dependent formation of a tyrosine-phosphorylated complex of NEC and PI 3'-kinase. Apparently, both PI 3'-kinase and phospholipase C(gamma), another substrate of the Neu kinase, simultaneously associated with the same activated NEC molecule. Nevertheless, immunofluorescence localization of PI 3'-kinase revealed no significant cellular redistribution of the enzyme after activation of the Neu kinase. Interestingly, PI 3'-kinase was localized primarily to the cell nucleus and to confined regions of the plasma membrane. Analysis of mutants of the Neu protein indicated that the oncogenic point-mutated Neu (Glu664) was permanently coupled to PI 3'-kinase; but two nontransforming versions of the oncoprotein, a kinase-defective protein and a carboxyl-terminally deleted Neu, were devoid of the constitutive association with PI 3'-kinase. Hence, we concluded that phosphatidylinositol 3'-kinase is a physiological substrate of the Neu receptor, but the regulation of this coupling is released upon oncogenic activation.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NCI NIH HHS [CA-51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11156; COCHET C, 1991, J BIOL CHEM, V266, P637; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HAZAN R, 1989, CELL GROWTH DIFFER, V1, P3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MATSUI H, 1984, CANCER RES, V44, P1002; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, CANCER CELLS MOL DIA, V7; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STANCOVSKI L, 1991, P NATL ACAD SCI USA, V88, P8691; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	62	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12266	12274						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351056				2022-12-25	WOS:A1992HY94700092
J	HORRIGAN, SK; RICH, CB; STREETEN, BW; LI, ZY; FOSTER, JA				HORRIGAN, SK; RICH, CB; STREETEN, BW; LI, ZY; FOSTER, JA			CHARACTERIZATION OF AN ASSOCIATED MICROFIBRIL PROTEIN THROUGH RECOMBINANT-DNA TECHNIQUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN SYNTHESIS; GLYCOPROTEIN; CELLS; AORTA; ACID; TRANSLATION; SEQUENCES; TISSUES; CULTURE; CLONING	The complete primary structure of a new extracellular protein associated with elastic fiber microfibrils was determined by recombinant DNA techniques. Antiserum to insoluble bovine ocular zonule protein was used to screen a lambda-gt11 cDNA expression library constructed from whole chick embryo poly(A)+ RNA. The cDNAs encoding immunoreactive fusion polypeptides were then used to rescreen the library by plaque hybridization. Nucleotide sequencing of overlapping cDNA clones revealed an open translation reading frame of 1326 bases beginning at an initiation start sequence and ending at a stop codon. The contiguous cDNA sequence contains a 3'-untranslated region of 563 bases with a possible polyadenylation site 16 bases upstream from the poly(A) tail. Primer extension of chick aortic mRNA taken together with the sequence data, reveals a 5'-untranslated region of 95 bases extending upstream from the translation start site. Northern blot analyses indicated that the isolated cDNA hybridized with a 2.1-kilobase mRNA in preparations, of whole chick embryo and chick embryonic aortic, heart, and muscle RNAs. The initial translation protein encoded by the cDNA is 53,932 kDa and possesses a hydrophilic amino acid composition with glutamic acid comprising 22% of the total amino acid residues. Antiserum was elicited to a synthetic peptide sequence (14 amino acids) encoded within the deduced protein primary structure. Western blots of extracted proteins from chick embryonic aortae cultured in the presence of beta-aminopropionitrile showed that the medium and a mild salt extract contained an immunoreactive protein possessing an apparent molecular mass of 58,000 whereas harsh denaturants extracted a 32,000-kDa protein. Pulse-chase experiments using radiolabeled lysine showed that the newly synthesized 58,000-kDa protein was chased into a 32,000-kDa protein within a 2-24-h period. Immunoelectron microscopy of tissue sections from chick aortae, bovine nuchal ligament, and human ocular zonules showed that the peptide-elicited antibody localized specifically to ultrastructurally definable microfibril structures.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, 80 E CONCORD ST, BOSTON, MA 02118 USA; SYRACUSE UNIV, DEPT BIOL, SYRACUSE, NY 13244 USA; SUNY HLTH SCI CTR, DEPT OPHTHALMOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PATHOL, SYRACUSE, NY 13210 USA	Boston University; Syracuse University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NEI NIH HHS [EY01602] Funding Source: Medline; NHLBI NIH HHS [HL30061, HL46100] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046100, R01HL030061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAULE VJ, 1988, BIOCHEM BIOPH RES CO, V154, P1054, DOI 10.1016/0006-291X(88)90247-1; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; CAMPAGNONE R, 1987, LAB INVEST, V56, P224; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; FAHRENBACH WH, 1966, ANAT RECORD, V155, P563, DOI 10.1002/ar.1091550409; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1980, BIOCHEMISTRY-US, V19, P857, DOI 10.1021/bi00546a005; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1983, CELL BIOL, V65, P345; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HORRIGAN SK, 1990, THESIS SYRACUSE U; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUCICH U, 1988, J CELL BIOL, V107, P3415; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; Maniatis T., 1982, MOL CLONING; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; POLLOCK J, 1990, J BIOL CHEM, V265, P3697; RICHMOND VL, 1981, BIOCHIM BIOPHYS ACTA, V669, P193, DOI 10.1016/0005-2795(81)90240-3; ROSS R, 1973, J HISTOCHEM CYTOCHEM, V21, P199, DOI 10.1177/21.3.199; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SERAFINIFRACASSINI A, 1981, BIOCHEMISTRY-US, V20, P5424, DOI 10.1021/bi00522a011; STREETEN BW, 1988, CURR EYE RES, V7, P139, DOI 10.3109/02713688808995743; STREETEN BW, 1983, INVEST OPHTH VIS SCI, V24, P119; STREETEN BW, 1981, INVEST OPHTH VIS SCI, V21, P130; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	40	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10087	10095						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374398				2022-12-25	WOS:A1992HT96500096
J	BUSIEK, DF; ROSS, FP; MCDONNELL, S; MURPHY, G; MATRISIAN, LM; WELGUS, HG				BUSIEK, DF; ROSS, FP; MCDONNELL, S; MURPHY, G; MATRISIAN, LM; WELGUS, HG			THE MATRIX METALLOPROTEASE MATRILYSIN (PUMP) IS EXPRESSED IN DEVELOPING HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; HUMAN ALVEOLAR MACROPHAGES; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; CYSTEINE SWITCH; GENE FAMILY; STROMELYSIN; PURIFICATION; ACTIVATION; HOMOLOGY	Matrilysin (PUMP, MMP-7) is a member of the metalloprotease gene family, whose constituents are responsible for the remodeling of extracellular matrix. The matrilysin protein is a 28-kDa zymogen possessing catalytic activities against a broad range of extracellular matrix substrates including proteoglycans, gelatin, fibronectin, laminin, and elastin. To gain insights into the biological expression of matrilysin in human cell types, we generated a monospecific, polyclonal antibody against a 16-amino acid sequence derived from its catalytic domain, a region which lacked significant homology with other matrix metalloenzymes. We found this antibody capable of precipitating a 28-kDa protein from the conditioned media of human bone marrow-derived promonocytes and human peripheral blood monocytes cultivated in vitro. Promonocyte matrilysin was rapidly converted to a 19-kDa form by organomercurial activation. While matrilysin was constitutively synthesized by bone marrow-derived promonocytes, its secretion was markedly up-regulated by the mononuclear phagocyte activator, lipopolysaccharide. Furthermore, despite its expression in monocyte precursors, blood monocytes, and monocyte-derived macrophages, matrilysin was not synthesized by human alveolar macrophages under any tested condition. In situ hybridization studies with matrilysin cRNA confirmed the presence of specific mRNA in both human promonocytes and monocytes. Moreover, a marked increase in hybridizable mRNA was observed with lipopolysaccharide treatment suggesting that matrilysin synthesis is pretranslationally regulated. In summary, this represents the first report documenting constitutive and regulated synthesis of matrilysin by a normal human cell type and suggests that matrilysin is expressed as a significant secreted product of mononuclear phagocytes at an intermediate stage of cellular differentiation.	WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT MED,DIV DERMATOL,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP,MED CTR,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT PATHOL,ST LOUIS,MO 63110; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAMS NIH HHS [AR-32087, AR-35805] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAINTON DF, 1978, J CLIN INVEST, V68, P1555; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CAMPBELL EJ, 1987, J BIOL CHEM, V262, P15862; CARACCIOLO D, 1987, J EXP MED, V166, P1851, DOI 10.1084/jem.166.6.1851; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURY JD, 1988, J IMMUNOL, V141, P4306; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SANDERSON RJ, 1977, J IMMUNOL, V118, P1409; Senior R. M., 1981, METHODS STUDYING MON, P69; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEBB EC, 1992, IN PRESS RECOMMENDAT; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918	34	108	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9087	9092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374384				2022-12-25	WOS:A1992HR85400060
J	BENHAMOU, M; STEPHAN, V; ROBBINS, KC; SIRAGANIAN, RP				BENHAMOU, M; STEPHAN, V; ROBBINS, KC; SIRAGANIAN, RP			HIGH-AFFINITY IGE RECEPTOR-MEDIATED STIMULATION OF RAT BASOPHILIC LEUKEMIA (RBL-2H3) CELLS INDUCES EARLY AND LATE PROTEIN-TYROSINE PHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-RELEASE; MAST-CELLS; KINASE-C; SECRETION; ACTIVATION; EXOCYTOSIS; MEMBRANE; P60C-SRC; SIGNALS	We reported previously that stimulation of RBL-2H3 cells through the high-affinity IgE receptor resulted in tyrosine phosphorylation of a 72-kDa protein (pp72) that was coupled to signal transduction. In the present study, although pp72 tyrosine phosphorylation was induced only by antigen triggering, stimulation of RBL-2H3 cells by either antigen or the calcium-ionophore A23187 led to increased tyrosine phosphorylation of a 110-kDa protein (pp110). This tyrosine phosphorylated protein was also observed when RBL-2H3 cells were transfected with the G protein-coupled m3 muscarinic receptor and then stimulated to secrete with carbachol. In contrast to tyrosine phosphorylation of pp72, antigen-induced pp110 tyrosine phosphorylation required extracellular calcium, was absent in cells depleted of protein kinase C, and was detected between 1 and 5 min after stimulation. The protein-tyrosine kinase inhibitor genistein blocked both histamine release and tyrosine phosphorylation induced by A23187. Altogether, the data suggest a role for pp110 in secretion. However, protein kinase C activation induced pp110 tyrosine phosphorylation but not histamine release demonstrating that pp110 tyrosine phosphorylation alone is not sufficient for degranulation. We conclude that tyrosine phosphorylation of pp72 is associated with the early steps of IgE receptor-generated signaling, whereas pp110 tyrosine phosphorylation occurs secondary to calcium influx and protein kinase C activation.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	BENHAMOU, M (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM IA31,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Benhamou, Marc/0000-0001-7763-3795				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BORDIER C, 1979, J BIOL CHEM, V254, P2565; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OLIVER JM, 1988, PROG ALLERGY, V42, P184; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; RENDU F, 1989, BLOOD, V73, P1545; SIEGHART W, 1978, NATURE, V275, P329, DOI 10.1038/275329a0; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130	20	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7310	7314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373133				2022-12-25	WOS:A1992HN48500020
J	BOSCH, F; RODRIGUEZGIL, JE; HATZOGLOU, M; GOMEZFOIX, AM; HANSON, RW				BOSCH, F; RODRIGUEZGIL, JE; HATZOGLOU, M; GOMEZFOIX, AM; HANSON, RW			LITHIUM INHIBITS HEPATIC GLUCONEOGENESIS AND PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-REGULATORY REGION; ISOLATED RAT ADIPOCYTES; GLYCOGEN-SYNTHASE; FRUCTOSE 2,6-BISPHOSPHATE; ADENYLATE-CYCLASE; CHIMERIC GENES; GTP GENE; INSULIN; CELLS; IDENTIFICATION	Incubation of isolated hepatocytes from fasted rats with 20 mM LiCl for 1 h decreased glucose production from lactate, pyruvate, and alanine. In addition, phosphoenolpyruvate carboxykinase (PEPCK) gene expression in FTO-2B rat hepatoma cells was inhibited by treatment with LiCl. Lithium was also able to counteract the increased PEPCK mRNA levels caused by both Bt2cAMP and dexamethasone, in a concentration-dependent manner. A chimeric gene containing the PEPCK promoter (-550 to +73) linked to the amino-3-glycosyl phosphotransferase (neo) structural gene was transduced into FTO-2B cells using a Moloney murine leukemia virus-based retrovirus. In these infected cells, 20 mM LiCl decreased both the concentration of neo mRNA transcribed from the PEPCK-neo chimeric gene and MRNA from the endogenous PEPCK gene. Lithium also inhibited the stimulatory effect of Bt2cAMP and dexamethasone on both genes. The stability of neo mRNA was not altered by lithium, since in cells infected with retrovirus containing only the neo gene transcribed via the retroviral 5'-LTR and treated with 20 mM LiCl, no change in neo mRNA levels was observed. The intraperitoneal administration of LiCl to rats caused a decrease in hepatic PEPCK mRNA, indicating that lithium could also modify gene expression in vivo. The effects of lithium were not due to an increase in the concentration of insulin in the blood but were correlated with an increase in hepatic glycogen and fructose 2,6-bisphosphate levels. These results indicate that lithium ions, at concentrations normally used therapeutically for depression in humans, can inhibit glucose synthesis in the liver by a mechanism which can selectively modify the expression of hepatic phosphoenolpyruvate carboxykinase.	CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	BOSCH, F (corresponding author), AUTONOMOUS UNIV BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN.		Rodriguez-Gil, Joan E./F-8748-2016	Rodriguez-Gil, Joan E./0000-0002-1112-9884; BOSCH, FATIMA/0000-0002-7705-5515	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, R37DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21859, DK 24451] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; Battey, 1986, BASIC METHODS MOL BI; BELMAKER RH, 1981, BIOL PSYCHIAT, V16, P333; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BEYAERT R, 1989, P NATL ACAD SCI USA, V86, P9494, DOI 10.1073/pnas.86.23.9494; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOSCH F, 1986, J BIOL CHEM, V261, P6927; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; CHENG K, 1983, MOL CELL BIOCHEM, V56, P177; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P66, DOI 10.1016/0005-2736(68)90009-6; DOBNER PR, 1988, J BIOL CHEM, V263, P13983; DOUSA TP, 1974, ENDOCRINOLOGY, V95, P1359, DOI 10.1210/endo-95-5-1359; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; EBSTEIN R, 1976, NATURE, V259, P411, DOI 10.1038/259411a0; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; FONTELA T, 1987, DIABETOLOGIA, V30, P183, DOI 10.1007/BF00274225; FONTELA T, 1986, ACTA ENDOCRINOL-COP, V111, P342, DOI 10.1530/acta.0.1110342; FORN J, 1975, LITHIUM RES THERAPY, P487; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HAUGAARD ES, 1974, BIOCHEM PHARMACOL, V23, P1675, DOI 10.1016/0006-2952(74)90394-3; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; NEWMAN ME, 1987, NEUROPHARMACOLOGY, V26, P211, DOI 10.1016/0028-3908(87)90211-5; NYFELER F, 1979, FEBS LETT, V108, P197, DOI 10.1016/0014-5793(79)81209-0; NYFELER F, 1981, BIOCHIM BIOPHYS ACTA, V675, P17, DOI 10.1016/0304-4165(81)90064-7; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROSSETTI L, 1989, DIABETES, V38, P648, DOI 10.2337/diabetes.38.5.648; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; VANDEWERVE G, 1977, BIOCHEM J, V162, P135, DOI 10.1042/bj1620135; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2888	2893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371108				2022-12-25	WOS:A1992HD15400014
J	HIZI, A; SHAHARABANY, M; TAL, R; HUGHES, SH				HIZI, A; SHAHARABANY, M; TAL, R; HUGHES, SH			THE EFFECTS OF CYSTEINE MUTATIONS ON THE REVERSE TRANSCRIPTASES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-H; DNA-POLYMERASE; ESCHERICHIA-COLI; DOMAIN; MUTAGENESIS; RIBONUCLEASE; ORGANIZATION; EXPRESSION	Chemical modification of HIV-1 and HIV-2 (human immunodeficiency virus, types 1 and 2) reverse transcriptases (RT) with three thiol reactive compounds selectively inhibits the RNase H function of the enzyme. HIV-1 RT has 2 cysteines (at positions 38 and 280); HIV-2 RT has 3 (38, 280, 445). Both of the cysteines in HIV-1 RT are in the polymerase domain. To investigate the role of the cysteines in the structure and function of the HIV RTs, we have converted each cysteine to serine and made combinations of the mutations. Since HIV-1 RT has alanine at position 445, we have also substituted alanine for serine at this position in HIV-2 RT. Neither of the single mutations in HIV-1 RT nor the double mutation mimics the effects of the chemical modification. The serine 280 mutation has little effect on either polymerase or RNase H; the serine 38 mutation affects both activities, as does the 38/280 double mutant. The 38 and 280 serine mutations in HIV-2 RT resemble the equivalent mutations in HIV-1 RT. Substitution of serine or alanine at position 445 (which lies in the RNase H domain) diminishes, but does not abolish, the RNase H activity of HIV-2 without affecting polymerase activity. The RNase H activity of a mutant HIV-1 RT with serine at position 280 is completely resistant to inactivation by the three thiol reactive compounds we tested, which demonstrates that cysteine 280 is the critical residue. We suggest that the reason the mutation (cysteine 280 to serine) does not mimic the chemical modification is because the chemical modification produces a greater change in the structure of the protein. We also suggest that position 280 lies at or near the important points of contact between the RNase H and polymerase domains, so that chemical modification of this position, which lies within the polymerase domain, distorts the RNase H domain.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	HIZI, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,BLDG 539,FREDERICK,MD 21702, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [R01-AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; MYERS G, 1989, HUMAN RETROVIRUSES A; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RUCHETON M, 1979, VIROLOGY, V97, P221, DOI 10.1016/0042-6822(79)90392-1; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; Weiss R, 1985, RNA TUMOR VIRUSES	22	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1293	1297						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370463				2022-12-25	WOS:A1992GY96000095
J	LI, SJ; CRONAN, JE				LI, SJ; CRONAN, JE			THE GENE ENCODING THE BIOTIN CARBOXYLASE SUBUNIT OF ESCHERICHIA-COLI ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DEHYDROGENASE MULTIENZYME COMPLEX; BACTERIOPHAGE-T7 DNA-POLYMERASE; AMINO-ACID SEQUENCE; CARRIER PROTEIN; RECOMBINANT CLONES; CODING SEQUENCE; ALPHA-SUBUNIT; CLONING; EXPRESSION	We report the molecular cloning and DNA sequence of the gene encoding the biotin carboxylase subunit of Escherichia coli acetyl-CoA carboxylase. The biotin carboxylase gene encodes a protein of 449 residues that is strikingly similar to amino-terminal segments of two biotin-dependent carboxylase proteins, yeast pyruvate carboxylase and the alpha-subunit of rat propionyl-CoA carboxylase. The deduced biotin carboxylase sequence contains a consensus ATP binding site and a cysteine-containing sequence preserved in all sequenced bicarbonate-dependent biotin carboxylases that may play a key catalytic role. The gene encoding the biotin carboxyl carrier protein (BCCP) subunit of acetyl-CoA carboxylase is located upstream of the biotin carboxylase gene and the two genes are cotranscribed. As previously reported by others, the BCCP sequence encoded a protein of 16,688 molecular mass. However, this value is much smaller than that (22,500 daltons) obtained by analysis of the protein. Amino-terminal amino acid sequencing of the purified BCCP protein confirmed the deduced amino acid sequence indicating that BCCP is a protein of atypical physical properties. Northern and primer extension analyses demonstrate that BCCP and biotin carboxylase are transcribed as a single mRNA species that contains an unusually long untranslated leader preceding the BCCP gene. We have also determined the mutational alteration in a previously isolated acetyl-CoA carboxylase (fabE) mutant and show the lesion maps within the BCCP gene and results in a BCCP species defective in acceptance of biotin. Translational fusions of the carboxyl-terminal 110 or 84 (but not 76) amino acids of BCCP to beta-galactosidase resulted in biotinated beta-galactosidase molecules and production of one such fusion was shown to result in derepression of the biotin biosynthetic operon.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	LI, SJ (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; ALIX JH, 1989, DNA-J MOLEC CELL BIO, V8, P779, DOI 10.1089/dna.1989.8.779; ARPS PJ, 1987, J BACTERIOL, V169, P1061, DOI 10.1128/jb.169.3.1061-1070.1987; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V1, pCH4; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROWNER MF, 1989, J BIOL CHEM, V264, P12680; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; DEVEAUX LC, 1986, J BACTERIOL, V167, P920, DOI 10.1128/jb.167.3.920-927.1986; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; EASOM RA, 1989, PROTEINS, V5, P224, DOI 10.1002/prot.340050306; FALL RR, 1973, J BIOL CHEM, V248, P2078; FALL RR, 1972, J BIOL CHEM, V247, P8005; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HAASE FC, 1982, J BIOL CHEM, V257, P1994; HARDER ME, 1972, P NATL ACAD SCI USA, V69, P3105, DOI 10.1073/pnas.69.11.3105; HILL ROBERT L., 1965, ADVANCE PROTEIN CHEM, V20, P37, DOI 10.1016/S0065-3233(08)60388-5; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBLUM JS, 1988, GENE, V63, P75, DOI 10.1016/0378-1119(88)90547-1; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; LIM F, 1988, J BIOL CHEM, V263, P11493; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LYNEN F, 1972, BIOCH SOC S, V35, P5; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P3982, DOI 10.1093/nar/17.10.3982; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; NYUNOYA H, 1983, P NATL ACAD SCI USA, V77, P2119; OGITA T, 1988, BIOCHEMISTRY-US, V27, P8028, DOI 10.1021/bi00421a009; POLAKIS SE, 1974, J BIOL CHEM, V244, P6657; POST LE, 1990, J BIOL CHEM, V265, P7742; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REED KE, 1991, J BIOL CHEM, V266, P11425; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; SWACK JA, 1978, ANAL BIOCHEM, V87, P114, DOI 10.1016/0003-2697(78)90575-4; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4325, DOI 10.1021/bi00412a020; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4317, DOI 10.1021/bi00412a019; WEI YG, 1986, GENE, V48, P251, DOI 10.1016/0378-1119(86)90083-1	62	209	243	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					855	863						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370469				2022-12-25	WOS:A1992GY96000029
J	MAURICE, M; PICHARD, L; DAUJAT, M; FABRE, I; JOYEUX, H; DOMERGUE, J; MAUREL, P				MAURICE, M; PICHARD, L; DAUJAT, M; FABRE, I; JOYEUX, H; DOMERGUE, J; MAUREL, P			EFFECTS OF IMIDAZOLE DERIVATIVES ON CYTOCHROMES-P450 FROM HUMAN HEPATOCYTES IN PRIMARY CULTURE	FASEB JOURNAL			English	Note						CELL LYSATE; HEPATOCYTE CULTURE; MICROSOME	OXIDATIVE DRUG-METABOLISM; HUMAN-LIVER MICROSOMES; GENETIC-POLYMORPHISM; ANTIMYCOTIC AGENTS; KETOCONAZOLE; CYTOCHROME-P-450; INDUCTION; RAT; CYCLOSPORINE; INHIBITION	The expression of several forms of cytochrome P450 including P450 1A2, 2D6, 2E1 and 3A was investigated in human hepatocytes maintained in primary culture for 96 h in the absence or presence of 50-mu-M of various imidazole derivatives. These included ketoconazole, clotrimazole, miconazole, fluconazole, secnidazole and metronidazole. In addition, the typical inducers rifampicin and beta-naphthoflavone were used for comparison. Western and Northern blot analysis of microsomes and RNA prepared from these cultures as well as de novo synthesis experiments revealed that, among the imidazole derivatives tested, only clotrimazole was a strong rifampicin-like inducer of P450 3A. The expression of the other forms of P450 tested was not affected by the treatments. Analysis of the inhibition of 13 monoxygenase activities, including ethoxyresorufin and phenacetin O-deethylases, coumarin 7-alpha-, lauric acid 11- and 12-, mephenytoin 4-, debrisoquin 4-, and aniline hydroxylases, benzphetamine, aminopyrine, mephenytoin and erythromycin demethylases, and cyclosporin oxidase (representative of 10 different forms of P450 in human liver microsomes) revealed that ketoconazole was a strong and selective in vitro inhibitor of P450 3A (cyclosporin oxidase) with a K(i) < 1-mu-M. Clotrimazole and miconazole were also strong inhibitors of P450 3A-mediated activities in contrast to the other imidazole derivatives.	CNRS, INSERM, U128, ROUTE MENDE, BP 5051, F-34033 MONTPELLIER, FRANCE; CTR PAUL LAMARQUE, INST CANC, DEPT CHIRURG & NUTR, F-34094 MONTPELLIER, FRANCE; HOP ST ELOI, SERV CHIRURG C, F-34059 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Daujat-Chavanieu, Martine/AAU-2908-2020; Daujat-Chavanieu, Martine/T-5155-2018	Daujat-Chavanieu, Martine/0000-0001-5560-1610; Daujat-Chavanieu, Martine/0000-0001-5560-1610				ATIBA JO, 1989, BRIT J CLIN PHARMACO, V28, P161, DOI 10.1111/j.1365-2125.1989.tb05409.x; BACK DJ, 1989, BRIT J CLIN PHARMACO, V28, P166, DOI 10.1111/j.1365-2125.1989.tb05410.x; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BEGUE JM, 1983, BIOCHEM PHARMACOL, V32, P1643, DOI 10.1016/0006-2952(83)90341-6; BONFILS C, 1990, EUR J BIOCHEM, V188, P187, DOI 10.1111/j.1432-1033.1990.tb15387.x; BORK RW, 1989, J BIOL CHEM, V264, P910; BURKE MD, 1975, DRUG METAB DISPOS, V3, P245; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; COLLIGNON P, 1989, LANCET, V1, P1262; DAUJAT M, 1991, IN PRESS LIFE SCI; DAUJAT M, 1991, METHOD ENZYMOL, V206, P345; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; EHNINGER G, 1989, LANCET, V2, P104; FABRE G, 1988, BIOCHEM PHARMACOL, V37, P4389, DOI 10.1016/0006-2952(88)90622-3; FERGUSON RM, 1982, LANCET, V2, P882; FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HARMSWORTH WL, 1990, XENOBIOTICA, V20, P1053, DOI 10.3109/00498259009046826; HOSTETLER KA, 1989, MOL PHARMACOL, V35, P279; HOUSTON JB, 1988, BIOCHEM PHARMACOL, V37, P401, DOI 10.1016/0006-2952(88)90206-7; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KIRSCH DR, 1988, GENE, V68, P229, DOI 10.1016/0378-1119(88)90025-X; LAVRIJSEN K, 1986, BIOCHEM PHARMACOL, V35, P1867, DOI 10.1016/0006-2952(86)90305-9; MAURICE M, 1991, EUR J BIOCHEM, V200, P511, DOI 10.1111/j.1432-1033.1991.tb16212.x; MEREDITH CG, 1985, DRUG METAB DISPOS, V13, P156; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; MORGENSTERN GR, 1982, LANCET, V2, P1342; NIEMEGEERS CJE, 1981, ARCH INT PHARMACOD T, V251, P26; OTTON SV, 1988, J PHARMACOL EXP THER, V247, P242; PASANEN M, 1988, BIOCHEM PHARMACOL, V37, P3861, DOI 10.1016/0006-2952(88)90067-6; PICHARD L, 1990, DRUG METAB DISPOS, V18, P711; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; RITTER JK, 1987, BIOCHEM PHARMACOL, V36, P2783, DOI 10.1016/0006-2952(87)90265-6; RITTER JK, 1987, DRUG METAB DISPOS, V15, P335; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; SESARDIC D, 1990, BRIT J CLIN PHARMACO, V29, P651, DOI 10.1111/j.1365-2125.1990.tb03686.x; Shaw J. T. B., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P125; SHEETS JJ, 1984, DRUG METAB DISPOS, V12, P603; SHIMADA T, 1986, J BIOL CHEM, V261, P909; THOMSON RG, 1988, BIOCHEM PHARMACOL, V37, P3975, DOI 10.1016/0006-2952(88)90082-2; VERONESE ME, 1990, DRUG METABOLIZING EN, P203; WHITE DJG, 1984, TRANSPLANTATION, V37, P214	43	281	285	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					752	758		10.1096/fasebj.6.2.1371482	http://dx.doi.org/10.1096/fasebj.6.2.1371482			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1371482				2022-12-25	WOS:A1992GZ44000018
J	BEAULIEU, AD; PAQUIN, R; RATHANASWAMI, P; MCCOLL, SR				BEAULIEU, AD; PAQUIN, R; RATHANASWAMI, P; MCCOLL, SR			NUCLEAR SIGNALING IN HUMAN NEUTROPHILS - STIMULATION OF RNA-SYNTHESIS IS A RESPONSE TO A LIMITED NUMBER OF PROINFLAMMATORY AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; NUCLEOTIDE REGULATORY PROTEINS; PERTUSSIS TOXIN; MOLECULAR-CLONING; TYROSINE KINASE; CALCIUM MOBILIZATION; SELECTIVE SYNTHESIS; RABBIT NEUTROPHILS; MESSENGER-RNA	At inflammatory sites, neutrophils are stimulated by a range of proinflammatory molecules which elicit a number of cellular responses. Considerable information on the cytoplasmic events that occur following activation of neutrophils at the cell membrane level already exists. In this study, we have focused on the ability of neutrophil agonists to initiate nuclear signaling events by investigating the induction of de novo RNA synthesis. Of a total of 14 different known potent leukocyte agonists, only three had a significant effect on the induction of RNA synthesis in neutrophils; the formylated oligopeptide formyl-methionyl-leucyl-phenylalanine (fMet-Leu-Phe), granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. All three agonists induced de novo RNA synthesis in neutrophils at concentrations known to be optimal for the activation of a number of other cellular responses occurring in inflammation. Of significance was the observation that activation of RNA synthesis in neutrophils is a G-protein-mediated event, is also dependent on tyrosine phosphorylation, but is not influenced by cAMP. Finally, we have demonstrated that all three agonists also induce de novo synthesis of a limited number of proteins, with granulocyte-macrophage colony-stimulating factor and fMet-Leu-Phe having the most potent effect. These studies define the effects of neutrophil agonists on de novo RNA and protein synthesis in a proinflammatory context and suggest that these events in neutrophils occur in a restricted fashion, highly dependent on the stimuli present at sites of inflammation.			BEAULIEU, AD (corresponding author), CHU LAVAL,CTR RECH,CTR RECH INFLAMMAT IMMUNOL & RHUMATOL,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.		Rathanaswami, Palaniswami/AAL-3979-2021; Rathanaswami, Palaniswami/AAL-7192-2021					BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BEAULIEU AD, 1987, J RHEUMATOL, V14, P656; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCO NA, 1990, BLOOD, V75, P2049; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COREY SJ, 1989, J BIOL CHEM, V264, P14165; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EID NS, 1987, J EXP MED, V165, P1448, DOI 10.1084/jem.165.5.1448; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GRANELLIPIPERNO A, 1979, J EXP MED, V149, P284, DOI 10.1084/jem.149.1.284; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IMOTO M, 1987, J ANTIBIOT, V40, P1471, DOI 10.7164/antibiotics.40.1471; JACK RM, 1988, J IMMUNOL, V140, P4286; KRAFT AS, 1987, BLOOD, V70, P356; KREIS C, 1989, J IMMUNOL, V143, P1961; LAFLEUR M, 1987, J BIOL CHEM, V262, P2111; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maniatis T., 1982, MOL CLONING; MCCOLL SR, 1990, BIOCHEM BIOPH RES CO, V172, P1209, DOI 10.1016/0006-291X(90)91577-F; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCOLL SR, 1989, BLOOD, V73, P588; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NACCACHE PH, 1990, BLOOD, V76, P2098; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHIRAFUJI N, 1990, BLOOD, V75, P17; TIKU K, 1986, J IMMUNOL, V136, P3677; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; UMEZAWA K, 1988, HORIZONS ANTIBIOTIC, P74; VARTIO T, 1982, J BIOL CHEM, V257, P8862; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WAKSMAN Y, 1990, J IMMUNOL, V144, P3437	44	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					426	432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370448				2022-12-25	WOS:A1992GY43900069
J	NEVE, KA; KOZLOWSKI, MR; ROSSER, MP				NEVE, KA; KOZLOWSKI, MR; ROSSER, MP			DOPAMINE D2 RECEPTOR STIMULATION OF NA+/H+ EXCHANGE ASSESSED BY QUANTIFICATION OF EXTRACELLULAR ACIDIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; ARACHIDONIC-ACID RELEASE; PROLACTIN SECRETION; SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; GROWTH-FACTORS; CELLS; RAT; INHIBITION; ACTIVATION	A microphysiometer was used to quantify the rate of extracellular acidification by C6 glioma cells and L fibroblasts expressing recombinant dopamine D2 receptors. The dopamine D2 receptor agonist, quinpirole, accelerated the rate of acidification of the medium by C6 cells expressing either the short or long form of D2 receptors, D2(415) and D2(444), but not by wild-type cells that were not transfected with a D2 receptor cDNA. The rate of acidification increased with increasing concentrations of quinpirole up to 100 nM. Inhibition of the response by the dopamine D2 antagonist, spiperone, provided additional evidence that the enhanced extracellular acidification resulted from stimulation of D2 receptors. To test the hypothesis that D2 receptor-stimulated extracellular acidification was due to transport of protons by a Na+/H+ antiporter and reflected intracellular alkalinization, the effect of two inhibitors of Na+/H+ exchange, amiloride and methyl-isobutyl-amiloride, was determined. Both compounds inhibited quinpirole-induced extracellular acidification at concentrations that did not alter D2 receptor-mediated inhibition of adenylylcyclase or radioligand binding to D2 receptors. In addition, quinpirole-induced extracellular acidification was greatly inhibited by removal of sodium from the extracellular medium, confirming the participation of Na+/H+ exchange in the extrusion of acid. Quinpirole (100 nM) also increased the rate of extracellular acidification by L cells expressing D2(415), LZR1 cells. Treatment with pertussis toxin (100 ng/ml for 18 h) had no effect on the quinpirole-induced acid extrusion by C6D2(415) and LZR1 cells, although the same pertussis toxin treatment regimen completely prevented inhibition of adenylylcyclase. We conclude that recombinant D2 receptors accelerate Na+/H+ exchange in C6 cells and L fibroblasts by a pathway that does not involve inhibition of adenylylcyclase or pertussis toxin-sensitive G proteins.	OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT SCREENING & BIOCHEM RES,WALLINGFORD,CT 06492	Oregon Health & Science University; Bristol-Myers Squibb	NEVE, KA (corresponding author), OREGON HLTH SCI UNIV,VET AFFAIRS MED CTR,PORTLAND,OR 97201, USA.			Kozlowski, Michael/0000-0003-1213-7015	NIMH NIH HHS [MH45372] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045372] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERT PR, 1990, J BIOL CHEM, V265, P2098; AMOROSO S, 1991, BIOCHEM PHARMACOL, V41, P1279, DOI 10.1016/0006-2952(91)90098-P; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; DAVIES C, 1974, J ENDOCRINOL, V61, P411, DOI 10.1677/joe.0.0610411; DIXON SJ, 1987, J BIOL CHEM, V262, P3626; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GANZ MB, 1990, J BIOL CHEM, V265, P8989; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; JOYCE JN, 1991, J PHARMACOL EXP THER, V257, P1253; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MALGAROLI A, 1987, J BIOL CHEM, V262, P13920; MASSERANO JM, 1983, MOL CELL BIOCHEM, V53-4, P129; MELLER E, 1987, MOL PHARMACOL, V31, P592; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1981, CELL, V23, P789, DOI 10.1016/0092-8674(81)90443-8; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1991, MOL PHARMACOL, V39, P570; NEVE KA, 1989, MOL PHARMACOL, V36, P446; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAPIRSTEIN VS, 1984, J NEUROCHEM, V43, P1098, DOI 10.1111/j.1471-4159.1984.tb12849.x; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TALOR Z, 1989, LIFE SCI, V45, P517, DOI 10.1016/0024-3205(89)90102-1; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5	39	64	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25748	25753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361188				2022-12-25	WOS:A1992KD07300027
J	KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K				KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K			P53 MOSAICISM WITH AN EXON 8 GERMLINE MUTATION IN THE FOUNDER OF A CANCER-PRONE PEDIGREE	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-MUTATIONS; BREAST-CANCER; LINE MUTATION; DNA; PROTEIN; CARCINOMAS	Changes in the tumor-suppressor gene p53 are frequently acquired during the course of malignant development of human tumors. Recently, constitutional heterozygous mutations in p53 exon 7 have been identified as the primary cause of cancer predisposition in cases of the familial Li-Fraumeni cancer syndrome. These findings underline the need for extensive mutation screening in families with high cancer incidence. This report describes the detection and follow-up by two-dimensional single-strand conformation polymorphism analysis (2DSSCP) of a new germline mutation of p53 exon 8 in a case of suspected Li-Fraumeni syndrome. Although a high cancer incidence had been reported in the family history of the father of siblings suffering from brain tumor and rhabdomyosarcoma, a constitutional heterozygous p53 mutation was identified only in the affected children. Retrospective analysis of archival tissue of a half-sister who died several years ago from a tumor of previously uncertain diagnosis revealed the same mutation. The mutation had therefore occurred in the germ cells of the mother, who thus appears to be a mosaic. The cancer predisposition of the paternal ancestors must have been due to other factors.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,DEPT PEDIAT,A-1010 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHIBA I, 1990, ONCOGENE, V5, P1603; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HELMUTH R, 1990, AM J HUM GENET, V47, P515; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VARLEY JM, 1991, ONCOGENE, V6, P413; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WILLIAMS WR, 1985, FAM CANCER, P151; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1977, NATL CANCER I MONOGR, V57, P70	42	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2169	2173						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359493				2022-12-25	WOS:A1992JW66500009
J	CHINKERS, M; WILSON, EM				CHINKERS, M; WILSON, EM			LIGAND-INDEPENDENT OLIGOMERIZATION OF NATRIURETIC PEPTIDE RECEPTORS - IDENTIFICATION OF HETEROMERIC RECEPTORS AND A DOMINANT NEGATIVE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE GUANYLATE-CYCLASE; ADRENAL ZONA GLOMERULOSA; EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; EXTRACELLULAR DOMAIN; POLYACRYLAMIDE GELS; CATALYTIC ACTIVITY; ACTIVITY REQUIRES; ENZYME SUBUNITS; ATRIAL	Activation of many single-transmembrane receptors requires ligand-induced receptor oligomerization. We have examined the oligomerization of the atrial natriuretic peptide receptor, NPR-A, using epitope-tagged receptor in a co-immunoprecipitation assay. Unlike other single-transmembrane receptors, NPR-A oligomerized in a ligand-independent fashion. Extracellular receptor sequences were both necessary and sufficient for oligomer formation. NPR-A was also able to oligomerize with the related natriuretic peptide receptor, NPR-B. A truncated NPR-A lacking most of the cytoplasmic domain blocked activation of the full-length receptor, presumably through formation of an inactive heteromer. These results indicate that oligomerization of this single-transmembrane receptor is important for the transduction of a conformational change across the plasma membrane but are not consistent with models in which natriuretic peptide receptor oligomerization serves merely to bring intracellular domains together.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	CHINKERS, M (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; ISHIDO M, 1986, BIOCHEM BIOPH RES CO, V140, P101, DOI 10.1016/0006-291X(86)91063-6; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MANNIX ET, 1991, J APPL PHYSIOL, V71, P1340, DOI 10.1152/jappl.1991.71.4.1340; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1987, J BIOL CHEM, V262, P10252; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; MUKOYAMA M, 1991, BIOCHEM BIOPH RES CO, V180, P431, DOI 10.1016/S0006-291X(05)81311-7; NAKANE M, 1990, J BIOL CHEM, V265, P16841; OGAWA Y, 1991, CIRC RES, V69, P491, DOI 10.1161/01.RES.69.2.491; PORTER JG, 1989, J BIOL CHEM, V264, P14179; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RADANY EW, 1983, J BIOL CHEM, V258, P8346; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA S, 1991, BIOCHEM BIOPH RES CO, V175, P759, DOI 10.1016/0006-291X(91)91631-L; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454	57	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18589	18597						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382057				2022-12-25	WOS:A1992JN50200054
J	HOCHHAUSER, D; STANWAY, CA; HARRIS, AL; HICKSON, ID				HOCHHAUSER, D; STANWAY, CA; HARRIS, AL; HICKSON, ID			CLONING AND CHARACTERIZATION OF THE 5'-FLANKING REGION OF THE HUMAN TOPOISOMERASE-II-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; THYMIDINE KINASE GENE; HUMAN-LEUKEMIA CELLS; DNA TOPOISOMERASES; EXPRESSION; RECOMBINATION; SEGREGATION; CHROMOSOMES; CEREVISIAE; SEQUENCE	Topoisomerases are essential enzymes for DNA metabolism in prokaryotes and eukaryotes. In human cells, DNA topoisomerase II enzyme activity can be modulated by both viral transformation and changes in proliferation status. To identify elements important for regulation of topoisomerase II-alpha gene expression, genomic DNA clones covering the 5'-end of the gene were isolated. The intron/exon structure of a 2.5-kilobase region encompassing the translation start site was determined. Transcription was found to initiate at multiple sites clustered around 90 base pairs 5' to the ATG initiation codon. Transient expression of chimeric topoisomerase II-reporter gene constructs in HeLa cells revealed that the 5'-flanking region exhibited promoter activity. The region -90 to -1 upstream of the major transcription start site was shown by deletion analysis to include a promoter. This minimal promoter lacks a TATA box, is moderately GC-rich, and contains a high frequency of CpG dinucleotides; characteristic of a "housekeeping" gene promoter. Maximal promoter activity was observed using a fragment extending to position -562. Putative regulatory elements are contained within and immediately upstream of the minimal promoter region. The regulatory region of the topoisomerase II-alpha gene identified here is similar in basic structure to those of the human thymidine kinase and DNA polymerase alpha-genes, which are also controlled by proliferation-specific factors.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND	University of Oxford			Hickson, Ian/AAJ-7548-2020; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Hochhauser, Daniel/0000-0001-5522-9281; Hickson, Ian/0000-0002-0583-566X				BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BENSON JD, 1990, J VIROL, V64, P9, DOI 10.1128/JVI.64.1.9-15.1990; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BODLEY AL, 1987, NATL CANCER I MONOGR, V4, P31; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSS W, 1984, CANCER RES, V44, P5857; Sambrook J, 1989, MOL CLONING LABORATO; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEBB CD, 1991, CANCER RES, V51, P6543; WOESSNER RD, 1990, CANCER RES, V50, P2901; ZWELLING LA, 1988, CANCER RES, V48, P6625	33	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18961	18965						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382064				2022-12-25	WOS:A1992JN50200106
J	GRINSTEIN, S; FURUYA, W				GRINSTEIN, S; FURUYA, W			CHEMOATTRACTANT-INDUCED TYROSINE PHOSPHORYLATION AND ACTIVATION OF MICROTUBULE-ASSOCIATED PROTEIN-KINASE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PERITONEAL NEUTROPHILS; PHOSPHOTYROSYL PROTEIN; RESPIRATORY BURST; THREONINE; IDENTIFICATION; OXIDASE; ERKS	Activation of human neutrophils by the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) induces tyrosine phosphorylation of several polypeptides, including a prominent band of almost-equal-to 41 kDa. A polypeptide of identical electrophoretic mobility was recognized by a monoclonal antibody raised against a sequence corresponding to amino acids 325-345 of ERK-1, one of a family of mitogen-activated protein (MAP) kinases. To establish the possible identity of these polypeptides, extracts from control and fMLP-treated cells were immunoprecipitated with immobilized antiphosphotyrosine antibodies. Reactivity with anti-ERK-1 antibodies was observed only in the precipitate of chemoattractant-stimulated cells. These data imply that a MAP kinase constitutes at least part of the tyrosine-phosphorylated 41-kDa polypeptide. By using an in vitro renaturation assay, treatment of intact cells with fMLP was found to stimulate several protein kinases, including one of almost-equal-to 41 kDa. Renaturation of samples immunoprecipitated with antiphosphotyrosine antibodies revealed the presence of an active protein kinase in chemoattractant-stimulated, but not in control cells. The immunoprecipitated kinase comigrated with the 41-kDa tyrosine phosphorylated polypeptide and the anti-ERK-1 reactive band. We conclude that a MAP kinase closely related or identical to ERK-1 is tyrosine phosphorylated and activated when human neutrophils are stimulated by chemotactic peptides. The rapid phosphorylation of this kinase, which is apparent within seconds, is compatible with a role in the activation of the respiratory burst and/or other neutrophil responses.			GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERKOW RL, 1990, BLOOD, V75, P2445; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1991, NATURE, V353, P170; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; TAUBER AI, 1987, BLOOD, V69, P711; TORRES M, 1991, Journal of Cell Biology, V115, p274A	24	141	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18122	18125						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381363				2022-12-25	WOS:A1992JM22300098
J	GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D				GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D			STRUCTURAL ORGANIZATION OF THE MURINE C-KIT PROTOONCOGENE	ONCOGENE			English	Article								The murine Kit receptor gene on chromosome 5 has been found to be frequently involved in germline mutations and rearrangements, leading to a characteristic set of severe developmental defects, known as the W phenotype. Here we describe the structure of the murine c-kit gene, based on restriction analysis of genomic phage clones and sequence determination of exon-intron boundaries. The Kit-coding region is distributed over 21 exons, most of which have sizes that range between 100 and 200 base pairs. The 3' non-translated sequence and the 3' end of the coding region form a single large exon, which encompasses 2.3 kb and is flanked by polyadenylation signals. The entire region spans a genomic distance of at least 70 kb. Though the exonic demarcations of c-kit show remarkable similarity to those of the human c-fms gene (which encodes the highly related colony-stimulating factor 1 receptor), no correlation could be found between the sizes of introns that separate homologous exon pairs. The data suggest that evolutionary pressures were confined to the conservation of structures of coding exons, whereas flanking regions were subject to large changes, owing to insertions and deletions. Finally, the analysis of the Kit genomic structure reveals that the inherited mutations of the Kit gene that have been reported thus far occur at various dispersed positions within the gene. Hence, the entire gene appears to have as yet unknown features which cause it to be frequently subject to mutations in murine germline tissues.	CHAIM SHEBA MED CTR, INST HEMATOL, IL-52621 TEL HASHOMER, ISRAEL	Chaim Sheba Medical Center	GOKKEL, E (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012					BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; McLachlan A.D., 1980, PROTEINS RELATED SUB, V28, P29; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOBAL K, 1990, LEUKEMIA, V4, P486; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	62	44	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1423	1429						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377813				2022-12-25	WOS:A1992HZ97100022
J	METZ, SA; RABAGLIA, ME; PINTAR, TJ				METZ, SA; RABAGLIA, ME; PINTAR, TJ			SELECTIVE INHIBITORS OF GTP SYNTHESIS IMPEDE EXOCYTOTIC INSULIN RELEASE FROM INTACT RAT ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PANCREATIC-ISLETS; PROTEIN-KINASE-C; GUANINE-NUCLEOTIDES; ADENYLATE-CYCLASE; MYCOPHENOLIC-ACID; LIPOXYGENASE INHIBITORS; ARACHIDONIC-ACID; MAMMALIAN-CELLS; PHOSPHOLIPASE-C; HUMAN-PLATELETS	To investigate whether GTP concentrations can be a regulatory step in exocytotic hormone secretion, we treated isolated rat islets with mycophenolic acid (MPA) or mizoribine, two selective inhibitors of de novo GTP synthesis. When islets were cultured over-night in purine-free medium containing the drug, MPA reduced GTP levels by up to 81 +/- 1%; guanine circumvented this block via the nucleotide "salvage" pathway. MPA concomitantly inhibited glucose (16.7 mM)-induced insulin secretion in batch-type incubations (or perifusions), by up to 68% at 50-mu-g/ml. Although the inhibition of secretion occurred over a similar concentration range as the reduction in total GTP content, the two variables were not directly correlated. However, the secretory effects also were prevented by adding guanine, but not hypoxanthine or xanthine, to the culture medium. Similar results for GTP content and insulin release were seen using mizoribine. Insulin content was modestly (-18%) reduced by MPA but indices of fractional release (release/insulin content) were also markedly impaired. Although MPA also reduced ATP levels more modestly (-39%) and increased UTP (+87%), these were not the cause of the secretory defect since adenine restored ATP and UTP nearly to normal, but did not alter the reduction in GTP content or insulin secretion. MPA also inhibited secretion induced by amino acid or by a phorbol ester but had virtually no effect on release induced by a depolarizing concentration of K+, suggesting that GTP depletion does not merely impede Ca+ influx or directly block Ca2+-activated exocytosis. However, a severe reduction of GTP content did not prevent the pertussis toxin-sensitive inhibition of insulin release induced by epinephrine, suggesting that the function of heterotrimeric GTP-binding proteins is not limited by ambient GTP concentrations. Although these studies do not elucidate the exact site(s) in the exocytotic cascade which depend on intact GTP stores, they do provide the first direct evidence that GTP is required (and can be rate limiting) for insulin release.	UNIV WISCONSIN,ENDOCRINOL SECT,MADISON,WI 53792; UNIV WISCONSIN,DEPT MED,MADISON,WI 53792; WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007389, R01DK037312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37312, DK-HL07389-11] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMSON SB, 1991, J IMMUNOL, V147, P231; ANDERSON WB, 1974, J BIOL CHEM, V249, P7041; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAPITO K, 1976, BIOCHEM J, V158, P335, DOI 10.1042/bj1580335; CARLIER MF, 1991, J BIOL CHEM, V266, P12361; COHEN MB, 1983, CANCER RES, V43, P1587; COHEN MB, 1981, J BIOL CHEM, V256, P8713; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DUNNE MJ, 1986, PFLUG ARCH EUR J PHY, V407, P564, DOI 10.1007/BF00657518; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EUGUI EM, 1991, TRANSPLANT P, V23, P15; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FRANKLIN TJ, 1977, EUR J BIOCHEM, V77, P113, DOI 10.1111/j.1432-1033.1977.tb11648.x; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEISBUHLER T, 1984, CIRC RES, V54, P536, DOI 10.1161/01.RES.54.5.536; GOLD G, 1982, J CLIN INVEST, V69, P554, DOI 10.1172/JCI110481; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRANDT R, 1986, BIOCHEM J, V237, P669, DOI 10.1042/bj2370669; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HARTMAN NR, 1991, MOL PHARMACOL, V40, P118; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HOENIG M, 1987, METABOLISM, V36, P295, DOI 10.1016/0026-0495(87)90192-2; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; JACKSON RC, 1977, BIOCHEM J, V166, P1; JOHNSON GS, 1979, J BIOL CHEM, V254, P95; JONES PM, 1988, BIOCHEM J, V254, P397, DOI 10.1042/bj2540397; KATADA T, 1981, J BIOL CHEM, V256, P8310; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1980, FEBS LETT, V117, P172, DOI 10.1016/0014-5793(80)80938-0; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; KOYAMA H, 1983, BIOCHEM PHARMACOL, V32, P3547, DOI 10.1016/0006-2952(83)90301-5; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEE HJ, 1985, CANCER RES, V45, P5512; LUMPERT CJ, 1990, BIOCHEM J, V269, P639, DOI 10.1042/bj2690639; MARYNISSEN G, 1990, METABOLISM, V39, P87, DOI 10.1016/0026-0495(90)90153-4; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEHLER PS, 1980, J CLIN INVEST, V66, P1334, DOI 10.1172/JCI109986; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; METZ SA, 1989, BIOCHEM PHARMACOL, V38, P1849, DOI 10.1016/0006-2952(89)90421-8; METZ SA, 1988, DIABETES, V37, P65, DOI 10.2337/diabetes.37.1.65; METZ SA, 1990, ARCH BIOCHEM BIOPHYS, V283, P417, DOI 10.1016/0003-9861(90)90663-J; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; METZ SA, 1985, P NATL ACAD SCI USA, V82, P198, DOI 10.1073/pnas.82.1.198; MORGAN A, 1990, BIOCHEM J, V269, P521, DOI 10.1042/bj2690521; MORRIS RE, 1991, TRANSPLANT P, V23, P19; NGUYEN BT, 1984, CANCER RES, V44, P2272; NGUYEN BT, 1986, BIOCHEM J, V234, P263, DOI 10.1042/bj2340263; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; RIZZO MT, 1990, CELL SIGNAL, V2, P509, DOI 10.1016/0898-6568(90)90073-J; ROBERTSON RP, 1991, DIABETES, V40, P1, DOI 10.2337/diabetes.40.1.1; RODWELL VW, 1988, HARPERS BIOCH, P344; ROSENBERG EM, 1987, DIABETES, V36, P37, DOI 10.2337/diabetes.36.1.37; SAKAGUCHI K, 1975, CANCER RES, V35, P1643; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SIRCAR JC, 1983, PROSTA LEUKOTR MED, V11, P373, DOI 10.1016/0262-1746(83)90089-6; SMITH CM, 1977, J CYCLIC NUCL PROT, V3, P347; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; SRIBNEY M, 1977, BIOCHEM BIOPH RES CO, V79, P749, DOI 10.1016/0006-291X(77)91175-5; STOEHR SJ, 1990, BLOOD, V75, P479; SWEENEY MJ, 1972, CANCER RES, V32, P1803; THAMS P, 1986, DIABETOLOGIA, V29, P888, DOI 10.1007/BF00870145; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; ULLRICH S, 1989, FEBS LETT, V247, P401, DOI 10.1016/0014-5793(89)81379-1; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; ULLRICH S, 1990, BIOCHEM J, V270, P273, DOI 10.1042/bj2700273; WELSH N, 1991, BIOCHEM J, V275, P23, DOI 10.1042/bj2750023; WILSON BS, 1989, J IMMUNOL, V143, P259; WOLF BA, 1987, BIOCHEM J, V242, P137, DOI 10.1042/bj2420137; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507; ZUNKLER BJ, 1986, IRCS MED SCI-BIOCHEM, V14, P354	75	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12517	12527						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352288				2022-12-25	WOS:A1992HZ48300025
J	JIN, YJ; BURAKOFF, SJ; BIERER, BE				JIN, YJ; BURAKOFF, SJ; BIERER, BE			MOLECULAR-CLONING OF A 25-KDA HIGH-AFFINITY RAPAMYCIN BINDING-PROTEIN, FKBP25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; T-CELL ACTIVATION; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; MACROLIDES FK-506; DISTINCT; CYCLOPHILIN; IMMUNOPHILIN; CYCLOSPORINE	Two FK506 binding proteins of molecular mass 12 kDa (FKBP12) and 13 kDa (FKBP13) have been identified as common cellular receptors of the immunosuppressants FK506 and rapamycin. Here we report the molecular cloning and overexpression of a 25-kDa rapamycin and FK506 binding protein (termed FKBP25) with peptidylprolyl cis-trans-isomerase (PPIase) activity. The amino acid sequence, predicted from the FKBP25 cDNA, shares identity with FKBP12 (44%) and FKBP13 (47%) in the C-terminal 97 amino acids. Unlike either FKBP12 or FKBP13, the nucleotide sequence of FKBP25 contains a number of putative nuclear localization sequences. The PPIase activity of recombinant FKBP25 was comparable with that of FKBP12. The PPIase activity of FKBP25 was far more sensitive to inhibition by rapamycin (IC50 = 50 nM) than FK506 (IC50 = 400 nM). PPIase activity of 100 nM FKBP25 was almost completely inhibited by 150 nm rapamycin while only 90% inhibition was achieved by 4-mu-M FK506. These data demonstrate that FKBP25 has a higher affinity for rapamycin than for FK506 and suggest that this cellular receptor may be an important target molecule for immunosuppression by rapamycin.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	JIN, YJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Bierer, Barbara/0000-0001-6448-8170				BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1986, NUCLEOCYTOPLASMIC TR, P185; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017	29	84	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10942	10945						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375932				2022-12-25	WOS:A1992HX16900004
J	LERNER, DR; RAIKHEL, NV				LERNER, DR; RAIKHEL, NV			THE GENE FOR STINGING NETTLE LECTIN (URTICA-DIOICA AGGLUTININ) ENCODES BOTH A LECTIN AND A CHITINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BARLEY LECTIN; DNA; CLONING; TOBACCO; ENDOCHITINASE; ACCUMULATION; RHIZOMES	Chitin-binding proteins are present in a wide range of plant species, including both monocots and dicots, even though these plants contain no chitin. To investigate the relationship between in vitro antifungal and insecticidal activities of chitin-binding proteins and their unknown endogenous functions, the stinging nettle lectin (Urtica dioica agglutinin, UDA) cDNA was cloned using a synthetic gene as the probe. The nettle lectin cDNA clone contained an open reading frame encoding 374 amino acids. Analysis of the deduced amino acid sequence revealed a 21-amino acid putative signal sequence and the 86 amino acids encoding the two chitin-binding domains of nettle lectin. These domains were fused to a 19-amino acid "spacer" domain and a 244-amino acid carboxyl extension with partial identity to a chitinase catalytic domain. The authenticity of the cDNA clone was confirmed by deduced amino acid sequence identity with sequence data obtained from tryptic digests, RNA gel blot, and polymerase chain reaction analyses. RNA gel blot analysis also showed the nettle lectin message was present primarily in rhizomes and inflorescence (with immature seeds) but not in leaves or stems. Chitinase enzymatic activity was found when the chitinase-like domain alone or the chitinase-like domain with the chitin-binding domains were expressed in Escherichia coli. This is the first example of a chitin-binding protein with both a duplication of the 43-amino acid chitin-binding domain and a fusion of the chitin-binding domains to a structurally unrelated domain, the chitinase domain.	MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824	Michigan State University								BEDNAREK SY, 1991, PLANT CELL, V3, P1195, DOI 10.1105/tpc.3.11.1195; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CHAPOT MP, 1986, FEBS LETT, V195, P231, DOI 10.1016/0014-5793(86)80166-1; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; DALE RMK, 1987, METHOD ENZYMOL, V155, P204; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAIT MJ, 1980, NUCL ACIDS RES S SER, V7, P243; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; HUESING JE, 1991, PHYTOCHEMISTRY, V30, P3565, DOI 10.1016/0031-9422(91)80066-A; HUESING JE, 1991, PHYTOCHEMISTRY, V30, P785, DOI 10.1016/0031-9422(91)85252-U; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEAH R, 1991, J BIOL CHEM, V266, P1564; LEE H, 1991, J BIOL CHEM, V266, P15944; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; Maniatis T., 1982, MOL CLONING; Nagy F., 1988, PLANT MOL BIOL MAN B, VB4, P1; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; NEUHAUS JM, 1991, PLANT MOL BIOL, V16, P141, DOI 10.1007/BF00017924; PARSONS TJ, 1989, P NATL ACAD SCI USA, V86, P7895, DOI 10.1073/pnas.86.20.7895; PAYNE G, 1990, P NATL ACAD SCI USA, V87, P98, DOI 10.1073/pnas.87.1.98; PEUMANS WJ, 1984, FEBS LETT, V177, P99, DOI 10.1016/0014-5793(84)80989-8; PEUMANS WJ, 1984, PLANTA, V160, P222, DOI 10.1007/BF00402858; RAIKHEL NV, 1991, DEV GENET, V12, P255, DOI 10.1002/dvg.1020120402; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SILFLOW CD, 1979, BIOCHEMISTRY-US, V18, P2725, DOI 10.1021/bi00580a006; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDAMME EJM, 1988, PLANT PHYSIOL, V86, P598, DOI 10.1104/pp.86.2.598; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z	38	82	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11085	11091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375935				2022-12-25	WOS:A1992HX16900026
J	BAUMGARTEN, LB; TOSCAS, K; VILLEREAL, ML				BAUMGARTEN, LB; TOSCAS, K; VILLEREAL, ML			DIHYDROPYRIDINE-SENSITIVE L-TYPE CA2+ CHANNELS IN HUMAN FORESKIN FIBROBLAST CELLS - CHARACTERIZATION OF ACTIVATION WITH THE GROWTH-FACTOR LYS-BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM CHANNELS; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; ACINAR-CELLS; ALPHA-1-SUBUNIT; ANTAGONISTS; MESSENGER; CURRENTS; RECEPTOR; INFLUX	We have previously characterized the calcium response of cultured human fibroblasts (HSWP cells) to stimulation by the mitogen Lys-bradykinin (BK). We have reported a biphasic response which includes a rapid rise to a peak that appears to result from mobilization of internal calcium, and a plateau phase, which is due to influx of external calcium (Byron, K., Babnigg, G., Villereal, M. L. (1992) J. Biol. Chem. 267, 108-118). In this paper we examine participation of L-type voltage operated calcium channels in the calcium entry phase of BK-stimulated HSWP cells. We show that there is an increase in Ca-45(2+) uptake and an increase in intracellular free calcium concentration ([Ca2+]i) as measured by fura-2, when HSWP cells are stimulated with the L-channel agonist Bay K 8644 under depolarizing conditions. Furthermore, both of these effects are inhibited by low doses of the dihydropyridine antagonist nitrendipine. We also report that BK stimulation of Ca-45(2+) uptake can be significantly inhibited by low doses of nitrendipine, while nitrendipine treatment has no effect on the BK-induced rise in [Ca2+]i, as measured by fura-2. These results suggest that under normal conditions the portion of the BK-stimulated Ca2+ influx which is mediated by a nitrendipine-sensitive entry pathway is invisible to the fura-2 technique used to measure [Ca2+]i. This suggests that the nitrendipine-sensitive influx pathway admits calcium preferentially into an intracellular store that is isolated from fura-2. This idea is supported by the observation that in media where calcium has been replaced by 2 mm Ba2+ nitrendipine inhibits most of the BK-stimulated Ba2+ influx.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR003322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151, R01GM028359] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR-03322] Funding Source: Medline; NIGMS NIH HHS [GM-28359, 5T32-GM-07151] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGAMASCHI S, 1990, EUR NEUROL, V30, P6; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; BYRON KL, 1990, THESIS U CHICAGO; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAZELTON BJ, 1981, BIOCHEM J, V194, P707, DOI 10.1042/bj1940707; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KWAN CY, 1990, J BIOL CHEM, V265, P678; LAI Y, 1990, J BIOL CHEM, V265, P20839; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MORTON ME, 1988, J BIOL CHEM, V263, P613; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; RENAUD JF, 1984, BIOCHEM BIOPH RES CO, V125, P405, DOI 10.1016/S0006-291X(84)80382-4; ROSENBERG RL, 1986, SCIENCE, V231, P1564, DOI 10.1126/science.2420007; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; TUANA BS, 1990, CAN J PHYSIOL PHARM, V68, P1482, DOI 10.1139/y90-225; VAGHY PL, 1987, AM J CARDIOL, V59, pA9, DOI 10.1016/0002-9149(87)90170-6; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; VILLEREAL ML, 1991, REV PHYSL BIOCH PHAR, V119, P67; VILVEN J, 1988, NATURE, V336, P587, DOI 10.1038/336587a0	28	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10524	10530						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375223				2022-12-25	WOS:A1992HV09000048
J	LOMBARDO, CR; WILLARDSON, BM; LOW, PS				LOMBARDO, CR; WILLARDSON, BM; LOW, PS			LOCALIZATION OF THE PROTEIN 4.1-BINDING SITE ON THE CYTOPLASMIC DOMAIN OF ERYTHROCYTE-MEMBRANE BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL-MEMBRANE; ANION-TRANSPORT PROTEIN; ANKYRIN-BINDING SITE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEREDITARY ELLIPTOCYTOSIS; EXCHANGE PROTEIN; GLYCOPHORIN-A; 4.1 BINDING; ASSOCIATION; SPECTRIN	Of the several proteins that bind along the cytoplasmic domain of erythrocyte membrane band 3, only the sites of interaction of proteins 4.1 and 4.2 remain to be at least partially localized. Using five independent techniques, we have undertaken to map and characterize the binding site of band 4.1 on band 3. First, transfer of a radioactive cross-linker (I-125-2-(p-azido-salicylamido) ethyl-1-3-dithiopropionate) from purified band 4.1 to its binding sites on stripped inside-out erythrocyte membrane vesicles (stripped IOVs) revealed major labeling of band 3, glycophorin C, and glycophorin A. Proteolytic mapping of the stripped IOVs then demonstrated that the label on band 3 was confined largely to a fragment comprising residues 1-201. Second, competitive binding experiments with Fab fragments of monoclonal and peptide-specific polyclonal antibodies to numerous epitopes along the cytoplasmic domain of band 3 displayed stoichiometric competition only with Fabs to epitopes between residues 1 and 91 of band 3. Weak competition was also observed with Fabs to a sequence of the cytoplasmic domain directly adjacent to the membrane-spanning domain, but only at 50-100-fold excess of Fab. Third, band 4.1 protected band 3 from chymotryptic hydrolysis at tyrosine 46 and to a much lesser extent at a site within the junctional peptide connecting the membrane-spanning and cytoplasmic domains of band 3. Fourth, ankyrin, which has been previously shown to interact with band 3 both near a putative central hinge and at the N terminus competed with band 4.1 for band 3 in stripped IOVs. Since band 4.1 does not associate with band 3 near the flexible central hinge, the competition with ankyrin can be assumed to derive from a mutual association with the N terminus. Finally, a synthetic peptide corresponding to residues 1-15 of band 3 was found to mildly inhibit band 4.1 binding to stripped IOVs. Taken together, these data suggest that band 4.1 binds band 3 predominantly near the N terminus, with a possible secondary site near the junction of the cytoplasmic domain and the membrane.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528; Willardson, Barry/0000-0002-8503-2268	NIGMS NIH HHS [GM 24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOISIO N, 1985, BLOOD, V65, P46; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANSTEE DJ, 1984, BIOCHEM J, V218, P615, DOI 10.1042/bj2180615; APPELL KC, 1981, J BIOL CHEM, V256, P1104; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; CHASIS JA, 1985, J CLIN INVEST, V75, P1919, DOI 10.1172/JCI111907; CHASIS JA, 1988, J CELL BIOL, V107, P1351, DOI 10.1083/jcb.107.4.1351; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; CONBOY J, 1986, NEW ENGL J MED, V315, P680, DOI 10.1056/NEJM198609113151105; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIS L, 1989, J BIOL CHEM, V264, P9665; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JINBU Y, 1984, BIOCHIM BIOPHYS ACTA, V773, P237, DOI 10.1016/0005-2736(84)90087-7; JOYL JC, 1990, BIOCHEMISTRY-US, V29, P8916; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KAY MMB, 1988, P NATL ACAD SCI USA, V85, P492, DOI 10.1073/pnas.85.2.492; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOMBARDO CR, 1990, J CELL BIOL, V111, P46; LOMBARDO CR, 1992, THESIS PURDUE U; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1991, BLOOD, V77, P1581; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MCGUIRE M, 1988, BLOOD, V72, P287; MORIYAMA R, 1989, ARCH BIOCHEM BIOPHYS, V274, P130, DOI 10.1016/0003-9861(89)90423-2; MORRISON M, 1985, BIOCHEMISTRY-US, V24, P6311, DOI 10.1021/bi00343a041; MUELLER TJ, 1981, ERYTHROCYTE MEMBRANE, V2, P95; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NIGG EA, 1980, BIOCHEMISTRY-US, V19, P1887, DOI 10.1021/bi00550a024; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PETRUCCI TC, 1991, BIOCHEMISTRY-US, V30, P413, DOI 10.1021/bi00216a016; PINDER JC, 1989, BIOCHEM J, V264, P423, DOI 10.1042/bj2640423; PRADHAN D, 1991, BIOCHEMISTRY-US, V30, P7754, DOI 10.1021/bi00245a012; RACHMILEWITZ EA, 1985, CLIN HAEMATOL, V14, P163; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; SEARS DA, 1975, J LAB CLIN MED, V86, P722; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI IH, 1982, J BIOL CHEM, V257, P1438; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WALDER JA, 1984, J BIOL CHEM, V259, P238; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WEINSTEIN RS, 1978, J SUPRAMOL STR CELL, V8, P325, DOI 10.1002/jss.400080310; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WILLARDSON BM, 1990, THESIS PURDUE U, V3	65	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9540	9546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374405				2022-12-25	WOS:A1992HT96500017
J	JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H				JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H			EXPRESSION OF TRUNCATED TRANSCRIPTS OF THE PROTOONCOGENE C-FPS/FES IN HUMAN LYMPHOMA AND LYMPHOID LEUKEMIA-CELL LINES	ONCOGENE			English	Article							FUJINAMI SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; HODGKINS-DISEASE; BURKITTS-LYMPHOMA; TRANSFORMING GENE; ANTIGEN RECEPTOR; TRANSGENIC MICE; FPS PROTEIN; DIFFERENTIATION	The human c-fps/fes proto-oncogene is expressed as a transcript of about 3.0 kb in both normal and leukemic myeloid cells. We have detected truncated c-fps/fes transcripts of about 0.9 kb in a panel of human lymphoma and lymphoid leukemia cell lines, but not in normal untransformed hematopoietic cells. Analysis of the chromatin structure of the c-fps/fes gene revealed DNAase I-hypersensitive sites in the 5' region of the gene and in exon 16. The presence and absence of these sites correlates with the expression of the 3.0 kb and 0.9 kb c-fps/fes RNAs respectively. The truncated transcripts initiate at two distinct sites within exon 16 of the c-fps/fes gene. The genomic region 5' to the transcription initiation sites is G + C rich but does not contain typical promoter consensus sequences. Sequence analysis of a cDNA clone of the truncated c-fps/fes transcripts did not reveal any point mutation and the truncated transcripts are normally spliced using the regular splice donor and acceptor sites. A putative open reading frame encompasses the phosphotransfer motif and the autophosphorylation site of the fps/fes kinase domain. In vitro transcription/translation of a cDNA clone corresponding to the truncated c-fps/fes transcripts revealed a protein of 17 kDa. There are no translocations or rearrangements in or around the c-fps/fes gene in cell lines which express the truncated c-fps/fes transcripts. This alternative transcription of c-fps/fes may indicate a novel activation process of this proto-oncogene.	UNIV COLOGNE,MED KLIN 1,JOSEPH STELZMANNSTR 9,W-5000 COLOGNE 41,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL SECT,B-3000 LOUVAIN,BELGIUM; GESELL STRAHLEN & UMWELTFORSCH MBH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED MOLEK BIOL,W-8000 MUNICH,GERMANY	University of Cologne; KU Leuven								ALCALAY M, 1990, ONCOGENE, V5, P267; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BERNHEIM A, 1983, CANCER GENET CYTOGEN, V8, P223, DOI 10.1016/0165-4608(83)90138-3; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DUBY AD, 1986, P NATL ACAD SCI USA, V83, P4890, DOI 10.1073/pnas.83.13.4890; DYNYN WS, 1983, CELL, V35, P79; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1980, CELL, V22, P757, DOI 10.1016/0092-8674(80)90552-8; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FONATSCH C, 1982, INT J CANCER, V30, P321, DOI 10.1002/ijc.2910300311; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GARDNER MB, 1970, NATURE, V226, P807, DOI 10.1038/226807a0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; JUCKER M, 1990, HEMATOL ONCOL, V8, P191, DOI 10.1002/hon.2900080404; Kamesaki H, 1989, Recent Results Cancer Res, V117, P83; KAMESAKI H, 1986, BLOOD, V68, P285; KOCH K, 1990, NUCLEIC ACIDS RES, V18, P5918, DOI 10.1093/nar/18.19.5918; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; MORAN MF, 1988, ONCOGENE, V3, P665; PARK M, 1986, CELL, V45, P95; PAULES RS, 1988, ONCOGENE, V3, P59; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROTH MS, 1988, BLOOD, V71, P1744; SADOWSKI I, 1987, ONCOGENE, V1, P181; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SAVELYEVA L, 1988, CANCER GENET CYTOGEN, V34, P63, DOI 10.1016/0165-4608(88)90170-7; SCHAADT M, 1988, Cancer Reviews, V10, P108; SCHWENK HU, 1975, BLUT, V31, P299, DOI 10.1007/BF01634146; SHACKELFORD DA, 1987, J IMMUNOL, V138, P613; SNYDER SP, 1969, NATURE, V221, P1074, DOI 10.1038/2211074a0; VANBOKHOVEN A, 1991, IN PRESS MOL BIOL RE; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER A, 1987, J CLIN CHEM CLIN BIO, V25, P578	61	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					943	952						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373879				2022-12-25	WOS:A1992HP64200014
J	NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E				NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E			ANALYSIS OF GENE AMPLIFICATION IN ARCHIVAL TISSUE BY DIFFERENTIAL POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; DNA AMPLIFICATION; INTERFERON GENE; EXPRESSION; CARCINOMA; SEQUENCE; ERBB-2	Oncogene amplification is found in many human tumors, and its detection may have important prognostic value. However, analysis of gene amplification may be hampered by inadequate tissue or poor DNA quality. We have previously described a polymerase chain reaction (PCR)-based procedure called differential PCR that can detect variations in gene dosage using miniscule amounts of tumor DNA [Frye, R.A., Benz, C.C. & Liu, E. (1989). Oncogene, 4, 1153-1157]. We now report the optimization of this technique for the analysis of oncogene amplification in paraffin-embedded archival tissues. We find that differential PCR is able to detect amplification of the HER2 (c-erbB-2) and the epidermal growth factor receptor (EGFR) genes and can be used to arrive at a semiquantitative estimate of gene dosage. Furthermore, our approach can determine gene amplification in samples in which the DNA is significantly degraded. Using differential PCR on paraffin-embedded tissues from cases previously investigated by standard DNA extraction and dot-blot procedures, good correlation between the two methods was found. Approaches are described to overcome technical problems posed by factors that affect the differential PCR, including the method of DNA extraction and extreme fragmentation of the DNA (< 200 base pairs). Furthermore, the resulting analytical algorithm reported herein has proved effective in detecting oncogene amplification in archival breast cancer specimens from standard pathology laboratories. Thus, differential PCR will be particularly helpful in the analysis of tumor specimens that are archived, small in size or rare in occurrence.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED & GENET, CB 7295, CHAPEL HILL, NC 27599 USA; DUKE UNIV, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University			Liu, Edison/C-4141-2008					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALLABIO A, 1990, HUM GENET, V84, P571; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; EHRLICH HA, 1989, PCR TECHNOLOGY; FRYE RA, 1989, ONCOGENE, V4, P1153; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; IGLEHART JD, 1990, CANCER RES, V50, P6701; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIU E, 1992, ONCOGENE, V7, P1027; Maniatis T., 1982, MOL CLONING; MIES C, 1991, AM J SURG PATHOL, V15, P169, DOI 10.1097/00000478-199102000-00010; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; OHNO S, 1982, NUCLEIC ACIDS RES, V10, P967, DOI 10.1093/nar/10.3.967; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHOU DJ, 1989, ONCOGENE, V4, P105	24	130	134	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1019	1025						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349162				2022-12-25	WOS:A1992HP64200025
J	HARTMAN, J; HUANG, Z; RADO, TA; PENG, SY; JILLING, T; MUCCIO, DD; SORSCHER, EJ				HARTMAN, J; HUANG, Z; RADO, TA; PENG, SY; JILLING, T; MUCCIO, DD; SORSCHER, EJ			RECOMBINANT SYNTHESIS, PURIFICATION, AND NUCLEOTIDE BINDING CHARACTERISTICS OF THE 1ST NUCLEOTIDE BINDING DOMAIN OF THE CYSTIC-FIBROSIS GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; IDENTIFICATION; TRANSPORT; PROTEINS	The majority of mutations which lead to clinical cystic fibrosis are located within the two predicted nucleotide binding domains of the cystic fibrosis gene product. We have used a prokaryotic expression system to synthesize and purify the first nucleotide binding domain (NBD-1, amino acids 426-588) with and without the most common mutation associated with the disease (the deletion of phenylalanine at position 508, DELTA-F508). Both wild type and DELTA-F508 NBD-1 bind ATP-agarose in a quantitatively comparable manner; this binding was inhibited by excess Na2ATP, trinitrophenol-ATP, or 8-azido-ATP. Irreversible NBD-1 labeling by an ATP analog was demonstrated using [P-32]8-azido-ATP. This covalent labeling was inhibited by preincubation with Na2ATP, with half-maximal inhibition for Na2ATP occurring at approximately 5 mM for both the wild type and DELTA-F508 nucleotide binding domain. These experiments are among the first to confirm the expectation that the cystic fibrosis transmembrane conductance regulator NBD-1 binds nucleotide. Since, under the conditions used in our study, NBD-1 without phenylalanine 508 displays very similar nucleotide binding characteristics to the wild type protein, our results support previous structural models which predict that the DELTA-F508 mutation should not cause an alteration in ATP binding.	UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Jilling, Tamas/0000-0002-6200-3851; Hartman, John/0000-0003-1176-6469; Sorscher, Eric J./0000-0001-9341-3354				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; HALEY B, 1988, BIOLINE ICN BIOCHEMI, V2, P6; HARTMAN J, 1991, PEDIATR PULMONOLOG S, V6, pA39; HUANG Z, 1991, LANCET, V337, P1115; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KAREM BS, 1990, P NATL ACAD SCI USA, V87, P8447; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	20	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6455	6458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372605				2022-12-25	WOS:A1992HM05300002
J	VONZASTROW, M; KOBILKA, BK				VONZASTROW, M; KOBILKA, BK			LIGAND-REGULATED INTERNALIZATION AND RECYCLING OF HUMAN BETA-2-ADRENERGIC RECEPTORS BETWEEN THE PLASMA-MEMBRANE AND ENDOSOMES CONTAINING TRANSFERRIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; DOWN-REGULATION; A431 CELLS; BINDING; PROTEINS; DESENSITIZATION; AGONIST; SEQUESTRATION; LOCALIZATION; RECOGNITION	Agonist-regulated redistribution of human beta-2-adrenergic receptors was examined in 293 cells. A specific antiserum recognizing the carboxyl-terminal hydrophilic domain of the receptor was developed, characterized, and used for immunocytochemical localization of receptors in fixed cells by conventional fluorescence and confocal fluorescence microscopy. The beta-adrenergic agonist isoproterenol induced redistribution of receptors from the surface of cells into small (< 1-mu-m diameter) punctate accumulations which were detected in cells within 2 min of agonist addition. The time course of receptor redistribution paralleled that of receptor sequestration measured by ligand binding, and receptor redistribution was reversible in the presence of the beta-adrenergic antagonist alprenolol. Optical sections imaged through cells by confocal microscopy localized receptor accumulations within the cytoplasm. To address the question of receptor internalization further, a mutant receptor possessing an engineered antigenic epitope in the amino-terminal hydrophilic domain was constructed, transfected into cells, and localized using both a monoclonal antibody recognizing the epitope tag (receptor ectodomain) and an antiserum recognizing the carboxyl terminus (receptor endodomain). In untreated cells most receptor antigen was detected at the cell surface, as assessed by accessibility to ectodomain antibodies in unpermeabilized specimens. In isoproterenol-treated cells, however, little receptor antigen was detected at the cell surface. Punctate receptor accumulations present in isoproterenol-treated cells were labeled by antibodies only following permeabilization of cells, as expected if these receptor accumulations were intracellular. Finally, internalized beta-adrenergic receptors colocalized with transferrin receptors, which are markers of endosomal membranes. These data provide several lines of evidence establishing that beta-adrenergic receptors undergo ligand-regulated internalization, they suggest that internalized receptors may be recycled back to the cell surface, and they provide the first direct indication that these processes involve the same endosomal membrane system passaged by constitutively recycling receptors.	STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT PSYCHIAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CARDIOVASC MED, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHUANG DM, 1979, P NATL ACAD SCI USA, V76, P3024, DOI 10.1073/pnas.76.6.3024; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; CLARK RB, 1985, J CYCLIC NUCL PROT, V10, P97; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; DOSS RC, 1981, J BIOL CHEM, V256, P2281; FREDERICK RC, 1985, J CELL BIOL, V29, P127; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HERTEL C, 1983, J CYCLIC NUCL PROT, V9, P119; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; KAVERI SV, 1987, EUR J BIOCHEM, V167, P449, DOI 10.1111/j.1432-1033.1987.tb13358.x; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; MARSHEMA I, 1980, MOL PHARMACOL, V18, P370; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; STILES GL, 1984, J BIOL CHEM, V259, P8655; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WOODS JW, 1989, EUR J CELL BIOL, V50, P132; ZEMCIK BA, 1988, BIOCHEM J, V251, P333, DOI 10.1042/bj2510333	41	328	338	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3530	3538						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371121				2022-12-25	WOS:A1992HD15400107
J	LINN, T; GREENBLATT, J				LINN, T; GREENBLATT, J			THE NUSA AND NUSG PROTEINS OF ESCHERICHIA-COLI INCREASE THE INVITRO READTHROUGH FREQUENCY OF A TRANSCRIPTIONAL ATTENUATOR PRECEDING THE GENE FOR THE BETA-SUBUNIT OF RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-DEPENDENT TERMINATION; BACTERIOPHAGE-LAMBDA; RIBOSOMAL-PROTEINS; NUCLEOTIDE-SEQUENCE; TRYPTOPHAN OPERON; MESSENGER-RNA; DNA; SITES; GROWTH; REGION	The genes for the beta (rpoB) and beta' (rpoC) subunits of Escherichia coli RNA polymerase are the distal members of a complex transcriptional unit that contains four upstream ribosomal protein genes. The RNA polymerase subunit genes are transcribed at a lower frequency than the ribosomal protein genes as a result of termination at an attenuator preceding rpoB. A purified in vitro transcription system was developed using linear DNA templates that carry the attenuator. The ability of known termination and antitermination proteins to modulate termination at the attenuator was tested. Both NusA and NusG increase the frequency of transcriptional readthrough at the attenuator whereas NusB, S10, and Rho had no significant effect in this system.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	LINN, T (corresponding author), UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON N6A 5C1,ONTARIO,CANADA.							AXELROD VD, 1978, NUCLEIC ACIDS RES, V10, P3549; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BARRY G, 1979, P NATL ACAD SCI USA, V76, P4922, DOI 10.1073/pnas.76.10.4922; BLUMENTHAL RM, 1980, J BACTERIOL, V142, P1049, DOI 10.1128/JB.142.3.1049-1054.1980; BRUCKNER R, 1981, MOL GEN GENET, V183, P277, DOI 10.1007/BF00270629; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; DAS A, 1976, MOL BASIS HOST VIRUS, P459; DENNIS PP, 1977, J MOL BIOL, V115, P603, DOI 10.1016/0022-2836(77)90105-X; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; FARNHAM PJ, 1982, CELL, V29, P945, DOI 10.1016/0092-8674(82)90457-3; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; GRAYHACK EJ, 1982, CELL, V51, P631; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; HAYWARD RS, 1978, MOL GEN GENET, V159, P89, DOI 10.1007/BF00401752; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; LITTLE DL, 1980, J BIOL CHEM, V255, P3536; MAHER DL, 1977, MOL GEN GENET, V155, P203, DOI 10.1007/BF00393161; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MORGAN BA, 1984, NUCLEIC ACIDS RES, V12, P5465, DOI 10.1093/nar/12.13.5465; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; NODWELL JR, 1991, IN PRESS GENES DEV; PEACOCK S, 1985, GENE, V33, P227, DOI 10.1016/0378-1119(85)90097-6; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; RALLING G, 1987, J BACTERIOL, V169, P2277, DOI 10.1128/jb.169.5.2277-2280.1987; RALLING G, 1984, J BACTERIOL, V158, P279, DOI 10.1128/JB.158.1.279-285.1984; RALLING G, 1985, MOL GEN GENET, V201, P379, DOI 10.1007/BF00331327; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Sambrook J, 1989, MOL CLONING LABORATO; SCAIFE J, 1976, RNA POLYMERASE, P207; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SIGMUND CD, 1988, BIOCHEMISTRY-US, V27, P5622, DOI 10.1021/bi00415a034; STEWARD KL, 1991, J MOL BIOL, V218, P23, DOI 10.1016/0022-2836(91)90870-C; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; TAYLOR WE, 1979, GENE, V6, P331, DOI 10.1016/0378-1119(79)90073-8; WARD DF, 1981, NATURE, V292, P212, DOI 10.1038/292212a0; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423; ZARUCKISCHULZ T, 1979, P NATL ACAD SCI USA, V76, P6115, DOI 10.1073/pnas.76.12.6115; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675	56	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1449	1454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370474				2022-12-25	WOS:A1992HA48500012
J	LI, XJ; WU, YN; NORTH, RA; FORTE, M				LI, XJ; WU, YN; NORTH, RA; FORTE, M			CLONING, FUNCTIONAL EXPRESSION, AND DEVELOPMENTAL REGULATION OF A NEUROPEPTIDE-Y RECEPTOR FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							I-125 PEPTIDE-YY; RAT-BRAIN; PANCREATIC-POLYPEPTIDE; BINDING SITES; K RECEPTOR; CDNA; NEURONS	Neuropeptide Y, peptide YY, and pancreatic polypeptide are homologous 36-amino acid peptides that differ from most other peptide transmitters by having a relatively rigid conformation in aqueous solutions, defined as the pancreatic polypeptide fold, and a critical C-terminal tyrosine amide. These peptides serve as gastrointestinal hormones and neurotransmitters. A cDNA encoding a novel G protein-coupled receptor activated by neuropeptide Y was cloned from Drosophila by use of degenerate oligonucleotide primers and polymerase chain reaction amplification of cDNA prepared from transcripts expressed early in embryogenesis. The cDNA encodes a protein of 449 amino acids with the characteristics of a G protein-coupled receptor and shares significant amino acid identity with mammalian tachykinin receptors. When expressed in Xenopus oocytes, the PR4 protein is activated by mammalian neuropeptides in the order: peptide YY > neuropeptide Y >> pancreatic polypeptide. Northern analysis showed that PR4 receptor is expressed at equivalent levels in adult Drosophila head and body and that the expression of the PR4 receptor is regulated during development. The molecular characterization of this receptor should lead to a better understanding of the functional role of this important family of hormone receptors in adult organisms and during development.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PHARMACOL, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022					CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FLOOD JF, 1987, BRAIN RES, V421, P280, DOI 10.1016/0006-8993(87)91297-2; HOKFELT T, 1983, NEUROSCI LETT, V29, P217; KINSON J, 1988, BRAIN RES, V446, P379; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; LUNDBERG JM, 1983, NEUROSCI LETT, V42, P167, DOI 10.1016/0304-3940(83)90401-9; LYNCH DR, 1989, J NEUROSCI, V9, P2607; MARTEL JC, 1990, NEUROSCIENCE, V36, P255, DOI 10.1016/0306-4522(90)90367-D; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; OTDONOHUE TL, 1985, PEPTIDES, V6, P755; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; SAUDOU F, 1990, EMBO J, V9, P3611, DOI 10.1002/j.1460-2075.1990.tb07572.x; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2514, DOI 10.1073/pnas.79.8.2514; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940; WOLFGANG W, 1991, IN PRESS DEVELOPMENT; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	26	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370455				2022-12-25	WOS:A1992GY43900003
J	ALAI, M; MUI, ALF; CUTLER, RL; BUSTELO, XR; BARBACID, M; KRYSTAL, G				ALAI, M; MUI, ALF; CUTLER, RL; BUSTELO, XR; BARBACID, M; KRYSTAL, G			STEEL FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF THE PROTOONCOGENE PRODUCT, P95(VAV), IN HUMAN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; GROWTH-FACTOR; KINASE RECEPTOR; W-LOCUS; VAV PROTOONCOGENE; PROTO-ONCOGENE; KIT LIGAND; SI-LOCUS; MOUSE; IDENTIFICATION	Steel factor (SF) (also called stem cell factor, mast cell growth factor, or c-kit ligand) is a recently cloned hemopoietic growth factor that is produced by bone marrow stromal cells, fibroblasts, and hepatocytes. In both mouse and man it acts synergistically with several colony stimulating factors, including interleukin-3 (IL-3) and granulocyte macrophage-colony stimulating factor (GM-CSF), to induce the proliferation and differentiation of primitive hemopoietic precursor cells. In order to study its mechanism of action and to explore the molecular basis for its synergistic activity we have examined the proteins that become tyrosine phosphorylated in response to SF, IL-3, and GM-CSF. We report herein that SF, but not IL-3 or GM-CSF, dramatically stimulates the tyrosine phosphorylation of the product of the recently discovered proto-oncogene, vav, in two SF-responsive human cell lines, M07E and TF-1. Although phosphorylation is very rapid, reaching maximal levels within 2 min at 37-degrees-C, co-immunoprecipitation studies suggest that c-kit may either not associate directly with p95vav or bind to it with very low affinity. Nonetheless, our data suggest that c-kit may utilize p95vav to mediate downstream signaling in hemopoietic cells.	BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,601 W 10TH AVE,VANCOUVER V5Z 1L3,BC,CANADA; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	British Columbia Cancer Agency; Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Krystal, Gerald/0000-0002-1961-6281				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1990, Experimental Hematology (Charlottesville), V18, P620; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KANAKURA Y, 1990, BLOOD, V76, P706; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5083; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGE B, 1987, BLOOD, V70, P192; LERNER NB, 1991, BLOOD, V77, P1876; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	137	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18021	18025						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381360				2022-12-25	WOS:A1992JM22300083
J	ASTROM, J; ASTROM, A; VIRTANEN, A				ASTROM, J; ASTROM, A; VIRTANEN, A			PROPERTIES OF A HELA CELL-3' EXONUCLEASE SPECIFIC FOR DEGRADING POLY(A) TAILS OF MAMMALIAN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL EXORIBONUCLEASE; BINDING-PROTEIN; RAT-LIVER; POLYADENYLATION; TRANSLATION; POLYMERASE; CLEAVAGE; SITE; DEADENYLATION; PURIFICATION	A HeLa cell 3'-exonuclease with properties of a mammalian mRNA poly(A) tail-removing enzyme has been characterized. The exonuclease shows high specificity for the poly(A) tail, and it is single strand-specific and requires a 3'-hydroxyl group for its activity. During degradation 5'-AMP is liberated as a product, and a 3'-OH group is left on the last adenosine residue of the remaining poly(A) tail. The activity is inhibited by 5'-AMP and can be competed by poly(A)-containing mRNA or poly(A). Based on these findings we propose a reaction pathway for poly(A) tail removal catalyzed by the HeLa cell poly(A) tail-specific 3' exonuclease.			ASTROM, J (corresponding author), UNIV UPPSALA, CTR BIOMED, DEPT MED GENET, BOX 589, S-75123 UPPSALA, SWEDEN.							ABRAHAM AK, 1978, P NATL ACAD SCI USA, V75, P2085, DOI 10.1073/pnas.75.5.2085; ABRAHAM AK, 1980, EUR J BIOCHEM, V110, P1, DOI 10.1111/j.1432-1033.1980.tb04836.x; ASTROM A, 1991, EUR J BIOCHEM, V202, P765, DOI 10.1111/j.1432-1033.1991.tb16431.x; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; FARNUM SM, 1990, GENE DEV, V4, P2278; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KUMAGAI H, 1985, BIOCHIM BIOPHYS ACTA, V827, P431, DOI 10.1016/0167-4838(85)90229-8; KUMAGAI H, 1979, BIOCHIM BIOPHYS ACTA, V566, P192, DOI 10.1016/0005-2744(79)90261-4; KWAN CN, 1977, BIOCHIM BIOPHYS ACTA, V479, P322, DOI 10.1016/0005-2787(77)90114-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARUS HM, 1967, P NATL ACAD SCI USA, V57, P1386, DOI 10.1073/pnas.57.5.1386; LAZARUS HM, 1968, P NATL ACAD SCI USA, V60, P1503, DOI 10.1073/pnas.60.4.1503; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; MULLER WE, 1980, H-S Z PHYSIOL CHEM, V361, P469; MULLER WEG, 1978, EUR J BIOCHEM, V86, P283, DOI 10.1111/j.1432-1033.1978.tb12309.x; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHRODER HC, 1980, J BIOL CHEM, V255, P4535; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SPORN MB, 1969, BIOCHEMISTRY-US, V8, P1698, DOI 10.1021/bi00832a053; TARUI Y, 1989, EUR J BIOCHEM, V186, P591, DOI 10.1111/j.1432-1033.1989.tb15249.x; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	34	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18154	18159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355481				2022-12-25	WOS:A1992JM22300103
J	DEGUCHI, T				DEGUCHI, T			SEQUENCES AND EXPRESSION OF ALLELES OF POLYMORPHIC ARYLAMINE N-ACETYLTRANSFERASE OF HUMAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION PHARMACOGENETICS; NUCLEOTIDE-SEQUENCE; SLOW ACETYLATION; CLONING; GENE; GENOTYPE; CELLS; CDNA; ACID	Fifty human livers obtained at autopsy were analyzed for N-acetyltransferase and classified into six genotypes. Determination of N-acetyltransferase activity and proteins from supernatants of liver homogenates indicate that genotype I corresponds to rapid acetylator, genotypes II and III to intermediate acetylator, and genotypes IV, V, and VI to slow acetylator phenotypes. Northern blot analysis shows that levels of mRNA for N-acetyltransferase in the livers do not markedly differ among the six genotypes. Three alleles of the N-acetyltransferase gene were cloned and sequenced. mRNA is coded in two exons. Comparison of alleles 2 and 3, which correspond to low N-acetyltransferase activity, with allele 1, which corresponds to high N-acetyltransferase activity, revealed several polymorphisms. Two gene sequence differences occur in the coding exons of alleles 2 and 3, one of which would produce different amino acids in the proteins. Those sequence differences that lead to amino acid substitutions result in a loss of BamHI and TaqI sites for alleles 2 and 3, respectively. Expression studies of the alleles in Chinese hamster ovary cells show that allele 1 expresses high levels of N-acetyltransferase activity and enzyme protein, while alleles 2 and 3 express low levels of both protein and activity.	TOKYO METROPOLITAN INST NEUROSCI,DEPT MOLEC NEUROBIOL,FUCHU,TOKYO 183,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								ABUZEID M, 1991, MOL CARCINOGEN, V4, P81, DOI 10.1002/mc.2940040112; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BLUM M, 1989, P NATL ACAD SCI USA, V86, P9554, DOI 10.1073/pnas.86.23.9554; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; EBISAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P1252, DOI 10.1016/0006-291X(91)90676-X; GRANT DM, 1989, NUCLEIC ACIDS RES, V17, P3978, DOI 10.1093/nar/17.10.3978; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HICKMAN D, 1991, BIOCHEM PHARMACOL, V42, P1007, DOI 10.1016/0006-2952(91)90282-A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTELL KJ, 1991, MOL PHARMACOL, V40, P218; MASHIMO M, 1992, IN PRESS HUMAN GENET; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; OHSAKO S, 1988, J BIOL CHEM, V263, P7534; OHTOMI M, 1989, EUR J BIOCHEM, V185, P253, DOI 10.1111/j.1432-1033.1989.tb15110.x; Sambrook J., 1989, MOL CLONING, P916; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; STAFFORD J, 1983, NATURE, V306, P77, DOI 10.1038/306077a0; SUNAHARA S, 1961, SCIENCE, V134, P1530, DOI 10.1126/science.134.3489.1530; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; WEBER WW, 1984, FED PROC, V43, P2332; WEBER WW, 1985, PHARMACOL REV, V37, P25	24	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18140	18147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381364				2022-12-25	WOS:A1992JM22300101
J	EPPLER, CM; ZYSK, JR; CORBETT, M; SHIEH, HM				EPPLER, CM; ZYSK, JR; CORBETT, M; SHIEH, HM			PURIFICATION OF A PITUITARY RECEPTOR FOR SOMATOSTATIN - THE UTILITY OF BIOTINYLATED SOMATOSTATIN ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NUCLEOTIDE-BINDING-PROTEIN; PERTUSSIS TOXIN BLOCKS; ANTERIOR-PITUITARY; AFFINITY-CHROMATOGRAPHY; INSULIN-RECEPTOR; CELL-LINE; D2-DOPAMINE RECEPTOR; POLYACRYLAMIDE GELS; ADENYLATE-CYCLASE	A somatostatin (SRIF) receptor and its associated G(i) regulatory proteins was purified from GH4C1 rat pituitary cells by: 1) saturation of the membrane-bound receptor with biotinyl-NH-[Leu8,D-Trp22,Tyr25] SRIF28 (bio-S28); 2) solubilization of receptor-ligand (R.L) complex with deoxycholate-lysophosphatidylcholine (D.L); 3) adsorption of solubilized receptor-ligand complex to immobilized streptavidin; and 4) elution of receptor and G-protein by GTP. The receptor, a glycoprotein with an average M(r) of 85,000, was then purified to substantial homogeneity on immobilized wheat germ agglutinin. The 85-kDa glycoprotein was identified as a SRIF receptor by several criteria. (a) It had the same size as the chemically cross-linked R.[I-125]L complex. (b) Yield of the purified protein increased and plateaued in the same range of bio-S28 concentrations where specific high affinity binding reached saturation. (c) It was copurified with appropriate G-protein subunits. The 85-kDa receptor and two other proteins with M(r) values of 35,000 and 40,000, the sizes of G(beta) and G(alpha), did not appear in eluates from control streptavidin columns done with SRIF receptors loaded with nonbiotinylated S14. The 40-kDa protein was identified as a G(i-alpha) by ADP-ribosylation from [P-32]NAD catalyzed by pertussis toxin. (d) Both the chemically cross-linked R.[I-125]L complex and SRIF receptor purified from [S-35]methionine-labeled GH4C1 cells were reduced in size to about 38 kDa by endoglycosidase F. (e) Amino acid sequence from the purified receptor was nearly identical with that of a recently cloned SRIF receptor subtype.			EPPLER, CM (corresponding author), AMER CYANAMID CO,DEPT BIOCHEM & PHYSIOL,DIV AGR RES,POB 400,PRINCETON,NJ 08540, USA.							AMHARDT M, 1987, J CLIN INVEST, V80, P1455; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLOOM SR, 1975, GUT, V16, P834; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRAZEAU P, 1972, SCIENCE, V129, P77; BRENNAN DP, 1987, J BIOL CHEM, V262, P14795; BROWN M, 1981, ENDOCRINOLOGY, V108, P2391, DOI 10.1210/endo-108-6-2391; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; CUBERO A, 1984, J BIOL CHEM, V259, P1344; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FINN FM, 1984, P NATL ACAD SCI-BIOL, V81, P7328, DOI 10.1073/pnas.81.23.7328; FINN FM, 1990, METHOD ENZYMOL, V184, P244; FISHMAN JB, 1987, J BIOL CHEM, V262, P14049; GHEBREHIWET B, 1988, J IMMUNOL METHODS, V110, P251, DOI 10.1016/0022-1759(88)90111-1; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAZUM E, 1986, J BIOL CHEM, V261, P3043; HE HT, 1989, P NATL ACAD SCI USA, V86, P1480, DOI 10.1073/pnas.86.5.1480; HE HT, 1990, MOL PHARMACOL, V37, P614; HEIMAN ML, 1987, NEUROENDOCRINOLOGY, V45, P429, DOI 10.1159/000124788; HOFFMAN K, 1976, P NATL ACAD SCI USA, V73, P3516; HULMES JD, 1992, BIOCHEM BIOPH RES CO, V184, P131, DOI 10.1016/0006-291X(92)91168-P; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; KNUHTSEN S, 1988, BIOCHEM J, V254, P641, DOI 10.1042/bj2540641; KNUHTSEN S, 1990, J BIOL CHEM, V265, P1129; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; KOHANSKI RA, 1985, J BIOL CHEM, V260, P5014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; LIMBURD LE, 1976, J BIOL CHEM, V252, P799; LOMASNEY JW, 1986, J BIOL CHEM, V261, P7710; MAGUIRE ME, 1976, MOL PHARMACOL, V12, P335; MARIE J, 1990, BIOCHEMISTRY-US, V29, P8943, DOI 10.1021/bi00490a009; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOREL A, 1983, J BIOL CHEM, V258, P8273; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; PATEL YC, 1986, ANNU REV PHYSIOL, V48, P551; PAUL S, 1986, PEPTIDES, V7, P147, DOI 10.1016/0196-9781(86)90177-4; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REGAN JW, 1986, J BIOL CHEM, V261, P3894; REISINE T, 1985, J PHARMACOL EXP THER, V235, P551; REISINE T, 1985, J PHARMACOL EXP THER, V232, P275; REISINE T, 1990, J PHARMACOL EXP THER, V254, P646; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; SENOGLES SE, 1988, J BIOL CHEM, V263, P18996; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHORR RGL, 1982, P NATL ACAD SCI-BIOL, V79, P2778, DOI 10.1073/pnas.79.9.2778; SRIKANT CB, 1981, NATURE, V294, P259, DOI 10.1038/294259a0; SRIKANT CB, 1981, ENDOCRINOLOGY, V108, P341, DOI 10.1210/endo-108-1-341; SZECOWKA J, 1989, REGUL PEPTIDES, V24, P215, DOI 10.1016/0167-0115(89)90218-8; THERMOS K, 1990, AM J PHYSIOL, V259, pE216, DOI 10.1152/ajpendo.1990.259.2.E216; TRAN VT, 1985, SCIENCE, V228, P492, DOI 10.1126/science.2858917; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WATSON S, 1990, TRENDS PHARM SCI S, V12, P1; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZEGGARI M, 1987, EUR J BIOCHEM, V164, P667, DOI 10.1111/j.1432-1033.1987.tb11178.x	69	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15603	15612						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353497				2022-12-25	WOS:A1992JG11300056
J	ALLAN, CM; FIDGE, NH; KANELLOS, J				ALLAN, CM; FIDGE, NH; KANELLOS, J			ANTIBODIES TO THE CARBOXYL TERMINUS OF HUMAN APOLIPOPROTEIN-A-I - THE PUTATIVE CELLULAR-BINDING DOMAIN OF HIGH-DENSITY LIPOPROTEIN-3 AND CARBOXYL-TERMINAL STRUCTURAL HOMOLOGY BETWEEN APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-A-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGEN-BROMIDE FRAGMENTS; MONOCLONAL-ANTIBODIES; APOA-I; IMMUNOCHEMICAL CHARACTERIZATION; CHOLESTEROL ACYLTRANSFERASE; PLASMA-MEMBRANES; RAT-LIVER; IDENTIFICATION; LOCALIZATION; EPITOPES	We have studied the binding of I-125-labeled high density lipoproteins (HDL3) to liver plasma membranes, which are thought to contain specific HDL receptor sites, using anti-peptide antibodies directed against two sites in the carboxyl-terminal region of human apoA-I. Two distinct antibody populations raised to peptides corresponding to amino acid residues 205-220 and 230-243, respectively, recognized regions of apoA-I that are exposed in the lipid environment of HDL3. However, anti-AI[230-243] IgG, but not anti-AI [205-220] IgG, recognized HDL2, suggesting that residues 205-220 of apoA-I are expressed differently in the two HDL populations. In addition, anti-AI[230-243] IgG showed strong cross-reactivity toward apoA-II. Epitope mapping studies showed that anti-AI[230-243] binds to an epitope located in the carboxyl-terminus of apoA-II, demonstrating significant structural homology between the carboxyl-terminal of apoA-II, demonstrating significant structural homology between the carboxyl-terminal regions of apoA-I and A-II, two candidate proteins for mediating the specific cellular interaction of HDL3. Fab fragments from anti-AI [205-220] and anti-AI[230-243] inhibited the binding of I-125-HDL3 to liver plasma membranes by approximately 80% and 60%, respectively. These findings are in agreement with our recent work using isolated CNBr fragments of apoA-I (Morrison, J., Fidge, N. H., and Tozuka, M. (1991) J. Biol. Chem. 266, 18780-18785), which suggest that the carboxyl-terminal region of apoA-I contains a binding domain which mediates the specific interaction of HDL3 with liver plasma membranes, possibly through the involvement of specific HDL receptors.			ALLAN, CM (corresponding author), BAKER MED RES INST,PROT CHEM & MOLEC BIOL UNIT,PRAHRAN,VIC 3181,AUSTRALIA.							ALLAN CM, 1991, J LIPID RES, V32, P595; BEKAERT ED, 1988, CLIN CHEM, V34, P1030; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1986, J BIOL CHEM, V261, P495; CHACKO GK, 1984, BIOCHIM BIOPHYS ACTA, V795, P417, DOI 10.1016/0005-2760(84)90093-6; CHACKO GK, 1987, J LIPID RES, V28, P332; CHACKO GK, 1982, BIOCHIM BIOPHYS ACTA, V712, P129, DOI 10.1016/0005-2760(82)90094-7; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; CURTISS LK, 1985, J BIOL CHEM, V260, P2982; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; EHNHOLM C, 1986, J LIPID RES, V27, P1259; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FIDGE N, 1989, BIOCHIM BIOPHYS ACTA, V1003, P84, DOI 10.1016/0005-2760(89)90103-3; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIDGE NH, 1974, CLIN CHIM ACTA, V52, P15, DOI 10.1016/0009-8981(74)90383-0; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; Fleischer S, 1974, Methods Enzymol, V31, P6; FONG BS, 1985, J CLIN INVEST, V75, P1804, DOI 10.1172/JCI111893; GORINI G, 1969, J IMMUNOL, V103, P1125; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZYK E, 1988, BIOCHIM BIOPHYS ACTA, V962, P131, DOI 10.1016/0005-2760(88)90104-X; HOEG JM, 1985, ARTERIOSCLEROSIS, V5, P228, DOI 10.1161/01.ATV.5.3.228; HOGLE DM, 1988, J LIPID RES, V29, P1221; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JACKSON RL, 1972, BIOCHIM BIOPHYS ACTA, V285, P36, DOI 10.1016/0005-2795(72)90178-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, J BIOL CHEM, V247, P7519; MACIEJKO JJ, 1983, NEW ENGL J MED, V309, P385, DOI 10.1056/NEJM198308183090701; MAO SJT, 1980, BIOCHIM BIOPHYS ACTA, V620, P447; MAO SJT, 1980, J BIOL CHEM, V255, P3448; MAO SJT, 1979, BIOCHEMISTRY-US, V18, P3984, DOI 10.1021/bi00585a022; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCOVINA S, 1990, J LIPID RES, V31, P375; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; MORRISON JR, 1989, CIRCULATION S2, V80, P455; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; PIO F, 1988, BIOCHIM BIOPHYS ACTA, V959, P160, DOI 10.1016/0005-2760(88)90027-6; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SCHONFELD G, 1977, J BIOL CHEM, V252, P6655; SILBERMAN SR, 1987, BIOCHEMISTRY-US, V26, P5833, DOI 10.1021/bi00392a038; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; SWANEY JB, 1980, J BIOL CHEM, V255, P877; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197	47	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13257	13261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377682				2022-12-25	WOS:A1992JB74600028
J	SCHAFER, BL; BISHOP, RW; KRATUNIS, VJ; KALINOWSKI, SS; MOSLEY, ST; GIBSON, KM; TANAKA, RD				SCHAFER, BL; BISHOP, RW; KRATUNIS, VJ; KALINOWSKI, SS; MOSLEY, ST; GIBSON, KM; TANAKA, RD			MOLECULAR-CLONING OF HUMAN MEVALONATE KINASE AND IDENTIFICATION OF A MISSENSE MUTATION IN THE GENETIC-DISEASE MEVALONIC ACIDURIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; HUMAN-FIBROBLASTS; ESCHERICHIA-COLI; INBORN ERROR; GAL OPERON; PROTEIN; REDUCTASE; CHOLESTEROL; SEQUENCE; TRANSCRIPTION	Mevalonic aciduria is the first proposed inherited disorder of the cholesterol/isoprene biosynthetic pathway in humans, and it is presumed to be caused by a mutation in the gene coding for mevalonate kinase. To elucidate the molecular basis of this inherited disorder, a 2.0-kilobase human mevalonate kinase cDNA clone was isolated and sequenced. The 1188-base pair open reading frame coded for a 396-amino acid polypeptide with a deduced M(r) of 42,450. The predicted protein sequence displayed similarity to those of galactokinase and the yeast RAR1 protein, indicating that they may belong to a common gene family. Southern hybridization studies demonstrated that the mevalonate kinase gene is located on human chomosome 12 and is a single copy gene. No major rearrangements were detected in the mevalonic aciduria subject. The relative size (2 kilobases) and amounts of human mevalonate kinase mRNA were not changed in mevalonic aciduria fibroblasts. Approximately half of the mevalonic aciduria cDNA clones encoding mevalonate kinase contained a single base substitution (A to C) in the coding region at nucleotide 902 that changed an asparagine residue to a threonine residue. The presence of this missense mutation was confirmed by polymerase chain reaction amplification and allele-specific hybridization of the genomic DNAs from the proband and the proband's father and brother. Similar analysis failed to detect this mutation in the proband's mother, seven normal subjects, or four additional mevalonic aciduria subjects, indicating that the mutation does not represent a common gene polymorphism. Functional analysis of the defect by transient expression confirmed that the mutation produced an enzyme with diminished activity. Our data suggest that the index case is a compound heterozygote for a mutation in the mevalonate kinase gene.	BAYLOR UNIV,MED CTR,KIMBERLY H COURTWRIGHT & JOSEPH W SUMMERS METAB DIS CTR,DALLAS,TX 75246	Baylor University; Baylor University Medical Center	SCHAFER, BL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT METAB DIS,POB 400,PRINCETON,NJ 08543, USA.			Bishop, Richard/0000-0002-3965-7478				ADAMS CW, 1988, J BACTERIOL, V170, P203, DOI 10.1128/jb.170.1.203-212.1988; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARGOS P, 1985, EUR J BIOCHEM, V152, P651, DOI 10.1111/j.1432-1033.1985.tb09244.x; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; BHAT PJ, 1990, GENETICS, V125, P281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1980, J LIPID RES, V21, P505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRON BA, 1984, J BACTERIOL, V158, P269, DOI 10.1128/JB.158.1.269-278.1984; DEBOUCK C, 1985, NUCLEIC ACIDS RES, V13, P1841, DOI 10.1093/nar/13.6.1841; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GIBSON KM, 1990, J LIPID RES, V31, P515; GIBSON KM, 1989, BAYLOR U MED CTR P, V2, P15; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; KEARSEY SE, 1987, MOL GEN GENET, V210, P509, DOI 10.1007/BF00327205; KOZICH V, 1991, J INHERIT METAB DIS, V14, P265, DOI 10.1007/BF01800602; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD S, 1986, P NATL ACAD SCI USA, V83, P2187, DOI 10.1073/pnas.83.7.2187; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; MOHANDAS T, 1986, SOMAT CELL MOLEC GEN, V12, P89, DOI 10.1007/BF01560731; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; PORTER JW, 1985, METHOD ENZYMOL, V110, P71; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8192, DOI 10.1093/nar/16.16.8192	36	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13229	13238						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377680				2022-12-25	WOS:A1992JB74600024
J	DECKERSHEBESTREIT, G; SIMONI, RD; ALTENDORF, K				DECKERSHEBESTREIT, G; SIMONI, RD; ALTENDORF, K			INFLUENCE OF SUBUNIT-SPECIFIC ANTIBODIES ON THE ACTIVITY OF THE F0 COMPLEX OF THE ATP SYNTHASE OF ESCHERICHIA-COLI .1. EFFECTS OF SUBUNIT B-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; POLAR LOOP REGION; H+-ATPASE; UNCF-PROTEIN; MEMBRANE; F1F0; RECONSTITUTION; PREDICTION; F-0; PURIFICATION	Incubation of F1-stripped everted membrane vesicles with antibodies against subunit b of the ATP synthase from Escherichia coli resulted in an inhibition of the binding of F1 to F0, whereas the proton translocation remained unaffected. Incubation of unstripped everted membrane vesicles with anti-b antibodies resulted in a partial loss of F1, and the remaining membrane-bound ATP-hydrolyzing activity is uncoupled from proton translocation. Similar results were obtained when F(ab')2 or Fab fragments were used. The immunoblot analysis of truncated b' subunits different in length showed that the antigenic determinants are located in the carboxyl-terminal half of the polypeptide chain.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University	DECKERSHEBESTREIT, G (corresponding author), UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY.							ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; BERZBORN RJ, 1990, Z NATURFORSCH C, V45, P772; BIRD CR, 1985, EMBO J, V4, P1381, DOI 10.1002/j.1460-2075.1985.tb03790.x; CURTIS SE, 1988, PHOTOSYNTH RES, V18, P223, DOI 10.1007/BF00042986; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12370; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Douglas M, 1979, Methods Enzymol, V56, P58; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRIEDL P, 1983, EMBO J, V2, P99, DOI 10.1002/j.1460-2075.1983.tb01388.x; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; HEMROLIN J, 1983, J BIOL CHEM, V258, P14550; HENSEL M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P63, DOI 10.1016/0005-2728(90)90007-Q; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOPPE J, 1983, J BIOL CHEM, V258, P2882; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LOO TW, 1982, BIOCHEM BIOPH RES CO, V106, P400, DOI 10.1016/0006-291X(82)91124-X; Maniatis T., 1982, MOL CLONING; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; OTTO J, 1989, FEBS LETT, V250, P625, DOI 10.1016/0014-5793(89)80810-5; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; ROOS P, 1983, Z NATURFORSCH C, V38, P799; SCHNEIDER E, 1985, EUR J BIOCHEM, V153, P105, DOI 10.1111/j.1432-1033.1985.tb09274.x; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STEFFENS K, 1982, FEBS LETT, V142, P151, DOI 10.1016/0014-5793(82)80240-8; STEFFENS K, 1987, J BIOL CHEM, V262, P6334; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12364	12369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376322				2022-12-25	WOS:A1992HY94700106
J	KOST, C; STUBER, W; EHRLICH, HJ; PANNEKOEK, H; PREISSNER, KT				KOST, C; STUBER, W; EHRLICH, HJ; PANNEKOEK, H; PREISSNER, KT			MAPPING OF BINDING-SITES FOR HEPARIN, PLASMINOGEN-ACTIVATOR INHIBITOR-1, AND PLASMINOGEN TO VITRONECTINS HEPARIN-BINDING REGION REVEALS A NOVEL VITRONECTIN-DEPENDENT FEEDBACK MECHANISM FOR THE CONTROL OF PLASMIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; ANTITHROMBIN-III; AFFINITY-CHROMATOGRAPHY; STRUCTURAL REQUIREMENTS; MONOCLONAL-ANTIBODIES; IDENTIFICATION; PURIFICATION; COMPLEMENT	Vitronectin (VN) has been implicated as a major matrix-associated regulator component of plasminogen activation by serving as a potent stabilizing cofactor of plasminogen activator inhibitor-1 (PAI-1). The direct binding of heparin, plasminogen as well as PAI-1 in its latent and active form to immobilized VN was studied in the absence or presence of competitors. Monoclonal antibodies against the carboxyl-terminal portion of VN inhibited both PAI-1 and plasminogen binding, whereas heparin, heparan sulfate with a high degree of sulfation, or dextran sulfate interfered with PAI-1 binding (K(D) = 20 nM) only. Utilizing synthetic peptides encompassing overlapping sequences of the heparin-binding domain of VN, adjacent heparin and PAI-1-binding sites were localized within the sequence 348-370 of VN. Although a number of other serine protease inhibitors which do not form binary complexes with VN contain a reactive-site Ser at their P1'-position, a reactive-site P1' mutant of PAI-1 (Met --> Ser) showed comparable if not increased binding to VN. Binding of Lys-plasminogen and active-site-blocked plasmin was at least 10-fold higher in affinity (K(D) = 85-100 nM) compared to Glu-plasminogen (K(D) approximately 1-mu-M) and could be inhibited by lysine analogs but not by glycosaminoglycans or PAI-1, indicating that heteropolar plasmin(ogen) binding of VN occurs to an adjacent segment upstream to the heparin and PAI-1-binding sites. This contention was further supported in binding studies with plasmin-modified VN which lost both heparin and PAI-1 binding but exhibited 2-3-fold higher capacity to bind plasminogen. The essential plasmin(ogen)-binding site was mapped by ligand blot analysis to the carboxyl-terminal portion of proteolytically trimmed VN (M(r) = 61,000). Moreover, treatment of the extracellular matrix of human umbilical vein endothelial cells with plasmin resulted in partial degradation of matrix-associated VN and concomitant release of PAI-1, but increased the ability of the matrix by about 2-fold to bind plasminogen. These results are indicative of differential interactions of VN with components of the plasminogen activation system, whereby plasmin itself may provoke the switch of VN from an anti-fibrinolytic into a pro-fibrinolytic cofactor. This process reflects a novel role for the adhesive protein and its degradation product(s) in the possible feedback regulation of localized plasmin formation at extracellular sites.	MAX PLANCK INST PHYSIOL & CLIN RES, KERCKHOFF KLIN, HAEMOSTASIS RES UNIT, SPRUDELHOF 11, W-6350 BAD NAUHEIM, GERMANY; BEHRINGWERKE AG, RES LABS, W-3550 MARBURG, GERMANY; CLB, DEPT MOLEC BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Kerckhoff Clinic; Max Planck Society								BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BREIPOHL G, 1989, INT J PEPT PROT RES, V34, P262; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; HAMILTON KK, 1985, J CLIN INVEST, V76, P261, DOI 10.1172/JCI111956; HATTEY E, 1987, THROMB RES, V45, P485, DOI 10.1016/0049-3848(87)90311-2; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JORGENSEN AM, 1985, BIOCHEM J, V231, P59, DOI 10.1042/bj2310059; KLAGSBRUN M, 1987, METHOD ENZYMOL, V147, P95; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LANE DA, 1987, J BIOL CHEM, V262, P16343; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; NOE G, 1988, J BIOL CHEM, V263, P11729; PODACK ER, 1979, J BIOL CHEM, V254, P9908; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1990, NEW TRENDS HAEMOSTAS, P135; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STACK MS, 1991, THROMB HAEMOSTASIS, V65, P722; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WIMAN B, 1990, SEMIN THROMB HEMOST, V16, P207, DOI 10.1055/s-2007-1002671	56	133	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12098	12105						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376317				2022-12-25	WOS:A1992HY94700069
J	LUDWIG, T; RUTHER, U; METZGER, R; COPELAND, NG; JENKINS, NA; LOBEL, P; HOFLACK, B				LUDWIG, T; RUTHER, U; METZGER, R; COPELAND, NG; JENKINS, NA; LOBEL, P; HOFLACK, B			GENE AND PSEUDOGENE OF THE MOUSE CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - GENOMIC ORGANIZATION, EXPRESSION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; ALPHA-AMYLASE GENE; TRANSCRIPTION FACTOR; LYSOSOMAL-ENZYMES; BINDING-PROTEIN; CELLS; CLONING; SEQUENCES; CDNA; RNA	The cation-dependent mannose 6-phosphate receptor (CD-MPR) is one of the two transmembrane proteins involved in transport of lysosomal enzymes. We have cloned the mouse CD-MPR gene and also a very unusual processed-type CD-MPR pseudogene. They are both present at one copy per haploid genome and map to chromosomes 6 and 3, respectively. Comparison of the complete 10-kilobase (kb) sequence of the functional gene with the cDNA indicates that it contains seven exons. Exon 1 encodes the 5'-untranslated region of the mRNA, the others (exons 2-7) encode the luminal, transmembrane, and cytoplasmic domains of the CD-MPR. Exon 7 also contains a 1.2-kb-long 3'-untranslated region of the mRNA. A unique transcription-initiation site was determined by primer extension of mouse liver mRNA. The promoter elements in the 5' upstream region of this site resemble those contained in genes constitutively transcribed. However, Northern blot analysis demonstrates that the CD-MPR is variably expressed in adult mouse tissues and during mouse development. The pseudogene, which is flanked by direct repeats, is almost colinear with the cDNA indicating that it presumably arose by reverse transcription of an mRNA. However, the pseudogene differs from the cDNA. It contains at its 5' end, an additional 340-nucleotide (nt) sequence homologous to the promoter region of the functional gene. This sequence exhibits some promoter activity in vitro. Furthermore, a 24-nt insertion interrupts the region homologous to the 5'-noncoding region of the cDNA. In the functional gene, this 24-nt sequence occurs between exon 1 and 2, where it is flanked by typical consensus sequences of exon/intron boundaries. Therefore, it may represent an additional exon of the functional gene. These two features of the pseudogene suggest that expression of the CD-MPR gene may be regulated by use of different promoters and/or alternative splicing.	UNIV HEIDELBERG, DEPT PHARMACOL, W-6900 HEIDELBERG, GERMANY; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, FREDERICK, MD 21701 USA; CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; UNIV MED & DENT NEW JERSEY, PISCATAWAY, NJ 08854 USA	Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick; Rutgers State University Medical Center	LUDWIG, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, POSTFACH 102209, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Ludwig, Thomas/Q-6484-2016; HOFLACK, Bernard/AAZ-6668-2020	Ludwig, Thomas/0000-0003-3461-2585; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Green EL, 1981, GENETICS PROBABILITY, P77; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HOGAN A, 1991, DEVELOPMENT, V113, P363; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KLIER HJ, 1991, EUR J BIOCHEM, V197, P23, DOI 10.1111/j.1432-1033.1991.tb15877.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA ZM, 1991, J BIOL CHEM, V266, P10589; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; OZAWA K, 1988, J BIOL CHEM, V263, P10922; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SKLAR MM, 1989, J BIOL CHEM, V264, P16733; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1988, J BIOL CHEM, V263, P2585; TOSI M, 1981, NUCLEIC ACIDS RES, V9, P2313, DOI 10.1093/nar/9.10.2313; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	49	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12211	12219						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376319				2022-12-25	WOS:A1992HY94700084
J	LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C				LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C			THE HER2 (C-ERBB-2) ONCOGENE IS FREQUENTLY AMPLIFIED IN INSITU CARCINOMAS OF THE BREAST	ONCOGENE			English	Note							SURGICAL ADJUVANT BREAST; PROTEIN OVEREXPRESSION; CANCER; AMPLIFICATION; EXPRESSION; SURVIVAL; PROJECT; GENE	Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. Gene amplification detected in these archival tissues by differential polymerase chain reaction (PCR) was found in 48% of in situ carcinomas and in 21% of stage II lesions (chi(2) = 7.62, p less-than-or-equal-to 0.01). In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less-than-or-equal-to 0.025) and stage II cancers (p less-than-or-equal-to 0.0005). This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.	UNIV CALIF SAN FRANCISCO,CANC RES INST,M-1283,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; UNIV N CAROLINA,DEPT MED,CURRICULUM GENET,CHAPEL HILL,NC 27599; ROSWELL PK CANC INST,DEPT PATHOL,BUFFALO,NY; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; Roswell Park Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [U10CA037055, P01CA044768, U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [5U10-CA31946-08, 5U10-CA37055-08, P01 CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; BRESEN AL, 1990, BRIT J CANCER, V62, P585; CLARK GM, 1991, CANCER RES, V51, P944; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FRYE RA, 1989, ONCOGENE, V4, P1153; HANNA W, 1990, MODERN PATHOL, V3, P455; IGLEHART JD, 1990, CANCER RES, V50, P6701; LODATO RF, 1990, MODERN PATHOL, V3, P449; NEUBAUER A, 1992, ONCOGENE, V7, P1019; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; ROGERS LW, 1989, DIAGNOSTIC HISTOPATH; RUSSO J, 1990, LAB INVEST, V62, P244; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SESHADRI R, 1989, INT J CANCER, V43, P270, DOI 10.1002/ijc.2910430218; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1989, INT J CANCER, V43, P270; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOR AD, 1989, CANCER RES, V49, P7147; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902	24	193	205	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1027	1032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349163				2022-12-25	WOS:A1992HP64200026
J	MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B				MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B			MUTATIONS OF THE P53 GENE IN HUMAN MYELOMA CELL-LINES	ONCOGENE			English	Note							MULTIPLE-MYELOMA; GROWTH; INTERLEUKIN-6; EVOLUTION; LEUKEMIA; PROTEIN	Mutations affecting the p53 gene have been found associated with many human malignancies, but little is as yet known about multile myeloma. We investigated p53 gene alterations in 10 human myeloma cell lines (HMCL), half of these being dependent upon exogenous interleukin 6(IL-6) for in vitro growth, similar to freshly explanted myeloma cells. Using a polymerase chain reaction - single-strand conformation polymorphism (PCR-SSCP) approach, eight of the 10 HMCL were found to bear a mutated p53 gene. All the mutations were single base substitutions with a predominance of G:C to A:T transitions. There was no apparent relation between the presence of a mutation and IL-6 requirement of the cell line. Interestingly, in two cell lines (XG-2 and XG-4) the SSCP pattern showed the presence of both the wild-type and the mutated allele and, upon reverse PCR on RNA, both alleles were found to be concomitantly expressed at the RNA level. Moreover, three freshly explanted tumor samples had the same p53 gene status (mutated versus wild type) as the HMCL that were derived from them. These results show that p53 mutations are frequent in HMCL. Although no apparent relation could be evidenced with the loss of exogenous IL-6 requirement, it may prove interesting to investigate further potential relations between the presence of a mutated p53 allele and gradual autonomy for cell growth.	INSERM,U291,99 RUE PUECH VILLA,F-34100 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34094 MONTPELLIER 5,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,CONSULAT IMMUNORHUMATOL,F-34059 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; DURIE BGM, 1985, BLOOD, V66, P548; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAMILTON MS, 1990, BRIT J HAEMATOL, V75, P378, DOI 10.1111/j.1365-2141.1990.tb04352.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 1990, Eur Cytokine Netw, V1, P193; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOORE GE, 1968, NEW YORK STATE J MED, V68, P2054; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P447; PALUMBO AP, 1989, CANCER RES, V49, P4701; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J., 1989, MOL CLONING; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SNATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG XG, 1989, BLOOD, V74, P11	30	97	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1015	1018						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373872				2022-12-25	WOS:A1992HP64200024
J	LOEB, KR; HAAS, AL				LOEB, KR; HAAS, AL			THE INTERFERON-INDUCIBLE 15-KDA UBIQUITIN HOMOLOG CONJUGATES TO INTRACELLULAR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PURIFICATION; EXPRESSION; CELLS; PROTEOLYSIS; DEGRADATION; PRECURSOR; CLONING	We have previously identified a 15-kDa interferon-induced protein that is recognized by affinity-purified rabbit polyclonal antibodies against ubiquitin (Haas, A. L., Ahrens, P., Bright, P. M., and Ankel, H. (1987) J. Biol. Chem. 262, 11315-11323). This ubiquitin cross-reactive protein (UCRP) possesses significant homology to a tandem diubiquitin sequence. Since the biological effects of ubiquitin arise from its covalent ligation to intracellular target proteins, we hypothesized that the multiple cellular responses to interferon are mediated in part by an analogous conjugation pathway for UCRP. Rabbit polyclonal antibodies specific for UCRP were prepared against homogeneous recombinant protein. Affinity-purified anti-UCRP antibodies detected the induction of UCRP in interferon-beta-treated A549 cells and recognized a group of high molecular weight UCRP conjugates on immunoblots of sodium dodecyl sulfate-polyacrylamide gel electrophoresis-resolved cell extracts. Both free and conjugated UCRP are constitutively present at low levels in untreated cells, suggesting a role for UCRP ligation in normal cellular regulation, and significantly accumulate following interferon treatment. The temporal induction of free UCRP following interferon treatment preceded a delayed increase in UCRP conjugates. Treatment of A549 cells with type I interferons (alpha and beta) strongly induced the expression of free and conjugated UCRP, whereas the response to type 11 interferon (gamma) was significantly less. A survey of selected cultured cell lines showed differential induction of free versus conjugated UCRP pools in response to interferon. Interferon-beta treatment of A549, MG63, and U937 cells induced high levels of both free and conjugated UCRP, whereas only free UCRP levels increased in Daudi, Namalwa, and K562 cells. These results confirm that UCRP represents a functional ubiquitin homolog participating in a parallel pathway of post-translational ligation and provides a novel mechanism for the response of susceptible cells to the effects of interferon exposure.	MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRENS PB, 1990, J GEN VIROL, V71, P1674; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BOND U, 1988, J BIOL CHEM, V263, P2386; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; EVANS T, 1984, EMBO J, V3, P2975, DOI 10.1002/j.1460-2075.1984.tb02243.x; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; FELTHAM N, 1989, J INTERFERON RES, V9, P493, DOI 10.1089/jir.1989.9.493; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, CURRENT COMMUNICATIO, P178; HAAS AL, 1988, UBIQUITIN, P73; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HOUGH R, 1986, J BIOL CHEM, V261, P2391; KNIGHT E, 1988, J BIOL CHEM, V263, P4520; KNIGHT E, 1991, J IMMUNOL, V46, P2280; KORANT BD, 1984, J BIOL CHEM, V259, P14859; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; MAYER EM, 1987, J NEUROCHEM, V49, P1815; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RECHSTEINER M, 1988, UBIQITIN; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P116; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WEST MHP, 1980, NUCLEIC ACIDS RES, V8, P4671, DOI 10.1093/nar/8.20.4671; WILKINSON KD, 1981, J BIOL CHEM, V256, P9234	35	323	340	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7806	7813						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373138				2022-12-25	WOS:A1992HN48500085
J	KAUMAYA, PTP; VANBUSKIRK, AM; GOLDBERG, E; PIERCE, SK				KAUMAYA, PTP; VANBUSKIRK, AM; GOLDBERG, E; PIERCE, SK			DESIGN AND IMMUNOLOGICAL PROPERTIES OF TOPOGRAPHIC IMMUNOGENIC DETERMINANTS OF A PROTEIN ANTIGEN (LDH-C4) AS VACCINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SYNTHETIC PEPTIDES; LACTATE DEHYDROGENASE-C4; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; ANTIBODY; COMPLEX; SITES; RESOLUTION; SEQUENCE	Antibodies elicited by immunization with short peptides containing antigenic determinants have been shown, in general, to bind with greatly reduced affinity to the corresponding region in the native proteins. Thus, contiguous linear peptides have not proven to be effective immunogens in generating high affinity neutralizing or protective antibodies and consequently appear to be poor prospects for vaccines. The molecular basis for such reduced reactivity is clear from the crystal structure determination of antibody Fabs bound to protein antigens, which showed the complementarity between interfaces to be lock-and-key-like and extending over a large area (750 angstrom2) involving discontinuous segments of the polypeptide chain. Thus, small perturbations in the secondary and tertiary structure of the antigen have profound effects on the fit of the antigen and its corresponding antibody. Because short peptides are unlikely to assume any particular conformation in solution, the fit is likely to be poor. New strategies are therefore required to produce conformationally stable peptides that mimic the critical structural features of the protein antigenic site. Here we show that a putative topographic determinant of the testis-specific isozyme of lactate dehydrogenase C4 (LDH-C4), designed and synthesized to adopt a well defined alpha-helical secondary and tertiary structure (four-helix bundle motif) in aqueous solutions, is highly immunogenic in both rabbits and mice, inducing IgG antibodies that bind to native LDH-C4. This engineered conformational 40-residue peptide is considerably more effective in inducing antibodies, as compared with the corresponding linear peptide. The antibody response is obtained without coupling the peptide to a carrier protein, suggesting that the peptide contains a T-cell antigenic determinant. The strategy described here to produce a conformationally stable peptide that mimics the native structure may have general applications in vaccine design.	OHIO STATE UNIV,COLL MED,DEPT OBSTET & GYNECOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED BIOCHEM,COLUMBUS,OH 43210; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,EVANSTON,IL 60201	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Northwestern University	KAUMAYA, PTP (corresponding author), OHIO STATE UNIV,COLL MED,CTR COMPREHENS CANC,SUITE 302,410 W 12TH AVE,COLUMBUS,OH 43210, USA.		Kaumaya, Pravin T. P/E-3354-2011		NIAID NIH HHS [AI25790] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025790] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BORRASCUESTA F, 1988, EUR J IMMUNOL, V18, P199, DOI 10.1002/eji.1830180203; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DRYBERG T, 1986, J EXP MED, V164, P1344; DYSON HJ, 1985, NATURE, V318, P480; EFIMOV AV, 1984, FEBS LETT, V166, P33, DOI 10.1016/0014-5793(84)80039-3; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FRANCIS MJ, 1987, NATURE, V330, P168, DOI 10.1038/330168a0; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; GOLDBERG E, 1981, FERTIL STERIL, V35, P214; GOLDBERG E, 1908, ISOZYES CURRENT TOPI, V14, P103; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOGREFE HH, 1987, J BIOL CHEM, V262, P13155; HOGREFE HH, 1989, J BIOL CHEM, V264, P10513; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JEMMERSON R, 1990, EUR J IMMUNOL, V20, P579, DOI 10.1002/eji.1830200318; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KAUMAYA PTP, 1991, PEPTIDES 1990, P611; KAUMAYA PTP, 1990, PEPTIDES CHEM STRUCT, P709; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LAU SY, 1984, J BIOL CHEM, V239, P13253; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MULLER S, 1990, VACCINE, V8, P308, DOI 10.1016/0264-410X(90)90086-2; MUTTER M, 1986, Z NATURFORSCH B, V41, P1315, DOI 10.1515/znb-1986-1020; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMOLENSKI LA, 1990, EUR J IMMUNOL, V20, P953, DOI 10.1002/eji.1830200502; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWARD MW, 1987, IMMUNOL TODAY, V8, P51, DOI 10.1016/0167-5699(87)90239-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TULIP WR, 1989, COLD SH Q B, V54, P257; VANREGENMORTEL MHV, 1987, TRENDS BIOCHEM SCI, V12, P237, DOI 10.1016/0968-0004(87)90117-4	44	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6338	6346						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372905				2022-12-25	WOS:A1992HK31800092
J	IRONS, CE; SEI, CA; HIDAKA, H; GLEMBOTSKI, CC				IRONS, CE; SEI, CA; HIDAKA, H; GLEMBOTSKI, CC			PROTEIN-KINASE-C AND CALMODULIN KINASE ARE REQUIRED FOR ENDOTHELIN-STIMULATED ATRIAL-NATRIURETIC-FACTOR SECRETION FROM PRIMARY ATRIAL MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE SECRETION; VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; RAT CARDIOCYTES; PHORBOL ESTERS; GROWTH-FACTORS; CELLS; EXPRESSION; CALCIUM; RELEASE	Endothelin (ET), a potent stimulator of atrial natriuretic factor (ANF) secretion in atrial myocyte cultures, has been hypothesized to act via the stimulation of protein kinase C (PKC). This study was carried out in order to determine if ET activates PKC in atrial cultures and whether this activation fully accounts for the effects of ET on ANF secretion. By monitoring the phosphorylation of p80 upon exposure to phorbol ester or ET, it was shown that ET activated PKC in atrial cultures, but to a lesser extent than phorbol ester. In contrast, ET stimulated ANF secretion to a level five times greater than phorbol ester, indicating that PKC activation alone does not fully account for the effects of ET on ANF secretion. Down-regulation of PKC or exposure to the PKC inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H7) resulted in a 50% decrease in ET-stimulated ANF secretion. Interestingly, increasing calcium influx with BAY K 8644 stimulated ANF secretion but did not effect the phosphorylation of p80, indicating a PKC-independent pathway of ANF secretion. Similarly, a component of ET-stimulated secretion that required calcium influx was independent of PKC activation but was sensitive to the Ca2+/calmodulin kinase (CaMK) inhibitor KN-62. Complete inhibition of ET-mediated ANF secretion was obtained only in the presence of both H7 and KN-62. These results demonstrate that ET activates PKC in atrial myocyte cultures and that the full effects of ET on ANF secretion require both PKC and Ca2+/calmodulin kinase activities.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN	California State University System; San Diego State University; California State University System; San Diego State University; Nagoya University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERS DM, 1991, EXCITATION CONTRACTI, P143; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; ETSCHEID BG, 1991, CELL REGUL, V2, P229, DOI 10.1091/mbc.2.3.229; FABIATO A, 1986, BIOPHYS J, V49, pA190; FEARON CW, 1987, J BIOL CHEM, V262, P9515; FUKUDA Y, 1989, BIOCHEM BIOPH RES CO, V164, P1431, DOI 10.1016/0006-291X(89)91830-5; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; IIDA H, 1989, AM J PHYSIOL, V256, pC608, DOI 10.1152/ajpcell.1989.256.3.C608; ISHIKAWA N, 1990, J PHARMACOL EXP THER, V254, P598; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; JETT MF, 1987, ARCH BIOCHEM BIOPHYS, V255, P354, DOI 10.1016/0003-9861(87)90403-6; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER MR, 1989, CIRCULATION S2, V80, P194; LEDSOME JR, 1985, CAN J PHYSIOL PHARM, V63, P739, DOI 10.1139/y85-121; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANNING PT, 1985, SCIENCE, V229, P395, DOI 10.1126/science.2990050; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SCHIEBINGER RJ, 1986, AM J PHYSIOL, V251, P1095; SCHLENDER KK, 1991, J BIOL CHEM, V266, P2811; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWARTZ D, 1985, SCIENCE, V229, P397, DOI 10.1126/science.3160114; SEI CA, 1990, J BIOL CHEM, V265, P7166; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	51	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5211	5216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371996				2022-12-25	WOS:A1992HH74700035
J	CHOU, CF; SMITH, AJ; OMARY, MB				CHOU, CF; SMITH, AJ; OMARY, MB			CHARACTERIZATION AND DYNAMICS OF O-LINKED GLYCOSYLATION OF HUMAN CYTOKERATIN-8 AND CYTOKERATIN-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE RESIDUES; INTERMEDIATE FILAMENTS; EPIDERMAL KERATINS; GLYCOPROTEINS; EXPRESSION; CELLS; PHOSPHORYLATION; PROTEINS; POLYPEPTIDES; HEPATOCYTES	The glycosylation of human cytokeratin (CK) 8 and 18 was studied after metabolic labeling of HT29 colonic cells with [H-3]glucosamine. Labeling of CK8/18 was not inhibited by tunicamycin, suggesting that glycosylation was not N-linked. Acid hydrolysis of CK8 and CK18, purified from [H-3]glucosamine-labeled cells, generated free glucosamine. In the presence of UDP-[H-3]galactose, galactosyltransferase catalyzed the labeling of cytokeratin 8 and 18. Beta-Elimination of t he [H-3]galactose- labeled CK8/18 generated the disaccharide N-acetyllactosaminitol, indicating that cytokeratin 8 and 18 contain single O-linked N-acetylglucosamine residues. Using chemical analysis, the stoichiometry of glycosylation was found to be 1.5 and 2 molecules of N-acetylglucosamine/protein molecule of CK8 and CK18, respectively. Peptide maps of [H-3] glucosamine-labeled CK8/18 showed that multiple peptides were labeled with the amino sugar. The biosynthetic and degradation rates of the carbohydrate moiety were faster than the protein core as determined by metabolic radiolabeling or pulse-chase experiments, respectively. Our results show that CK8 and 18 are glycosylated at multiple sites with a single O-linked N-acetylglucosamine. Furthermore, CK8/18 glycosylation is a dynamic process which is likely to have functional relevance.	VET ADM MED CTR, DEPT MED, DIV GASTROENTEROL, PALO ALTO, CA 94304 USA; BECKMAN CTR, PROGRAM MOLEC & GENET MED, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHOU, CF (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL, RM 51069, STANFORD, CA 94305 USA.			Omary, Bishr/0000-0002-8624-2347				BLOEMENDAL H, 1989, BIOCHIM BIOPHYS ACTA, V1007, P245, DOI 10.1016/0167-4781(89)90144-9; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DENK H, 1987, EXP CELL RES, V173, P137, DOI 10.1016/0014-4827(87)90339-9; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; GILMARTIN ME, 1984, J CELL BIOL, V98, P1144, DOI 10.1083/jcb.98.3.1144; HART GW, 1989, CIBA F SYMP, V145, P102; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KING IA, 1989, J BIOL CHEM, V264, P14022; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; MCTAVISH CF, 1983, FEBS LETT, V154, P251, DOI 10.1016/0014-5793(83)80159-8; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MULLIS KG, 1990, J VIROL, V64, P5317, DOI 10.1128/JVI.64.11.5317-5323.1990; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OMARY MB, 1991, AIDS, V5, P275, DOI 10.1097/00002030-199103000-00005; PEREZ MS, 1989, J IMMUNOL, V142, P3662; QUARONI A, 1991, J BIOL CHEM, V266, P11923; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; ROBERTS GP, 1983, BIOCHEM J, V212, P355, DOI 10.1042/bj2120355; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; YEAGLE PL, 1990, BIOCHEMISTRY-US, V29, P1508, DOI 10.1021/bi00458a023	36	191	196	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3901	3906						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371281				2022-12-25	WOS:A1992HE60700056
J	BO, M; BOIME, I				BO, M; BOIME, I			IDENTIFICATION OF THE TRANSCRIPTIONALLY ACTIVE GENES OF THE CHORIONIC GONADOTROPIN-BETA GENE-CLUSTER INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; SUBUNIT GENES; EXPRESSION; ALPHA; TISSUE; CELLS	The chorionic gonadotropin beta (CG-beta) subunit is encoded by a multigene cluster composed of six homologous sequences (genes or pseudogenes). They are primarily distinguished by sequences in the 5' nontranslated region of the first exon. To determine which CG-beta genes are active in vivo, we employed the reverse transcription-polymerase chain reaction technique. DNA complementary to RNA from placenta tissue and a choriocarcinoma cell line was subjected to polymerase chain reaction with CG-beta-specific primers. The amplified DNA was cloned into M13 and sequenced. Most of steady-state CG-beta mRNAs are transcribed from CG-beta genes, 5, 3, and 8. The level of expression is beta-5 > beta-3 = beta-8 > beta-7, beta-1/2. Transcripts from the CG-beta-1 and CG-beta-2 genes, which were previously considered pseudogenes because of their noncanonical splice site, were detected. These CG-beta transcripts arising from alternative splicing sites in the CG-beta-1/2 genes were also detected in polysomes which suggests they are translation-competent. Northern blotting with a CG-beta-1/2 probe revealed low amounts of CG-beta-1/2 transcripts which were smaller than the transcripts of the other genes. The results indicate that at least five, and possibly all six, CG-beta genes are transcribed in vivo, and at least one of them (CG-beta-1 and/or CG-beta-2) undergoes alternative splicing.			BO, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110, USA.							BOIME I, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1322, DOI 10.1073/pnas.71.4.1322; BOORSTEIN WR, 1982, NATURE, V300, P419, DOI 10.1038/300419a0; BOOTHBY M, 1981, J BIOL CHEM, V256, P5121; DARNELL RB, 1984, MOL CELL BIOL, V4, P829, DOI 10.1128/MCB.4.5.829; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GRAHAM MY, 1987, NUCLEIC ACIDS RES, V15, P4437, DOI 10.1093/nar/15.11.4437; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OTANI T, 1988, J BIOL CHEM, V263, P7322; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; POLICASTRO PF, 1986, J BIOL CHEM, V261, P5907; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TALMADGE K, 1984, NUCLEIC ACIDS RES, V12, P8415, DOI 10.1093/nar/12.22.8415; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TALMADGE K, 1983, DNA-J MOLEC CELL BIO, V2, P281, DOI 10.1089/dna.1983.2.281; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WONG M, 1989, J BIOL CHEM, V264, P12867; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	21	120	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3179	3184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371113				2022-12-25	WOS:A1992HD15400057
J	BOULANGER, P; LETELLIER, L				BOULANGER, P; LETELLIER, L			ION CHANNELS ARE LIKELY TO BE INVOLVED IN THE 2 STEPS OF PHAGE-T5 DNA PENETRATION INTO ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE; COLIPHAGE-T5 DNA; TRANSPORT; INJECTION; INFECTION; PROTEIN; FLUXES	Phage T5 injects its DNA into Escherichia coli cells in two steps; 8% of the chromosome is first injected, and then there is a pause during which proteins encoded by this DNA fragment are synthesized allowing the remaining DNA to be injected. Using a potassium-selective electrode, we show that the injection of the two DNA fragments is associated with an efflux in two steps, of cytoplasmic potassium. The rate of efflux is linearly related to the number of added phages suggesting that each phage induces the formation of at least one channel in the inner membrane. The first efflux occurs even in depolarized cells suggesting that the insertion and the opening of the channel can take place in the absence of the electrochemical gradient of protons (DELTA-mu(H)+). The channel is in a closed configuration during the time required for the synthesis of the phage-encoded proteins; this closing and the second efflux are prevented by the depolarization of the cell. The insertion of the channel in the inner membrane requires a fluid membrane. The results obtained suggest that the function of this channel is to translocate phage T5 DNA.	UNIV PARIS 11, BIOMEMBRANES LAB, CNRS, UA 1116, BAT 433, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOOTH IR, 1979, BIOCHEM J, V182, P687, DOI 10.1042/bj1820687; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BRADLEY DE, 1967, BACTERIOL REV, V31, P230, DOI 10.1128/MMBR.31.4.230-314.1967; BRAUN V, 1973, BIOCHIM BIOPHYS ACTA, V323, P87, DOI 10.1016/0005-2736(73)90433-1; DUCKWORTH DH, 1976, ARCH BIOCHEM BIOPHYS, V172, P319, DOI 10.1016/0003-9861(76)90083-7; GLENN J, 1980, ARCH BIOCHEM BIOPHYS, V201, P576, DOI 10.1016/0003-9861(80)90547-0; HEUTERSPREUTE M, 1987, GENE, V52, P155; Hille B, 1984, IONIC CHANNELS EXCIT; LABEDAN B, 1980, BIOCHEM BIOPH RES CO, V93, P625, DOI 10.1016/0006-291X(80)91124-9; LABEDAN B, 1973, J MOL BIOL, V75, P213, DOI 10.1016/0022-2836(73)90017-X; LABEDAN B, 1976, VIROLOGY, V75, P368, DOI 10.1016/0042-6822(76)90035-0; LABEDAN B, 1981, P NATL ACAD SCI-BIOL, V78, P215, DOI 10.1073/pnas.78.1.215; LABEDAN B, 1984, J VIROL, V49, P273, DOI 10.1128/JVI.49.1.273-275.1984; LANNI YT, 1960, VIROLOGY, V10, P501, DOI 10.1016/0042-6822(60)90132-X; LANNI YT, 1968, BACTERIOL REV, V32, P227, DOI 10.1128/MMBR.32.3.227-242.1968; LANNI YT, 1965, P NATL ACAD SCI USA, V53, P969, DOI 10.1073/pnas.53.5.969; LETELLIER L, 1989, BIOCHIMIE, V71, P167, DOI 10.1016/0300-9084(89)90147-8; MALTOUF AF, 1983, J BACTERIOL, V153, P124, DOI 10.1128/JB.153.1.124-133.1983; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCCORQUODALE D J, 1975, Critical Reviews in Microbiology, V4, P101, DOI 10.3109/10408417509111574; McCorquodale D. J., 1988, BACTERIOPHAGES, V1, P439; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; RHOADS DB, 1976, J GEN PHYSIOL, V49, P221; SHECHTER E, 1974, EUR J BIOCHEM, V49, P61, DOI 10.1111/j.1432-1033.1974.tb03811.x; SHECHTER E, 1985, MOL CYTOLOGY ESCHERI; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	32	53	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3168	3172						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371112				2022-12-25	WOS:A1992HD15400055
J	CHADWICK, CC; TIMERMAN, AP; SAITO, A; MAYRLEITNER, M; SCHINDLER, H; FLEISCHER, S				CHADWICK, CC; TIMERMAN, AP; SAITO, A; MAYRLEITNER, M; SCHINDLER, H; FLEISCHER, S			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF AN INOSITOL POLYPHOSPHATE RECEPTOR FROM CEREBELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; 1,4,5-TRISPHOSPHATE RECEPTOR; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; SMOOTH-MUSCLE; BRAIN; SOLUBILIZATION; PURIFICATION; PROTEIN; 1,3,4,5-TETRAKISPHOSPHATE	An inositol polyphosphate receptor has been purified from bovine cerebellum which consists of three different polypeptides with M(r) of 111,000, 102,000, and 52,000. Negative staining electron microscopy reveals globular-like structures 10-13 nm in diameter. The receptor has a Stokes radius of 400,000 daltons as determined by molecular sieve high performance liquid chromatography. The receptor preparation binds inositol 1,3,4,5-tetrakisphosphate, inositol hexaphosphate (or phytol), and inositol 1,4,5-trisphosphate (IP4, IP6, and IP3, respectively) with submicromolar affinity (0.19, 0.15, and 0.54-mu-M, respectively) at conditions approximating physiological ionic strength and pH. The purified receptor preparation, when reconstituted into planar bilayers, displays ion channel activity, preferentially permeable to K+. Permeability ratios of the channel are P(K+)/PN(Na+) approximately 5 and P(K+)/P(Cl) approximately 19. In symmetrical 100 mM KCl, the channel is characterized by long open times (minutes) with a conductance of 7.2 picosiemens. The channel is selectively modulated by IP4. That is, at 1-mu-M IP4, the mean open time decreased substantially to rapid flicker behavior and the channel is completely closed at 10-mu-M IP4. IP6 and IP3 did not modulate the channel under similar conditions. Thus, the channel appears to be an IP4-modulated K+ channel.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA; JOHANNES KEPLER UNIV, INST BIOPHYS, A-4040 LINZ, AUSTRIA	Vanderbilt University; Johannes Kepler University Linz					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHADWICK C C, 1991, Biophysical Journal, V59, p525A; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DONIE F, 1990, FEBS LETT, V268, P194, DOI 10.1016/0014-5793(90)81006-A; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; IRVINE RF, 1989, INOSITOL LIPIDS CELL, P135; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1989, MOL PHARMACOL, V36, P391; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P105; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MAYRLEITNER M, 1991, Biophysical Journal, V59, p525A; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOLLEMAN A, 1991, J BIOL CHEM, V266, P5658; OROURKE FA, 1985, J BIOL CHEM, V260, P956; PALADE P, 1989, MOL PHARMACOL, V36, P664; PETERSEN OH, 1989, CELL CALCIUM, V10, P375, DOI 10.1016/0143-4160(89)90063-8; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8	32	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3473	3481						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371119				2022-12-25	WOS:A1992HD15400100
J	ABRAMS, CS; RUGGERI, ZM; TAUB, R; HOXIE, JA; NAGASWAMI, C; WEISEL, JW; SHATTIL, SJ				ABRAMS, CS; RUGGERI, ZM; TAUB, R; HOXIE, JA; NAGASWAMI, C; WEISEL, JW; SHATTIL, SJ			ANTIIDIOTYPIC ANTIBODIES AGAINST AN ANTIBODY TO THE PLATELET GLYCOPROTEIN (GP) IIB-IIIA COMPLEX MIMIC GP IIB-IIIA BY RECOGNIZING FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR RECOGNITION DOMAIN; GAMMA-CHAIN; ALPHA-CHAIN; ACTIVATED PLATELETS; BINDING-SITE; VONWILLEBRAND-FACTOR; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; RNA-POLYMERASE; LIGAND-BINDING	Binding of the adhesive ligand fibrinogen and the monoclonal antibody PAC1 to platelet glycoprotein (GP) IIb-IIIa is dependent on cell activation and inhibited by Arg-Gly-Asp (RGD)-containing peptides. Previously, we identified a sequence in a hypervariable region of PACI (mu-CDR3) that mimics the activity of the antibody. Here we examine whether monoclonal antibodies to this idiotypic determinant in PAC1 can mimic GP IIb-IIIa by binding to fibrinogen. Mice were immunized with a peptide derived from the mu-CDR3 of PAC1. Four antibodies were obtained that recognized fibrinogen as well as a recombinant form of the variable region of PAC1. However, they did not bind to other RGD-containing proteins, including von Willebrand factor, fibronectin, and vitronectin. Several studies suggested that these anti-PAC1 peptide antibodies were specific for GP IIb-IIIa recognition sites in fibrinogen. Three such sites have been proposed: two RGD-containing regions in the A-alpha-chain, and the COOH terminus of the gamma-chain (gamma-400-411). Two of the antibodies inhibited fibrinogen binding to activated platelets, and all four antibodies bound to the fibrinogen A-alpha-chain on immunoblots. Antibody binding to immobilized fibrinogen was partially inhibited by monoclonal antibodies specific for the two A-alpha-chain RGD regions. However, the anti-PAC1 peptide antibodies also bound to plasmin-derived fibrinogen fragments X and D100, which contain gamma-400-411 but lack one or both A-alpha(RGD) regions. This binding was inhibited by an antibody specific for gamma-400-411. When fragment D100 was converted to D80, which lacks gamma-400-411, antibody binding was reduced significantly (p < 0.01). Electron microscopy of fibrinogen-antibody complexes confirmed that each antibody could bind to sites on the A-alpha and gamma-chains. These studies demonstrate that certain anti-PAC1 peptide antibodies mimic GP IIb-IIIa by binding to platelet recognition sites in fibrinogen. Furthermore, they suggest that the gamma-400-411 region of fibrinogen may exist in a conformation similar to that of an A-alpha(RGD) region of the molecule.	UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT HUMAN GENET, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT ANAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Scripps Research Institute; Scripps Research Institute; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL 30954, HL 31950, HL 40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL030954, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BONA C, 1984, RECEPTOR BIOCH METHO, V4, P141; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; ERLANGER BF, 1991, BIOCHEM SOC T, V19, P138, DOI 10.1042/bst0190138; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GELIEBTER J, 1987, FOCUS, V9, P5; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KENNETT RH, 1982, MONOCLONAL ANTIBODIE, P365; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MARSTON FAO, 1989, DNA CLONING PRACTICA, P59; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; NIEWIAROWSKI S, 1977, BLOOD, V49, P635; PEERSCHKE EIB, 1986, BLOOD, V67, P385; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; REES AR, 1987, IMMUNOL TODAY, V8, P44, DOI 10.1016/0167-5699(87)90237-4; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUDEE ML, 1981, ULTRAMICROSCOPY, V7, P193, DOI 10.1016/0304-3991(81)90010-3; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SLAYTER HS, 1983, ANN NY ACAD SCI, V408, P131, DOI 10.1111/j.1749-6632.1983.tb23241.x; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUB R, 1989, J BIOL CHEM, V264, P259; THORSEN LI, 1987, THROMB RES, V47, P315, DOI 10.1016/0049-3848(87)90145-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WILLIAMS JF, 1989, BIOTECHNIQUES, V7, P762; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZIBLER B, 1990, BIOCHEMISTRY-US, V29, P10032	70	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2775	2785						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370832				2022-12-25	WOS:A1992HB53200099
J	CREIGHTON, S; HUANG, MM; CAI, H; ARNHEIM, N; GOODMAN, MF				CREIGHTON, S; HUANG, MM; CAI, H; ARNHEIM, N; GOODMAN, MF			BASE MISPAIR EXTENSION KINETICS - BINDING OF AVIAN-MYELOBLASTOSIS REVERSE-TRANSCRIPTASE TO MATCHED AND MISMATCHED BASE PAIR TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-ALPHA; SPONTANEOUS MUTATION; ENZYMATIC AMPLIFICATION; INSERTION FIDELITY; ESCHERICHIA-COLI; CHAIN-REACTION; MECHANISM	We investigate the enzymatic basis for the inefficient extension of single base mismatches by DNA polymerase compared with the extension of correct base pairs. Inefficient mismatch extension could result from either a reduced binding of the enzyme to mispaired versus correctly paired DNA template-primer termini, or from a lowered intrinsic rate of extension of mispairs by a bound enzyme, or from a combination of both factors. Avian myeloblastosis reverse transcriptase is used to measure the affinities (equilibrium dissociation constants) for the four matched and twelve mismatched base pair configurations situated at a primer 3'-terminus. The binding affinities are analyzed by two different assays employing polyacrylamide gels. The first assay uses steady-state kinetics to measure the efficiency of elongating correct and incorrect base pairs and to evaluate the enzyme's dissociation constants for matched and mismatched termini. The estimated K(D) values obtained in the steady-state analysis fall within a range of approximately 0.1-20 nM. The efficiencies of extending two of the mispairs, G.G and C.C, are too low to allow a determination of K(D) by the kinetics method. The second assay uses equilibrium binding to measure the ratio of polymerase bound to matched compared with mismatched termini, K(D(right))/K(D(wrong). The affinity ratios, including values for G.G and C.C mispairs, are in the range of about 0.4-4.2. While around 1 order of magnitude difference is observed in the relative binding affinities of the polymerase for matched and mismatched primer termini, the relative extension efficiencies vary over more than 5 orders of magnitude. Therefore, it appears that inefficient mismatch extension is caused primarily by a kinetic block inhibiting elongation from mispaired primer 3'-termini rather than to a difference in binding.			CREIGHTON, S (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,MOLEC BIOL SECT,LOS ANGELES,CA 90089, USA.			Arnheim, Norman/0000-0003-1247-1347	NIGMS NIH HHS [GM21422, GM36745, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R01GM042554, R37GM036745, R01GM036745, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BURTALG D, 1972, J BIOL CHEM, V247, P241; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; DELSAL G, 1980, NUCLEIC ACIDS RES, V15, P10047; DETERA SD, 1981, J BIOL CHEM, V256, P6933; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1983, J MOL BIOL, V165, P669, DOI 10.1016/S0022-2836(83)80273-3; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; GELFAND DN, 1989, PRC PROTOCOLS GUIDE, P129; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SEGAL IH, 1975, ENZYME KINETICS, P325; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	35	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2633	2639						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370828				2022-12-25	WOS:A1992HB53200081
J	TEDIN, K; BREMER, H				TEDIN, K; BREMER, H			TOXIC EFFECTS OF HIGH-LEVELS OF PPGPP IN ESCHERICHIA-COLI ARE RELIEVED BY RPOB MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; GUANOSINE TETRAPHOSPHATE; STRINGENT CONTROL; PROMOTER SELECTIVITY; SYNTHESIS INVITRO; RIBONUCLEIC-ACID; OMEGA SUBUNIT; BETA-SUBUNIT; RELA GENE; POLYMERASE	A controversy has surrounded the questions of whether or not guanosine tetraphosphate (ppGpp) is a specific inhibitor of bacterial rRNA and tRNA synthesis, especially during normal exponential growth, and whether the RNA polymerase is the target of ppGpp action. To answer these questions, a pBR322-derived plasmid, pKT28, was constructed that carries the Escherichia coli relA gene encoding a ppGpp synthetase under control of the lacUV5 promoter. The plasmid was used to transform the ppGpp reporter strain VH271 in which expression of beta-galactosidase from an rrnB P1 promoter is inhibited by ppGpp. In the presence of high concentrations of lac inducer, bacteria of the transformed strain accumulate ppGpp with the result that synthesis of rRNA and beta-galactosidase is inhibited and growth ceases. At low concentrations of inducer, growth is only reduced and cells form small white colonies on X-gal indicator plates. After continued incubation, these colonies form blue sectors of faster growing mutant cells. Phage P1 transduction experiments showed that these mutants have mutations cotransducing with rpoB, the gene encoding the beta-subunit of RNA polymerase. One particular mutant strain, KT13, had acquired partial resistance to ppGpp inhibition of rRNA synthesis. The mutation in this strain was cloned by in vivo recombination into an rpoB plasmid. The presence of this plasmid conferred increased resistance to overproduction of ppGpp. These results suggest that ppGpp is a specific inhibitor of rRNA synthesis, even in the absence of amino acid starvation, and that RNA polymerase is involved as the target of ppGpp action.	UNIV TEXAS,MOLEC & CELL BIOL PROGRAM,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas				Tedin, Karsten/0000-0003-2109-0730				ALFOLDI L, 1962, J MOL BIOL, V5, P348, DOI 10.1016/S0022-2836(62)80077-1; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BREEDEN L, 1980, MOL GEN GENET, V179, P119, DOI 10.1007/BF00268453; BREEDEN L, 1980, MOL GEN GENET, V179, P125, DOI 10.1007/BF00268454; BREMER H, 1987, NATO ASI SER, V14, P63; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHURCHWARD G, 1983, MOL GEN GENET, V192, P506, DOI 10.1007/BF00392197; COLLINS J, 1976, 9 A BENZ S CONTR RIB, P356; FRIESEN JD, 1974, P NATL ACAD SCI USA, V71, P3465, DOI 10.1073/pnas.71.9.3465; GENTRY D, 1991, J BACTERIOL, V173, P3901, DOI 10.1128/JB.173.12.3901-3903.1991; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GENTRY DR, 1989, J BACTERIOL, V171, P1271, DOI 10.1128/jb.171.3.1271-1277.1989; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GLASS RE, 1986, MOL GEN GENET, V203, P265, DOI 10.1007/BF00333964; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HELMSTETTER CE, 1967, J MOL BIOL, V24, P417, DOI 10.1016/0022-2836(67)90228-8; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; HUYNH TV, 1985, DNA CLONING, V1, P56; IGARASHI K, 1989, NUCLEIC ACIDS RES, V17, P8755, DOI 10.1093/nar/17.21.8755; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LITTLE R, 1983, J BACTERIOL, V155, P1426, DOI 10.1128/JB.155.3.1426-1428.1983; METZGER S, 1988, J BIOL CHEM, V263, P15699; Miller J.H., 1972, EXPT MOL GENETICS; NENE V, 1983, FEBS LETT, V153, P307, DOI 10.1016/0014-5793(83)80630-9; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OOSTRA BA, 1981, MOL GEN GENET, V183, P54, DOI 10.1007/BF00270138; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; PEDERSEN FS, 1977, EUR J BIOCHEM, V76, P91, DOI 10.1111/j.1432-1033.1977.tb11573.x; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SILVERSTONE AE, 1972, MOL GEN GENET, V118, P223, DOI 10.1007/BF00333459; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; XIAO H, 1991, J BIOL CHEM, V266, P5980; YOSHINAGA K, 1977, BIOCHIM BIOPHYS ACTA, V479, P172, DOI 10.1016/0005-2787(77)90137-X	56	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2337	2344						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370817				2022-12-25	WOS:A1992HB53200036
J	HIROSE, S; PRINCE, GM; SEVLEVER, D; RAVI, L; ROSENBERRY, TL; UEDA, E; MEDOF, ME				HIROSE, S; PRINCE, GM; SEVLEVER, D; RAVI, L; ROSENBERRY, TL; UEDA, E; MEDOF, ME			CHARACTERIZATION OF PUTATIVE GLYCOINOSITOL PHOSPHOLIPID ANCHOR PRECURSORS IN MAMMALIAN-CELLS - LOCALIZATION OF PHOSPHOETHANOLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; TRYPANOSOMA-BRUCEI; STRUCTURAL CHARACTERIZATION; MASS-SPECTROMETRY; BIOSYNTHESIS; OLIGOSACCHARIDES; MUTANTS; IDENTIFICATION; GLYCAN	A number of mammalian cell surface proteins are anchored by glycoinositol phospholipid (GPI) structures that are preassembled and transferred to them in the endoplasmic reticulum. The GPIs in these proteins contain linear ethanolamine (EthN)-phosphate (P)-6ManManManGlcN core glycan sequences bearing an additional EthN-P attached to the Man residue (Man 1) proximal to GlcN. The biochemical precursors of mammalian GPI anchor structures are incompletely characterized. In this study, putative [H-3]Man-labeled GPI precursors were obtained by in vitro GDP-[H-3] Man labeling of HeLa cell microsomes and by in vivo [H-3]Man labeling of class B and F Thy-1 negative murine lymphoma mutants known to accumulate incomplete GPIs. The high performance liquid chromatography-purified in vitro and accumulated in vivo GPI products were structurally analyzed by nitrous acid deamination, hydrofluoric acid, trifluoroacetic acid hydrolysis, biosynthetic labeling, and exoglycosidase treatment. The data were consistent with a biosynthetic scheme in which Man and EthN-P are added stepwise to the developing glycan. Several additional points were demonstrated: 1) putative mammalian GPI precursors contain incomplete core glycans corresponding to those in previously characterized trypanosome GPI precursors. 2) The proximal EthN-P found in mature mammalian GPI anchor structures is added to Man 1 prior to incorporation of Man 2 and Man 3. 3) Glycans in the incomplete GPIs that accumulate in classes B and F lymphoma mutants consist of Man2- and Man3GlcN in which EthN-P is linked to Man 1. 4) Distal EthN-P linked to the 6-position of Man, characteristic of the complete GPI core, is found both in a subsequent GPI species with the glycan sequence EthN-P-6ManMan(EthN-P-->)ManGlcN and in a more polar GPI product.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BANGS JD, 1988, J BIOL CHEM, V263, P17697; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, IN PRESS J BIOL CHEM; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1992, IN PRESS J CELL BIOL; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1990, J BIOL CHEM, V265, P9033; ORLEAN P, 1991, OCT AM SOC BIOCH MOL, V4; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VARKI A, 1980, J BIOL CHEM, V255, P847	24	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16968	16974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380957				2022-12-25	WOS:A1992JL05300039
J	HASHIMOTO, Y; ORELLANA, A; GIL, G; HIRSCHBERG, CB				HASHIMOTO, Y; ORELLANA, A; GIL, G; HIRSCHBERG, CB			MOLECULAR-CLONING AND EXPRESSION OF RAT-LIVER N-HEPARAN SULFATE SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; BLOOD GROUP-A; HYDROXYSTEROID SULFOTRANSFERASE; MESSENGER-RNA; CDNA; BINDING; IDENTIFICATION; PROTEIN	N-Heparan sulfate sulfotransferase catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to the nitrogen of glucosamine in heparan sulfate. The enzyme has been previously purified to apparent homogeneity from rat liver (Brandan, E., and Hirschberg, C. B. (1988) J. Biol. Chem. 263, 2417-2422). We have now cloned the rat liver enzyme using the following strategy: (a) the amino acid sequence was obtained from tryptic peptides of the purified protein, (b) mixed oligonucleotides were generated based on the sequence of the tryptic peptides, (c) a polymerase chain reaction fragment was obtained using mixed oligonucleotide interprimer amplification of cDNA, and (d) this fragment was used to screen rat liver lambda-gt 10 and lambda-ZAP libraries. Three clones were obtained, one of which seems to contain the complete coding sequence of the N-heparan sulfate sulfotransferase (N-HSST). Evidence that the cDNA clone corresponds to the previously purified and characterized N-HSST was the following: (a) the predicted sequence of the N-HSST contains all of the 11 tryptic peptides obtained from the purified protein, (b) when a cDNA containing the sequence coding for the N-HSST was introduced in a eukaryotic expression vector and transfected in COS-1 cells, the enzyme activity was expressed 9-fold over controls, and (c) the characteristic of the predicted protein fits with the purified protein in terms of molecular weight, membrane localization, and its being an N-linked glycoprotein. The size of the longest cDNA isolated is 4.1 kilobases, which is in close agreement with the 4.2-kilobase size of one of the mRNA observed in Northern analyses. In addition, messages of 7.0 and 8.5 kilobases were also observed, suggesting that a large portion is untranslated. The latter messages were the major mRNA species detected.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Orellana, Ariel/AAE-4866-2021; Orellana, Ariel/E-2166-2014	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS S, V14; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P400; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	54	152	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15744	15750						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379236				2022-12-25	WOS:A1992JG11300075
J	LARKIN, M; AHERN, TJ; STOLL, MS; SHAFFER, M; SAKO, D; OBRIEN, J; YUEN, CT; LAWSON, AM; CHILDS, RA; BARONE, KM; LANGERSAFER, PR; HASEGAWA, A; KISO, M; LARSEN, GR; FEIZI, T				LARKIN, M; AHERN, TJ; STOLL, MS; SHAFFER, M; SAKO, D; OBRIEN, J; YUEN, CT; LAWSON, AM; CHILDS, RA; BARONE, KM; LANGERSAFER, PR; HASEGAWA, A; KISO, M; LARSEN, GR; FEIZI, T			SPECTRUM OF SIALYLATED AND NONSIALYLATED FUCO-OLIGOSACCHARIDES BOUND BY THE ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE E-SELECTIN - DEPENDENCE OF THE CARBOHYDRATE BINDING-ACTIVITY ON E-SELECTIN DENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DIFFERENTIATION ANTIGENS; MONOCLONAL-ANTIBODIES; CONFORMATIONAL-ANALYSIS; PROBES NEOGLYCOLIPIDS; GROUP-B; GROUP-H; RECOGNITION; PROTEINS; LECTINS	Carbohydrate recognition by the human endothelial-leukocyte adhesion molecule, E-selectin, has been investigated by binding studies using H-3-labeled Chinese hamster ovary cells expressing different levels of the transfected full-length adhesion molecule and a series of structurally defined oligosaccharides linked to the lipid phosphatidylethanolamine dipalmitoate (neoglycolipids) and synthetic glycolipids chromatographed on silica gel plates or immobilized on plastic wells. Evidence is presented for density-dependent binding of the membrane-associated E-selectin not only to 3'-sialyl-lacto-N-fucopentaose II (3'-S-LNFP-II) and 3'sialyl-lacto-N-fucopentaose III (3'-S-LNFP-III) which express the sialyl Le(a) and sialyl Le(x) antigens, respectively, but also to the nonsialylated analogue LNFP-II; there is a threshold density of E-selectin required for binding to these sialylated sequences, and binding to the nonsialylated analogue is a property only of cells with the highest density of E-selectin expression. The presence of fucose linked to subterminal rather than to an internal N-acetylglucosamine is shown to be a requirement for E-selectin binding, and although the presence of sialic acid 3-linked to the terminal galactose of the LNFP-II or LNFP-III sequences substantially enhances E-selectin binding, the presence of 6-linked sialic acid abolishes binding. E-selectin binding is unaffected in the presence of the blood group H fucose (alpha-1-2 linked to galactose to form the Le(b) antigen). However, the binding is abolished when in addition alpha-1-3-linked N-acetylgalactosamine to the galactose (blood group A antigen) is present. These results indicate that some E-selectin-mediated adhesive events may be influenced by blood group status.	CLIN RES CTR, MRC, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND; CLIN RES CTR, MRC, CLIN MASS SPECTROMETRY SECT, HARROW HA1 3UJ, MIDDX, ENGLAND; GENET INST, CAMBRIDGE, MA 01240 USA; GIFU UNIV, DEPT APPL BIOORGAN CHEM, GIFU 50111, JAPAN	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit; Gifu University								ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; BECHTEL B, 1990, J BIOL CHEM, V265, P2028; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DEJANA E, 1992, LAB INVEST, V66, P324; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1984, BIOCHEM SOC T, V12, P591, DOI 10.1042/bst0120591; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1981, TRENDS BIOCHEM SCI, V6, P333, DOI 10.1016/0968-0004(81)90119-5; FEIZI T, 1989, CIBA F S, V145, P62; Feizi T, 1991, CURR OPIN STRUC BIOL, V1, P766, DOI 10.1016/0959-440X(91)90176-T; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1983, EUR J IMMUNOL, V13, P306, DOI 10.1002/eji.1830130407; HAKOMORI S, 1974, ANTIGENS, V2, P79; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABAT EA, 1982, AM J CLIN PATHOL, V78, P281, DOI 10.1093/ajcp/78.3.281; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P549, DOI 10.1080/07328309108543931; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P729, DOI 10.1080/07328309108543946; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICARD JK, 1984, BIOCHEM SOC T, V12, P653, DOI 10.1042/bst0120653; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; THOGERSEN H, 1982, CAN J CHEM, V60, P44, DOI 10.1139/v82-009; THORPE SJ, 1984, BIOSCIENCE REP, V4, P673, DOI 10.1007/BF01121021; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1	48	133	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13661	13668						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377689				2022-12-25	WOS:A1992JB74600089
J	VIRGOLINI, I; LI, SR; SILLABER, C; MAJDIC, O; SINZINGER, H; LECHNER, K; BETTELHEIM, P; VALENT, P				VIRGOLINI, I; LI, SR; SILLABER, C; MAJDIC, O; SINZINGER, H; LECHNER, K; BETTELHEIM, P; VALENT, P			CHARACTERIZATION OF PROSTAGLANDIN (PG)-BINDING SITES EXPRESSED ON HUMAN BASOPHILS - EVIDENCE FOR A PROSTAGLANDIN-E(1), PROSTAGLANDIN-I(2), AND A PROSTAGLANDIN-D(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITES; HUMAN-BLOOD BASOPHILS; HISTAMINE-RELEASE; MAST-CELLS; MEDIATOR RELEASE; PROSTACYCLIN RECEPTORS; MEMBRANE STRUCTURES; ADENYLATE-CYCLASE; HUMAN LEUKOCYTES; IN-VITRO	Recent data suggest that prostaglandins (PGs) are involved in the regulation of basophil activation. The aim of this study was to characterize the basophil PG-binding sites by means of radioreceptor assays using H-3-labeled PGs. Scatchard analysis for pure (>95%) chronic myeloid leukemia (CML) basophils revealed two classes of PGE1-binding sites differing in their affinity for the natural ligand (B(max1) = 217 +/- 65 fmol/10(8) cells; K(d1) = 0.5 +/- 0.2 nM; B(max2) = 2462 +/- 381 fmol/10(8) cells; K(d2) = 47 +/- 20 nM; IC50 = PGE1 < PGI2 < PGD2 < PGE2 < PGF2-alpha) as well as two classes of PGI2 (iloprost)-binding sites (B(max1) = 324 +/- 145 fmol/10(8) cells; K(d1) = 0.5 +/- 0.3 nM; B(max2) = 2541 +/- 381; K(d2) = 27 +/- 6 nM; IC50 = PGI2 < PGE1 < PGD2 < PGE2 < PGF2-alpha. In addition, CML basophils exhibited a single class of PGD2-binding sites (B(max) = 378 +/- 98 fmol/10(8) cells; K(d) = 13 +/- 4 nM; IC50: PGD2 < PGI2 < PGE1 < PGE2 < PGF2-alpha). In contrast, we were unable to detect specific saturable PGE2-binding sites. Primary and immortalized (KU812) CML basophils revealed an identical pattern of PG receptor expression. Basophils (KU812) expressed significantly (p < 0.001) lower number of PGE1 (PGI2)-binding sites (B(max1): 9% (20%) of control; B(max2): 36% (50%) of control) when cultured with recombinant interleukin 3 (rhIL-3), a basophil-activating cytokine, whereas rhIL-2 had no effect on PG receptor expression. Functional significance of binding of PGs to basophils was provided by the demonstration of a dose-dependent increase in cellular cAMP upon agonist activation, with PGE1 (ED50 = 1.7 +/- 1.1 nM) and PGI2 (ED50 = 2.8 +/- 2.3 nM) being the most potent compounds. These findings suggest that human basophils express specific receptors for PGE1, PGI2 as well as for PGD2.	UNIV VIENNA, LUDWIG BOLTZMANN INST NUCL MED, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, INST IMMUNOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, DEPT MED 1, A-1090 VIENNA, AUSTRIA	Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna	VIRGOLINI, I (corresponding author), UNIV VIENNA, DEPT NUCL MED, GARNISONGASSE 13, A-1090 VIENNA, AUSTRIA.		Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; LI, Shuren/0000-0001-7827-8051				AMIOT M, 1986, J IMMUNOL, V136, P1752; ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; ARMSTRONG RA, 1986, BRIT J PHARMACOL, V87, P543, DOI 10.1111/j.1476-5381.1986.tb10196.x; BOURNE HR, 1972, J IMMUNOL, V108, P695; Coleman R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P467; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P533; COOPER B, 1979, J CLIN INVEST, V64, P586, DOI 10.1172/JCI109497; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; FERNANDEZBOTRAN R, 1984, J IMMUNOL, V133, P2662; GOODMAN MG, 1986, J IMMUNOL, V137, P3753; GOODWIN JS, 1979, CELL IMMUNOL, V43, P150, DOI 10.1016/0008-8749(79)90158-8; GRIFFIN JD, 1984, BLOOD, V63, P904; HIRAI K, 1988, J IMMUNOL, V141, P3958; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; HOLTER W, 1985, CLIN EXP IMMUNOL, V62, P600; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; JOHNSTON SL, 1990, CURR OPIN IMMUNOL, V2, P513, DOI 10.1016/0952-7915(90)90004-Z; Keen M, 1989, Eicosanoids, V2, P193; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KNAPP W, 1983, ANN NY ACAD SCI, V420, P251, DOI 10.1111/j.1749-6632.1983.tb22210.x; KNAPP W, 1984, MED ONCOL TUMOR PHAR, V1, P257; KOLLER U, 1985, CLIN EXP IMMUNOL, V59, P613; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1991, ANN NY ACAD SCI, V629, P48; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LICHTENSTEIN LM, 1972, PROSTAGLANDINS CELLU, P293; LISZKA K, 1983, AM J HEMATOL, V15, P219, DOI 10.1002/ajh.2830150303; LOMBROSO M, 1984, PROSTAGLANDINS, V27, P321, DOI 10.1016/0090-6980(84)90083-2; MACDERMOT J, 1981, BIOCHEM PHARMACOL, V30, P2041, DOI 10.1016/0006-2952(81)90220-3; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MAJDIC O, 1981, BLOOD, V58, P1127; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MIZUNO Y, 1983, PROSTAG OTH LIPID M, V26, P785, DOI 10.1016/0090-6980(83)90062-X; PETERS SP, 1984, J PHARMACOL EXP THER, V228, P400; PETERS SP, 1985, ALLERGY, P111; SAMPSON D, 1967, BLOOD-J HEMATOL, V29, P722, DOI 10.1182/blood.V29.5.722.722; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAFER AI, 1979, J BIOL CHEM, V254, P2914; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SIMKIN NJ, 1987, J IMMUNOL, V138, P1074; SKUBALLA W, 1983, ADV PROSTAG THROMB L, V11, P299; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; STAIN C, 1987, BLOOD, V70, P1872; STOCKINGER H, 1990, BLOOD, V75, P1820; SULLIVAN TJ, 1976, AM J PATHOL, V85, P437; TAUBER AI, 1973, J IMMUNOL, V111, P27; THIERAUCH KH, 1988, PROSTAGLANDINS, V35, P855, DOI 10.1016/0090-6980(88)90112-8; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; VALENT P, 1990, J IMMUNOL, V145, P1885; VIRGOLINI I, 1988, PROSTAGLANDINS, V36, P807, DOI 10.1016/0090-6980(88)90058-5; VIRGOLINI I, 1988, BRIT J CANCER, V58, P584, DOI 10.1038/bjc.1988.264; VIRGOLINI I, 1989, BRIT J CANCER, V59, P407, DOI 10.1038/bjc.1989.81; VIRGOLINI I, 1989, THROMB HAEMOSTASIS, V62, P243; WATANABE T, 1991, BLOOD, V78, P2328; Wilson N H, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P491	66	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12700	12708						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377673				2022-12-25	WOS:A1992HZ48300050
J	COOK, RK; BLAKE, WT; RUBENSTEIN, PA				COOK, RK; BLAKE, WT; RUBENSTEIN, PA			REMOVAL OF THE AMINO-TERMINAL ACIDIC RESIDUES OF YEAST ACTIN - STUDIES INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABEL FINGERPRINTINGS SHOW; RABBIT SKELETAL-MUSCLE; SACCHAROMYCES-CEREVISIAE; DICTYOSTELIUM-DISCOIDEUM; BINDING SITES; SEQUENCE; MYOSIN; CELLS; GENE; PROTEINS	We have examined the role of the acidic residues Asp2 and Glu4 at the NH2 terminus of Saccharomyces cerevisiae actin through site-directed mutagenesis. In DNEQ actin, these residues have been changed to Asn2 and Gln4, whereas in DELTA-DSE actin, the Asp2-Ser-Glu tripeptide has been deleted. Both mutant actins can replace wild type yeast actin. Peptide mapping studies reveal that DNEQ, like wild type actin, retains the initiator Met and is NH2 terminally acetylated, whereas DELTA-DSE has a free NH2 terminus and has lost the initiator Met. Interestingly, microscopic examination of filaments of these two actins reveal the appearance of bundled filaments. The DNEQ bundles are smaller and more ordered, whereas the DELTA-DSE bundles are larger and more loosely organized. Additionally both mutant actins activate the ATPase activity of rabbit muscle myosin S1 fragment to a lesser extent than wild type. We have also developed a sensitive assay for actin function in vivo that enabled us to detect a slight defect in the ability of these mutant actins to support secretion, an important function in yeast. Thus, although the mutant actins resulted in no gross phenotypic changes, we were able to detect a defect in actin function through this assay. From these studies we can conclude that 1) although NH2-terminal negative charges are not essential to yeast life, the loss of such charges does result in a slight defect in the actins' ability to support secretion, 2) removal of the NH2-terminal negative charges promotes the bundling of actin filaments, and 3) actins lacking NH2-terminal negative charges are unable to activate the myosin S1 ATPase activity as well as wild type actin.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS S, 1990, J BIOL CHEM, V265, P19652; ASPENSTROM P, 1991, EUR J BIOCHEM, V200, P35, DOI 10.1111/j.1432-1033.1991.tb21045.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CLEEVES AE, 1989, J CELL BIOL, V109, P2939; COOK RK, 1991, J BIOL CHEM, V266, P16825; DASGUPTA G, 1991, BIOCHEMISTRY-US, V30, P9961, DOI 10.1021/bi00105a021; DOI Y, 1987, EUR J BIOCHEM, V164, P89, DOI 10.1111/j.1432-1033.1987.tb10997.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; ELZINGA M, 1986, METHODS PROTEIN SCI, P615; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Goldstein A, 1975, Methods Enzymol, V42, P504; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GREER C, 1982, MOL CELL BIOL, V2, P1279, DOI 10.1128/MCB.2.10.1279; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; REDMAN K, 1981, J BIOL CHEM, V256, P3226; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0	42	121	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9430	9436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1349604				2022-12-25	WOS:A1992HR85400109
J	REPONEN, P; SAHLBERG, C; HUHTALA, P; HURSKAINEN, T; THESLEFF, I; TRYGGVASON, K				REPONEN, P; SAHLBERG, C; HUHTALA, P; HURSKAINEN, T; THESLEFF, I; TRYGGVASON, K			MOLECULAR-CLONING OF MURINE 72-KDA TYPE-IV COLLAGENASE AND ITS EXPRESSION DURING MOUSE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; BRONCHIAL EPITHELIAL-CELLS; METASTATIC TUMOR-CELLS; HUMAN-SKIN; INTERSTITIAL COLLAGENASE; FIBROBLAST COLLAGENASE; EXTRACELLULAR-MATRIX; INDUCED TRANSIN; GENE; GELATINASE	We report the isolation of a cDNA clone providing the first and complete sequence of mouse 72-kDa type IV collagenase. The clone contains 2800 nucleotides with a 1986-nucleotide open reading frame coding for 662 amino acids. The amino acid sequence includes a 29-residue signal peptide, an 80-residue propeptide, and a 553-residue enzyme proper. The sequence identity between the mouse and human enzymes is 96% with all cysteine residues conserved. The carboxyl-terminal domain of the mouse enzyme contains two more residues than the human enzyme. Northern hybridization analysis revealed considerable expression of the enzyme gene in newborn mouse lung, heart, kidney, and psoas muscle tissues, whereas only weak or no signals were observed in liver, spleen, and brain. Expression of the gene was substantially reduced in the same tissues of 3-month-old mice. In situ hybridization analysis of 72-kDa type IV collagenase expression in 10-15-day-old mouse embryos showed that the gene was intensely expressed in mesenchymal cells. Brain and surface ectoderm were completely negative. The epithelial tissue component of developing organs was negative with the exception of salivary gland. Although the expression varied somewhat between different mesenchymal tissues, no temporal or spatial changes could be associated with the advancement of epithelial branching morphogenesis. These findings together with our previous data on the expression of 72-kDa type IV collagenase in human tumors indicate that this enzyme has some very specific roles both in the physiological and pathological degradation of extracellular matrix. Furthermore, it has become clear that the closely related 92-kDa type IV collagenase differs completely with respect to expression pattern as well as gene regulation. The mouse cDNA clones reported in this study may provide important tools unraveling the actual roles of these enzymes in vivo.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND; UNIV HELSINKI,DEPT PEDODONT & ORTHODONT,SF-00300 HELSINKI,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09399] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS GE, 1990, CANCER RES, V50, P1113; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FINI ME, 1987, ARTHRITIS RHEUM, V30, P1254, DOI 10.1002/art.1780301108; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; Maniatis T., 1982, MOL CLONING; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MARTRISIAN LM, 1985, EMBO J, V4, P1435; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOLL UM, 1990, CANCER RES, V50, P6162; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1989, J CELL SCI, V92, P487; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; PYKE C, 1992, IN PRESS CANCER RES; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216; SALO T, 1983, J BIOL CHEM, V258, P3058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; SELTZER JL, 1989, J BIOL CHEM, V264, P19583; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; THESLEFF I, 1990, CELL DIFFER DEV, V32, P383, DOI 10.1016/0922-3371(90)90054-Z; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; URA H, 1989, CANCER RES, V49, P4615; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5	55	190	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7856	7862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373140				2022-12-25	WOS:A1992HN48500092
J	ASSARAF, YG; FEDER, JN; SHARMA, RC; WRIGHT, JE; ROSOWSKY, A; SHANE, B; SCHIMKE, RT				ASSARAF, YG; FEDER, JN; SHARMA, RC; WRIGHT, JE; ROSOWSKY, A; SHANE, B; SCHIMKE, RT			CHARACTERIZATION OF THE COEXISTING MULTIPLE MECHANISMS OF METHOTREXATE RESISTANCE IN MOUSE 3T6-R50 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENES; SQUAMOUS-CELL CARCINOMA; HAMSTER OVARY CELLS; FLOW-CYTOMETRY; MESSENGER-RNA; AMPLIFICATION; TRIMETREXATE; TRANSPORT; LINE; HEAD	We have studied the discrepancy in the degree of methotrexate (MTX) resistance that exists between two clonal cell lines, mouse 3T6 R50 cells and Chinese hamster ovary B11 0.5 cells that overexpress comparable levels of dihydrofolate reductase, yet exhibit a 100-fold difference in MTX resistance while maintaining similar sensitivity to the lipophilic antifolates trimetrexate and piritrexim. These data suggested that R50 cells may possess additional mechanism(s) of antifolate resistance, such as MTX transport alteration. Flow cytometric analysis using fluorescein methotrexate revealed comparable levels of fluorescein MTX displacement with lipophilic antifolates in viable R50 and B11 0.5 cells, but marked insensitivity of R50 cells to MTX competition, thus suggesting a poor uptake of MTX into R50 cells. Analysis of the kinetic parameters of dihydrofolate reductase from R50 cells neither showed alterations in enzyme affinities for various antifolates nor in the Michaelis constant for folic acid and NADPH nor a change in the pH activity optimum. R50 cell-free extracts contained wild-type levels of folylpoly-gamma-glutamyl synthetase activity. However, following metabolic labeling with [H-3]MTX, no MTX polyglutamates could be detected in R50 cells. We conclude that the high level of MTX resistance in R50 cells is multifactorial, including overexpression of dihydrofolate reductase, reduced MTX transport, and possibly altered formation of MTX polyglutamates. The potential interactions between the different modalities of MTX resistance in R50 cells are being discussed.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOCHEM,SAN FRANCISCO,CA 94143; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Berkeley	ASSARAF, YG (corresponding author), TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL.		rosowsky, andre/N-6602-2017		NATIONAL CANCER INSTITUTE [R01CA041991, P01CA019589, R01CA016318] Funding Source: NIH RePORTER; NCI NIH HHS [CA16318, CA19589, CA41991] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1978, J BIOL CHEM, V253, P1357; ASSARAF YG, 1989, CYTOMETRY, V10, P50, DOI 10.1002/cyto.990100109; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1989, ANAL BIOCHEM, V178, P287, DOI 10.1016/0003-2697(89)90640-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P21; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; COWAN KH, 1984, J BIOL CHEM, V259, P793; DUCH DS, 1982, CANCER RES, V42, P3987; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1988, CANCER RES, V48, P6986; GEYER PK, 1984, J BIOL CHEM, V259, P7206; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; HABER DA, 1981, J BIOL CHEM, V256, P9501; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; JONES PP, 1980, SELECTED METHODS CEL, P398; KAMEN BA, 1984, BIOCHEM PHARMACOL, V33, P1697, DOI 10.1016/0006-2952(84)90298-3; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; KELLEMS RE, 1979, J BIOL CHEM, V254, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MELERA PW, 1984, MOL CELL BIOL, V4, P38, DOI 10.1128/MCB.4.1.38; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P5924, DOI 10.1073/pnas.76.11.5924; NAKAMURA H, 1972, J BIOL CHEM, V247, P179; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PIZZORNO G, 1988, CANCER RES, V48, P2149; ROSOWSKY A, 1985, CANCER RES, V45, P6205; ROTHENBE.SP, 1966, ANAL BIOCHEM, V16, P176, DOI 10.1016/0003-2697(66)90095-9; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SETZER DR, 1980, CELL, V22, P361, DOI 10.1016/0092-8674(80)90346-3; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1979, METHOD CANCER RES, V16, P382; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; WRIGHT JE, 1987, BIOCHEM PHARMACOL, V36, P2209, DOI 10.1016/0006-2952(87)90152-3	42	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5776	5784						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372892				2022-12-25	WOS:A1992HK31800012
J	PUOPOLO, K; KUMAMOTO, C; ADACHI, I; MAGNER, R; FORGAC, M				PUOPOLO, K; KUMAMOTO, C; ADACHI, I; MAGNER, R; FORGAC, M			DIFFERENTIAL EXPRESSION OF THE B-SUBUNIT OF THE VACUOLAR H+-ATPASE IN BOVINE-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; NEUROSPORA-CRASSA CONTAINS; MESSENGER-RNAS; ALPHA-SUBUNIT; BETA-SUBUNIT; SULFOLOBUS-ACIDOCALDARIUS; F1-LIKE STRUCTURE; CDNA SEQUENCE; VIMENTIN GENE	The B subunit is one of two nucleotide-binding polypeptides found in all members of the vacuolar class of H+-translocating ATPases. We have isolated a cDNA clone encoding the bovine brain B (58 kDa) subunit and have deduced its amino acid sequence. The bovine brain amino acid sequence is 99% identical to a partial cDNA reported from human brain. Northern blot analysis of RNA isolated from bovine tissues and a bovine kidney cell line reveals that two messages of approximately 3.2 and 2.0 kilobases (kb) are expressed in all tissues examined except brain, where only the 3.2-kb message can be detected. Northern blotting of RNA isolated from human fibroblast and human lung tumor cell lines reveals that three messages of approximately 6.0, 3.2, and 2.0 kb are expressed, whereas only the 3.2-kb message is expressed in a human brain tumor cell line. This is the first demonstration of tissue-specific expression of multiple forms of a vacuolar H+ATPase subunit. We have also isolated a partial cDNA clone from bovine brain which appears to encode an isoform of the B subunit. The deduced amino acid sequence is 82% identical to the major bovine brain B subunit sequence; it does not hybridize with either the 3.2- or 2.0-kb message on Northern blot. Southern blot analysis of bovine genomic DNA with probes derived from both isolated cDNAs indicates that the bovine B subunit is encoded by a multigene family.	TUFTS UNIV, SCH MED, DEPT PHYSIOL & MOLEC BIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University			Puopolo, Karen/AAY-7748-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOLOGY G; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRIEDMAN KD, 1990, PCR PROTOCOLS GUIDE, P253; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HEILIG R, 1980, CELL, V20, P625, DOI 10.1016/0092-8674(80)90309-8; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIRATA R, 1990, J BIOL CHEM, V265, P6726; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, J BIOL CHEM, V264, P1775; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS; SETZER DR, 1982, J BIOL CHEM, V257, P5143; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Watson J.D., 1987, MOL BIOL GENE, V1; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	56	118	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3696	3706						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371275				2022-12-25	WOS:A1992HE60700026
J	REINES, D				REINES, D			ELONGATION FACTOR-DEPENDENT TRANSCRIPT SHORTENING BY TEMPLATE-ENGAGED RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; FACTOR-SII; DROSOPHILA-MELANOGASTER; PREMATURE TERMINATION; REPLICATION PROTEINS; LATE PROMOTERS; C-MYC; GENE; INVITRO; PURIFICATION	In addition to polynucleotide polymerization, DNA polymerases and bacterial RNA polymerase can also remove nucleotides from the growing end of nucleic acid chains. For DNA polymerases this activity is an important factor in establishing fidelity in DNA synthesis. This report describes a novel in vitro activity of RNA polymerase II whereby it cleaves an RNA chain contained within an active elongation complex. These elongation complexes are arrested at a previously identified, naturally occurring transcriptional pause site in a human gene. The new 3'-end revealed by this cleavage remains associated with an active elongation complex and is capable of being extended by RNA polymerase II. Nascent RNA cleavage is evident after removal of free nucleotides and is dependent upon a divalent metal cation and transcription elongation factor SII. This function of SII could be important in its function as an activator of transcription elongation. It is also possible that the transcript cleavage activity of RNA polymerase II represents a proofreading function of the enzyme.			REINES, D (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM-46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FLORES O, 1989, J BIOL CHEM, V264, P8913; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUANG CC, 1981, J BIOL CHEM, V256, P4087; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; KAHN JD, 1989, J MOL BIOL, V205, P291, DOI 10.1016/0022-2836(89)90342-2; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KORNBERG A, 1980, DNA REPLICATION, P127; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MAITRA U, 1967, J BIOL CHEM, V242, P4897; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REEMS JA, 1991, J BIOL CHEM, V266, P4878; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1991, J BIOL CHEM, V266, P10510; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SKARNES WC, 1988, J MOL BIOL, V203, P153, DOI 10.1016/0022-2836(88)90099-X; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509	54	185	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3795	3800						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371280				2022-12-25	WOS:A1992HE60700041
J	MCDONALD, TV; NGHIEM, PT; GARDNER, P; MARTENS, CL				MCDONALD, TV; NGHIEM, PT; GARDNER, P; MARTENS, CL			HUMAN-LYMPHOCYTES TRANSCRIBE THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE AND EXHIBIT CF-DEFECTIVE CAMP-REGULATED CHLORIDE CURRENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL-LINE T84; CYCLIC-AMP; CHANNEL; IDENTIFICATION; EXPRESSION; TRANSPORT; MUTATIONS; CA-2+; ACID	Cystic fibrosis (CF) is the most common lethal genetic disease among Caucasians, primarily affecting epithelial tissues of the lung and gut. Mutations in a single gene, the cystic fibrosis transmembrane conductance regulator (CFTR), are responsible for this disease. Whether a physiological defect exists in the immune system of CF patients has remained controversial. A chloride ion transport defect has been described in human CF-derived lymphocytes; however, it has not been possible to detect CFTR mRNA in lymphocytes. We report here that normal human B-lymphoblasts display whole cell Cl- conductances induced by calcium-mediated pathways, volume regulation, and cAMP which are equivalent to currents described in epithelial cells. B-lymphoblasts from CF-affected humans demonstrated defective Cl- conductance regulation by cAMP but preserved regulation by calcium-mediated and volume regulation mechanisms. CFTR involvement in cAMP regulation of Cl- conductance in lymphocytes is further supported by our demonstration of the presence of appropriately spliced CFTR mRNA segments in human B and T lymphocytes as detected by an optimized reverse-transcription and polymerase chain reaction approach. The identity of the amplified products was confirmed by hybridization to CFTR-specific probes and DNA sequencing. Furthermore, the 3'-end of the gene was found in a T cell cDNA library. We conclude that CFTR mRNA is expressed in lymphocytes, consistent with the cAMP regulation of chloride transport present in normal lymphocytes but defective in CF-derived lymphocytes.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,FALK CURC,STANFORD,CA 94305; DNAX RES INST MOLEC & CELLULAR BIOL INC,RES INST,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NCI NIH HHS [CA09302] Funding Source: Medline; NHLBI NIH HHS [2HLC470] Funding Source: Medline; NIDDK NIH HHS [DK41324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P6799; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Frizzell R A, 1987, Prog Clin Biol Res, V254, P101; GRAY LS, 1986, J IMMUNOL, V136, P3032; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAGIWARA G, 1989, SCIENCE, V246, P1049, DOI 10.1126/science.2479979; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNUTSEN AP, 1988, INT ARCH ALLER A IMM, V85, P208, DOI 10.1159/000234504; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LAHAT N, 1989, J CLIN IMMUNOL, V9, P287, DOI 10.1007/BF00918660; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MATTHEWS WJ, 1980, NEW ENGL J MED, V302, P245, DOI 10.1056/NEJM198001313020501; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PROCHAZKA G, 1988, J IMMUNOL, V141, P1288; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LABORATO; SCHOUMACHER RA, 1987, SCIENCE, V248, P1416; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRONG TV, 1990, PED PULMONOL S, V5, pA195; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WARD CL, 1990, PED PULMONOL S, V5, pA215; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3242	3248						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371114				2022-12-25	WOS:A1992HD15400067
J	PARKER, TG; CHOW, KL; SCHWARTZ, RJ; SCHNEIDER, MD				PARKER, TG; CHOW, KL; SCHWARTZ, RJ; SCHNEIDER, MD			POSITIVE AND NEGATIVE CONTROL OF THE SKELETAL ALPHA-ACTIN PROMOTER IN CARDIAC-MUSCLE - A PROXIMAL SERUM RESPONSE ELEMENT IS SUFFICIENT FOR INDUCTION BY BASIC FIBROBLAST GROWTH-FACTOR (FGF) BUT NOT FOR INHIBITION BY ACIDIC FGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; TRANSCRIPTIONAL ACTIVATION; REGULATORY SEQUENCES; MOLECULAR-CLONING; GENE-EXPRESSION; XENOPUS EMBRYOS; MESSENGER-RNA; HIGH-AFFINITY; BINDING-SITE; DNA-BINDING	Like mechanical load in vivo, basic fibroblast growth factor (bFGF) selectively provokes cardiac expression of ''fetal'' genes including skeletal alpha-actin (SkA). Antithetically, acidic FGF (aFGF) suppresses SkA transcription. To define sites controlling SkA transcription in cardiac muscle cells, rat cardiac myocytes were transfected with internal-deletion and block-substitution mutations in the SkA promoter, including three motifs resembling the fos serum response element (SRE). The upstream, central, and proximal SREs each contributed to basal expression in cardiac myocytes. To determine whether identical elements mediate induction by bFGF versus inhibition by aFGF, the proximal SRE (SRE1) and fos SRE were positioned upstream from a neutral promoter. In cardiac myocytes, both the SRE1 and fos SRE were expressed at levels up to one-third that of the SkA promoter (nucleotides -202 to -11). Neither was expressed in quiescent cardiac fibroblasts. bFGF augmented SRE1-CAT activity, whereas aFGF produced no change; the fos SRE was induced by both. The transcriptional and mitogenic actions of aFGF were contingent on the presence of a putative nuclear translocation motif. Thus 1) the SkA SRE1 and fos SRE each suffice for tissue specificity in cardiac myocytes; 2) unlike the c-fos SRE, the SkA SRE1 is induced selectively by bFGF yet not aFGF; 3) sequences alternative or in addition to the SRE1 are obligatory for aFGF to suppress the SkA promoter; and 4) possible differences in intracellular localization are one basis for divergent actions of aFGF and bFGF in cardiac muscle cells.	BAYLOR COLL MED,MOLEC CARDIOL UNIT,ONE BAYLOR PLAZA,RM 506C,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [P50-HL42267, R01-HL38401, R01-HL39141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039141, P50HL042267, R01HL038401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BAIRD A, 1991, FIBROBLAST GROWTH FA; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BISHOPRIC NH, 1991, J CELL BIOCHEM, V15, P192; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHIBA M, 1990, CIRCULATION, V82, P761; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1004; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOMURO I, 1989, J CLIN INVEST, V83, P1102, DOI 10.1172/JCI113989; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LIU L, 1991, J CELL BIOCHEM     S, V15, P171; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MULVAGH SL, 1987, BIOCHEM BIOPH RES CO, V147, P627, DOI 10.1016/0006-291X(87)90977-6; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARLOW MH, 1991, DEV BIOL, V146, P139, DOI 10.1016/0012-1606(91)90454-B; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VILLAREAL FJ, 1991, J CELL BIOCHEM, V15, P174; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	77	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3343	3350						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371118				2022-12-25	WOS:A1992HD15400082
J	WILSON, JM; GROSSMAN, M; WU, CH; CHOWDHURY, NR; WU, GY; CHOWDHURY, JR				WILSON, JM; GROSSMAN, M; WU, CH; CHOWDHURY, NR; WU, GY; CHOWDHURY, JR			HEPATOCYTE-DIRECTED GENE-TRANSFER INVIVO LEADS TO TRANSIENT IMPROVEMENT OF HYPERCHOLESTEROLEMIA IN LOW-DENSITY-LIPOPROTEIN RECEPTOR-DEFICIENT RABBITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; LIVER-TRANSPLANTATION; PLASMA-EXCHANGE; WHHL-RABBIT; EXPRESSION; ATHEROSCLEROSIS; HYPERLIPIDEMIA; DELIVERY; SYSTEM	Familial hypercholesterolemia is an inherited disease in humans, caused by a deficiency of low density lipoprotein (LDL) receptors, that we have used as a model for developing liver-directed gene therapies. Our strategy is to reconstitute hepatic LDL receptor expression in vivo by administering a DNA-protein complex that is capable of targeting the delivery of functional LDL receptor genes to hepatocytes. Infusion of this DNA-protein complex into the peripheral circulation of a rabbit animal model for familial hypercholesterolemia resulted in hepatocyte-specific gene transfer and a temporary amelioration of hypercholesterolemia. This noninvasive approach to gene therapy should have applications in the treatment of a wide spectrum of human diseases.	UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV CONNECTICUT,SCH MED,DEPT INTERNAL MED,FARMINGTON,CT 06030; YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,DEPT INTERNAL MED,BRONX,NY 10461	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Connecticut; Yeshiva University; Albert Einstein College of Medicine	WILSON, JM (corresponding author), UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.							BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DOBBINS WO, 1978, DIAGNOSTIC ELECTRON, V1, P253; FINER MH, 1990, METHODS MOL BIOL GEN, V7, P1; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; KANO M, 1987, ARTERIOSCLEROSIS, V7, P256, DOI 10.1161/01.ATV.7.3.256; KOCHRAN WG, 1957, EXPT DESIGNS, P127; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; STARZL TE, 1984, LANCET, V1, P1382; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; TRINDER P, 1974, ANN CLIN BIOCHEM, V12, P226; VANBEVEREN C, 1985, RNA TUMOR VIRUSES; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	21	203	303	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					963	967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370472				2022-12-25	WOS:A1992GY96000046
J	UEDA, K; OKAMURA, N; HIRAI, M; TANIGAWARA, Y; SAEKI, T; KIOKA, N; KOMANO, T; HORI, R				UEDA, K; OKAMURA, N; HIRAI, M; TANIGAWARA, Y; SAEKI, T; KIOKA, N; KOMANO, T; HORI, R			HUMAN P-GLYCOPROTEIN TRANSPORTS CORTISOL, ALDOSTERONE, AND DEXAMETHASONE, BUT NOT PROGESTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE LLC-PK1; MULTIDRUG-RESISTANCE GENE; EPITHELIAL TRANSPORT; ADRENAL-CORTEX; MDR1 CDNA; MEMBRANE; BINDING; LOCALIZATION; EXPRESSION; TISSUES	We expressed human MDR1 cDNA isolated from the human adrenal gland in porcine LLC-PK1 cells. A highly polarized epithelium formed by LLC-GA5-COL300 cells that expressed human P-glycoprotein specifically on the apical surface showed a multidrug-resistant phenotype and had 8.3-, 3.4-, and 6.5-fold higher net basal to apical transport of H-3-labeled cortisol, aldosterone, and dexamethasone, respectively, compared with host cells. But progesterone was not transported, although it inhibited azidopine photoaffinity labeling of human P-glycoprotein and increased the sensitivity of multidrug-resistant cells to vinblastine. An excess of progesterone inhibited the transepithelial transport of cortisol by P-glycoprotein. These results suggest that cortisol and aldosterone are physiological substrates for P-glycoprotein in the human adrenal cortex and that substances that efficiently bind to P-glycoprotein are not necessarily transported by P-glycoprotein.	KYOTO UNIV HOSP,FAC MED,DEPT PHARM,KYOTO 60601,JAPAN	Kyoto University	UEDA, K (corresponding author), KYOTO UNIV,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,KYOTO 60601,JAPAN.			Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; CARMICHAEL J, 1987, CANCER RES, V47, P936; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAUTH C, 1988, AM J PHYSIOL, V254, pF341; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORIO M, 1989, J BIOL CHEM, V264, P14880; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; MISFELDT DS, 1981, J MEMBRANE BIOL, V59, P13, DOI 10.1007/BF01870816; NAITO M, 1989, BIOCHEM BIOPH RES CO, V158, P1066, DOI 10.1016/0006-291X(89)92830-1; NAITO M, 1989, CANCER RES, V49, P1452; NISHIKAWA T, 1984, ENDOCRINOLOGY, V114, P486, DOI 10.1210/endo-114-2-486; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; QIAN XD, 1990, J BIOL CHEM, V265, P18753; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SUGAWARA I, 1988, CANCER RES, V48, P4611; TAIT S A S, 1970, Endocrinology, V86, P360; TAKAYAMA A, 1991, J PHARMACOL EXP THER, V257, P200; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, J BIOL CHEM, V262, P505; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282	28	610	630	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24248	24252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360010				2022-12-25	WOS:A1992KA26300019
J	CAO, HN; BANGALORE, L; DOMPE, C; BORMANN, BJ; STERN, DF				CAO, HN; BANGALORE, L; DOMPE, C; BORMANN, BJ; STERN, DF			AN EXTRA CYSTEINE PROXIMAL TO THE TRANSMEMBRANE DOMAIN INDUCES DIFFERENTIAL CROSS-LINKING OF P185(NEU) AND P185(NEU)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; POINT MUTATION; SENSORY RECEPTOR; CELL-SURFACE; PROTEIN; AGGREGATION; ACTIVATION; P185	The neu proto-oncogene encodes a receptor tyrosine kinase (p185) that is closely related to the epidermal growth factor receptor. It has been proposed that receptor tyrosine kinases are activated through oligomerization. Because this clustering model predicts that oligomerization of receptors is sufficient to activate them, we determined if p185 can be activated by introducing an extra cysteine proximal to the transmembrane domain. This should induce inter-receptor disulfide bonding and, according to the clustering model, activate the receptor. This amino acid substitution enhanced recovery of both normal and transforming neu proteins as dimers, with normal p185 recovered predominantly as monomers and transforming p185* as dimers. However, the cysteine substitution did not affect the transforming activity of the two proteins.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Yale University; Boehringer Ingelheim					NCI NIH HHS [CA45708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO HN, 1991, ONCOGENE, V6, P705; CARRAWAY KL, 1991, J BIOL CHEM, V266, P8899; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOBASHI Y, 1991, ONCOGENE, V6, P1151; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FLANAGAN JG, 1988, P NATL ACAD SCI USA, V85, P8057, DOI 10.1073/pnas.85.21.8057; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAMPS MP, 1988, ONCOGENE, V2, P305; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	27	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20489	20492						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356980				2022-12-25	WOS:A1992JR85800114
J	FUKUI, K; MIYAKE, Y				FUKUI, K; MIYAKE, Y			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF A HUMAN GENE ENCODING D-AMINO-ACID OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; NUCLEOTIDE-SEQUENCE; CATALYTIC FUNCTION; MESSENGER-RNA; KIDNEY; DNA; EXPRESSION; RATS; PROPARGYLGLYCINE; PURIFICATION	Genomic clones covering the entire sequence of the gene encoding human D-amino-acid oxidase (DAO) (EC 1.4.3.3), one of the principal and characteristic flavoenzymes of peroxisomes, were isolated from human placental genomic libraries with the aid of a previously cloned cDNA for human DAO as a probe. Nucleotide sequence analysis revealed that the gene, present as a single copy in the human genome, comprises 11 exons and spans 20 kilobase pairs. The protein sequences containing the catalytically important residues, Tyr-228 and His-307, are coded for by separate exons. Heterologous transcription initiation sites were identified by primer extension analysis, and the sequence of the 5'-flanking region of the DAO gene was found to show some features common to other mammalian genes, such as those of glucocorticoid and the cAMP-responsive element. An additional noteworthy feature is the presence of promoter-like sequences in the first intron of the gene. In addition, two sequences of alternating pyrimidine and purine nucleotides, (CA)20 and (CA)17, are also present in the first intron. Such sequences may play some role in the expression of the DAO gene in human tissues. With the use of genomic DNAs prepared from human and Chinese hamster somatic hybrid cells as templates for the polymerase chain reaction, the gene for DAO was localized to human chromosome 12.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,5-7-1 FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan				Fukui, Kiyoshi/0000-0002-7438-4938				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHAN AWK, 1979, J HISTOCHEM CYTOCHEM, V27, P751, DOI 10.1177/27.3.39098; COCHET M, 1982, NATURE, V297, P335, DOI 10.1038/297335a0; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; FUKUI K, 1986, BIOCHEM BIOPH RES CO, V141, P1222, DOI 10.1016/S0006-291X(86)80175-9; FUKUI K, 1988, BIOCHEMISTRY-US, V27, P6693, DOI 10.1021/bi00418a008; FUKUI K, 1991, FLAVINS AND FLAVOPROTEINS 1990, P143; GOLDFISCHER S, 1986, J PEDIATR-US, V108, P25, DOI 10.1016/S0022-3476(86)80764-8; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HAMILTON GA, 1979, P NATL ACAD SCI USA, V76, P2625, DOI 10.1073/pnas.76.6.2625; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HONJO T, 1979, CELL, V18, P559, DOI 10.1016/0092-8674(79)90072-2; HORIIKE K, 1975, J BIOCHEM-TOKYO, V78, P57; HORIIKE K, 1985, ACTA HISTOCHEM CYTOC, V18, P539, DOI 10.1267/ahc.18.539; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JACOBS P, 1987, GENE, V59, P55, DOI 10.1016/0378-1119(87)90266-6; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1620; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MARCOTTE P, 1976, BIOCHEMISTRY-US, V15, P3070, DOI 10.1021/bi00659a021; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; MIYAKE Y, 1987, FLAVINS FLAVOPROTEIN, P501; MIYANO M, 1991, J BIOCHEM-TOKYO, V109, P171, DOI 10.1093/oxfordjournals.jbchem.a123340; MOMOI K, 1990, J BIOCHEM-TOKYO, V108, P406, DOI 10.1093/oxfordjournals.jbchem.a123214; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; NAKAJIMA H, 1981, BIOMED RES-TOKYO, V2, P154, DOI 10.2220/biomedres.2.154; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TADA M, 1990, GENE, V90, P293, DOI 10.1016/0378-1119(90)90193-U; WATANABE F, 1989, BIOCHEM BIOPH RES CO, V165, P1422, DOI 10.1016/0006-291X(89)92762-9; WATANABE F, 1988, FEBS LETT, V238, P269, DOI 10.1016/0014-5793(88)80494-0; WATANABE F, 1989, J BIOCHEM-TOKYO, V105, P1024, DOI 10.1093/oxfordjournals.jbchem.a122760; WEBER JL, 1989, AM J HUM GENET, V44, P388	41	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18631	18638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356107				2022-12-25	WOS:A1992JN50200059
J	MIZOBATA, T; AKIYAMA, Y; ITO, K; YUMOTO, N; KAWATA, Y				MIZOBATA, T; AKIYAMA, Y; ITO, K; YUMOTO, N; KAWATA, Y			EFFECTS OF THE CHAPERONIN GROE ON THE REFOLDING OF TRYPTOPHANASE FROM ESCHERICHIA-COLI - REFOLDING IS ENHANCED IN THE PRESENCE OF ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ATP HYDROLYSIS; PROTEIN; BINDING; PURIFICATION; MECHANISM; ASSAY; GENE	The refolding of the tetrameric enzyme tryptophanase was facilitated by the chaperonin GroE. Maximum refolding yield of tryptophanase molecules (about 80%) was attained in the presence of a 15-fold excess of GroE 21-mer over tryptophanase monomer. The GroEL subunit was required for this improvement in refolding yield, whereas the GroES subunit was not. Light scattering experiments of the refolding reaction revealed that GroE bound to tryptophanase folding intermediates and suppressed their aggregation. The presence of ATP was required for the efficient dissociation of tryptophanase from GroEL. However, our experiments indicated that tryptophanase dissociated readily from GroEL in the presence of not only ATP, but also in the presence of non-hydrolyzable ATP analogues such as ATP-gamma-S (adenosine 5'-O-(3-thiotriphosphate)) and AMP-PNP (adenyl-5'-yl imidodiphosphate) as well. Surprisingly, the release of tryptophanase from GroEL was facilitated in the presence of ADP as well. We concluded that the binding of nucleotides such as ATP and ADP changed the conformation of GroEL and facilitated the dissociation of tryptophanase molecules. The conformation formed in the presence of ADP was distinct from the conformation formed in the presence of ATP, as shown by the selective dissociation of various folding proteins from the two conformations.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University; Kyoto University			Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KAWATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P756, DOI 10.1016/S0006-291X(05)80100-7; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; SUELTER CH, 1976, FEBS LETT, V66, P230, DOI 10.1016/0014-5793(76)80510-8; TANI S, 1990, BIOTECHNOL APPL BIOC, V12, P28; TOKUSHIGE M, 1989, BIOCHIMIE, V71, P711, DOI 10.1016/0300-9084(89)90087-4; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	34	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17773	17779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355477				2022-12-25	WOS:A1992JM22300048
J	ENGLEKA, KA; MACIAG, T				ENGLEKA, KA; MACIAG, T			INACTIVATION OF HUMAN FIBROBLAST GROWTH FACTOR-I (FGF-1) ACTIVITY BY INTERACTION WITH COPPER IONS INVOLVES FGF-1 DIMER FORMATION INDUCED BY COPPER-CATALYZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; NUCLEOTIDE-SEQUENCE; BIOLOGICAL-ACTIVITY; FACTOR FAMILY; FACTOR-I; HEPARIN; BINDING; ANGIOGENESIS; PURIFICATION; PROTEIN	Although the angiogenic proteins acidic fibroblast growth factor (FGF-1) and basic fibroblast growth factor (FGF-2) both interact with the transition metal copper, itself a putative modulator of angiogenesis, a role for copper in FGF function has not been established. Using nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis, we detect the complete conversion of recombinant forms of human FGF-1 monomer protein to FGF-1 homodimers after exposure to copper ions. In contrast, not all forms of bovine FGF-1 isolated from bovine brain or a recombinant preparation of human FGF-2 completely formed homodimers after exposure to copper ions under similar conditions. Since the copper-induced FGF-1 homodimers reverted to the monomer form in the presence of dithiothreitol, specific alkylation of cysteine residues by pyridylethylation prevented FGF-1 homodimer formation, and preformed FGF-1 homodimers could not be dissociated by the metal chelator EDTA, FGF-1 dimer formation appeared to result from the formation of intermolecular disulfide bonds by copper-induced oxidation of sulfhydryl residues. FGF-1 homodimers bound with similar apparent affinity as FGF-1 monomers to immobilized copper ions, both eluting at 60 mM imidazole. Both human FGF-1 monomer and dimer forms had a 6-fold higher apparent affinity for immobilized copper ions, as compared with human FGF-2, which eluted in the monomer form at 10 mM imidazole. Further, in contrast to FGF-1 monomers, which dissociate from immobilized heparin in 1.0 M NaCl, preformed FGF-1 homodimers had reduced apparent affinity for immobilized heparin and eluted at 0.4 M NaCl. In contrast, the apparent affinity of human FGF-2 for immobilized heparin was unaffected after exposure to copper ions. Heparin appeared to modulate the formation of copper-induced intermolecular disulfide bonds for FGF-1 but not FGF-2, since co-incubation of heparin and copper with FGF-1 monomers resulted in dimers and other oligomeric complexes. FGF-1 copper-induced homodimers failed to induce mitogenesis in [H-3]thymidine incorporation assays, an effect which could be reversed by treatment with dithiothreitol, whereas FGF-2-induced mitogenic activity was relatively unaffected by pretreatment with copper. The differences between human FGF-1 and FGF-2 in protein-copper interactions may be due to differing free thiol content and arrangement between the two proteins. A recombinant human FGF-1 mutant containing the two cysteines conserved throughout the FGF family of proteins but lacking a cysteine residue (Cys 131) present in wild-type human FGF-1 but not human FGF-2 readily formed copper-induced dimers. This suggests FGF-1-copper interactions may involve the cysteine residues conserved among all the members of the FGF family. Despite the differences in copper interactions between FGF-1 and FGF-2, copper-induced heterodimers between these two proteins were demonstrated, indicating FGF-1 and FGF-2 can form mixed thiols with each other. The difference in copper interactions between different forms of FGF-1 and FGF-2 are important in further attempts to determine any putative role for copper in FGF action.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA	American Red Cross					NHLBI NIH HHS [HL32348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALPERNELRAN H, 1985, SURG FORUM, V36, P498; ARAKAWA T, 1989, BIOCHEM BIOPH RES CO, V161, P335, DOI 10.1016/0006-291X(89)91601-X; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BERG JM, 1990, J BIOL CHEM, V265, P6513; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FOX GM, 1988, J BIOL CHEM, V263, P18452; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GRUSHKA E, 1982, ANAL LETT PT B, V15, P1277, DOI 10.1080/00032718208069533; GULLINO PM, 1986, ANTICANCER RES, V6, P153; HANNAN GN, 1982, J CELL PHYSIOL, V111, P207, DOI 10.1002/jcp.1041110213; HARPER JW, 1986, BIOCHEMISTRY-US, V25, P4097, DOI 10.1021/bi00362a017; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JONES DH, 1990, NATURE, V344, P793, DOI 10.1038/344793a0; JONES DH, 1990, BIOTECHNIQUES, V8, P172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MAQUART FX, 1988, FEBS LETT, V238, P343, DOI 10.1016/0014-5793(88)80509-X; MCAUSLAN BR, 1980, EXP CELL RES, V130, P147, DOI 10.1016/0014-4827(80)90051-8; MCKEEHAN WL, 1987, ANAL BIOCHEM, V164, P563, DOI 10.1016/0003-2697(87)90534-3; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PICKART L, 1987, BIOL COPPER COMPLEXE, P314; RAJU KS, 1982, J NATL CANCER I, V69, P1183; RAJU KS, 1984, CANCER RES, V44, P1579; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROWE JM, 1986, CANCER RES, V46, P1408; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHING Y, 1990, ANAL BIOCHEM, V185, P108, DOI 10.1016/0003-2697(90)90263-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1988, J BIOL CHEM, V263, P9059; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STIVALA SS, 1977, FED PROC, V36, P83; STRYDOM DJ, 1986, BIOCHEMISTRY-US, V25, P945, DOI 10.1021/bi00353a001; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; THOMPSON SA, 1992, J BIOL CHEM, V267, P2269; THOMPSON SA, 1991, METHOD ENZYMOL, V198, P96; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	56	90	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11307	11315						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375939				2022-12-25	WOS:A1992HX16900059
J	MENENDEZARIAS, L; RISCO, C; OROSZLAN, S				MENENDEZARIAS, L; RISCO, C; OROSZLAN, S			ISOLATION AND CHARACTERIZATION OF ALPHA-2-MACROGLOBULIN-PROTEASE COMPLEXES FROM PURIFIED MOUSE MAMMARY-TUMOR VIRUS AND CULTURE SUPERNATANTS FROM VIRUS-INFECTED CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-WEIGHT PROTEASE; MAMMALIAN-CELLS; TISSUE-CULTURE; RAT-LIVER; GAG; INHIBITORS; RETROVIRUSES; PURIFICATION	Cleavage of oligopeptide substrates mimicking the maturation sites in the Gag polyproteins of the mouse mammary tumor virus was assayed using lysed virus. Cleavage at the expected P1-P1' positions was detected in four of seven synthetic peptides. However, studies with specific inhibitors of retroviral proteases showed that only two of them could be unequivocally attributed to the viral enzyme. In an attempt to characterize other proteolytic activities that copurify with the virus, we isolated a multicatalytic high molecular mass protease (700 kDa) that copurifies with the virus. This protein has been identified as an alpha-2-macroglobulin-protein complex according to its biochemical properties and ultrastructure. The proteases forming these complexes are mainly serine proteases and can be inhibited by phenylmethylsulfonyl fluoride. However, other compounds such as chymostatin and elastatinal are more effective inhibitors. The relative efficacy of each compound depends on the substrate, since the complexes described herein appear to be multicatalytic. Elastatinal is a very good inhibitor of the cleavages found at Ala-Ala bonds in peptides representing the capsid/nucleocapsid site, while chymostatin inhibits certain cleavages at the carboxyl terminus of bonds involving leucine and valine in three of the substrates used. Therefore, the alpha-2-macroglobulin present in the cell culture medium is able to bind proteases, forming high molecular weight complexes, which are active against peptide substrates, copurify with the virus and are responsible for the nonviral proteolytic activities found in the purified virus. Elastase appears to be the main proteolytic activity which can be detected in the alpha-2-macroglobulin-protease complexes associated with the virus.	NCI, FREDERICK CANC RES & DEV CTR, MATH BIOL LAB, STRUCT BIOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MENENDEZARIAS, L (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA.		Menendez Arias, Luis/G-2436-2016; Risco, Cristina/K-4308-2014; Menendez Arias, Luis/N-7447-2016	Risco, Cristina/0000-0001-7501-5934; Menendez Arias, Luis/0000-0002-1251-6640	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN KB, 1983, J VIROL, V48, P765, DOI 10.1128/JVI.48.3.765-769.1983; ANDERSEN KB, 1989, J GEN VIROL, V70, P1921, DOI 10.1099/0022-1317-70-7-1921; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFIN JM, 1981, FUNDAMENTAL VIROLOGY, P645; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DANGOTT LJ, 1982, BIOCHEM BIOPH RES CO, V107, P1243, DOI 10.1016/S0006-291X(82)80131-9; FINE D, 1978, CANCER RES, V38, P3123; FINE DL, 1974, APPL MICROBIOL, V28, P1040, DOI 10.1128/AEM.28.6.1040-1046.1974; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; OWENS RB, 1972, J NATL CANCER I, V49, P1321; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SMITH GH, 1973, J VIROL, V11, P575, DOI 10.1128/JVI.11.4.575-584.1973; TANAKA H, 1972, VIROLOGY, V49, P61, DOI 10.1016/S0042-6822(72)80007-2; TANAKA K, 1986, J BIOL CHEM, V261, P5204; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; TSUJI A, 1989, J BIOL CHEM, V264, P16093; TSUJI A, 1991, BIOCHIM BIOPHYS ACTA, V1078, P85, DOI 10.1016/0167-4838(91)90096-I; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; WERB Z, 1982, J INVEST DERMATOL S1, V79, P154; YOSHINAKA Y, 1985, J VIROL, V55, P870, DOI 10.1128/JVI.55.3.870-873.1985; ZEYDEL M, 1986, CANCER RES, V46, P6438	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11392	11398						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375941				2022-12-25	WOS:A1992HX16900071
J	ESTEBAN, C; GEUSKENS, M; ENA, JM; MISHAL, Z; MACHO, A; TORRES, JM; URIEL, J				ESTEBAN, C; GEUSKENS, M; ENA, JM; MISHAL, Z; MACHO, A; TORRES, JM; URIEL, J			RECEPTOR-MEDIATED UPTAKE AND PROCESSING OF VITAMIN-D-BINDING PROTEIN IN HUMAN B-LYMPHOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN RECEPTORS; GROUP-SPECIFIC COMPONENT; HUMAN-LYMPHOCYTES; FATTY-ACIDS; GC-PROTEIN; RAT RHABDOMYOSARCOMA; PLASMA-MEMBRANE; SERUM-ALBUMIN; COATED PITS; ENDOCYTOSIS	Vitamin D-binding protein (DBP), a member of a multigene family including alpha-fetoprotein (AFP) and albumin, is a serum glycoprotein that reversibly binds and transports vitamin D and its metabolites to target cells. In this work, we demonstrate that normal and malignant human B-lymphocytes specifically bind and internalize DBP. Radioiodinated DBP (I-125-DBP) was used to follow the uptake of the protein by Raji cells, a human pre-B-lymphoma cell line. Time course studies of DBP uptake by these cells exhibited a saturable profile at both 4 and 37-degrees-C. The binding saturation curve obtained by incubating Raji cells at 4-degrees-C with different concentrations (1.5 nM to 1.5-mu-M) of I-125-DBP showed two saturation plateaus; Scatchard analysis showed the presence of two groups of receptor sites with a K(d1) of 2.04 x 10(-7) M (n1 = 42,161 +/- 4,336 sites/cell) and a K(d2) of 1.01 x 10(-6) M (n2 = 198,000 +/- 48,000 sites/cell). After incubation of Raji cells at 37-degrees-C with both fluorescein isothiocyanate (FITC) and horseradish peroxidase conjugates, DBP was internalized and could be localized in the cytoplasm. DBP-horseradish peroxidase conjugates were used to follow the uptake and to determine the endocytic pathway of the protein in Raji cells. The initial steps, contrary to those observed for AFP, did not apparently involve coated pits and vesicles. Small vesicles (approximately 50-60 nM) with electron-dense DBP-horseradish peroxidase reaction products were observed that could fuse with large endosomes. These endosomes appeared dispersed in the cytoplasm with some preferential localization in the Golgi centrosphere region. Pulse-chase experiments showed that only 10% of the uptaken protein was released in a nondegraded form. Accordingly, most DBP molecules accumulated in endosomes should be degraded in lysosomes, instead of being recycled back to the surface, as in the case of AFP. Contrary to malignant B-cells (Raji), the uptake ability for DBP of normal quiescent B-lymphocytes was very low. Specific binding and internalization of DBP-FITC by these cells were observed following mitogen-induced activation. Significant values of uptake were obtained at 37-degrees-C after 72 h of incubation in the presence of pokeweed mitogen. The binding of DBP-FITC was partially inhibited in the presence of an excess of unlabeled protein. Taken together, the actual results suggest that DBP receptors are constitutively expressed by malignant B-cells and in a transitory form by normal B-lymphocytes undergoing mitogen-induced activation. In analogy to the AFP/AFP receptor pathway of fatty acid transfer in cells, a dual-receptor model acting as a regulatory mechanism for delivery of vitamin D metabolites to growing cells is proposed.	INST RECH SCI CANC, CHIM PROT LAB, F-94802 VILLEJUIF, FRANCE; CNRS, CTR SOUTIEN RECH CANC, CYTOMETRIE LAB, F-94802 VILLEJUIF, FRANCE; UNIV LIBRE BRUXELLES, CYTOL & EMBRYOL MOLEC LAB, B-1640 RHODE ST GENESE, BELGIUM; UNIV ZARAGOZA FAC VET, DEPT TECNOL & BIOQUIM ALIMENTOS, E-50013 ZARAGOZA, SPAIN	Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles			Torres, Juan Maria/L-8768-2013; Quirós, Antonio Macho/H-1403-2012	Torres, Juan Maria/0000-0003-0443-9232; Quirós, Antonio Macho/0000-0002-9294-8709				ADRIAN GS, 1990, EXP CELL RES, V186, P385, DOI 10.1016/0014-4827(90)90321-Z; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BERGMANN JS, 1982, J CELL BIOCHEM, V20, P247, DOI 10.1002/jcb.240200305; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; CALVO M, 1989, BIOCHEM BIOPH RES CO, V163, P14, DOI 10.1016/0006-291X(89)92091-3; CONSTANS J, 1981, IMMUNOL LETT, V3, P159, DOI 10.1016/0165-2478(81)90120-6; COOKE NE, 1987, CYTOGENET CELL GENET, V44, P98, DOI 10.1159/000132351; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1979, J BIOL CHEM, V254, P5965; ENA JM, 1989, BIOCHEM INT, V19, P1; ESTEBAN C, 1991, INT J CANCER, V49, P425, DOI 10.1002/ijc.2910490320; GEUSKENS M, 1982, ONCODEV BIOL MED, V3, P291; GEUSKENS M, 1989, EUR J CELL BIOL, V50, P418; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GUOTH M, 1990, ENDOCRINOLOGY, V127, P2313, DOI 10.1210/endo-127-5-2313; LABORDA J, 1987, INT J CANCER, V40, P314, DOI 10.1002/ijc.2910400306; LEBOUTEILLER PP, 1983, J IMMUNOL METHODS, V61, P301, DOI 10.1016/0022-1759(83)90224-7; MACHII T, 1986, ACTA HAEMATOL-BASEL, V75, P26, DOI 10.1159/000206075; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; NAHON JL, 1988, J BIOL CHEM, V263, P11436; NAVAL J, 1985, P NATL ACAD SCI USA, V82, P3301, DOI 10.1073/pnas.82.10.3301; NEL AE, 1985, CLIN IMMUNOL IMMUNOP, V37, P191, DOI 10.1016/0090-1229(85)90150-3; NESTLER JE, 1987, ENDOCRINOLOGY, V120, P1996, DOI 10.1210/endo-120-5-1996; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PETRINI M, 1985, J BIOL CHEM, V260, P1804; PETRINI M, 1983, NATURE, V306, P73, DOI 10.1038/306073a0; PETRINI M, 1984, CLIN IMMUNOL IMMUNOP, V31, P282, DOI 10.1016/0090-1229(84)90248-4; PIKE JW, 1980, LIFE SCI, V26, P407, DOI 10.1016/0024-3205(80)90158-7; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; SANGER JM, 1990, P NATL ACAD SCI USA, V87, P5474, DOI 10.1073/pnas.87.14.5474; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SCHOENTGEN F, 1985, FEBS LETT, V185, P47, DOI 10.1016/0014-5793(85)80738-9; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; TORRES JM, 1991, INT J CANCER, V47, P110, DOI 10.1002/ijc.2910470120; TORRES JM, 1990, J IMMUNOL METHODS, V134, P163, DOI 10.1016/0022-1759(90)90377-8; TORRES JM, 1989, MOL IMMUNOL, V26, P851, DOI 10.1016/0161-5890(89)90141-7; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; URIEL J, 1983, BRIT J CANCER, V48, P261, DOI 10.1038/bjc.1983.181; Uriel J, 1989, J Nucl Med Allied Sci, V33, P12; URIEL J, 1987, J BIOL CHEM, V262, P3579; Uriel J., 1989, BIOL PROPERTIES ALPH, VII, P103; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VILLACAMPA MJ, 1984, BIOCHEM BIOPH RES CO, V122, P1322, DOI 10.1016/0006-291X(84)91236-1; WILLIAMS MH, 1988, BIOCHEM BIOPH RES CO, V153, P1019, DOI 10.1016/S0006-291X(88)81330-5	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10177	10183						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374401				2022-12-25	WOS:A1992HT96500109
J	SUBBARAMAIAH, K; SIMMS, SA				SUBBARAMAIAH, K; SIMMS, SA			PHOTOLABELING OF CHER METHYLTRANSFERASE WITH S-ADENOSYL-L-METHIONINE (ADOMET) - STUDIES ON THE ADOMET BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-MODIFICATION SYSTEM; TARGET-RECOGNIZING DOMAINS; II DNA METHYLTRANSFERASES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CYTOSINE METHYLTRANSFERASES; CATALYTIC MECHANISM; MODIFICATION ENZYME; PROTEIN; ADENOSYLMETHIONINE	CheR methyltransferase from Salmonella typhimurium was directly photolabeled with S-adenosyl-L-[methyl-H-3]methionine. The labeled protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then was detected by fluorography. The methylase-S-adenosyl-L-methionine adduct was found to be stable under the experimental conditions employed. Labeling was found to be a function of the concentration of enzyme, S-adenosyl-L-methionine (AdoMet), and the intensity and time of UV irradiation. The extent of labeling and protein methylation was found to be inhibited by S-adenosyl-L-homocysteine, S-adenosyl-L-ethionine, and sinefungin, which are known to compete with AdoMet for the same binding site on the enzyme. Our earlier data showed that the enzyme has 2 cysteine residues and that these are important for enzyme activity. Here, we show that sulfhydryl reagents inhibit the photolabeling of the substrate to the enzyme, indicating the presence of cysteine in the vicinity of the substrate-binding site. We also found that when Cys31 was modified to Ser, no photolabeling of CheR was observed, whereas a modification of Cys229 to Ser had little effect on the ability of AdoMet to label the enzyme. This suggests that Cys31 is located at or near AdoMet-binding site. The labeled protein was cleaved at tryptophan residues, generating two major fragments, each containing 1 cysteine residue. SDS-PAGE and fluorography of the cleaved products indicated the presence of the label being associated with the Cys31 fragment. Similar results were obtained when the labeled protein was cleaved at glutamic acid residues using V8 protease. A tryptic digest of the labeled protein showed two radioactive peptide peaks when subjected to separation on reverse phase high pressure liquid chromatography. The labeled peptides were further digested to free amino acids, and the labeled amino acid was identified as S-methylcysteine by thin layer chromatography. These results indicate that Cys31 may be involved with substrate binding, as well as with catalysis.	CUNY CITY COLL, DEPT CHEM, CONVENT AVE 138TH ST, NEW YORK, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)								BOUGUELERET L, 1984, NUCLEIC ACIDS RES, V12, P3659, DOI 10.1093/nar/12.8.3659; BOYD A, 1982, ANNU REV PHYSIOL, V44, P501, DOI 10.1146/annurev.ph.44.030182.002441; CHANDRASEGARAN S, 1987, STRUCTURE EXPRESSION, P149; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COX R, 1980, CANCER RES, V40, P61; HATTMAN S, 1985, J BACTERIOL, V164, P932, DOI 10.1128/JB.164.2.932-937.1985; HURT JH, 1984, BIOCHEM BIOPH RES CO, V122, P499; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KEALEY JT, 1991, BIOCHEMISTRY-US, V30, P9724, DOI 10.1021/bi00104a022; KISS A, 1985, NUCLEIC ACIDS RES, V13, P6403, DOI 10.1093/nar/13.18.6403; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LAUSTER R, 1987, FEBS LETT, V220, P167, DOI 10.1016/0014-5793(87)80897-9; LAUSTER R, 1989, J MOL BIOL, V206, P313, DOI 10.1016/0022-2836(89)90481-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNARELLI BM, 1985, P NATL ACAD SCI USA, V82, P4468, DOI 10.1073/pnas.82.13.4468; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; PAJARES MA, 1984, BIOCHEM J, V223, P61, DOI 10.1042/bj2230061; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; REICH NO, 1990, J BIOL CHEM, V265, P8929; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SCHONER B, 1983, GENE, V24, P227, DOI 10.1016/0378-1119(83)90083-5; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SOM S, 1991, J BIOL CHEM, V266, P2937; SOM S, 1990, J BIOL CHEM, V265, P4278; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SRPINGER WR, 1977, P NATL ACAD SCI USA, V74, P533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; SUBBARAMAIAH K, 1991, J BIOL CHEM, V266, P19023; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; THERIAULT G, 1985, NUCLEIC ACIDS RES, V13, P8441, DOI 10.1093/nar/13.23.8441; VIDGREN J, 1991, PROTEINS, V11, P233, DOI 10.1002/prot.340110309; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WU JC, 1987, J BIOL CHEM, V262, P4778; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; YU PH, 1984, CAN J BIOCHEM CELL B, V62, P964, DOI 10.1139/o84-123; YU PH, 1983, BIOCHIM BIOPHYS ACTA, V742, P517, DOI 10.1016/0167-4838(83)90269-8	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8636	8642						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349019				2022-12-25	WOS:A1992HQ18500101
J	PATTANAKITSAKUL, SN; ZHENG, JH; NATSUUMESAKAI, S; TAKAHASHI, M; NONAKA, M				PATTANAKITSAKUL, SN; ZHENG, JH; NATSUUMESAKAI, S; TAKAHASHI, M; NONAKA, M			ABERRANT SPLICING CAUSED BY THE INSERTION OF THE B2 SEQUENCE INTO AN INTRON OF THE COMPLEMENT C4 GENE IS THE BASIS FOR LOW C4 PRODUCTION IN H-2K MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-LIMITED PROTEIN; 4TH COMPONENT; MURINE COMPLEMENT; MOUSE COMPLEMENT; MOLECULAR MAP; S-REGION; C-4; SLP; CDNA; MHC	The serum level of the fourth component of complement (C4) in mice bearing the H-2k haplotype is only 1/10 to 1/20 of that of non-H-2k mice. We have analyzed C4 cDNA clones from B10.BR(H-2k) mouse liver and found aberrant C4 cDNA which contained a 200-base pair (bp) insertion between the exon 13 and exon 14 encoded sequences in addition to the normal C4 cDNA. The 5' 148 bp and the 3' 52 bp of this insert were derived from the B2 sequence, the short interspersed repeats of mouse genome, and the central part of intron 13, respectively. Sequence analysis of intron 13 of the C4k gene showed the presence of a complete copy of a B2 consensus sequence. The structure of aberrant C4 mRNA indicated that the possible 3' splice site in the B2 sequence and the cryptic 5' splice site in intron 13 were used. Both the insertion of the B2 sequence into intron 13 and the presence of aberrant mRNA in the liver were specific to H-2k-bearing mice, suggesting that the aberrant splicing due to the B2 insertion is the basis for low C4 expression in H-2k mice.	KANAZAWA UNIV,INST CANC RES,DEPT IMMUNOBIOL,13-1 TAKARAMACHI,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University			NONAKA, MASARU/G-4929-2014					AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX BJ, 1988, NUCLEIC ACIDS RES, V16, P6857, DOI 10.1093/nar/16.14.6857; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; KLEIN J, 1978, IMMUNOGENETICS, V6, P489, DOI 10.1007/BF01563941; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; MULLER U, 1987, EMBO J, V6, P369, DOI 10.1002/j.1460-2075.1987.tb04764.x; NAKAYAMA K, 1987, J IMMUNOL, V138, P620; NAKAYAMA K, 1990, IMMUNOGENETICS, V31, P361, DOI 10.1007/BF02115011; NONAKA M, 1985, IMMUNOL REV, V87, P81, DOI 10.1111/j.1600-065X.1985.tb01146.x; NONAKA M, 1985, J BIOL CHEM, V260, P936; NONAKA M, 1984, P NATL ACAD SCI-BIOL, V81, P6822, DOI 10.1073/pnas.81.21.6822; OGATA RT, 1984, P NATL ACAD SCI-BIOL, V81, P4908, DOI 10.1073/pnas.81.15.4908; OGATA RT, 1989, J BIOL CHEM, V264, P16565; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROOS MH, 1978, J IMMUNOL, V121, P1106; SACKSTEIN R, 1984, J IMMUNOL, V133, P1618; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEPICH DS, 1985, P NATL ACAD SCI USA, V82, P5895, DOI 10.1073/pnas.82.17.5895; SHREFFLER DC, 1976, TRANSPLANT REV-DENMA, V32, P140; SHREFFLER DC, 1982, HISTOCOMPATIBILITY A, P189; TAILLONMILLER PA, 1988, J IMMUNOL, V141, P2382; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7814	7820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373139				2022-12-25	WOS:A1992HN48500086
J	FIELD, MC; MENON, AK; CROSS, GAM				FIELD, MC; MENON, AK; CROSS, GAM			DEVELOPMENTAL VARIATION OF GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS IN TRYPANOSOMA-BRUCEI - INVITRO BIOSYNTHESIS OF INTERMEDIATES IN THE CONSTRUCTION OF THE GPI ANCHOR OF THE MAJOR PROCYCLIC SURFACE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; PHOSPHATIDYLINOSITOL; PROTEINS; CLEAVAGE	The African trypanosome, Trypanosoma brucei, expresses two abundant stage-specific glycosylphosphatidylinositol (GPI)-anchored glycoproteins, the procyclic acidic repetitive protein (PARP or procyclin) in the procyclic form, and the variant surface glycoprotein (VSG) in the mammalian bloodstream form. The GPI anchor of VSG can be readily cleaved by phosphatidylinositol (PI)-specific phospholipase C (PI-PLC), whereas that of PARP cannot, due to the presence of a fatty acid esterified to the inositol. In the bloodstream form trypanosome, a number of GPIs which are structurally related to the VSG GPI anchor have been identified. In addition, several structurally homologous GPIs have been described, both in vivo and in vitro, that contain acyl-inositol. In vivo the procyclic stage trypanosome synthesizes a GPI that is structurally homologous to the PARP GPI anchor, i.e. contains acylinositol. No PI-PLC-sensitive GPIs have been detected in the procyclic form. Using a membrane preparation from procyclic trypanosomes which is capable of synthesizing GPI lipids upon the addition of nucleotide sugars we find that intermediate glycolipids are predominantly of the acylinositol type, and the mature ethanolamine-phosphate-containing precursors are exclusively acylated. We suggest that the differences between the bloodstream and procyclic form GPI biosynthetic intermediates can be accounted for by the developmental regulation of an inositol acylhydrolase, which is active only in the bloodstream form, and a glyceride fatty acid remodeling system, which is only partially functional in the procyclic form.			FIELD, MC (corresponding author), ROCKEFELLER UNIV, MOLEC PARASITOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Field, Mark/AAD-6455-2021; Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Menon, Anant Kumar/0000-0001-6924-2698; Field, Mark/0000-0002-4866-2885	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUN R, 1979, ACTA TROP, V36, P289; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGSTLER M, 1991, GLYCOCONJUGATE J, V8, P269; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1991, TRENDS GLYCOSCI GLYC, V3, P107; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; WALTER EI, 1990, J IMMUNOL, V144, P1030	30	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5324	5329						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371998				2022-12-25	WOS:A1992HH74700051
J	HSIEH, JT; ZHAU, HE; WANG, XH; LIEW, CC; CHUNG, LWK				HSIEH, JT; ZHAU, HE; WANG, XH; LIEW, CC; CHUNG, LWK			REGULATION OF BASAL AND LUMINAL CELL-SPECIFIC CYTOKERATIN EXPRESSION IN RAT ACCESSORY SEX-ORGANS - EVIDENCE FOR A NEW CLASS OF ANDROGEN-REPRESSED GENES AND INSIGHT INTO THEIR PAIRWISE CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; EPIDERMAL GROWTH-FACTOR; VENTRAL PROSTATE; MESSENGER-RNA; TERMINAL DIFFERENTIATION; KERATIN EXPRESSION; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS; FACTOR-BETA; C-MYC	Co-expression of cytokeratin (CK) pairs has been found to be associated with specific epithelial cell types whose expressions are developmentally regulated. In the prostate, CK 8 and 18 have been identified as luminal cell-specific markers, and CK 5 and 15 have been identified as basal cell-specific markers. In this study, we report the cloning and sequencing of a full-length CK 8 cDNA (1.9 kilobases) from a rat ventral prostate (VP) cDNA library. Although the open reading frame shares 90% homology with mouse CK 8 sequences, nucleotide comparison revealed that rat CK 8 cDNA comprises a species-specific sequence on both 5' and 3' ends. The steady-state levels of CK 8 mRNA were elevated in VP, seminal vesicle (SV), and liver of a castrated rat but not in the other organs such as the coagulating gland, bladder, and thymus. Unlike the other androgen-repressed genes, elevated CK 8 mRNA levels persisted even after the glandular involution was completed, indicating that CK 8 is a new class of androgen-repressed gene. The regression of CK 8 expression may be androgen receptor-mediated, since androgen but not estrogen administration to castrated hosts repressed the CK 8 mRNA levels, and this effect can be antagonized by the simultaneous administration of an antiandrogen (4-hydroxyflutamide). Immunohistochemical staining of prostatic tissues reveals that the CK 8 filamentous structure is shifted reversibly from a uniform distribution to a predominantly basal surface upon androgen deprivation. We noted that the steady-state levels of CK 8 protein remain rather constant throughout the various hormonal treatment, and the steady-state levels of CK 8 mRNA and the rate of CK 8 protein synthesis are consistently elevated. These results suggest that the turnover rate of CK 8 protein may be elevated in the prostatic epithelium from the castrated host. Similarly, the steady-state levels of CK 15 and 18 mRNA in VP and SV are also repressed in an androgen-dependent manner. These data, taken together, indicate that pairwise control of luminal (and possibly basal) specific cytokeratin gene expression remains intact in both VP and SV tissues and that the levels of CK mRNAs expression are negatively regulated by androgen.	UNIV TORONTO,BENTING INST,DEPT CLIN BIOCHEM & MED,MOLEC CARDIOL LAB,TORONTO M5G 1L5,ONTARIO,CANADA	University of Toronto	HSIEH, JT (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA056307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038649] Funding Source: NIH RePORTER; NCI NIH HHS [CA56307] Funding Source: Medline; NIDDK NIH HHS [DK38649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTATTER T, 1985, J HISTOCHEM CYTOCHEM, V33, P415, DOI 10.1177/33.5.2580881; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHANG C, 1987, J BIOL CHEM, V262, P11901; CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719, DOI 10.1210/endo-125-5-2719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY DS, 1990, UROL CLIN N AM, V17, P461; COOPER D, 1985, LAB INVEST, V52, P243; DEKLERK DP, 1975, BENIGN PROSTATIC HYP, P43; FEITZ WFJ, 1986, J UROLOGY, V136, P922, DOI 10.1016/S0022-5347(17)45133-0; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; GLEAVE M, 1991, CANCER RES, V51, P3753; GUTHRIE PD, 1990, MOL ENDOCRINOL, V4, P1343, DOI 10.1210/mend-4-9-1343; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ISAACS JT, 1989, PROSTATE S, V2, P33; KATZ AE, 1989, CANCER RES, V49, P5889; KIM KH, 1987, J CELL BIOL, V105, P3039, DOI 10.1083/jcb.105.6.3039; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C., 1987, GENITAL SYSTEM, P239; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO, P312; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORITA T, 1988, GENE, V68, P109; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RAMAEKERS FCS, 1989, PROSTATE, V14, P323, DOI 10.1002/pros.2990140405; SALTZMAN AG, 1987, J BIOL CHEM, V262, P432; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMAT A, 1988, DIFFERENTIATION, V37, P40, DOI 10.1111/j.1432-0436.1988.tb00794.x; SHERWOOD ER, 1990, J UROLOGY, V143, P167, DOI 10.1016/S0022-5347(17)39903-2; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUGIMURA Y, 1986, BIOL REPROD, V34, P985, DOI 10.1095/biolreprod34.5.985; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104	47	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2303	2310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370816				2022-12-25	WOS:A1992HB53200031
J	DORFMAN, DM; WILSON, DB; BRUNS, GAP; ORKIN, SH				DORFMAN, DM; WILSON, DB; BRUNS, GAP; ORKIN, SH			HUMAN TRANSCRIPTION FACTOR GATA-2 - EVIDENCE FOR REGULATION OF PREPROENDOTHELIN-1 GENE-EXPRESSION IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ZINC FINGER; DNA-BINDING FACTOR; SEQUENCE; ACTIVATION; PROTEINS; LOCALIZATION; COMPLEXES; NUMBER; COMMON; FAMILY	Previously, we showed that the promoter of the gene encoding preproendothelin-1 (PPET-1) contains a GATA motif that is essential for activity and interacts with a nuclear factor similar in size and binding specificity to the erythroid transcription factor GATA-1. To identify this endothelial GATA-binding protein, a human endothelial cell cDNA library was screened with oligonucleotide probes for a portion of the zinc finger domain of GATA-1. A 2.6-kilobase cDNA encoding a 470 amino acid protein was obtained. Sequence analysis revealed a predicted protein which is the human counterpart of a related chicken protein, designated GATA-2. Human GATA-2 is expressed by a variety of cells, including erythroid, HeLa, and endothelial cells. A complex of a GATA-containing probe and recombinant GATA-2 expressed in COS cells comigrates with that present in gel shift experiments with nuclear extract derived from endothelial cells. In addition, expressed human GATA-2 protein transactivates reporter gene constructs containing either minimal GATA promoter elements or the native PPET-1 promoter in a cotransfection assay. Retinoic acid treatment of endothelial cells results in down-regulation of GATA-2 expression as well as down-regulation of PPET-1 gene expression. Human homologs of other known GATA-binding transcription factors are either absent from endothelial cells (in the case of GATA-1) or made in small quantities and not significantly affected by retinoic acid in these cells (in the case of GATA-3), making it unlikely that they regulate the PPET-1 gene. We propose that GATA-2 is the GATA-binding protein required for PPET-1 gene expression in endothelial cells.	HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	DORFMAN, DM (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115, USA.		Wilson, David/K-7433-2014	Wilson, David/0000-0002-1826-7745	NHLBI NIH HHS [5P32HL07574] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FIBACH E, 1982, LEUKEMIA RES, V6, P781, DOI 10.1016/0145-2126(82)90060-1; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TSAI S, 1989, NATURE, V339, P448; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILSON DB, 1990, MOL CELL BIOL, V10, P9854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	36	280	283	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1279	1285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370462				2022-12-25	WOS:A1992GY96000093
J	BAXTER, RC; BAYNE, ML; CASCIERI, MA				BAXTER, RC; BAYNE, ML; CASCIERI, MA			STRUCTURAL DETERMINANTS FOR BINARY AND TERNARY COMPLEX-FORMATION BETWEEN INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF BINDING PROTEIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; REDUCED AFFINITY; RECEPTOR-BINDING; FACTOR (IGF)-I; HUMAN-PLASMA; SUBUNIT; PURIFICATION; MUTANTS; ANALOGS	Structural analogs of recombinant human insulin-like growth factor-I (IGF-I), with alterations to each of the B, C, A, and D domains, have been tested for their ability to form binary complexes with IGF-binding protein-3 (IGFBP-3) and ternary complexes with IGFBP-3 and the acid-labile subunit (alpha-subunit). Two functionally distinct regions of IGF-I have been identified. The first, involving residues 3 and 4 and the alpha-helix between residues 8 and 18 of the B-domain, as well as residues 49-51 in the A-domain, appears important for IGFBP-3 binding, such that substitution of these residues results in decreased binary complex available for alpha-subunit binding. The second region, distal to the IGFBP-3-binding epitope and primarily involving the D-domain and B-domain near residue 24, with some involvement of the C-domain, appears slightly inhibitory to binary complex formation, such that analogs with a truncated D-domain or with a Gly4 bridge substituted for the C-domain show enhanced binding to IGFBP-3. However, binary complexes formed from these analogs bind the alpha-subunit with reduced affinity, the effect being most marked when substitution of the C-domain, or replacement of Tyr24, is superimposed on D-domain truncation. It is concluded that although the alpha-subunit does not itself bind IGF-I, its interaction with IGFBP-3 in the ternary complex is dependent on structural determinants on IGF-I distal to the IGFBP-3 binding domain.	MERCK SHARP & DOHME LTD,DEPT GROWTH BIOCHEM,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOCHEM ENDOCRINOL,RAHWAY,NJ 07065	Merck & Company; Merck & Company	BAXTER, RC (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT ENDOCRINOL,CAMPERDOWN,NSW 2050,AUSTRALIA.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				BALLARD J, 1989, ACTA ENDOCRINOL-COP, V121, P751, DOI 10.1530/acta.0.1210751; BAR RS, 1990, ENDOCRINOLOGY, V127, P3243, DOI 10.1210/endo-127-6-3243; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BAXTER RC, 1986, CLIN ENDOCRINOL, V24, P267, DOI 10.1111/j.1365-2265.1986.tb03267.x; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BLUNDELL TL, 1983, FED PROC, V42, P2592; CASCIERI MA, 1988, ENDOCRINOLOGY, V123, P373, DOI 10.1210/endo-123-1-373; CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3229, DOI 10.1021/bi00409a016; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CLEMMONS DR, 1990, J BIOL CHEM, V265, P12210; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HINTZ RL, 1981, J CLIN ENDOCR METAB, V53, P100, DOI 10.1210/jcem-53-1-100; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KAUFMANN U, 1977, J CLIN ENDOCR METAB, V44, P160, DOI 10.1210/jcem-44-1-160; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; Shimasaki S, 1991, MODERN CONCEPTS INSU, P343; WHITE RM, 1981, J CLIN ENDOCR METAB, V53, P49, DOI 10.1210/jcem-53-1-49	27	55	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					60	65						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370451				2022-12-25	WOS:A1992GY43900015
J	FUKUNAGA, K; SODERLING, TR; MIYAMOTO, E				FUKUNAGA, K; SODERLING, TR; MIYAMOTO, E			ACTIVATION OF CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-II AND PROTEIN-KINASE-C BY GLUTAMATE IN CULTURED RAT HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MICROTUBULE-ASSOCIATED PROTEIN-2; POSTSYNAPTIC DENSITY PROTEIN; CEREBELLAR GRANULE CELLS; SYNAPSIN-I; IMMUNOCYTOCHEMICAL LOCALIZATION; CA-2+-INDEPENDENT ACTIVITY; NMDA RECEPTORS; CYCLIC-AMP; CALMODULIN	In cultured rat hippocampal neurons, glutamate elevated the Ca2+-independent activity of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) through autophosphorylation when the neurons were incubated in Mg2+-free buffer, and this response was blocked by specific antagonists of the N-methyl-D-aspartate (NMDA) receptor. In addition, glutamate stimulated the transient translocation of protein kinase C (PKC) from the cytosol to the membrane fraction. This effect was not blocked by NMDA receptor antagonists but was partially blocked by DL-2-amino-3-phosphonopropionate. Quisqualate or trans-1-amoinocyclo-pentane-trans1,3-dicarboxylate produced a similar effect on the translocation of PKC. In the experiments with P-32-labeled cells, the phosphorylation of microtuble-associated protein 2 and synapsin I, as well as autophosphorylation of CaM kinase II, were found to be stimulated by exposure to glutamate. These results suggest that glutamate can activate CaM kinase II through the ionotropic NMDA receptor, which in turn increases the phosphorylation of microtuble-associated protein 2 and synapsin I. PKC was activated through the metabotropic glutamate receptor in the hippocampal neurons.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University	FUKUNAGA, K (corresponding author), KUMAMOTO UNIV,DEPT PHARMACOL,KUMAMOTO 860,JAPAN.				NINDS NIH HHS [NS 27037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; COLLEY PA, 1989, BRAIN RES, V495, P205, DOI 10.1016/0006-8993(89)90214-X; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FINN RC, 1980, NEUROSCI LETT, V19, P103, DOI 10.1016/0304-3940(80)90264-5; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FUKNAGA K, 1990, MOL CELL NEUROSCI, V1, P133; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KITANO T, 1987, J NEUROSCI, V7, P1520; KLANN E, 1991, J BIOL CHEM, V266, P24253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTSON MP, 1989, BRAIN RES, V490, P110, DOI 10.1016/0006-8993(89)90436-8; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1988, J BIOL CHEM, V263, P11540; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; ORIOKA M, 1992, J NEUROCHEM, V58, P1798; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; REYMANN KG, 1988, BRAIN RES, V461, P388, DOI 10.1016/0006-8993(88)90274-0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHOEPP DD, 1989, J NEUROCHEM, V53, P1865, DOI 10.1111/j.1471-4159.1989.tb09254.x; SCHOLZ WK, 1991, J NEUROSCI, V11, P2422; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; THIBAULT O, 1989, BRAIN RES, V476, P170, DOI 10.1016/0006-8993(89)91553-9; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAUCHI T, 1988, BIOCHIM BIOPHYS ACTA, V968, P77, DOI 10.1016/0167-4889(88)90046-8; ZATZ M, 1986, BRAIN RES, V385, P174, DOI 10.1016/0006-8993(86)91562-3	54	180	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22527	22533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1358879				2022-12-25	WOS:A1992JW71900084
J	BUSCHMAN, E; ARCECI, RJ; CROOP, JM; CHE, MX; ARIAS, IM; HOUSMAN, DE; GROS, P				BUSCHMAN, E; ARCECI, RJ; CROOP, JM; CHE, MX; ARIAS, IM; HOUSMAN, DE; GROS, P			MDR2 ENCODES P-GLYCOPROTEIN EXPRESSED IN THE BILE CANALICULAR MEMBRANE AS DETERMINED BY ISOFORM-SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; ATP-DEPENDENT TRANSPORT; MONOCLONAL-ANTIBODIES; MOUSE MDR1; CONJUGATED HYPERBILIRUBINEMIA; SECRETORY EPITHELIUM; CHINESE-HAMSTER; ORGANIC-ANIONS; HUMAN-CELLS	We have produced antibodies specific for the three P-glycoprotein (P-gp) isoforms encoded by the mouse mdr1, mdr2, and mdr3 genes. The anti-Mdr2 and anti-Mdr3 antibodies were generated against synthetic peptides derived from the "linker" region, whereas the anti-Mdr1 antibody was raised against a fusion protein containing the amino terminus of Mdr1. Western blot analysis showed that the three antibodies could discriminate between the three isoforms in membrane fractions from Hamster cells transfected with the corresponding full-length or chimeric mdr cDNAs. Immunocytochemistry studies of mdr-transfected cells showed that the three antibodies specifically recognized each P-gp isoform expressed in whole cells. Immunoblotting of normal mouse tissues revealed that the Mdr2 isoform was expressed at very high levels in liver canalicular membrane vesicles (CMV) but not in membrane vesicles prepared from the basolateral (sinusoidal) domain (SMV). Mdr3 was detected in intestinal brush border membrane vesicles and also in CMV, although at levels much lower than Mdr2. Mdr1 was not detected in CMV or SMV but was detected in endometrial tissue from the gravid uterus. Photolabeling experiments with [I-125]iodoarylazidoprazosin followed by immunoprecipitation with isoform-specific antibodies indicated that, in CMV, Mdr3 but not Mdr2 could bind the drug analogue.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	McGill University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA048162] Funding Source: NIH RePORTER; NCI NIH HHS [CA48162, CA011227] Funding Source: Medline; PHS HHS [35652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DONOWITZ M, 1987, AM J PHYSIOL, V252, P6723; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GREENBERGER LM, 1989, FEBS LETT, V2, P419; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HSING S, 1992, GASTROENTEROLOGY, V102, P879, DOI 10.1016/0016-5085(92)90173-V; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; QIAN XD, 1990, J BIOL CHEM, V265, P18753; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHURR E, 1989, CANCER RES, V49, P2729; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERBLIEK AM, 1988, GENE, V71, P407; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	54	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18093	18099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381362				2022-12-25	WOS:A1992JM22300094
J	WATANABE, T; KUME, T; OISHI, M				WATANABE, T; KUME, T; OISHI, M			ALTERATION OF PHOSPHOTYROSINE-CONTAINING PROTEINS AT THE EARLY STAGE OF ERYTHROID-DIFFERENTIATION OF MOUSE ERYTHROLEUKEMIA (MEL) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; INVITRO DIFFERENTIATION; TUMOR PROMOTER; HERBIMYCIN-A; GENISTEIN; INHIBITOR; INDUCTION; KINASES; POTENT; PHOSPHORYLATION	Following treatment of mouse erythroleukemia (MEL) cells with dimethyl sulfoxide and other typical erythroid inducing agents, the profile of cellular phosphotyrosine-containing proteins was drastically altered. We found that the level of almost all of the phosphotyrosine-containing proteins was either decreased or disappeared at a very early stage of differentiation. Addition of sodium orthovanadate (Na3VO4), a specific inhibitor of phosphotyrosine phosphatases, prevented the alteration as well as erythroid differentiation. Mutant MEL cells, which are resistant to differentiation by dimethyl sulfoxide, were apparently insensitive to the alteration. These results indicate that dephosphorylation of phosphotyrosine residues in cellular proteins is coupled with a reaction(s) which is responsible for triggering differentiation of MEL cells.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HONMA Y, 1989, CANCER RES, V49, P331; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; MARKOVITS J, 1989, CANCER RES, V49, P5111; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MELLONI E, 1989, J BIOL CHEM, V264, P18414; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAHASHI E, 1975, GANN, V66, P577; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; YOSHIDA M, 1987, CANCER RES, V47, P3688; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	23	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17116	17120						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380959				2022-12-25	WOS:A1992JL05300061
J	JANSSENS, SP; SHIMOUCHI, A; QUERTERMOUS, T; BLOCH, DB; BLOCH, KD				JANSSENS, SP; SHIMOUCHI, A; QUERTERMOUS, T; BLOCH, DB; BLOCH, KD			CLONING AND EXPRESSION OF A CDNA-ENCODING HUMAN ENDOTHELIUM-DERIVED RELAXING FACTOR NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL NADPH DIAPHORASE; VASCULAR ENDOTHELIUM; SMOOTH-MUSCLE; CELLS; RELEASE	Nitric oxide, which accounts for the biological activity of endothelium-derived relaxing factor (EDRF), is synthesized in endothelial cells from L-arginine by nitric oxide synthase (NOS). We report here the cloning and functional expression of a cDNA encoding human endothelial NOS. Oligonucleotides corresponding to amino acid sequences shared by cytochrome P450 reductase and the recently identified brain NOS were synthesized to amplify a partial cDNA encoding a bovine endothelial cell NOS-related protein. This partial cDNA was used to isolate a cDNA encoding a human vascular endothelial NOS. The translated human protein is 1294 amino acids long and shares 52% of its amino acid sequence with brain NOS. Using RNA blot hybridization, abundant endothelial NOS mRNA was detected in unstimulated human umbilical vein endothelial cells. To determine the functional activity of the endothelial protein, we ligated the cDNA into an expression vector and transfected it into NIH3T3 cells. Cells expressing this cDNA contained abundant NADPH diaphorase activity, a histochemical marker for NOS. In co-culture assays, nitric oxide production by transfected cells increased guanylate cyclase activity in reporter rat fetal lung fibroblasts. In addition, NOS-catalyzed conversion of arginine to citrulline in transfected cells was significantly increased by A23187, a calcium ionophore. Isolation of a cDNA encoding a calcium-regulated, constitutively expressed human endothelial NOS, capable of producing EDRF in blood vessels, will accelerate the characterization of the role of this enzyme in normal and abnormal endothelial regulation of vascular tone.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital				Bloch, Donald/0000-0002-6828-4754; Quertermous, Thomas/0000-0002-7645-9067	NHLBI NIH HHS [HL45895, HL42397] Funding Source: Medline; NIAMS NIH HHS [AR01866] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397, R29HL045895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001866] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COLLINS P, 1990, LANCET, V335, P94, DOI 10.1016/0140-6736(90)90551-F; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1778; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUSCHER TF, 1990, AM J HYPERTENS, V3, P317, DOI 10.1093/ajh/3.4.317; MARSDEN PA, 1990, AM J PHYSIOL, V258, pF1295, DOI 10.1152/ajprenal.1990.258.5.F1295; MARSDEN PA, 1991, SEMIN NEPHROL, V11, P169; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; Sambrook J, 1989, MOL CLONING LABORATO; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VANE JR, 1990, NEW ENGL J MED, V323, P27; YUI Y, 1991, J BIOL CHEM, V266, P3369; [No title captured]	28	567	606	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14519	14522						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378832				2022-12-25	WOS:A1992JF08800002
J	ROBERTSON, DE; NOLL, D; ROBERTS, MF				ROBERTSON, DE; NOLL, D; ROBERTS, MF			FREE AMINO-ACID DYNAMICS IN MARINE METHANOGENS - BETA-AMINO ACIDS AS COMPATIBLE SOLUTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOSPIRILLUM-HUNGATEI; HALOPHILIC BACTERIA; AMINOGLUTARIC ACID; NMR-SPECTROSCOPY; WATER-STRESS; OSMOREGULATION; GLUTAMATE; OSMOLYTE	Methanogenic archaebacteria respond to osmotic stress by accumulating a series of organic molecules which function as compatible solutes. In two strains of marine methanogenic archaebacteria, Methanogenium cariaci and Methanococcus thermolithotrophicus, four key organic solutes are observed: L-alpha-glutamate, beta-glutamate, N(epsilon)-acetyl-beta-lysine, and betaine. The first three of these are synthesized de novo; betaine is transported into the Mg. cariaci cells from the medium. Mesophilic Mg. cariaci will preferentially transport betaine from the extracellular medium if it is present to counterbalance the external NaCl. In its absence it synthesizes N(epsilon)-acetyl-beta-lysine as the dominant osmolyte. This zwitterionic compound occurs at levels in Mg. cariaci which are considerably greater (based on mu-mol/mg of protein) than in Mc. thermolithotrophicus grown in media of the same ionic strength. Intracellular potassium ion concentrations, determined by K-39 NMR spectroscopy and atomic absorption, differ significantly in the two cells. In Mc. thermolithotrophicus, intracellular K+ is balanced by the total concentration of anionic amino acid species, glutamate, and beta-glutamate. Turnover of the organic solutes has been monitored using C-13-pulse/C-12-chase, and N-15-pulse/N-14-chase experiments. Both beta-amino acids exhibit slower turnover rates when compared to L-alpha-glutamate or aspartate, consistent with their roles as compatible solutes. Biosynthetic information for the beta-amino acids is also provided by C-13-labeling experiments. Beta-glutamate shows a lag in C-13 uptake from (CO2)-C-13, indicative of its biosynthesis from a precursor (probably a macromolecule) not in equilibrium with the soluble L-alpha-glutamate pool. Confirmation of a novel route for beta-glutamate synthesis and the production of the beta-lysine moiety from the diaminopimelate pathway is deduced from [C-13(2)]acetate labeling patterns.	BOSTON COLL,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College								BAKHIET N, 1984, CURR MICROBIOL, V10, P195, DOI 10.1007/BF01627254; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; BOROWITZKA LJ, 1980, SCIENCE, V210, P650, DOI 10.1126/science.210.4470.650; BOTSFORD JL, 1984, ARCH MICROBIOL, V137, P124, DOI 10.1007/BF00414452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY RC, 1968, J BIOL CHEM, V243, P381; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; CHOI BS, 1986, BIOCHEMISTRY-US, V25, P2243, DOI 10.1021/bi00356a059; DANIELS L, 1984, BIOCHIM BIOPHYS ACTA, V768, P113, DOI 10.1016/0304-4173(84)90002-8; DOYLE RJ, 1988, MICROBIOL REV, V52, P554, DOI 10.1128/MMBR.52.4.554-567.1988; EKIEL I, 1983, J BACTERIOL, V156, P316, DOI 10.1128/JB.156.1.316-326.1983; EVANS JNS, 1986, SCIENCE, V231, P488, DOI 10.1126/science.3079919; GALINSKI EA, 1982, FEMS MICROBIOL LETT, V13, P357, DOI 10.1016/0378-1097(82)90191-4; GRIFFITH OW, 1986, ANNU REV BIOCHEM, V55, P855, DOI 10.1146/annurev.biochem.55.1.855; HENRICHS SM, 1985, APPL ENVIRON MICROB, V50, P543, DOI 10.1128/AEM.50.2.543-545.1985; IMHOFF JF, 1986, FEMS MICROBIOL LETT, V39, P57; JARRELL KF, 1984, CAN J MICROBIOL, V30, P663, DOI 10.1139/m84-099; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; KASHMAN Y, 1973, TETRAHEDRON, V29, P3655, DOI 10.1016/S0040-4020(01)93529-X; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; KENEALY WR, 1982, J BACTERIOL, V150, P1357, DOI 10.1128/JB.150.3.1357-1365.1982; KOGUT M, 1987, SCI PROG, V71, P381; Kushner DJ., 1985, BACTERIA, P171; LAI MC, 1991, J BACTERIOL, V173, P5252; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; MACKAY MA, 1983, MAR BIOL, V73, P301, DOI 10.1007/BF00392256; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MOSS M, 1987, J BIOL CHEM, V262, P14859; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; REED RH, 1986, FEMS MICROBIOL LETT, V39, P51; ROBERTS MF, 1990, J BIOL CHEM, V265, P18207; ROBERTSON DE, 1989, BIOCHIM BIOPHYS ACTA, V992, P320, DOI 10.1016/0304-4165(89)90091-3; ROBERTSON DE, 1990, APPL ENVIRON MICROB, V56, P1504, DOI 10.1128/AEM.56.5.1504-1508.1990; ROBERTSON DE, 1990, APPL ENVIRON MICROB, V56, P563, DOI 10.1128/AEM.56.2.563-565.1990; ROBERTSON DE, 1991, BIOFACTORS, V3, P1; SELTMANN G, 1989, J BASIC MICROB, V29, P547, DOI 10.1002/jobm.3620290820; SHPORER M, 1972, J MEMBRANE BIOL, V33, P385; SOWERS KR, 1990, P NATL ACAD SCI USA, V87, P9083, DOI 10.1073/pnas.87.23.9083; SPROTT GD, 1981, CAN J MICROBIOL, V27, P444, DOI 10.1139/m81-067; SUMMONS RE, 1981, PHYTOCHEMISTRY, V20, P1125, DOI 10.1016/0031-9422(81)83040-3; TAKEMOTO T, 1965, Yakugaku Zasshi, V85, P33; VREELAND RH, 1987, CRIT REV MICROBIOL, V14, P311, DOI 10.3109/10408418709104443; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YAP SF, 1983, ARCH MICROBIOL, V135, P224, DOI 10.1007/BF00414484	45	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14893	14901						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353078				2022-12-25	WOS:A1992JF08800060
J	JASCUR, T; GOLDENBERG, DP; VESTWEBER, D; SCHATZ, G				JASCUR, T; GOLDENBERG, DP; VESTWEBER, D; SCHATZ, G			SEQUENTIAL TRANSLOCATION OF AN ARTIFICIAL PRECURSOR PROTEIN ACROSS THE 2 MITOCHONDRIAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; CYTOCHROME-C PEROXIDASE; YEAST MITOCHONDRIA; INNER MEMBRANE; OUTER-MEMBRANE; CONTACT SITES; INTERMEMBRANE SPACE; FOLDING PATHWAY; IMPORT; TRANSPORT	We have constructed a chimeric mitochondrial precursor protein consisting of a mutant bovine pancreatic trypsin inhibitor coupled to the C terminus of a purified artificial precursor protein. This construct fails to complete its import into isolated mitochondria and becomes stuck across sites of close contact between the two mitochondrial membranes. When the mitochondria are then depleted of ATP and the intramolecular disulfide bridges of the trypsin inhibitor are cleaved by dithiothreitol, the trypsin inhibitor moiety is transported across the outer membrane into the intermembrane space. This translocation intermediate can be chased across the inner membrane by restoring the ATP levels in the matrix. These results show that translocation of pancreatic trypsin inhibitor across a biological membrane is prevented by its intramolecular disulfide bridges, that import into the matrix involves two distinct translocation system operating in tandem, and that ATP is required for protein translocation across the inner but not the outer membrane.	UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	University of Basel; Utah System of Higher Education; University of Utah				Vestweber, Dietmar/0000-0002-3517-732X	NIGMS NIH HHS [2 RO1 GM37803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1980, J BIOL CHEM, V255, P9918; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1992, IN PRESS CELL; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SUISSA M, 1982, J BIOL CHEM, V257, P3048; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13636	13641						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377688				2022-12-25	WOS:A1992JB74600085
J	PAUL, S; SUN, M; MODY, R; TEWARY, HK; STEMMER, P; MASSEY, RJ; GIANFERRARA, T; MEHROTRA, S; DREYER, T; MELDAL, M; TRAMONTANO, A				PAUL, S; SUN, M; MODY, R; TEWARY, HK; STEMMER, P; MASSEY, RJ; GIANFERRARA, T; MEHROTRA, S; DREYER, T; MELDAL, M; TRAMONTANO, A			PEPTIDOLYTIC MONOCLONAL-ANTIBODY ELICITED BY A NEUROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VASOACTIVE-INTESTINAL-PEPTIDE; HYDROLYSIS; AUTOANTIBODY; GENERATION; DIVERSITY; SITE	We report evidence that a monoclonal antibody raised by immunization with a vasoactive intestinal peptide (VIP)-carrier protein conjugate selectively hydrolyzes VIP and a fluorescence quenched decapeptide (FQ14-22D), representing the region of VIP most susceptible to autoantibody-mediated cleavage (residues 14-22). A high affinity of the antibody for VIP and a lower affinity for FQ14-22D were revealed by kinetic studies and further substantiated by potent inhibition of FQ14-22D cleaving activity by full-length VIP. Sequencing of FQ14-22D hydrolysis products indicated selective cleavage at one peptide bond. These observations suggest that antibodies induced against naturally occurring polypeptide antigens can express peptidolytic activity targeted for specific sequences in the recognition epitope.	UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA; IGEN INC, ROCKVILLE, MD 20852 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK	University of Nebraska System; University of Nebraska Medical Center; Scripps Research Institute	PAUL, S (corresponding author), UNIV NEBRASKA, MED CTR, DEPT ANESTHESIOL, OMAHA, NE 68198 USA.		Meldal, Morten/B-7626-2016	Meldal, Morten/0000-0001-6114-9018; GIANFERRARA, Teresa/0000-0003-0085-3567; Stemmer, Paul/0000-0003-3315-9846	NHLBI NIH HHS [HL40348, HL44126, HL02217] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126, R01HL040348, K04HL002217] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; HAMEL FG, 1986, ENDOCRINOLOGY, V118, P328, DOI 10.1210/endo-118-1-328; HARLOW E, 1988, ANTIBODIES LABORATOR; JUE R, 1978, BIOCHEMISTRY-US, V17, P5399, DOI 10.1021/bi00618a013; KOHEN F, 1980, BIOCHIM BIOPHYS ACTA, V629, P328, DOI 10.1016/0304-4165(80)90105-1; KOHEN F, 1980, FEBS LETT, V111, P427, DOI 10.1016/0014-5793(80)80842-8; MEI S, 1991, J BIOL CHEM, V266, P15571; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; SEGEL IH, 1975, ENZYME KINETICS, P150; SHUSTER AM, 1991, MOL BIOL+, V25, P478; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261	19	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13142	13145						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377678				2022-12-25	WOS:A1992JB74600008
J	SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH			DETECTION OF BOTH MUTANT AND WILD-TYPE P53-PROTEIN IN NORMAL SKIN FIBROBLASTS AND DEMONSTRATION OF A SHARED 2ND HIT ON P53 IN DIVERSE TUMORS FROM A CANCER-PRONE FAMILY WITH LI-FRAUMENI SYNDROME	ONCOGENE			English	Note							ONCOGENE; GENE; SUPPRESSION; MUTATIONS; PROTEIN; GROWTH	Germline transmission of mutant p53 gene in cancerprone families with Li-Fraumeni syndrome has revealed a new role for p53 in the genetic predisposition to cancer. The studies reported here focus on the analysis of the expression of normal and mutant p53 RNA and protein in germline configuration and demonstrate that normal skin fibroblasts derived from members of a family with Li-Fraumeni syndrome express mutant p53Gly --> Asp(245) protein and RNA at levels similar to the wild-type p53. Thus, these fibroblasts represent a unique biological system in which endogenous promoters are utilized for the expression of both mutant and normal p53. We have further extended the earlier observations on the analysis of mutant p53 with a limited number of tumors derived from individuals with Li-Fraumeni syndrome. Tumors arising from two different germ layers in four individuals in a single family clearly exhibited the loss of the wild-type allele and the retention of the mutant allele observed in the normal skin fibroblasts derived from the same individuals. These observations further support the notion that germline p53 mutation plays a key role in the tumorigenesis of individuals with Li-Fraumeni syndrome.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814; NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEMARS R, 1970, 23RD ANN S FUND CANC, P105; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	25	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373881				2022-12-25	WOS:A1992HP64200019
J	MAKITA, Z; VLASSARA, H; CERAMI, A; BUCALA, R				MAKITA, Z; VLASSARA, H; CERAMI, A; BUCALA, R			IMMUNOCHEMICAL DETECTION OF ADVANCED GLYCOSYLATION END-PRODUCTS INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; NONENZYMATIC GLYCOSYLATION; PROTEIN GLYCOSYLATION; DIABETES-MELLITUS; MAILLARD REACTION; HUMAN COLLAGEN; GLUCOSE; ALBUMIN; IDENTIFICATION; AMINOGUANIDINE	Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures, the measurement of AGE compounds in vivo has remained difficult. As an approach to the study of AGE formation in vivo, we prepared polyclonal antiserum to an AGE epitope(s) which forms in vitro after incubation of glucose with ribonuclease (RNase). This antiserum proved suitable for the detection of AGEs which form in vivo. Both diabetic tissue and serum known to contain elevated levels of AGEs readily competed for antibody binding. Cross-reactivity studies revealed the presence of a common AGE epitope(s) which forms after the incubation of diverse proteins with glucose. Cross-reactive epitopes also formed with glucose 6-phosphate or fructose. These data suggest that tissue AGEs which form in vivo appear to contain a common immunological epitope which cross-reacts with AGEs prepared in vitro, supporting the concept that immunologically similar AGE structures form from the incubation of sugars with different proteins (Horiuchi, S., Araki, N., and Morino, Y. (1991) J. Biol. Chem. 266, 7329-7332). None of the known AGEs, such as 4-furanyl-2-furoyl-1H-imidazole, 1-alkyl-2-formyl-3,4-diglycosylpyrrole, pyrraline, carboxymethyllysine, or pentosidine, were found to compete for binding to anti-AGE antibody. These data further suggest that the dominant AGE epitope which forms from the reaction of glucose with proteins under native conditions is immunologically distinct from the structurally defined AGEs described to date.	ROCKEFELLER UNIV, MED BIOCHEM LAB, NEW YORK, NY 10021 USA	Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; BOOKCHIN RM, 1968, BIOCHEM BIOPH RES CO, V32, P86, DOI 10.1016/0006-291X(68)90430-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUCALA R, 1983, MOL IMMUNOL, V20, P1289, DOI 10.1016/0161-5890(83)90159-1; CHANG JCF, 1985, J BIOL CHEM, V260, P7970; COHEN MP, 1980, BIOCHEM BIOPH RES CO, V95, P765, DOI 10.1016/0006-291X(80)90852-9; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; EBLE AS, 1983, J BIOL CHEM, V258, P9406; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; FARMAR JG, 1988, J ORG CHEM, V53, P2346, DOI 10.1021/jo00245a039; FLUCKIGER R, 1984, METHOD ENZYMOL, V106, P77; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HORIUCHI S, 1985, J BIOL CHEM, V260, P482; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOENIG RJ, 1977, J BIOL CHEM, V252, P2992; KOHN RR, 1984, DIABETES, V33, P57, DOI 10.2337/diabetes.33.1.57; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MICHEEL F, 1959, CHEM BER-RECL, V92, P2836, DOI 10.1002/cber.19590921127; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P740, DOI 10.1016/0006-291X(89)92372-3; NICHOLLS K, 1989, LAB INVEST, V60, P486; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; SCHWIMMER S, 1953, J AM CHEM SOC, V75, P4855, DOI 10.1021/ja01115a525; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9	37	494	553	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5133	5138						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371995				2022-12-25	WOS:A1992HH74700023
J	BAYLE, D; ROBERT, JC; BAMBERG, K; BENKOUKA, F; CHERET, AM; LEWIN, MJM; SACHS, G; SOUMARMON, A				BAYLE, D; ROBERT, JC; BAMBERG, K; BENKOUKA, F; CHERET, AM; LEWIN, MJM; SACHS, G; SOUMARMON, A			LOCATION OF THE CYTOPLASMIC EPITOPE FOR A K+-COMPETITIVE ANTIBODY OF THE (H+,K+)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PIG GASTRIC (H+; MONOCLONAL-ANTIBODY; H+/K+-ATPASE; PHOTOAFFINITY INHIBITOR; MOLECULAR-CLONING; CATALYTIC SUBUNIT; COMPLEMENTARY-DNA; H,K-ATPASE; H+,K+-ATPASE	The monoclonal antibody (mAb) 95-111 binds the alpha subunit of (H+,K+) -ATPase and inhibits the K+-ATPase activity. To map the epitope, all of the partial sequences of the alpha subunit were expressed in Escherichia coli HB101 using rabbit alpha subunit cDNA restriction fragments ligated into PuEx vector. Bacterial recombinant lysates were separated by sodium dodecyl sulfate-gel electrophoresis, and the epitope was detected by Western blotting. The antibody site was mapped between Cys529 and Glu561. This is close to the Lys517 that binds fluorescein isothiocyanate (FITC) and is considered to be between M4 and M5 close to the ATP binding domain. However, the mAb inhibition of ATPase is not ATP-competitive but is K+-competitive with a K(I) of 2 x 10(-9) M. The mAb also inhibits K+ quench of FITC fluorescence competitively with a K(I) of 8 x 10(-9) M. The K+ activation of ATPase activity and quench of FITC fluorescence are dependent on K+ binding to an E2 form of the enzyme from the extracytoplasmic surface. The mAb epitope is cytoplasmic since the K+-ATPase activity of ion-tight gastric vesicles is inhibited. The I-125-mAb 95-111 binds to a single class of sites with an apparent K(D) of 2.3 +/- 0.8 x 10(-9) M and K+ does not displace bound mAb. Hence, antibody binding to a Cytoplasmic Cys529-Glu561 epitope allosterically competes with K+-dependent reactions at extracytoplasmic sites.	HOP BICHAT, INSERM, U10, 170 BLVD NEY, F-75877 PARIS 18, FRANCE; WADSWORTH VET ADM HOSP, CURE INST, LOS ANGELES, CA 90073 USA; FAC SCI RABAT, RABAT, MOROCCO	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Mohammed V University in Rabat								BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYLE D, 1992, COMP BIOCHEM PHYS B, V101, P519, DOI 10.1016/0305-0491(92)90331-K; BENKOUKA F, 1989, BIOCHIM BIOPHYS ACTA, V987, P205, DOI 10.1016/0005-2736(89)90546-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; ROBERT JC, 1990, BIOCHIM BIOPHYS ACTA, V1024, P167, DOI 10.1016/0005-2736(90)90220-I; Sambrook J, 1989, MOL CLONING LABORATO; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; STANLEY KK, 1983, NUCLEIC ACIDS RES, V11, P4077, DOI 10.1093/nar/11.12.4077; TAMURA S, 1989, J BIOL CHEM, V264, P8580; VANUEM TJF, 1991, BIOCHEM J, V280, P243, DOI 10.1042/bj2800243; VANUEM TJF, 1990, BIOCHIM BIOPHYS ACTA, V1023, P56, DOI 10.1016/0005-2736(90)90009-D; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	32	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19060	19065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382067				2022-12-25	WOS:A1992JP59300010
J	HADARI, YR; TZAHAR, E; NADIV, O; ROTHENBERG, P; ROBERTS, CT; LEROITH, D; YARDEN, Y; ZICK, Y				HADARI, YR; TZAHAR, E; NADIV, O; ROTHENBERG, P; ROBERTS, CT; LEROITH, D; YARDEN, Y; ZICK, Y			INSULIN AND INSULINOMIMETIC AGENTS INDUCE ACTIVATION OF PHOSPHATIDYLINOSITOL 3'-KINASE UPON ITS ASSOCIATION WITH PP185 (IRS-1) IN INTACT RAT LIVERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; PROTEIN; PHOSPHORYLATION; SUBSTRATE; CELLS; H2O2; PURIFICATION; PI3-KINASE; 3-KINASE	The major cytosolic substrate of the insulin receptor is a 185-kDa phosphoprotein (IRS-1) that contains multiple putative attachment sites for the p85-alpha regulatory subunit of phosphatidylinositol 3'-kinase (PI3K). To examine the possible interaction of pp185 with p85-alpha in vivo, we injected insulin or insulinomimetic agents (a combination of H2O2 and vanadate (H/V)) into the portal vein of anesthetized rats. In this model system, H/V treatment and, to a lesser extent, injection of insulin resulted in rapid and sustained tyrosine phosphorylation of multiple cellular proteins, including pp185/IRS-1. The latter was found to undergo specific association with the p85-alpha regulatory subunit of PI3K but not with two other proteins that contain src homology domains. As p85-alpha was not detectably phosphorylated on tyrosine residues and did not appear to interact directly with the insulin receptor, we conclude that tyrosine phosphorylation of pp185 promotes its association with p85-alpha and the catalytic subunit of PI3K. The recruitment of the holoenzyme may also involve its enzymatic activation and thus constitute an important step in the transduction of insulin signals.	WEIZMANN INST SCI,DEPT CLIN IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; NIH,DIABET BRANCH,BETHESDA,MD 20892	Weizmann Institute of Science; University of Pennsylvania; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012; YARDEN, YOSEF/K-1467-2012; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				BACKER JM, 1992, J BIOL CHEM, V267, P1367; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KADOTA S, 1987, J BIOL CHEM, V262, P8252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NADIV O, 1992, ENDOCRINOLOGY, V130, P1515, DOI 10.1210/en.130.3.1515; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1992, IN PRESS CELL; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER Y, 1980, NATURE, V284, P556; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	28	119	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17483	17486						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381348				2022-12-25	WOS:A1992JM22300002
J	SMITH, JS; ROTH, MJ				SMITH, JS; ROTH, MJ			SPECIFICITY OF HUMAN IMMUNODEFICIENCY VIRUS-1 REVERSE TRANSCRIPTASE-ASSOCIATED RIBONUCLEASE-H IN REMOVAL OF THE MINUS-STRAND PRIMER, TRANSFER RNA(LYS3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ROUS-SARCOMA VIRUS; NUCLEOTIDE-SEQUENCE; RETROVIRAL DNA; RNASE-H; ESCHERICHIA-COLI; CIRCLE JUNCTION; CIRCULAR DNA; AIDS VIRUS; VIRAL-DNA	We have examined the specificity of human immunodeficiency virus-1 (HIV-1) reverse transcriptase-associated HNase H in removing the tRNA(Lys3) (-)-strand primer in vitro using a model substrate. This substrate represents an intermediate in the reverse transcription process where the tRNA(Lys3) primer has not yet been removed after (+)-strand strong stop DNA synthesis. The substrate consists of an RNA oligonucleotide corresponding to the 3'-terminal 17 nucleotides of the tRNA(Lys3) linked to U5 DNA and annealed to single-stranded DNA containing the U5 and the primer-binding site. Upon incubation with HIV-1 reverse transcriptase p66/p51 heterodimer, the minus-strand DNA product resulting from RNase H cleavage retained the 3'-rA from the model tRNA primer. Changing the 3'-terminal AMP of the model tRNA primer from rA to dA did not alter the RNase H cleavage site. Further, the retention of AMP was not dependent on recognition of adjacent U5 sequences or the CCA terminus of the model tRNA(Lys3). The synthetic RNA primer was released as an intact species by a single endonucleolytic cleavage 5' of the rA. The cleavage patterns of Moloney murine leukemia virus and avian myoblastosis virus RNase H activities on the HIV-1 model substrate were more heterogeneous compared to HIV-1 RNase H. This specificity of HIV-1 RNase H would result in linear DNA molecules with a single rA at the U5 terminus and would provide two bases adjacent to the conserved CA dinucleotide to be cleaved away during the integration process.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Roth, Monica/AAN-8742-2020					BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; Coffin J. M., 1990, VIROLOGY, P1437; COLICELLI J, 1986, J VIROL, V57, P674, DOI 10.1128/JVI.57.2.674-677.1986; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DUDDING LR, 1990, BIOCHEM BIOPH RES CO, V167, P244, DOI 10.1016/0006-291X(90)91757-J; ENGLAND TE, 1978, NATURE, V275, P561; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUGHES SH, 1981, P NATL ACAD SCI-BIOL, V78, P4299, DOI 10.1073/pnas.78.7.4299; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PAUZA CD, 1990, VIROLOGY, V179, P886; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHIMOTOHNO K, 1980, P NATL ACAD SCI-BIOL, V77, P7357, DOI 10.1073/pnas.77.12.7357; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VANBEVEREN C, 1985, RNA TUMOR VIRUSES, P559; VARMUS H, 1989, MOBILE DNA, P53; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VARMUS HE, 1984, RNA TUMOR VIRUSES, V1, P75; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WALLACE DM, 1986, METHOD ENZYMOL, V152, P41; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001	43	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15071	15079						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378844				2022-12-25	WOS:A1992JF08800083
J	ADAMO, HP; CARIDE, AJ; PENNISTON, JT				ADAMO, HP; CARIDE, AJ; PENNISTON, JT			USE OF EXPRESSION MUTANTS AND MONOCLONAL-ANTIBODIES TO MAP THE ERYTHROCYTE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CALCIUM-PUMP; AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CA-2+ PUMP; FUNCTIONAL DOMAINS; COMPLEMENTARY-DNA; CATALYTIC SUBUNIT; BINDING-PROTEIN	Deletion and truncation mutants of the human erythrocyte Ca2+ pump (hPMCA4b) were expressed in COS-1 cells. The reactivity patterns of these mutants with seven monoclonal antibodies were examined. Of the seven, six (JA9, JA3, 1G4, 4A4, 3E10 and 5F10) react from the cytoplasmic side. JA9 and JA3 reacted near the NH2 terminus and the COOH terminus of the molecule, respectively. 5F10 and 3E10 recognized portions of the large hydrophilic region in the middle of the protein. The epitopes of 1G4 and 4A4 were discontinuous and included residues from the long hydrophilic domain and residues between the proposed transmembrane domains M2 and M3. Antibody 1B10, which reacts from the extracellular side, recognized the COOH-terminal half of the molecule. These results show that the NH2 terminus, the COOH terminus, the region between M2 and M3, and the large hydrophilic region are all on the cytoplasmic side. This means that there are an even number of membrane crossings in both the NH2-terminal and the COOH-terminal halves. Between residues 75 and 300 there must be at least two membrane crossings, and there are at least two membrane crossings in the COOH-terminal half of the molecule.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic			Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, IN PRESS BIOCH J, V285; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARIDE AJ, 1988, BIOCHEM J, V255, P663; CARIDE AJ, 1989, BIOCHEM J, V264, P87, DOI 10.1042/bj2640087; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FESCHENKO MS, 1992, J BIOL CHEM, V267, P4097; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KESSLER F, 1990, J BIOL CHEM, V265, P16012; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PAPP B, 1989, J BIOL CHEM, V264, P4577; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Penniston JT, 1983, CALCIUM CELL FUNCTIO, P99; REGA AF, 1986, CALCIUM PUMP PLASMA; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WASSERMAN RH, 1991, HISTOCHEMISTRY, V96, P413, DOI 10.1007/BF00315999	35	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14244	14249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378439				2022-12-25	WOS:A1992JD32500071
J	TANAKA, M; OHNO, S; ADACHI, S; NAKAJIN, S; SHINODA, M; NAGAHAMA, Y				TANAKA, M; OHNO, S; ADACHI, S; NAKAJIN, S; SHINODA, M; NAGAHAMA, Y			PIG TESTICULAR 20-BETA-HYDROXYSTEROID DEHYDROGENASE EXHIBITS CARBONYL REDUCTASE-LIKE STRUCTURE AND ACTIVITY - CDNA CLONING OF PIG TESTICULAR 20-BETA-HYDROXYSTEROID DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; SALMO-GAIRDNERI; RAINBOW-TROUT; TESTIS; GENE; ENZYME; 17-ALPHA,20-BETA-DIHYDROXY-4-PREGNEN-3-ONE; PURIFICATION; PROTEIN	cDNA inserts encoding 20-beta-hydroxysteroid dehydrogenase (EC 1.1.1.53) were, for the first time, isolated and cloned from a pig testis cDNA library using synthetic oligonucleotides deduced from the partially determined amino acid sequences. The cDNA contains an open reading frame predicted to encode 289 amino acid residues. Surprisingly, it has 85% amino acid homology to human carbonyl reductase. The purified enzyme exhibited carbonyl reductase activity. Adenine-rich sequence was located in the 3'-untranslated region, which may mean that the gene originates by retroposition. RNA transcripts of 1.3, 3, and 6 kilobases were detected in poly(A)+ RNA extracted from pig testis by Northern blot hybridization. The steady-state level of the RNA species increased to a maximum in testes from 10-day-old pigs, but rapidly declined thereafter to the same levels found in testes of mature animals.	HOSEI UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN	Hosei University	TANAKA, M (corresponding author), NATL INST BASIC BIOL, REPROD BIOL LAB, OKAZAKI, AICHI 444, JAPAN.			TANAKA, MINORU/0000-0001-9100-1487				AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; COLEMAN JP, 1988, J BACTERIOL, V170, P2070, DOI 10.1128/jb.170.5.2070-2077.1988; ENGEL LL, 1961, ANNU REV BIOCHEM, V30, P499, DOI 10.1146/annurev.bi.30.070161.002435; FORREST GL, 1990, BIOCHIM BIOPHYS ACTA, V1048, P149, DOI 10.1016/0167-4781(90)90050-C; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUBENER HJ, 1958, H-S Z PHYSIOL CHEM, V313, P124, DOI 10.1515/bchm2.1958.313.1.124; JORNVALL H, 1984, FEBS LETT, V165, P190, DOI 10.1016/0014-5793(84)80167-2; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MAREKOV L, 1990, FEBS LETT, V266, P51, DOI 10.1016/0014-5793(90)81504-H; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; NAGAHAMA Y, 1990, PROG CLIN BIOL RES, V342, P385; NAKAJIN S, 1989, CHEM PHARM BULL, V37, P148; NAKAJIN S, 1987, CHEM PHARM BULL, V35, P2490; NAKAJIN S, 1988, J BIOCHEM-TOKYO, V104, P565, DOI 10.1093/oxfordjournals.jbchem.a122511; NESEMANN G, 1960, BIOCHEM Z, V333, P88; OHNO S, 1991, CHEM PHARM BULL, V39, P972; OHNO S, 1992, STEROID BIOCH MOL BI, V42, P17; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; SAKAI N, 1989, GEN COMP ENDOCR, V75, P231, DOI 10.1016/0016-6480(89)90075-0; SAKAI N, 1989, BIOMED RES-TOKYO, V10, P131, DOI 10.2220/biomedres.10.131; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; Spande T.F., 1967, DETERMINATION TRYPTO, P498; TAMAOKI B, 1966, STEROID DYNAMICS, P493; TANAKA M, 1992, J MOL ENDOCRINOL, V8, P53, DOI 10.1677/jme.0.0080053; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; UEDA H, 1984, J EXP ZOOL, V231, P435, DOI 10.1002/jez.1402310318; WERMUTH B, 1988, J BIOL CHEM, V263, P16185; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; YOUNG G, 1986, DEV BIOL, V118, P1, DOI 10.1016/0012-1606(86)90067-9	35	98	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13451	13455						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377683				2022-12-25	WOS:A1992JB74600057
J	BALZARINI, J; PEREZPEREZ, MJ; SANFELIX, A; CAMARASA, MJ; BATHURST, IC; BARR, PJ; DECLERCQ, E				BALZARINI, J; PEREZPEREZ, MJ; SANFELIX, A; CAMARASA, MJ; BATHURST, IC; BARR, PJ; DECLERCQ, E			KINETICS OF INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE BY THE NOVEL HIV-1-SPECIFIC NUCLEOSIDE ANALOG [2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOLE-2'',2''-DIOXIDE)THYMINE (TSAO-T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-III/LAV; 3'-AZIDO-3'-DEOXYTHYMIDINE; INVITRO; INFECTIVITY; DERIVATIVES; REPLICATION; POTENT; AGENTS	[2',5'-Bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-s piro-5"--(4"-amino-1",2"-oxathiole-2", 2"-dioxide)thymine (TSAO-T) is a representative of a novel class of nucleoside analogues that are endowed with a potent and specific activity against human immunodeficiency virus (HIV) type 1 and are targeted at the HIV-1 reverse transcriptase (RT). Inhibition of HIV-1 RT by TSAO-T was reversible and noncompetitive with respect to dGTP as the substrate and poly(C).oligo(dG) as the template/primer. In contrast with the nonnucleoside derivatives tetrahydroimidazo-[4,5,1-jk][1,41-benzodiazepin-2(1H)-thione (TIBO) (R-82150), nevirapine (BI-RG-587) and the HEPT derivative I-HEPU-SdM, TSAO-T was not inhibitory to HIV-1 RT in the presence of other homopolymeric template/primers. It did not interfere with the DNA-dependent DNA polymerase function of HIV-1 RT, HIV-2 RT, herpes simplex virus type 1 DNA polymerase, or Taq polymerase. However, TSAO-T proved inhibitory to the HIV-1 RT reaction primed by Escherichia coli 16S/23S rRNA, irrespective of the nature of the radiolabeled 2'-deoxynucleotide 5'-triphosphate (dNTP) used. TSAO-T does not act as a DNA chain terminator. It interacts with HIV-1 RT at a nonsubstrate (dNTP)-binding site.	INST QUIM MED,E-28006 MADRID,SPAIN; CHIRON CORP,EMERYVILLE,CA 94608	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG); Novartis	BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM.		Perez-Perez, Maria-Jesus/O-4580-2014; García, Ana Rosa San-Félix/G-5117-2015; Camarasa, María-José/N-8845-2019; Camarasa, María-José/B-6340-2015	Perez-Perez, Maria-Jesus/0000-0003-1336-7760; García, Ana Rosa San-Félix/0000-0003-4271-7598; Camarasa, María-José/0000-0002-4978-6468; Camarasa, María-José/0000-0002-4978-6468; De Clercq, Erik/0000-0002-2985-8890				BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BALZARINI F, 1992, IN PRESS ANTIMICROB; BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1986, BIOCHEM BIOPH RES CO, V140, P735, DOI 10.1016/0006-291X(86)90793-X; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P4961, DOI 10.1073/pnas.88.11.4961; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; BALZARINI J, 1992, IN PRESS P NATL ACAD; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CHU CK, 1989, J MED CHEM, V32, P612, DOI 10.1021/jm00123a018; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B; FRANK KB, 1991, J BIOL CHEM, V266, P14232; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; KUKLA MJ, 1991, J MED CHEM, V34, P746, DOI 10.1021/jm00106a040; LIAW YC, 1991, J AM CHEM SOC, V113, P1857, DOI 10.1021/ja00005a075; LIN TS, 1989, J MED CHEM, V32, P1891, DOI 10.1021/jm00128a034; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; Schinazi R. F., 1988, AIDS CHILDREN ADOLES, P126; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; TANORKA H, 1992, J MED CHEM, V35, P337; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	36	127	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11831	11838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376314				2022-12-25	WOS:A1992HY94700032
J	TAKATSUJI, H; YAMAUCHI, H; WATANABE, S; KATO, H; IKEDA, JE				TAKATSUJI, H; YAMAUCHI, H; WATANABE, S; KATO, H; IKEDA, JE			CAULIFLOWER MOSAIC-VIRUS REVERSE-TRANSCRIPTASE - ACTIVATION BY PROTEOLYTIC PROCESSING AND FUNCTIONAL ALTERATION BY TERMINAL DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE INHIBITION; MURINE LEUKEMIA-VIRUS; ESCHERICHIA-COLI; DNA-POLYMERASES; ELECTROPHORESIS; EXPRESSION	We have previously expressed the cauliflower mosaic virus (CaMV) reverse transcriptase (RTase) gene, the ORFV gene, in yeast in an active form (RTase-Y). An activity gel analysis revealed that the molecular size of RTase-Y as well as an RTase associated with the CaMV particles (RTase-V) is 60 kDa. This size is about 18 kDa smaller than that of the inactive form previously expressed in Escherichia coli (RTase-E) (78 kDa), which corresponds to the coding capacity estimated for the ORFV gene. To investigate the possible involvement of proteolytic processing in the de novo synthesis of CaMV RTase, we constructed a series of deletions from either terminus or both termini of the ORFV coding sequence and expressed them in E. coli. Among the various truncated RTases, those (denoted DELTA-N) that lack N-terminal peptide fragments 143-185 amino acids long were active on the synthetic RNA template-primer, poly(rC)-oligo(dG). Those RTases (denoted DELTA-C) lacking C-terminal peptide fragments 50-102 amino acids long and those lacking both termini (denoted DELTA-NC) were also active on this template. However, only the DELTA-N RTases showed enzyme properties indistinguishable from the RTase-Y in that they transcribed natural RNA into DNA and required either Mg2+ or Mn2+ for their activity. The length of the deletion corresponded approximately to the difference of the molecular weights between RTase-Y and RTase-E. These results suggest that CaMV RTase is translated in an inactive precursor form and then converted to an active form by proteolytic processing during de novo synthesis. We have also demonstrated that C-terminal deletions cause a loss of activity on a natural RNA template accompanied by an alteration in metal ion requirement. The inability to incorporate dTTP accounts for the loss of activity on the natural RNA template. However, the affinities for dTTP and the corresponding template, poly(rA)-oligo(dT), were found to be unaltered.	NATL INST AGROBIOL RESOURCES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan								BASU A, 1988, J BIOL CHEM, V263, P1648; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DION AS, 1974, J VIROL, V14, P40, DOI 10.1128/JVI.14.1.40-46.1974; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; GARDNER RC, 1981, NUCLEIC ACIDS RES, V9, P2871, DOI 10.1093/nar/9.12.2871; Hohn T, 1982, Curr Top Microbiol Immunol, V96, P194; HOHN T, 1985, TRENDS BIOCHEM SCI, V10, P205, DOI 10.1016/0968-0004(85)90193-8; HOWELL SH, 1982, ANNU REV PLANT PHYS, V33, P609, DOI 10.1146/annurev.pp.33.060182.003141; HULL R, 1983, TRENDS BIOCHEM SCI, V8, P119, DOI 10.1016/0968-0004(83)90231-1; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; MARCUS SL, 1974, J VIROL, V14, P853, DOI 10.1128/JVI.14.4.853-859.1974; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MODAK MJ, 1981, BIOCHIM BIOPHYS ACTA, V654, P227, DOI 10.1016/0005-2787(81)90176-3; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; PFEIFFER P, 1983, CELL, V33, P781, DOI 10.1016/0092-8674(83)90020-X; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHERD RJ, 1979, ANNU REV PLANT PHYS, V30, P405, DOI 10.1146/annurev.pp.30.060179.002201; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; TAKATSUJI H, 1986, NATURE, V319, P240, DOI 10.1038/319240a0; TOH H, 1985, EMBO J, V4, P1267, DOI 10.1002/j.1460-2075.1985.tb03771.x; TORRUELLA M, 1989, EMBO J, V8, P2819, DOI 10.1002/j.1460-2075.1989.tb08428.x; VOLOVITCH M, 1984, EMBO J, V3, P309, DOI 10.1002/j.1460-2075.1984.tb01801.x	23	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11579	11585						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375943				2022-12-25	WOS:A1992HX16900098
J	WILLE, H; MANDELKOW, EM; MANDELKOW, E				WILLE, H; MANDELKOW, EM; MANDELKOW, E			THE JUVENILE MICROTUBULE-ASSOCIATED PROTEIN MAP2C IS A ROD-LIKE MOLECULE THAT FORMS ANTIPARALLEL DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAU PROTEINS; BUNDLE FORMATION; BINDING DOMAIN; MOUSE-BRAIN; MAP-2; PHOSPHORYLATION; IDENTIFICATION; TUBULIN; WEIGHT; CDNA	We have developed a procedure to isolate the microtubule-associated protein 2c (MAP2c), a juvenile form of MAP2 occurring in mammalian brain. The shape, size, self-association, and antibody interactions of MAP2c were studied. Monomeric MAP2c is an elongated molecule with a length approximately 48 nm, considerably shorter than the higher molecular weight forms MAP2a or b of adult brain. Two monoclonal antibodies whose epitopes are near the N or C terminus, respectively, are located close to the opposite ends of the MAP2c rods. This places constraints on the types of internal folding of the molecule. MAP2c self-associates into dimers and fibrous aggregates. The dimers are predominantly antiparallel and nearly in register, as judged by antibody labeling.	DESY, MAX PLANCK UNIT STRUCT MOLEC BIOL, NOTKESTR 85, W-2000 HAMBURG 52, GERMANY	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society			Wille, Holger/C-2280-2008	Wille, Holger/0000-0001-5102-8706				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CHAPIN SJ, 1991, NATURE, V349, P24, DOI 10.1038/349024a0; COUCHIE D, 1985, FEBS LETT, V188, P331, DOI 10.1016/0014-5793(85)80397-5; CRANDALL JE, 1989, J NEUROCHEM, V53, P1910, DOI 10.1111/j.1471-4159.1989.tb09261.x; DINGUS J, 1991, J BIOL CHEM, V266, P18854; DOLL T, 1990, NUCLEIC ACIDS RES, V18, P361, DOI 10.1093/nar/18.2.361; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOTTLIEB RA, 1985, J CELL BIOL, V101, P1782, DOI 10.1083/jcb.101.5.1782; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HEINS S, 1991, J CELL SCI, P121; HERNANDEZ MA, 1986, EUR J BIOCHEM, V154, P41, DOI 10.1111/j.1432-1033.1986.tb09356.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KINDLER S, 1990, NUCLEIC ACIDS RES, V18, P2822, DOI 10.1093/nar/18.9.2822; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1990, NATURE, V345, P674, DOI 10.1038/345674a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TUCKER RP, 1988, J NEUROSCI, V8, P4503; TUCKER RP, 1988, PROTOPLASMA, V145, P195, DOI 10.1007/BF01349359; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V; WOODY RW, 1983, FEBS LETT, V141, P181; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	40	30	30	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10737	10742						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375231				2022-12-25	WOS:A1992HV09000080
J	MOSCARELLO, MA; PANG, H; PACEASCIAK, CR; WOOD, DD				MOSCARELLO, MA; PANG, H; PACEASCIAK, CR; WOOD, DD			THE N TERMINUS OF HUMAN MYELIN BASIC-PROTEIN CONSISTS OF C2, C4, C6, AND C8 ALKYL CARBOXYLIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; EXPRESSION; GENE	Peptide 1-21, generated by cyanogen bromide cleavage of each of two highly purified components of human myelin basic protein, components 1 and 8, gave a series of peaks in the fast atom bombardment mass spectra with m/z 2299, 2327, 2355, 2383, and 2411, indicating additions of 42, 70, 98, 126, and 154 atomic mass units respectively with m/z 2327 and 2355 as the dominant species. The pentafluorobenzyl esters prepared from an acid hydrolysate analyzed by negative ion chemical ionization gas chromatography mass spectrometry confirmed that C6, C-8, and C-10 fatty acids were present. These data demonstrated (i) that the N terminus of a myelin basic protein is not simply acetylated but containing C2, C4, C6, C-8, and C-10 fatty acids with C4 and C6 as the dominant species, (ii) the two components studied (C-1 and C-8) showed different relative amounts of C2 and C-8 in particular, and (iii) human myelin basic protein is the first protein to be reported with a complex N terminus consisting of several alkyl carboxylic acid species.	UNIV TORONTO,CARBOHYDRATE RES CTR,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	MOSCARELLO, MA (corresponding author), HOSP SICK CHILDREN,RES INST,DIV BIOCHEM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BARBER M, 1982, ANAL CHEM, V54, pA645; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CARNEGIE PR, 1969, BIOCHEM J, V111, P240, DOI 10.1042/bj1110240; CHEIFETZ S, 1984, ARCH BIOCHEM BIOPHYS, V233, P151, DOI 10.1016/0003-9861(84)90611-8; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; HASHIM GA, 1969, ARCH BIOCHEM BIOPHYS, V135, P324, DOI 10.1016/0003-9861(69)90546-3; HENION J, 1990, ATMOSPHERIC PRESSURE; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; MOSCARELLO MA, 1990, MYELIN BASIC PROTEIN, P25; PACEASCIAK CR, 1987, J CHROMATOGR LIBR, V37, P107; SCOBLE SA, 1990, METHOD ENZYMOL, V193, P519; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; WOOD DD, 1989, J BIOL CHEM, V264, P5121; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	15	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9779	9782						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374408				2022-12-25	WOS:A1992HT96500053
J	JIANG, WP; GORBEA, CM; FLANNERY, AV; BEYNON, RJ; GRANT, GA; BOND, JS				JIANG, WP; GORBEA, CM; FLANNERY, AV; BEYNON, RJ; GRANT, GA; BOND, JS			THE ALPHA-SUBUNIT OF MEPRIN-A - MOLECULAR-CLONING AND SEQUENCING, DIFFERENTIAL EXPRESSION IN INBRED MOUSE STRAINS, AND EVIDENCE FOR DIVERGENT EVOLUTION OF THE ALPHA-SUBUNIT AND BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY METALLOENDOPEPTIDASE; CLEAVAGE SITES; GROWTH-FACTOR; PLASMID DNA; MEP-1 GENE; MEMBRANE; PROTEIN; ACID; MICE; CHROMOSOME-17	Meprin A, a membrane-bound oligomeric metalloendopeptidase, contains two different subunits, alpha and beta. We report here the cloning and sequencing of the alpha-subunit cDNA. The translated polypeptide consists of 760 amino acids, including a preprosequence (77 amino acids) that precedes the NH2 terminus of the purified enzyme. The next 198 amino acids constitute the "astacin family" protease domain, which includes the astacin family signature sequence, HE(L,I)XHXXGFXHE(Q,H)XRXDRDX(Y,H)(V,I)X(I,V). An immunoglobulin/major histocompatibility complex protein signature was found at the end of the protease domain. At the COOH terminus of the alpha-subunit, there is an epidermal growth factor-like domain, followed by a transmembrane domain, and six additional amino acids. Ten potential glycosylation sites have been identified, and at least three of those sites are glycosylated. Northern blot analyses of kidney tissue from C57BL/6 and C3H/He mice indicate that variations in meprin A activity in these strains reflect differences in the levels of the alpha-subunit mRNA. Several internal peptide sequences obtained from the beta-subunit indicate that it is approximately 50% identical to the alpha-subunit. Furthermore, NH2-terminal sequence analyses (39 residues) indicate that rat and mouse-alpha are 79% identical, rat and mouse-beta are 74% identical, and that alpha and beta-subunits for both species are 47% identical. These data indicate that alpha and beta are closely related products of divergent evolution.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061; UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,ENGLAND; WASHINGTON UNIV,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Virginia Polytechnic Institute & State University; University of Liverpool; Washington University (WUSTL)			Beynon, Robert J/K-1408-2014	Beynon, Robert J/0000-0003-0857-495X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; BAIROCH A, 1990, PROSITE DICT PROTEIN; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1983, SCIENCE, V219, P1351, DOI 10.1126/science.6338590; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOND JS, 1984, P NATL ACAD SCI-BIOL, V81, P5542, DOI 10.1073/pnas.81.17.5542; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG SS, 1987, AM J PHYSIOL, V253, pC535, DOI 10.1152/ajpcell.1987.253.4.C535; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; Derynck R., 1987, ONCOGENES GENES GROW, P133; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLANNERY AV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P119, DOI 10.1016/0167-4838(91)90032-U; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZ T, 1987, TRANSLATIONAL REGULA, P413; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCKAY MJ, 1985, BIOCHEM BIOPH RES CO, V132, P171, DOI 10.1016/0006-291X(85)91003-4; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RECKELHOFF JF, 1988, IMMUNOGENETICS, V27, P298, DOI 10.1007/BF00376127; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; Sambrook J, 1989, MOL CLONING LABORATO; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STENFLO J, 1988, J BIOL CHEM, V263, P21; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZINGDE SM, 1986, ANAL BIOCHEM, V155, P10, DOI 10.1016/0003-2697(86)90216-2	46	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9185	9193						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374387				2022-12-25	WOS:A1992HR85400074
J	WILLIAMS, SE; ASHCOM, JD; ARGRAVES, WS; STRICKLAND, DK				WILLIAMS, SE; ASHCOM, JD; ARGRAVES, WS; STRICKLAND, DK			A NOVEL MECHANISM FOR CONTROLLING THE ACTIVITY OF ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - MULTIPLE REGULATORY SITES FOR 39-KDA RECEPTOR-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; HEYMANN NEPHRITIS; APOLIPOPROTEIN-E; BINDING-PROTEIN; GLYCOPROTEIN; LIVER; PURIFICATION; COMPLEXES; AFFINITY; CLONING	The alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha-2MR/LRP) consists of two polypeptides, 515 and 85 kDa, that are noncovalently associated. A 39-kDa polypeptide, termed the receptor-associated protein (RAP), interacts with the 515-kDa subunit after biosynthesis of these molecules and remains associated on the cell surface. This molecule regulates ligand binding of alpha-2MR/LRP (Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238). Titration and binding studies indica RAP binds to two equivalent binding sites on alpha-2MR/LRP, with a K(D) of 14 nm. Heterologous ligand displacement experiments demonstrated that RAP completely inhibits the binding of I-125-activated alpha-2M to human fibroblasts and to the purified alpha-2MR/LRP, with a K(i) of 23 and 26 nm, respectively. A direct correlation between the degree of binding of RAP to the receptor and the degree of ligand inhibition was observed, indicating that as the RAP binding sites are saturated, alpha-2MR/LRP loses its ability to bind ligands. Thus, the amount of RAP bound to alpha-2MR/LRP dictates the level of receptor activity. A model is proposed in which alpha-2MR/LRP contains multiple ligand binding sites, each regulated by a separate RAP site.	AMER RED CROSS,BIOCHEM LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200, K04HL002113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30200, HL-02113] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HALL PK, 1978, BIOCHEM J, V171, P27; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JONES JM, 1972, BIOCHEM J, V127, P187, DOI 10.1042/bj1270187; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRAUSE J, 1974, EUR J BIOCHEM, V41, P593, DOI 10.1111/j.1432-1033.1974.tb03301.x; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MAXFIELD FR, 1981, BIOCHEMISTRY-US, V20, P5353, DOI 10.1021/bi00521a041; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRAIGHT DL, 1988, BIOCHEMISTRY-US, V27, P2885, DOI 10.1021/bi00408a033; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	38	329	340	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9035	9040						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374383				2022-12-25	WOS:A1992HR85400052
J	LYONS, CR; ORLOFF, GJ; CUNNINGHAM, JM				LYONS, CR; ORLOFF, GJ; CUNNINGHAM, JM			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF AN INDUCIBLE NITRIC-OXIDE SYNTHASE FROM A MURINE MACROPHAGE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; HUMAN-NEUTROPHILS; NITROGEN-OXIDES; RELAXING FACTOR; NITRATE; RELEASE; INDUCTION; INFECTION; MESSENGER	Macrophages activated by exposure to cytokines and/or to endotoxin produce nitric oxide (NO.), a free radical that is a mediator of the host response to infection. Activation induces the expression of nitric oxide synthase, the enzyme that catalyzes formation of NO. from L-arginine and molecular oxygen. We report the cloning of a cDNA encoding the inducible nitric oxide synthase from a murine macrophage cell line, RAW264.7, exposed to interferon-gamma and lipopolysaccharide. Oocytes injected with mRNA transcribed from this cDNA demonstrate arginine-dependent production of nitrite, a stable metabolite of NO.. Nitrite production is blocked by the enzyme inhibitor, N(G)-monomethylarginine, and is independent of calcium/calmodulin. RAW264.7 cells demonstrate rapid accumulation of the nitric oxide synthase-encoding mRNAs upon activation. Comparison of the deduced amino acid sequence to the calcium/calmodulin-dependent nitric oxide synthase previously purified (Bredt, D. S., and Snyder, S. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 682-685) and cloned (Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Synder, S. H. (1991) Nature 351, 714-718) from rat brain identifies shared binding sites for the cofactors NADPH and flavins in the C-terminal half of both proteins and an additional conserved region near the N terminus that may recognize L-arginine and/or contribute to the active site.	BRIGHAM & WOMENS HOSP,RM 925,THORN BLDG,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ADAMS LB, 1990, J IMMUNOL, V144, P2725; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5295; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LA, 1982, ANAL BIOCHEM, V1256, P131; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1987, J IMMUNOL, V138, P550; HOLLINGER TG, 1984, J EXP ZOOL, V230, P427, DOI 10.1002/jez.1402300312; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIEW FY, 1990, J IMMUNOL, V145, P4306; Maniatis T, 1989, DECONTAMINATION DILU; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1542; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; YUI Y, 1991, J BIOL CHEM, V266, P12544	37	905	928	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6370	6374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372907				2022-12-25	WOS:A1992HK31800096
J	YANAGA, F; ABE, M; KOGA, T; HIRATA, M				YANAGA, F; ABE, M; KOGA, T; HIRATA, M			SIGNAL TRANSDUCTION BY TUMOR-NECROSIS-FACTOR-ALPHA IS MEDIATED THROUGH A GUANINE NUCLEOTIDE-BINDING PROTEIN IN OSTEOBLAST-LIKE CELL-LINE, MC3T3-E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID CYCLOOXYGENASE; EPIDERMAL GROWTH-FACTOR; PERTUSSIS TOXIN; CHEMOTACTIC PEPTIDE; MOLECULAR-CLONING; SMOOTH-MUSCLE; GTP-BINDING; RECEPTOR; STIMULATION; EXPRESSION	Transmembrane signalling mechanisms of tumor necrosis factor-alpha (TNF-alpha) were examined with special reference to the involvement of G-protein, in intact and permeabilized murine osteoblast-like cells. TNF-alpha stimulated the release of H-3 radioactivity from intact cells labeled with [H-3]arachidonic acid within 10 min in a dose dependent manner and the production of lyso forms of phospholipids, an event presumably mediated through the activation of phospholipase A2. Production of cAMP and inositol 1,4,5-trisphosphate was not affected by TNF-alpha. Pretreatment of the cells with pertussis toxin inhibited the liberation of [H-3]arachidonate. GTP-gamma-S (guanosine 5'-3-O-(thio)triphosphate) reduced the binding affinity of [I-125]TNF-alpha to beta-escin-permeabilized cells. The addition of TNF-alpha together with an unhydrolyzable analog of GTP, GTP-gamma-S, to the beta-escin-permeabilized cells prelabeled with [H-3]arachidonic acid led to a release of the H-3 radioactivity. The production of prostaglandin E2 (PGE2) was markedly stimulated by TNF-alpha in a dose over 100 ng/ml, with a latent time of about 3 h, and the stimulation was abolished by pretreatment with pertussis toxin. The time and dose requirements for this process differed from those for the possible activation of phospholipase A2, thereby indicating that other process(es) in addition to the activation of phospholipase A2 may be responsible for the enhanced production of PGE2. The activity of cyclooxygenase (i.e. the combined activities of prostaglandin endoperoxide synthase and PGH2-PGE2 isomerase) was stimulated by TNF-alpha with much the same time and dose requirements as for the production of PGE2, and the activation was found to be due to the increased amount of the enzyme, as assessed by a Western blot analysis with anti-cyclooxygenase antibody. This process was also sensitive to pertussis toxin. Therefore, receptors for TNF-alpha in MC3T3-E1 cells apparently couple to G-protein sensitive to pertussis toxin and the coupling regulates the activations of phospholipase A2 and the de novo synthesis of cyclooxygenase.	KYUSHU UNIV,FAC DENT,DEPT BIOCHEM,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC DENT,DEPT ORAL SURG 2,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DIS CHEST RES INST,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University								BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAVIS HW, 1990, BIOCHEM J, V270, P401, DOI 10.1042/bj2700401; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HAMACHI T, 1986, BIOCHIM BIOPHYS ACTA, V889, P136, DOI 10.1016/0167-4889(86)90097-2; HIRATA M, 1984, J BIOCHEM-TOKYO, V96, P9, DOI 10.1093/oxfordjournals.jbchem.a134834; IKEBE T, 1988, J IMMUNOL, V140, P827; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; ITOH T, 1983, J PHYSIOL-LONDON, V337, P609, DOI 10.1113/jphysiol.1983.sp014645; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SILK ST, 1989, J BIOL CHEM, V264, P21466; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; YANAGA F, 1991, BIOCHIM BIOPHYS ACTA, V1094, P139; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	43	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5114	5121						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371994				2022-12-25	WOS:A1992HH74700020
J	RAN, S; BENOS, DJ				RAN, S; BENOS, DJ			IMMUNOPURIFICATION AND STRUCTURAL-ANALYSIS OF A PUTATIVE EPITHELIAL CL- CHANNEL PROTEIN ISOLATED FROM BOVINE TRACHEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE CHLORIDE CHANNEL; CYSTIC-FIBROSIS; CELL-LINE; MEMBRANE; RECONSTITUTION; PHOSPHORYLATION; NITROCELLULOSE; SOLUBILIZATION; PURIFICATION; QUANTITIES	We have purified to homogeneity a 38-kDa protein (called p38) from bovine tracheal epithelium. This protein, when reconstituted into liposomes, mediates stilbene disulfonate-sensitive I--125 conductive uptake. On nonreduced or partially reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis, this protein associates into a doublet of 62-64 kDa. In some experiments a multimer of 140 kDa was also observed. Rabbit polyclonal anti-P38 antibodies have been produced and used to immunopurify the native transporter. Upon reconstitution of the immunoaffinity-purified protein into liposomes, a 260-fold enhancement of 4,4'-bis(isothiocyano)-2,2'-stilbenedisulfonate and valinomycin-sensitive I--125 uptake was observed as compared to proteoliposomes containing unseparated material. On Western blots of total solubilized tracheal membrane proteins or semipurified fractions, the antibody recognized the 62-64-kDa doublet much better than the original 38-kDa antigen. Similar protein bands were detected in T84 and CFPAC cells as well. However, if apical membrane proteins were first separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions, the antibody recognized major bands at 140 and approximately 240 kDa. Upon partial reduction, immunolabeling of these proteins diminished with the concomitant appearance of the 62-64-kDa doublet. Upon complete reduction, the appearance of 32- and 38-kDa proteins was evident with the disappearance of the 62-64-kDa doublet. We hypothesize that the native Cl- channel is a heteromer containing at least four subunits connected by S-S bridges.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIDDK NIH HHS [DK42017] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], METHODS ENZYMOL B; BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BEAR CE, 1988, FEBS LETT, V237, P145, DOI 10.1016/0014-5793(88)80189-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUER W, 1990, BIOCHIM BIOPHYS ACTA, V1022, P229, DOI 10.1016/0005-2736(90)90118-8; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; EDELMAN A, 1990, PED PUBL S, V5, P42; FINN AL, 1989, P NATL ACAD SCI USA, V86, P7649, DOI 10.1073/pnas.86.19.7649; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1986, FED PROC, V45, P2757; GOGELEIN H, 1988, BIOCHIM BIOPHYS ACTA, V947, P521, DOI 10.1016/0304-4157(88)90006-8; GOGELEIN H, 1987, PFLUG ARCH EUR J PHY, V409, P122, DOI 10.1007/BF00584758; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JCK, 1986, NEUROCHEM RES, V11, P733, DOI 10.1007/BF00965341; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; NICHOLSON DW, 1986, BIOCHIM BIOPHYS ACTA, V856, P515, DOI 10.1016/0005-2736(86)90143-4; NILSSON BO, 1987, J IMMUNOL METHODS, V99, P67; PRESTON CP, 1990, 1990 P CF C WASH; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RAN S, 1991, J BIOL CHEM, V266, P4782; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P5340; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	41	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3618	3625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371273				2022-12-25	WOS:A1992HE60700014
J	SHAHARABANY, M; HIZI, A				SHAHARABANY, M; HIZI, A			THE CATALYTIC FUNCTIONS OF CHIMERIC REVERSE TRANSCRIPTASES OF HUMAN IMMUNODEFICIENCY VIRUSES TYPE-1 AND TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; H ACTIVITY; MUTATIONAL ANALYSIS; HIV-1 REPLICATION; ESCHERICHIA-COLI; RIBONUCLEASE; EXPRESSION; DOMAIN; AIDS; ORGANIZATION	The reverse transcriptases (RTs) from human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2, respectively) are relatively highly related yet there are several significant differences in their catalytic activities. In an attempt to relate these functional dissimilarities to the differences in amino acid sequences, we have employed a novel approach of constructing chimeric molecules composed of complementary amino acid sequences derived from the two HIV RTs. These recombinant proteins were analyzed for their enzymatic activities and for their sensitivity to tetrahydroimidazo[4, 5, 1-jk][1, 4]benzodiazepin-2[1H]-one and thione (TIBO), which selectively inhibits only HIV-1 RT. The active chimeric RTs were used to map the TIBO binding site on the HIV-1 RT molecules and to localize the putative sequences responsible for the high RNase H activity of HIV-1 RT relative to that of HIV-2 RT. The results suggest that TIBO interacts with amino acid residues located around residue 200 within the DNA polymerase domain of HIV-1 RT which shows a relatively low similarity to HIV-2 RT. The difference in the RNase H activity maps to a position in the DNA polymerase domain rather than to the RNase H domain. Out of the 12 chimeric RTs generated, four were either fully active or hyperactive, three others lost most of their catalytic activities, and the rest were totally inactive. The pattern of catalytic activities of these hybrid proteins can be explained by a model for the initial folding of HIV RTs, which entails the formation of three distinct and independently folded regions. Each region can be formed by amino acid sequences derived exclusively from either HIV-1 RT or HIV-2 RT.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIRSCH MS, 1988, J INFECT DIS, V157, P427, DOI 10.1093/infdis/157.3.427; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LAZO PA, 1990, SEMIN ONCOL, V17, P269; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1989, J BIOL CHEM, V264, P13975; MYERS G, 1991, HUMAN RETROVIRUSES A; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1989, MOBILE DNA, P53; Weiss R, 1985, RNA TUMOR VIRUSES	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3674	3678						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371274				2022-12-25	WOS:A1992HE60700022
J	LASSAM, N; BICKFORD, S				LASSAM, N; BICKFORD, S			LOSS OF C-KIT EXPRESSION IN CULTURED MELANOMA-CELLS	ONCOGENE			English	Article							TYROSINE KINASE RECEPTOR; W-MUTANT MICE; PROTO-ONCOGENE; SI-LOCUS; MOUSE; MELANOCYTES; LIGAND; MUTATIONS; GROWTH; KL	The proto-oncogene c-kit encodes a receptor tyrosine kinase which has been shown to play a key role in melanocyte development. In this report we asked whether the c-kit gene product is also involved in promoting the growth of transformed melanocytes. We found that, while c-Kit protein was readily observed in normal human neonatal and adult melanocytes, the majority of cell lines established from human melanoma samples did not express detectable levels of c-kit mRNA or protein. A similar pattern of differential expression was also observed in normal and transformed murine melanocytes. Our findings raise the possibility that a marked reduction in c-kit gene expression either promotes or is a consequence of transformation in melanocytes.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ONTARIO,CANADA; SUNNYBROOK MED CTR,TORONTO M4N 3M5,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	LASSAM, N (corresponding author), UNIV TORONTO,DIV MED ONCOL,TORONTO M5S 1A1,ONTARIO,CANADA.							BEAN MA, 1975, CANCER RES, V35, P2902; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAJAL SRY, 1991, AM J PATHOL, V138, P349; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FEINBERG AP, 1963, ANAL BIOCHEM, V132, P6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL; FLANAGAN JG, 1990, CELL, V63, P85; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1985, CANCER RES, V45, P5670; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; MAYER TC, 1970, DEV BIOL, V23, P297, DOI 10.1016/0012-1606(70)90100-4; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, P NATL ACAD SCI USA, V88, P2341; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J, 1989, MOL CLONING LABORATO; Silvers W.K., 1979, COAT COLORS MICE, P206; SILVERS WILLYS KENT, 1956, J MORPH, V99, P41, DOI 10.1002/jmor.1050990103; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULRICH A, 1990, CELL, V61, P23; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	149	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					51	56						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371338				2022-12-25	WOS:A1992HC22700007
J	ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E				ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E			BOMBESIN, VASOPRESSIN, AND ENDOTHELIN STIMULATION OF TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS - IDENTIFICATION OF A NOVEL TYROSINE KINASE AS A MAJOR SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; STABLE ASSOCIATION; DNA-SYNTHESIS; PROTEINS; NEUROPEPTIDES; RECEPTORS; PATHWAYS; PP60SRC; GROWTH	Neuropeptide-stimulated tyrosine phosphorylation of specific components in Swiss 3T3 cells was investigated using monoclonal antibodies directed against the src transformation-associated substrates p125 focal adhesion kinase (FAK), a novel type of cytosolic tyrosine kinase, and p130. Treatment of Swiss 3T3 cells with the mitogenic peptides bombesin, vasopressin, and endothelin caused a striking increase in the tyrosine phosphorylation of p125FAK, as judged either by anti-phosphotyrosine (anti-Tyr(P)) Western blots of anti-p125FAK immunoprecipitates, or by anti-p125FAK immunoblots of anti-Tyr(P) immunoprecipitates. Bombesin-stimulated tyrosine phosphorylation of p125FAK was detectable within seconds and concentration-dependent (half-maximum effect of 0.3 nM). Neuropeptides also stimulated the tyrosine phosphorylation of a second component of M(r) 130,000, previously identified as the major p130 phosphotyrosyl protein in src-transformed cells. Bombesin stimulated p130 tyrosine phosphorylation with kinetics and concentration dependence similar to those observed for p125FAK. This is the first report to identify substrates for neuropeptide-stimulated tyrosine phosphorylation; the finding that one of these substrates is a tyrosine kinase suggests the existence of a novel signal transduction pathway in the action of mitogenic neuropeptides.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FORCE T, 1991, J BIOL CHEM, V266, P6650; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	18	325	326	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19031	19034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382065				2022-12-25	WOS:A1992JP59300003
J	BIRD, GS; OBIE, JF; PUTNEY, JW				BIRD, GS; OBIE, JF; PUTNEY, JW			FUNCTIONAL HOMOGENEITY OF THE NONMITOCHONDRIAL CA2+ POOL IN INTACT MOUSE LACRIMAL ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; EXOCRINE PANCREAS; NONMUSCLE CELLS; CA-2+ RELEASE; 2ND MESSENGER; HEPATOCYTES; TRISPHOSPHATE; OSCILLATIONS	In the absence of extracellular Ca2+, treatment of mouse lacrimal acinar cells with maximal concentrations of methacholine released Ca2+ from intracellular stores. No additional Ca2+ was mobilized by subsequent application of the intracellular Ca2+-ATPase inhibitor, thapsigargin, the stable inositol 1,4,5-trisphosphate ((1,4,5)IP3) analog, inositol 2,4,5-trisphosphate ((2,4,5)IP3) (by microinjection), or the Ca2+ ionophore, ionomycin. However, following prolonged activation of cells by methacholine in the presence of extracellular Ca2+, Ca2+ accumulated into a pool which was released by ionomycin but not by thapsigargin. This latter accumulation was blocked by prior microinjection of ruthenium red, indicating that it represents mitochondrial uptake. In saponin-permeabilized lacrimal cells, two Ca2+-sequestering pools were detected: (i) a ruthenium red-sensitive, thapsigargin-insensitive pool, presumed to be the mitochondria; and (ii) a ruthenium red-insensitive, thapsigargin-sensitive pool. Only the thapsigargin-sensitive pool accumulated Ca2+ at concentrations similar to those in unstimulated cells. The thapsigargin-sensitive Ca2+ pool was sensitive to (1,4,5)IP3; however, in contrast to findings in intact cells, only 44% of this pool was releasable by (1,4,5)IP3 or (2,4,5)IP3. These data indicate that, in intact lacrimal acinar cells, all exchangeable (ionomycin-sensitive) Ca2+ resides in a pool which responds homogeneously to agonists, (1,4,5)IP3, and thapsigargin. Prolonged elevation of [Ca2+]i results in Ca2+ accumulation into a second, ruthenium red-sensitive pool, presumably mitochondria. Finally, permeabilization of the cells fragments the non-mitochondrial pool, resulting in two pools, one sensitive and one insensitive to (1,4,5)IP3.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BLAUSTEIN MP, 1980, J PHYSIOLOGY PARIS, V76, P459; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P61, DOI 10.1016/0143-4160(91)90008-3; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; POGGIOLI J, 1982, PFLUG ARCH EUR J PHY, V392, P239, DOI 10.1007/BF00584303; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; STOLZE H, 1980, AM J PHYSIOL, V238, pG338, DOI 10.1152/ajpgi.1980.238.4.G338; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; UEDA T, 1986, J BIOL CHEM, V261, P3184; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; ZHAO H, 1990, J BIOL CHEM, V265, P21419	32	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18382	18386						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382054				2022-12-25	WOS:A1992JN50200025
J	CARRILLO, N; CECCARELLI, EA; KRAPP, AR; BOGGIO, S; FERREYRA, RG; VIALE, AM				CARRILLO, N; CECCARELLI, EA; KRAPP, AR; BOGGIO, S; FERREYRA, RG; VIALE, AM			ASSEMBLY OF PLANT FERREDOXIN-NADP+ OXIDOREDUCTASE IN ESCHERICHIA-COLI REQUIRES GROE MOLECULAR CHAPERONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED-CHLOROPLASTS; EXPRESSION; PROTEINS; SPINACH; REDUCTASE; PURIFICATION; CDNA; PLASTOCYANIN; PENICILLINS; SEQUENCE	We have recently reported the expression in Escherichia coli of an enzymatically competent ferredoxin-NADP+ oxidoreductase from cloned pea genes encoding either the mature enzyme or its precursor protein (Ceccarelli, E. A., Viale, A. M., Krapp, A. R., and Carrillo, N. (1991) J. Biol. Chem. 266, 14283-14287). Processing to the mature form by bacterial protease(s) and FAD assembly occurred in the bacterial cytosol. Expression of ferredoxin-NADP+ reductase in chaperonin-deficient (groE-) mutants of E. coli resulted in partial reductase assembly at permissive growth temperatures (i.e. 30-degrees-C), and in total breakdown of holoenzyme assembly, and accumulation as aggregated inclusion bodies at non-permissive temperatures (i.e. 42-degrees-C). Coexpression in these mutants of a cloned groESL operon from the phototrophic bacterium Chromatium vinosum resulted in partial or total recoveries of ferredoxin-NADP+ reductase assembly. The overall results indicate that bacterial chaperonins are required for the productive folding/assembly of eucaryotic ferredoxin-NADP+ reductase expressed in E. coli.	UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT MICROBIOL,RA-2000 ROSARIO,ARGENTINA	National University of Rosario	CARRILLO, N (corresponding author), UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT CIENCIAS BIOL,SUIPACHA 531,RA-2000 ROSARIO,ARGENTINA.		Ceccarelli, Eduardo A./M-8699-2014	Ceccarelli, Eduardo A./0000-0001-5776-3306				ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; CARRILLO N, 1987, CURRENT TOPICS PHOTO, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COUGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835; COURTRIGHT JB, 1970, J BACTERIOL, V102, P722, DOI 10.1128/JB.102.3.722-728.1970; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; LINDSTROM EB, 1970, J BACTERIOL, V101, P218; LORIMER GH, 1991, 3RD INT C PLANT MOL; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; Maniatis T, 1989, DECONTAMINATION DILU; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MICHALOWSKI CB, 1989, PLANT PHYSIOL, V89, P817, DOI 10.1104/pp.89.3.817; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NORDLING M, 1990, FEBS LETT, V276, P98, DOI 10.1016/0014-5793(90)80517-M; ROTHSTEIN SJ, 1985, P NATL ACAD SCI USA, V82, P7955, DOI 10.1073/pnas.82.23.7955; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; VANCAMP W, 1990, P NATL ACAD SCI USA, V87, P9903, DOI 10.1073/pnas.87.24.9903; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALEY SG, 1974, BIOCHEM J, V139, P789, DOI 10.1042/bj1390789; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; ZANETTI G, 1982, EUR J BIOCHEM, V126, P453, DOI 10.1111/j.1432-1033.1982.tb06801.x; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	34	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15537	15541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353496				2022-12-25	WOS:A1992JG11300045
J	DAY, CL; STOWELL, KM; BAKER, EN; TWEEDIE, JW				DAY, CL; STOWELL, KM; BAKER, EN; TWEEDIE, JW			STUDIES OF THE N-TERMINAL HALF OF HUMAN LACTOFERRIN PRODUCED FROM THE CLONED CDNA DEMONSTRATE THAT INTERLOBE INTERACTIONS MODULATE IRON RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL BRUSH-BORDER; HUMAN-SERUM TRANSFERRIN; HUMAN LACTOTRANSFERRIN; BINDING SITE; RESOLUTION; FRAGMENTS; PROTEINS; APOLACTOFERRIN; OVOTRANSFERRIN; EXPRESSION	The factors influencing iron binding and release by lactoferrin have been addressed by comparison of the native full length molecule (Lf) with the N-terminal half of human lactoferrin (Lf(N)) produced from the cloned cDNA expressed in baby hamster kidney (BHK) cells. The coding sequences for Lf(N) were inserted into the expression vector pNUT between the metallothionein promoter and the human growth hormone transcription termination sequences. Transformed BHK cells were grown in roller bottles where concentrations of Lf(N) as high as 35 mg/liter were obtained. The pure protein, produced by the transformed BHK cells, was characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, protein blotting and immunodetection, N-terminal sequence analysis, UV-visible spectroscopy, electron spin resonance spectroscopy, and measurements of metal binding and release. By these criteria Lf(N) was found to be correctly processed, glycosylated, and able to bind iron reversibly. Both UV-visible and electron spin resonance spectra of the half molecule were very similar to those of native lactoferrin and the full length lactoferrin produced in BHK cells, but there were marked differences in the pH at which iron release occurred. Iron release from Lf(N) occurs in the pH range 6.0-4.0, compared with 4.0-2.5 for native lactoferrin and 6.2-4.0 for transferrin. These results suggest that the more facile release of iron from Lf(N) compared with native lactoferrin results from the absence of stabilizing contacts between the N- and C-terminal halves and that the characteristic difference in pH stability between lactoferrins and transferrins is due primarily to differences in these interactions.	MASSEY UNIV,DEPT CHEM & BIOCHEM,PALMERSTON NORTH,NEW ZEALAND	Massey University				Day, Catherine/0000-0003-1571-4367; Baker, Edward/0000-0003-2456-7661	NICHD NIH HHS [HD-20859] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020859] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AINSCOUGH EW, 1980, BIOCHEMISTRY-US, V19, P4072, DOI 10.1021/bi00558a026; AINSCOUGH EW, 1983, J INORG BIOCHEM, V18, P103, DOI 10.1016/0162-0134(83)80014-2; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AISEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P314, DOI 10.1016/0005-2795(72)90283-8; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BAGGIOLINI M, 1970, Journal of Experimental Medicine, V131, P559, DOI 10.1084/jem.131.3.559; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BIRGENS HS, 1983, SCAND J HAEMATOL, V34, P383; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; BROCK JH, 1985, METALLOPROTEINS 2, P183; BROWNMASON A, 1984, J BIOL CHEM, V259, P1866; BROXMEYER HE, 1978, J EXP MED, V148, P1052, DOI 10.1084/jem.148.4.1052; CHASTEEN ND, 1983, ADV INORG BIOCHEM, V5, P201; COX TM, 1979, BIOCHIM BIOPHYS ACTA, V588, P120, DOI 10.1016/0304-4165(79)90377-5; DAVIDSON LA, 1988, AM J PHYSIOL, V254, pG580, DOI 10.1152/ajpgi.1988.254.4.G580; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FLETCHER J, 1968, NATURE, V218, P1211, DOI 10.1038/2181211a0; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; HU WL, 1988, BIOCHEM J, V249, P435, DOI 10.1042/bj2490435; HU WL, 1990, BIOCHEMISTRY-US, V29, P535, DOI 10.1021/bi00454a030; IKEDA H, 1985, FEBS LETT, V182, P305, DOI 10.1016/0014-5793(85)80321-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND D, 1984, BIOCHIM BIOPHYS ACTA, V787, P90, DOI 10.1016/0167-4838(84)90111-0; LEGRAND D, 1990, BIOCHEM J, V266, P575; LEGRAND D, 1986, BIOCHEM J, V236, P839, DOI 10.1042/bj2360839; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; LONNERDAL B, 1976, AM J CLIN NUTR, V29, P1127; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; NORRIS GE, 1989, J MOL BIOL, V209, P329, DOI 10.1016/0022-2836(89)90283-0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Parry R M Jr, 1974, Adv Exp Med Biol, V48, P141; REITER B, 1983, INT J TISSUE REACT, V5, P87; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Sambrook J, 1989, MOL CLONING LABORATO; STOWELL KM, 1991, BIOCHEM J, V276, P349, DOI 10.1042/bj2760349; TSUDA E, 1988, BIOCHEMISTRY-US, V27, P5646, DOI 10.1021/bi00415a038; VANSNICK JL, 1976, J EXP MED, V144, P1568, DOI 10.1084/jem.144.6.1568; WEINBERG ED, 1974, SCIENCE, V184, P952, DOI 10.1126/science.184.4140.952; WILLIAMS J, 1988, BIOCHEM J, V251, P849, DOI 10.1042/bj2510849; WOODWORTH RC, 1991, BIOCHEMISTRY-US, V30, P10824, DOI 10.1021/bi00109a002; ZAK O, 1985, BIOCHIM BIOPHYS ACTA, V829, P348, DOI 10.1016/0167-4838(85)90243-2	48	71	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13857	13862						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378432				2022-12-25	WOS:A1992JD32500014
J	WIEDERANDERS, B; BROMME, D; KIRSCHKE, H; VONFIGURA, K; SCHMIDT, B; PETERS, C				WIEDERANDERS, B; BROMME, D; KIRSCHKE, H; VONFIGURA, K; SCHMIDT, B; PETERS, C			PHYLOGENETIC CONSERVATION OF CYSTEINE PROTEINASES - CLONING AND EXPRESSION OF A CDNA CODING FOR HUMAN CATHEPSIN-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; BOVINE SPLEEN; CELLS; NUCLEOTIDE; FIBROBLASTS; INHIBITORS; GENE	A 1.8-kilobase full-length cDNA of human cathepsin S, a lysosomal cysteine proteinase, has been isolated. The single long open reading frame encodes a polypeptide of 331 amino acids consisting of a 15-amino acid NH2-terminal signal peptide, a propeptide of 99 amino acids, and a mature polypeptide of 217 amino acids. The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide. The NH2-terminal amino acid sequence of the mature polypeptide was confirmed by sequencing cathepsin S purified from human spleen. The cDNA detects a 1.9-kilobase transcript in poly(A)+ RNA from human fibroblasts. Expression of human cathepsin S in transfected baby hamster kidney cells resulted in up to more than 300-fold cathepsin S activity as compared to untransfected controls. In the expressing baby hamster kidney cells, human cathepsin S is transported to the lysosomes via the mannose 6-phosphate receptor pathway as shown by density gradient centrifugation, immunofluorescence, and detection of the 37-kDa cathepsin S precursor in the medium in the presence of NH4Cl. The deduced amino acid sequence of human cathepsin S exhibits a substantial degree of similarity with other human cysteine proteinases and papain indicating that they have a common ancestral gene and are members of a gene family.	MARTIN LUTHER UNIV,INST PHYSIOL CHEM,O-4020 HALLE,GERMANY; UNIV GOTTINGEN,INST BIOCHEM 2,W-3400 GOTTINGEN,GERMANY	Martin Luther University Halle Wittenberg; University of Gottingen								ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Baker E.N., 1987, BIOL MACROMOL, V3, P314; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P116; BAUDYS M, 1990, BIOL CHEM H-S, V371, P485, DOI 10.1515/bchm3.1990.371.1.485; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROMME D, 1989, BIOCHEM J, V264, P475; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PETERS CWB, 1987, EMBO J, V6, P1170; PRAEKELT UM, 1988, PLANT MOL BIOL, V10, P193, DOI 10.1007/BF00027396; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; RITONJA A, 1991, FEBS LETT, V283, P329, DOI 10.1016/0014-5793(91)80620-I; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKETA K, 1987, ELECTROPHORESIS, V8, P409, DOI 10.1002/elps.1150080908; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	37	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13708	13713						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377692				2022-12-25	WOS:A1992JB74600096
J	MING, L; NAN, Z; HO, AD				MING, L; NAN, Z; HO, AD			GENOMIC ORGANIZATION OF THE PUTATIVE HUMAN HOMEOBOX PROTOONCOGENE HOX-11 (TCL-3) AND ITS ENDOGENOUS EXPRESSION IN T-CELLS	ONCOGENE			English	Article								The HOX-11 (TCL-3) gene, which is abnormally expressed in the leukemic cells of some patients with T-cell acute lymphoblastic leukemia, is a new member of the homeobox gene family. It is structurally altered by the t(10;14) chromosomal translocation, resulting in head-to-tail juxtaposition of HOX-11 with the T-cell receptor delta-chain gene. In order to understand the normal functions of HOX-11 and its role in T-cell leukemia, we have determined the exon-intron structure of the HOX-11 gene. By using oligonucleotide primers flanking an intron of the HOX-11 gene, we have developed a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay for the expression of HOX-11. We detected HOX-11 expression in multiple cell lineages including normal T cells and two T-cell lines in which the HOX-11 gene appeared to be unaltered in structure. Our results suggest that deregulation of the endogenous expression of HOX-11 in normal T cells represents an essential step towards the formation of this type of T-cell leukemia.	UNIV OTTAWA, DEPT MED, OTTAWA K1N 6N5, ONTARIO, CANADA	University of Ottawa	MING, L (corresponding author), UNIV OTTAWA, NE ONTARIO REG CANC CTR, 41 RAMSEY LAKE RD, SUDBURY P3E 5J1, ONTARIO, CANADA.							BOEHM T, 1991, ONCOGENE, V6, P695; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GREEN AR, 1991, ONCOGENE, V6, P475; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MCGUIRE EA, 1991, BLOOD, V77, P599; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHUGHART K, 1988, BRIT J CANCER, V58, P9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; VISVADER J, 1991, ONCOGENE, V6, P187; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	22	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1325	1330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352396				2022-12-25	WOS:A1992HZ97100010
J	KOH, GY; NUSSENZVEIG, DR; OKOLICANY, J; PRICE, DA; MAACK, T				KOH, GY; NUSSENZVEIG, DR; OKOLICANY, J; PRICE, DA; MAACK, T			DYNAMICS OF ATRIAL NATRIURETIC FACTOR-GUANYLATE CYCLASE RECEPTORS AND RECEPTOR-LIGAND COMPLEXES IN CULTURED GLOMERULAR MESANGIAL AND RENOMEDULLARY INTERSTITIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CLEARANCE RECEPTOR; ADRENAL ZONA GLOMERULOSA; CYCLIC-GMP ACCUMULATION; VASCULAR SMOOTH-MUSCLE; RAT RENAL GLOMERULI; INSULIN-RECEPTORS; FUNCTIONAL EXPRESSION; CYTOPLASMIC DOMAIN; C RECEPTORS; BINDING	The dynamics of the guanylate cyclase receptor of atrial natriuretic factor (GC(A)-ANF receptor) were investigated in cultured glomerular mesangial and renomedullary interstitial cells from the rat. In these cells, the GC(A)-ANF receptor did not mediate internalization and lysosomal hydrolysis of I-125-ANF1-28 and did not undergo ligand-induced endocytosis. Glomerular mesangial cells were able, however, to mediate internalization and lysosomal hydrolysis of I-125-ANF1-28 via clearance ANF (C-ANF) receptors and to promote rapid receptor-mediated internalization and lysosomal hydrolysis of I-125-(Sar1) angiotensin II. Radioligand specifically bound to surface GC(A)-ANF receptors was rapidly dissociated at 37-degrees-C (k(off) > 0.8 min-1), with a Q10(30-37-degrees-C) > 6. The dissociation was markedly slower at subphysiological temperatures (Q10(4-30-degrees-C), 2-3) or in the presence of 0.5 mM amiloride. The results demonstrate that the GC(A)-ANF receptor, contrary to C-ANF receptors and most other polypeptide hormone receptors, is a membrane resident protein that does not mediate internalization and lysosomal hydrolysis of ligand. The termination of the interaction of ANF with GC(A)-ANF receptors results from a physiological process that leads to rapid dissociation of receptor-ligand complexes. The unique dynamics of GC(A)-ANF receptor-ligand complexes are likely to contribute importantly to stimulus-response homeostasis of ANF.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,CTR CARDIOVASC,DEPT MED,NEW YORK,NY 10021	Cornell University; Cornell University			Koh, Gou Young/C-1615-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014241] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-14241] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DELEAN A, 1986, LIFE SCI, V39, P1109, DOI 10.1016/0024-3205(86)90203-1; FONTOURA BMA, 1990, AM J PHYSIOL, V258, pC692, DOI 10.1152/ajpcell.1990.258.4.C692; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER F, 1988, J BIOL CHEM, V263, P9395; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HOLLENBERG MD, 1979, PHARMACOL REV, V30, P393; HUGHES RJ, 1988, MOL ENDOCRINOL, V2, P117, DOI 10.1210/mend-2-2-117; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LAROSE L, 1991, BIOCHEMISTRY-US, V30, P8990, DOI 10.1021/bi00101a012; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MAACK T, 1988, BIOL MOL ASPECTS ATR, P57; MAGNUSSON S, 1989, BIOCHEM J, V257, P651, DOI 10.1042/bj2570651; MARSHALL S, 1985, J BIOL CHEM, V260, P4128; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MISONO KS, 1985, BIOCHEM BIOPH RES CO, V130, P994, DOI 10.1016/0006-291X(85)91713-9; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OHLSTEIN EH, 1985, HYPERTENSION, V7, P306, DOI 10.1161/01.HYP.7.2.306; OKOLICANY J, 1991, CAN J PHYSIOL PHARM, V69, P1561, DOI 10.1139/y91-232; PANDEY KN, 1991, FASEB J, V5, pA1020; PORTER JG, 1989, J BIOL CHEM, V264, P6689; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1985, BIOCHEM BIOPH RES CO, V127, P433, DOI 10.1016/S0006-291X(85)80179-0; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONNE O, 1980, J BIOL CHEM, V255, P7449; SUZUKI M, 1987, AM J PHYSIOL, V253, pF917, DOI 10.1152/ajprenal.1987.253.5.F917; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661	45	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11987	11994						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351054				2022-12-25	WOS:A1992HY94700053
J	TAYLOR, DB; GARTNER, TK				TAYLOR, DB; GARTNER, TK			A PEPTIDE CORRESPONDING TO GPIIB-ALPHA 300-312, A PRESUMPTIVE FIBRINOGEN GAMMA-CHAIN BINDING-SITE ON THE PLATELET INTEGRIN GPIIB/IIIA, INHIBITS THE ADHESION OF PLATELETS TO AT LEAST 4 ADHESIVE LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; AMINO-ACID-SEQUENCE; VITRONECTIN RECEPTOR; RECOGNITION SITE; FIBRONECTIN RECEPTOR; SYNTHETIC PEPTIDES; CROSS-LINKING; BETA-SUBUNIT; CONFORMATION	The platelet fibrinogen (Fg) receptor (GPIIb/IIIa) is an integrin which plays a critical role in hemostasis by recognizing at least the four adhesive ligands: Fg, fibronectin (Fn), vitronectin (Vn), and von Willebrand factor (vWf). We reported that residues 309-312 of GPIIb(alpha) appear to comprise at least part of a Fg binding site on the Fg receptor (Gartner, T. K., and Taylor, D. B. (1990) Thromb. Res. 60, 291-309). Here we report that the peptide GPIIb(alpha) 300-312 (G13) inhibits platelet aggregation and binds Fg and Vn. Significantly, this peptide inhibits the adhesion of stimulated platelets to Fg, Fn, Vn, and vWf, but not the adhesion of resting platelets to Fn. Thus, GPIIb 300-312 may constitute a specific but common recognition site on GPIIb/IIIa for both LGGAKQAGDV- and RGD-containing ligands.			TAYLOR, DB (corresponding author), MEMPHIS STATE UNIV, DEPT BIOL, MEMPHIS, TN 38152 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL042523, R01HL046152] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42523, HL46152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; AMRANI DL, 1991, THROMB HAEMOSTASIS, V65, P1069; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENNETT JS, 1990, SEMIN HEMATOL, V27, P186; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1991, ANN NY ACAD SCI, V614, P214; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1990, THROMB RES, V60, P291, DOI 10.1016/0049-3848(90)90108-O; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GARTNER TK, 1991, P SOC EXP BIOL MED, V198, P649; GARTNER TK, 1987, BLOOD S, V70, pA351; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1990, J CELL BIOCH S, V14, pA139; HARKER LA, 1990, HEMATOLOGY, P1559; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIRSCHBAUM NE, 1992, IN PRESS BLOOD; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MURANOG G, 1980, PLATELET DISORDERS, P101; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P831; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAYLOR DB, 1991, J CELL BIOL, V115, pA1169; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035	57	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11729	11733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376310				2022-12-25	WOS:A1992HY94700016
J	BREDT, DS; FERRIS, CD; SNYDER, SH				BREDT, DS; FERRIS, CD; SNYDER, SH			NITRIC-OXIDE SYNTHASE REGULATORY SITES - PHOSPHORYLATION BY CYCLIC AMP-DEPENDENT PROTEIN-KINASE, PROTEIN-KINASE-C, AND CALCIUM CALMODULIN PROTEIN-KINASE - IDENTIFICATION OF FLAVIN AND CALMODULIN BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; RELAXING FACTOR; STIMULATION; RELAXATION; REDUCTASE; RECEPTOR; RELEASE; FMN; FAD	Nitric oxide (NO) is an important molecular messenger accounting for endothelial-derived relaxing activity in blood vessels, mediating cytotoxic actions of macrophages, and functioning as a neurotransmitter in the brain and periphery. NO synthase (NOS) from brain has been purified to homogeneity and molecularly cloned. We now report that NOS is stoichiometrically phosphorylated by cAMP dependent protein kinase, protein kinase C, and calcium/calmodulin-dependent protein kinase, with each kinase phosphorylating a different serine site on NOS. Activation of PKC in transfected cells reduces NOS enzyme activity by almost-equal-to 77% in intact cells and by 50% in protein homogenates from these cells. Utilizing fluorescence spectroscopy we find that purified monomer NOS contains 1 molar equivalent of both FMN and FAD. This stoichiometry is supported by enzymatic digestion of the flavins with phosphodiesterase, and titration of the FMN with a specific FMN binding protein. We demonstrate that purified NOS is labeled by a photoaffinity derivative of calmodulin. These recognition sites on NOS provide multiple means for regulation of NO levels and "cross-talk" between second messenger systems.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bredt, David/J-4872-2012		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRESLOW MJ, 1992, EUR J PHARMACOL, V210, P105, DOI 10.1016/0014-2999(92)90659-R; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1987, EUR J PHARMACOL, V137, P167, DOI 10.1016/0014-2999(87)90218-4; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RUBANYI GM, 1989, J PHARMACOL EXP THER, V249, P858; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; VERMILION JL, 1981, J BIOL CHEM, V256, P266; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	44	577	592	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10976	10981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375933				2022-12-25	WOS:A1992HX16900010
J	GEBLER, JC; AEBERSOLD, R; WITHERS, SG				GEBLER, JC; AEBERSOLD, R; WITHERS, SG			GLU-537, NOT GLU-461, IS THE NUCLEOPHILE IN THE ACTIVE-SITE OF (LAC-Z) BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; SEQUENCE; IDENTIFICATION; SUBSTITUTION; GLYCOSIDASE; MUTAGENESIS; HYDROLYSIS; ALKYLATION; RESIDUE; TYR-503	The covalent intermediate formed during catalysis by the lac Z beta-galactosidase from Escherichia coli can be trapped by reaction of the enzyme with 2',4'-dinitrophenyl 2-deoxy-2-fluoro-beta-D-galactopyranoside, thereby inactivating the enzyme. Kinetic parameters for this inactivation process with the holo- and apoenzymes have been determined. The intermediate so formed turns over only very slowly (t1/2 = 11.5 h) resulting in reactivation of the enzyme. The nucleophilic amino acid involved has been identified as Glu-537 by using a tritium-labeled inactivator to label the enzyme, then cleaving the labeled protein into peptides and purifying and sequencing the labeled peptide. This residue is conserved in five homologous beta-galactosidases and is different from that (Glu-461) proposed to be the nucleophile (Herrchen, M., and Legler, G. (1984) Eur. J. Biochem. 138, 527-531) on the basis of affinity labeling studies with conduritol C cis-epoxide. A role for glutamic acid residue 461 as the acid/base catalyst is proposed and justified.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia			Gebler, John/F-7114-2011	Gebler, John/0000-0003-0372-3725				BADER DE, 1988, BIOCHEM BIOPH RES CO, V153, P301, DOI 10.1016/S0006-291X(88)81222-1; BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BERVEN LA, 1986, CARBOHYD RES, V156, P282, DOI 10.1016/S0008-6215(00)90123-X; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BUTTERWORTH RF, 1971, SYNTH-INT J METHODS, P70; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; CUPPLES CG, 1988, GENETICS, V120, P637; DESCHAVANNE PJ, 1978, J BIOL CHEM, V253, P833; EDWARDS RA, 1990, BIOCHEM BIOPH RES CO, V171, P33, DOI 10.1016/0006-291X(90)91352-S; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; FOWLER AV, 1978, J BIOL CHEM, V253, P5283; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HAYNES LJ, 1955, ADV CARBOHYDR CHEM, V10, P213; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HUBER RE, 1979, BIOCHEMISTRY-US, V18, P4090, DOI 10.1021/bi00586a005; IMOTO T, 1972, ENZYMES, V7, P617; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KOENERS HJ, 1980, RECL TRAV CHIM PAY B, V99, P355; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LEGLER G, 1981, FEBS LETT, V135, P139, DOI 10.1016/0014-5793(81)80962-3; LEGLER G, 1990, ADV CARBOHYD CHEM, V48, P362; Lemieux R.U., 1971, PURE APPL CHEM, V25, P527; LOEFFLER RST, 1979, BIOCHEM J, V177, P145, DOI 10.1042/bj1770145; MCCLOSKEY CM, 1955, ORGANIC SYNTHESES CO, V3, P434; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3202, DOI 10.1021/bi00767a010; ONODERA KONOSHIN, 1968, CARBOHYD RES, V6, P276, DOI 10.1016/S0008-6215(00)81449-4; PAULSEN H, 1974, CHEM BER-RECL, V107, P1590, DOI 10.1002/cber.19741070519; RING M, 1985, BIOCHEM BIOPH RES CO, V131, P675, DOI 10.1016/0006-291X(85)91290-2; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; RING M, 1988, BIOCHEM BIOPH RES CO, V152, P1050, DOI 10.1016/S0006-291X(88)80390-5; ROSENBERG S, 1981, BIOCHEMISTRY-US, V20, P3189, DOI 10.1021/bi00514a031; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; SHELLING JG, 1984, CARBOHYD RES, V132, P241, DOI 10.1016/0008-6215(84)85222-2; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SINNOTT ML, 1973, BIOCHEM J, V133, P81, DOI 10.1042/bj1330081; SINNOTT ML, 1973, BIOCHEM J, V133, P89, DOI 10.1042/bj1330089; SINNOTT ML, 1978, BIOCHEM J, V175, P525, DOI 10.1042/bj1750525; SINNOTT ML, 1978, FEBS LETT, V94, P1, DOI 10.1016/0014-5793(78)80894-1; STOCKS HW, 1985, MOL BIOL EVOL, V2, P469; TRIUMBUR DE, 1992, J BIOL CHEM, V267, P10248; TULL D, 1991, J BIOL CHEM, V266, P15621; Wallenfels K., 1972, ENZYMES, V7, P617; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; YARIV J, 1971, FEBS LETT, V15, P24, DOI 10.1016/0014-5793(71)80070-4	49	169	172	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11126	11130						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350782				2022-12-25	WOS:A1992HX16900032
J	PALLANCK, L; LI, SH; SCHULMAN, LH				PALLANCK, L; LI, SH; SCHULMAN, LH			THE ANTICODON AND DISCRIMINATOR BASE ARE MAJOR DETERMINANTS OF CYSTEINE TRANSFER-RNA IDENTITY INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-SYNTHESIS; GENES; CONSTRUCTION; SPECIFICITY; INITIATION; METHIONINE; GLUTAMINE; CODON	Mutants of the Escherichia coli initiator tRNA (tRNA(fMet)) have been used to examine the role of the anticodon and discriminator base in in vivo aminoacylation of tRNAs by cysteinyl-tRNA synthetase. Substitution of the methionine anticodon CAU with the cysteine anticodon GCA was found to allow initiation of protein synthesis by the mutant tRNA from a complementary initiation codon in a reporter protein. Sequencing of the protein revealed that cysteine comprised about half of the amino acid at the N terminus. An additional mutation, converting the discriminator base of tRNA(GCA)fMet from A73 to the base present in tRNA(Cys) (U73), resulted in a 6-fold increase in the amount of protein produced and insertion of greater-than-or-equal-to 90% cysteine in response to the complementary initiation codon. Substitution of C73 or G73 at the discriminator position led to insertion of little or no cysteine, indicating the importance of U73 for recognition of the tRNA by cysteinyl-tRNA synthetase. Single base changes in the anticodon of tRNA(GCA)fMet) containing U73 from GCA to UCA, GUA, GCC, and (GCG (changes underlined) eliminated or dramatically reduced cysteine insertion by the mutant initiator tRNA indicating that all three cysteine anticodon bases are essential for specific aminoacylation of the tRNA with cysteine in vivo.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV BIOL & CANC, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [T32GMO7491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAKRABURTTY K, 1975, NUCLEIC ACIDS RES, V2, P1793, DOI 10.1093/nar/2.10.1793; CHAMBERS RW, 1973, J BIOL CHEM, V248, P5549; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; FRAVOLA L, 1964, BIOKHIMIYA, V29, P1177; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PALLANCK L, 1992, IN PRESS TRANSFER RN; SCHULMAN LH, 1973, J BIOL CHEM, V248, P1341; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SMITH D, 1989, J MOL BIOL, V206, P503, DOI 10.1016/0022-2836(89)90497-X; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	26	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7221	7223						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373131				2022-12-25	WOS:A1992HN48500008
J	HESS, P; PAYVAR, F				HESS, P; PAYVAR, F			HORMONE WITHDRAWAL TRIGGERS A PREMATURE AND SUSTAINED GENE ACTIVATION FROM DELAYED SECONDARY GLUCOCORTICOID RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CASEIN GENE; ALPHA-2U GLOBULIN SYNTHESIS; ONGOING PROTEIN-SYNTHESIS; CULTURED RAT HEPATOCYTES; DNA-BINDING; GROWTH-HORMONE; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; ALPHA-2U-GLOBULIN GENE; C-JUN	Glucocorticoid regulatory elements, denoted GREs and delayed secondary GREs (sGREs), bind the purified glucocorticoid receptors via distinctive sequence motifs and confer a primary and delayed secondary hormone inducibility, respectively, upon a linked reporter construct in stably transfected mammalian cells. The delayed secondary responses, but not the primary responses, are preceded by a time lag of several hours and blocked by protein synthesis inhibitors. In this report, we further characterized and distinguished these hormonal inductions. A 206-base pair DNA fragment from the hepatic rat alpha-2u-globulin (RUG) gene, containing at least two delayed sGREs, was specifically activated by glucocorticoids in a dose-dependent manner via a process which is sensitive to receptor antagonist RU486. Delayed sGRE-stimulated production of correctly initiated transcripts was preceded by a time lag of 2 h, a time when the GRE-mediated induction had reached maximal levels. A pulse of glucocorticoids sustained maximal activation of the delayed secondary response but not the primary response. In fact, hormone withdrawal triggered a premature induction of this delayed secondary response, suggesting that delayed sGREs are under both negative and positive control of the hormone receptor. Two separable elements of the 206-base pair fragment, including the 29-base pair sequence of a single receptor binding site, activated the reporter expression as effectively with transient, pulsatile exposure to hormone as with continuous exposure. Our results suggest that the information content of a hormonal pulse is retained, or ''memorized,'' more persistently by a receptor binding site of delayed sGREs than those of the prototypical GREs.	ST LOUIS UNIV,SCH MED,EA DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Saint Louis University					NCRR NIH HHS [RR05388] Funding Source: Medline; NIDDK NIH HHS [DK36385] Funding Source: Medline; NIGMS NIH HHS [T32GM08109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008109] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CHATTERJEE B, 1983, J BIOL CHEM, V258, P688; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CLEVER U, 1966, P NATL ACAD SCI USA, V56, P1470, DOI 10.1073/pnas.56.5.1470; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; FEIGELSON P, 1979, CELL NUCLEUS D, V8, P229; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GOODMAN HS, 1990, MOL ENDOCRINOL, V4, P1661, DOI 10.1210/mend-4-11-1661; HACHE RJG, 1987, MOL CELL BIOL, V7, P3538, DOI 10.1128/MCB.7.10.3538; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HESS P, 1990, P NATL ACAD SCI USA, V87, P2564, DOI 10.1073/pnas.87.7.2564; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KULKARNI AB, 1985, P NATL ACAD SCI USA, V82, P2579, DOI 10.1073/pnas.82.9.2579; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; LYNCH KR, 1982, CELL, V28, P185, DOI 10.1016/0092-8674(82)90388-9; MIYABE S, 1983, ENDOCRINOLOGY, V112, P2174, DOI 10.1210/endo-112-6-2174; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; MUNCK A, 1917, J STEROID BIOCHEM, V7, P1117; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NEBES VL, 1990, BIOCHEM BIOPH RES CO, V166, P133, DOI 10.1016/0006-291X(90)91921-E; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; PAYVAR F, 1983, NOBEL S, V57, P267; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; RAAKA BM, 1983, J BIOL CHEM, V258, P417; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGOLD GM, 1978, J TOXICOL ENV HEALTH, V4, P457, DOI 10.1080/15287397809529671; ROY AK, 1982, J BIOL CHEM, V257, P7834; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TAM SP, 1986, SCIENCE, V234, P1234, DOI 10.1126/science.3022381; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WIDMAN LE, 1982, J CELL PHYSIOL, V112, P316, DOI 10.1002/jcp.1041120303; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YAMAMOTO KR, 1989, AM ZOOL, V29, P537; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YAMAMOTO KR, 1983, NOBEL S, V57, P285; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMURA M, 1990, ENDOCRINOLOGY, V126, P427, DOI 10.1210/endo-126-1-427	53	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3490	3497						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371120				2022-12-25	WOS:A1992HD15400102
J	CHAN, JC; SCANLON, M; ZHANG, HZ; JIA, LB; YU, DH; HUNG, MC; FRENCH, M; EASTMAN, EM				CHAN, JC; SCANLON, M; ZHANG, HZ; JIA, LB; YU, DH; HUNG, MC; FRENCH, M; EASTMAN, EM			MOLECULAR-CLONING AND CHARACTERIZATION OF V-MOS-ACTIVATED TRANSFORMATION-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SARCOMA-VIRUS; INDUCED TRANSIN; GENE-PRODUCT; ONCOGENE; EXPRESSION; RNA; BACTERIOPHAGE; COLLAGENASE; FIBROBLASTS; MUTANTS	Using monoclonal antibodies we previously detected two forms of transformation-associated proteins, a 64-kDa protein and a 68-kDa protein, in temperature-sensitive 110-Moloney murine sarcoma virus-mutant-transformed rat kidney 6m2 cells. The identity and functions of the transformation-associated proteins were previously unknown. By molecular cloning techniques and immunoscreening, we have isolated two cDNA clones (34A and 79B3) that were found by Western blot analysis to code for a monoclonal anti-transformation-associated protein antibody-reactive polypeptide of approximately 58 kDa. Limited restriction enzyme mapping indicated 34A and 79B3 are two different cDNA clones. The nucleotide sequence of 34A cDNA was determined, and a search of GenBank revealed that it is identical to that of rat transin-2. The deduced amino acid sequence of 34A shares 71% sequence identity with rat transin and 41-76% identity with six human metalloproteinases. The limited restriction enzyme mapping and partial nucleotide sequencing data indicated that 79B3 may be the rat transin gene. When either 34A cDNA or 79B3 cDNA was used as a probe in Northern blot analysis, one mRNA band of approximately 1.9 kilobases was detected in 6m2 cells grown at the permissive temperature of 33-degrees-C, at which the cells exhibited transformation properties, and a much lower level in 6m2 cells grown at the nonpermissive temperature of 39-degrees-C, at which the cells reverted to normal phenotypes. These results suggest that at 39-degrees-C, these two genes were not transcribed at the same level as at 33-degrees-C. Zymogram and Western blot analysis of 6m2 cells further confirmed that the 64- and 68-kDa proteins have metalloproteinase activities and that the synthesis of metalloproteinases was also temperature-sensitive. Apparently, the two proteins we formerly designated transformation-associated proteins are members of the rat transin gene family. Therefore, within v-mos transformed 6m2 cells, the absence of transformation-associated protein (metalloproteinase) synthesis at the nonpermissive temperature was due to the absence of transcription of two rat transin genes.	LARK SEQUENCING TECHNOL INC,HOUSTON,TX 77024		CHAN, JC (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381				BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERGER SL, 1987, METHOD ENZYMOL, V152, P113; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHAN JC, 1986, BIOCHEM BIOPH RES CO, V134, P1223, DOI 10.1016/0006-291X(86)90381-5; CHAN JC, 1990, INT J CANCER, V46, P864, DOI 10.1002/ijc.2910460519; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMARS M, 1990, J VIROL, V64, P1421, DOI 10.1128/JVI.64.4.1421-1428.1990; LI W, 1987, VIROLOGY, V16, P691; LI WJ, 1987, INTERVIROLOGY, V28, P50, DOI 10.1159/000149996; LI WJ, 1989, CANCER RES, V49, P1746; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; NASH M, 1984, J VIROL, V50, P478, DOI 10.1128/JVI.50.2.478-488.1984; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPINUCCI C, 1988, JNCI-J NATL CANCER I, V80, P1416, DOI 10.1093/jnci/80.17.1416; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZHANG HZ, 1989, CANCER RES, V49, P5766; 1989, TITERING AMPLIFYING	22	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1099	1103						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370458				2022-12-25	WOS:A1992GY96000068
J	GREENBERG, SG; DAVIES, P; SCHEIN, JD; BINDER, LI				GREENBERG, SG; DAVIES, P; SCHEIN, JD; BINDER, LI			HYDROFLUORIC ACID-TREATED TAU-PHF PROTEINS DISPLAY THE SAME BIOCHEMICAL-PROPERTIES AS NORMAL TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SHARE ANTIGENIC DETERMINANTS; ALZHEIMERS-DISEASE; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; PROMOTING FACTORS; BRAIN; COMPONENT; ELECTROPHORESIS	Tau (tau) is a major constituent of paired helical filaments (PHF) found in Alzheimer's disease. The current study examines the possibility that the distinct properties of PHF-associated tau-proteins (tau(PHF)) result from post-translational modifications of normal soluble-tau (tau(s)). Following hydrofluoric acid (HF) treatment, tau(PHF) proteins are heat- and acid-stable, soluble in 2-(N-morpholino)ethanesulfonic acid buffers and display the same molecular weight, pI, and immunochemical properties as normal tau(s). Alkaline phosphatase treatment of dissociated PHF results in similar, although less extensive, electrophoretic changes and a reduction in PHF-1 immunoreactivity. Therefore, phosphorylation of normal tau(s). appears to be responsible for the distinct properties of tau(PHF). Although our results suggest that all of the normal tau-isoforms are in PHF, the relative abundance of individual tau-species differs in HF-treated PHF and tau(s) samples. Moreover, the loss of PHF following HF treatment suggests that post-translational modifications contribute to the structural stability of PHF.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; UNIV ALABAMA,SCH MED & DENT,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham	GREENBERG, SG (corresponding author), WM BURKE MED RES INST,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.				NIA NIH HHS [AG09031] Funding Source: Medline; PHS HHS [38623] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; BANCHER C, 1990, NEUROBIOL AGING, V11, P281; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DAVIES P, 1990, NEUROBIOL AGING, V10, P408; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GHANBARI H A, 1989, Society for Neuroscience Abstracts, V15, P1042; GHANBARIH, 1990, SOC NEUR ABSTR, V16, P282; GOEDERT M, 1991, NEUROSCI LETT, V126, P149, DOI 10.1016/0304-3940(91)90541-Z; GOEDERT M, 1990, EMBO J, V13, P4245; GREENBERG S G, 1989, Society for Neuroscience Abstracts, V15, P1038; GREENBERG SG, 1990, NEUROBIOL AGING, V11, P285; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HELANDER IM, 1989, FEBS LETT, V250, P565, DOI 10.1016/0014-5793(89)80797-5; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; KOSIK KS, 1984, P NATL ACAD SCI-BIOL, V81, P7941, DOI 10.1073/pnas.81.24.7941; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7948; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; Kwan S.P., 1980, GENETIC ENG, V2, P31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1991, SCIENCE, V251, P673; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PERRY G, 1987, BRAIN RES, V420, P233, DOI 10.1016/0006-8993(87)91243-1; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDEDA K, 1990, J NEUROSCI, V10, P3295; VINCENT IJ, 1990, BRAIN RES, V531, P127, DOI 10.1016/0006-8993(90)90765-4; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; WOLOZIN BL, 1988, P NATL ACAD SCI USA, V16, P6202; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	46	495	510	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					564	569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370450				2022-12-25	WOS:A1992GY43900088
J	ERICKSON, RH; SUZUKI, Y; SEDLMAYER, A; KIM, YS				ERICKSON, RH; SUZUKI, Y; SEDLMAYER, A; KIM, YS			BIOSYNTHESIS AND DEGRADATION OF ALTERED IMMATURE FORMS OF INTESTINAL DIPEPTIDYL PEPTIDASE-IV IN A RAT STRAIN LACKING THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; AMINOPEPTIDASE-IV; EPITHELIAL-CELLS; ALKALINE-PHOSPHATASE; DIETARY-PROTEIN; SODIUM-BUTYRATE; SUGAR CHAINS; TRANSPORT; EXPRESSION; PLASMA	We have used a strain of rat (Fischer 344) lacking brush border membrane dipeptidyl peptidase IV activity to examine its effect on the intestinal assimilation of prolyl peptides. In addition, we have examined the biochemical basis for the enzyme deficiency. An analysis of several brush border membrane hydrolases in different regions of the small intestine demonstrates that these rats lack only dipeptidyl peptidase IV. They also have a greatly reduced ability to hydrolyze and absorb in vivo peptides of the NH2-X-Pro-Y type which are known substrates for the enzyme. Immunoblot analysis with polyclonal and monoclonal antibody indicates that the animals lack an identifiable dipeptidyl peptidase IV protein in intestinal epithelial cells. Levels and types of dipeptidyl peptidase IV mRNA were analyzed in several tissues and found to be similar to that of control animals. Biosynthetic labeling of intestinal explants revealed that two distinct forms (102 and 108 kDa) of dipeptidyl peptidase IV are initially synthesized by deficient rats, in contrast to the single protein (106 kDa) observed in normal animals. Pulse-chase labeling experiments (+/- endoglycosidase H) show that these two altered forms of dipeptidyl peptidase IV, although initially glycosylated with N-linked high mannose carbohydrate, fail to be processed to the mature complex glycosylated form and undergo intracellular degradation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	ERICKSON, RH (corresponding author), VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIDDK NIH HHS [DK17938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017938, R01DK017938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpers D. H., 1987, PHYSL GASTROINTESTIN, P1469; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BELLA AM, 1982, ARCH BIOCHEM BIOPHYS, V218, P156, DOI 10.1016/0003-9861(82)90330-7; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG YC, 1979, CLIN SCI, V57, P1; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DANIELSEN EM, 1984, FEBS LETT, V166, P28, DOI 10.1016/0014-5793(84)80038-1; DANIELSEN EM, 1989, J BIOL CHEM, V264, P13726; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; ERICKSON RH, 1990, ANNU REV MED, V41, P133; ERICKSON RH, 1985, BIOCHIM BIOPHYS ACTA, V756, P258; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GUAN D, 1988, AM J PHYSIOL, V255, pG212, DOI 10.1152/ajpgi.1988.255.2.G212; GUM JR, 1987, J BIOL CHEM, V262, P1092; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HARADA M, 1989, J CHROMATOGR-BIOMED, V493, P176, DOI 10.1016/S0378-4347(00)82721-8; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOPSUHAV.VK, 1969, HISTOCHEMISTRY, V17, P30, DOI 10.1007/BF00306327; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW SH, 1991, J BIOL CHEM, V266, P13391; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MORITA A, 1982, CANCER RES, V42, P4540; MORITA A, 1983, J CLIN INVEST, V72, P610, DOI 10.1172/JCI111009; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NATORI Y, 1989, AM J PATHOL, V134, P405; OGATA S, 1989, J BIOL CHEM, V264, P3596; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SILK DBA, 1974, CLIN SCI MOL MED, V46, P393, DOI 10.1042/cs0460393; SONG IS, 1986, GASTROENTEROLOGY, V91, P1234, DOI 10.1016/S0016-5085(86)80022-1; TAKASAKI S, 1991, BIOCHEMISTRY-US, V30, P9102, DOI 10.1021/bi00101a028; THOMPSON NL, 1991, BIOCHEM J, V273, P497, DOI 10.1042/bj2730497; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P1476; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426; YAMASHITA K, 1988, BIOCHEMISTRY-US, V27, P5565, DOI 10.1021/bi00415a026; YOSHIOKA M, 1987, AM J PHYSIOL, V253, pG781, DOI 10.1152/ajpgi.1987.253.6.G781	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21623	21629						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356989				2022-12-25	WOS:A1992JV01100058
J	SHASKUS, J; GRECO, D; ASNANI, LP; LEWIS, EJ				SHASKUS, J; GRECO, D; ASNANI, LP; LEWIS, EJ			A BIFUNCTIONAL GENETIC REGULATORY ELEMENT OF THE RAT DOPAMINE BETA-HYDROXYLASE GENE INFLUENCES CELL TYPE SPECIFICITY AND 2ND MESSENGER-MEDIATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXTINGUISHER; INTESTINAL-PEPTIDE GENE; NEURO-BLASTOMA CELLS; DNA-BINDING PROTEINS; TRANS-ACTING FACTOR; MAMMALIAN-CELLS; CYCLIC-AMP; TYROSINE-HYDROXYLASE; INDUCIBLE GENES; TSE1 ENCODES	Dopamine beta-hydroxylase, the enzyme which converts dopamine to norepinephrine, is expressed in a cell type-restricted pattern in neuroendocrine tissue. A segment of the rat gene containing 395 bases of 5'-flanking sequence regulates expression of a reporter gene in a cell type-selective pattern in mammalian cell cultures. Using deletion mutants of the 5'-flanking sequence, we have identified a 30-base genetic regulatory element, designated DB1, which enhances transcription from a heterologous promoter 5-20-fold in neuroendocrine cell lines. DB1-specific DNA-protein complexes are found in nuclear extracts from all cell lines examined, but the migration pattern differs between cell lines. The 5'-flanking region of the dopamine beta-hydroxylase gene is also responsive to cyclic AMP and phorbol ester treatment of SHSY-5Y neuroblastoma cells. The simultaneous presence of both effectors results in synergistic increases in DBH1 mRNA and reporter gene activity. The second messenger regulatory element was localized to the region containing the DB1 element, and reporter plasmids containing multiple copies of the DB1 element are responsive to treatment with inducers. The results of this study identify a cis-acting regulatory element which influences both cell type selectivity and second messenger responsiveness of the rat dopamine beta-hydroxylase gene.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, L224, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MOLEC & MED GENET, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN B, 1988, J BIOL CHEM, V263, P15578; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCARONE V, 1989, CANCER RES, V49, P219; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FINK JS, 1991, J BIOL CHEM, V266, P3882; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KVETNANSKY R, 1971, MOL PHARMACOL, V7, P81; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LEDOUARIN NM, 1990, ANN NY ACAD SCI, V599, P131; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POWERS AC, 1989, J BIOL CHEM, V264, P10048; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LABORATO; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	48	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18821	18830						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382062				2022-12-25	WOS:A1992JN50200087
J	JELINEK, MA; HASSELL, JA				JELINEK, MA; HASSELL, JA			REVERSION OF MIDDLE T ANTIGEN-TRANSFORMED RAT-2 CELLS BY KREV-1 - IMPLICATIONS FOR THE ROLE OF P21C-RAS IN POLYOMAVIRUS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PUTATIVE EFFECTOR DOMAIN; GENE-PRODUCT; CELLULAR PROTEINS; TUMOR-ANTIGEN; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	Polyomavirus middle T antigen mediates transformation of cells, at least in part, by its association with and activation of the intrinsic protein tyrosine kinase activity of pp60c-src. pp60c-src, by analogy with pp60v-src, elicits cell proliferation through a signal transduction pathway that includes p21c-ras. Therefore, we tested the possibility that middle T antigen acts upstream of and in the same proliferative signaling pathway as p21c-ras. Co-transfection of Rat-2 cells with plasmids expressing human Krev-1, a dominant suppressor of Ki-ras transformation, and mT antigen resulted in a dose-dependent reduction of mT antigen-induced foci. Krev-1 did not affect the transforming activity of SV40 large T antigen, demonstrating that the transformation-suppressing activity of Krev-1 is specific. To determine the effect of Krev-1 on stably transformed cell lines, Krev-1 DNA was introduced into middle T antigen-transformed Rat-2 cells along with a G418 resistance marker. Of the G418-resistant colonies examined, 1% were morphologically untransformed. Characterization of several morphological revertants revealed that, with the exception of one cell line, all of the cell lines expressed middle T antigen, which was associated with pp60c-src, whose tyrosine kinase activity was similar to that found in the parental transformed cell lines. To determine whether other phenotypic traits associated with transformation were altered in these cell lines, their growth rates and ability to form colonies in agar suspension were examined. The majority of the revertants had longer doubling times, and grew less efficiently in agar suspension compared with their transformed parents. A direct correlation was observed between Krev-1 RNA and protein expression and the efficiency with which the revertants formed colonies in suspension. These results suggest that p21c-ras lies downstream of middle T antigen and pp60c-src in the same proliferative signal transduction pathway.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPRENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAVIDSON D, 1987, J VIROL, V61, P1226, DOI 10.1128/JVI.61.4.1226-1239.1987; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEATHERSTONE MS, 1984, NUCLEIC ACIDS RES, V12, P7235, DOI 10.1093/nar/12.18.7235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARUYAMA K, 1981, J VIROL, V37, P1028, DOI 10.1128/JVI.37.3.1028-1043.1981; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NILSSON SV, 1983, J VIROL, V46, P284, DOI 10.1128/JVI.46.1.284-287.1983; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEINBERG B, 1978, CELL, V13, P19, DOI 10.1016/0092-8674(78)90134-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4616; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	86	37	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1687	1698						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380149				2022-12-25	WOS:A1992JJ37600003
J	LAROCHELLE, WJ; PIERCE, JH; MAYSIROFF, M; GIESE, N; AARONSON, SA				LAROCHELLE, WJ; PIERCE, JH; MAYSIROFF, M; GIESE, N; AARONSON, SA			5 PDGF-B AMINO-ACID SUBSTITUTIONS CONVERT PDGF-A TO A PDGF B-LIKE TRANSFORMING MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-HORMONE RECEPTOR; V-SIS; GENE; BINDING; CHAIN; MUTAGENESIS; IDENTIFICATION; DIMERIZATION; LOCALIZATION	We used site-directed mutagenesis to determine the minimum number of PDGF B residues needed to convert PDGF A to a potently transforming PDGF B-like molecule. Substitution of two PDGF B subdomains, 106-115 and 135-144, were found to be critical. These substitutions were sufficient to broaden the ability of PDGF A to activate beta as well as alpha-platelet-derived growth factor (PDGF) receptors and increase its transforming efficiency to that of PDGF B. Within subdomain I, either PDGF B residues Arg- 109 and Asn-115 or Arg-109, Leu-110, and Arg-113, in combination with subdomain II PDGF B residues Asn-136, Arg-137, and Arg-142 were identified as being essential. Those mutants with transforming ability comparable with PDGF B showed significantly lower efficiencies of beta-receptor triggering. Thus, our studies identify a small number of PDGF B amino acids indispensable for beta-PDGF receptor interaction and suggest that a low level of beta-PDGF receptor activation is sufficient to dramatically increase PDGF transforming efficiency in NIH 3T3 cells.			LAROCHELLE, WJ (corresponding author), NIH,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	28	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17074	17077						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380958				2022-12-25	WOS:A1992JL05300054
J	JONES, D; SAWICKI, G; WOZNIAK, M				JONES, D; SAWICKI, G; WOZNIAK, M			SEQUENCE, STRUCTURE, AND EXPRESSION OF A WASP VENOM PROTEIN WITH A NEGATIVELY CHARGED SIGNAL PEPTIDE AND A NOVEL REPEATING INTERNAL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; ENDOPARASITIC WASP; SECONDARY STRUCTURE; CHELONUS-SP; BEE VENOM; PREDICTION; CDNA; DNA; CURVIMACULATUS	An expression cDNA library prepared from mRNA from the venom gland of a parasitic wasp, Chelonus sp. near curvimaculatus, was screened with polyclonal antibodies against a 33-kDa venom protein from this wasp. Immunoreactive clones were sequenced, yielding a complete inferred sequence for a protein with an NH2 terminus identical with that of the 33-kDa protein. The structure of the cDNA showed an apparent encoded signal peptide, which was unusual in possessing 2 glutamic acid residues juxtapositioned next to, or replacing, the conventional basic residues. The bulk of the mature protein sequence which follows the NH2-terminal, 5000-kDa hydrophobic domain is composed of a dozen tandem repeats of a highly charged, approximately 14-residue sequence, except for the truncated eighth repeat which terminates in the only proline in this large domain. The primary structure is not closely related to any sequence in the GenBank data bank. Secondary structure analysis identified a turn occurring at or near each of 12 invariantly conserved serine residues. Further, the codon used for this serine was invariant, whereas other serines in the protein (including a nearly invariant serine 2 residues away) used various codons. Results of epitope mapping experiments supported a proposed tertiary structure in which the NH2-terminal 5-kDa forms a hydrophobic core, overlain with the charged repeats. Northern analysis of poly(A) RNA from the venom gland of young adult female wasps showed expression of a single 1-kilobase transcript, for which there is no corresponding message in normal or parasitized host larvae. The remarkable structure of this protein and structural data on other wasp venom proteins suggest an evolutionary pattern in which some proteins critical for venom function evolve by internal tandem duplication, and which are secreted after biosynthesis by a different mechanism from that used for proteins with classical signal peptides containing basic residues.	UNIV KENTUCKY,SCH BIOL SCI,LEXINGTON,KY 40506	University of Kentucky	JONES, D (corresponding author), UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40506, USA.		Wozniak, Mieczyslaw/S-8215-2018	Wozniak, Mieczyslaw/0000-0002-1655-971X	NIGMS NIH HHS [GM33997] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1989, PROTEIN STRUCTURE PR; Banks B.E.C., 1986, VENOMS HYMENOPTERA, P330; BENESKI DA, 1980, P NATL ACAD SCI-BIOL, V77, P639, DOI 10.1073/pnas.77.1.639; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P110; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P29; CHELLIAH J, 1990, J GEN VIROL, V71, P2353, DOI 10.1099/0022-1317-71-10-2353; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DELIMA ME, 1988, BIOCHEM BIOPH RES CO, V151, P187, DOI 10.1016/0006-291X(88)90577-3; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P39717; DUCANCEL F, 1988, NUCLEIC ACIDS RES, V16, P9048, DOI 10.1093/nar/16.18.9048; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GATINEAU E, 1988, EUR J BIOCHEM, V171, P535, DOI 10.1111/j.1432-1033.1988.tb13822.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HARVEY AL, 1984, J PHYSIOL-PARIS, V79, P222; HELLMANN GM, 1983, VIROLOGY, V124, P434, DOI 10.1016/0042-6822(83)90359-8; HONES J, 1987, FEBS LETT, V212, P193, DOI 10.1016/0014-5793(87)81343-1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JENG TW, 1978, P NATL ACAD SCI USA, V75, P600, DOI 10.1073/pnas.75.2.600; JONES D, 1986, J INVERTEBR PATHOL, V47, P105, DOI 10.1016/0022-2011(86)90168-0; JONES D, 1986, EXP PARASITOL, V61, P10, DOI 10.1016/0014-4894(86)90129-3; JONES D, 1990, ARCH INSECT BIOCHEM, V13, P95, DOI 10.1002/arch.940130109; JONES D, 1990, ADVANCES IN INVERTEBRATE REPRODUCTION 5, P157; JONES D, 1992, PARASITES PATHOGENS; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIL G, 1980, EUR J BIOCHEM, V111, P49, DOI 10.1111/j.1432-1033.1980.tb06073.x; KREIL G, 1990, TRENDS BIOCHEM SCI, V15, P23, DOI 10.1016/0968-0004(90)90126-V; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAEMMLI UK, 1973, J MOL BIOL, V80; LELUK J, 1989, TOXICON, V27, P105, DOI 10.1016/0041-0101(89)90410-8; LEMEUR M, 1981, CELL, V23, P56116; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LU YA, 1991, MOL IMMUNOL, V28, P1047; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nakajima T., 1986, P309; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; Piek T., 1986, VENOMS HYMENOPTERA; POSCH M, 1983, J BIOL CHEM, V258, P1761; ROMEY G, 1984, J PHYSL PARIS, V79, P254; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; STOLTZ DB, 1988, J GEN VIROL, V69, P903, DOI 10.1099/0022-1317-69-4-903; TAYLOR T, 1990, BIOCHIM BIOPHYS ACTA, V1035, P37, DOI 10.1016/0304-4165(90)90170-2; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VLASAK R, 1984, EUR J BIOCHEM, V145, P279, DOI 10.1111/j.1432-1033.1984.tb08549.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTHER C, 1976, J INSECT PHYSIOL, V22, P1187, DOI 10.1016/0022-1910(76)90092-5; WEBB BA, 1990, P NATL ACAD SCI USA, V87, P4961, DOI 10.1073/pnas.87.13.4961	53	24	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14871	14878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378841				2022-12-25	WOS:A1992JF08800057
J	POTTER, LR; GARBERS, DL				POTTER, LR; GARBERS, DL			DEPHOSPHORYLATION OF THE GUANYLYL CYCLASE-A RECEPTOR CAUSES DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ATRIAL-NATRIURETIC-FACTOR; PROTEIN-KINASE-C; RAT LUNG MEMBRANES; PEPTIDE RECEPTOR; CYCLIC-GMP; CGMP ACCUMULATION; ACTIVATION; PHOSPHORYLATION; MUSCLE; PURIFICATION	Atrial natriuretic peptide (ANP) binds to the guanylyl cyclase-A (GC-A) receptor found in tissues such as the kidney and adrenal gland, resulting in marked elevations of the intracellular signaling molecule, cGMP. Here, GC-A is shown to exist as a phosphoprotein when expressed in human embryonic 293 cells. The P-32 is principally associated with phosphoserine, with only trace amounts of phosphothreonine. The addition of ANP causes a time-dependent dephosphorylation of the receptor, as well as desensitization, which is not due to an ANP-mediated decrease in the amount of receptor protein. The mobility of GC-A on sodium dodecyl sulfate-polyacrylamide gel electrophoresis increases after treatment of cells with ANP, and protein phosphatase 2A induces the same mobility shift. The protein phosphatase also catalyzes dephosphorylation of GC-A, and this is directly correlated with decreases in ANP-stimulatable guanylyl cyclase activity. Okadaic acid, an inhibitor of protein phosphatase 2A, blocks both the dephosphorylation and the desensitization. Therefore, in contrast to many other cell surface receptors, GC-A is desensitized by ligand-induced dephosphorylation.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute	POTTER, LR (corresponding author), VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALLERMANN BJ, 1988, BIOCHEM BIOPH RES CO, V157, P755, DOI 10.1016/S0006-291X(88)80314-0; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG CH, 1990, EUR J PHARM-MOLEC PH, V189, P111, DOI 10.1016/0922-4106(90)90237-R; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; RAMARAO CS, 1988, J BIOL CHEM, V263, P1524; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SEKIYA M, 1991, LIFE SCI, V48, P1067, DOI 10.1016/0024-3205(91)90508-9; SHARMA RK, 1989, PROGR ATRIAL PEPTIDE, V3, P43; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; WARD GE, 1983, P NATL ACAD SCI-BIOL, V80, P5578, DOI 10.1073/pnas.80.18.5578; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	36	200	206	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14531	14534						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353076				2022-12-25	WOS:A1992JF08800005
J	JOHNSON, GD; HERSH, LB				JOHNSON, GD; HERSH, LB			CLONING A RAT MEPRIN CDNA REVEALS THE ENZYME IS A HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MICROVILLAR MEMBRANE; AMINO-ACID SEQUENCE; MOUSE KIDNEY; GEL-ELECTROPHORESIS; PROTEINS; PROTEASE; ENDOPEPTIDASE-2; NITROCELLULOSE; PURIFICATION; INSITU	The structure of the kidney microvillar membrane metallopeptidase meprin (EC 3.4.24.18) from rats has been examined. Previously reported to be a homotetramer, we demonstrate that the enzyme is composed of two similar but distinct subunits through tryptic peptide mapping and the sequencing of peptides of the papain solubilized form of the enzyme. Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis reveals that the native rat meprin tetramer is dissociated by detergent into disulfide-linked heterodimers. A full-length cDNA clone encoding one of the meprin subunits has been isolated and sequenced. The cDNA contains an open reading frame of 668 amino acids, coding for a polypeptide of molecular weight 75,054. The enzyme contains the zinc binding sequence HEFLH and a potential membrane-spanning region near its amino terminus. Comparison of this clone with peptide sequences from mouse meprins A and B shows that the clone is a B type or beta-subunit. Northern blot analysis is consistent with the existence of two distinct subunits and further indicates that rat meprin subunits may be differentially expressed in various rat tissues.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDA NIH HHS [DA02243] Funding Source: Medline; NIGMS NIH HHS [GM08297] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BOND JS, 1983, BIOCHEM J, V209, P251, DOI 10.1042/bj2090251; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLZ RL, 1990, ANAL BIOCHEM, V191, P314; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZWILLING R, 1981, FEBS LETT, V127, P75, DOI 10.1016/0014-5793(81)80344-4	28	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13505	13512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377685				2022-12-25	WOS:A1992JB74600065
J	SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP				SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP			ERBB-2 AUTOPHOSPHORYLATION IS REQUIRED FOR MITOGENIC ACTION AND HIGH-AFFINITY SUBSTRATE COUPLING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; EGF RECEPTOR; ONCOGENE PRODUCT; NEU ONCOGENE; 3T3 CELLS; GENE	Autophosphorylation of gp185(erbB-2) in vivo is confined to its carboxy terminus and is required for optimal erbB-2 transforming activity under conditions of receptor overexpression. It remains unresolved, however, to what extent autophosphorylation regulates erhB-2 mitogenic signaling in normal cells, nor is the biochemical basis for such a regulatory function known. To address these issues, we utilized a chimeric molecule encompassing the extracellular domain of the epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and intracellular domains of the erbB-2 product. In this EGFR/erbB-2 chimera, erbB-2 kinase activity is regulated by EGF binding. An EGFR/erbB-2 mutant bearing multiple Tyr --> Phe substitutions at erbB-2 autophosphorylation sites (EGFR/erbB-2 5P) displayed markedly reduced phosphotyrosine content following EGF stimulation in comparison with the non-mutated chimera. When expressed in NR6 cells, the EGFR/erhB-2 5P mutant was unable to deliver a sizeable mitogenic signal when activated by EGF at physiological levels. In intact cells, the 5P mutant was still able to stimulate phosphorylation of the gamma-isozyme of phospholipase C (PLC-gamma), a prototype erhB-2 substrate, although with a delayed time course, indicating that the 5P mutation decreased the affinity of the erbB-2 kinase for this substrate. This conclusion was further supported by the inability of the 5P mutant to associate with PLC-gamma in co-immunoprecipitation experiments. We infer that a major role of autophosphorylation is to increase the affinity of the erbB-2 kinase for its cellular substrates, so that, under physiological conditions, autophosphorylation is absolutely required for erbB-2 mitogenic signaling.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1D23,BETHESDA,MD 20892; REGINA ELENA INST CANC RES,I-00158 ROME,ITALY; UNIV COPENHAGEN,INST MICROBIOL,DK-1168 COPENHAGEN,DENMARK; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Di Fiore, Pier Paolo/K-2130-2012; Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Di Fiore, Pier Paolo/0000-0002-2252-0950; Helin, Kristian/0000-0003-1975-6097; Segatto, Oreste/0000-0003-2561-1142				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HALEY JD, 1989, ONCOGENE, V4, P273; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HELIN K, 1991, ONCOGENE, V6, P825; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1989, MOL CELL BIOL, V9, P1771; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3719	41	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1339	1346						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352397				2022-12-25	WOS:A1992HZ97100012
J	EHRLICH, HJ; GEBBINK, RK; KEIJER, J; PANNEKOEK, H				EHRLICH, HJ; GEBBINK, RK; KEIJER, J; PANNEKOEK, H			ELUCIDATION OF STRUCTURAL REQUIREMENTS ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 FOR BINDING TO HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; CELL-GROWTH FACTOR; ANTI-THROMBIN-III; ANTITHROMBIN-III; HUMAN-PLASMA; PURIFICATION; COFACTOR; SITE; ARGININE-47; MECHANISM	Plasminogen activator inhibitor 1 (PAI-1), a member of the serpin superfamily of proteins, has been demonstrated previously to interact functionally with the glycosaminoglycan heparin (Ehrlich, H. J., Keijer, J., Preissner, K. T., Klein Gebbink, R., and Pannekoek, H. (1991) Biochemistry 30, 1021-1028). Heparin specifically enhances the rate of association between PAI-1 and thrombin about 2 orders of magnitude, whereas no effect is detected with other serine proteases (e.g. factor Xa). For the heparin-dependent serpins antithrombin III and heparin cofactor II, basic amino acid residues in and around the helix D subdomain were proposed to be involved in the binding of glycosaminoglycans. Here we employed site-directed mutagenesis of full-length PAI-1 cDNA to identify the amino acid residues that mediate heparin binding. To that end, 15 single-point mutants of PAI-1, each having individual arginyl, lysyl, or histidyl residues replaced by a neutral (alanyl) residue ("ala-scan"), and one double mutant were constructed, expressed in Escherichia coli, and purified to apparent homogeneity. The purified biologically active proteins were subjected to the following analyses: (i) heparin-dependent inhibition of thrombin; (ii) heparin-dependent formation of sodium dodecyl sulfate-stable complexes with thrombin; and (iii) binding to and elution from heparin-Sepharose. Based on the data presented, we propose that the amino acid residues Lys65, Lys69, Arg76, Lys80 and Lys88 constitute major determinants for heparin binding of PAI-1. These residues are located in and around the helix D domain and are conserved in the other heparin-dependent thrombin inhibitors, antithrombin III and heparin cofactor II.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB,DEPT MOLEC BIOL, PLESMANLAAN 125, 1066 CX AMSTERDAM, NETHERLANDS				Keijer, Jaap/J-8089-2013	Keijer, Jaap/0000-0002-9720-7491				ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKHOUS KM, 1939, AM J PHYSIOL, V125, P863; CHANG JY, 1989, J BIOL CHEM, V264, P3111; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KEIJER J, 1991, BLOOD, V78, P1254; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERS JWJ, 1988, FIBRINOLYSIS S1, V2; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; Maniatis T., 1982, MOL CLONING; MIMURO J, 1989, J BIOL CHEM, V264, P936; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OWEN MC, 1987, BLOOD, V69, P1275; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PAQUES EP, 1986, THROMB RES, V42, P797, DOI 10.1016/0049-3848(86)90116-7; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STATHAKIS NE, 1977, J CLIN INVEST, V60, P855, DOI 10.1172/JCI108840; STEIN PL, 1989, J BIOL CHEM, V264, P15441; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	44	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11606	11611						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375944				2022-12-25	WOS:A1992HX16900102
J	LANCASTER, JR; LANGREHR, JM; BERGONIA, HA; MURASE, N; SIMMONS, RL; HOFFMAN, RA				LANCASTER, JR; LANGREHR, JM; BERGONIA, HA; MURASE, N; SIMMONS, RL; HOFFMAN, RA			EPR DETECTION OF HEME AND NONHEME IRON-CONTAINING PROTEIN NITROSYLATION BY NITRIC-OXIDE DURING REJECTION OF RAT-HEART ALLOGRAFT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; L-ARGININE; ACTIVATED MACROPHAGES; HEMOGLOBIN; CELLS; COMPLEXES; VASODILATORS; GENERATION; INHIBITION; PATHWAY	The paramagnetic molecule nitric oxide (NO), produced from L-arginine by a specific enzyme (NO synthase), has been shown to be involved in a surprising variety of mammalian cellular responses, including the regulation of T cell immunity to alloantigens in vitro. In cytotoxic activated macrophages, NO production results in a characteristic pattern of alteration of iron-containing enzyme function that is mimicked by exposure to NO. Electron paramagnetic resonance (EPR) studies have shown the formation of iron-nitrosyl species during macrophage activation and also during sepsis, indicating that alteration of iron-containing protein function may be the result of the well-documented tendency of NO to bind to metal ions. We have recently shown that the NO synthesis induced during alloantigenic activation of rat splenocytes inhibits lymphocyte proliferation and cytotoxic T-lymphocyte generation. This report demonstrates that iron-nitrosyl EPR signals similar to those observed in macrophages and during sepsis are present in the blood and in the grafted t issue of rats during the rejection of allogeneic (but not syngeneic) heart grafts. These signals are found in the blood and at the site of allograft rejection, but are not found in other tissues (such as spleen and lung), and are obliterated by administration of the immunosuppressant FK506. These results directly demonstrate the formation of iron-nitrosyl complexes during vascularized allograft rejection and suggest that consequent destruction of iron-containing protein function plaYs an important role in the rejection response.	UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15261 USA; UTAH STATE UNIV, DEPT CHEM & BIOCHEM, LOGAN, UT 84322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; Utah State University					NIAID NIH HHS [AI-16869] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI016869, R37AI016869, R01AI016869] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBINA JE, 1989, J IMMUNOL, V143, P3641; ALIEV DI, 1986, STUD BIOPHYS, V115, P173; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BASOSI R, 1975, J CHEM SOC PERK T 2, P423, DOI 10.1039/p29750000423; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; DERVARTA.DV, 1973, BIOCHIM BIOPHYS ACTA, V292, P496, DOI 10.1016/0005-2728(73)90055-8; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; GOTO T, 1991, TRANSPL P, V23, P2713; HANCOCK WW, 1987, J IMMUNOL, V138, P164; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; JEZOWSKATREZEBI.X, 1973, J MOL STRUCT, V19, P635; KON H, 1968, J BIOL CHEM, V243, P4350; KRUSZYNA H, 1987, TOXICOL APPL PHARM, V91, P429, DOI 10.1016/0041-008X(87)90064-0; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANGREHR JM, 1992, TRANSPLANTATION, V53, P632, DOI 10.1097/00007890-199203000-00027; LANGREHR JM, 1991, SURGERY, V110, P335; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOURO SRW, 1981, BIOCHIM BIOPHYS ACTA, V670, P56, DOI 10.1016/0005-2795(81)90048-9; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MICHALSKI WP, 1987, ARCH MICROBIOL, V147, P304, DOI 10.1007/BF00463493; MILLS CD, 1991, J IMMUNOL, V146, P2719; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORSE RH, 1980, J BIOL CHEM, V255, P7876; MURASE N, 1987, TRANSPLANT P, V19, P71; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; SALERNO JC, 1976, BIOCHEM BIOPH RES CO, V73, P833, DOI 10.1016/0006-291X(76)90884-6; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, IN PRESS ADV ENZYMOL; VANIN A. F., 1967, BIOKHIMIYA, V32, P277; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; YUI Y, 1991, J BIOL CHEM, V266, P12544	47	194	196	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10994	10998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375934				2022-12-25	WOS:A1992HX16900013
J	RICE, KM; LIENHARD, GE; GARNER, CW				RICE, KM; LIENHARD, GE; GARNER, CW			REGULATION OF THE EXPRESSION OF PP160, A PUTATIVE INSULIN-RECEPTOR SIGNAL PROTEIN, BY INSULIN, DEXAMETHASONE, AND 1-METHYL-3-ISOBUTYLXANTHINE IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PRIMARY CULTURED ADIPOCYTES; TYROSINE KINASE-ACTIVITY; RAT ADIPOCYTES; ADIPOSE DIFFERENTIATION; GLUCOSE TRANSPORTER; HEXOSE-TRANSPORT; PHOSPHORYLATION; RESPONSIVENESS; CELLS	pp160, a cytosolic protein with M(r) of approximately 160,000, is phosphorylated on tyrosine in response to insulin and is considered to be involved in signaling from the insulin receptor. The expression of pp160 during the differentiation of 3T3-L1 fibroblasts to adipocytes and in adipocytes has been investigated using quantitative immunoblotting with antibodies against a peptide from pp160. Between day 6 and day 8 of differentiation induced by insulin, dexamethasone (Dex), and 1-methyl-3-isobutylxanthine (Mix), pp160 expression increased 10-20-fold over the amount present in confluent fibroblasts. Omission of either insulin or Dex resulted in reduced expression of pp160 and in incomplete adipogenesis. Chronic treatment of fully differentiated adipocytes for 24 h with either insulin, Dex, or Mix alone in the presence of serum resulted in a decrease in the expression of pp160 by 70-85%. Chronic exposure to insulin caused a significant increase in the apparent size of pp160 to 172 kDa. Alkaline phosphatase treatment lowered the M(r) of pp160 from both insulin-treated and basal cells to 150,000. These results demonstrate that pp160 is expressed in 3T3-L1 adipocytes during the time when insulin receptors are expressed in large numbers and that the maintenance of pp160 concentrations in adipocytes can be regulated by insulin, Mix, and Dex. The decreased expression of pp160 caused by these factors may be related to postreceptor insulin resistance.	TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,LUBBOCK,TX 79430; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Dartmouth College					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; JANAKIDEVI K, 1988, ANAL BIOCHEM, V172, P78, DOI 10.1016/0003-2697(88)90413-7; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KURIHARCUCH W, 1983, J CELL PHYSIOL, V114, P39, DOI 10.1002/jcp.1041140107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMA FB, 1991, ENDOCRINOLOGY, V128, P2415, DOI 10.1210/endo-128-5-2415; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; RESH MD, 1982, J BIOL CHEM, V257, P6978; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10163	10167						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374400				2022-12-25	WOS:A1992HT96500107
J	SHANKAR, R; DELAMOTTE, CA; DICORLETO, PE				SHANKAR, R; DELAMOTTE, CA; DICORLETO, PE			3-DEAZAADENOSINE INHIBITS THROMBIN-STIMULATED PLATELET-DERIVED GROWTH-FACTOR PRODUCTION AND ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE-1-MEDIATED MONOCYTIC CELL-ADHESION IN HUMAN AORTIC ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITOR; TISSUE PLASMINOGEN-ACTIVATOR; FACTOR-LIKE PROTEIN; PHOSPHOLIPID METHYLATION; PROSTACYCLIN PRODUCTION; TRANSCRIPTIONAL REGULATION; VONWILLEBRAND-FACTOR; FACTOR-BETA; A-CHAIN; RELEASE	Injury to the vascular endothelium and the subsequent inflammatory response are considered prerequisites for the development of atherosclerosis. Platelet-derived growth factor (PDGF) production by and monocyte adhesion to aortic endothelial cells (EC) may participate in this inflammatory process and therefore are two potential targets for control by anti-inflammatory agents. Our previous studies have demonstrated that monocyte adhesion and PDGF production are stimulated by thrombin in EC. Here, we provide evidence that treatment of EC with the anti-inflammatory agent 3-deazaadenosine (c3 Ado) effectively abolished thrombin-stimulated PDGF production and monocyte adhesion. c3 Ado had no significant effect on either basal monocyte adhesion or constitutive PDGF production. c3 Ado was also effective in negating monocyte adhesion induced by other agonists, such as interleukin-1, phorbol 12-myristate 13-acetate (PMA), and lipopolysaccharide. Northern analysis demonstrated that c3 Ado significantly reduced thrombin- and PMA-stimulated steady-state levels of PDGF-A chain, PDGF-B chain, and endothelial-leukocyte adhesion molecule-1 (ELAM-1) mRNAs. Nuclear run-on studies demonstrated that a marked transcriptional activation of these genes by thrombin and PMA was abrogated by c3 Ado treatment. The transcriptional rate of the alpha-tubulin gene was unaffected by the drug. Antibody binding studies with an anti-ELAM-1 monoclonal antibody 7A9 revealed that thrombin-stimulated EC expression of ELAM-1 was abolished by c3 Ado, indicating that the suppression of ELAM-1 expression on EC surface may be a mechanism by which c3 Ado interferes with monocyte adhesion. Experiments with the nucleoside transport inhibitor nitrobenzylthioinosine suggested that the transport of c3 Ado into EC was required for its inhibitory activity. In addition, L-homocysteine thiolactone was found to potentiate the inhibitory activity of c3 Ado, suggesting that the accumulation of intracellular c3 Ado homocysteine may be the underlying mechanism by which c3 Ado inhibits thrombin-induced EC function. Taken together, these results indicate that C3 Ado may prove effective against vascular injury and inflammation through its ability to inhibit induction of both monocyte adhesion and PDGF production.	CLEVELAND CLIN FDN,RES INST NC1,DEPT VASC CELL BIOL & ATHEROSCLEROSIS RES,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL034727, K04HL001561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 1561, HL 29582, HL 34727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKSAMIT RR, 1983, J BIOL CHEM, V258, P20; AKSAMIT RR, 1982, J BIOL CHEM, V257, P621; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Borchardt R. T., 1986, BIOL METHYLATION DRU, P227; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CHIANG PK, 1986, BIOL METHYLATION DRU, P239; CHIANG PK, 1985, METHOD PHARMACOL, V6, P127; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DANIEL TO, 1988, J BIOL CHEM, V263, P19815; DEGROOT PG, 1984, J BIOL CHEM, V259, P3329; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1989, J IMMUNOL, V143, P3666; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DICORLETO PE, 1991, FASEB J, V5, pA1602; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FUKUSHIMA M, 1989, INVEST OPHTH VIS SCI, V30, P1576; GAMBLE JR, 1988, SCIENCE, V242, P97; GARCIACASTRO I, 1983, J BIOL CHEM, V258, P4345; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GHIBO D, 1988, J BIOL CHEM, V263, P19437; GIMBRONE MA, 1990, NY ACAD SCI, V598, P77; GRABER N, 1990, J IMMUNOL, V145, P819; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HELDIN CH, 1979, P NATL ACAD SCI USA, V76, P3722, DOI 10.1073/pnas.76.8.3722; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HOSHI H, 1986, IN VITRO CELL DEV B, V22, P51; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; LEONARD EJ, 1978, BIOCHEM BIOPH RES CO, V84, P102, DOI 10.1016/0006-291X(78)90269-3; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MCKEEHAN WL, 1980, IN VITRO CELL DEV B, V16, P475; MEDZIHRADSKY JL, 1984, J IMMUNOL, V133, P946; MEDZIHRADSKY JL, 1983, IMMUNOPHARMACOLOGY, V6, P51, DOI 10.1016/0162-3109(83)90016-4; MEDZIHRADSKY JL, 1982, J IMMUNOPHARMACOL, V4, P29, DOI 10.3109/08923978209031073; MORITA Y, 1982, BIOCHEM PHARMACOL, V31, P2111, DOI 10.1016/0006-2952(82)90428-2; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POBER JS, 1986, J IMMUNOL, V136, P12680; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRUS KL, 1986, PFLUEGERS ARCH, V407, pS32; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAZIN A, 1988, P NATL ACAD SCI USA, V85, P9003, DOI 10.1073/pnas.85.23.9003; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICHES DWH, 1985, J LEUKOCYTE BIOL, V37, P545, DOI 10.1002/jlb.37.5.545; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SEDMAK D, 1989, FASEB Journal, V3, pA634; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; STOPFORD CR, 1985, P NATL ACAD SCI USA, V82, P4060, DOI 10.1073/pnas.82.12.4060; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUNG SSJ, 1985, J BIOL CHEM, V260, P546; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; YAGAWA K, 1986, FEBS LETT, V201, P287, DOI 10.1016/0014-5793(86)80625-1; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220; ZIMMERMAN TP, 1984, J BIOL CHEM, V259, P1122; ZIMMERMAN TP, 1986, BIOL METHYLATION DRU, P417	64	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9376	9382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374393				2022-12-25	WOS:A1992HR85400102
J	WANG, XK; LEE, G; LIEBHABER, SA; COOKE, NE				WANG, XK; LEE, G; LIEBHABER, SA; COOKE, NE			HUMAN CYSTEINE-RICH PROTEIN - A MEMBER OF THE LIM DOUBLE-FINGER FAMILY DISPLAYING COORDINATE SERUM INDUCTION WITH C-MYC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; T-CELL ONCOGENE; MESSENGER-RNA; DEVELOPMENTAL REGULATION; ZINC ENZYMES; GENE-PRODUCT; 3T3 CELLS; TRANSCRIPTION; GROWTH; IDENTIFICATION	We previously reported the structure of the placentally derived human cysteine-rich (hcrp) cDNA and demonstrated that it encodes a highly conserved and widely distributed zinc finger-like protein. We now report that the expression of both the mouse and human crp genes is induced as a primary response to serum in quiescent Balb/c 3T3 cells and in human fibroblasts. The profile of this primary response is remarkably parallel to that of c-myc in the Balb/c 3T3 cell line. The structure of the 23.2-kilobase hcrp gene demonstrates that it is a member of a gene superfamily encoding proteins sharing a highly characteristic 52-amino acid "LIM/double-finger" motif. The evolutionarily conserved structure of cysteine-rich protein, its structural similarity to a number of developmentally critical proteins, its distinctive tissue distribution, and its primary response to early events in the cell cycle suggest that crp plays an important role in cell function.	UNIV PENN, DEPT MED & HUMAN GENET,RM 700,CLIN RES BLDG, 422 CURIE BLVD, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032035] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25147] Funding Source: Medline; NIGMS NIH HHS [GM32035] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; Foulkes, 1991, HORMONAL CONTROL REG, P257; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Goossens M, 1981, Methods Enzymol, V76, P805; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	61	101	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9176	9184						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374386				2022-12-25	WOS:A1992HR85400073
J	BORZILLO, GV; ENDO, K; TSUJIMOTO, Y				BORZILLO, GV; ENDO, K; TSUJIMOTO, Y			BCL-2 CONFERS GROWTH AND SURVIVAL ADVANTAGE TO INTERLEUKIN-7-DEPENDENT EARLY PRE-B CELLS WHICH BECOME FACTOR INDEPENDENT BY A MULTISTEP PROCESS IN CULTURE	ONCOGENE			English	Article							HUMAN FOLLICULAR LYMPHOMA; BONE-MARROW; CHROMOSOMAL BREAKPOINT; GENE; EXPRESSION; PROTEIN; T(14-18); ONCOGENE; DEATH; TRANSLOCATION	Early pre-B cells derived from mouse lymphoid bone marrow cultures were expanded on a surrogate stromal cell line composed of NIH3T3 fibroblasts engineered to secrete interleukin 7 (IL-7). Three immortal, IL-7-dependent cell lines were generated and infected with recombinant retroviruses to determine the effects of the human follicular B-cell lymphoma gene, bcl-2, on immature stages of B-cell development. Cells expressing bcl-2 grew at rates similar to those of control (vector only) cells when plated on bone marrow stromal lines, but exhibited a c. two-fold net proliferative advantage when grown in liquid medium supplemented with IL-7 alone. Bcl-2 prevented apoptosis when the infected early pre-B-cell lines were deprived of IL-7 and other growth factors provided by stromal cells. Following factor deprivation, a subset of cells expressing bcl-2 survived indefinitely. Two such cultures spontaneously gave rise to factor-independent variants which grew slowly in unsupplemented liquid culture and formed agar colonies, yet still responded positively to IL-7 and kit ligand, and negatively to gamma-interferon. Bcl-2 thus provides a survival capacity and modest growth advantage to early pre-B cells, which may recapitulate its effects in human B cells bearing t(14;18) translocations and ultimately contribute to transformation.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	St Jude Children's Research Hospital; The Wistar Institute					NCI NIH HHS [CA-51864, CA-50551, CA-09346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, R01CA051864, R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BERTOLI LF, 1988, BLOOD, V72, P94; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DORSHKIND K, 1989, J IMMUNOL METHODS, V123, P93, DOI 10.1016/0022-1759(89)90033-1; FUKUHARA S, 1979, CANCER RES, V39, P3119; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; RICHARDSON ME, 1987, BLOOD, V70, P444; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITLOCK CA, 1987, METHOD ENZYMOL, V150, P275; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0	39	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					869	876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373874				2022-12-25	WOS:A1992HP64200005
J	LEACHMAN, SA; GALLAGHER, PJ; HERRING, BP; MCPHAUL, MJ; STULL, JT				LEACHMAN, SA; GALLAGHER, PJ; HERRING, BP; MCPHAUL, MJ; STULL, JT			BIOCHEMICAL-PROPERTIES OF CHIMERIC SKELETAL AND SMOOTH-MUSCLE MYOSIN LIGHT CHAIN KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN BINDING DOMAIN; AMINO-ACID SEQUENCE; SENSITIVE METHOD; CDNA; PHOSPHORYLATION; PURIFICATION; EXPRESSION; ORGANIZATION; INSITU; SITE	The molecular and biochemical properties of myosin light chain kinases from chicken skeletal and smooth muscle were investigated by recombinant DNA techniques. Deletion of the amino-terminal region of either the smooth or skeletal muscle myosin light chain kinase resulted in a decrease in V(max) with no significant change in K(m) values for light chain substrates. Skeletal/smooth muscle chimeric kinases were inactive when a 65-residue region amino-terminal of the catalytic core was exchanged between the two forms. Changing alanine 494 to glutamic acid within this region in the chicken skeletal muscle myosin light chain kinase increased the K(m) values for light chains 10-fold. These results are consistent with the hypothesis that the region amino-terminal of the catalytic core in myosin light chain kinases is involved in light chain recognition. A skeletal muscle kinase which contained the smooth muscle calmodulin binding domain remained regulated by Ca2+/calmodulin. Thus, the calmodulin binding domains of smooth and skeletal muscle myosin light chain kinases share structural elements necessary for regulation.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			McPhaul, Michael/AAC-7124-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26043, R37 HL026043, R01 HL026043, R01 HL026043-20] Funding Source: Medline; NIGMS NIH HHS [5T-32 GM08014, T32 GM008014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI IC, 1989, J BIOL CHEM, V264, P15843; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FOYT HL, 1985, J BIOL CHEM, V260, P7765; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1989, AM J PHYSIOL, V256, pC399, DOI 10.1152/ajpcell.1989.256.2.C399; HERRING BP, 1990, J BIOL CHEM, V265, P16588; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kamm K E, 1987, Prog Clin Biol Res, V245, P183; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Landon, 1977, Methods Enzymol, V47, P145; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYR GW, 1983, BIOCHEMISTRY-US, V22, P4316, DOI 10.1021/bi00287a024; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MOORE RL, 1985, J CELL PHYSIOL, V125, P301, DOI 10.1002/jcp.1041250219; MOORE RL, 1984, AM J PHYSIOL, V247, pC462, DOI 10.1152/ajpcell.1984.247.5.C462; NUNNALLY MH, 1984, J BIOL CHEM, V259, P1776; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; Sambrook J, 1989, MOL CLONING LABORATO; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TOKIMITSU I, 1987, ARCH BIOCHEM BIOPHYS, V256, P455, DOI 10.1016/0003-9861(87)90602-3; URDAL DL, 1984, J CHROMATOGR, V296, P171, DOI 10.1016/S0021-9673(01)96410-6; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4930	4938						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371510				2022-12-25	WOS:A1992HF64200095
J	JUDWARE, R; PETRYSHYN, R				JUDWARE, R; PETRYSHYN, R			MECHANISM OF ACTION OF A CELLULAR INHIBITOR OF THE DSRNA-DEPENDENT PROTEIN-KINASE FROM 3T3-F442A CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HUMAN IMMUNODEFICIENCY VIRUS-1; FUNCTIONAL EXPRESSION; TRANSLATIONAL CONTROL; EIF-2-ALPHA KINASE; 3T3 CELLS; INTERFERON; ACTIVATION; BINDING; REGION	When mouse 3T3-F442A preadipocyte fibroblasts reach confluence in the appropriate culture medium, their growth is arrested, and the cells undergo terminal differentiation to adipocytes. Two proteins that may be involved in this process are interferon and the interferon-induced double-stranded RNA (dsRNA)-dependent protein kinase (DAI). In 3T3-F442A cells, interferon and DAI are transiently expressed with a maximum level of active kinase appearing at confluence. Interestingly, the level of active DAI was found to be low when cells were maintained under conditions nonpermissive for differentiation. This reduction in DAI was at least partly because of the presence of elevated levels of a specific inhibitor of DAI, termed dRF, which appeared to be a reversible inhibitor of the autophosphorylation (activation) of DAI. In the present study, the mechanism of action of dRF was investigated. Photocross-linking experiments indicated that dRF prevented the binding of ATP to DAI. Since the binding of ATP to DAI is dsRNA-dependent, we examined the effect of dRF on the binding of dsRNA to the kinase using RNA mobility shift assays. dRF was found to prevent the formation of DAI.dsRNA complexes without a direct effect on the dsRNA. This suggests that dRF exerts its effect through an interaction with DAI.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,750 E ADAMS ST,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					PHS HHS [E309T] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; Demaeyer E., 1988, INTERFERONS OTHER RE; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNTER T, 1975, J BIOL CHEM, V250, P409; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KURIHARCUCH W, 1978, P NATL ACAD SCI USA, V75, P6107, DOI 10.1073/pnas.75.12.6107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEUSING MA, 1987, CELL, V48, P691; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21685	21690						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356990				2022-12-25	WOS:A1992JV01100067
J	RINCON, M; TUGORES, A; LOPEZBOTET, M				RINCON, M; TUGORES, A; LOPEZBOTET, M			CYCLIC-AMP AND CALCIUM REGULATE AT A TRANSCRIPTIONAL LEVEL THE EXPRESSION OF THE CD7 LEUKOCYTE DIFFERENTIATION ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; ALPHA-SUBUNIT GENE; NF-KAPPA-B; MONOCLONAL-ANTIBODY; MESSENGER-RNA; INTERLEUKIN-2 PRODUCTION; RECEPTOR EXPRESSION; RIBONUCLEIC-ACID; BINDING; FOS	CD7 is a 40-kDa cell surface glycoprotein expressed on T-cell precursors before their entry into the thymus during fetal development and whose functional role remains uncertain. T-cell activation has been shown to increase the expression of this surface molecule. In this report we describe the intracellular signals and the mechanisms involved in the regulation of CD7 antigen expression on human T lymphocytes. The elevation of intracellular calcium by using the A23187 ionophore increased the cell surface expression of CD7, whereas protein kinase C activation caused its down-regulation. Interestingly, the increase of intracellular cAMP with Bt2cAMP stimulated CD7 expression as well. Up-regulation of CD7 on the cell surface following either Bt2cAMP or calcium ionophore stimulation of T lymphocytes correlated with a raise of the steady-state levels of CD7-specific mRNA, without de novo protein synthesis requirements. No differences between the half-life of basal CD7 mRNA and that induced by either Bt2cAMP or calcium ionophore were detected. Run-on experiments showed that both stimuli enhanced the transcriptional rate of the CD7 gene. Our results provide the evidence for a positive regulatory effect mediated by cAMP on the expression of a leucocyte differentiation antigen.			RINCON, M (corresponding author), UNIV AUTONOMA MADRID, HOSP PRINCESA, SECC INMUNOL, C DIEGO LEON 62, E-28006 MADRID, SPAIN.		Tugores, Antonio/AAE-7939-2021; Lopez-Botet, Miguel/I-5434-2014	Lopez-Botet, Miguel/0000-0003-4882-065X; Tugores, Antonio/0000-0002-1849-9239				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAMBURU J, 1991, J IMMUNOL, V147, P714; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CARRERA AC, 1988, EUR J IMMUNOL, V18, P961, DOI 10.1002/eji.1830180620; CHAPLIN DD, 1980, BIOL BASIS IMMUNODEF, P269; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; COSMAN D, 1987, IMMUNOL TODAY, V8, P16, DOI 10.1016/0167-5699(87)90826-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; EMARA M, 1989, HUM IMMUNOL, V25, P87, DOI 10.1016/0198-8859(89)90073-6; EMARA M, 1991, FASEB J, V5, pA994; ERICKSON JM, 1981, GENE, V16, P19; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARPOLD MM, 1981, MOL CELL BIOL, V1, P188, DOI 10.1128/MCB.1.2.188; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; HAYNES BF, 1979, P NATL ACAD SCI USA, V76, P5829, DOI 10.1073/pnas.76.11.5829; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JUNG LKL, 1988, EUR J IMMUNOL, V18, P711, DOI 10.1002/eji.1830180509; JUNG LKL, 1986, J CLIN INVEST, V77, P940, DOI 10.1172/JCI112393; JUNG LKL, 1990, FASEB J, V4, pA1935; LAZAROVITS AI, 1988, TRANSPLANT P, V20, P1253; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LINK M, 1983, BLOOD, V62, P722; LOPEZBOTET M, 1987, EUR J IMMUNOL, V17, P1167, DOI 10.1002/eji.1830170814; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTER JS, 1988, J IMMUNOL, V140, P3233; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORISHIMA Y, 1982, J IMMUNOL, V129, P1091; QUACH TT, 1984, MOL PHARMACOL, V26, P255; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENSENDEZ E, 1986, J CELL BIOL, V103, P2145; RINCON M, 1988, EUR J IMMUNOL, V18, P1791, DOI 10.1002/eji.1830181121; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SPITS H, 1985, EUR J IMMUNOL, V15, P88, DOI 10.1002/eji.1830150117; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VODINELICH L, 1983, BLOOD, V62, P1108; WALKER C, 1983, J IMMUNOL, V130, P1770; WARE RE, 1991, J IMMUNOL, V147, P2787; WARE RE, 1991, FASEB J, V5, pA991; WARE RE, 1989, J IMMUNOL, V143, P3632; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZUTTER MM, 1990, LEUKEMIA RES, V14, P23, DOI 10.1016/0145-2126(90)90142-V	61	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18026	18031						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381361				2022-12-25	WOS:A1992JM22300084
J	HOLOHAN, PD; WHITE, KE; SOKOL, PP; REBBEOR, J				HOLOHAN, PD; WHITE, KE; SOKOL, PP; REBBEOR, J			PHOTOAFFINITY-LABELING OF THE ORGANIC CATION/H+ EXCHANGER IN RENAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; ALPHA-1-ADRENERGIC RECEPTOR; RABBIT KIDNEY; TRANSPORT; MECHANISMS; EXPRESSION; DRUGS; IDENTIFICATION	The brush border membrane of the proximal tubule contains two efflux pathways for organic cations from the cell to the tubular fluid: a P-glycoprotein and an organic cation[H+ exchanger. There is evidence that they transport many of the same substrates. Their structural relatedness is unknown and is the subject of this report. The experimental approach was to identify the exchanger with photoaffinity labeling reagents. The rationale was that if the P-glycoprotein and the organic cation/H+ exchanger transport many of the same substrates, then they might be photoaffinity labeled by the same reagents. [I-125]Iodoarylazidoprazosin and [H-3]azidopine are two reagents, which have been used, to photoaffinity label the P-glycoprotein. We found that several polypeptides were photolabeled in a time- and concentration-dependent manner. The photoincorporation into only two of these polypeptides (41 and 28 kDa) was blocked extensively by the presence of known substrates for the exchanger. The photoaffinity labeling of only the 41-kDa polypeptide was affected by treatment with the chemical reagents, N-ethylmaleimide and dithiothreitol, which are known to affect the exchanger reaction. The findings are consistent with the interpretation that a 41-kDa polypeptide is, or is a component of, the exchanger.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543	Bristol-Myers Squibb	HOLOHAN, PD (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041265] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44736] Funding Source: Medline; NIGMS NIH HHS [GM41265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1981, AM J PHYSIOL, V240, pF1, DOI 10.1152/ajprenal.1981.240.1.F1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAUTH C, 1988, AM J PHYSIOL, V254, pF351, DOI 10.1152/ajprenal.1988.254.3.F351; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FORD JM, 1990, PHARMACOL REV, V42, P155; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRANTHAM JJ, 1986, KIDNEY, P663; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HOLOHAN PD, 1990, PHARMACOLOGIST, V32, P179; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; INABA M, 1977, CANCER RES, V37, P4629; KINSELLA JL, 1979, J PHARMACOL EXP THER, V209, P443; KINSELLA JL, 1979, BIOCHIM BIOPHYS ACTA, V552, P468, DOI 10.1016/0005-2736(79)90191-3; LIEBERMAN DM, 1989, BIOCHEM BIOPH RES CO, V162, P244, DOI 10.1016/0006-291X(89)91988-8; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAFIZADEH C, 1986, PFLUG ARCH EUR J PHY, V407, P404, DOI 10.1007/BF00652625; ROSS CR, 1983, ANNU REV PHARMACOL, V23, P65, DOI 10.1146/annurev.pa.23.040183.000433; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SEIDMAN CE, 1984, BIOCHEMISTRY-US, V23, P3765, DOI 10.1021/bi00311a031; SKOVSGAARD T, 1978, CANCER RES, V38, P1785; SOKOL PP, 1990, BIOCHEM PHARMACOL, V40, P1421, DOI 10.1016/0006-2952(90)90415-H; SOKOL PP, 1989, J PHARMACOL EXP THER, V251, P937; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; SOKOL PP, 1988, BIOCHIM BIOPHYS ACTA, V940, P209, DOI 10.1016/0005-2736(88)90196-4; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; SOKOL PP, 1986, J BIOL CHEM, V261, P3282; SOMOGYI A, 1987, TRENDS PHARMACOL SCI, V8, P354, DOI 10.1016/0165-6147(87)90146-5; STEFFENS TG, 1989, AM J PHYSIOL, V256, pF596, DOI 10.1152/ajprenal.1989.256.4.F596; STEFFENS TG, 1991, TRENDS BIOMEMBR BIOE, V1, P93; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TERMAN BI, 1986, J BIOL CHEM, V261, P5603; WEINER IM, 1985, KIDNEY PHYSL PATHOPH, P1703; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903	41	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13513	13519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352295				2022-12-25	WOS:A1992JB74600066
J	BIRNBAUMER, M; ANTARAMIAN, A; THEMMEN, APN; GILBERT, S				BIRNBAUMER, M; ANTARAMIAN, A; THEMMEN, APN; GILBERT, S			DESENSITIZATION OF THE HUMAN V2 VASOPRESSIN RECEPTOR - HOMOLOGOUS EFFECTS IN THE ABSENCE OF HETEROLOGOUS DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SENSITIVE ADENYLATE-CYCLASE; DEPENDENT PROTEIN-KINASE; CELL-LINE LLC-PK1; PHOSPHORYLATION; IDENTIFICATION; TRANSITION; RHODOPSIN; MEMBRANES; CLONING	Three main pathways have been implicated in desensitization of receptors that stimulate adenylylcyclase (AC): cAMP-mediated phosphorylation; cAMP-independent phosphorylation, and receptor internalization. Cell lines derived from the murine Ltk- cell were found useful in exploring the contribution of cAMP-dependent phosphorylation in V2 vasopressin receptor desensitization. The HTB-2 cell expresses the human V2 vasopressin receptor, introduced by transfection of human genomic DNA, and the prostaglandin E1 (PGE1) receptor, endogenous to the Ltk- cell. The A7 cell expresses the hamster beta-2-adrenoceptor, which undergoes the above-mentioned desensitization processes. Treatment of HTB-2 cells with arginine-vasopressin (AVP) had no effect on AC responsiveness to PGE1, but promoted desensitization of the AVP response. This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters. AVP treatment caused a decrease in cell surface receptors to approximately 75% of control without changes in K(D), as determined by Scatchard analysis. When cAMP was increased by treatment with 10-mu-M PGE1 and isobutylmethylxanthine, desensitization of the PGE1 receptor was observed but not of the AVP receptor. In A7 cells the same treatment caused, as expected, a 3-fold right shift in the dose-response curve for AC stimulation by isoproterenol, indicating that L cells can mediate heterologous desensitization. These data demonstrate that the V2 vasopressin and the PGE1 receptors undergo homologous desensitization in the absence of cAMP-mediated phosphorylation and that this component is not required for vasopressin receptor internalization.			BIRNBAUMER, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.				NIDDK NIH HHS [DK-41244, DK-27685] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244, P30DK027685] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR N, 1990, CELL SIGNAL, V2, P153, DOI 10.1016/0898-6568(90)90018-6; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GUDDERMAN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LESTER BR, 1985, MOL CELL ENDOCRINOL, V40, P193, DOI 10.1016/0303-7207(85)90175-3; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROY C, 1981, J BIOL CHEM, V256, P3423; ROY C, 1981, J BIOL CHEM, V256, P3415; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; SU YF, 1980, J BIOL CHEM, V255, P7410; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	30	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11783	11788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376312				2022-12-25	WOS:A1992HY94700024
J	ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M				ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M			IDENTIFICATION AND ANALYSIS OF THE RET PROTOONCOGENE PROMOTER REGION IN NEUROBLASTOMA CELL-LINES AND MEDULLARY-THYROID CARCINOMAS FROM MEN2A-PATIENTS	ONCOGENE			English	Article							FACTOR RECEPTOR GENE; MESSENGER-RNA; MOLECULAR-CLONING; EXPRESSION; DNA; PROTOONCOGENE; TRANSCRIPTION; SEQUENCES; VECTORS; TRANSFORMATION	The human ret proto-oncogene (proto-ret), encoding a receptor tyrosine kinase, is highly expressed in neuroblastomas, medullary thyroid carcinomas (MTCs) and pheochromocytomas, which are all tumors of cells originating from the neural crest. In studies on the transcription mechanism of proto-ret, we identified the transcription start site and the promoter region by chloramphenicol acetyl transferase (CAT) assay. A sequence upstream from the transcription start site (- 167 to + 98 bp) showed definite promoter activity in both proto-ret mRNA-positive neuroblastoma NB39-nu cells and proto-ret mRNA-negative HeLa cells. The promoter sequence had a high GC content and contained four tandemly repeated GC boxes without a TATA box. Putative binding sequences for SP-1, AP-2 and epidermal growth factor receptor-specific transcription factor (ETF) and also the transcription-suppressing factor, GC factor (GCF), were found in the repeated GC box region. Southern blot analysis of DNAs of neuroblastoma cell lines and primary MTCs showed that the high proto-ret expression in these tumors is not caused by gross genetic changes in the promoter region, suggesting the possible involvement of a region(s) other than the sequence from - 167 to + 98 bp or a minor genetic change(s) in the promoter region.	NATL CANC CTR,DIV CARCINOGENESIS,1-1 TSUKIJI-5,CHUO KU,TOKYO 104,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,FUKUSHIMA KU,OSAKA 553,JAPAN; SAPPORO MED COLL,DEPT INTERNAL MED 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MED GENET,FUKUSHIMA KU,OSAKA 553,JAPAN	National Cancer Center - Japan; Osaka University; Sapporo Medical University; Osaka University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREEN MR, 1980, CELL, V22, P231, DOI 10.1016/0092-8674(80)90171-3; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; IKEDA I, 1990, ONCOGENE, V5, P1291; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITOH F, 1989, Tumor Research, V24, P1; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYAZAKI J, 1989, GENE, V79, P269; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1990, ONCOGENE, V5, P1595; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YAMAMOTO M, 1991, JPN J CLIN ONCOL, V21, P149; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1201	1206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350670				2022-12-25	WOS:A1992HU64200018
J	GITT, MA; MASSA, SM; LEFFLER, H; BARONDES, SH				GITT, MA; MASSA, SM; LEFFLER, H; BARONDES, SH			ISOLATION AND EXPRESSION OF A GENE ENCODING L-14-II, A NEW HUMAN SOLUBLE LACTOSE-BINDING LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MESSENGER-RNA; MOLECULAR-CLONING; ELASTIN RECEPTOR; PROTEIN; GALACTOSE; CDNA; RIBOSOMES; MUSCLE; FAMILY	In the course of screening a human hepatoma cDNA library with antibody raised against a mammalian lectin with subunit molecular weight of about 14,000, we detected a partial cDNA encoding a related but distinct protein that was possibly a homologous lectin (Gitt and Barondes, 1986). We here report the isolation and sequencing of a full-length cDNA for this protein from a HepG2 cDNA library. The cDNA encodes a protein with subunit molecular weight of 14,650. Expression of the coding sequence in Escherichia coli yields a product that binds to a lactose affinity column and is specifically eluted with lactose, confirming that this new protein is a lectin. Like its well studied relative, here called L- 14-I, the new lectin, L- 14-II, exists as a homodimer in solution. The two related human lectins have 43% amino acid sequence identity. The genomic DNA encoding L-14-II (LGALS2) contains four exons with similar intron placement to L-14-I (LGALS1); but the genomic upstream region, which contains several sequences characteristic of regulatory elements, differs significantly from L-14-I.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,DEPT PSYCHIAT,BOX F-0984,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALLEN HJ, 1991, BIOCHEMISTRY-US, V30, P8904, DOI 10.1021/bi00100a026; BARONDES SH, 1984, SCIENCE, V223, P1159; BEYER EC, 1980, J BIOL CHEM, V255, P4236; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Maniatis T., 1982, MOL CLONING; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; ODA Y, 1991, GENE, V99, P279; OHARA T, 1986, BIOCHIM BIOPHYS ACTA, V884, P344, DOI 10.1016/0304-4165(86)90183-2; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAZ A, 1991, CANCER RES, V51, P2173; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847	37	114	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10601	10606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375225				2022-12-25	WOS:A1992HV09000059
J	MALOUF, NN; MCMAHON, D; OAKELEY, AE; ANDERSON, PAW				MALOUF, NN; MCMAHON, D; OAKELEY, AE; ANDERSON, PAW			A CARDIAC TROPONIN-T EPITOPE CONSERVED ACROSS PHYLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; THIN FILAMENT; CONTRACTILE PROTEINS; ADULT ISOFORMS; RABBIT; TROPOMYOSIN; GENE; EXPRESSION; BINDING	Troponin T is a thin filament protein that is important in regulating striated muscle contraction. We have raised a monoclonal antibody against rabbit cardiac troponin T, monoclonal (mAb) 13-11, that recognizes its epitope in cardiac troponin T isoforms from fish, bird, and mammal but not from frog. The number of these isoforms expressed in cardiac muscle varies among species and during development. Cardiac troponin T isoforms were not found in adult skeletal muscle, while they were expressed transiently in immature skeletal muscle. We have mapped the epitope recognized by mAb 13-11 using rabbit cardiac troponin T isoforms. Analysis of stepwise cyanogen bromide digestion, which allowed association of the epitope to regions spanning methionine residues, coupled with immunoactivity of synthetic peptides, corresponding to sequences containing methionine residues, indicated that mAb 13-11 recognized its epitope in a 17-residue sequence containing the methionine at position 68, SKPKPRPFMPNLVPPKI. Comparison of skeletal and cardiac troponin T sequences suggested that the epitope was contained within the sequence FMPNLVPPKI. Synthetic peptides PFMPNLVPPKI and FMPNLVPPKI were recognized by mAb 13-11 on slot-blots. Enzyme-linked immunosorbent assay demonstrated mAb 13-11 recognized, in order of descending affinity, the 17-, 11-, and 10-residue sequence. Preabsorption of mAb 13-11 with each of these sequences blocked the recognition of the 17-residue peptide by mAb 13-11. The domain, PFMPNLVPPKI is encoded by the 5' region of the cardiac gene exon 10 and is present in hearts across a broad range of phyla. These findings suggest that this cardiac troponin T-specific sequence confers onto myofilaments structural and functional properties unique to the heart.	DUKE UNIV, MED CTR, DEPT PEDIAT, POB 3218, DURHAM, NC 27710 USA; DUKE UNIV, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27514 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042250, R01HL037358, R01HL020749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20749, HL 37358, HL 42250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PAW, 1988, CIRC RES, V63, P742, DOI 10.1161/01.RES.63.4.742; ANDERSON PAW, 1989, CIRC RES, V65, P1087, DOI 10.1161/01.RES.65.4.1087; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRIGGS MM, 1987, J MUSCLE RES CELL M, V8, P1, DOI 10.1007/BF01767259; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; EBASHI S, 1984, J MOL CELL CARDIOL, V16, P129, DOI 10.1016/S0022-2828(84)80701-4; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1989, J BIOL CHEM, V264, P14471; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MALOUF NN, 1986, J HISTOCHEM CYTOCHEM, V34, P347, DOI 10.1177/34.3.3950385; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; ORDAHL CP, 1986, DEV BIOL, V117, P488, DOI 10.1016/0012-1606(86)90315-5; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; RAGGI A, 1989, BIOCHIM BIOPHYS ACTA, V997, P135, DOI 10.1016/0167-4838(89)90145-3; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SCHIAFFINO S, 1991, J CELL BIOCHEM     S, V15, P149; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1978, BIOCHEM J, V169, P229, DOI 10.1042/bj1690229; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; WILLARD AS, 1990, P INT C ELECTRON MIC, V12, P364; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	38	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9269	9274						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374390				2022-12-25	WOS:A1992HR85400086
J	KHANDJIAN, EW; TREMBLAY, S				KHANDJIAN, EW; TREMBLAY, S			PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS MODULATED IN MOUSE KIDNEY-CELLS INFECTED WITH POLYOMAVIRUS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; LARGE TUMOR-ANTIGEN; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; DNA-BINDING PROTEIN; SIMIAN-VIRUS 40; CELLULAR RNA; RB GENE; NUCLEAR MATRIX; EXPRESSION	Lytic infection with polyomavirus, an oncogenic DNA-containing virus, leads in G0-arrested primary baby mouse kidney (BMK) cell cultures to a mitotic host reaction. In the present work, we examined the expression of the retinoblastoma gene (RB) and of its product (Rb) in virus-infected BMK with the aim of correlating its modulation with the sequential activation of cellular processes leading to the induction of S phase by virus. In contrast to cell cycle-regulated genes whose expression is induced by viral infection, expression of RB is not altered during the transition from G0/G1 to S phase. In BMK cell cultures irreversibly arrested in the G0 phase of the cell cycle, an unphosphorylated species is the only detectable form of the RB protein (Rb). Time course analysis showed that in polyoma-infected cells induced to re-enter the S phase of the cell cycle the appearance of the phosphorylated forms of Rb coincided in time with the accumulation of large T antigen and preceded DNA synthesis. During the late phase of infection, the majority of Rb was present as phosphorylated forms. Ongoing DNA synthesis was not required for the cells to phosphorylate Rb, indicating that this post-translational modification takes place during the activation of the cellular DNA-synthesizing apparatus. Using hamster anti-polyoma tumor serum, it was observed that the underphosphorylated form of Rb co-precipitated with polyoma large T antigen extracted from infected cells late during infection. Our data add more evidence to the proposal that interactions between viral early proteins encoded by DNA tumor viruses and the product of RB may play a pivotal role in the mitogenic effect induced by viral infection.	HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY G1L 3L5,QUEBEC,CANADA	Laval University	KHANDJIAN, EW (corresponding author), UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA.							BASERGA R, 1985, BIOL CELL REPRODUCTI; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL RB, 1988, ONCOGENE, V2, P437; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEGHON VG, 1986, P NATL ACAD SCI USA, V83, P8947, DOI 10.1073/pnas.83.23.8947; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1350; Fakan S, 1980, Int Rev Cytol, V65, P255; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; GRENSPAN DS, 1979, VIROLOGY, V99, P413; HANCOCK R, 1982, INT REV CYTOL, V79, P165; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUMPHREY GW, 1987, EXP CELL RES, V171, P122, DOI 10.1016/0014-4827(87)90256-4; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KLEIN H, 1979, J BIOL CHEM, V254, P1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARRIOTT SJ, 1985, J VIROL, V56, P365, DOI 10.1128/JVI.56.2.365-372.1985; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P6611, DOI 10.1093/nar/11.19.6611; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P1039, DOI 10.1093/nar/11.4.1039; MATTER JM, 1982, NUCLEIC ACIDS RES, V10, P7643, DOI 10.1093/nar/10.23.7643; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PALME K, 1980, FEBS LETT, V118, P229, DOI 10.1016/0014-5793(80)80225-0; PALME K, 1983, ELECTROPHORESIS, P403; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; POCHRON S, 1980, J BIOL CHEM, V255, P4411; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROSSINI M, 1979, P NATL ACAD SCI USA, V76, P4441, DOI 10.1073/pnas.76.9.4441; SALOMON C, 1977, NUCLEIC ACIDS RES, V4, P1483, DOI 10.1093/nar/4.5.1483; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOMAS NSB, 1991, ONCOGENE, V6, P317; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TURLER H, 1980, MOL CELL BIOCHEM, V32, P63; WAHRMANN JP, 1980, BIOCHIM BIOPHYS ACTA, V612, P421, DOI 10.1016/0005-2744(80)90125-4; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	73	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					909	917						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373878				2022-12-25	WOS:A1992HP64200010
J	CSANK, C; MARTINDALE, DW				CSANK, C; MARTINDALE, DW			ISOLEUCYL-TRANSFER RNA-SYNTHETASE FROM THE CILIATED PROTOZOAN TETRAHYMENA-THERMOPHILA - DNA-SEQUENCE, GENE-REGULATION, AND LEUCINE ZIPPER MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUTRITIONAL SHIFT-UP; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; STARVED TETRAHYMENA; RIBOSOME SYNTHESIS; YEAST; RECOGNITION; PYRIFORMIS; EXPRESSION	We have determined the nucleotide sequence of a protozoan aminoacyl-tRNA synthetase. The isoleucyl-tRNA synthetase (ileRS) gene [ilsA; formerly cupC, Martindale, D. W., Martindale, H. M., and Bruns, P. J. (1986) Nucleic Acids Res. 14, 1341-1354] from the ciliate Tetrahymena thermophila was sequenced and found to have eight introns, four transcription start sites, and a putative polypeptide of 1081 amino acids. A polypeptide 20 amino acids longer could be made if a transcribed in-frame ATG close to the start sites and with suboptimal sequence context is used. This gene was identified through hybridization and amino acid sequence similarity to the previously cloned and sequenced ileRS (cytoplasmic) gene from Saccharomyces cerevisiae [Englisch, U., Englisch, S., Markmeyer, P., Schischkoff, J., Sternbach, H., Kratzin, H., and Cramer, F. (1987) Biol. Chem. Hoppe-Seyler 368, 971-979; Martindale, D. W., Gu, Z. M., and Csank, C. (1989) Curr. Genet. 15, 99-106] with which it shares 47% of its amino acids. We also compared it to ileRS genes from E. coli and an archaebacterium. Two leucine zippers motifs were identified in the carboxyl-terminal domain of the polypeptide; one of these motifs is in the same area as the zinc finger motif found in the E. coli enzyme. The transcription pattern of the ilsA gene was monitored under various culture conditions and parallels changes in protein synthesis.	MCGILL UNIV, DEPT MICROBIOL, MACDONALD CAMPUS, Ste Anne De Bellevue H9X 1C0, QUEBEC, CANADA	McGill University								ANDREASEN PH, 1984, EUR J BIOCHEM, V140, P485, DOI 10.1111/j.1432-1033.1984.tb08128.x; BEC G, 1989, J BIOL CHEM, V264, P21131; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CAMERON IL, 1971, EXP CELL RES, V65, P265, DOI 10.1016/0014-4827(71)90001-2; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; DREISIG H, 1984, EUR J BIOCHEM, V140, P477, DOI 10.1111/j.1432-1033.1984.tb08127.x; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FASIOLO F, 1985, J BIOL CHEM, V260, P5571; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; FETT R, 1991, J BIOL CHEM, V266, P1448; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; HALLBERG RL, 1976, J CELL BIOL, V71, P383, DOI 10.1083/jcb.71.2.383; HANSEN TS, 1991, GENE, V105, P143, DOI 10.1016/0378-1119(91)90144-Z; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HARRIS CL, 1987, J BACTERIOL, V169, P2718, DOI 10.1128/jb.169.6.2718-2723.1987; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HECK JD, 1988, J BIOL CHEM, V263, P868; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HOROWITZ S, 1987, NUCLEIC ACIDS RES, V15, P141, DOI 10.1093/nar/15.1.141; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P11266, DOI 10.1021/bi00503a016; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JENAL U, 1991, J BIOL CHEM, V266, P10570; JORDANA X, 1987, J BIOL CHEM, V262, P7189; KARRER KM, 1986, MOL BIOL CILIATED PR; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTINDALE DW, 1985, J PROTOZOOL, V32, P644, DOI 10.1111/j.1550-7408.1985.tb03094.x; MARTINDALE DW, 1982, EXP CELL RES, V140, P227, DOI 10.1016/0014-4827(82)90172-0; MARTINDALE DW, 1986, NUCLEIC ACIDS RES, V14, P1341, DOI 10.1093/nar/14.3.1341; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; MOWAT D, 1974, EXP CELL RES, V84, P282, DOI 10.1016/0014-4827(74)90407-8; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEIDHARDT FC, 1975, ANNU REV MICROBIOL, V29, P215, DOI 10.1146/annurev.mi.29.100175.001243; NUREKI O, 1991, J BIOL CHEM, V266, P3268; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARKER J, 1974, J BIOL CHEM, V249, P1044; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STARGELL LA, 1990, NUCLEIC ACIDS RES, V18, P6637, DOI 10.1093/nar/18.22.6637; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	73	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4592	4599						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371507				2022-12-25	WOS:A1992HF64200049
J	ORR, DC; FIGUEIREDO, HT; MO, CL; PENN, CR; CAMERON, JM				ORR, DC; FIGUEIREDO, HT; MO, CL; PENN, CR; CAMERON, JM			DNA CHAIN TERMINATION ACTIVITY AND INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE BY CARBOCYCLIC 2',3'-DIDEHYDRO-2',3'-DIDEOXYGUANOSINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHADENOPATHY-ASSOCIATED VIRUS; HTLV-III; INVITRO; REPLICATION; POLYMERASES; 2',3'-DIDEOXYNUCLEOSIDES; PHOSPHONOFORMATE; INFECTIVITY; THERAPY; POTENT	Carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine (carbovir, NSC 614846) is an anti-retroviral agent that may be useful in the treatment of AIDS. We have examined the ability of (-)-enantiomeric carbovir triphosphate to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (EC 2.7.7.49). A comparison of inhibition kinetics was made with 3'-azido-2',3'-dideoxythymidine triphosphate and phosphonoformate. Inhibition of the reverse transcriptase was evaluated using poly(rA) . oligo(dT)12-18, poly(rC).oligo(dG)12-18, or influenza virion RNA template with a specific oligodeoxynucleotide as primer. (-)-Carbovir 5'-triphosphate was shown to be a potent inhibitor of HIV-1 reverse transcriptase with an apparent K(i) similar to that of 3'-azido-2 3'-dideoxythymidine triphosphate. Chain elongation studies utilizing an MS2 RNA template showed that (-)-carbovir 5'-triphosphate terminated transcription at positions identical to those where dideoxy-GTP terminated. This indicates that (-)-carbovir 5'-monophosphate is incorporated into the newly synthesized DNA and terminates transcription at that point. We conclude that (-)-carbovir 5'-triphosphate is a potent inhibitor of the HIV-1 reverse transcriptase enzyme and that (-)-carbovir most likely inhibits HIV by activity at the triphosphate level by a combination of direct competition for binding of the natural deoxynucleoside triphosphates to the reverse transcriptase and chain termination.	GLAXO GRP RES LTD,DEPT VIROL,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO GRP RES LTD,DEPT MED CHEM 2,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline; GlaxoSmithKline								BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; COATES JAV, 1991, ANTIVIR RES, V15, P161, DOI 10.1016/0166-3542(91)90033-N; DAGANI R, 1987, CHEM ENG NEWS, V65, P41, DOI 10.1021/cen-v065n047.p041; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HEIDENREICH O, 1990, EUR J BIOCHEM, V192, P621, DOI 10.1111/j.1432-1033.1990.tb19268.x; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MCKENNA CE, 1987, BIOCHEM PHARMACOL, V36, P3103, DOI 10.1016/0006-2952(87)90618-6; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; NAKASHIMA H, 1986, ANTIMICROB AGENTS CH, V30, P933, DOI 10.1128/AAC.30.6.933; OBERG B, 1983, PHARMACOL THERAPEUT, V19, P387; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SABOURIN CLK, 1978, ARCH BIOCHEM BIOPHYS, V187, P96, DOI 10.1016/0003-9861(78)90010-3; SANDSTROM EG, 1985, LANCET, V1, P1480; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIN PS, 1985, BIOCHEM PHARMACOL, V34, P4075, DOI 10.1016/0006-2952(85)90392-2; STARNES MC, 1987, J BIOL CHEM, V262, P988; STARNES MC, 1988, J BIOL CHEM, V263, P5132; STARNES MC, 1988, VIRUS GENES, V2, P241; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VRANG L, 1987, ANTIVIR RES, V7, P139, DOI 10.1016/0166-3542(87)90002-7; VRANG L, 1986, ANTIMICROB AGENTS CH, V29, P867, DOI 10.1128/AAC.29.5.867; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9	26	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4177	4182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371285				2022-12-25	WOS:A1992HE60700090
J	DEBOER, HC; PREISSNER, KT; BOUMA, BN; DEGROOT, PG				DEBOER, HC; PREISSNER, KT; BOUMA, BN; DEGROOT, PG			BINDING OF VITRONECTIN-THROMBIN-ANTITHROMBIN-III COMPLEX TO HUMAN ENDOTHELIAL-CELLS IS MEDIATED BY THE HEPARIN BINDING-SITE OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; EXTRACELLULAR-MATRIX; IDENTIFICATION; PURIFICATION; ASSOCIATION; INHIBITION; AFFINITY; CULTURE; PLASMA; SERUM	The interaction of vitronectin-thrombin-antithrombin III (VN.TAT) complex with endothelial cells (EC) was investigated. Binding was specific and time- and concentration-dependent. Kinetics revealed an apparent dissociation constant of 16 nm and 1.7 x 10(5) binding sites/endothelial cell. The binding determinant of the ternary complex was located on the VN moiety. Since the association of VN to TAT adds its specific properties to the VN.TAT complex, the involvement of the heparin binding domain and the cell attachment site of VN was investigated. Neither addition of RGD peptide nor blocking of the vitronectin receptor with a monoclonal antibody interfered with VN.TAT binding to EC. Addition of heparin, a VN-derived peptide comprising two heparin binding consensus sequences or a monoclonal antibody directed against the heparin binding domain on VN, completely inhibited VN.TAT binding to EC. These results indicate that the interaction is mediated through the heparin binding domain of VN. Digestion of heparan sulfate proteoglycans resulted in a decrease of VN.TAT binding to EC, indicating the involvement of heparin-like structures on the EC surface. Our findings point to an unrecognized mechanism by which VN may act as scavenger in order to enhance the clearance of end products of the clotting system via binding of the ternary VN.TAT complex to the luminal surface of EC.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,W-6350 BAD NAUHEIM,GERMANY	Kerckhoff Clinic; Max Planck Society	DEBOER, HC (corresponding author), UNIV HOSP UTRECHT,DEPT HAEMATOL,BOX 85500,3508 GA UTRECHT,NETHERLANDS.							BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BHAKDI S, 1988, CLIN EXP IMMUNOL, V74, P459; BJORK I, 1982, J BIOL CHEM, V257, P9487; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DESWART CAM, 1984, THROMB HAEMOSTASIS, V52, P66; HAMATI HF, 1989, J CELL BIOL, V108, P2495, DOI 10.1083/jcb.108.6.2495; ILL CR, 1985, J BIOL CHEM, V260, P5610; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KNOLLER S, 1991, EUR J BIOCHEM, V195, P801, DOI 10.1111/j.1432-1033.1991.tb15769.x; KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; MIMURO J, 1989, J BIOL CHEM, V264, P936; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P399; ROSENBERG RD, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)80523-6; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	23	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2264	2268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370815				2022-12-25	WOS:A1992HB53200025
J	SUNG, LA; FOWLER, VM; LAMBERT, K; SUSSMAN, MA; KARR, D; CHIEN, S				SUNG, LA; FOWLER, VM; LAMBERT, K; SUSSMAN, MA; KARR, D; CHIEN, S			MOLECULAR-CLONING AND CHARACTERIZATION OF HUMAN FETAL LIVER TROPOMODULIN - A TROPOMYOSIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE; ALPHA-TROPOMYOSIN; SKELETAL-MUSCLE; IDENTIFICATION; PURIFICATION; SEQUENCE; MYOSIN; ACTIN; CELLS; CDNA	Human erythrocyte tropomodulin is a novel tropomyosin regulatory protein that binds to the end of erythrocyte tropomyosin and blocks head-to-tail association of tropomyosin along actin filaments. It has been proposed to play a role in modulating the association of tropomyosin with the spectrin-actin complex in the erythrocyte membrane skeleton. Immunoscreening of a human fetal liver cDNA expression library in lambda-gt11, followed by 5'-end extension by polymerase chain reaction from the same library, yielded a composite cDNA sequence of 2665 base pairs (bp). It contains a 34-bp 5'-untranslated region, a 1.6-kilobase (kb) 3'-untranslated region, and a complete open reading frame of 1077 bp that encodes a protein of 359 amino acids with a calculated molecular mass of 40.6 kDa and a pI of 4.8. Authenticity of the tropomodulin cDNA was confirmed by a complete sequence match of 49 predicted amino acids with the sequences of three tryptic peptides of the erythrocyte tropomodulin. The sequence has no internal repeats and no significant homology with any known proteins. Secondary structure predictions indicate that tropomodulin may consist of a series of seven or eight short alpha-helical segments and fold into a somewhat compact shape. The tropomyosin binding activity has been mapped to an N-terminal region containing residues 39-138. Nine independent PCR clones, five from a human reticulocyte cDNA library and four from the fetal liver cDNA library, revealed identical N-terminal 103 amino acids, suggesting that the sequence reported here may also be of erythrocyte tropomodulin. Northern analysis of human reticulocyte RNA showed two hybridizing bands of 2.7 and 1.6 kb, indicating that the 2665-bp cDNA sequence reported here was that of the longer transcript.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	SUNG, LA (corresponding author), UNIV CALIF SAN DIEGO, DEPT APPL MECH & ENGN SCI BIOENGN, BSB 5028, MAIL CODE 0643, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL-44147, HL-43026] Funding Source: Medline; NIGMS NIH HHS [GM-34225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043026, R37HL044147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHIEN S, 1990, BIORHEOLOGY, V27, P327; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1985, J CELL BIOL, V100, P47, DOI 10.1083/jcb.100.1.47; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; PARRY DAD, 1975, J MOL BIOL, V98, P519, DOI 10.1016/S0022-2836(75)80084-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; SUNG LA, 1991, FASEB J, V5, pA1625; SUSSMAN MA, 1990, J MOL NEUROSCI, V2, P163, DOI 10.1007/BF02896841; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WINKELMANN JC, 1988, BLOOD, V72, P328; WONG AJ, 1985, J BIOL CHEM, V260, P46; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	32	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2616	2621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370827				2022-12-25	WOS:A1992HB53200079
J	YAMAMOTO, KK; POUSETTE, A; CHOW, P; WILSON, H; ELSHAMI, S; FRENCH, CK				YAMAMOTO, KK; POUSETTE, A; CHOW, P; WILSON, H; ELSHAMI, S; FRENCH, CK			ISOLATION OF A CDNA-ENCODING A HUMAN SERUM MARKER FOR ACUTE-PANCREATITIS - IDENTIFICATION OF PANCREAS-SPECIFIC PROTEIN AS PANCREATIC PROCARBOXYPEPTIDASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE GENE FAMILY; AMINO-ACID SEQUENCE; CELLULAR-DAMAGE; RAT CARBOXYPEPTIDASE; ESCHERICHIA-COLI; ASSAY; DNA; PURIFICATION; POLYMERASE; CLONING	A human pancreas-specific protein (PASP), previously characterized as a serum marker for acute pancreatitis and pancreatic graft rejection, has been identified as pancreatic procarboxypeptidase B (PCPB). cDNAs encoding PASP/PCPB were isolated from a human pancreas cDNA library using a combination of nucleic acid hybridization screening and immunoscreening with antisera raised against native PASP. The deduced amino acid sequence of PASP/PCPB cDNA predicts the translation of a 416-amino acid preproenzyme with a 15-amino acid signal/leader peptide and a 95-amino acid activation peptide. The proenzyme portion of this protein has 76% identity with rat PCPB and 84% identity with bovine carboxypeptidase B. DNA and RNA blot analyses indicate that human PCPB mRNA (1,400 nucleotides) is transcribed from a single locus in the human genome in a tissue-specific fashion. N-terminal sequencing of native PASP and the specific immunoreactivity of bacterially expressed PASP/PCPB with native PASP antibodies confirm the identification of PASP as human pancreatic PCPB.	DIAGNOST PROD CORP,DEPT MOLEC BIOL,5700 W 96TH ST,LOS ANGELES,CA 90045; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; AVILES FX, 1985, BIOCHEM BIOPH RES CO, V130, P97, DOI 10.1016/0006-291X(85)90387-0; BARKIN JS, 1986, POSTGRAD MED, V79, P241, DOI 10.1080/00325481.1986.11699327; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DELK AS, 1985, CLIN CHEM, V31, P1294; FERNSTAD R, 1989, PANCREAS, V4, P44, DOI 10.1097/00006676-198902000-00007; FERNSTAD R, 1989, DIABETES, V38, P55, DOI 10.2337/diab.38.1.S55; FERNSTAD R, 1990, PANCREAS, V5, P42, DOI 10.1097/00006676-199001000-00006; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HONEY NK, 1986, HUM GENET, V72, P27, DOI 10.1007/BF00278813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOOSSA AR, 1984, NEW ENGL J MED, V311, P639, DOI 10.1056/NEJM198409063111005; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; POUSETTE A, 1988, PANCREAS, V3, P642, DOI 10.1097/00006676-198812000-00003; POUSETTE A, 1988, PANCREAS, V3, P421, DOI 10.1097/00006676-198808000-00009; REECK GR, 1972, BIOCHEMISTRY-US, V11, P3947, DOI 10.1021/bi00771a018; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2575	2581						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370825				2022-12-25	WOS:A1992HB53200072
J	NAKATA, K; MOTOMURA, M; NAKABAYASHI, H; IDO, A; TAMAOKI, T				NAKATA, K; MOTOMURA, M; NAKABAYASHI, H; IDO, A; TAMAOKI, T			A POSSIBLE MECHANISM OF INVERSE DEVELOPMENTAL REGULATION OF ALPHA-FETOPROTEIN AND ALBUMIN GENES - STUDIES WITH EPIDERMAL GROWTH-FACTOR AND PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; EXPRESSION; EXTRACT; RNA	Epidermal growth factor (EGF) and 12-O-tetradecanoylphorbol-13-acetate (TPA) synergistically suppress activities of the promoter and enhancer of the human alpha-fetoprotein (AFP) gene in HuH-7 human hepatoma cells as analyzed by transient transfection assays using the chloramphenicol acetyltransferase gene as a reporter. In contrast to the AFP gene, albumin promoter and enhancer activities were not affected by EGF and TPA. Unexpectedly, however, Northern blot analysis revealed that the albumin mRNA level as well as the AFP mRNA level were reduced by treatment with EGF and TPA. We propose that in HuH-7 cells, the AFP enhancer stimulates the albumin promoter as well as the AFP promoter; and consequently, inhibition of the AFP enhancer by EGF and TPA results in reduction of both AFP and albumin mRNA levels. The significance of the involvement of the AFP enhancer in albumin transcription is discussed in relation to the inverse pattern of expression of the AFP and albumin genes in neonatal growth.	UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary								BELANGER L, 1983, ADV ENZYME REGUL, V21, P73, DOI 10.1016/0065-2571(83)90009-2; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; MOOIBROEK MJ, 1988, BIOCHEM CELL BIOL, V66, P557, DOI 10.1139/o88-066; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKABAYASHI H, 1989, J BIOL CHEM, V264, P266; NAKABAYASHI H, 1991, IN PRESS MOL CELL BI; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAO K, 1990, MOL CELL BIOL, V10, P1461, DOI 10.1128/MCB.10.4.1461; NAKAO K, 1991, BIOCHEM BIOPH RES CO, V174, P1294, DOI 10.1016/0006-291X(91)91562-Q; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; URANO Y, 1984, GENE, V32, P255; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WATANABE K, 1987, J BIOL CHEM, V262, P4812	24	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1331	1334						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370467				2022-12-25	WOS:A1992GY96000101
J	ABRAHAMSEN, MS; LI, RS; DIETRICHGOETZ, W; MORRIS, DR				ABRAHAMSEN, MS; LI, RS; DIETRICHGOETZ, W; MORRIS, DR			MULTIPLE DNA ELEMENTS RESPONSIBLE FOR TRANSCRIPTIONAL REGULATION OF THE ORNITHINE DECARBOXYLASE GENE BY PROTEIN KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED LYMPHOCYTES; CYCLIC-AMP; MESSENGER-RNA; PHORBOL ESTER; FACTOR ATF; 5'-UNTRANSLATED REGION; PREINITIATION COMPLEX; SOMATOSTATIN GENE; CATALYTIC SUBUNIT; EUKARYOTIC CELLS	Transcription of the ornithine decarboxylase (ODC) gene is rapidly elevated by activation of protein kinase A (PKA). The additive influence of three cis-acting elements is responsible for this regulation in an adrenal carcinoma cell line. Two sites, CRE2 at -48 base pairs (bp) relative to the start of transcription and CRE3 at +95 bp, are identical to the core motif of the cAMP-responsive element (CRE) of the somatostatin gene and are conserved in the mouse, rat, and human ODC genes. Mutation of CRE2 resulted in a substantial decrease in basal promoter activity, as well as a 5-fold decrease in inducibility of the ODC promoter by PKA. CRE3 did not contribute to the basal activity of the ODC promoter, but mutation of this site resulted in a 2-fold decrease in inducibility by PKA. Deletion of a 45-bp sequence (GC-box) located 5' of CRE2, also resulted in a 2-fold decrease in inducibility of the ODC promoter. DNase I protection revealed the presence of protein binding at CRE2, the TATA box, and the GC-box of the ODC promoter. Mutation of CRE2 resulted in loss of protection of this sequence, as well as the 3' extension of the footprint over the TATA box, without affecting interactions at the GC box. Antibodies to the well characterized CRE-binding protein CREB recognized proteins binding to CRE2, suggesting that binding of CREB, or an antigenically related protein, is important for the activity of CRE2. Additionally, recombinant CREB bound to a DNA probe containing the CRE2 sequence.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011; Li, Runsheng/AFR-9519-2022	Li, Runsheng/0000-0003-1563-1844	NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIDCR NIH HHS [DE08229] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; DAY RN, 1989, J BIOL CHEM, V264, P431; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRENS A, 1990, J BIOL CHEM, V265, P11810; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO K, 1990, J BIOL CHEM, V265, P13036; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MACH M, 1986, J BIOL CHEM, V261, P1697; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MARTON LJ, 1987, INHIBITION POLYAMINE, P70; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; OBRIEN TG, 1976, CANCER RES, V36, P2644; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHIMMER BP, 1977, MOL CELL ENDOCRINOL, V8, P135, DOI 10.1016/0303-7207(77)90025-9; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; UHLER MD, 1986, J BIOL CHEM, V261, P5360; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WHITE MW, 1987, MOL CELL BIOL, V7, P3004, DOI 10.1128/MCB.7.8.3004; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	71	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18866	18873						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356108				2022-12-25	WOS:A1992JN50200093
J	YONEDA, K; HOHL, D; MCBRIDE, OW; WANG, M; CEHRS, KU; IDLER, WW; STEINERT, PM				YONEDA, K; HOHL, D; MCBRIDE, OW; WANG, M; CEHRS, KU; IDLER, WW; STEINERT, PM			THE HUMAN LORICRIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; EPIDERMAL ALPHA-KERATIN; CROSS-LINKED ENVELOPE; HUMAN INVOLUCRIN GENE; CORNIFIED ENVELOPE; CELL-ENVELOPE; THERMUS-AQUATICUS; DNA-POLYMERASE; FILAGGRIN; PROTEIN	Loricrin is the major protein component of the cornified cell envelope of terminally differentiated mammalian epidermal (stratum corneum) cells. Using a specific human cDNA clone, we have isolated and characterized the human loricrin gene. We show that it has a very simple structure of a single intron of 1188 base pairs (bp) in the 5'-untranslated region; there are no introns in coding sequences. By use of rodent-human somatic cell hybrids, followed by in situ hybridization with a biotin-labeled genomic DNA clone, the single-copy gene maps to chromosome location 1q21. Polymerase chain reaction analyses of genomic DNAs from different individuals show that human loricrin consists of two allelic size variants, due to sequence variations in its second glycine loop domain, and these variants segregate in the human population by normal Mendelian mechanisms. Furthermore, there are multiple sequence variants within these two size class alleles due to various deletions of 12 bp (4 amino acids) in the major loop of this glycine loop domain. By use of a specific loricrin antibody, we show by immunogold electron microscopy that loricrin initially appears in the granular layer of human epidermis and forms composite keratohyalin granules with profilaggrin, but localizes to the cell periphery (cell envelope) of fully differentiated stratum corneum cells.	NIAMS,SKIN BIOL LAB,BLDG 10,RM 9N228,BETHESDA,MD 20892; NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Hohl, Daniel M/N-7554-2016					ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; BADEN HP, 1987, J INVEST DERMATOL, V89, P454, DOI 10.1111/1523-1747.ep12460759; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HANIGAN H, 1978, BIOCHIM BIOPHYS ACTA, V522, P589, DOI 10.1016/0005-2744(78)90090-6; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JESSEN H, 1986, J INVEST DERMATOL, V87, P737, DOI 10.1111/1523-1747.ep12456866; KIM IG, 1992, J BIOL CHEM, V267, P7710; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P510; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LOBITZ CJ, 1982, J INVEST DERMATOL, V78, P150, DOI 10.1111/1523-1747.ep12506301; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; Odland G.F, 1991, PHYSL BIOCH MOL BIOL, P3; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; SHVETS YP, 1990, MOL BIOL, V24, P663; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; STEDINERT PM, 1991, INT J BIOL MACROMOL, V13, P130; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; TEZUKA T, 1987, J INVEST DERMATOL, V88, P47, DOI 10.1111/1523-1747.ep12464862; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; YONEDA K, 1991, J INVEST DERMATOL, V96, pA541; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	42	95	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18060	18066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355480				2022-12-25	WOS:A1992JM22300089
J	QUITSCHKE, WW; GOLDGABER, D				QUITSCHKE, WW; GOLDGABER, D			THE AMYLOID BETA-PROTEIN PRECURSOR PROMOTER - A REGION ESSENTIAL FOR TRANSCRIPTIONAL ACTIVITY CONTAINS A NUCLEAR FACTOR BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; MESSENGER-RNA; ALZHEIMERS-DISEASE; DNA-BINDING; TRANSGENIC MICE; ACTIN PROMOTER; FACTOR AP-1; GENE; EXPRESSION; SEQUENCE	A manifestation of Alzheimer's disease is the presence of amyloid depositions in brains of afflicted individuals. A major component of these depositions is the amyloid beta-protein, which is a truncated form of the larger amyloid beta-protein precursor (APP). To investigate the regulation of APP gene expression, the APP promoter and selected deletions were placed 5' to the reporter gene chloramphenicol acetyltransferase. The promoter deletions were transfected into different cell lines that showed variant levels of endogenous APP transcripts. Transient transfection assays showed that 96 base pairs 5' to the transcriptional start site are sufficient for cell type-specific promoter activity. A nuclear factor that binds to this region in a sequence-specific manner was identified by mobility shift electrophoresis, DNase footprinting, and methylation interference. The DNase-protected region covers about 25 base pairs on both strands (position -31 to -55). Mutations within this domain revealed a sequence of 12 base pairs that is crucial for factor binding. This sequence overlaps with the consensus sequences for transcription factors AP-1 and AP-4. However, competition experiments suggest that the nuclear factor that binds to the APP promoter is distinct from both AP-1 and AP-4. Factor binding to the characterized recognition sequence is observed in nuclear extracts originating from human, mouse, and rat cells, suggesting a high degree of conservation.			QUITSCHKE, WW (corresponding author), SUNY STONY BROOK, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA.				NIA NIH HHS [AG09320] Funding Source: Medline; NINDS NIH HHS [NS30994] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009320] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; GABUZDA DH, 1989, MOL CELL BIOL, V9, P2728, DOI 10.1128/MCB.9.6.2728; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Goldgaber DES, 1991, BRAIN RES REV, V16, P89; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P575, DOI 10.1016/0197-4580(91)90089-3; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Maniatis T, 1989, MOL CLONING; MANNING RW, 1988, MOL BRAIN RES, V3, P293, DOI 10.1016/0169-328X(88)90052-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBAKIS NK, 1987, LANCET, V1, P384; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; WIRAK DO, 1991, SCIENCE, V253, P323, DOI 10.1126/science.1857970; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	57	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17362	17368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380960				2022-12-25	WOS:A1992JL05300094
J	HUGHES, CE; CATERSON, B; WHITE, RJ; ROUGHLEY, PJ; MORT, JS				HUGHES, CE; CATERSON, B; WHITE, RJ; ROUGHLEY, PJ; MORT, JS			MONOCLONAL-ANTIBODIES RECOGNIZING PROTEASE-GENERATED NEOEPITOPES FROM CARTILAGE PROTEOGLYCAN DEGRADATION - APPLICATION TO STUDIES OF HUMAN LINK PROTEIN CLEAVAGE BY STROMELYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ARTICULAR-CARTILAGE; BOVINE NASAL CARTILAGE; AGE-RELATED-CHANGES; IDENTIFICATION; HETEROGENEITY; METALLOPROTEINASES; INVOLVEMENT; INSITU	Monoclonal antibodies were raised that specifically recognize the NH2-terminal neoepitope sequence present in link protein cleavage products derived from stromelysin-degraded proteoglycan aggregate. Competitive enzyme-linked immunosorbent assay, using synthetic peptides as inhibitors, showed that one of these antibodies (CH-3) required, for antibody recognition, the free NH2-terminal amino acid isoleucine (residue 17 of the intact protein) in the sequence NH2-IQAENG at the stromelysin cleavage site of link protein 3. Human proteoglycan aggregate was digested with recombinant human stromelysin, bovine chymotrypsin, bovine trypsin, and porcine elastase, and their respective link protein degradation products were tested for immunoreactivity with antibody CH-3. Only stromelysin- and chymotrypsin-generated link protein 3 were recognized by antibody CH-3. Both of these enzymes generate link protein NH2 termini with the sequence 17IQAENG... ; hence these studies indicated that monoclonal antibody CH-3 recognized this neoepitope sequence in only specific proteolytically modified link protein molecules. Since the occurrence of link protein 3 increases with aging, the incidence of CH-3 epitope in proteoglycans isolated from human knee articular cartilage of individuals of different ages was investigated. The prevalence of CH-3 epitope was found to be highest in newborn and adolescent articular cartilage samples. However, little CH-3 epitope was detected in older adult cartilage, although considerably more link protein 3 was present in these samples. These results suggest that additional proteolytic agents are responsible for the increased occurrence of link protein degradation products with aging.	UNIV N CAROLINA, DEPT SURG, DIV ORTHOPED SURG, CHAPEL HILL, NC 27599 USA; MCGILL UNIV, DEPT SURG, MONTREAL H3A 2T5, QUEBEC, CANADA; SHRINERS HOSP CRIPPLED CHILDREN, MONTREAL H3G 1AG, QUEBEC, CANADA	University of North Carolina; University of North Carolina Chapel Hill; McGill University			Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010	Caterson, Bruce/0000-0001-6016-0661; Hughes, Clare/0000-0003-4726-5877	NIAMS NIH HHS [AR32666] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032666] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAKER JR, 1979, J BIOL CHEM, V254, P2387; BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P95, DOI 10.1016/0003-2697(86)90231-9; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; CATERSON B, 1985, J BIOL CHEM, V260, P13348; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; GREGORY JD, 1973, BIOCHEM J, V133, P383, DOI 10.1042/bj1330383; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HERING TM, 1990, J BIOL CHEM, V265, P2375; HUGHES C, 1991, BIOCHEM J, V279, P733, DOI 10.1042/bj2790733; HUI KY, 1983, SCIENCE, V222, P1129, DOI 10.1126/science.6648524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGLEDIC S, 1983, J BIOL CHEM, V258, P4759; LIU J, 1991, J ORTHOPAED RES, V9, P568, DOI 10.1002/jor.1100090413; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; MORT JS, 1983, BIOCHEM J, V214, P269, DOI 10.1042/bj2140269; MORT JS, 1985, BIOCHEM J, V232, P805, DOI 10.1042/bj2320805; MURPHY G, 1990, BIOCHEM SOC T, V18, P812, DOI 10.1042/bst0180812; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NGUYEN Q, 1991, BIOCHEM J, V278, P143, DOI 10.1042/bj2780143; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; ROUGHLEY PJ, 1982, J BIOL CHEM, V257, P1908; SANDY JD, 1991, J BIOL CHEM, V266, P8683; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	28	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16011	16014						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379586				2022-12-25	WOS:A1992JJ45800002
J	LOOMIS, CA; KOLEGA, J; MANABE, M; SUN, TT				LOOMIS, CA; KOLEGA, J; MANABE, M; SUN, TT			CHARACTERIZATION OF A KERATINOCYTE-SPECIFIC EXTRACELLULAR EPITOPE OF DESMOGLEIN - IMPLICATIONS FOR DESMOGLEIN HETEROGENEITY AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; CONSTITUTIVE TRANSMEMBRANE GLYCOPROTEIN; HUMAN EPIDERMAL-KERATINOCYTES; AMINO-ACID-SEQUENCE; POLYACRYLAMIDE GELS; PEMPHIGUS FOLIACEUS; CADHERIN FAMILY; BIOCHEMICAL-IDENTIFICATION; DESMOSOMAL GLYCOPROTEIN	Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established. We describe here the characterization of a new monoclonal antibody, AE23, against an extracellular epitope of desmoglein. Both the AE23 epitope and another epitope, defined by the previously characterized DG3.4 antibody, reside on a 160-kDa human epidermal desmoglein as evidenced by their identical solubility profile, their coexistence in a 130-kDa desmoglein degradative product, their coadsorption by an AE23 immunoaffinity column, and the identical changes in the two antigens' electrophoretic mobility after air oxidation and deglycosylation. The AE23 epitope is resistant to various endoglycosidases, suggesting that sugar moieties are not involved. Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s). However, these two epitopes do not always coexist on the same desmoglein molecule. For example, tissue surveys showed that although the DG3.4 epitope is present in the desmogleins of all epithelial cell types, the AE23 epitope is limited to normal keratinocytes. Moreover, electron microscopic localization data indicate that whereas the DG3.4 epitope is detected in the submembranous plaques of desmosomes, the AE23 epitope is present in the intercellular space of both desmosomal and nondesmosomal areas. These results raise the possibility that there exist several biochemically closely related isoforms of desmoglein, one (AE23+/DG3.4+) restricted to epidermal desmosomes, one (AE23+/DG3.4-) uniformly distributed along the keratinocyte cell surface, and another (AE23-/DG3.4+) present in desmosomes of simple epithelia and basal cells of cultured keratinocytes. The uniform distribution of at least one desmoglein-related antigen in the intercellular space of keratinocytes coupled with the realization that different isoforms of desmogleins form a subfamily of cadherins suggest that desmoglein(s) may play a more general role in keratinocyte adhesion than previously appreciated.	NYU MED CTR, KAPLAN COMPREHENS CANC CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University	LOOMIS, CA (corresponding author), NYU MED CTR, KAPLAN COMPREHENS CANC CTR, DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA.		Kolega, John/J-8386-2016; Sun, Tung-Tien/J-4425-2015	Kolega, John/0000-0001-6933-8681; Sun, Tung-Tien/0000-0002-6841-1063	NEI NIH HHS [EY4722] Funding Source: Medline; NIADDK NIH HHS [AM34511] Funding Source: Medline; NIAMS NIH HHS [AR39749] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034511] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; COHEN SM, 1983, J BIOL CHEM, V258, P243; CONNELL ND, 1983, CELL, V34, P245, DOI 10.1016/0092-8674(83)90155-1; COWIN P, 1984, J CELL SCI, V66, P119; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; Cowin P, 1985, CELL CONTACT, P427; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; GARROD DR, 1986, J CELL SCI, P221, DOI 10.1242/jcs.1986.Supplement_4.14; GODING JW, 1983, MONOCLONAL ANTIBODIE, P188; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; GUIDICE GJ, 1984, J CELL BIOCHEM, V26, P35; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOLEGA J, 1989, DIFFERENTIATION, V42, P54, DOI 10.1111/j.1432-0436.1989.tb00607.x; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; Miggiano V., 1982, RES DISCL, V217, P155; MILLER K, 1987, EMBO J, V6, P885, DOI 10.1002/j.1460-2075.1987.tb04834.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGUIN WM, 1987, CURR TOP DEV BIOL, V22, P97; OGUIN WM, 1989, J CELL BIOL, V109, P2313, DOI 10.1083/jcb.109.5.2313; PASADAR M, 1989, J CELL BIOL, V109, P163; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RUBINSTEIN N, 1987, AM J DERMATOPATH, V96, P510; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P184; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P177; SHEETZ MP, 1979, BIOCHIM BIOPHYS ACTA, V557, P122, DOI 10.1016/0005-2736(79)90095-6; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; SHIDA H, 1982, J CELL BIOCHEM, V20, P113, DOI 10.1002/jcb.240200204; SKERROW CJ, 1974, J CELL BIOL, V63, P524, DOI 10.1083/jcb.63.2.524; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; STANLEY JR, 1986, J INVEST DERMATOL, V87, P197, DOI 10.1111/1523-1747.ep12695334; STANLEY JR, 1986, J IMMUNOL, V136, P1127; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; STERNBERGER LA, 1979, IMMUNOCYTOCHEMISTRY, P122; SUHRBIER A, 1986, J CELL SCI, V81, P223; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WAITE JH, 1976, ANAL BIOCHEM, V70, P279, DOI 10.1016/S0003-2697(76)80070-X; WANG K, 1982, METHOD ENZYMOL, V85, P514; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580	55	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16676	16684						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379602				2022-12-25	WOS:A1992JJ45800104
J	RICHTERCOOK, NJ; HOWARD, KJ; CIRINO, NM; WOHRL, BM; LEGRICE, SFJ				RICHTERCOOK, NJ; HOWARD, KJ; CIRINO, NM; WOHRL, BM; LEGRICE, SFJ			INTERACTION OF TRANSFER RNA(LYS-3) WITH MULTIPLE FORMS OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL CHELATE ADSORBENT; ESCHERICHIA-COLI; TRANSFER-RNA; CROSS-LINKING; EXPRESSION; POLYMERASE; PURIFICATION; HETERODIMER; SUBUNIT; DOMAIN	The interaction of several forms (p51, p66, and p66/p51) of recombinant human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) with a synthetic derivative of its cognate replication primer, tRNA(Lys-3), has been determined by gel-mobility shift analysis. While p66/p51 RT is proficient in tRNA binding, preparations of p66 and p51 display only weak binding at elevated protein:tRNA ratios, despite the former containing both RNA-dependent DNA polymerase and ribonuclease H (RNase H) activity. Gel permeation analysis of purified p66 RT indicate this to be predominantly monomeric, suggesting that dimerization may be a prerequisite for efficient TRNA binding. Prolonged incubation of a mixture of the 66- and 51-kDa polypeptides results in heterodimer reconstitution, restoration of tRNA binding, and recovery of appreciable levels of RNA-dependent DNA polymerase activity. Under the same conditions, both the tRNA binding and RNA-dependent DNA polymerase activities of the 66- and 51-kDa polypeptides are unaffected, suggesting that they remain in the monomeric conformation.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NIAID NIH HHS [AI31147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HOSTOMSKY Z, 1992, IN PRESS J VIROL, V66; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TUKALO MA, 1987, BIOCHEMISTRY-US, V26, P5200, DOI 10.1021/bi00390a045; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	31	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15952	15957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379242				2022-12-25	WOS:A1992JG11300103
J	GRAVES, RJ; FELZENSZWALB, I; LAVAL, J; OCONNOR, TR				GRAVES, RJ; FELZENSZWALB, I; LAVAL, J; OCONNOR, TR			EXCISION OF 5'-TERMINAL DEOXYRIBOSE PHOSPHATE FROM DAMAGED DNA IS CATALYZED BY THE FPG PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC-APYRIMIDINIC SITES; ENDONUCLEASE-III; BETA-ELIMINATION; PHYSICAL ASSOCIATION; OXIDATIVE DAMAGE; ABASIC SITES; AP SITES; GLYCOSYLASE; REPAIR; BACTERIOPHAGE-T4	Homogeneous Fpg protein of Escherichia coli has DNA glycosylase activity which excises some purine bases with damaged imidazole rings, and an activity excising deoxyribose (dR) from DNA at abasic (AP) sites leaving a gap bordered by 5'- and 3'-phosphoryl groups. In addition to these two reported activities, we show that the Fpg protein also catalyzes the excision of 5'-terminal deoxyribose phosphate (dRp) from DNA, which is the principal product formed by the incision of AP endonucleases at abasic sites. Moreover, the rate of the Fpg protein catalysis for the 2,6-diamino-4-hydroxy-5-formamidopyrimidine-DNA glycosylase activity is slower than the activities excising dR from abasic sites and dRp from abasic sites preincised by endonucleases. The product released by the Fpg protein in the excision of 5'-terminal dRp from an abasic site preincised by an AP endonuclease is a single base-free unsaturated dRp, suggesting that the excision results from beta-elimination. The release of 5'-terminal dRp by crude extracts of E. coli from wild type and fpg- mutant strains shows that the Fpg protein is one of the major EDTA-resistant activities catalyzing this reaction.	INST GUSTAVE ROUSSY,CNRS,URA 147,INSERM,U140,REPARAT LESIONS RADIO & CHIMIOINDUITES,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			Felzenszwalb, Israel/AAH-4915-2020	Felzenszwalb, Israel/0000-0003-1677-197X; O'Connor, Timothy/0000-0001-5848-3592				BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BOITEUX S, 1989, CARCINOGENESIS, V10, P1905, DOI 10.1093/carcin/10.10.1905; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREIMER L, 1980, NUCLEIC ACIDS RES, V8, P6199, DOI 10.1093/nar/8.24.6199; BRICTEUXGREGOIRE S, 1989, NUCLEIC ACIDS RES, V17, P6269, DOI 10.1093/nar/17.15.6269; CHETSANGA CJ, 1982, CANCER RES, V42, P2616; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CLEMENTS JE, 1978, J BIOL CHEM, V253, P2990; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; CUNNINGHAM RP, 1990, MUTAT RES, V236, P173; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; MANOHARAN M, 1989, J AM CHEM SOC, V110, P1620; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P119; MICHAELS ML, 1991, MUTAT RES, V19, P3629; MOSBAUGH DW, 1982, J BIOL CHEM, V257, P575; MULLER E, 1990, NUCLEIC ACIDS RES, V18, P5969, DOI 10.1093/nar/18.20.5969; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	41	139	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14429	14435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378443				2022-12-25	WOS:A1992JD32500097
J	HERBST, R; SHEARMAN, MS; OBERMEIER, A; SCHLESSINGER, J; ULLRICH, A				HERBST, R; SHEARMAN, MS; OBERMEIER, A; SCHLESSINGER, J; ULLRICH, A			DIFFERENTIAL-EFFECTS OF W-MUTATIONS ON P145(C-KIT) TYROSINE KINASE-ACTIVITY AND SUBSTRATE INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; STEM-CELL FACTOR; GTPASE-ACTIVATING PROTEIN; SITE-SPECIFIC MUTAGENESIS; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION	The c-kit gene, mapped to the dominant white spotting (W) locus of the mouse (Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P., and Bernstein, A. (1988) Nature 335, 88-89; Geissler, E. N., Ryan, M. A., and Housman, D. E. (1988) Cell 55, 185-192), encodes a receptor tyrosine kinase, p145c-kit. Germline mutations at the W locus lead to loss of function alterations in p145c-kit, and result in mice with developmental defects of varying severity in the melanocytic, hematopoietic stem cell, and primordial germ cell lineages. To investigate in more detail the effect of W mutations on p145c-kit signaling, three mutations, W42, W(v), and W41, that confer severe, intermediate, and mild phenotypic characteristics, respectively, were introduced into the human p145c-kit tyrosine kinase domain. These mutations attenuated the intrinsic tyrosine kinase activity of the receptor to different degrees. In addition, they had differential effects on the interaction of the p145c-kit substrates, phospholipase C-gamma, GTPase-activating protein, and the receptor-binding subunit of phosphatidylinositol 3'-kinase, p85. Notably, the W(v) mutation, while retaining significant receptor tyrosine kinase activity, was unable to bind phospholipase C(gamma) and GTPase-activating protein, but could still associate with p85. These results suggest that the location of W mutations may be an important determinant of the specificity of substrate association and phosphorylation, and may explain, at least in part, the cell type-specific defects associated with certain W alleles.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EGHTEDARZADEH MK, 1986, NUCLEIC ACIDS RES, V14, P5115, DOI 10.1093/nar/14.12.5115; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1988, BLOOD, V72, P463; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HERBST R, 1991, J BIOL CHEM, V266, P19908; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Little CC, 1937, P NATL ACAD SCI USA, V23, P535, DOI 10.1073/pnas.23.10.535; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	76	31	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13210	13216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377679				2022-12-25	WOS:A1992JB74600021
J	PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ				PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ			EXPRESSION OF THE C-ERBB-3 PROTEIN IN NORMAL HUMAN ADULT AND FETAL TISSUES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; ANTIBODIES; LOCALIZATION; CELLS	c-erbB-3 is a member of the type I family of growth factor receptors which includes the epidermal growth factor (EGF) receptor and c-erhB-2. Whereas for EGF receptor and c-erbB-2 the expression patterns in normal tissues are well documented, there is currently little information available about the sites of c-erhB-3 expression. In order to examine the normal tissue distribution of c-erbB-3, polyclonal antibodies were raised against eight synthetic peptides corresponding to distinct sites on the intracellular domain of c-erbB-3. Of these, three produced antibodies which reacted with a 160-kDa protein on immunoblots of human embryonal cells (293 cells) transfected with the cDNA encoding c-erbB-3, and two of the three antibodies immunoprecipitated a protein of similar size from the same cells. These antibodies were used for immunochemical staining of a wide variety of normal human adult and fetal tissues employing formalin-fixed, paraffin-embedded material. The c-erbB-3 protein was identified in cells of the gastrointestinal, reproductive, respiratory and urinary tracts as well as the skin, endocrine and nervous system in a distribution distinctly different from that observed for EGF receptor and c-erbB-2. The level of expression of the mRNA for c-erbB-3 was also examined in extracts of a selection of fetal tissues. In general the sites of mRNA and protein expression were concordant.	HAMMERSMITH HOSP,MOLEC PATHOL LAB,ICRF,ONCOL GRP,LONDON W12 0HS,ENGLAND; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA; HAMMERSMITH HOSP,RPMS,GASTROENTEROL UNIT,LONDON W12 0HS,ENGLAND	Imperial College London; Bristol-Myers Squibb; Imperial College London	PRIGENT, SA (corresponding author), HAMMERSMITH HOSP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND.		PLOWMAN, Greg D/E-2012-2011	Selden, Angela/0000-0003-2648-443X				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMJANOV I, 1986, LAB INVEST, V55, P588; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GULLICK WJ, 1986, CANCER RES, V46, P285; GULLICK WJ, 1986, EUR J BIOCHEM, V158, P245, DOI 10.1111/j.1432-1033.1986.tb09744.x; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULLICK WJ, 1989, MOL BIOL CANCER, P38; GUSTERSON B, 1984, CELL BIOL INT REP, V8, P649, DOI 10.1016/0309-1651(84)90045-6; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRESS MF, 1990, ONCOGENE, V5, P953; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	21	166	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377811				2022-12-25	WOS:A1992HZ97100004
J	SCHOLZEN, T; ARNDT, E				SCHOLZEN, T; ARNDT, E			THE ALPHA-OPERON EQUIVALENT GENOME REGION IN THE EXTREME HALOPHILIC ARCHAEBACTERIUM HALOARCULA (HALOBACTERIUM) MARISMORTUI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; ENCODING RIBOSOMAL-PROTEINS; NUCLEOTIDE-SEQUENCE; RNA-POLYMERASE; ESCHERICHIA-COLI; MESSENGER-RNA; BACILLUS-STEAROTHERMOPHILUS; GENE-CLUSTER; SUBUNIT; EVOLUTION	The genome region of the extreme halophilic archaebacterium Haloarcula marismortui equivalent to the alpha-operon of Escherichia coli has been characterized. In H. marismortui, the alpha-operon was found to be located immediately upstream from the S9 gene cluster. The gene order in the halobacterial-alpha-operon, given according to the gene products, is tRNA(Ser), HmaS13, HmaS4, HmaS11, and HmaRp-alpha. Compared to the corresponding operon from E. coli, the halobacterial gene organization differs in (i) the presence of a gene for tRNA(Ser) (GCU), (ii) the reversed order of the genes for the ribosomal proteins HmaS11 and HmaS4, and (iii) the absence of the gene coding for the ribosomal protein L17. The primary structure of HmaRp-alpha shows high similarity to a subunit of eukaryotic RNA polymerase II (YeaRpB3, HsaRpB33), whereas the similarity to the eubacterial-alpha-subunit of RNA polymerase is only weak.	MAX PLANCK INST MOLEC GENET,ABT WITTMANN,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society				Scholzen, Thomas/0000-0002-5556-9144				AIBA H, 1981, J BIOL CHEM, V256, P1905; ARNDT E, 1988, J BIOL CHEM, V263, P16063; ARNDT E, 1986, FEBS LETT, V194, P227, DOI 10.1016/0014-5793(86)80090-4; ARNDT E, 1990, FEBS LETT, V267, P193, DOI 10.1016/0014-5793(90)80923-7; ARNDT E, 1990, J BIOL CHEM, V265, P3034; ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; ARNDT E, 1991, BIOCHIMIE, V73, P657, DOI 10.1016/0300-9084(91)90045-3; BEDWELL D, 1985, NUCLEIC ACIDS RES, V13, P3891, DOI 10.1093/nar/13.11.3891; BERGMANN U, 1990, BIOCHIM BIOPHYS ACTA, V1050, P56, DOI 10.1016/0167-4781(90)90141-N; BOYLAN SA, 1989, J BACTERIOL, V171, P2553, DOI 10.1128/jb.171.5.2553-2562.1989; BROCKMOLLER J, 1988, BIOCHEMISTRY-US, V27, P3372, DOI 10.1021/bi00409a038; CHAN YL, 1991, BIOCHEM BIOPH RES CO, V178, P1212, DOI 10.1016/0006-291X(91)91022-5; DECKMAN IC, 1985, BIOCHEMISTRY-US, V24, P7860, DOI 10.1021/bi00348a002; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; HATAKEYAMA T, 1988, EUR J BIOCHEM, V172, P703, DOI 10.1111/j.1432-1033.1988.tb13945.x; HUDSON L, 1981, NATURE, V294, P422, DOI 10.1038/294422a0; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; KIMURA M, 1988, FEBS LETT, V240, P15, DOI 10.1016/0014-5793(88)80332-6; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LAKE JA, 1990, RIBOSOME, P579; LINDEMANN H, 1976, FEBS LETT, V71, P251, DOI 10.1016/0014-5793(76)80944-1; MANIAITS T, 1982, MOL CLONING LABORATO; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; ORCUTT BC, 1982, 82050108710 NAT BIOC; OREN A, 1990, INT J SYST BACTERIOL, V40, P209, DOI 10.1099/00207713-40-2-209; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; PATI UK, 1990, J BIOL CHEM, V265, P8400; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REINBOLT J, 1973, FEBS LETT, V36, P250, DOI 10.1016/0014-5793(73)80383-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SCHWARTZ RM, 1978, ATLAS PROTEIN SEQUEN, V3, P353; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; STEEL LF, 1987, NUCLEIC ACIDS RES, V15, P10285, DOI 10.1093/nar/15.24.10285; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAGUCHI M, 1982, ZBL BAKT MIK HYG I C, V3, P200, DOI 10.1016/S0721-9571(82)80033-1; YONATH A, 1990, RIBOSOME, P134	42	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12123	12130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376318				2022-12-25	WOS:A1992HY94700072
J	MENDEZ, R; MORENO, A; DEHARO, C				MENDEZ, R; MORENO, A; DEHARO, C			REGULATION OF HEME-CONTROLLED EUKARYOTIC POLYPEPTIDE-CHAIN INITIATION FACTOR-II ALPHA-SUBUNIT KINASE OF RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STABILIZED TRANSLATIONAL INHIBITOR; EIF-2-ALPHA KINASE; GLOBIN SYNTHESIS; PEPTIDE; GLUTATHIONE; ACTIVATION; DISULFIDE; COMPONENT; SPECTRIN	We have obtained highly purified preparations of the heme-controlled eukaryotic initiation factor 2-alpha-subunit (eIF-2-alpha) kinase (HCI) from rabbit reticulocyte lysates containing five different polypeptides. One of these is a 87-kDa (p87) phosphopeptide which appears to show an autokinase activity. The controlled digestion with trypsin of HCI preparations leads to the suggestion that phosphorylation of p87 is not needed for kinase activity and, furthermore, that another 89-kDa polypeptide could be the kinase catalytic subunit. In agreement with this, monoclonal antibodies directed against p87 do not interfere with eIF-2-alpha kinase activity. Moreover, the anti-p87 antibodies and those directed against the mammalian 90-kDa heat shock protein recognize the same p87 polypeptide from rabbit reticulocyte lysates. Upon incubation of the HCI preparation with hemin (5-10-mu-M), the eIF-2-alpha kinase is converted into an inactive form and appears to become associated with related peptides forming high molecular weight complexes which can be reversibly activated by 2-mercaptoethanol. The maintenance of the integrity of the porphyrin ring is absolutely required for kinase inactivation and although the presence of metal ion is not essential, the iron and cobalt metalloporphyrins are more effective than protoporphyrin IX. The formation of the inactive form of HCI by hemin is prevented by either N-ethylmaleimide, monoclonal antibodies directed against p87, or phosphorylation of p87. The data strongly suggest that hemin regulates eIF-2-alpha kinase activity by promoting formation of the inactive dimer HCI.p87 via disulfide bonds and direct binding of hemin. A model of HCI regulation is discussed.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)				Mendez, Raul/0000-0002-1952-6905				ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DAWSON RMC, 1969, DATA BIOCH RES, P293; DEHARO C, 1983, P NATL ACAD SCI-BIOL, V80, P6843; GAITERO F, 1989, FEBS LETT, V257, P297, DOI 10.1016/0014-5793(89)81556-X; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P642, DOI 10.1016/0005-2787(78)90149-1; HRONIS TS, 1986, J BIOL CHEM, V261, P6234; HRONIS TS, 1981, J BIOL CHEM, V256, P1409; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; JACKSON RJ, 1982, NATO ADV STUDY I S A, V41, P363; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; KUDLICKI W, 1985, P NATL ACAD SCI USA, V82, P5332, DOI 10.1073/pnas.82.16.5332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTS RL, 1989, J BIOL CHEM, V264, P15542; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PALOMO C, 1985, ARCH BIOCHEM BIOPHYS, V239, P497, DOI 10.1016/0003-9861(85)90718-0; PELAEZ F, 1989, FEBS LETT, V250, P523, DOI 10.1016/0014-5793(89)80789-6; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SANZ A, 1985, J VIROL, V54, P199, DOI 10.1128/JVI.54.1.199-206.1985; SCHENDEL PF, 1973, J BIOL CHEM, V248, P8319; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654	33	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11500	11507						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350784				2022-12-25	WOS:A1992HX16900086
J	SLAPAK, CA; LECERF, JM; DANIEL, JC; LEVY, SB				SLAPAK, CA; LECERF, JM; DANIEL, JC; LEVY, SB			ENERGY-DEPENDENT ACCUMULATION OF DAUNORUBICIN INTO SUBCELLULAR COMPARTMENTS OF HUMAN LEUKEMIA-CELLS AND CYTOPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ASCITES TUMOR-CELLS; MURINE ERYTHROLEUKEMIA-CELLS; ANTHRACYCLINE-RESISTANT; DOXORUBICIN TRANSPORT; DRUG-RESISTANCE; FLOW-CYTOMETRY; LIVING CELLS; PROTON PUMP; ADRIAMYCIN	Anthracycline accumulation was evaluated by flow cytometry or radiolabeled drug assays in cells and cytoplasts (enucleated cells) prepared from parental and multidrug-resistant human K562 leukemia cells. Treatment with energy inhibitors, such as dinitrophenol (DNP) or sodium azide/deoxyglucose, led to a marked decrease in daunorubicin accumulation in parental cells and cytoplasts. Another ionophore, monensin, also caused a significant decrease in daunorubicin accumulation; however, ATPase inhibitors ouabain, vanadate, and N-ethylmaleimide had little or no effect. The lysosomotropic agents chloroquine and methylamine caused a moderate decrease in anthracycline accumulation. Fluorescence microscopy showed that the DNP-sensitive daunorubicin uptake occurred in a nonnuclear subcellular compartment. Studies using increasing daunorubicin concentrations demonstrated fluorescence quenching that occurred in the nonnuclear, DNP-sensitive compartment. The effect of inhibitors on the accumulation of rhodamine 123 and acridine orange strongly implicated lysosomes as the principal compartment of this inhibitable daunorubicin accumulation. Cytoplasts from P-glycoprotein containing multidrug-resistant K562 cells demonstrated a verapamil-reversible, decreased daunorubicin accumulation that was observed in resistant whole cells. Verapamil pretreatment of cytoplasts from resistant cells revealed the subcellular DNP-sensitive uptake present in parental cytoplasts. These studies demonstrate that cytoplasts are an effective means to study drug transport in mammalian cells without nuclear drug binding. Parental K562 cells and cytoplasts exhibit an energy-dependent accumulation of daunorubicin into cytoplasmic organelles that is also present in resistant cells and cytoplasts when P-glycoprotein mediated efflux is inhibited.	TUFTS UNIV,SCH MED,136 HARRISON AVE,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02111	Tufts University; Tufts Medical Center					NCI NIH HHS [F32-CA08774, CA-01613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA S, 1984, J CELL PHYSIOL, V120, P271, DOI 10.1002/jcp.1041200303; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHERVINSKY DS, 1976, J MED, V7, P63; DALMARK M, 1981, SCAND J CLIN LAB INV, V41, P633, DOI 10.3109/00365518109090508; DALMARK M, 1981, J GEN PHYSIOL, V78, P349, DOI 10.1085/jgp.78.4.349; DALMARK M, 1983, SCAND J CLIN LAB INV, V43, P241; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; Darzynkiewicz Z., 1990, FLOW CYTOMETRY SORTI, V2nd, P291; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; DECORTI G, 1989, CANCER RES, V49, P1921; EKSBORG S, 1978, J PHARM SCI, V67, P782, DOI 10.1002/jps.2600670613; FORGAC M, 1984, J BIOL CHEM, V259, P8101; GIGLI M, 1989, CANCER RES, V49, P560; GOSALVEZ M, 1974, EUR J CANCER, V10, P567, DOI 10.1016/0014-2964(74)90044-9; HARIO M, 1988, P NATL ACAD SCI USA, V85, P3580; HEYTLER PG, 1962, BIOCHEM BIOPH RES CO, V7, P272, DOI 10.1016/0006-291X(62)90189-4; HILL BT, 1976, EUR J CANCER, V12, P541, DOI 10.1016/0014-2964(76)90160-2; HINDENBURG AA, 1989, CANCER RES, V49, P4607; INABA M, 1979, CANCER RES, V39, P2200; INABA M, 1978, BIOCHEM PHARMACOL, V27, P2123, DOI 10.1016/0006-2952(78)90284-8; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KLOHS WB, 1989, MOL PHARMACOL, V34, P180; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MIKKELSEN RB, 1977, J MOL MED, V2, P33; MORIYAMA Y, 1982, J BIOCHEM-TOKYO, V92, P1333, DOI 10.1093/oxfordjournals.jbchem.a134053; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; POOLE DT, 1972, BIOCHIM BIOPHYS ACTA, V266, P463, DOI 10.1016/0005-2736(72)90102-2; Reed P W, 1979, Methods Enzymol, V55, P435; SEHESTED M, 1987, JNCI-J NATL CANCER I, V78, P171, DOI 10.1093/jnci/78.1.171; SIEGFRIED JM, 1985, BIOCHEM PHARMACOL, V34, P593, DOI 10.1016/0006-2952(85)90251-5; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SKOVSGAARD T, 1978, BIOCHEM PHARMACOL, V27, P1221, DOI 10.1016/0006-2952(78)90455-0; SLAPAK CA, 1990, CANCER RES, V50, P7895; SPETH PAJ, 1985, CYTOMETRY, V6, P143, DOI 10.1002/cyto.990060210; STEINBERG TH, 1984, J INFECT DIS, V149, P397, DOI 10.1093/infdis/149.3.397; SUNDMANENGBERG B, 1990, CANCER CHEMOTH PHARM, V25, P252, DOI 10.1007/BF00684881; TAPIERO H, 1982, CYTOMETRY, V2, P298; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VOLLOCH V, 1987, J CELL BIOL, V105, P137, DOI 10.1083/jcb.105.1.137; WIGLER MH, 1975, BIOCHEM BIOPH RES CO, V63, P669, DOI 10.1016/S0006-291X(75)80436-0; WISEMAN A, 1985, SOMAT CELL MOLEC GEN, V11, P541, DOI 10.1007/BF01534720; WONG W, 1985, BLOOD, V66, P999; YANOVICH S, 1983, CANCER RES, V43, P4167; YANOVICH S, 1989, CANCER RES, V49, P4499; YATSCOFF RW, 1981, SOMAT CELL GENET, V7, P1, DOI 10.1007/BF01544744	48	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10638	10644						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350280				2022-12-25	WOS:A1992HV09000065
J	LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ				LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ			CHARACTERIZATION OF THE 5' UNTRANSLATED REGION OF THE HUMAN C-FGR GENE AND IDENTIFICATION OF THE MAJOR MYELOMONOCYTIC C-FGR PROMOTER	ONCOGENE			English	Article							NF-KAPPA-B; PROTO-ONCOGENE; MESSENGER-RNA; CELL-LINES; EXPRESSION; PROTOONCOGENE; VIRUS; DIFFERENTIATION; TRANSCRIPTS; ACTIVATION	In this study, we have characterized the 5' region of the human c-fgr proto-oncogene and identified the major myelomonocytic c-fgr promoter. Seven distinct 5' untranslated exons were identified and localized to a region extending 13 kb upstream from the first coding exon. Two major promoters were identified, one utilized exclusively in Epstein-Barr virus (EBV)-infected B-lymphocyte cell lines, and the other functional only in myelomonocytic cells. Differential promoter utilization and alternative splicing of the 5' untranslated exons give rise to at least six distinct c-fgr mRNA species that differ only in their 5' untranslated regions. Two major mRNAs were identified, c-fgr A and c-fgr 4; these two mRNAs were detected exclusively in EBV-infected B-lymphocyte cell lines and myelomonocytic cells respectively. We have previously demonstrated that c-fgr is transcriptionally activated in U937 cells treated with either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or cycloheximide (CHX). We now show that a DNA fragment extending from -772 to +97 (with respect to the transcription initiation site upstream from exon M4) is responsive to TPA but not CHX treatment in U937 cells. These results suggest that TPA and CHX induce c-fgr mRNA accumulation by different mechanisms.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,ST LOUIS,MO 63110; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038682, R37DK038682, R56DK038682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49712] Funding Source: Medline; NIDDK NIH HHS [DK 38682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICKELL PM, 1988, BRIT J CANCER, V58, P704, DOI 10.1038/bjc.1988.294; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; INOUE K, 1987, ONCOGENE, V1, P301; INOUE K, 1990, MOL CELL BIOL, V10, P1789, DOI 10.1128/MCB.10.4.1789; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERKINS SL, 1991, IN PRESS J LEUKOCYTE; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; ULRICH MJ, 1990, BLOOD, V75, P990; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	31	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					877	884						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373875				2022-12-25	WOS:A1992HP64200006
J	BUREAU, MH; KHRESTCHATISKY, M; HEEREN, MA; ZAMBROWICZ, EB; KIM, H; GRISAR, TM; COLOMBINI, M; TOBIN, AJ; OLSEN, RW				BUREAU, MH; KHRESTCHATISKY, M; HEEREN, MA; ZAMBROWICZ, EB; KIM, H; GRISAR, TM; COLOMBINI, M; TOBIN, AJ; OLSEN, RW			ISOLATION AND CLONING OF A VOLTAGE-DEPENDENT ANION CHANNEL-LIKE MR-36,000 POLYPEPTIDE FROM MAMMALIAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; OUTER MITOCHONDRIAL-MEMBRANE; BENZODIAZEPINE-RECEPTOR; POLYACRYLAMIDE GELS; HIPPOCAMPAL-NEURONS; SUBUNIT COMPOSITION; RAT-BRAIN; PROTEIN; PURIFICATION; SEQUENCE	A polypeptide of M(r) 36,000 (36 kDa) was isolated from detergent-solubilized membrane fractions of mammalian brain on a benzodiazepine affinity column utilized for the purification of the gamma-aminobutyric acid/benzodiazepine receptor protein, followed by preparative gel electrophoresis. Partial protein sequence for two fragments of the 36-kDa polypeptide allowed the isolation of cDNA clones from a rat hippocampal library. An open reading frame coding a sequence of 295 amino acid residues containing the two probe peptide sequences with minor differences, and a putative N-terminal signal peptide of 25 residues was found. Hydropathy index revealed no regions of alpha-helix suitable for membrane spanning, but several areas of alternating hydrophilic and hydrophobic residues consistent with beta-strands. The sequence of this brain protein was 24% identical to that of a yeast mitochondrial protein, the voltage-dependent anion channel (VDAC), and over 70% identical with the VDAC from human B lympocytes. The gamma-aminobutyric acid type A (GABA(A)) receptor/36-kDa preparation purified on benzodiazepine affinity column has channel-forming activity in lipid bilayer membranes that is virtually identical to VDAC isolated from mitochondria of various sources, indicating that the 36-kDa protein is a new member of the VDAC family of proteins. An antiserum raised against the purified 36-kDa polypeptide was able to precipitate [H-3]muscimol binding activity, indicating a tight association with the GABA(A) receptor protein in vitro and copurification on the benzodiazepine affinity column due to this association. Further studies are needed to determine whether such an association occurs in vivo.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV LIEGE,BIOCHIM GEN & COMPAREE LAB,B-4020 LIEGE,BELGIUM; UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Liege; University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022256, R01NS028772, R01NS022071] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28772, NS22256, NS22071] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BENKE D, 1991, J BIOL CHEM, V266, P4478; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1989, J BIOENERG BIOMEMBR, V21, P471, DOI 10.1007/BF00762519; BUREAU M, 1990, MOL PHARMACOL, V37, P497; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1985, BIOCHIM BIOPHYS ACTA, V813, P230; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KIRKNESS EF, 1988, J NEUROCHEM, V50, P356, DOI 10.1111/j.1471-4159.1988.tb02920.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MY, 1991, AM J PHYSIOL, V260, pC371, DOI 10.1152/ajpcell.1991.260.2.C371; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PARK D, 1991, J NEUROCHEM, V56, P1972, DOI 10.1111/j.1471-4159.1991.tb03455.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1980, NATURE, V286, P285, DOI 10.1038/286285a0; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	42	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8679	8684						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373732				2022-12-25	WOS:A1992HQ18500107
J	CHAN, HC; KAETZEL, MA; NELSON, DJ; HAZARIKA, P; DEDMAN, JR				CHAN, HC; KAETZEL, MA; NELSON, DJ; HAZARIKA, P; DEDMAN, JR			ANTIBODY AGAINST A CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR-DERIVED SYNTHETIC PEPTIDE INHIBITS ANION CURRENTS IN HUMAN COLONIC CELL-LINE T84	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNELS; AIRWAY EPITHELIUM; IDENTIFICATION; GENE; EXPRESSION; TRANSPORT; CAMP	The cystic fibrosis (CF) phenotype is characterized by a regulatory defect in Cl- permeability in epithelia. A gene (250,000 base pairs) that is associated with this autosomal genetic disorder has been identified. To determine the cellular function of the recently cloned gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), we have produced antibody against a synthetic peptide deduced from the CFTR cDNA sequence corresponding to positions 505-511. This site includes phenylalanine 508, the deletion of which is the most commonly expressed mutation in CF. We sought to determine whether the anti-CFTR505-511 peptide antibody could modulate the activation of the volume-sensitive, Ca2+-dependent, as well as the cAMP-dependent Cl- conductances present in the Cl--secreting human colonic T84 cell line. Affinity-purified anti-CFTR505-511 antibody was introduced into the cytoplasm of individual T84 cells and its function studied using the whole-cell patch-clamp technique. Although cAMP-dependent Cl- current activation was inhibited in cells perfused with the anti-CFTR505-511 peptide antibody, Ca2+-dependent anion current activation remained unaffected. Chloride current activation, which accompanies cellular swelling, was partially attenuated in anti-CFTR505-511 antibody-loaded cells as compared with control cells perfused with either saline or irrelevant antibody. These results further support a role for CFTR in anion transport in epithelial cells and suggest its possible involvement in a number of anion transport pathways in chloride secretory epithelia.	UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77225	University of Texas System	CHAN, HC (corresponding author), UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637, USA.		Chan, Hsiao Chang/E-1507-2016		NIDDK NIH HHS [R01 DK41740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Fanconi G UE, 1936, WIEN MED WOCHENSCHR, V86, P753; GOODFELLOW P, 1989, CYSTIC FIBROSIS, P1; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRINSTEIN S, 1983, AM J PHYSIOL, V245, pC160, DOI 10.1152/ajpcell.1983.245.1.C160; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HAZARIKA P, 1988, LIFE SCI, V42, P2525, DOI 10.1016/0024-3205(88)90352-9; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	29	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8411	8416						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373728				2022-12-25	WOS:A1992HQ18500071
J	BEBENEK, K; ROBERTS, JD; KUNKEL, TA				BEBENEK, K; ROBERTS, JD; KUNKEL, TA			THE EFFECTS OF DNTP POOL IMBALANCES ON FRAMESHIFT FIDELITY DURING DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; TRIPHOSPHATE POOLS; MAMMALIAN-CELLS; POLYMERASE-I; MUTAGENESIS; MUTATION; BACTERIOPHAGE-T4; MISALIGNMENT; SPECIFICITY; COMPLEX	The use of unequal concentrations of the four deoxynucleoside triphosphates (dNTPs) in DNA polymerization reactions alters base substitution error rates in a predictable way. Less is known about the effects of substrate imbalances on base addition and deletion error rates. Thus, we examined pool bias effects on frameshift fidelity during DNA synthesis catalyzed by replicative DNA polymerases. Imbalanced pools altered the frameshift fidelity of the human immunodeficiency virus type-1 reverse transcriptase. Both mutagenic and antimutagenic effects were observed for minus-one, plus-one, and minus-two nucleotide errors, in a highly sequence-specific manner. Most of this specificity can be rationalized by either of two models. One involves frameshifts initiated by pool bias-induced nucleotide misinsertion, and the other involves pool bias-initiated template-primer slippage. Several examples of complex mutations were also recovered more than once in small mutant collections. These contained closely spaced single-base substitution and minus-one base frameshift changes. The two changes occurred at a frequency much higher than predicted if they were generated independently. This suggests that when the polymerase makes one mistake, the probability that it will make a second mistake within the next few incorporations increases significantly. Perturbation of dNTP pools also affected the frameshift fidelity of the replicative yeast DNA polymerase-alpha. In reactions containing a low concentration of one dNTP, the error rate increased for one-nucleotide deletions at homopolymeric template nucleotides complementary to the dNTP whose concentration was low. We extended this approach to determine the frameshift fidelity of simian virus 40 origin-dependent semiconservative replication of double-stranded DNA in extracts of human cells. In reactions performed with an equal concentration of all four dNTPs, replication was highly accurate for minus-one-nucleotide errors. However, when the concentration of one dNTP was decreased, the replication error rate increased at complementary, homopolymeric template positions. This response provides an approach for describing frameshift accuracy during replication of the leading and lagging strands.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				ARECCO A, 1988, MUTAT RES, V200, P165, DOI 10.1016/0027-5107(88)90079-6; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; COHEN MB, 1981, J BIOL CHEM, V256, P8713; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P362; KUNZ BA, 1982, ENVIRON MUTAGEN, V4, P695; KUNZ BA, 1988, MUTAT RES, V200, P133, DOI 10.1016/0027-5107(88)90076-0; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; MEUTH M, 1984, MUTAT RES, V126, P107, DOI 10.1016/0027-5107(84)90051-4; PHEAR G, 1987, P NATL ACAD SCI USA, V84, P4450, DOI 10.1073/pnas.84.13.4450; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SARGENT RG, 1989, MOL GEN GENET, V217, P13; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SCHAAPER RM, 1982, MOL GEN GENET, V185, P404, DOI 10.1007/BF00334131; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1990, ANTIMUTAGENESIS ANTI, V2, P289	30	132	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3589	3596						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371272				2022-12-25	WOS:A1992HE60700010
J	FAKHRAI, H; MAINES, MD				FAKHRAI, H; MAINES, MD			EXPRESSION AND CHARACTERIZATION OF A CDNA FOR RAT-KIDNEY BILIVERDIN REDUCTASE - EVIDENCE SUGGESTING THE LIVER AND KIDNEY ENZYMES ARE THE SAME TRANSCRIPT PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE; MESSENGER-RNAS; SEQUENCE DATA; FORMS; VARIANTS; ACID; PURIFICATION; BROMOBENZENE; PATTERN; BRAIN	Biliverdin reductase is a unique dual cofactor- and PH-dependent enzyme that converts biliverdin to bilirubin and displays extensive inter-organ pI and molecular weight microheterogeneity. Presently we have explored the molecular basis for these properties. The amino acid composition and the sequences of NH2 termini plus five tryptic fragments of purified rat liver and kidney enzymes were obtained. A 62-nucleotide DNA probe was designed and in combination with antibody was used to screen a rat kidney cDNA library. A cDNA sequence of 1108 base pairs (bp) containing an 885-bp open reading frame was generated. The cloned cDNA probe detected a single mRNA of approximately 1500 bp in liver and kidney. The open reading frame encodes a 295 amino acid protein. Methionine and aspartic acid residues at positions 1 and 2 of the deduced protein are removed during processing. The deduced amino acid composition of the mature protein closely matched that of the purified rat liver and kidney enzymes. All liver peptides were found in the deduced amino acid sequence of kidney enzyme and the NH2 termini of both enzymes were identical. The expressed protein co-migrated with purified reductase and was recognized by antiserum to the enzyme. The expressed reductase displayed two distinct pH optima using a different cofactor at each pH: NADH at the lower pH 6.7-6.9 range and NADPH at pH 8.5-8.7. The findings suggest that the liver and kidney enzymes are the products of the same transcript(s) and that their microheterogeneity may reflect tissue-specific post-translational modifications.	UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester					NIEHS NIH HHS [ES04066, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, P30ES001247] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; CASCONE O, 1989, EUR J BIOCHEM, V179, P123, DOI 10.1111/j.1432-1033.1989.tb14529.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRYDMAN J, 1990, BIOCHIM BIOPHYS ACTA, V1040, P119, DOI 10.1016/0167-4838(90)90155-9; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P617, DOI 10.1016/0003-9861(89)90477-3; HUANG TJ, 1990, MOL PHARMACOL, V37, P25; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P114; MAINES MD, 1990, MOL PHARMACOL, V38, P481; MAINES MD, 1986, J BIOL CHEM, V261, P411; Maniatis T., 1982, MOL CLONING; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIGNEY EM, 1988, BIOCHEM J, V255, P431, DOI 10.1042/bj2550431; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPES R, 1982, PROTEIN PURIFICATION, P21; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; SUN Y, 1990, J BIOL CHEM, V265, P8212; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	29	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4023	4029						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371282				2022-12-25	WOS:A1992HE60700072
J	WALTER, EI; RATNOFF, WD; LONG, KE; KAZURA, JW; MEDOF, ME				WALTER, EI; RATNOFF, WD; LONG, KE; KAZURA, JW; MEDOF, ME			EFFECT OF GLYCOINOSITOLPHOSPHOLIPID ANCHOR LIPID GROUPS ON FUNCTIONAL-PROPERTIES OF DECAY-ACCELERATING FACTOR PROTEIN IN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPID MEMBRANE ANCHOR; FACTOR DAF; C-3 CONVERTASES; GLYCOSYL-PHOSPHATIDYLINOSITOL; LATERAL DIFFUSION; SURFACE PROTEINS; HUMAN-SERUM; COMPLEMENT	The inositol ring in the glycoinositolphospholipid (GPI) anchor of human decay-accelerating factor (DAF) is unmodified in nucleated cells, whereas it is fatty acid acylated in erythrocytes (E(hu)). To assess the effect of this and of the glycerol sn-2-associated acyl substituent on the abilities of DAF to cell membrane incorporate and function, 1) endogenous (physiologically anchored) DAF proteins bearing three- and two-"footed" GPI anchors were purified from E(hu) and HeLa cells and 2) synthetic DAF variants bearing alternative one-"footed" anchors (retaining either the sn-1 glycerol- or inositol-associated lipid) were prepared by alkaline hydroxylamine treatment and phosphatidylinositol-specific phospholipase D digestion of E(hu) DAF, respectively. The different DAF species were added to antibody-sensitized sheep erythrocytes (E(sh)A) and their abilities to insert into the plasma membranes of the cells and control subsequent complement activation on their surfaces were compared. DAF proteins bearing all four GPI anchor structures adhered to the E(sh) hemolytic intermediates and inhibited expression of C3 convertase (C4b2a BAR) activity. However, mixing of DAF-treated E(sh)A with untreated E(sh)AC142 and stripping of cell-associated DAF proteins with vesicles showed that only the physiologically anchored proteins remained stably associated with the lipid bilayer and functioned intrinsically. Both three- and two-"footed" E(hu) and HeLa DAF proteins exhibited comparable ability to incorporate and function in the intermediates as well as to accumulate to levels 1000-fold higher/cell in Schistosoma mansoni schistosomula. These findings indicate that 1) an intact inositolphospholipid-containing GPI anchor is necessary for stable membrane integration and intrinsic function, 2) endogenous GPI anchors (with either unsubstituted and acylated inositol) incorporate and function with comparable efficiency, and 3) the transfer of either endogenous DAF form can account for the previously described circumvented uptake of human C3b by blood stage schistosomula.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University	WALTER, EI (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106, USA.				NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK3818] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCH AS, 1986, J EXP MED, V163, P221, DOI 10.1084/jem.163.1.221; BOUMA SR, 1977, J BIOL CHEM, V252, P6759; COOK SL, 1980, BIOCHEMISTRY-US, V19, P4601, DOI 10.1021/bi00561a010; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JOINER KA, 1988, J BIOL CHEM, V263, P11327; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; KINOSHITA T, 1986, J IMMUNOL, V136, P3390; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MOLD C, 1990, J IMMUNOL, V145, P3836; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; RAMALHO-PINTO F J, 1987, Memorias do Instituto Oswaldo Cruz, V82, P213, DOI 10.1590/S0074-02761987000800037; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; RATNOFF WD, 1990, BLOOD S1, V76, P389; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SMITH JD, 1983, PHYSL TREMATODES, P229; THOMAS J, 1987, BIOPHYS J, V51, P522; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; WALTER EI, 1990, J IMMUNOL, V144, P1030; ZALMAN LS, 1987, J EXP MED, V166, P947, DOI 10.1084/jem.166.4.947	41	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1245	1252						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370460				2022-12-25	WOS:A1992GY96000088
J	REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R				REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R			THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR IS REQUIRED FOR THE PROLIFERATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							MYELOID LEUKEMIC-CELLS; HUMAN-BREAST-CANCER; FACTOR-I RECEPTORS; HUMAN-LYMPHOCYTES; NUCLEAR ANTIGEN; C-MYC; EXPRESSION; DIFFERENTIATION; BINDING; CYCLE	We have investigated the role of the insulin-like growth factor one (IGF1) receptor and its relationship to the proto-oncogene c-myb in the growth of two types of hemopoietic cells: mitogen-stimulated human peripheral blood mononuclear cells and a human promyelocytic cell line (HL-60). Using the antisense strategy and the reverse transcriptase polymerase chain reaction (RT-PCR), we show that expression of the IGF1 receptor is required for the entry into S phase of both stimulated lymphocytes and HL-60 cells. The inhibition of DNA synthesis by antisense oligomers to the IGF1 receptor RNA is accompanied by an inhibition of the expression of the mRNA for a DNA synthesis gene, proliferating cell nuclear antigen (PCNA), the co-factor of DNA polymerase delta. Inhibition of c-myb expression results in a decrease in IGF1 receptor mRNA levels; on the other hand, inhibition of IGF1 receptor expression has no effect on c-myb mRNA levels. A tentative temporal relationship between these three genes (c-myb, IGF1 receptor, PCNA) is proposed.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,BLUEMLE LIFE SCI BLGD,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042383] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM 42383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BASERGA R, IN PRESS CELL BIOL B; BASERGA R, 1992, IN PRESS ANN NY ACAD; BRAVO R, 1987, NATURE, V326, P545; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEMMONS DR, 1981, TISSUE GROWTH FACTOR, P161; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CRAIG RW, 1984, CANCER RES, V44, P442; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLDRING MB, 1991, EUKARYOTIC GENE EXPR, V1, P301; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GROSSO LE, 1985, CANCER RES, V45, P847; HARTMANN W, 1988, LEUKEMIA, V2, P241; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; LEE PDK, 1986, J CLIN ENDOCR METAB, V62, P28, DOI 10.1210/jcem-62-1-28; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MIGLIACCIO G, 1990, EXP HEMATOL, V18, P1049; PEKONEN F, 1988, CANCER RES, V48, P1353; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; PEYRAT JP, 1988, CANCER RES, V48, P6429; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REED JC, 1986, P NATL ACAD SCI USA, V84, P3892; REISS K, 1991, CANCER RES, V51, P5997; SELL C, 1992, IN PRESS J CELL PHYS; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VENTURELLI D, 1990, CANCER RES, V50, P7371; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	46	99	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2243	2248						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359494				2022-12-25	WOS:A1992JW66500016
J	SILVERSTEIN, RL; BAIRD, M; LO, SK; YESNER, LM				SILVERSTEIN, RL; BAIRD, M; LO, SK; YESNER, LM			SENSE AND ANTISENSE CDNA TRANSFECTION OF CD36 (GLYCOPROTEIN-IV) IN MELANOMA-CELLS - ROLE OF CD36 AS A THROMBOSPONDIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; ENDOTHELIAL-CELLS; COMPLEX-FORMATION; TISSUE ACTIVATOR; HUMAN-MONOCYTES; BINDING	Thrombospondin (TSP) is a multifunctional matrix and platelet glycoprotein that interacts with cell surfaces and may play a role in mediating cell adhesion, platelet aggregation, platelet-monocyte interactions, cell proliferation, angiogenesis, tumor metastasis, and protease generation. To clarify and confirm the function of CD36 (glycoprotein IV) as a TSP receptor, we now describe a transfected cell model using human melanoma cells genetically manipulated by sense or antisense cDNA transfection to express either high or near zero levels of CD36. Surface expression was confirmed by flow cytometry with monoclonal anti-CD36 IgG and quantified by measuring radiolabeled antibody binding. Bowes melanoma cells, which in their wild type did not express CD36 and did not bind radiolabeled TSP, when transfected with the sense construct bound TSP in a 1:1 stoichiometric ratio with CD36 expression. Conversely, C32 melanoma cells, which in their wild type expressed high levels of CD36 and bound radiolabeled TSP at a 1:1 stoichiometric ratio, did not express CD36 and did not bind TSP when transfected with an antisense construct. In addition, transfected Bowes cells and wild type C32 cells, unlike wild type Bowes cells, adhered to activated platelets in a TSP-dependent manner. These data, i.e. the gain of function with sense cDNA transfection and loss of function with antisense transfection, strongly support the TSP receptor function of CD36. The distribution of this protein in vascular cells and tissues and observations that it may participate in signal transduction events suggest that TSP-CD36 interactions may play a role in mediating some of the pathophysiological processes associated with TSP.	CORNELL UNIV, MED CTR, COLL MED, SPECIALIZED CTR THROMBOSIS RES, NEW YORK, NY 10021 USA	Cornell University	SILVERSTEIN, RL (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, 1300 YORK AVE, RM C606, NEW YORK, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042540, P50HL018828, P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL42540, P50 HL18828, P01 HL46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BALE MD, 1985, J BIOL CHEM, V260, P7502; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERK GI, 1989, BLOOD, V70, P346; CATIMEL B, 1991, COLLOQ INSE, V206, P41; CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P54; DIXIT VM, 1984, J BIOL CHEM, V259, P100; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SUN X, 1991, J CLIN INVEST, V87, P171, DOI 10.1172/JCI114967; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TUSZYNSKI GP, 1991, J CLIN INVEST, V87, P1387, DOI 10.1172/JCI115144; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; YAMAMOTO N, 1990, BLOOD, V76, P1698	51	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16607	16612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379600				2022-12-25	WOS:A1992JJ45800095
J	HOTCHIN, NA; WATT, FM				HOTCHIN, NA; WATT, FM			TRANSCRIPTIONAL AND POSTTRANSLATIONAL REGULATION OF BETA-1 INTEGRIN EXPRESSION DURING KERATINOCYTE TERMINAL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN FIBRONECTIN RECEPTOR; ROUS-SARCOMA VIRUS; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; CELL-ADHESION; PROTEIN; BIOSYNTHESIS; INVOLUCRIN; COLLAGEN	During suspension-induced terminal differentiation of human epidermal keratinocytes, the alpha-5-beta-1 integrin is down-regulated in two stages: first, the ability of the receptor to bind fibronectin is reduced; later, the receptor is lost from the cell surface, and the level of the subunit mRNAs declines. We have begun to examine the mechanisms that regulate these events. Pulse-chase experiments showed that when keratinocytes were placed in suspension to induce terminal differentiation maturation of the beta-1 subunit and its associated alpha-subunits was prevented. The inhibition of maturation was at the stage of N-linked glycosylation in the Golgi, because the immature integrin subunits were sensitive to endoglycosidase H digestion and the inhibition could be mimicked in adherent cells by treatment with 1-deoxymannojirimycin. In 1-deoxymannojirimycin-treated adherent keratinocytes, immature integrin subunits reached the cell surface; however, in keratinocytes induced to differentiate in suspension, no beta-1-integrin precursors were detected on the cell surface. Thus commitment to terminal differentiation results in a block both in integrin glycosylation and transport to the cell surface; down-regulation of receptor function must therefore involve modulation of pre-existing receptor on the cell surface. Although fibronectin or rabbit antiserum to alpha-5-beta-1 can inhibit suspension-induced terminal differentiation they did not overcome the inhibition of glycosylation. Nuclear run-on assays showed that transcription of the alpha-5 and beta-1 genes was switched off during suspension-induced terminal differentiation, and treatment of adherent keratinocytes with actinomycin D suggested that the half-lives of the alpha-5 and beta-1 mRNAs were similar in adherent and suspended cells. Thus, loss of alpha-5-beta-1 from the cell surface reflects both inhibition of transcription of the subunit genes and inhibition of maturation and intracellular transport of newly synthesized subunits.			HOTCHIN, NA (corresponding author), IMPERIAL CANC RES FUND,KERATINOCYTE LAB,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154; Hotchin, Neil/0000-0002-1844-7607				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARGRAVES WS, 1986, J BIOL CHEM, V261, P2922; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DESTROOPER B, 1991, EUR J BIOCHEM, V199, P25; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HEINO J, 1989, J BIOL CHEM, V264, P380; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIGNATELLI M, 1990, P NATL ACAD SCI USA, V87, P1541, DOI 10.1073/pnas.87.4.1541; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STANLEY JR, 1980, J INVEST DERMATOL, V74, P54, DOI 10.1111/1523-1747.ep12514618; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SYMINGTON BE, 1990, J BIOL CHEM, V265, P14069; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAPLEY P, 1989, ONCOGENE, V4, P325; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TODA K, 1987, J INVEST DERMATOL, V88, P412, DOI 10.1111/1523-1747.ep12469745; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1988, BIOCHEM SOC T, V16, P666, DOI 10.1042/bst0160666; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	52	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14852	14858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378840				2022-12-25	WOS:A1992JF08800054
J	NEEPER, M; SCHMIDT, AM; BRETT, J; YAN, SD; WANG, F; PAN, YCE; ELLISTON, K; STERN, D; SHAW, A				NEEPER, M; SCHMIDT, AM; BRETT, J; YAN, SD; WANG, F; PAN, YCE; ELLISTON, K; STERN, D; SHAW, A			CLONING AND EXPRESSION OF A CELL-SURFACE RECEPTOR FOR ADVANCED GLYCOSYLATION END-PRODUCTS OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; SUPERFAMILY; CONTAINS; BINDING; DOMAINS; TISSUE; GENE	Advanced glycosylation end products of proteins (AGEs) are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. A approximately 35-kDa polypeptide with a unique NH2-terminal sequence has been isolated from bovine lung and found to be present on the surface of endothelial cells where it mediates the binding of AGEs (receptor for advanced glycosylation end product or RAGE). Using-an oligonucleotide probe-based on the amino-terminal sequence of RAGE, an apparently full-length cDNA of 1.5 kilobases was isolated from a bovine lung cDNA library. This cDNA encoded a 394 amino acid mature protein comprised of the following putative domains: an extracellular domain of 332 amino acids, a single hydrophobic membrane spanning domain of 19 amino acids, and a carboxyl-terminal domain of 3 amino acids. A partial clone encoding the human counterpart of RAGE, isolated from a human lung library, was found to be approximately 90% homologous to the bovine molecule. Based on computer analysis of the amino acid sequence of RAGE and comparison with databases, RAGE is a new member of the immunoglobulin superfamily of cell surface molecules and shares significant homology with MUC 18, NCAM, and the cytoplasmic domain of CD20. Expression of the RAGE cDNA in 293 cells allowed them to bind I-125-AGE-albumin in a saturable and dose-dependent manner (K(d) approximately 100 nM), blocked by antibody to RAGE. Western blots of 293 cells transfected with RAGE cDNA probed with anti-RAGE IgG demonstrated expression of immunoreactive protein compared to its absence in mock-transfected cells. These results suggest that RAGE functions as a cell surface receptor for AGEs, which could potentially mediate cellular effects of this class of glycosylated proteins.	MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC BIOL, BLDG 16-100, SUMNEYTOWN PIKE, W POINT, PA 19486 USA; MERCK SHARP & DOHME LTD, DEPT BIOL DATA, RAHWAY, NJ 07065 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, NUTLEY, NJ 07110 USA	Merck & Company; Merck & Company; Columbia University; Roche Holding				Elliston, Keith/0000-0002-9110-9233	NHLBI NIH HHS [HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BRETT J, 1988, J CELL BIOL, V106, P240; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; COZZOLINO FM, 1990, CIRCULATION S, V82, P142; DAUGHERTY BL, 1991, NUCLEIC ACIDS RES, V19, P2471, DOI 10.1093/nar/19.9.2471; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN J, 1991, BIOCHEMISTRY-US, V30, P1505; DYER DG, 1991, J BIOL CHEM, V266, P11654; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FUCHS R, 1990, NUCLEIC ACIDS RES, V18, P4319, DOI 10.1093/nar/18.15.4319; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; Maniatis T., 1982, MOL CLONING; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1989, J BIOL CHEM, V264, P21597; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WAUTIER JL, 1991, BLOOD S, V78, P341; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	33	1233	1326	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14998	15004						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378843				2022-12-25	WOS:A1992JF08800074
J	HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK				HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK			DETECTION OF HETEROZYGOUS MUTATIONS IN THE RB1 GENE IN RETINOBLASTOMA PATIENTS USING SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS AND POLYMERASE CHAIN-REACTION SEQUENCING	ONCOGENE			English	Article							BASE-PAIR SUBSTITUTIONS; SUSCEPTIBILITY GENE; POINT MUTATIONS; DNA FRAGMENTS; EXPRESSION; GERMLINE	Several families segregating the autosomal dominant form of the hereditary retinoblastoma predisposition gene have been analysed for the causative mutation. We have used the single-strand conformation polymorphism (SSCP) technique to screen for mutations, exon by exon, in the RBI gene in affected patients from these families. The SSCP technique has proved a rapid and simple technique which relies on the sequence-dependent migration of single-stranded DNA in a non-denaturing polyacrylamide gel. Oligonucleotide primers flanking all 27 exons and the promoter region of the RB1 gene are reported here. The polymerase chain reaction (PCR)amplified products range in size from 212 to 625 bp and include a flanking intron sequence which allows detection of mutations in these regions. The sensitivity of SSCP is optimal when DNA fragments are approximately 200 bp long. Consequently, restriction enzyme sites for each amplified region were identified, reducing the size of the PCR products analysed to less than 250 bp. Bands with aberrant migration patterns were observed on SSCP gels in the lymphocyte DNA from two patients with bilateral, familial retinoblastoma. Sequence analysis of these DNA fragments revealed the causative mutations. These consisted of a 1-bp insertion of a T in the coding strand of exon 20 and a G --> A mutation in the coding strand of exon 14. This approach has proved to be a powerful method for the rapid detection of germline mutations in the RB1 gene, a programme which can be extended to individuals with new mutations.	INST CHILD HLTH,DEPT HAEMATOL & ONCOL,ICRF,ONCOL GRP,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Onadim, Zerrin/AAX-6490-2021	Onadim, Zerrin/0000-0002-8594-9586; Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GANGULY A, 1990, NUCLEIC ACIDS RES, V18, P3933, DOI 10.1093/nar/18.13.3933; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INNES MA, 1990, PCR PROTOCOLS GUIDE, P54; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; ONADIM Z, 1991, J MED GENET, V28, P312, DOI 10.1136/jmg.28.5.312; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOGEL W, 1979, HUM GENET, V51, P1; WARTELL RM, 1990, NUCLEIC ACIDS RES, V18, P2699, DOI 10.1093/nar/18.9.2699; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS JF, 1989, BIOTECHNIQUES, V7, P283; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	31	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1445	1451						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352398				2022-12-25	WOS:A1992HZ97100026
J	HILLGARTNER, FB; CHEN, W; GOODRIDGE, AG				HILLGARTNER, FB; CHEN, W; GOODRIDGE, AG			OVEREXPRESSION OF THE ALPHA-THYROID HORMONE RECEPTOR IN AVIAN CELL-LINES - EFFECTS ON EXPRESSION OF THE MALIC ENZYME GENE ARE SELECTIVE AND CELL-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; V-ERBA ONCOGENE; TISSUE-SPECIFIC EXPRESSION; ACID SYNTHASE GENE; C-ERBA; RESPONSE ELEMENT; ERYTHROBLASTOSIS VIRUS; RETROVIRAL VECTORS; NUCLEAR RECEPTORS; LIPOGENIC ENZYMES	The role of the alpha-thyroid hormone receptor (TR-alpha) in regulation of transcription of the gene for chicken malic enzyme was analyzed in fibroblast cell lines normally unresponsive to triiodothyronine (T3). The gene for this transcription factor was introduced stably and overexpressed using a replication-competent retroviral vector. In chick embryo fibroblasts (CEF), overexpression of TR-alpha decreased malic enzyme activity by 90% in the absence of T3. Addition of T3 almost completely restored malic enzyme activity to the level of similarly treated control CEF infected with virus lacking TR-alpha. These TR-alpha-induced changes in malic enzyme activity were mediated by alterations in transcription of the malic enzyme gene. Similar results were obtained when transcriptional activity of TR-alpha was analyzed using a transient co-transfection system. Thus, the unliganded TR-alpha is a transcriptional repressor of the malic enzyme gene; binding of T3 to the receptor abolishes this repression. In contrast, stable overexpression of TR-alpha in QT6 cells had no effect on malic enzyme expression in the absence or presence of T3. Nuclear T3 binding was equally high in CEF and QT6 cells overexpressing TR-alpha. These findings suggest that cell-specific factors control the ability of TR-alpha to regulate the malic enzyme gene. Overexpression of TR-alpha in CEF had no effect on the expression of fatty acid synthase and acetyl-CoA carboxylase, lipogenic enzymes that are stimulated by T3 in hepatocytes in culture. Thus, gene-specific factors also may control the transcriptional activity of TR-alpha.			HILLGARTNER, FB (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, F32DK008097] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 21954] Funding Source: Medline; NIDDK NIH HHS [DK 08097, DK 25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BACK DW, 1986, J BIOL CHEM, V261, P2555; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISCHER PWF, 1978, ARCH BIOCHEM BIOPHYS, V190, P334; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLYNIAS MJ, 1984, BIOCHEMISTRY-US, V23, P3454, DOI 10.1021/bi00310a011; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GOODRIDGE AG, 1989, J NUTR, V119, P299, DOI 10.1093/jn/119.2.299; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MA XJ, 1990, J BIOL CHEM, V265, P18435; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MILSTED A, 1987, DNA-J MOLEC CELL BIO, V6, P213, DOI 10.1089/dna.1987.6.213; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; ROBINSON HL, 1976, J VIROL, V18, P856, DOI 10.1128/JVI.18.3.856-866.1976; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1976, P NATL ACAD SCI USA, V73, P3877, DOI 10.1073/pnas.73.11.3877; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; TAKAI T, 1988, J BIOL CHEM, V263, P2651; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WISE EM, 1964, P NATL ACAD SCI USA, V52, P1255, DOI 10.1073/pnas.52.5.1255; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	52	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12299	12306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351057				2022-12-25	WOS:A1992HY94700096
J	MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS				MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS			CLONING AND CHARACTERIZATION OF A THERMOLABILE V-SRC GENE FOR USE IN REVERSIBLE TRANSFORMATION OF MAMMALIAN-CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN KINASE-C; 3T3 CELLS; GROWTH; DIFFERENTIATION; FIBROBLASTS; EXPRESSION; PP60V-SRC; COMMUNICATION; POLYMERASE	The use of temperature-sensitive (ts) src mutants for studies of cell transformation and differentiation has been limited by the availability of cloned ts-src genes that are inactivated at temperatures compatible with growth of mammalian celts. In this report, we describe the cloning and characterization of the tsLA90src gene, which displays tight thermal sensitivity at 39.5-degrees-C. Nucleotide sequence comparison of tsLA90 and wild-type src genes from the Schmidt-Ruppin subgroup A and D strains of Rous sarcoma virus (RSV) revealed four amino acid differences in tsLA90src. Substitution of one of these residues (Lys-280) from tsLA90src with its wild-type homolog (Glu-280) caused a reversion to a wild-type src phenotype. The cloned tsLA90 gene, designated tsUP1, was introduced into avian and mammalian retroviral vectors. Chicken embryo fibroblasts and immortalized mouse 3T3 cells infected with these viral vectors displayed a temperature-dependent transformed phenotype as assessed by cell morphology, secretion of plasminogen activator, transcriptional activation of the primary response genes, Egr-1 and TIS 10, and stimulation of tyrosine phosphorylation. In addition, chicken myoblasts (infected with RSVtsUP1) showed a temperature-dependent differentiation into myotubes. Thus, this cloned src gene should be ideally suited for inducing reversible transformation and differentiation of mammalian cells in culture.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104; CUNY HUNTER COLL,DEPT BIOL SCI,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021	Howard Hughes Medical Institute; University of Pennsylvania; City University of New York (CUNY) System; Hunter College (CUNY)					NCI NIH HHS [CA46677, CA27951, CA08900-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027951, R01CA046677, R29CA046677, R37CA027951, F32CA008900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; GIOTTA GJ, 1980, BRAIN RES, V202, P445, DOI 10.1016/0006-8993(80)90154-7; GOLDBERG AR, 1974, CELL, V2, P95, DOI 10.1016/0092-8674(74)90097-X; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN JW, 1990, ONCOGENE, V5, P467; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUTO M, 1977, P NATL ACAD SCI USA, V74, P4173, DOI 10.1073/pnas.74.10.4173; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OSSWOSKI L, 1973, J EXP MED, V138, P1056; PANET R, 1985, J BIOL CHEM, V260, P5752; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; REDDY S, 1990, J VIROL, V64, P3545, DOI 10.1128/JVI.64.7.3545-3550.1990; ROSE B, 1986, J MEMBRANE BIOL, V94, P129, DOI 10.1007/BF01871193; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508	36	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1207	1214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375718				2022-12-25	WOS:A1992HU64200019
J	LANGLAND, JO; JACOBS, BL				LANGLAND, JO; JACOBS, BL			CYTOSOLIC DOUBLE-STRANDED RNA-DEPENDENT PROTEIN-KINASE IS LIKELY A DIMER OF PARTIALLY PHOSPHORYLATED MR = 66,000 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; INTERFERON ACTION; SYNTHESIS INITIATION; GENE-EXPRESSION; BETA-INTERFERON; VACCINIA VIRUS; EARLY STAGE; MECHANISM; PURIFICATION; FIBROBLASTS	The work described in this report suggests the existence of two biochemically distinguishable forms of the interferon-inducible, double-stranded RNA-dependent protein kinase. Kinase isolated from the cytosolic fraction (S-100) and the ribosome salt wash fraction of interferon-treated cells differed in their chromatographic properties. S-100 kinase eluted from a gel filtration column with M(r) = 140,000-160,000 and was predominantly anionic in nature, whereas ribosomal kinase eluted with M(r) = 66,000 and was predominantly cationic in nature. Purified preparations of S-100 kinase contained the M(r) = 66,000 subunit, P1, as the only polypeptide present in stoichiometric amounts, and thus the S-100 kinase appears to be a dimer of P1 subunits. Dimerization of the S-100 kinase was dependent on the phosphorylation state of the enzyme. Kinase isolated from S-100 was partially phosphorylated. Dephosphorylation of the S-100 kinase by treatment with alkaline phosphatase resulted in a monomeric form of the enzyme with biochemical characteristics similar to that of the ribosome salt wash kinase.	ARIZONA STATE UNIV,DEPT MICROBIOL,TEMPE,AZ 85287; ARIZONA STATE UNIV,BIOCHEM & MOLEC BIOL PROGRAM,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe					NCI NIH HHS [CA 48654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048654, R29CA048654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY MJ, 1985, J BIOL CHEM, V260, P1240; CHU NM, 1989, J HISTOCHEM CYTOCHEM, V37, P257, DOI 10.1177/37.2.2536057; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAS HK, 1981, J BIOL CHEM, V256, P6491; FINTER NB, 1973, INTERFERONS INTERFER, V2; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GUPTA SL, 1981, VIROLOGY, V111, P331, DOI 10.1016/0042-6822(81)90337-8; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JACOBS BL, 1988, J INTERFERON RES, V8, P821, DOI 10.1089/jir.1988.8.821; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KIMCHI A, 1979, J BIOL CHEM, V254, P9846; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LASKY SR, 1982, J BIOL CHEM, V257, P1087; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO NG, 1983, J BIOL CHEM, V258, P5232; MOSSNER E, 1980, H-S Z PHYSIOL CHEM, V361, P543, DOI 10.1515/bchm2.1980.361.1.543; OCHOA S, 1979, ANNU REV BIOCHEM, V48, P549, DOI 10.1146/annurev.bi.48.070179.003001; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; REVEL M, 1978, ANNU REV BIOCHEM, V47, P1079, DOI 10.1146/annurev.bi.47.070178.005243; RICE AP, 1984, J VIROL, V50, P229, DOI 10.1128/JVI.50.1.229-236.1984; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; Samuel C E, 1981, Methods Enzymol, V79, P168; SAMUEL CE, 1977, VIROLOGY, V83, P56, DOI 10.1016/0042-6822(77)90210-0; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1982, J BIOL CHEM, V257, P1791; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SEN GC, 1978, J BIOL CHEM, V253, P5915; Stewart W, 1979, INTERFERON SYSTEM; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WHITAKERDOWLING P, 1983, VIROLOGY, V131, P128, DOI 10.1016/0042-6822(83)90539-1; WONG ST, 1982, J BIOL CHEM, V257, P5231; ZILBERSTEIN A, 1976, FEBS LETT, V68, P119, DOI 10.1016/0014-5793(76)80418-8; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	40	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10729	10736						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375230				2022-12-25	WOS:A1992HV09000079
J	GRABAREK, J; RAYCHOWDHURY, M; RAVID, K; KENT, KC; NEWMAN, PJ; WARE, JA				GRABAREK, J; RAYCHOWDHURY, M; RAVID, K; KENT, KC; NEWMAN, PJ; WARE, JA			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF PROTEIN-KINASE-C ISOZYMES IN PLATELETS AND HEL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; IONIZED CALCIUM-CONCENTRATION; MEMBRANE GLYCOPROTEIN-IIB; PHORBOL ESTER; CA-2+ MOBILIZATION; BLOOD-PLATELETS; RAT-BRAIN; LINE HEL; EXPRESSION; AEQUORIN	To determine if selective activation of individual isozymes of protein kinase C (PKC) might explain the apparently divergent effects of PKC stimulation on platelets, we purified and characterized the isozymes from both platelets and human erythroleukemia (HEL) cells, a cell line that has many features of megakaryocytes. Two peaks of platelet PKC activity were resolved by hydroxylapatite chromatography; immunoblot analysis revealed that these two peaks represented the alpha and beta-isozymes of PKC. In contrast, HEL cells produced only a single peak that contained the beta-isozyme. None of the other PKC isozymes were detected in these fractions. The cytosol of platelets and HEL cells, however, were both found to contain the PKC-delta isozyme. Northern hybridization analyses and mRNA amplification by the polymerase chain reaction demonstrated the presence of mRNA encoding the alpha, beta, and delta-PKC isozymes in platelets, but only the beta and delta-isozymes in HEL cells. Phorbol myristate acetate (PMA), thrombin, or an endoperoxide analog induced the phosphorylation of the 47-kDa substrate of PKC (pleckstrin) found in platelets and HEL cells; preincubation of either HEL cell or platelets with PMA reduced the intracellular Ca2+ rise induced by thrombin. Thus, although both HEL cells and platelets contain PKC-beta and the recently described PKC-delta isozymes, the widely distributed a isozyme of PKC is absent in HEL cells; however, isozymes other than PKC-alpha are sufficient for some PMA-mediated functions that are similar to those seen in stimulated platelets.	BETH ISRAEL HOSP, DIV CARDIOVASC,HARVARD THORNDIKE LAB,GZ 409, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT ANAT & CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Versiti Blood Center of Wisconsin; Medical College of Wisconsin				Ravid, Katya/0000-0002-9918-3024	NHLBI NIH HHS [HL38820, HL02271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002271, R01HL038820, R29HL038820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRAY PF, 1987, J CLIN INVEST, V80, P1812, DOI 10.1172/JCI113277; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; CROUCH MF, 1989, J BIOL CHEM, V264, P584; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GAILANI D, 1990, BRIT J HAEMATOL, V74, P192, DOI 10.1111/j.1365-2141.1990.tb02565.x; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; JOHNSON PC, 1985, J BIOL CHEM, V260, P2069; KIEFFER N, 1986, J BIOL CHEM, V261, P5854; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LYMAN S, 1990, BLOOD, V75, P2343; LYONS RM, 1975, J CLIN INVEST, V56, P924, DOI 10.1172/JCI108172; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAYEUX PR, 1989, J PHARMACOL EXP THER, V250, P923; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISHIZUKA Y, 1988, CANCER, V10, P1892; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PONCZ M, 1987, BLOOD, V69, P219; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; ROSA JP, 1989, J BIOL CHEM, V264, P12596; SAITOH M, 1989, BLOOD, V74, P2001; SIESS W, 1988, BIOCHEM J, V255, P309; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V122, P158, DOI 10.1016/0006-291X(84)90453-4; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202; WARE JA, 1989, AM J PHYSIOL, V256, pC35, DOI 10.1152/ajpcell.1989.256.1.C35; WARE JA, 1985, BIOCHEM BIOPH RES CO, V133, P98, DOI 10.1016/0006-291X(85)91846-7; WARE JA, 1986, J CLIN INVEST, V77, P878, DOI 10.1172/JCI112385; WILLIAMS AG, 1990, BLOOD, V76, P721; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	56	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10011	10017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374394				2022-12-25	WOS:A1992HT96500085
J	YANG, BZ; DING, JH; ENGHILD, JJ; BAO, Y; CHEN, YT				YANG, BZ; DING, JH; ENGHILD, JJ; BAO, Y; CHEN, YT			MOLECULAR-CLONING AND NUCLEOTIDE-SEQUENCE OF CDNA-ENCODING HUMAN MUSCLE GLYCOGEN DEBRANCHING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE COMPLEX; RABBIT SKELETAL-MUSCLE; ALPHA-GLUCOSIDASE; GENE; HYBRIDIZATION; PURIFICATION; HOMOLOGY; CHAIN	cDNA comprising the entire length of the human muscle glycogen debranching enzyme was cloned and its nucleotide sequence determined. The debrancher mRNA includes a 4545-base pair coding region and a 2371-base pair 3'-nontranslated region. The calculated molecular mass of the debrancher protein derived from cDNA sequence is 172,614 daltons, consistent with the estimated size of purified protein (M(r) 165,000 +/- 500). A partial amino acid sequence (13 internal tryptic peptides with a total of 213 residues) determined on peptides derived from purified porcine muscle debrancher protein confirmed the identity of the cDNA clone. Comparison of the amino acid sequence predicted from the human glycogen debrancher cDNA with the partial protein sequence of the porcine debrancher revealed a high degree (88%) of interspecies sequence identity. RNA blot analysis showed that debrancher mRNA in human muscle, lymphoblastoid cells, and in porcine muscle are all similar in size (approximately 7 kilobases). Two patients with inherited debrancher deficiency had a reduced level of debrancher mRNA, whereas two other patients had no detectable abnormality in RNA blots. The isolation of the debrancher cDNA and determination of its primary structure is an important step toward defining the structure-function relationship of this multifunctional enzyme and in understanding the molecular basis of the type III glycogen storage disease.	DUKE UNIV,MED CTR,DEPT PEDIAT,POB 3028,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039078] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIDDK NIH HHS [DK 39078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMURA A, 1988, J BIOL CHEM, V263, P9271; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; BECKER JU, 1977, BIOCHEMISTRY-US, V16, P291, DOI 10.1021/bi00621a021; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Brown B. I., 1968, CARBOHYD METABOL, V2, P123; CHEN YT, 1987, AM J HUM GENET, V41, P1002; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; DING JH, 1990, J PEDIATR, V119, P95; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLARD BK, 1977, BIOCHEMISTRY-US, V16, P2978; GORDON RB, 1972, BIOCHIM BIOPHYS ACTA, V289, P97, DOI 10.1016/0005-2744(72)90112-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HOWELL RR, 1983, METABOLIC BASIS INHE, P141; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATSURAGI N, 1987, J BACTERIOL, V169, P2301, DOI 10.1128/jb.169.5.2301-2306.1987; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE EYC, 1970, BIOCHEMISTRY-US, V9, P2347, DOI 10.1021/bi00813a019; LEE EYC, 1970, MIAMI WINTER S, V1, P139; MARTINIUK F, 1990, DNA CELL BIOL, V9, P85, DOI 10.1089/dna.1990.9.85; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKAMURA Y, 1984, GENE, V28, P263, DOI 10.1016/0378-1119(84)90265-8; NELSON TE, 1979, ACS SYM SER, V88, P131; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; TAYLOR C, 1975, EUR J BIOCHEM, V51, P105, DOI 10.1111/j.1432-1033.1975.tb03911.x; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; WALKER GJ, 1967, BIOCHEM J, V105, P937, DOI 10.1042/bj1050937; WEBER IT, 1978, NATURE, V274, P433, DOI 10.1038/274433a0; WERRIES E, 1990, J PROTOZOOL, V37, P576, DOI 10.1111/j.1550-7408.1990.tb01268.x; WHITE RC, 1974, BIOCHIM BIOPHYS ACTA, V365, P274, DOI 10.1016/0005-2795(74)90271-2	36	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9294	9299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374391				2022-12-25	WOS:A1992HR85400090
J	PATEL, RC; SEN, GC				PATEL, RC; SEN, GC			IDENTIFICATION OF THE DOUBLE-STRANDED RNA-BINDING DOMAIN OF THE HUMAN INTERFERON-INDUCIBLE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; MR 68,000; PHOSPHORYLATION; 2-AMINOPURINE; INDUCTION; VIRUS; PURIFICATION; ACTIVATION; EIF-2; DAI	The interferon-inducible double-stranded (ds) RNA-activated protein kinase (p68 kinase) is a physiologically important enzyme that regulates the rate of cellular and viral protein synthesis by phosphorylating and thereby inactivating the peptide chain initiation factor 2. We have generated a cDNA clone of the human p68 kinase by polymerase chain reaction cloning using the recently published sequence of this enzyme. Active enzyme was synthesized by in vitro transcription-translation of the cDNA clone. This system was used for mapping the dsRNA-binding domain of the enzyme. Progressive deletions from the carboxyl terminus were introduced by digesting the cDNA with suitable restriction enzymes. Expression of proteins harboring deletions from the amino terminus was achieved by cloning DNA fragments into appropriately constructed expression vectors. Affinity of the truncated proteins for dsRNA was examined by testing their capacity to bind to dsRNA-agarose beads. Our results demonstrated that the dsRNA-binding domain lies at the amino terminus of the protein. A truncated protein containing the first 170 amino acid residues from the amino terminus could bind to dsRNA. However, deletion of 34 residues from the amino terminus or 41 residues from the carboxyl terminus of this truncated protein eliminated its dsRNA-binding activity. Comparison of the primary structure and the secondary structure of this region of p68 kinase and the corresponding region of 2'-5'-oligoadenylate synthetase revealed no apparent similarity.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2-103,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22510] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUFFETJANVRESSE C, 1986, J INTERFERON RES, V6, P85, DOI 10.1089/jir.1986.6.85; DUBOIS MF, 1990, VIROLOGY, V179, P591, DOI 10.1016/0042-6822(90)90126-C; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GATZE MG, 1987, EMBO J, V6, P689; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; HANS SK, 1988, SCIENCE, V241, P42; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P463; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1978, J BIOL CHEM, V253, P5915; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WHITAKERDOWLING P, 1984, VIROLOGY, V137, P171, DOI 10.1016/0042-6822(84)90020-5; ZILBERSTEIN A, 1976, FEBS LETT, V68, P119, DOI 10.1016/0014-5793(76)80418-8; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	30	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7671	7676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373135				2022-12-25	WOS:A1992HN48500067
J	SHI, GP; MUNGER, JS; MEARA, JP; RICH, DH; CHAPMAN, HA				SHI, GP; MUNGER, JS; MEARA, JP; RICH, DH; CHAPMAN, HA			MOLECULAR-CLONING AND EXPRESSION OF HUMAN ALVEOLAR MACROPHAGE CATHEPSIN-S, AN ELASTINOLYTIC CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; PLASMINOGEN-ACTIVATOR; DEGRADATION; PROTEINASE; NUCLEOTIDE; FIBROBLASTS; CLEAVAGE; INVITRO; SMOKERS; FORMS	Human alveolar macrophages (HAM) express an elastase activity of acidic pH optimum inhibitable by cysteine protease inhibitors. Recent studies indicate that the only known eukaryotic elastinolytic cysteine protease, cathepsin L, cannot completely account for this activity. In order to search for additional cysteine proteases with elastinolytic activity, low degeneracy oligonucleotide primers based on regions of strong homology among the known cysteine proteases were used to screen reverse-transcribed HAM RNA for cysteine proteases by the polymerase chain reaction. Among the cDNA sequences generated was a 493-base pair product highly homologous to bovine cathepsin S. Screening of a HAM cDNA eukaryotic expression library with this cDNA yielded a 1.7-kilobase full-length cDNA highly homologous to bovine cathepsin S (approximately 85% identical). This cDNA predicts a 331-amino acid preprocathepsin. Expression of this cDNA in COS cells revealed the active enzyme to be a single chain 28-kDa protease, as judged by active site labeling with a novel iodinated analogue of N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucylamido-(4-guanido)butane (E-64). The recombinant enzyme was found to be elastinolytic toward H-3-labeled elastin (bovine ligamentum nuchae) at pH 5.5 but with 25% of this activity retained at pH 7.0. Labeling of HAM with the active site probe revealed these cells express a 28-kDa cysteine protease, and Northern blot analysis revealed the presence of a approximately 1.7-kilobase cathepsin S mRNA. These data establish that human macrophages express at least two cysteine proteases with elastinolytic activity. The relatively broad pH range of human cathepsin S activity suggests this enzyme may contribute to the contact-dependent elastase activity of live human alveolar macrophages.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53708; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53708	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Munger, John/0000-0002-9679-2983	PHS HHS [44712, 35653] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1987, CURRENT PROTOCOLS MO, V1; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; CHAPMAN HA, 1984, J CLIN INVEST, V74, P1693, DOI 10.1172/JCI111586; EIDELMAN D, 1990, AM REV RESPIR DIS, V141, P1547, DOI 10.1164/ajrccm/141.6.1547; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; FONG D, 1986, P NATL ACAD SCI USA, V83, P2909, DOI 10.1073/pnas.83.9.2909; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MORI K, 1980, TETRAHEDRON, V36, P87, DOI 10.1016/0040-4020(80)85029-0; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; REILLY JJ, 1991, AM J PHYSIOL, V261, pL41, DOI 10.1152/ajplung.1991.261.2.L41; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WAHL GM, 1987, METHOD ENZYMOL, V152, P415; WERB Z, 1980, J EXP MED, V152, P1537, DOI 10.1084/jem.152.6.1537; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5	28	281	297	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7258	7262						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373132				2022-12-25	WOS:A1992HN48500013
J	SUGIMOTO, Y; NAMBA, T; HONDA, A; HAYASHI, Y; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S				SUGIMOTO, Y; NAMBA, T; HONDA, A; HAYASHI, Y; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S			CLONING AND EXPRESSION OF A CDNA FOR MOUSE PROSTAGLANDIN-E RECEPTOR EP(3) SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLLECTING TUBULE CELLS; ADENYLATE-CYCLASE; BINDING PROTEIN; METABOLISM; MEDULLA; DNA	A functional cDNA clone for mouse EP3 subtype of prostaglandin (PG) E receptor was isolated from a mouse cDNA library using polymerase chain reaction based on the sequence of the human thromboxane A2 receptor and cross-hybridization screening. The mouse EP3 receptor consists of 365 amino acid residues with putative seven-transmembrane domains. The sequence revealed significant homology to the human thromboxane A2 receptor. Ligand binding studies using membranes of COS cells transfected with the cDNA revealed specific [H-3]PGE2 binding. The binding was displaced with unlabeled PGs in the order of PGE2 = PGE1 > iloprost > PGF2-alpha > PGD2. The EP3-selective agonists, M&B 28,767 or GR 63799X, potently competed for the [H-3]PGE2 binding, but no competition was found with EP1- or EP2-selective ligands. PGE2 and M&B 28,767 decreased forskolin-induced cAMP formation in a concentration-dependent manner in Chinese hamster ovary cells permanently expressing the cDNA. Northern blot analysis demonstrated that the EP3 mRNA is expressed abundantly in kidney, uterus, and mastocytoma P-815 cells and in a lesser amount in brain, thymus, lung, heart, stomach, and spleen.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Sugimoto, Yukihiko/AAV-6470-2021; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Sugimoto, Yukihiko/0000-0001-6973-932X; Hayashi, Yasunori/0000-0002-7560-3004				BRUNTON LL, 1976, J BIOL CHEM, V251, P3037; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COLLINS PW, 1986, J MED CHEM, V29, P437, DOI 10.1021/jm00154a001; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HEDQVIST P, 1972, NEUROPHARMACOLOGY, V11, P177, DOI 10.1016/0028-3908(72)90090-1; HEDQVIST P, 1972, PROSTAGLANDINS, P410; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MORII H, 1991, J NEUROCHEM, V57, P1281, DOI 10.1111/j.1471-4159.1991.tb08291.x; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1991, PROSTAGLANDINS, V42, P225, DOI 10.1016/0090-6980(91)90112-S; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WATANABE T, 1986, J BIOL CHEM, V261, P3430; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119	35	405	420	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6463	6466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372606				2022-12-25	WOS:A1992HM05300004
J	SADOWSKI, HB; WHEELER, TT; YOUNG, DA				SADOWSKI, HB; WHEELER, TT; YOUNG, DA			GENE-EXPRESSION DURING 3T3-L1 ADIPOCYTE DIFFERENTIATION - CHARACTERIZATION OF INITIAL RESPONSES TO THE INDUCING AGENTS AND CHANGES DURING COMMITMENT TO DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ENHANCER BINDING-PROTEIN; FIBROBLAST GROWTH-FACTOR; ADIPOSE CONVERSION; INSULIN-RECEPTORS; MESSENGER-RNA; PREADIPOCYTE DIFFERENTIATION; ELECTROPHORETIC SEPARATION; RESPONSIVENESS INVITRO; DIHYDROTELEOCIDIN-B	The mouse 3T3-L1 fibroblastic cell line rapidly differentiates to an adipocyte phenotype when post-confluent cells are treated for 48 h in fetal calf serum-containing medium supplemented with 1-mu-M dexamethasone (D), 0.5 mM methylisobutylxanthine (M) and 10-mu-g/ml insulin (I). D and I act synergistically to commit the cells to differentiate 24-48 h after initiating treatment, and this is blocked by the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate. In order to identify cellular proteins involved in the differentiation process we analyzed differentiating 3T3-L1 cells using two-dimensional electrophoresis on large format gels. We observed changes in over 300 proteins during differentiation (over 100 within 5 h of initiating differentiation) and many of these are also changed at the level of mRNA (by analysis of in vitro translation products). About 75% of the initial changes were maximally induced by treatment with a combination of M and I, while no more than 10 proteins and their corresponding mRNAs were maximally induced by D within 3.5 h. Another 10 proteins were synergistically regulated by the combination of all three agents (DMI) within 3.5 h. Additional species were induced at later times. Five of these were synergistically induced by treatments that lead to differentiation, were first expressed at elevated levels during commitment and remained elevated in fully differentiated adipocytes. One or more of these proteins could well have a functional role in the commitment to and/or expression of the adipocyte differentiation program.	UNIV ROCHESTER, MED CTR,DEPT MED,E HENRY KEUTMANN LAB, ENDOCRINE METAB UNIT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT RADIAT BIOL & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, CTR ENVIRONM HLTH SCI, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA47650] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1984, EXP CELL RES, V152, P368, DOI 10.1016/0014-4827(84)90638-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG TH, 1978, J BIOL CHEM, V253, P4693; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COLBERT RA, 1986, P NATL ACAD SCI USA, V83, P72, DOI 10.1073/pnas.83.1.72; COLBERT RA, 1986, ENDOCRINOLOGY, V119, P2598, DOI 10.1210/endo-119-6-2598; COLBERT RA, 1986, J BIOL CHEM, V261, P4733; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; ELKS ML, 1985, J CELL PHYSIOL, V124, P191, DOI 10.1002/jcp.1041240204; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GAMOU S, 1986, CELL STRUCT FUNCT, V11, P21, DOI 10.1247/csf.11.21; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOPKINS NK, 1981, BIOCHIM BIOPHYS ACTA, V663, P457, DOI 10.1016/0005-2760(81)90174-0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Reed B C, 1980, Adv Enzyme Regul, V18, P97, DOI 10.1016/0065-2571(80)90011-4; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SHIMIZU Y, 1983, CANCER RES, V43, P4974; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEINBERG MM, 1982, J CELL PHYSIOL, P37; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VORIS BP, 1980, ANAL BIOCHEM, V104, P478, DOI 10.1016/0003-2697(80)90103-7; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	53	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4722	4731						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371508				2022-12-25	WOS:A1992HF64200067
J	PUKAC, LA; OTTLINGER, ME; KARNOVSKY, MJ				PUKAC, LA; OTTLINGER, ME; KARNOVSKY, MJ			HEPARIN SUPPRESSES SPECIFIC 2ND MESSENGER PATHWAYS FOR PROTOONCOGENE EXPRESSION IN RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; INDEPENDENT PATHWAYS; PROLIFERATION; FOS; RNA; INHIBITION; ACTIVATION; INDUCTION	We investigated the molecular mechanisms underlying the ability of heparin to inhibit vascular smooth muscle cell (VSMC) growth. Previous experiments have shown that heparin inhibits induction of c-fos and c-myc protooncogene mRNA in rat VSMC stimulated by phorbol 12-myristate 13-acetate (PMA) but not when stimulated by epidermal growth factor (EGF) (Pukac, L. A., Castellot, J. J., Wright, T. C., Caleb, B. L., and Karnovsky, M. J. (1990) Cell Regul. 1, 435-443). The present experiments show that these mitogens activate distinct second messenger pathways in VSMC, because PMA but not EGF induction of c-fos and c-myc mRNA was suppressed in protein kinase C (PKC) down-regulated VSMC; this suggests that EGF does not act through a PKC-dependent pathway for induction of these genes. Heparin inhibited serum stimulation of c-fos mRNA in control VSMC, but heparin did not inhibit the smaller but significant serum stimulation of c-fos mRNA in PKC down-regulated VSMC, indicating that heparin may selectively inhibit PKC-dependent, but not PKC-independent, stimulation of gene expression. To further determine if heparin inhibits non-PKC pathways, VSMC were treated with dibutyryl cAMP, 3-isobutyl-1-methyl-xanthine, and Ca2+ ionophore A23187; stimulation of c-fos mRNA by this treatment was not inhibited by heparin. DNA synthesis and cell proliferation were inhibited in rat VSMC exposed briefly to heparin during the G0/G1 phase of the cell cycle. These experiments indicate heparin can act early in the cell cycle and suggest PKC-dependent but not PKC-independent signaling pathways for gene expression are selectively sensitive to heparin inhibition.			PUKAC, LA (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017747, R37HL017747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; REILLY CF, 1988, J CELL PHYSIOL, V136, P23, DOI 10.1002/jcp.1041360104; REILLY CF, 1987, J CELL PHYSIOL, V131, P149, DOI 10.1002/jcp.1041310203; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199	25	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3707	3711						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371276				2022-12-25	WOS:A1992HE60700027
J	MIRELS, L; BALL, WD				MIRELS, L; BALL, WD			NEONATAL RAT SUBMANDIBULAR-GLAND PROTEIN SMG-A AND PAROTID SECRETORY PROTEIN ARE ALTERNATIVELY REGULATED MEMBERS OF A SALIVARY PROTEIN MULTIGENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ACINAR-CELLS; MOUSE; EXPRESSION; SEQUENCES; AMYLASE; GENE; LOCALIZATION; COORDINATION; EXTIRPATION	Submandibular gland-A (SMG-A) is a major secretory product of the neonatal rat submandibular gland but is not synthesized by the acinar cells of the adult gland. The leucine-rich protein is a predominant product of the adult rat parotid gland. Preliminary data had indicated that the leucine-rich protein and SMG-A might be identical proteins whose expression was differently regulated in the parotid and submandibular salivary glands. cDNA clones encoding SMG-A and the leucine-rich protein were identified by homology to a major mouse parotid gland product, parotid secretory protein (PSP), and characterized. The leucine-rich protein shares extensive sequence homology with mouse PSP throughout its 5'-untranslated, protein coding and 3'-untranslated regions, prompting our suggestion that it should henceforth be referred to as rat PSP. SMG-A is more divergent, having greatest identity with rat and mouse PSP in its signal peptide and 3'-untranslated sequences. Transcripts homologous to SMG-A and rat PSP, but more closely related to SMG-A, were identified in rat sublingual gland by Northern blot analysis. These findings indicate that rat SMG-A and PSP arise from alternatively regulated members of a multigene family.	COLUMBIA UNIV,SCH DENT & ORAL SURG,NEW YORK,NY 10027; HOWARD UNIV,COLL MED,DEPT ANAT,WASHINGTON,DC 20059; HOWARD UNIV,COLL MED,CTR CANC,WASHINGTON,DC 20059	Columbia University; Howard University; Howard University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009428, R01DE006635] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06635, DE-09428] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1409; BALL WD, 1984, EUR J CELL BIOL, V33, P112; BALL WD, 1978, DIFFERENTIATION, V10, P147, DOI 10.1111/j.1432-0436.1978.tb00957.x; BALL WD, 1988, DEV BIOL, V125, P265, DOI 10.1016/0012-1606(88)90210-2; CHANG WWL, 1974, ANAT RECORD, V178, P187, DOI 10.1002/ar.1091780204; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; CUTLER LS, 1974, DEV BIOL, V41, P31, DOI 10.1016/0012-1606(74)90280-2; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DENNY PC, 1990, ANAT REC, V226, P489, DOI 10.1002/ar.1092260411; DICKINSON DP, 1989, MOL BIOL EVOL, V6, P80; DICKINSON DP, 1987, BIOCHEM BIOPH RES CO, V149, P784, DOI 10.1016/0006-291X(87)90436-0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANKS CT, 1971, AM J ANAT, V130, P195, DOI 10.1002/aja.1001300206; HEINRICH G, 1987, J BIOL CHEM, V262, P5262; JOHNSON DA, 1984, ARCH ORAL BIOL, V29, P215, DOI 10.1016/0003-9969(84)90058-X; KELLER PJ, 1975, BIOCHIM BIOPHYS ACTA, V379, P562, DOI 10.1016/0005-2795(75)90162-2; KOUSVELARI EE, 1984, BIOCHEM J, V222, P17, DOI 10.1042/bj2220017; MADSEN HO, 1985, NUCLEIC ACIDS RES, V13, P1, DOI 10.1093/nar/13.1.1; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MINAGUCHI K, 1989, J DENT RES, V68, P2, DOI 10.1177/00220345890680010201; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MOREIRA JE, 1991, AM J ANAT, V191, P167, DOI 10.1002/aja.1001910204; MOREIRA JE, 1990, DEV BIOL, V139, P370, DOI 10.1016/0012-1606(90)90306-4; OWERBACH D, 1980, GENETICS, V95, P129; POULSEN K, 1986, EMBO J, V5, P1891, DOI 10.1002/j.1460-2075.1986.tb04441.x; REDMAN RS, 1971, DEV BIOL, V25, P248, DOI 10.1016/0012-1606(71)90030-3; ROBINOVITCH MR, 1969, ARCH ORAL BIOL, V14, P935, DOI 10.1016/0003-9969(69)90270-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW P, 1986, J MOL BIOL, V192, P567, DOI 10.1016/0022-2836(86)90277-9; SHAW P, 1986, CELL, V47, P107, DOI 10.1016/0092-8674(86)90371-5; SHAW PH, 1984, GENE, V29, P77, DOI 10.1016/0378-1119(84)90168-9; TABAK LA, 1985, ARCH BIOCHEM BIOPHYS, V242, P383, DOI 10.1016/0003-9861(85)90222-X; WALLACH D, 1975, BIOCHIM BIOPHYS ACTA, V382, P552, DOI 10.1016/0005-2736(75)90222-9; YAGIL C, 1985, VIRCHOWS ARCH B, V49, P83, DOI 10.1007/BF02912087; YAMASHINA S, 1972, J HISTOCHEM CYTOCHEM, V20, P855, DOI 10.1177/20.11.855; ZAJICEK G, 1985, ANAT REC, V213, P150, DOI 10.1002/ar.1092130206	39	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2679	2687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370829				2022-12-25	WOS:A1992HB53200087
J	MORIKAMI, A; AISO, K; ASAHI, T; NAKAMURA, K				MORIKAMI, A; AISO, K; ASAHI, T; NAKAMURA, K			THE DELTA'-SUBUNIT OF HIGHER-PLANT 6-SUBUNIT MITOCHONDRIAL F1-ATPASE IS HOMOLOGOUS TO THE DELTA-SUBUNIT OF ANIMAL MITOCHONDRIAL F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHLOROPLAST ATPASE; EPSILON-SUBUNIT; ALPHA-SUBUNIT; SWEET-POTATO; BETA-SUBUNIT; PURIFICATION; SEQUENCES; OPERON; GENES	Mitochondrial F1-ATPases purified from several dicotyledonous plants contain six different subunits of alpha, beta, gamma, delta, delta', and epsilon. Previous N-terminal amino acid sequence analyses indicated that the gamma-, delta-, and epsilon-subunits of the sweet potato mitochondrial F1 correspond to the gamma-subunit, the oligomycin sensitivity-conferring protein and the epsilon-subunit of animal mitochondrial F1F0 complex (Kimura, T., Nakamura, K., Kajiura, H., Hattori, H., Nelson, N., and Asahi, T. (1989) J. Biol. Chem. 264, 3183-3186). However, the N-terminal amino acid sequence of the delta'-subunit did not show any obvious homologies with known protein sequences. A cDNA clone for the delta'-subunit of the sweet potato mitochondrial F1 was identified by oligonucleotide-hybridization selection of a cDNA library. The 1.0-kilobase-long cDNA contained a 600-base pair open reading frame coding for a precursor for the delta'-subunit. The precursor for the delta'-subunit contained N-terminal presequence of 21-amino acid residues. The mature delta'-subunit is composed of 179 amino acids and its sequence showed similarities of about 31-36% amino acid positional identity with the delta-subunit of animal and fungal mitochondrial F1 and about 18-25% with the epsilon-subunit of bacterial F1 and chloroplast CF1. The sweet potato delta'-subunit contains N-terminal sequence of about 45-amino acid residues that is absent in other related subunits. It is concluded that the six-subunit plant mitochondrial F1 contains the subunit that is homologous to the oligomycin sensitivity-conferring protein as one of the component in addition to five subunits that are homologous to subunits of animal mitochondrial F1.	NAGOYA UNIV,SCH AGR,BIOCHEM LAB,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University								COX GB, 1987, BIOCHIM BIOPHYS ACTA, V890, P195, DOI 10.1016/0005-2728(87)90020-X; DUNN PPJ, 1985, BIOCHEM J, V225, P821, DOI 10.1042/bj2250821; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; ENGELBRECHT S, 1989, EUR J BIOCHEM, V181, P485, DOI 10.1111/j.1432-1033.1989.tb14750.x; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HORAK A, 1985, BIOCHIM BIOPHYS ACTA, V810, P310, DOI 10.1016/0005-2728(85)90215-4; HORAK A, 1990, FEBS LETT, V274, P9, DOI 10.1016/0014-5793(90)81316-G; HORAK A, 1987, BIOCHIM BIOPHYS ACTA, V893, P190, DOI 10.1016/0005-2728(87)90039-9; HOWE CJ, 1985, PLANT MOL BIOL, V4, P333, DOI 10.1007/BF02418255; IWASAKI Y, 1983, ARCH BIOCHEM BIOPHYS, V227, P164, DOI 10.1016/0003-9861(83)90359-4; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KIMURA T, 1990, J BIOL CHEM, V265, P6079; KRUSE B, 1984, EUR BIOENERG C REP B, V3, P607; QUAZZANI C, 1991, PLANT SCI, V74, P53; RANDALL SK, 1985, PLANT PHYSIOL, V79, P957, DOI 10.1104/pp.79.4.957; SHINOZAKI K, 1983, GENE, V24, P147; SPITSBERG VL, 1985, PLANT PHYSIOL, V77, P339, DOI 10.1104/pp.77.2.339; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER R, 1988, FEBS LETT, V230, P109, DOI 10.1016/0014-5793(88)80652-5; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	22	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					72	76						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370454				2022-12-25	WOS:A1992GY43900017
J	MENDOZA, JA; BUTLER, MC; HOROWITZ, PM				MENDOZA, JA; BUTLER, MC; HOROWITZ, PM			CHARACTERIZATION OF A STABLE, REACTIVATABLE COMPLEX BETWEEN CHAPERONIN-60 AND MITOCHONDRIAL RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; BOVINE LIVER RHODANESE; ESCHERICHIA-COLI; TERTIARY STRUCTURE; PROTEINS; GROEL; PURIFICATION; STATE; ATP	Efficient formation of the cpn60-rhodanese complex can be achieved by mixing unfolded rhodanese with excess cpn60 at low temperature. By employing these conditions, a stable and highly reactivatable complex is formed. The complex is not formed when native enzyme is used. Concentrations of NaCl, as high as 0.75 M, do not have any effect on the formation or disruption of the binary complex. cpn60-bound rhodanese contains an exposed hydrophobic surface, as detected by the binding of the fluorescent reporter, 1-anilinonaphthalene-8-sulfonic acid. The intrinsic fluorescence of cpn60-bound rhodanese reports that the average tryptophan is in an intermediate environment between that found in unfolded and native states. This form of rhodanese has an accessibility to quenching by acrylamide or iodide that is intermediate between the unfolded and native forms of the enzyme. Protease susceptibility studies show that rhodanese bound to cpn60 exhibits a trypsin digestion pattern similar to the native enzyme, although it is more rapidly proteolyzed. The results suggest that the conformation of cpn60-bound rhodanese resembles a native-like conformation, but with increased flexibility. Further, only intact rhodanese or enzyme lacking its N-terminal sequence can interact with cpn60 and form a stable binary complex. The protein fragment corresponding to the rhodanese N-terminal sequence did not form part of a stable complex with cpn60.			MENDOZA, JA (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1990, J BIOL CHEM, V265, P5967; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VONHIPPEL PH, 1964, SCIENCE, V145, P577, DOI 10.1126/science.145.3632.577; WEBER G, 1964, J BIOL CHEM, V239, P1415; WESTLEY J, 1959, J BIOL CHEM, V234, P2325; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24648	24654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360012				2022-12-25	WOS:A1992KA26300075
J	CLONEY, LP; WU, HB; HEMMINGSEN, SM				CLONEY, LP; WU, HB; HEMMINGSEN, SM			EXPRESSION OF PLANT CHAPERONIN-60 GENES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; BACTERIOPHAGE-LAMBDA INFECTION; SUBUNIT BINDING-PROTEIN; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; GROEL; CHLOROPLASTS; COMPLEXES; PRECURSOR	We have examined the expression in Escherichia coli of genes encoding a plant chloroplast molecular chaperone, chaperonin-60. Purified plant chaperonin-60 is distinct in that it contains two polypeptides, p60cpn-60alpha and p60cpn-60beta, which have divergent amino acid sequences (Hemmingsen, S. M., and Ellis, R. J. (1986) Plant Physiol. 80, 269-276; Martel, R., Cloney, L. P., Pelcher, L. E., and Hemmingsen, S. M. (1990) Gene (Amst.) 94, 181-187). The precise polypeptide composition(s) of the active tetradecameric specie(s) (cpn60(14)) has not been determined. Genes encoding the mature forms of the Brassica napus chaperonin polypeptides have been expressed separately and in combination in E. coli to produce three novel strains: alpha, beta, and alphabeta. The plant cpn60 polypeptides accumulated in soluble forms and to similar high levels in each. There was no conclusive evidence that p60cpn-60alpha assembled into cpn60(14) species in a cells. In beta and alphabeta cells, the plant gene products assembled efficiently into cpn60(14) species. Thus, the assembly of p60cpn-60alpha required the presence of p60cpn-60beta, whereas the assembly of p60cpn-60beta could occur in the absence of p60cpn-60alpha. Significant proportions of the endogenous groEL polypeptides were not assembled into tetradecameric groEL14 in beta and alphabeta cells. Analysis of the tetradecameric species that did form indicated the presence of novel hybrid cpn60(14) species that contained both plant and bacterial cpn60 polypeptides.	NATL RES COUNCIL CANADA,INST PLANT BIOTECHNOL,110 GYMNASIUM PL,SASKATOON S7N 0W9,SASKATCHEWAN,CANADA	National Research Council Canada								AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAHL H, 1987, GENE DEV, V1, P57, DOI 10.1101/gad.1.1.57; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLONEY LP, 1992, J BIOL CHEM, V267, P23333; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, PLANT J, V1, P9, DOI 10.1111/j.1365-313X.1991.00009.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; KOCHAN J, 1982, J BACTERIOL, V149, P1166, DOI 10.1128/JB.149.3.1166-1170.1982; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; ROY H, 1988, TRENDS BIOCHEM SCI, V13, P163, DOI 10.1016/0968-0004(88)90139-9; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	30	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23327	23332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358882				2022-12-25	WOS:A1992JY16300094
J	HATAKEYAMA, K; HARADA, T; KAGAMIYAMA, H				HATAKEYAMA, K; HARADA, T; KAGAMIYAMA, H			IMP DEHYDROGENASE INHIBITORS REDUCE INTRACELLULAR TETRAHYDROBIOPTERIN LEVELS THROUGH REDUCTION OF INTRACELLULAR GTP LEVELS - INDICATIONS OF THE REGULATION OF GTP CYCLOHYDROLASE-I ACTIVITY BY RESTRICTION OF GTP AVAILABILITY IN THE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOPTERIN COFACTOR BIOSYNTHESIS; NITRIC-OXIDE SYNTHASE; INTERFERON-GAMMA; 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE; PURIFICATION; MACROPHAGES; METABOLISM; ACTIVATION; ACID; FIBROBLASTS	GTP cyclohydrolase I exhibits a positive homotropic cooperative binding to GTP, which raises the possibility of a role for GTP in regulating the enzyme reaction (Hatakeyama, K., Harada. T., Suzuki, S., Watanabe, Y., and Kagamiyama, H. (1989) J. Biol. Chem. 264, 21660-21664). We examined whether or not the intracellular GTP level is within the range of affecting GTP cyclohydrolase I activity, using PC-12 rat pheochromocytoma and IMR-32 human neuroblastoma cells. Since GTP cyclohydrolase I was the rate-limiting enzyme for the biosynthesis of tetrahydrobiopterin in these cell lines, the intracellular activities of this enzyme were reflected in the tetrahydrobiopterin contents. We found that the addition of guanine or guanosine increased GTP but not tetrahydrobiopterin in these cells. On the other hand, three IMP dehydrogenase inhibitors, tiazofurin, 2-amino-1,3,4-thiadiazole, and mycophenolic acid, decreased both GTP and tetrahydrobiopterin in a parallel and dose-dependent manner, and these effects were reversed by the simultaneous addition of guanine or guanosine. There was no evidence suggesting that these inhibitors inhibited other enzymes involved in the biosynthesis and regeneration of tetrahydrobiopterin. Comparing intracellular activities of GTP cyclohydrolase I in the inhibitor-treated cells with its substrate-velocity curve, we estimated that the intracellular concentration of free GTP is 150 muM at which point the activity of GTP cyclohydrolase I is elicited at its maximum velocity. Below this GTP concentration, GTP cyclohydrolase I activity is rapidly decreased. Therefore GTP can be a regulator for tetrahydrobiopterin biosynthesis.			HATAKEYAMA, K (corresponding author), OSAKA MED COLL,DEPT MED CHEM,TAKATSUKI,OSAKA 569,JAPAN.							BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOTTENSTEIN JE, 1983, ADV CELL NEUROBIOL, V4, P333; BRAUTIGAM M, 1984, J NEUROCHEM, V42, P390, DOI 10.1111/j.1471-4159.1984.tb02690.x; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CARTER SB, 1969, NATURE, V223, P848, DOI 10.1038/223848a0; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; COTE LJ, 1975, J NEUROBIOL, V6, P233, DOI 10.1002/neu.480060209; CRAINE JE, 1972, J BIOL CHEM, V247, P6082; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; EARLE MF, 1983, CANCER RES, V43, P133; FERRE J, 1988, CLIN CHIM ACTA, V271, P271; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; FRANKLIN TJ, 1977, EUR J BIOCHEM, V777, P113; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HASLER T, 1986, P319; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; INOUE Y, 1991, J BIOL CHEM, V266, P20791; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P3839, DOI 10.1016/0006-2952(82)90300-8; JOHNSON GS, 1979, J BIOL CHEM, V254, P95; KAUFMAN S, 1967, ANNU REV BIOCHEM, V36, P171, DOI 10.1146/annurev.bi.36.070167.001131; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; KETTLER R, 1974, NATURE, V249, P476, DOI 10.1038/249476a0; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KWON NS, 1989, J BIOL CHEM, V264, P20496; LIU MS, 1984, J BIOL CHEM, V259, P5078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; NELSON JA, 1977, CANCER RES, V37, P182; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; OCHI K, 1981, J BIOL CHEM, V256, P6866; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SMITH CM, 1977, J CYCLIC NUCL PROT, V3, P347; SMITH GK, 1986, J BIOL CHEM, V261, P2725; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TIETZ A, 1964, J BIOL CHEM, V239, P4081; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	48	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20734	20739						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356983				2022-12-25	WOS:A1992JT97800036
J	SRIVATSAN, J; SMITH, DF; CUMMINGS, RD				SRIVATSAN, J; SMITH, DF; CUMMINGS, RD			THE HUMAN BLOOD FLUKE SCHISTOSOMA-MANSONI SYNTHESIZES GLYCOPROTEINS CONTAINING THE LEWIS-X ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LECTIN-AFFINITY-CHROMATOGRAPHY; SURFACE GLYCOPROTEINS; CARBOHYDRATE EPITOPES; MONOCLONAL-ANTIBODY; ADULT WORMS; BINDING; MEMBRANE; IDENTIFICATION; FRACTIONATION	Infection of vertebrates with the parasitic blood fluke Schistosoma mansoni induces a variety of host immune responses, which are directed against both protein and carbohydrate antigens. In this report, we describe our studies on the structures of antigenic oligosaccharides derived from glycoproteins synthesized by S. mansoni. Immobilized antibodies derived from the sera of infected hamsters and mice bind to a family of high molecular weight Asn-linked oligosaccharides in glycoproteins from the adult parasite. Structural analysis of the major antigenic oligosaccharides revealed that they have high amounts of fucose-linked alpha1,3 to N-acetylglucosamine residues within the linear repeating disaccharide (3Galbeta1-4GlcNAcbeta1)n, a poly-N-acetyllactosamine sequence containing the Lewis X antigenic blood group. The remarkable ability of S. mansoni to synthesize these vertebrate-type oligosaccharides may have implications in both the mechanisms of host-parasite interactions and on the development of vaccines to prevent this disease in humans.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI026725, R01AI026725] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26725] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI PO, 1991, MOL BIOCHEM PARASIT, V45, P215, DOI 10.1016/0166-6851(91)90088-N; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BENNETT JL, 1977, J PARASITOL, V63, P250, DOI 10.2307/3280054; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CINCANU I, 1984, CARBOHYD RES, V131, P209; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; COLLEY DG, 1989, PARASITOL TODAY, V5, P350, DOI 10.1016/0169-4758(89)90106-3; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; DONALD ASR, 1986, BIOCHEM J, V236, P821, DOI 10.1042/bj2360821; DUNNE DW, 1990, PARASITOL TODAY, V6, P45, DOI 10.1016/0169-4758(90)90068-F; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1978, J BIOL CHEM, V253, P6814; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GRYZCH JM, 1987, J EXP MED, V165, P865; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HAYUNGA EG, 1986, J PARASITOL, V72, P913, DOI 10.2307/3281844; HAYUNGA EG, 1986, J PARASITOL, V72, P283, DOI 10.2307/3281607; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; LINDER E, 1982, PARASITOLOGY, V85, P503, DOI 10.1017/S0031182000056286; LINDER E, 1991, J PARASITOL, V77, P391, DOI 10.2307/3283126; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; MACGREGOR AN, 1985, MOL BIOCHEM PARASIT, V16, P163, DOI 10.1016/0166-6851(85)90084-2; MAKAARU CK, 1992, J BIOL CHEM, V267, P2251; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; NAKATA N, 1991, GLYCOCONJUGATE J, V8, P250; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OMERALI P, 1986, J IMMUNOL, V137, P3601; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SANO M, 1992, J BIOL CHEM, V267, P1522; SIMPSON AJG, 1980, PARASITOLOGY, V81, P1, DOI 10.1017/S0031182000054986; STOFFYN P, 1971, J LIPID RES, V12, P318; SZILAGYI PJ, 1985, ANAL BIOCHEM, V148, P260, DOI 10.1016/0003-2697(85)90655-4; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; WEISS JB, 1986, J IMMUNOL, V136, P4275; WEISS JB, 1985, J IMMUNOL, V135, P1421; XU CB, 1991, EUR J IMMUNOL, V21, P1801, DOI 10.1002/eji.1830210804; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	53	111	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20196	20203						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356976				2022-12-25	WOS:A1992JR85800072
J	IADEMARCO, MF; MCQUILLAN, JJ; ROSEN, GD; DEAN, DC				IADEMARCO, MF; MCQUILLAN, JJ; ROSEN, GD; DEAN, DC			CHARACTERIZATION OF THE PROMOTER FOR VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR NECROSIS FACTOR; ELAM-1 GENE-TRANSCRIPTION; GATA-BINDING PROTEIN; DNA-BINDING; ENDOTHELIAL-CELLS; INTEGRIN VLA-4; MESSENGER-RNA; FACTOR-ALPHA; SIALYL-LEX	Vascular cell adhesion molecule-1 (VCAM-1) was first identified as a protein that appears on the surface of endothelial cells after exposure to inflammatory cytokines. Through interaction with its integrin counter receptor VLA-4, VCAM-1 mediates cell-cell interactions important for immune function. We have cloned and begun characterization of the promoter for the VCAM-1 gene. In a series of transfection assays into human umbilical vein endothelial cells (HUVECs), we find that silencers between positions -1.641 kilobases and -288 base pairs restrict promoter activity, and that treatment with tumor necrosis factor-alpha overcomes this inhibition and activates the promoter through two NF-kappa-B sites located at positions -77 and -63 base pairs of the VCAM-1 gene. This responsiveness appears cell-specific since constructs containing the VCAM-1 NF-kappa-B sites are not responsive to tumor necrosis factor-alpha in the T-cell line Jurkat. The two VCAM-1 NF-kappa-B sites, which differ slightly in their sequence, form distinct complexes in gel retardation assays, suggesting that they interact with different NF-kappa-B-site binding proteins. The distribution of these proteins could then control activity of the NF-kappa-B sites. We conclude that the pattern of VCAM-1 expression in HUVECs is controlled by a combination of these silencers and NF-kappa-B sites.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, BOX 8052, 660 S EUCLID, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, P01HL029594, R01HL043418] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43418, HL07317, HL29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ALBELDA SM, 1990, CANCER RES, V50, P6757; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FELDMAN LE, 1991, CANCER RES, V51, P1065; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HORTON MA, 1989, J BONE MINER RES, V4, P803; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE ME, 1991, J BIOL CHEM, V266, P16188; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OSBORN L, 1989, P NATL ACAD SCI USA, V85, P1482; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PORTER SD, 1986, NATURE, V320, P766, DOI 10.1038/320766a0; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSEN GD, 1992, IN PRESS CELL; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	66	339	363	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16323	16329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379595				2022-12-25	WOS:A1992JJ45800053
J	MOORMAN, JR; PALMER, CJ; JOHN, JE; DURIEUX, ME; JONES, LR				MOORMAN, JR; PALMER, CJ; JOHN, JE; DURIEUX, ME; JONES, LR			PHOSPHOLEMMAN EXPRESSION INDUCES A HYPERPOLARIZATION-ACTIVATED CHLORIDE CURRENT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC MYOCYTES; SARCOLEMMAL PROTEIN; INTACT MYOCARDIUM; LAEVIS OOCYTES; CONDUCTANCE; CLONING; MUSCLE; PHOSPHORYLATION; ADRENALINE; CHANNEL	A new type of chloride channel has been identified by functional expression of phospholemman, a 72-amino acid cardiac sarcolemmal protein with a single transmembrane domain. Xenopus oocytes injected with phospholemman RNA developed a chloride-selective current, which was activated by hyperpolarizing pulses. The current activated very slowly with a pronounced sigmoidal delay, did not inactivate, and increased in amplitude with trains of pulses, depolarized holding potentials, and low extracellular pH. Point mutations within the single transmembrane region abolished the sigmoidal delay of expressed currents. Phospholemman appears to be the smallest plasma membrane channel protein yet known. The structure is dissimilar to any chloride channel described thus far.	UNIV VIRGINIA,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT ANESTHESIOL,CHARLOTTESVILLE,VA 22908; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT PHARMACOL,INDIANAPOLIS,IN 46202	University of Virginia; University of Virginia; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	MOORMAN, JR (corresponding author), UNIV VIRGINIA,DEPT MED CARDIOL,CHARLOTTESVILLE,VA 22908, USA.		Moorman, J Randall/ABG-9946-2020	Durieux, Marcel/0000-0003-1479-7666				BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BLATZ AL, 1985, BIOPHYS J, V47, P119, DOI 10.1016/S0006-3495(85)83884-4; CHESNOYMARCHAIS D, 1983, J PHYSIOL-LONDON, V342, P277, DOI 10.1113/jphysiol.1983.sp014851; CHESNOYMARCHAIS D, 1982, NATURE, V299, P359; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSSTEIN S A N, 1991, Biophysical Journal, V59, p197A; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; LOO DDF, 1981, CAN J PHYSIOL PHARM, V59, P7, DOI 10.1139/y81-002; MATSUOKA S, 1990, J PHYSIOL-LONDON, V425, P579, DOI 10.1113/jphysiol.1990.sp018119; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; PALADE PT, 1977, J GEN PHYSIOL, V69, P879, DOI 10.1085/jgp.69.6.879; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PARKER I, 1985, PROC R SOC SER B-BIO, V223, P279, DOI 10.1098/rspb.1985.0002; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PERES A, 1983, PFLUG ARCH EUR J PHY, V399, P157, DOI 10.1007/BF00663914; PERLMAN S, 1970, BIOCHEM BIOPH RES CO, V40, P941, DOI 10.1016/0006-291X(70)90994-0; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; TAGLIETTI V, 1984, J CELL PHYSIOL, V121, P576, DOI 10.1002/jcp.1041210317; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; WARNER AE, 1972, J PHYSIOL-LONDON, V227, P291, DOI 10.1113/jphysiol.1972.sp010033	30	140	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14551	14554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378834				2022-12-25	WOS:A1992JF08800010
J	HSU, MY; EAGLE, SG; INOUYE, M; INOUYE, S				HSU, MY; EAGLE, SG; INOUYE, M; INOUYE, S			CELL-FREE SYNTHESIS OF THE BRANCHED RNA-LINKED MSDNA FROM RETRON-EC67 OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; MYXOCOCCUS-XANTHUS; DNA	msDNA-Ec67 is produced in a clinical strain of Escherichia coli and composed of a 67-base single-stranded DNA, which is linked to the 2'-OH group of the 15th rG residue of a 58-base RNA molecule by a 2,5'-phosphodiester phosphodiester linkage (Lampson, B. C., Sun, J., Hsu, M.-Y., Vallejo-Ramirez, J., Inouye, S., and Inouye, M. (1989) Science 243, 1033-1038). The production of msDNA-Ec67 is dependent upon retron-Ec67, which consists of the msr-msd region and the gene for reverse transcriptase (RT). These two elements were separately cloned into plasmids; p67-BH0.6 contained the msr-msd region and pRT-67 contained the RT gene under the lpp-lac promoter-operator. msDNA-Ec67 was produced only when cells were transformed with both plasmids. In addition, msDNA-Ec67 was synthesized in a cell-free system using total RNA prepared from cells harboring plasmid p67-BH0.6 and purified Ec67-RT. Using this cell-free system, the priming reaction, during initiation of DNA synthesis, was demonstrated to be a specific template-directed event; only dTTP was incorporated into a 132-base precursor RNA yielding a 133-base compound. This specific dT addition could be altered to dA or dC by simply substituting the 118th A residue of the putative msr-msd transcript with a T or G residue. The priming reaction was blocked when A was substituted for G at the 15th residue of the precursor RNA transcript, which corresponds to the branched rG residue in msDNA. DNA chain elongation could be terminated by adding ddNTP in the cell-free system, forming a sequence ladder. The DNA sequence determined from this ladder completely agreed with the msDNA sequence. The RT extension reaction was completely blocked when the RNA preparation was treated with RNase A but not when the preparation was treated with DNase. This clearly demonstrates that RNA but not DNA is responsible for the msDNA production. A part of the fully extended cell-free product contained a 13-base RNA strand resistant to RNase A, which is consistent with the previously proposed model. In this model, the 5'-end sequence of the msr-msd transcript (a2; bases 1-13) forms a duplex with the 3'-end sequence (al) of the same transcript, thus serving as a primer, as well as a template for msDNA synthesis by RT. Our results are inconsistent with a model recently proposed by Lease and Yee (Lease, R. A., and Yee, T. (1991) J. Biol. Chem. 266, 14497-14503).			HSU, MY (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; HSU MY, 1989, J BIOL CHEM, V264, P6214; INOUYE M, 1991, TRENDS BIOCHEM SCI, V16, P18, DOI 10.1016/0968-0004(91)90010-S; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P162; INOUYE S, 1991, SCIENCE, V252, P969, DOI 10.1126/science.1709758; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LEASE RA, 1991, J BIOL CHEM, V266, P14497; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Miller J. H., 1972, EXPT MOL GENETICS, P433; MIYATA S, 1992, IN PRESS P NATL ACAD; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991	19	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13823	13829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378431				2022-12-25	WOS:A1992JD32500009
J	HUANG, SS; HUANG, JS				HUANG, SS; HUANG, JS			PURIFICATION AND CHARACTERIZATION OF THE NEU/ERB B2 LIGAND-GROWTH FACTOR FROM BOVINE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST CANCER; HER-2 NEU ONCOGENE; FACTOR RECEPTOR; POINT MUTATION; PROTEIN; GENE; EXPRESSION; PRODUCT; TRANSFORMATION	A neu/erb B2 ligand growth factor (NEL-GF) was purified to homogeneity from bovine kidney by a procedure involving ammonium sulfate fractionation (35-70% saturation) followed by sequential column chromatography on DEAE-cellulose (DE52), Sulfadex (sulfated Sephadex G-50), heparin-Sepharose 4B, and Superdex 75 (fast protein liquid chromatography). NEL-GF was found to be a 25-kDa polypeptide according to the analysis by gel filtration on Superdex 75 and 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). NEL-GF also down-regulated the cell surface neu/erb B2 gene product in DHFR/G-8 cells. NEL-GF was mitogenic toward NIH 3T3 cells, DHFR/G-8 cells, A431 cells (human epidermoid carcinoma cells), and SK-BR-3 cells (human breast carcinoma cells) but inactive toward bovine aorta endothelial cells. NEL-GF was sensitive to 0.1% trifluoroacetic acid but resistant to 5% beta-mercaptoethanol and appeared to be distinct from a neu protein-specific activating factor (Davis, J. G., Hamuro, J., Shim, C. Y., Samanta, A., Greene, M. I., and Dobashi, K. (1991) Biochem. Biophys. Res. Commun. 179, 1536-1542) and a 30-kDa glycoprotein which competed with a monoclonal antibody for binding to the neu/erb B2 gene product (Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., and Lippman, M. E. (1990) Science 249, 1552-1555).			HUANG, SS (corresponding author), ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KUO MD, 1990, J BIOL CHEM, V265, P16455; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PATERSON MC, 1991, CANCER RES, V51, P550; PRESS MF, 1990, ONCOGENE, V5, P953; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TATEISHI M, 1991, EUR J CANCER, V27, P1372, DOI 10.1016/0277-5379(91)90012-3; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	27	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11508	11512						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350785				2022-12-25	WOS:A1992HX16900087
J	LARSEN, GR; SAKO, D; AHERN, TJ; SHAFFER, M; ERBAN, J; SAJER, SA; GIBSON, RM; WAGNER, DD; FURIE, BC; FURIE, B				LARSEN, GR; SAKO, D; AHERN, TJ; SHAFFER, M; ERBAN, J; SAJER, SA; GIBSON, RM; WAGNER, DD; FURIE, BC; FURIE, B			P-SELECTIN AND E-SELECTIN - DISTINCT BUT OVERLAPPING LEUKOCYTE LIGAND SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; COMPLEMENT REGULATORY PROTEINS; LYMPHOCYTE HOMING RECEPTOR; HUMAN-ENDOTHELIAL CELLS; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; ADHESION MOLECULE-1; INDUCIBLE RECEPTOR; PLASMA-MEMBRANE; SIALYL-LEX	P-selectin on platelets and endothelial cells and E-selectin on endothelial cells are leukocyte receptors that recognize lineage-specific carbohydrates on neutrophils and monocytes. The proposed ligands for these receptors contain the Le(x) core and sialic acid. Since other investigators have shown that both E-selectin and P-selectin bind to sialylated Le(x), we evaluated whether E-selectin and P-selectin recognize the same counter-receptor on leukocytes. The interaction of HL60 cells with Chinese hamster ovary (CHO) cells expressing P-selectin or E-selectin was studied. To determine whether a protein component is required in addition to sialyl Le(x) for either P-selectin or E-selectin recognition, HL60 cells or neutrophils were digested with proteases, including chymotrypsin, elastase, proteinase Glu-C, ficin, papain, or thermolysin. Cells treated with these proteases bound E-selectin but not P-selectin. Fucosidase or neuraminidase treatment of HL60 cells markedly decreased binding to both E-selectin- and P-selectin-expressing CHO cells. Growth of HL60 cells in tunicamycin inhibited the ability of these cells to support P-selectin-mediated binding and, to a lesser extent, E-selectin-mediated binding. Purified P-selectin inhibited CHO:P-selectin binding to HL60 cells, but incompletely inhibited CHO:E-selectin binding to HL60 cells. However, purified soluble E-selectin inhibited CHO:P-selectin and CHO:E-selectin binding to HL60 cells equivalently and completely. COS cells, unable to bind to E-selectin or P-selectin, bound E-selectin but not P-selectin upon transfection with alpha-1,3-fucosyltransferase or alpha-1,3/1,4-fucosyltransferase. Similarly, LEC 11 cells expressing sialyl Le(x) bound E-selectin- but not P-selectin-expressing CHO cells. Sambucus nigra lectin, specific for the sialyl-2,6-beta-Gal/GalNAc linkage, inhibited P-selectin but not E-selectin binding to HL60 cells. Although sialic acid and Le(x) are components of the P-selectin ligand and the E-selectin ligand, these results indicate that the ligands are related, having overlapping specificities, but are structurally distinct. A protein component containing sialyl Le(x) in proximity to sialyl-2,6-beta-Gal structures on the P-selectin ligand may contribute to its specificity for P-selectin.	NEW ENGLAND MED CTR HOSP,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University	LARSEN, GR (corresponding author), GENET INST,CAMBRIDGE,MA 02140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008297, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443, HL08297, HL02542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEEUWENBERG JFM, 1989, EUR J IMMUNOL, V19, P715, DOI 10.1002/eji.1830190422; LEVY K, 1989, BLOOD, V73, P1324; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MURAKAMI H, 1991, J BIOL CHEM, V266, P15414; NAUSEEF WM, 1983, BLOOD, V62, P636; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RASSOULZADEGAN M, 1982, NATURE, V295, P257, DOI 10.1038/295257a0; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	42	158	164	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11104	11110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375936				2022-12-25	WOS:A1992HX16900029
J	TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M				TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M			INTRAGENIC HOMOZYGOUS DELETION OF THE WT1-GENE IN WILMS-TUMOR	ONCOGENE			English	Article							CHROMOSOME-11; GENE; 11P13; LOCUS; DNA; HETEROZYGOSITY; ASSOCIATION; MUTATION; ALLELES; CANCER	One example of intragenic homozygous deletion of the WT1 gene on chromosome 11p13 was found after screening 42 samples of Wilms' tumor DNA from Japanese patients. After construction of a restriction map for the genomic sequence covering the 3' half of the gene, the deletion was analysed at the nucleotide sequence level. The deletion occurred in the patient's germline on his paternal chromosome, and most of the short arm of his maternal chromosome 11 was subsequently lost in the tumor. The size of the deletion was about 8 kb, removing exons 6 and 7 and resulting in premature termination. The deletion seemed to be created by recombination between short homologous sequences found in an Alu repeat, with a 16-bp duplication left at the junction. This case conforms to a two-hit model for the genesis of a certain group of tumors, and supports the hypothesis that WT1 is one of the recessive oncogenes responsible for Wilms' tumor.	NIHON UNIV,COLL AGR & VET MED,NUCLE ACID SCI LAB,FUJISAWA,KANAGAWA 252,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,TOKYO 113,JAPAN; NATL CHILDRENS HOSP,TOKYO 154,JAPAN	Nihon University; University of Tokyo; National Center for Child Health & Development - Japan	TADOKORO, K (corresponding author), NATL CHILDRENS HOSP,MED RES CTR,3-35-31 TAISHIDO,TOKYO 154,JAPAN.							ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; PAL N, 1990, ONCOGENE, V5, P1665; Parkin D., 1988, INT INCIDENCE CHILDH, V1st; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P2514, DOI 10.1093/nar/19.9.2514; TADOKORO K, 1991, NUCLEIC ACIDS RES, V24, P6967; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; YAMADA M, 1985, P NATL ACAD SCI USA, V82, P3567, DOI 10.1073/pnas.82.11.3567; YAMADA M, 1982, GENE, V18, P309; YAMADA M, 1988, JPN J CANCER RES, V79, P670, DOI 10.1111/j.1349-7006.1988.tb02219.x	31	49	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1215	1221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350671				2022-12-25	WOS:A1992HU64200020
J	DUSANTERFOURT, I; CASADEVALL, N; LACOMBE, C; MULLER, O; BILLAT, C; FISCHER, S; MAYEUX, P				DUSANTERFOURT, I; CASADEVALL, N; LACOMBE, C; MULLER, O; BILLAT, C; FISCHER, S; MAYEUX, P			ERYTHROPOIETIN INDUCES THE TYROSINE PHOSPHORYLATION OF ITS OWN RECEPTOR IN HUMAN ERYTHROPOIETIN-RESPONSIVE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 RECEPTOR; SIGNAL TRANSDUCTION; PROTEINS; ACTIVATION; EXPRESSION; CLONING	Using the human erythropoietin-responsive hematopoietic cell line UT-7, we showed that erythropoietin (Epo) rapidly and specifically induced the tyrosine phosphorylation of its own receptor (M(r) 75,000) and increased the tyrosine phosphorylation of other proteins of M(r) 140,000,120,000,95,000,60,000,57,000, and 42,000. Neither granulocyte-macrophage colony-stimulating factor, interleukin 3, interleukin 6, nor the kit ligand induced the phosphorylation of the M(r) 75,000 receptor protein, although these growth factors induced the phosphorylation of other proteins. Crosslinking experiments using I-125-Epo indicated that the UT-7 cells expressed three Epo receptor subunits, of M(r) 100,000, 85,000, and 75,000, among which only the M(r) 75,000 subunit was tyrosine-phosphorylated following activation with Epo.	HOP COCHIN, ICGM, INSERM, U332, F-75674 PARIS 14, FRANCE; UNIV REIMS, UFR SCI, BIOCHIM LAB, F-51062 REIMS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Universite de Reims Champagne-Ardenne	DUSANTERFOURT, I (corresponding author), HOP COCHIN, ICGM, INSERM, U152, 27 RUE FAUBOURG ST JACQUES, F-75674 PARIS 14, FRANCE.		Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FUNG MR, 1991, J IMMUNOL, V147, P1253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS K, 1990, BLOOD, V76, pA147; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERMINE O, 1991, BLOOD S, V78, pA292; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JONES SS, 1990, BLOOD, V76, P31; KANAKURA Y, 1990, BLOOD, V76, P706; KOMATSU N, 1991, CANCER RES, V51, P341; KRANTZ SB, 1991, BLOOD, V77, P419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYEUX P, 1986, EXP HEMATOL, V14, P801; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; QUELLE FW, 1991, J BIOL CHEM, V266, P609; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WINKELMANN JC, 1990, BLOOD, V76, P24; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	33	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10670	10675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375226				2022-12-25	WOS:A1992HV09000070
J	LEV, S; YARDEN, Y; GIVOL, D				LEV, S; YARDEN, Y; GIVOL, D			A RECOMBINANT ECTODOMAIN OF THE RECEPTOR FOR THE STEM-CELL FACTOR (SCF) RETAINS LIGAND-INDUCED RECEPTOR DIMERIZATION AND ANTAGONIZES SCF-STIMULATED CELLULAR-RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; C-KIT RECEPTOR; INTERMOLECULAR ALLOSTERIC ACTIVATION; TYROSINE KINASE-ACTIVITY; HUMAN INSULIN-RECEPTOR; EXTRACELLULAR DOMAIN; SELF-PHOSPHORYLATION; SI-LOCUS; V-KIT; BINDING	The stem cell factor (SCF) is a polypeptide ligand that is essential for the development of germ cells, hematopoietic progenitor cells, and melanocyte precursors. It binds to a tyrosine kinase membrane receptor that is encoded by the c-kit proto-oncogene. We have constructed an expression vector that directs the synthesis of the entire extracellular ligand-binding domain of the Kit/SCF receptor. When expressed and amplified in Chinese hamster ovary cells, a secreted 90-kDa glycoprotein could be harvested from the growth medium of the cells in a soluble form. This extracellular portion of the Kit/SCF receptor, denoted Kit-X, was recognized by antibodies specific to the SCF receptor; and when injected into animals, it raised antibodies that were reactive with the complete membrane form of the receptor. Direct binding and covalent cross-linking of radiolabeled SCF showed that Kit-X fully retained high affinity ligand binding and also underwent efficient dimerization in the presence of the ligand. The capacity of Kit-X to act as an antagonist of SCF was assayed on cultured cells that overexpress the receptor. Simultaneous addition of SCF and Kit-X to these cells resulted in a stoichiometric inhibition of SCF binding and a consequent decrease in autophosphorylation of the SCF receptor on tyrosine residues. The inhibition extended to later SCF-mediated responses, including the association of the receptor with phosphatidylinositol 3'-kinase and coupling to the Raf1 protein kinase. These results indicate that the recombinant ectodomain of the Kit-SCF receptor can be used as a specific antagonist of SCF actions and may enable detailed molecular analysis of ligand-receptor interactions.			LEV, S (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCHET C, 1988, J BIOL CHEM, V263, P3290; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWER SK, 1989, J IMMUNOL, V142, P4314; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPP UR, 1988, HDB ONCOGENES, P213; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHERR CJ, 1990, BLOOD, V75, P1; Silvers W.K., 1979, COAT COLORS MICE, P206; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	53	51	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10866	10873						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375232				2022-12-25	WOS:A1992HV09000098
J	RUSSO, RN; SHAPER, NL; TAATJES, DJ; SHAPER, JH				RUSSO, RN; SHAPER, NL; TAATJES, DJ; SHAPER, JH			BETA-1,4-GALACTOSYLTRANSFERASE - A SHORT NH2-TERMINAL FRAGMENT THAT INCLUDES THE CYTOPLASMIC AND TRANSMEMBRANE DOMAIN IS SUFFICIENT FOR GOLGI RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-SURFACE GALACTOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; PYRUVATE-KINASE; E1 GLYCOPROTEIN; SIGNAL ANCHOR; MESSENGER-RNA; EXPRESSION; PROTEIN; LOCALIZATION	Beta-1,4-galactosyltransferase (beta-1,4-GT) is a Golgi-resident, type II membrane-bound glycoprotein that functions in the coordinate biosynthesis of complex oligosaccharides. Additionally, beta-1,4-GT has been localized to the cell surface of a variety of cell types and tissues where it is proposed to function in intercellular recognition and/or adhesion. Thus beta-1,4-GT is an appropriate molecule to be used in analyzing the molecular basis for retention of a membrane-bound enzyme in the Golgi complex and its subsequent or alternative transport to the cell surface. Previously we have shown that the gene for bovine and murine beta-1,4-GT is unusual in that it specifies a short (SGT) and long (LGT) form of the enzyme (Russo, R. N., Shaper, N. L., and Shaper, J. H. (1990) J. Biol. Chem. 265, 3324-333 1). The only difference between the two related forms is in the primary structure of the cytoplasmic domains, where LGT has an NH2-terminal extension of 13 amino acids. In this study, we have tested the hypothesis that LGT and SGT are differentially retained in the Golgi or directed to the cell surface. LGT, SGT or chimeric proteins, containing the NH2-terminal cytoplasmic and transmembrane domain of SGT and LGT fused to the cytoplasmic protein pyruvate kinase, were each stably expressed in Chinese hamster ovary cells. Proteins expressed from each construct were localized by immunofluorescence staining exclusively to a perinuclear region, identified as the Golgi by co-localization with wheat germ agglutinin. Furthermore, the subcellular distribution of both SGT and LGT was restricted to the trans-Golgi compartment as assessed by EM immunoelectron microscopy. These data suggest that both forms of beta-1,4-GT are resident trans-Golgi proteins and that an NH2-terminal segment containing the cytoplasmic and transmembrane domains of SGT (39 amino acids) or LGT (52 amino acids) is sufficient for Golgi retention.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,CELL STRUCT & FUNCT LAB,ROOM 1-127,600 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Vermont					NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG J, 1991, J CELL SCI, V98, P567; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1988, J CELL BIOL, V107, P865, DOI 10.1083/jcb.107.3.865; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P1490; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE EU, 1989, J BIOL CHEM, V264, P13848; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PENNO MB, 1989, P NATL ACAD SCI USA, V86, P6057, DOI 10.1073/pnas.86.16.6057; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1990, THESIS J HOPKINS U; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER JH, 1990, 19TH SOC COMPL CARB; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TAATJES DJ, 1990, J HISTOCHEM CYTOCHEM, V38, P233, DOI 10.1177/38.2.1688898; TOKUYASU KT, 1980, 38TH P M EL MICR SOC, P760; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	55	92	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9241	9247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374389				2022-12-25	WOS:A1992HR85400082
J	PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC				PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC			ONCOGENE-MEDIATED TRANSFORMATION OF FETAL-RAT COLON INVITRO	ONCOGENE			English	Article							PP60C-SRC PROTEIN-KINASE; INTESTINAL EPITHELIAL-CELLS; C-MYC ONCOGENES; SUCRASE-ISOMALTASE; COLORECTAL CANCERS; MONOLAYER-CULTURE; GENE-MUTATIONS; HA-RAS; V-MYC; LINES	Short-term maintenance of fetal rat colonic tissue in vitro has been demonstrated using a collagen matrix organ culture system. The introduction of single (v-myc, v-ras(H), v-src) oncogenes or combinations of oncogenes (v-myc/ras(H), v-myc/src) into normal colon mucosal elements was established using retroviral vectors, resulting in enhanced proliferation and migration of epithelial cells from the lumen of tissue implants. Expression of a single oncogene in normal colon epithelium did not result in the establishment of cell lines. In contrast, expression of cooperating oncogenic elements resulted in cell lines in > 80% of experiments, revealing different morphological characteristics dependent upon the oncogene combination used. Confirmation of the expression of viral transcripts was determined using Northern blot analysis and viral oncoprotein expression using Western blot analysis (p21) and an immunoprecipitation kinase assay (src). Expression of keratin filaments was lost following passaging of cell lines but could be induced by the myc/ras transformants by growth on Rat-1 feeder layers. This induction phenomenon was not observed with myc/src lines, and although these expressed high levels of surcase isomaltase the epithelial origin of these cells is unclear. Karyotypic analysis performed on three myc/ras-transformed cell lines revealed a normal chromosome complement associated with transformation. In this report we describe a novel in vitro transformation system for normal rat colonic epithelium mediated by the introduction of oncogene elements using different retroviral vector constructs. The potential to generate cell lines representing different stages of neoplastic progression using relevant genetic components presents significant advantages for the study of cellular and molecular interactions underlying colon neoplastic progression.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,CANC BIOL LAB, 50 BINNEY ST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CYTOGENET LAB, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Pories, Susan/AAB-1757-2019	Pories, Susan/0000-0001-7315-9993	NATIONAL CANCER INSTITUTE [R01CA042944, P01CA044704, R23CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA42944, CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUTRUP H, 1978, IN VITRO CELL DEV B, V14, P868; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CATTERMOLE JA, 1989, J IMMUNOL, V142, P3746; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOPRA DP, 1981, IN VITRO CELL DEV B, V17, P441, DOI 10.1007/BF02626745; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; CZERNICHOW B, 1989, INT J CANCER, V44, P238, DOI 10.1002/ijc.2910440209; DANES BS, 1982, J NATL CANCER I, V69, P1271; DEMILIA JC, 1991, ONCOGENE, V6, P303; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBSON PR, 1989, GASTROENTEROLOGY, V96, P283, DOI 10.1016/0016-5085(89)91549-7; HAHN U, 1990, GASTROENTEROLOGY, V98, P322, DOI 10.1016/0016-5085(90)90821-H; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEDINGER M, 1987, DIFFERENTIATION, V36, P71, DOI 10.1111/j.1432-0436.1987.tb00182.x; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KONDO Y, 1985, EXP CELL RES, V159, P158, DOI 10.1016/S0014-4827(85)80045-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MESSER M, 1966, ANAL BIOCHEM, V14, P376, DOI 10.1016/0003-2697(66)90280-6; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEGREL R, 1983, EXP CELL RES, V143, P427, DOI 10.1016/0014-4827(83)90069-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; PAETAU A, 1985, ACTA NEUROPATHOL, V65, P190, DOI 10.1007/BF00686997; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; QUARONI A, 1985, J CELL BIOL, V100, P1611, DOI 10.1083/jcb.100.5.1611; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUARONI A, 1989, GASTROENTEROLOGY, V96, P535, DOI 10.1016/0016-5085(89)91584-9; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VIDRICH A, 1987, GASTROENTEROLOGY, V92, P1683; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WIEHLE RD, 1990, ONCOGENE, V5, P787; WILTZ O, 1990, IN PRESS GASTROENTER; YEH KY, 1980, IN VITRO CELL DEV B, V16, P976; ZWEIBAUM A, 1983, INT J CANCER, V32, P407, DOI 10.1002/ijc.2910320403	53	8	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					885	893						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373876				2022-12-25	WOS:A1992HP64200007
J	IKEDA, M; HAMANO, K; SHIBATA, T				IKEDA, M; HAMANO, K; SHIBATA, T			EPITOPE MAPPING OF ANTI-RECA PROTEIN IGGS BY REGION SPECIFIED POLYMERASE CHAIN-REACTION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; RECOMBINATION	Monoclonal IgGs were shown to be useful for the specific inhibition of a set of activities of the recA protein, a key protein in homologous genetic recombination. The mapping of the epitopes for these IgGs and site-directed mutagenesis based on the mapping will facilitate location of the functionally active sites on the tertiary structure of the protein, which is being solved by means of physicochemical techniques. We developed a novel technique for region-specified mutagenesis and applied the technique to epitope mapping. Using the polymerase chain reaction in the presence of deoxyinosine triphosphate, we introduced random base substitutions specifically into a region of the recA gene defined by a pair of primers. RecA mutants exhibiting altered antigenicity were selected, in plaque-immunoblotting experiments, from libraries of mutagenized recA genes constructed on the lambda-gt11 expression vector. Mutant recA genes were obtained at the frequency of about 10(-2) among the plaques expressing fused recA genes and then each one was expressed as a whole protein, which was characterized by enzyme-linked immunosorbent assay. Analyzing the DNA sequences of the mutant recA genes, we located at the amino acid sequence level the epitopes for two anti-recA IgGs which could not be located in previous studies. One of the antibodies was shown to prevent self-assembly of the recA protein and the other was suggested to inhibit the binding of double-stranded DNA. Thus, the active sites involved in these functions would be located in the space around or near the relevant epitope.	INST PHYS & CHEM RES,MICROBIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN								Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; IKAWA S, 1989, J BIOL CHEM, V264, P21167; IKEDA M, 1990, J BIOL CHEM, V265, P8948; KARU AE, 1982, BIOCHIMIE, V64, P723, DOI 10.1016/S0300-9084(82)80118-1; MAKINO O, 1987, J BIOL CHEM, V262, P12237; MAKINO O, 1985, J BIOL CHEM, V260, P5402; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1991, BIOCHIMIE, V73, P209, DOI 10.1016/0300-9084(91)90204-E; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	18	20	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6291	6296						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372903				2022-12-25	WOS:A1992HK31800086
J	NECKAMEYER, WS; WHITE, K				NECKAMEYER, WS; WHITE, K			A SINGLE LOCUS ENCODES BOTH PHENYLALANINE-HYDROXYLASE AND TRYPTOPHAN-HYDROXYLASE ACTIVITIES IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE-CONTAINING NEURONS; SEROTONIN-CONTAINING NEURONS; TYROSINE-HYDROXYLASE; DOPA DECARBOXYLASE; ESCHERICHIA-COLI; MESSENGER-RNA; SEQUENCE; EXPRESSION; GENE; MELANOGASTER	We have used a full-length clone encoding rabbit tryptophan hydroxylase (TRH) to isolate the Drosophila homologue (DTPH). Southern analysis of Drosophila genomic DNA reveals a pattern indicative of a single gene. The single transcript is expressed in adult head and body mRNA but is also detected in mRNA from early embryos. The embryonic transcript is ubiquitously expressed and appears to concentrate in yolk granules. In situ hybridization of TRH-homologous antisense RNA probe to sectioned tissue from third instar larvae demonstrated the presence of this transcript in fat body and cuticular tissue. Developmental immunoblot analysis using antibodies raised against a beta-galactosidase-Drosophila fusion protein revealed a 45-kDa embryonic protein also detected in female abdomens and a 50-kDa protein found in larval and adult stages. Immunocytochemical analysis of the Drosophila protein in the larval central nervous system showed that it appeared to be present in both serotonin- and catecholamine-containing neurons. A nonfusion protein generated in Escherichia coli hydroxylates both tryptophan and phenylalanine. We propose that there are only two aromatic amino acid hydroxylase genes in Drosophila: one encoding tyrosine hydroxylase, DTH, and DTPH, a gene encoding both tryptophan and phenylalanine hydroxylase activities.			NECKAMEYER, WS (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023510] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO 4671] Funding Source: Medline; NINDS NIH HHS [NS23510] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1986, J NEUROSCI, V6, P3682; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; ENGELS WR, 1986, FOCUS, V8, P6; GELTOSKY JE, 1980, BIOCHEM GENET, V18, P781, DOI 10.1007/BF00484593; GENETT HE, 1987, P NATL ACAD SCI USA, V82, P617; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Ichiyama A, 1976, Adv Exp Med Biol, V74, P103; ITOH N, 1985, DROS INF SERVICE, V61, P89; KATAROVA Z, 1990, EUR J NEUROSCI, V2, P190, DOI 10.1111/j.1460-9568.1990.tb00412.x; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; KUHN DM, 1980, P NATL ACAD SCI-BIOL, V77, P4688, DOI 10.1073/pnas.77.8.4688; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LIVINGSTONE MS, 1983, NATURE, V303, P67, DOI 10.1038/303067a0; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MARTINMORRIS LE, 1990, DEVELOPMENT, V110, P185; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORALES G, 1990, GENE, V93, P213, DOI 10.1016/0378-1119(90)90227-I; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RENSON J, 1962, J BIOL CHEM, V237, P2261; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VALLES AM, 1986, J NEUROSCI, V6, P1482; VALLES AM, 1988, J COMP NEUROL, V268, P414, DOI 10.1002/cne.902680310; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4199	4206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371286				2022-12-25	WOS:A1992HE60700093
J	MARGUET, D; BERNARD, AM; VIVIER, I; DARMOUL, D; NAQUET, P; PIERRES, M				MARGUET, D; BERNARD, AM; VIVIER, I; DARMOUL, D; NAQUET, P; PIERRES, M			CDNA CLONING FOR MOUSE THYMOCYTE-ACTIVATING MOLECULE - A MULTIFUNCTIONAL ECTO-DIPEPTIDYL PEPTIDASE-IV (CD26) INCLUDED IN A SUBGROUP OF SERINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; MEMBRANE GLYCOPROTEIN; AMINOPEPTIDASE-N; BP-1/6C3 ANTIGEN; SEQUENCE; COLLAGEN; PROTEIN; HEPATOCYTES; INVOLVEMENT; ANTIBODIES	Thymocyte-activating molecule (THAM) was initially characterized as a developmentally regulated, dimeric cell-surface molecule capable of activating mouse thymocytes and T lymphocytes upon monoclonal antibody (mAb)-mediated cross-linking. We recently obtained structural evidence indicating that this molecule is the mouse homologue of the human T cell-activating ectoenzyme CD26 (dipeptidyl peptidase IV, DPP IV). We describe here the cloning and the characterization of THAM cDNA. Two clones (3.3 and 2.8 kilobases) were isolated. THAM-3.3 cDNA contains an open reading frame of 2,280 nucleotides that encodes a protein of 760 amino acids having a calculated size of 87,500 Da. Complete N-glycosylation at each of the nine potential sites would result in a mature 110,000-Da molecule. Protein sequence comparisons revealed a significant homology (in particular in the COOH-terminal domain) between THAM and the rat or human DPP IV or the yeast dipeptidyl aminopeptidase B molecules (92, 85, and 30% sequence identity, respectively). Structural comparison of serine proteases (i.e. acyl-amino acid hydrolase or prolyl endopeptidase) with the most conserved domain of THAM identified a stretch of 200 amino acids containing a putative catalytic triad arranged in a novel topological order (Ser-624, Asp-702, and His-734) thereby defining a subfamily of nonclassical serine proteases. Expression of THAM during thymus ontogeny was found to be mainly regulated at the transcriptional level as determined by RNase protection assay. To investigate directly some of the functions which have been ascribed to DPP IV, we transfected an ovalbumin/A(q)-reactive, THAM- T hybridoma cell line with THAM-3.3 cDNA. The resultant transfectants acquired (i) DPP IV enzymatic activity that precisely paralleled the density of surface-expressed THAM; (ii) an M(r) = 115,000 (reduced) and 110,00/128,000 (nonreduced) molecule that could be immunoprecipitated by the THAM-specific mAb H194-112; and (iii) the capacity of being triggered by this mAb to release interleukin-2. These data indicate that a single cDNA species can encode a multifunctional molecule (e.g. activation signal-transducing structure and ectopeptidase), the heterodimeric state of which very likely results from a differential post-translational modification of the same protein core.	INSERM, U178, UNITE RECH DIFFERENCIAT & NEUROENDOCRINOL CELLULES, F-94807 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	MARGUET, D (corresponding author), CNRS, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE.		Marguet, Didier/AGO-5421-2022; Darmoul, Dalila/M-5812-2018; Marguet, Didier/B-9946-2008	Marguet, Didier/0000-0003-3198-5095; Darmoul, Dalila/0000-0002-1206-0655; 				ABBS MT, 1983, CLIN SCI, V65, P551, DOI 10.1042/cs0650551; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GORVEL JP, 1990, J IMMUNOL, V144, P2899; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HANSKI C, 1985, BIOL CHEM H-S, V366, P1169, DOI 10.1515/bchm3.1985.366.2.1169; HEGEN M, 1990, J IMMUNOL, V144, P2908; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HONG WJ, 1988, J BIOL CHEM, V263, P16892; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HUSSAIN MM, 1985, BIOCHIM BIOPHYS ACTA, V815, P306, DOI 10.1016/0005-2736(85)90301-3; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Maniatis T, 1989, MOL CLONING; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MARQUEZ C, 1990, EUR J IMMUNOL, V20, P947, DOI 10.1002/eji.1830200436; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAQUET P, 1991, CURR OPIN IMMUNOL, V3, P326, DOI 10.1016/0952-7915(91)90032-V; NAQUET P, 1988, J IMMUNOL, V141, P4101; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OGATA S, 1989, J BIOL CHEM, V264, P3596; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PIERRES A, 1984, J IMMUNOL, V132, P2775; PONT S, 1985, EUR J IMMUNOL, V15, P1222, DOI 10.1002/eji.1830151215; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; VIVIER I, 1991, J IMMUNOL, V147, P447; WELCH PA, 1990, INT IMMUNOL, V2, P697, DOI 10.1093/intimm/2.8.697; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YOSHIMOTO T, 1981, J BIOCHEM, V90, P325, DOI 10.1093/oxfordjournals.jbchem.a133477	50	103	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2200	2208						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370813				2022-12-25	WOS:A1992HB53200015
J	SMITH, D; BURGIN, AB; HAAS, ES; PACE, NR				SMITH, D; BURGIN, AB; HAAS, ES; PACE, NR			INFLUENCE OF METAL-IONS ON THE RIBONUCLEASE-P REACTION - DISTINGUISHING SUBSTRATE BINDING FROM CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA PRECURSORS; ESCHERICHIA-COLI; M1 RNA; ENZYME; REQUIREMENTS; COMPONENT; CLEAVAGE; SUBUNIT; SITE	A high yield, photoactivated cross-linking reaction between a modified tRNA and RNase P RNA was used as a quantitative assay of substrate binding affinity. The cross-linking assay allows the effects of metal ions on substrate binding to be measured independently and in the absence of the pre-tRNA cleavage reaction. The results of this assay, in conjunction with the conventional cleavage assay, support the following conclusions about the nature of the RNase P RNA-tRNA binding interaction. (i) Monovalent cations act primarily to enhance enzyme-substrate binding, presumably by functioning as counterions. This enhancement can be attributed to a reduction in the tRNA off-rate. (ii) Although divalent cation is required for cleavage, the enzyme-substrate complex can form in the absence of divalent cation; the essential role of divalent cation in the reaction is thus catalytic. (iii) Ca2+ is as efficient as Mg2+ in promoting binding but supports catalysis only at a low rate.	INDIANA UNIV, INST MOLEC & CELLULAR BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	SMITH, D (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034527, R37GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527, GM13712] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BROWN JW, 1991, J BACTERIOL, V173, P3855, DOI 10.1128/JB.173.12.3855-3863.1991; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARTER BJ, 1990, J BIOL CHEM, V265, P7100; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GARDINER KJ, 1985, J BIOL CHEM, V260, P5415; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; Haydock K, 1985, Prog Clin Biol Res, V172A, P87; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PACE NR, 1990, J BIOL CHEM, V265, P3587; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; SURRATT CK, 1990, J BIOL CHEM, V265, P22513; TU AT, 1974, MET IONS BIOL SYST, V1, P2; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; Yarus M, 1979, Prog Nucleic Acid Res Mol Biol, V23, P195; YARUS M, 1983, GENE FUNCTION PROKAR, P23	24	140	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2429	2436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370819				2022-12-25	WOS:A1992HB53200050
J	BLOCHBERGER, TC; VERGNES, JP; HEMPEL, J; HASSELL, JR				BLOCHBERGER, TC; VERGNES, JP; HEMPEL, J; HASSELL, JR			CDNA TO CHICK LUMICAN (CORNEAL KERATAN SULFATE PROTEOGLYCAN) REVEALS HOMOLOGY TO THE SMALL INTERSTITIAL PROTEOGLYCAN GENE FAMILY AND EXPRESSION IN MUSCLE AND INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CORE PROTEIN; LINKAGE-REGION; COLLAGEN; DECORIN; IDENTIFICATION; FIBROMODULIN; LOCALIZATION; SEQUENCE; BIGLYCAN	A 1.9-kb cDNA clone to chick lumican (keratan sulfate proteoglycan) was isolated by screening an expressing vector library made from chick corneal RNA with antiserum to chick corneal lumican. The cDNA clone contained an open reading frame coding for a 343-amino acid protein, M(r) = 38,640. Structural features of the deduced sequence include: a 18-amino acid signal peptide, cysteine residues at the N- and C-terminal regions, and a central leucine-rich region (comprising 62% of the protein) containing nine repeats of the sequence LXXLXLXXNXL/I, where X represents any amino acid. Lumican contains three variations of this sequence that are tandemly linked to form a unit and three units tandemly linked to form the leucine-rich region. The sequential arrangement of these repeats and their spacing suggest that this region arose by duplication. The deduced sequence shows five potential N-linked glycosylation sites, four of which are in the leucine-rich region. These sites are also potential keratan sulfate attachment sites. The cDNA clone to lumican hybridizes to a 2.0-kb mRNA found in tissues other than cornea, predominantly muscle and intestine. Radiolabeling and immunoprecipitation studies show that lumican core protein is also synthesized by these tissues. The primary structure of lumican is similar to fibromodulin, decorin, and biglycan, which indicates it belongs to the small interstitial proteoglycan gene family. The expression of lumican in tissues other than cornea indicates a broader role for lumican besides contributing to corneal transparency.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BLOCHBERGER, TC (corresponding author), UNIV PITTSBURGH, SCH MED, EYE & EAR INST PITTSBURGH, DEPT OPHTHALMOL, PITTSBURGH, PA 15213 USA.				NEI NIH HHS [EY08104, 5-P30-EY08098] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008104, R37EY008104, P30EY008098] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CINTRON C, 1978, J ULTRA MOL STRUCT R, V65, P13, DOI 10.1016/S0022-5320(78)90017-5; CONRAD GW, 1970, DEV BIOL, V21, P292, DOI 10.1016/0012-1606(70)90126-0; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; GLOSSL J, 1983, BIOCHEM J, V215, P295; HART GW, 1976, J BIOL CHEM, V251, P6513; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E D, 1969, Monogr Dev Biol, V1, P1; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Maurice DM, 1984, EYE B, V1, P1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRECENGOST PK, IN PRESS ARCH BIOCH; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; STUHLSATZ HW, 1971, HOPPESEYLERS Z PHYSL, V252, P289; SUGRUE SP, 1991, INVEST OPHTH VIS SCI, V32, P140; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TOOLE BP, 1971, DEV BIOL, V26, P28, DOI 10.1016/0012-1606(71)90104-7; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	43	211	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					347	352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370446				2022-12-25	WOS:A1992GY43900057
J	SINICROPE, FA; DUDEJA, PK; BISSONNETTE, BM; SAFA, AR; BRASITUS, TA				SINICROPE, FA; DUDEJA, PK; BISSONNETTE, BM; SAFA, AR; BRASITUS, TA			MODULATION OF P-GLYCOPROTEIN-MEDIATED DRUG TRANSPORT BY ALTERATIONS IN LIPID FLUIDITY OF RAT-LIVER CANALICULAR MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; INTESTINAL MICROVILLUS MEMBRANES; NA+-H+ EXCHANGE; PLASMA-MEMBRANE; CROSS-RESISTANCE; LEUCINE AMINOPEPTIDASE; PHOTOACTIVE ANALOGS; ADENYLATE-CYCLASE; GENE-PRODUCT; TUMOR-CELLS	P-glycoprotein (P-gp) is believed to function as an ATP-dependent efflux pump for natural product anti-cancer drugs in multidrug-resistant (MDR) tumor cells and in certain normal tissues. P-gp has been localized to the apical plasma membrane of the bile canaliculus where it has been shown to transport [H-3]daunomycin. In this study, we investigated whether alterations in membrane lipid fluidity of canalicular membrane vesicles (CMV) could modulate the P-gp-mediated accumulation of [H-3]daunomycin and [H-3]vinblastine. Accumulation of both cytotoxic agents was stimulated by ATP, exhibited temperature dependence and osmotic sensitivity, and followed Michaelis-Menten kinetics. Alterations in CMV lipid fluidity were induced by the known fluidizers, 2-(2-methoxyethoxy)ethyl 8-(cis-2-n-octylcyclopropyl)octanoate (A2C) and benzyl alcohol, and were assessed by fluorescence polarization techniques using the fluorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH). Both A2C (2.5-5.0 muM) and benzyl alcohol (10-20 mM) produced a dose-dependent increase in CMV lipid fluidity. Moreover, both fluidizers, at the above doses, significantly inhibited (p < 0.05) the ATP-dependent accumulation of [H-3]daunomycin. [H-3]Vinblastine accumulation was also inhibited by A2C (p < 0.05). Lower doses of A2C (0.6 muM) and benzyl alcohol (1 mM) failed to influence either lipid fluidity or P-gp-mediated drug accumulation. Kinetic analysis revealed that A2C (5.0 muM) noncompetitively inhibited [H-3]daunomycin accumulation and uncompetitively inhibited [H-3]vinblastine accumulation with apparent K(i) values of almost-equal-to 1.5 and almost-equal-to 1.2 muM, respectively. Verapamil competitively inhibited P-gp-mediated accumulation of [H-3]daunomycin but failed to alter the fluidity of CMV. Taken together, the present results demonstrate that while increases in membrane fluidity of CMV are not necessarily required to inhibit P-gp-mediated drug accumulation, they can inhibit these processes, at least in CMV. Alterations in the physical state of CMV, therefore, appear to be at least one important modulator of P-gp function.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago					NATIONAL CANCER INSTITUTE [R01CA036745, R29CA047652, R37CA036745, R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078, CA-47652, CA-36745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BIEDLER JL, 1970, CANCER RES, V30, P1174; BRASITUS TA, 1979, BIOCHEMISTRY-US, V18, P4136, DOI 10.1021/bi00586a013; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BRASITUS TA, 1980, BIOCHEMISTRY-US, V19, P2763, DOI 10.1021/bi00553a035; BRASITUS TA, 1986, BIOCHIM BIOPHYS ACTA, V855, P16, DOI 10.1016/0005-2736(86)90183-5; BRASITUS TA, 1988, ADV MEMBRANE FLUIDIT, V2, P227; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DAVIS RA, 1978, P NATL ACAD SCI USA, V75, P4130, DOI 10.1073/pnas.75.9.4130; DIPPLE I, 1978, BIOCHEM J, V174, P179, DOI 10.1042/bj1740179; DUDEJA PK, 1991, ARCH BIOCHEM BIOPHYS, V284, P338, DOI 10.1016/0003-9861(91)90305-3; DUDEJA PK, 1991, AM J PHYSIOL, V260, pG586, DOI 10.1152/ajpgi.1991.260.4.G586; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUFFY MM, 1984, CANCER RES, V44, P1863; HARIG JM, 1989, AM J PHYSIOL, V256, pG618, DOI 10.1152/ajpgi.1989.256.3.G618; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; INOUE M, 1983, J BIOL CHEM, V258, P5183; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; KEEFFE EB, 1980, GASTROENTEROLOGY, V79, P222; KESSEL D, 1988, BIOCHEM PHARMACOL, V37, P4253, DOI 10.1016/0006-2952(88)90603-X; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1977, J BIOL CHEM, V252, P1990; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLS PR, 1987, HEPATOLOGY, V7, P61, DOI 10.1002/hep.1840070114; MONTAUDON D, 1986, CANCER RES, V46, P5602; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; NAITO M, 1989, CANCER RES, V49, P1452; RAMU A, 1983, CANCER RES, V43, P5533; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SCHACHTER D, 1984, HEPATOLOGY, V4, P140, DOI 10.1002/hep.1840040124; SCHROEDER F, 1988, BIOCHIM BIOPHYS ACTA, V946, P85, DOI 10.1016/0005-2736(88)90460-9; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; SIMON FR, 1980, J CLIN INVEST, V65, P851, DOI 10.1172/JCI109737; SKOVSGAARD T, 1978, CANCER RES, V38, P4722; SWEET WD, 1986, BIOCHIM BIOPHYS ACTA, V861, P53, DOI 10.1016/0005-2736(86)90370-6; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P265; WHETTON AD, 1983, BIOCHEM PHARMACOL, V32, P1601, DOI 10.1016/0006-2952(83)90334-9; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	59	141	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24995	25002						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1360981				2022-12-25	WOS:A1992KB60300016
J	WEISZ, OA; MACHAMER, CE; HUBBARD, AL				WEISZ, OA; MACHAMER, CE; HUBBARD, AL			RAT-LIVER DIPEPTIDYLPEPTIDASE-IV CONTAINS COMPETING APICAL AND BASOLATERAL TARGETING INFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; CANINE KIDNEY-CELLS; HEPATOCYTE PLASMA-MEMBRANE; VESICULAR STOMATITIS-VIRUS; AMINO-ACID SEQUENCE; AMINOPEPTIDASE-N; PEPTIDASE-IV; MDCK CELLS; INTRACELLULAR-TRANSPORT; VIRAL GLYCOPROTEINS	Madin-Darby canine kidney (MDCK) cells deliver endogenous apical and basolateral proteins directly to the appropriate domains. We are investigating the molecular signals on a model plasma membrane hydrolase, dipeptidylpeptidase IV (DPPIV). Most newly synthesized rat liver DPPIV is delivered directly to the apical surface of transfected MDCK cells; however, about 20% is delivered first to the basolateral surface and reaches the apical surface via transcytosis (Casanova, J. E., Mishumi, Y., Ikehara, Y., Hubbard, A. L., and Mostov, K. E. (1991) J. Biol. Chem. 266, 24428-24432). A soluble form of DPPIV (solDPPIV) containing only the lumenal domain of the protein was efficiently transported and secreted by stably transfected MDCK cells. If this domain contains apical sorting information, we would expect 80% of the soluble protein to be secreted apically. Surprisingly, 95% of the secreted solDPPIV was found in the apical medium. The high efficiency of apical secretion suggested that the transmembrane domain and cytoplasmic tail of DPPIV might contain competing basolateral targeting information. To test this hypothesis, we investigated the trafficking of a chimera in which the cytoplasmic tail and transmembrane domains of DPPIV were joined to lysozyme, an exogenous protein which should not contain sorting information. This protein was delivered predominantly to the basolateral surface. Our results suggest that the lumenal domain of DPPIV carries dominant apical sorting information while the transmembrane domain and cytoplasmic tail of the molecule contains competing basolateral sorting information.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014114, R01GM029185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44375] Funding Source: Medline; NIGMS NIH HHS [GM29185, GM14114] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; ELOVSON J, 1980, J BIOL CHEM, V255, P5816; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; HUBBARD AL, 1991, CELL, V66, P907; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW SH, 1991, J BIOL CHEM, V266, P19710; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; OJAKIAN GK, 1990, AM J PHYSIOL, V258, pC390, DOI 10.1152/ajpcell.1990.258.3.C390; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RODRIGUEZBOULAN E, 1989, ANNU REV PHYSIOL, V51, P741, DOI 10.1146/annurev.physiol.51.1.741; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; TIRUPPATHI C, 1986, ANAL BIOCHEM, V153, P330, DOI 10.1016/0003-2697(86)90100-4; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATT VM, 1989, J BIOL CHEM, V264, P5480; WEISZ O A, 1991, Journal of Cell Biology, V115, p194A; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923	51	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22282	22288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1358878				2022-12-25	WOS:A1992JW71900047
J	MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S				MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S			CHARACTERIZATION OF A PAIRED BOX-CONTAINING AND HOMEOBOX-CONTAINING QUAIL GENE (PAX-QNR) EXPRESSED IN THE NEURORETINA	ONCOGENE			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; LEUKEMIA VIRUSES; MESSENGER-RNAS; TARGET-CELLS; NEURAL-TUBE; HOMEODOMAIN; PROTEIN; MYC; DIFFERENTIATION	The retina is an integral part of the central nervous system, and consists of two layers, the outer pigmented layer and the inner sensory layer or neuroretina (NR). The NR layer contains several strata of cells (glial and neuronal) derived from proliferating neuroectodermal precursors that differentiate after terminal mitosis. In vitro, NR cells can differentiate not only into neuronal and glial types, but also into pigment and lens cells. Quail (Coturnix coturnix japonica) NR cells (QNR) infected with MC29 transforming retrovirus become pigmented after several passages in vitro. In order to characterize the genes expressed in these pigmented MC29 QNR, a cDNA library was prepared from these cells. After differential screening we have isolated a cDNA clone which identifies an RNA expressed in NR but not in the pigmented layer of the retina. This cDNA encodes a protein related to that of Drosophila, mouse and zebrafish paired box- and homeobox-containing segmentation genes and is called Pax-QNR. The expression of Pax-QNR in the NR is confined to the ganglionic cell layer and to the lower part of the inner nuclear layer containing the amacrine or correlation neurones.	INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014					ALEMA S, 1985, MOL CELL BIOL, V5, P538, DOI 10.1128/MCB.5.3.538; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FAUQUET M, 1990, P NATL ACAD SCI USA, V87, P1546, DOI 10.1073/pnas.87.4.1546; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GAUZZI S, 1990, EMBO J, V9, P3631; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOSTES B, 1991, MECH DEVELOP, V33, P27; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maniatis T., 1982, MOL CLONING; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Okada T.S., 1976, TESTS TERATOGENICITY, P91; QUEVA C, 1992, IN PRESS DEVELOPMENT, V114; ROMANOFF A, 1954, AVIAN EMBRYO, P382; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; SAULE S, 1981, J VIROL, V38, P409, DOI 10.1128/JVI.38.2.409-419.1981; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VENNSTROM B, 1981, J VIROL, V39, P625; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	42	98	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1721	1728						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354346				2022-12-25	WOS:A1992JJ37600007
J	NINOMIYA, H; SIMS, PJ				NINOMIYA, H; SIMS, PJ			THE HUMAN-COMPLEMENT REGULATORY PROTEIN CD59 BINDS TO THE ALPHA-CHAIN OF C8 AND TO THE B-DOMAIN OF C9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID SEQUENCE; HUMAN-ERYTHROCYTES; TARGET MEMBRANES; 9TH COMPONENT; MESSENGER-RNA; INSERTION; C5B-9; HOMOLOGY; BILAYERS	The erythrocyte membrane inhibitor of the human terminal complement proteins, surface antigen CD59, has previously been shown to enter into a detergent-resistant complex with either the membrane-bound complex of C5b-8 or C5b-9 (Meri, S., Morgan, B. P., Davies, A., Daniels, R. H., Olavesen, M. G., Waldmann, H. and Lachmann, P. J. (1990) Immunology 71, 1-9; Rollins, S. A., Zhao, J., Ninomiya, H., and Sims, P. J. (1991) J. Immunol, 146,2345-2351). In order to further define the interactions that underlie the complement-inhibitory function of CD59, we have examined the binding interactions between I-125-CD59 and the isolated components of human complement membrane attack complex, C5b6, C7, C8, and C9. By density gradient analysis, we were unable to detect interaction of I-125-CD59 with any of these isolated complement components in solution. Specific binding of I-125-CD59 to C8 and C9 was detected when these human complement proteins were adsorbed to either plastic or to nitrocellulose, suggesting that a conformational change that accompanies surface adsorption exposes a CD59-binding site that is normally buried in these serum proteins. The binding of I-125-CD59 to plastic-adsorbed C8 and C9 was saturable and competed by excess unlabeled CD59, with half-maximal binding observed at I-125-CD59 concentrations of 80 and 36 nM, respectively. No specific binding of I-125-CD59 was detected for surface-adsorbed human C5b6 or C7 nor was such binding observed for C8 or C9 isolated from rabbit serum. Binding of CD59 to human C8 and C9 was not mediated by the phospholipid moiety of CD59, implying association by protein-protein interaction. In order to further define the binding sites for CD59, ligand blotting with I-125-CD59 was performed after separation of CS into its noncovalently associated subunits (C8-alpha-gamma and C8-beta) and after alpha-thrombin digestion of C9. These experiments revealed specific and saturable binding of I-125-CD59 to C8-alpha-gamma-subunit (half-maximal binding at 75 nM), but not to C8-beta, and specific and saturable binding to the 37-kDa fragment (C9b) of thrombin-cleaved C9 (half-maximal binding at 35 nM), but not to the 25-kDa C9a fragment. Partial reduction of C8-alpha-gamma revealed that only C8-alpha polypeptide exhibited affinity for CD59, and no specific binding to the C8-gamma-chain was detected. No binding of I-125-CD59 was observed to either of the two C9 fragments derived by digestion with trypsin (20 and 52 kDa), an enzyme that cleaves at a single site within the C9b domain. Taken together, these results suggest that the CD59 recognition site(s) that underlies its C5b-9-inhibitory function represents a structure that is common to the alpha-subunit of human C8 and to the C9b domain of human C9.	OKLAHOMA MED RES FDN,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [2RO1-HL36061, 1R01-HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL036061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESECKER G, 1982, J BIOL CHEM, V257, P2584; CHAKRAVARTI DN, 1989, P NATL ACAD SCI USA, V86, P2799, DOI 10.1073/pnas.86.8.2799; DAVE SJ, 1990, J IMMUNOL, V144, P3087; DECKERT M, 1992, J IMMUNOL, V148, P672; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HAMILTON KK, 1990, BLOOD, V76, P2572; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOWARD OMZ, 1987, BIOCHEMISTRY, V26; KORTY PE, 1991, J IMMUNOL, V146, P4092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1989, NATURE, V341, P63, DOI 10.1038/341063a0; LAINE RO, 1988, BIOCHEMISTRY, V27; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P8404; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PALFREE RGE, 1991, IMMUNOL TODAY, V12, P170, DOI 10.1016/0167-5699(91)90086-9; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; PODACK ER, 1981, P NATL ACAD SCI-BIOL, V78, P4544, DOI 10.1073/pnas.78.7.4544; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; STANLEY KK, 1986, MOL IMMUNOL, V23, P451, DOI 10.1016/0161-5890(86)90108-2; STECKEL EW, 1983, J BIOL CHEM, V258, P4318; STEWART JL, 1985, BIOCHEMISTRY-US, V24, P4598, DOI 10.1021/bi00338a018; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P589, DOI 10.1093/oxfordjournals.jbchem.a122900; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	32	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13675	13680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377690				2022-12-25	WOS:A1992JB74600091
J	DECKERSHEBESTREIT, G; ALTENDORF, K				DECKERSHEBESTREIT, G; ALTENDORF, K			INFLUENCE OF SUBUNIT-SPECIFIC ANTIBODIES ON THE ACTIVITY OF THE F0 COMPLEX OF THE ATP SYNTHASE OF ESCHERICHIA-COLI .2. EFFECTS OF SUBUNIT C-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR LOOP REGION; H+-ATPASE; PROTEOLIPID SUBUNIT; UNCE PROTEIN; F1F0; MEMBRANE; DICYCLOHEXYLCARBODIIMIDE; RECONSTITUTION; MUTATIONS; FRAGMENTS	After incubation of F1-stripped everted membrane vesicles with antibodies against subunit c of the ATP synthase of Escherichia coli the proton translocation through the open F0 channel was blocked. Rebinding of F1 to those vesicles is affected by the antibody concentration used. In general, the use of F(ab')2 or Fab fragments prepared from anti-c antibodies gave similar results. However, using Fab fragments a higher amount of antigenic binding sites was necessary to block the F0 complex completely, whereas extremely low amounts of Fab fragments were necessary to inhibit the binding of F1. This can be explained by an antigenic determinant of subunit c, which is only accessible to the smaller Fab fragments with a molecular mass of approximately 50,000. Incubation of F1-containing everted membranes with anti-c antibodies showed that the binding of the antibodies resulted in a displacement of F1, while simultaneously the proton translocation through F0 has been blocked. Such a displacement can only be observed after incubation with IgG molecules or F(ab')2 fragments. Fab fragments were not able to displace the F1 part, indicating that the ability of antibodies and F(ab')2 fragments to produce cross-links is responsible for the loss of F1 from the membranes.			DECKERSHEBESTREIT, G (corresponding author), UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY.							ALTENDORF K, 1979, FUNCTION MOL ASPECTS, P53; ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; DAVIES ME, 1978, J IMMUNOL METHODS, V21, P305, DOI 10.1016/0022-1759(78)90157-6; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DECKERSHEBESTREIT G, 1986, J BIOL CHEM, V261, P4878; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1987, BIOCHEMISTRY-US, V26, P5486, DOI 10.1021/bi00391a041; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FIMMEL AL, 1985, BIOCHIM BIOPHYS ACTA, V808, P252, DOI 10.1016/0005-2728(85)90007-6; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GODINOT C, 1986, BIOCHIMIE, V68, P367, DOI 10.1016/S0300-9084(86)80003-7; HENSEL M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P63, DOI 10.1016/0005-2728(90)90007-Q; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; HOPPE J, 1980, EUR J BIOCHEM, V112, P17, DOI 10.1111/j.1432-1033.1980.tb04981.x; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; LOO TW, 1982, BIOCHEM BIOPH RES CO, V106, P400, DOI 10.1016/0006-291X(82)91124-X; LOO TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P274, DOI 10.1016/0005-2736(83)90532-1; MADSEN LH, 1976, J IMMUNOL METHODS, V9, P355, DOI 10.1016/0022-1759(76)90210-6; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOODY MF, 1987, J MOL BIOL, V193, P759, DOI 10.1016/0022-2836(87)90357-3; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; NALIN CM, 1987, CURR TOP BIOENERG, V15, P273; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STEFFENS K, 1987, J BIOL CHEM, V262, P6334; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WACHTER E, 1980, FEBS LETT, V113, P265, DOI 10.1016/0014-5793(80)80606-5	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12370	12374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376323				2022-12-25	WOS:A1992HY94700107
J	FAURE, R; BAQUIRAN, G; BERGERON, JJM; POSNER, BI				FAURE, R; BAQUIRAN, G; BERGERON, JJM; POSNER, BI			THE DEPHOSPHORYLATION OF INSULIN AND EPIDERMAL GROWTH-FACTOR RECEPTORS - ROLE OF ENDOSOME-ASSOCIATED PHOSPHOTYROSINE PHOSPHATASE(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASES; RAT-LIVER; POLYACRYLAMIDE GELS; PHOSPHORYLATION; ACTIVATION; CLONING; KINASE; EXPRESSION; ADIPOCYTES; INVIVO	The autophosphorylation, from [gamma-P-32]ATP, of insulin and epidermal growth factor receptors in rat liver endosomes peaked at 2-5 min and declined thereafter. When autophosphorylation from either [gamma-P-32]ATP or unlabeled ATP was stopped after 5 min by adding excess EDTA +/- ATP, the phosphotyrosine (PY) content of each receptor decreased at 37-degrees-C with a t1/2 of 1.6 min. This was equally so whether the PY content of P-32-labeled receptors was analyzed by autoradiography of KOH-treated gels or by Western blotting with PY antibodies of immunoprecipitated receptors. The dephosphorylation reaction was strictly dependent on the presence of sulfhydryl, was unaffected by the addition of rat liver cytosol, and was temperature-dependent. The phosphotyrosine phosphatase(s) (PTPase(s)) appeared to be tightly anchored to the endosomal membrane, since the dephosphorylation reaction was unaffected by sodium carbonate and 0.6 M KCl treatments. However, treatment with Triton X-100 abolished dephosphorylation, implying an intimate association between the PTPase(s) and its substrate in an intact membrane environment. The powerful insulinomimetic agent pervanadate was the most potent inhibitor (50% inhibition at 1-mu-M). Increasing the dose of injected ligand augmented the rate of insulin and decreased that of EGF receptor dephosphorylation, respectively. Immunoblotting with specific antibodies failed to identify PTPase IB or T-cell PTPase in ENs, whereas positive signals were seen in plasma membrane. These studies indicate that the phosphorylation state of receptor tyrosine kinases is dynamically regulated, with dephosphorylation, by closely associated PTPase(s), playing an important role.	MCGILL UNIV,DEPT ANAT,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021					BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOURASSA C, 1988, ANAL BIOCHEM, V169, P356, DOI 10.1016/0003-2697(88)90295-3; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRUPPUSO PA, 1990, J CLIN INVEST, V85, P1754, DOI 10.1172/JCI114632; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KHAN MN, 1981, J BIOL CHEM, V257, P5969; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; NECHAY BR, 1986, FASEB J, V45, P123; PEASE RJ, 1985, BIOCHEM J, V228, P137, DOI 10.1042/bj2280137; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1989, ADV PROTEIN PHOSPHAT, V5, P149; WHITE MF, 1986, ENZYMES, V17, P247; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	44	127	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11215	11221						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375938				2022-12-25	WOS:A1992HX16900046
J	ERWIN, JL; ANDERSON, SM				ERWIN, JL; ANDERSON, SM			ANALYSIS OF PHOSPHOTYROSINE-CONTAINING PROTEINS PRESENT IN V-SRC-INFECTED MYELOID PROGENITOR CELLS	ONCOGENE			English	Note							AVIAN-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; LINE; KINASES; GAP; RECEPTORS; GENE	We examined the phosphotyrosine-containing proteins in v-src-infected myeloid cells. Proteins with relative molecular weights (M(r)) of 180 000, 175 000, 135 000, 125 000, 120 000, 90 000, 75 000, and 60 000 were present in v-src-infected but not in uninfected 32D c13 cells. Stimulation of 32D c13 cells with interleukin 3 (IL-3) resulted in the tyrosine phosphorylation of a protein of 150 000 (M(r)), which was not phosphorylated in v-src-infected 32D ct3 cells. A panel of monoclonal antibodies directed against phosphotyrosine-containing proteins in v-src-transformed chicken embryo fibroblasts (3C4, 2A7, 2B12 and 4F11, directed against p210, p125, p120 and p85 respectively) was used to characterize these substrates. We did not observe tyrosine phosphorylation of proteins recognized by these four monoclonal antibodies in either IL-3-stimulated or v-src-infected 32D c13 cells. However, we did detect tyrosine phosphorylation of proteins recognized by these monoclonal antibodies in v-src-transformed NIH3T3 cells. Tyrosine phosphorylation of GTPase-activating protein (GAP)-and the GAP-associated proteins p62 and p190 was observed in v-src-infected 32D c13 cells. Stimulation of 32D c13 celts with IL-3 does not induce phosphorylation of GAP or the GAP-associated proteins p62 or p190. These results suggest that substrates for v-src vary between different cell types.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA45241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUGER A, 1991, ONCOGENE, V6, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; METCALF D, 1985, BLOOD, V65, P357; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROVERA G, 1987, ONCOGENE, V1, P29; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	28	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1101	1107						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375716				2022-12-25	WOS:A1992HU64200007
J	RITTLING, SR; DENHARDT, DT				RITTLING, SR; DENHARDT, DT			P53 MUTATIONS IN SPONTANEOUSLY IMMORTALIZED 3T12 BUT NOT 3T3 MOUSE EMBRYO CELLS	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; ACTIVATING MUTATIONS; SIMIAN VIRUS-40; GENE-MUTATIONS; RAS ONCOGENE; LUNG-CANCER; FIBROBLASTS; CULTURE; PROTEIN; LINES	We have asked whether p53 mutations are involved in the process of spontaneous immortalization of mouse embryo cells. Cells from Swiss mouse embryos were used to prepare 3T3 and 3T12 lines according to the protocol of Todaro & Green [(1963). J. Cell Biol., 17, 299-313]. After the cells emerged from crisis, p53 sequences were amplified by polymerase chain reaction (PCR) from both RNA and DNA. The sequence of the aggregated cDNA from each of six 3T3 lines showed no evidence of mutation. PCR-amplified p53 cDNA from two 3T3 lines was cloned, and individual clones in M13mp19 were partially sequenced. One cell line showed a single, non-coding nucleotide change in 2/8 independent clones. Nine cDNA clones from the second 3T3 lines were sequenced, and no single nucleotide changes appeared more than once. The mutations which appeared only once were not detected in clones of genomic DNA. Since these apparent mutations are probably reverse transcriptase or Taq polymerase errors, we conclude that both the 3T3 lines contained only wild-type p53. In two out of three independent 3T12 lines however, missense mutations were readily observed in the aggregate cDNA sequence. Restriction fragment length polymorphism and Southern blot analyses of the genomic DNA indicated that these cells were homozygous for the mutations. The p53 protein molecules in four cell lines were analysed by immunoprecipitation: one 3T12 line showed the pattern of antibody reactivity characteristic of some p53 mutants, while the others displayed the wild-type pattern. We conclude that p53 mutations arise and are strongly selected for during immortalization according to the 3T12 but not the 3T3 protocol.			RITTLING, SR (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,POB 1059,PISCATAWAY,NJ 08855, USA.				NIA NIH HHS [AG07972] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007972] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AARONSON SA, 1968, SCIENCE, V162, P24; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AUSUBEL FM, 1989, JCURRENT PROTOCOLS M; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DENHARDT DT, 1991, EXP CELL RES, V192, P128, DOI 10.1016/0014-4827(91)90167-S; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KELMAN Z, 1989, BLOOD, V74, P2318; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACIEIRACOELHO A, 1976, GERONTOLOGY, V22, P3, DOI 10.1159/000212121; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	52	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					935	942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349164				2022-12-25	WOS:A1992HP64200013
J	RANGNEKAR, VV; WAHEED, S; RANGNEKAR, VM				RANGNEKAR, VV; WAHEED, S; RANGNEKAR, VM			INTERLEUKIN-1-INDUCIBLE TUMOR-GROWTH ARREST IS CHARACTERIZED BY ACTIVATION OF CELL TYPE-SPECIFIC EARLY GENE-EXPRESSION PROGRAMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; PROTO-ONCOGENE FOS; NECROSIS FACTOR; C-MYC; EARLY RESPONSE; IL-1; ENCODES; LINE; BETA; DIFFERENTIATION	Human melanoma cells, A375-C6, were "committed" to growth arrest within a few hours of exposure to interleukin-1 (IL-1). Co-treatment with actinomycin D rescued the cells from the "commitment," suggesting that "early" gene activation events may be crucial for growth arrest. To understand the mechanism of IL-1 action, we are studying early genes whose expression is induced by the cytokine. Five early genes associated with IL-1 action in the melanoma cells were isolated by differential screening of a cDNA library, which was enriched for sequences representing IL-1 responsive genes (IRGs). Nucleotide sequencing identified four of the genes as gro-alpha, gro-beta, c-jun and nur77/NGF1-B/NAK1, respectively, while the fifth was judged as novel by GenBank search and designated IRG-9. None of the early genes was uniquely associated with the antiproliferative action of IL-1: other growth-inhibitory as well as growth-stimulatory signals induced these genes in diverse cell types. However, analysis of the induction patterns of the IRGs and other well known early genes revealed that IL-1 action in the melanoma cells is characterized by activation of a unique primary gene expression program. This program was defined by the magnitude and temporal pattern of induction of the five IRGs, feeble induction of c-fos, and lack of induction of Egr-1 and c-myc. We present evidence that this program is growth arrest-specific in the melanoma cells and that distinct cell type-specific programs are associated with IL-1 growth-regulatory actions in other tumor cells. Based on these data, we propose that early genes may play multifunctional roles in tumor growth control, but specificity for the growth arrest action of IL-1 is determined by the composite early gene induction program.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago					NCI NIH HHS [PTHB1 R29CA52839] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BOHMANN D, 1987, SCIENCE, V238, P1336; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1985, CANCER SURV, V4, P655; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ENDO Y, 1988, J IMMUNOL, V141, P2342; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HORUK R, 1987, J BIOL CHEM, V262, P16275; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KILLIAN PL, 1986, J IMMUNOL, V136, P4509; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LIU JW, 1991, J BIOL CHEM, V266, P5929; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MANIATIS T, 1982, MOL CLONING LAB MANU; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUSHIMA K, 1985, PHYSL METABOLIC IMMU, P253; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MUNOZ E, 1991, J IMMUNOL, V146, P136; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; NAKAMURA S, 1986, JPN J CANCER RES, V77, P767; ONOZAKI K, 1985, J IMMUNOL, V135, P314; ONOZAKI K, 1988, J IMMUNOL, V140, P112; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; USAI N, 1991, CANCER RES, V51, P769; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VILCEK J, 1987, J BIOL CHEM, V262, P11908; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	57	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6240	6248						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372901				2022-12-25	WOS:A1992HK31800079
J	HOLLANDER, N				HOLLANDER, N			MEMBRANE DYNAMICS OF THE PHOSPHATIDYLINOSITOL-ANCHORED FORM AND THE TRANSMEMBRANE FORM OF THE CELL-ADHESION PROTEIN LFA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; LATERAL DIFFUSION; PLASMA-MEMBRANE; LYMPHOCYTES-T; COATED PITS; SURFACE; GLYCOPROTEIN; ENDOCYTOSIS	The cell adhesion glycoprotein LFA-3 is expressed on the cell surface of nucleated cells in both a membrane-spanning form and a glycosyl phosphatidylinositol-anchored form. To determine whether distinct membrane anchors direct the dynamics of a given protein, the turnover of biosynthetically S-35-labeled and biotin surface-labeled LFA-3 molecules was followed. It is shown here that (a) expression of the two LFA-3 forms is regenerated with similar kinetics after enzymatic removal from the cell surface; (b) neither of the distinct LFA-3 molecules undergoes constitutive internalization; and (c) transmembrane and glycosyl phosphatidylinositol-anchored LFA-3 have an unusually long life span with an identical half-life of 50 h. Thus, the type of membrane anchor is not affecting turnover characteristics of a particular cell surface glycoprotein.			HOLLANDER, N (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL.							ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HE TA, 1986, EMBO J, V5, P2489; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LOW MG, 1978, BIOCHIM BIOPHYS ACTA, V508, P565, DOI 10.1016/0005-2736(78)90100-1; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUBLIN DM, 1986, J IMMUNOL, V137, P1629; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MONOS DS, 1983, J IMMUNOL, V131, P341; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; TAUSK F, 1989, J IMMUNOL, V143, P3295; WALNER BP, 1987, J EXP MED, V166, P923	37	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5663	5667						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372008				2022-12-25	WOS:A1992HH74700099
J	WOLF, FW; MARKS, RM; SARMA, V; BYERS, MG; KATZ, RW; SHOWS, TB; DIXIT, VM				WOLF, FW; MARKS, RM; SARMA, V; BYERS, MG; KATZ, RW; SHOWS, TB; DIXIT, VM			CHARACTERIZATION OF A NOVEL TUMOR NECROSIS FACTOR-ALPHA-INDUCED ENDOTHELIAL PRIMARY RESPONSE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTE CHEMOATTRACTANT; HUMAN VASCULAR ENDOTHELIUM; COLONY-STIMULATING FACTOR; ADHESION MOLECULE-1; C-MYC; PROCOAGULANT ACTIVITY; INSITU HYBRIDIZATION; PROTO-ONCOGENE; GROWTH-FACTOR; CELLS	The response of endothelial cells to the cytokine tumor necrosis factor-alpha (TNF) is complex, involving the induction and suppression of multiple genes and gene products. Differential screening of a TNF-stimulated, cycloheximide-treated human umbilical vein endothelial cell library has resulted in the cloning of several novel cDNAs whose protein products are involved in the primary response of the endothelium to TNF. One of these cDNAs, designated B12, is further characterized here. B12 is encoded by a 3.5-kilobase transcript and is induced rapidly and transiently by TNF. Transcript expression is found to be developmentally regulated in a tissue-specific manner, with B12 message being differentially expressed in the heart and liver during mouse embryogenesis. The open reading frame of B12 predicts a 316-amino acid sequence rich in charged residues, particularly at the carboxyl terminus, and has neither significant homology to other known proteins nor to any extant sequence motifs. B12 is found to be a highly conserved single-copy gene which is located in the q22 --> q23 region of human chromosome 17. Polyclonal antibodies raised against a large portion of the B12 open reading frame immunoprecipitate a 36-kilodalton polypeptide from wheat germ lysates programmed to translate in vitro transcribed B12 mRNA. The B12 protein is further shown to be induced in human umbilical vein endothelial cells by TNF, and the protein is shown to be rapidly de graded.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, BOX 0602, ANN ARBOR, MI 48109 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Roswell Park Cancer Institute; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHLBI NIH HHS [HL45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BROUDY VC, 1987, J IMMUNOL, V139, P464; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; CAWTHON RM, 1991, GENOMICS, V9, P446, DOI 10.1016/0888-7543(91)90410-G; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Grunfeld C, 1990, Adv Intern Med, V35, P45; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Marston F. A. O., 1987, DNA CLONING, P59; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; ROBAYE B, 1991, AM J PATHOL, V138, P447; ROBINSON EA, 1989, P NATL ACAD SCI USA, V86, P1850, DOI 10.1073/pnas.86.6.1850; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIEFF CA, 1988, BLOOD, V72, P1316; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TRACEY KJ, 1989, LANCET, V1, P1122; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	63	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1317	1326						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370465				2022-12-25	WOS:A1992GY96000099
J	YAMAUCHI, A; UCHIDA, S; KWON, HM; PRESTON, AS; ROBEY, RB; GARCIAPEREZ, A; BURG, MB; HANDLER, JS				YAMAUCHI, A; UCHIDA, S; KWON, HM; PRESTON, AS; ROBEY, RB; GARCIAPEREZ, A; BURG, MB; HANDLER, JS			CLONING OF A NA+-DEPENDENT AND CL--DEPENDENT BETAINE TRANSPORTER THAT IS REGULATED BY HYPERTONICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA; ACID; OSMOREGULATION; PROTEIN; CELLS; BLOOD; RAT	Many hypertonic bacteria, plants, marine animals, and the mammalian renal medulla are protected from the deleterious effects of high intracellular concentrations of electrolytes by accumulating high concentrations of the nonperturbing osmolyte betaine. When kidney-derived Madin-Darby canine kidney (MDCK) cells are cultured in hypertonic medium, they accumulate betaine to 1,000 times its medium concentration. This results from induction by hypertonicity of high rates of betaine transport into cells. We have isolated a cDNA (BGT-1) encoding a renal betaine transporter by screening an MDCK cell cDNA library for expression of a betaine transporter in Xenopus oocytes. The cDNA encodes a single protein of 614 amino acids, with an estimated molecular weight of 69 kDa. The deduced amino acid sequence exhibits highly significant sequence and topographic similarity to brain gamma-amino-n-butyric acid (GABA) and noradrenaline transporters, suggesting that the renal BGT-1 is a member of the brain GABA/noradrenaline transporter gene family. Expression in oocytes indicates that the BGT-1 protein has both betaine and GABA transport activities that are Cl-- as well as Na+-dependent and functionally similar to betaine and GABA transport in MDCK cells. Northern hybridization indicates that transporter mRNA is localized to the kidney medulla and is induced in MDCK cells by hypertonicity.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,725 N WOLFE ST,BALTIMORE,MD 21205; NHLBI,KIDNEY & ELECTROLYTE METAB LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Robey, R. Brooks/J-7099-2013; Uchida, Shinichi/D-1111-2013	Robey, R. Brooks/0000-0001-5059-3965; 				BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BOWERY NG, 1976, NATURE, V264, P281, DOI 10.1038/264281a0; FERKANY JW, 1978, LIFE SCI, V22, P2121, DOI 10.1016/0024-3205(78)90456-3; GERMANN WJ, 1986, J GEN PHYSIOL, V88, P237, DOI 10.1085/jgp.88.2.237; GOODYER PR, 1985, BIOCHIM BIOPHYS ACTA, V818, P45, DOI 10.1016/0005-2736(85)90136-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWON HM, 1991, AM J PHYSIOL, V260, pF258, DOI 10.1152/ajprenal.1991.260.2.F258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; NEEDHAM L, 1987, BIOCHIM BIOPHYS ACTA, V899, P44, DOI 10.1016/0005-2736(87)90237-9; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARKER JC, 1981, FED PROC, V40, P2872; ROBEY RB, 1991, J BIOL CHEM, V266, P10400; SCHOUSBOE A, 1979, J NEUROCHEM, V33, P181, DOI 10.1111/j.1471-4159.1979.tb11720.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRIGHT EM, 1985, BIOCHIM BIOPHYS ACTA, V818, P271, DOI 10.1016/0005-2736(85)90568-1; WRIGHT S H, 1989, FASEB Journal, V3, pA858; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	24	391	400	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					649	652						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370453				2022-12-25	WOS:A1992GY43900100
J	BLASBAND, A; SCHRYVER, B; PAPKOFF, J				BLASBAND, A; SCHRYVER, B; PAPKOFF, J			THE BIOCHEMICAL-PROPERTIES AND TRANSFORMING POTENTIAL OF HUMAN WNT-2 ARE SIMILAR TO WNT-1	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE MAMMARY ONCOGENE; EPITHELIAL-CELL LINE; NUCLEOTIDE-SEQUENCE; SARCOMA VIRUS; MURINE INT-1; EXPRESSION; GENE; DROSOPHILA; WINGLESS	Wnt-2 is a member of the Wnt gene family that includes the proto-oncogene Wnt-1 (formerly Int-1). Although the predicted protein product of the Wnt-2 gene has only 38% amino acid identity with Wnt-1, it exhibits significant conservation of structural properties, including a hydrophobic signal sequence and invariant spacing and conservation of 22 cysteine residues. We have sought to characterize the biological and biochemical properties of Wnt family members and here present a characterization of Wnt-2 protein and a comparison with Wnt-1. We demonstrate, using both CHO and AtT-20 cells transfected with human Wnt-2 cDNA, that Wnt-2 encodes a 33 kl)a protein that is modified by N-linked glycosylation to a 35 kDa species. Secreted Wnt-2 protein was detected in the culture medium only after cells were treated with suramin indicating that, like Wnt-1 protein, Wnt-2 is tightly associated with the cell surface. Expression of Wnt-2 cDNA in the mammary epithelial cell line C57 mg results in loss of density-inhibited growth and induces a transformed phenotype in monolayer culture similar to the effects produced by Wnt-1. These results indicate that Wnt-2 shares several biochemical and biological characteristics with Wnt-1 and suggests that other Wnt family members, by virtue of conserved structural features, may also exhibit similar properties.	SYNTEX INC,S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304	Syntex Corporation								BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GILMAN M, 1989, CURRENT PROTOCOLS MO; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PETCU DJ, 1988, VIROLOGY, V167, P385, DOI 10.1016/0042-6822(88)90099-2; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287	39	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					153	161						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371336				2022-12-25	WOS:A1992HC22700021
